assay_test_type,bao_format,assay_tissue,assay_category,assay_id,src_id,src_assay_id,assay_subcellular_fraction,description,tid,assay_type,cell_id,chembl_id,assay_cell_type,doc_id,assay_tax_id,curated_by,assay_strain,variant_id,confidence_score,relationship_type,assay_organism,tissue_id
,BAO_0000019,,,1,1,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,12052,B,,CHEMBL615117,,11087,,Autocuration,,,8,H,,
,BAO_0000219,,,2,1,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,22226,F,,CHEMBL615118,,684,,Autocuration,,,0,U,,
,BAO_0000019,,,3,1,,,,22226,B,,CHEMBL615119,,15453,,Autocuration,,,0,U,,
,BAO_0000249,,,4,1,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,104729,B,,CHEMBL615120,,17841,9913.0,Autocuration,,,4,H,Bos taurus,
,BAO_0000219,,,5,1,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,F,163.0,CHEMBL615121,143B,17430,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6,1,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,F,163.0,CHEMBL615122,143B,17430,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7,1,,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,80001,F,163.0,CHEMBL615123,143B,13799,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,8,1,,,In vitro cell cytotoxicity was determined against 143B cell line,80001,F,163.0,CHEMBL615124,143B,17774,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,9,1,,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,80001,F,163.0,CHEMBL615125,143B,3801,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,10,1,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,F,163.0,CHEMBL615126,143B,17430,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,11,1,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,F,163.0,CHEMBL615127,143B,17430,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,12,1,,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,80001,F,163.0,CHEMBL615128,143B,17774,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000218,,,13,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,F,,CHEMBL857900,,11324,1280.0,Intermediate,,,1,N,Staphylococcus aureus,
,BAO_0000218,,,14,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,F,,CHEMBL615129,,11324,1280.0,Intermediate,,,1,N,Staphylococcus aureus,
,BAO_0000218,,,15,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,F,,CHEMBL615130,,11324,1280.0,Intermediate,,,1,N,Staphylococcus aureus,
,BAO_0000218,,,16,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,F,,CHEMBL615131,,11324,1280.0,Intermediate,,,1,N,Staphylococcus aureus,
,BAO_0000357,,,17,1,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,100122,A,,CHEMBL884521,,11347,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,18,1,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),12054,B,,CHEMBL615132,,16474,,Autocuration,,,8,H,,
,BAO_0000019,,,19,1,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,12054,B,,CHEMBL615133,,10091,,Autocuration,,,8,H,,
,BAO_0000357,,,20,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,B,,CHEMBL615134,,16474,,Autocuration,,,8,H,,
,BAO_0000357,,,21,1,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),12054,B,,CHEMBL615135,,16474,,Autocuration,,,8,H,,
,BAO_0000357,,,22,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,B,,CHEMBL615136,,16474,,Autocuration,,,8,H,,
,BAO_0000357,,,23,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,B,,CHEMBL615137,,16474,,Autocuration,,,8,H,,
,BAO_0000357,,,24,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,B,,CHEMBL615138,,16474,,Autocuration,,,8,H,,
,BAO_0000219,,,25,1,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",22226,B,,CHEMBL836324,,14352,,Autocuration,,,0,U,,
,BAO_0000357,,,26,1,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,12054,B,,CHEMBL615139,,5646,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,27,1,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),12054,B,,CHEMBL615140,,5646,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000219,,,28,1,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,12426,B,,CHEMBL615141,,10997,,Autocuration,,,8,H,,
,BAO_0000357,,,29,1,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,12054,B,,CHEMBL615142,,6309,3847.0,Autocuration,,,8,H,soya bean,
,BAO_0000357,,,30,1,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,12054,B,,CHEMBL615143,,167,3847.0,Autocuration,,,8,H,Glycine max,
,BAO_0000357,,,31,1,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,12054,B,,CHEMBL615144,,167,3847.0,Autocuration,,,8,H,Glycine max,
,BAO_0000357,,,32,1,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,12054,B,,CHEMBL872867,,11087,3847.0,Autocuration,,,8,H,Glycine max,
,BAO_0000357,,,33,1,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,12054,B,,CHEMBL615145,,11087,3847.0,Autocuration,,,8,H,Glycine max,
,BAO_0000357,,,34,1,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,B,,CHEMBL615146,,13622,3847.0,Autocuration,,,8,H,Glycine max,
,BAO_0000357,,,35,1,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,B,,CHEMBL615147,,13622,3847.0,Autocuration,,,8,H,Glycine max,
,BAO_0000019,,,36,1,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,22226,A,,CHEMBL615148,,11347,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,37,1,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,22226,B,,CHEMBL615149,,5926,562.0,Autocuration,,,0,U,Escherichia coli,
,BAO_0000019,,,38,1,,,Dissociation constant with dimeric 16S rRNA RNA construct B,22226,B,,CHEMBL615150,,4567,,Autocuration,,,0,U,,
,BAO_0000225,,,39,1,,,Dissociation constant towards 16S rRNA construct A,22222,B,,CHEMBL615151,,3782,,Intermediate,,,3,M,,
,BAO_0000225,,,40,1,,,Dissociation constant towards 16S rRNA construct B,22222,B,,CHEMBL615152,,3782,,Intermediate,,,3,M,,
,BAO_0000225,,,41,1,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,100263,B,,CHEMBL615153,,4466,562.0,Expert,,,3,M,Escherichia coli,
,BAO_0000225,,,42,1,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,100263,B,,CHEMBL615154,,6592,562.0,Expert,,,3,M,Escherichia coli,
,BAO_0000019,,,43,1,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,B,,CHEMBL615155,,898,,Autocuration,,,8,H,,
,BAO_0000019,,,44,1,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,B,,CHEMBL615156,,898,,Autocuration,,,8,H,,
,BAO_0000019,,,45,1,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,B,,CHEMBL615157,,13163,9606.0,Autocuration,,,8,H,Homo sapiens,
,BAO_0000019,,,46,1,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,B,,CHEMBL615158,,13163,9606.0,Autocuration,,,8,H,Homo sapiens,
,BAO_0000019,,,47,1,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,B,,CHEMBL615159,,10691,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,48,1,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,B,,CHEMBL615172,,10691,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,49,1,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,B,,CHEMBL615173,,10691,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,50,1,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,B,,CHEMBL615174,,10691,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,51,1,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,B,,CHEMBL884518,,898,,Autocuration,,,8,H,,
,BAO_0000357,,,52,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),11512,B,,CHEMBL615175,,912,,Autocuration,,,8,H,,
,BAO_0000357,,,53,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,11512,B,,CHEMBL615176,,912,,Autocuration,,,8,H,,
,BAO_0000357,,,54,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,11512,B,,CHEMBL615177,,912,,Autocuration,,,8,H,,
,BAO_0000249,,,55,1,,Membranes,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,104740,B,,CHEMBL615178,,15103,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000219,,,56,1,,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,80002,F,506.0,CHEMBL615179,1A9,5116,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,57,1,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,104835,F,,CHEMBL615180,Oocytes,14578,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000219,,,58,1,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,104821,F,,CHEMBL615181,Oocytes,14578,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000219,,,59,1,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,104848,F,,CHEMBL615182,Oocytes,14578,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000219,,,60,1,,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,80002,F,506.0,CHEMBL615183,1A9,4787,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,61,1,,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,80002,F,506.0,CHEMBL615184,1A9,4787,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,62,1,,,Cytotoxic activity against human ovarian cancer (1A9) cell line,80002,F,506.0,CHEMBL615185,1A9,3547,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,63,1,,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,80002,F,506.0,CHEMBL615186,1A9,3547,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,64,1,,,Effective dose of compound against replication of 1A9 cell line was evaluated,80002,F,506.0,CHEMBL615187,1A9,6726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,65,1,,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,80002,F,506.0,CHEMBL885343,1A9,3455,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,66,1,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),80002,F,506.0,CHEMBL615188,1A9,5726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,67,1,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,80002,F,506.0,CHEMBL615189,1A9,5726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,68,1,,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,80002,F,506.0,CHEMBL615190,1A9,5726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,69,1,,,Inhibitory activity against Taxol resistant 1A9 cell lines,80002,F,506.0,CHEMBL615191,1A9,3395,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,70,1,,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,80002,F,506.0,CHEMBL615192,1A9,3415,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,71,1,,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,80002,F,506.0,CHEMBL827083,1A9,3415,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,72,1,,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,80002,F,506.0,CHEMBL615193,1A9,17099,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,73,1,,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,80002,F,506.0,CHEMBL615194,1A9,17099,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,74,1,,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,80002,F,506.0,CHEMBL615195,1A9,17099,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,75,1,,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,80002,F,506.0,CHEMBL615196,1A9,17099,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,76,1,,,Inhibitory concentration against Jurkat cells,81072,F,503.0,CHEMBL615197,Jurkat,17721,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,77,1,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,22226,F,,CHEMBL615198,,1229,,Intermediate,,,0,U,,
,BAO_0000357,,,78,1,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,100121,A,,CHEMBL615199,,11347,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,79,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,B,,CHEMBL615200,,17117,,Expert,,,8,H,,
,BAO_0000357,,,80,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,B,,CHEMBL615201,,17117,,Expert,,,8,H,,
,BAO_0000357,,,81,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",11231,B,,CHEMBL615202,,17117,,Expert,,,8,H,,
,BAO_0000251,,,82,1,,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11231,B,,CHEMBL615203,,11375,5476.0,Autocuration,,,8,H,Candida albicans,
,BAO_0000251,,,83,1,,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11231,B,,CHEMBL615204,,11375,5476.0,Autocuration,,,8,H,Candida albicans,
,BAO_0000251,,,84,1,,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11231,B,,CHEMBL615205,,11375,4932.0,Autocuration,,,8,H,Saccharomyces cerevisiae,
,BAO_0000251,,,85,1,,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11231,B,,CHEMBL615206,,11375,4932.0,Autocuration,,,8,H,Saccharomyces cerevisiae,
,BAO_0000251,Liver,,86,1,,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",12083,B,,CHEMBL615207,,11375,9823.0,Autocuration,,,8,H,Sus scrofa,2107.0
,BAO_0000019,,,87,1,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",11231,B,,CHEMBL827084,,791,10116.0,Autocuration,,,8,H,Rattus norvegicus,
,BAO_0000019,,,88,1,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",11231,B,,CHEMBL615208,,791,10116.0,Autocuration,,,8,H,Rattus norvegicus,
,BAO_0000019,,,89,1,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",11231,B,,CHEMBL615209,,791,10116.0,Autocuration,,,8,H,Rattus norvegicus,
,BAO_0000251,Liver,,90,1,,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",12083,B,,CHEMBL615210,,11375,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,91,1,,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,B,,CHEMBL615211,,11375,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,92,1,,Microsomes,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,B,,CHEMBL615212,,153,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000357,,,93,1,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),11377,B,,CHEMBL615213,,8269,,Expert,,,8,H,,
,BAO_0000357,,,94,1,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,11377,B,,CHEMBL615273,,8269,,Expert,,,8,H,,
,BAO_0000219,,,95,1,,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,81020,F,726.0,CHEMBL615274,HepG2,17653,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,96,1,,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,81020,F,726.0,CHEMBL615275,HepG2,14277,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,97,1,,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,81020,F,726.0,CHEMBL615276,HepG2,1717,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,98,1,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,81020,F,726.0,CHEMBL615277,HepG2,14091,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,99,1,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,81020,F,726.0,CHEMBL615326,HepG2,14091,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,100,1,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,50606,F,,CHEMBL883130,,17653,10407.0,Expert,,,1,N,Hepatitis B virus,
,BAO_0000219,,,101,1,,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,81020,F,726.0,CHEMBL884519,HepG2,13105,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,102,1,,,Concentration required to inhibit 50% of 2.2.15 cell line,81020,F,726.0,CHEMBL615327,HepG2,1717,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,103,1,,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,81020,A,726.0,CHEMBL615328,HepG2,13105,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,104,1,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,50587,F,,CHEMBL615329,2.2.15,13600,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,105,1,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,50587,F,,CHEMBL615330,2.2.15,13467,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,106,1,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",50606,F,,CHEMBL615331,2.2.15,17477,10407.0,Expert,,,1,N,Hepatitis B virus,
,BAO_0000218,,,107,1,,,In vitro anti-HBV activity in 2.2.15 cells,50587,F,,CHEMBL615332,2.2.15,1593,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,108,1,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,50587,F,,CHEMBL615333,2.2.15,1593,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,109,1,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,50587,F,,CHEMBL615334,2.2.15,15089,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,110,1,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,50587,F,,CHEMBL615335,2.2.15,15089,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,111,1,,,Cytotoxicity in 2.2.15 cells,50587,F,,CHEMBL615336,2.2.15,1593,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,112,1,,,Cytotoxicity in 2.2.15 cells; Not determined,50587,F,,CHEMBL615337,2.2.15,1593,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,113,1,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,50587,F,,CHEMBL615338,2.2.15,13600,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,114,1,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,50587,F,,CHEMBL615339,2.2.15,13467,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,115,1,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,50587,F,,CHEMBL615340,2.2.15,13467,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,116,1,,,Antiviral activity against HBV was determined in 2.215 cell line,81020,F,726.0,CHEMBL615341,HepG2,14764,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000251,,,117,1,,Microsomes,Inhibition of 20-HETE synthesis in human renal microsomes,22226,B,,CHEMBL615342,,6531,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,118,1,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,22226,B,,CHEMBL615343,,17322,,Autocuration,,,0,U,,
,BAO_0000219,,,119,1,,,Inhibitory concentration against 2008 (ovarian) cells,80612,F,388.0,CHEMBL615344,2008,17072,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,120,1,,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,80612,F,388.0,CHEMBL615345,2008,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,121,1,,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),80612,F,388.0,CHEMBL615346,2008,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,122,1,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,80612,F,388.0,CHEMBL615347,2008,17146,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,123,1,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,80612,F,388.0,CHEMBL615348,2008,17146,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,124,1,,,In vitro inhibition of 2008/R ovarian cancer cell line,80613,F,561.0,CHEMBL827085,2008/R,10797,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,125,1,,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,80613,F,561.0,CHEMBL615349,2008/R,10797,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,126,1,,,In vitro inhibition of 2008/S ovarian cancer cell line,80614,F,389.0,CHEMBL615350,2008/S,10797,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,127,1,,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,80614,F,389.0,CHEMBL615351,2008/S,10797,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000220,,,128,1,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,100256,B,,CHEMBL615352,,4823,9606.0,Expert,,,2,S,Homo sapiens,
,BAO_0000220,,,129,1,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,100256,B,,CHEMBL615353,,12912,9606.0,Intermediate,,,2,S,Homo sapiens,
,BAO_0000220,,,130,1,,,Inhibition of chymotrypsin-like activity of 20S proteasome,100256,B,,CHEMBL615354,,2957,,Expert,,,2,S,,
,BAO_0000220,,,131,1,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,100256,B,,CHEMBL615355,,2957,,Expert,,,2,S,,
,BAO_0000220,,,132,1,,,Inhibitory activity against 20S proteosome,100256,B,,CHEMBL615356,,3260,,Intermediate,,,2,S,,
,BAO_0000019,,,133,1,,,Compound was tested for inhibitory activity against tryptase,22226,B,,CHEMBL615357,,3451,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,134,1,,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,81020,F,726.0,CHEMBL615358,HepG2,13885,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,135,1,,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,81020,F,726.0,CHEMBL827086,HepG2,13885,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,136,1,,,Compound was tested for the inhibition of Alpha-glucosidase,22226,B,,CHEMBL615359,,3676,,Autocuration,,,0,U,,
,BAO_0000357,,,137,1,,,Inhibitory concentration against human neutrophil elastase (HNE),235,B,,CHEMBL615360,,6043,,Autocuration,,,8,H,,
,BAO_0000218,Heart,,138,1,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,22226,F,,CHEMBL615361,,11140,10116.0,Autocuration,,,0,U,Rattus norvegicus,948.0
,BAO_0000019,,,139,1,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,F,,CHEMBL615362,,10543,,Autocuration,,,8,H,,
,BAO_0000019,,,140,1,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,F,,CHEMBL615363,,10543,,Expert,,,8,H,,
,BAO_0000357,,,141,1,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,B,,CHEMBL615364,,10543,,Autocuration,,,8,H,,
,BAO_0000019,,,142,1,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,F,,CHEMBL615365,,10543,,Expert,,,8,H,,
,BAO_0000219,,,143,1,,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,80360,F,524.0,CHEMBL615366,P338,11365,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,144,1,,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,80360,F,524.0,CHEMBL615367,P338,11365,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,145,1,,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,80384,F,554.0,CHEMBL615368,PBL,11803,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,146,1,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,22226,F,,CHEMBL615369,,11803,9940.0,Autocuration,,,0,U,Ovis aries,
,BAO_0000019,,,147,1,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,22226,F,,CHEMBL615370,,11803,9940.0,Autocuration,,,0,U,Ovis aries,
,BAO_0000357,,,148,1,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),191,B,,CHEMBL615673,,12278,,Autocuration,,,8,H,,
,BAO_0000019,,,149,1,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,22226,F,,CHEMBL615674,,8249,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,150,1,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,22226,F,,CHEMBL615675,,8249,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,151,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,22226,F,635.0,CHEMBL615676,CCRF-CEM,8249,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,152,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,22226,F,635.0,CHEMBL615677,CCRF-CEM,8249,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,153,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,22226,F,635.0,CHEMBL615678,CCRF-CEM,8249,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,154,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,22226,F,635.0,CHEMBL615679,CCRF-CEM,8249,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,155,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,22226,F,,CHEMBL615680,,8249,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,156,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,22226,F,,CHEMBL615681,,8249,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000249,,,157,1,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,104290,B,,CHEMBL857972,,16992,,Autocuration,,,6,H,,
,BAO_0000218,,,158,1,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,50264,F,,CHEMBL857899,,10543,1314.0,Intermediate,,,1,N,Streptococcus pyogenes,
,BAO_0000218,,,159,1,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),50527,F,,CHEMBL615371,,17833,10335.0,Intermediate,,,1,N,Human herpesvirus 3,
,BAO_0000218,,,160,1,,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,50527,F,468.0,CHEMBL615372,HEL,17290,10335.0,Expert,,,1,N,vericilla zoster virus,
,BAO_0000218,,,161,1,,,Antiviral activity against 07/1 strain of VZV; ND: No data,50527,F,,CHEMBL615373,,17290,10335.0,Intermediate,,,1,N,vericilla zoster virus,
,BAO_0000218,,,162,1,,,Antiviral activity against 07/1 strain of VZV; ND=No data,50527,F,,CHEMBL615374,,17290,10335.0,Intermediate,,,1,N,vericilla zoster virus,
,BAO_0000218,,,163,1,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",50145,F,,CHEMBL615375,,10932,561.0,Intermediate,,,1,N,escherichia cloac,
,BAO_0000019,,,164,1,,,Ratio of Ki at A2 to Ki at A1 receptors,22226,B,,CHEMBL615376,,9707,,Autocuration,,,0,U,,
,BAO_0000249,,,165,1,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",11143,B,,CHEMBL615377,,2346,5476.0,Expert,,,8,H,Candida albicans,
,BAO_0000357,,,166,1,,,"Inhibition of 1,3-beta-glucan synthase",18077,B,,CHEMBL615378,,2205,284593.0,Expert,,,8,H,Candida glabrata CBS 138,
,BAO_0000219,,,167,1,,,Inhibition of growth of 1-87 human tumor cell line,80609,F,832.0,CHEMBL615379,1-87 tumor cell line,11900,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,168,1,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,12166,B,,CHEMBL615380,,14864,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,169,1,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),100171,B,,CHEMBL615381,,16474,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,170,1,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,100171,B,,CHEMBL615382,,16474,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,171,1,,,% inhibition against soybean 1-lipoxygenase (SLO),100171,B,,CHEMBL615383,,16474,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,172,1,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,100171,B,,CHEMBL615384,,16474,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,173,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,100171,B,,CHEMBL615385,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,174,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,100171,B,,CHEMBL615386,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,175,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,100171,B,,CHEMBL615387,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,176,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,100171,B,,CHEMBL615388,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,177,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,100171,B,,CHEMBL615214,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,178,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,100171,B,,CHEMBL827087,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,179,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,100171,B,,CHEMBL615215,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,180,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,100171,B,,CHEMBL615216,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,181,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,100171,B,,CHEMBL615217,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,182,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,100171,B,,CHEMBL615218,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000357,,,183,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,100171,B,,CHEMBL615219,,3094,3847.0,Autocuration,,,9,D,Glycine max,
,BAO_0000019,,,184,1,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,22226,B,,CHEMBL615220,,10413,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000219,,,185,1,,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),80049,F,294.0,CHEMBL615221,C3H 10T1/2,16929,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000019,,,186,1,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,22226,F,,CHEMBL615222,,1229,,Intermediate,,,0,U,,
,BAO_0000357,,,187,1,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11489,B,,CHEMBL615223,,16587,,Autocuration,,,8,H,,
,BAO_0000357,,,188,1,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11862,B,,CHEMBL615224,,16587,,Autocuration,,,8,H,,
,BAO_0000357,,,189,1,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,11862,B,,CHEMBL615225,,16587,,Autocuration,,,8,H,,
,BAO_0000357,,,190,1,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,11489,B,,CHEMBL615226,,16587,,Autocuration,,,8,H,,
,BAO_0000357,,,191,1,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,11862,B,,CHEMBL615227,,16587,,Autocuration,,,8,H,,
,BAO_0000019,,,192,1,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,12347,F,,CHEMBL615228,,8058,9913.0,Expert,,,9,D,Bos taurus,
,BAO_0000357,,,193,1,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,100120,B,,CHEMBL615229,,9065,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,Adrenal gland,,194,1,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,100120,B,,CHEMBL615230,,8865,10116.0,Expert,,,9,D,Rattus norvegicus,2369.0
,BAO_0000357,,,195,1,,,Inhibition of rat adrenal 11-beta-hydroxylase,100120,B,,CHEMBL615231,,9066,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,196,1,,,Inhibition of rat adrenal 11-beta-hydroxylase,100120,B,,CHEMBL884520,,8394,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,197,1,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,100120,B,,CHEMBL615232,,8394,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,198,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,10328,B,,CHEMBL615233,,6431,,Autocuration,,,8,H,,
,BAO_0000357,,,199,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,B,,CHEMBL827088,,6431,,Autocuration,,,8,H,,
,BAO_0000357,,,200,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,B,,CHEMBL615234,,6431,,Autocuration,,,8,H,,
,BAO_0000019,,,201,1,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,11134,F,,CHEMBL615235,,9295,,Autocuration,,,8,H,,
,BAO_0000019,,,202,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,B,,CHEMBL615236,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,203,1,,,Compound was tested in vitro for inhibition of 12-LO human platelet,11134,B,,CHEMBL615237,,13622,,Autocuration,,,8,H,,
,BAO_0000019,,,204,1,,,Inhibitory concentration against human platelet 12-lipoxygenase,11134,F,,CHEMBL615238,,12079,,Autocuration,,,8,H,,
,BAO_0000019,,,205,1,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,11134,B,,CHEMBL615239,,13622,,Autocuration,,,8,H,,
,BAO_0000019,,,206,1,,,Inhibitory concentration against human platelet 12-lipoxygenase,11134,F,,CHEMBL615240,,12079,9606.0,Autocuration,,,9,D,Homo sapiens,
,BAO_0000019,,,207,1,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,11835,B,,CHEMBL615241,,13500,,Expert,,,8,H,,
,BAO_0000357,,,208,1,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,11601,B,,CHEMBL615242,,13723,,Expert,,,8,H,,
,BAO_0000019,,,209,1,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),11134,B,,CHEMBL615243,,16474,,Autocuration,,,8,H,,
,BAO_0000019,,,210,1,,,Inhibitory activity against human platelet 12-lipoxygenase,11134,B,,CHEMBL615244,,1630,,Autocuration,,,8,H,,
,BAO_0000019,,,211,1,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,11134,B,,CHEMBL615245,,167,,Autocuration,,,8,H,,
,BAO_0000019,,,212,1,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),11134,B,,CHEMBL615246,,16474,,Autocuration,,,8,H,,
,BAO_0000019,,,213,1,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,11134,B,,CHEMBL615247,,167,,Autocuration,,,8,H,,
,BAO_0000019,,,214,1,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,11134,B,,CHEMBL615248,,16474,,Autocuration,,,8,H,,
,BAO_0000357,,,215,1,,,Inhibitory activity towards porcine 12-lipoxygenase,11601,B,,CHEMBL615249,,10091,,Autocuration,,,8,H,,
,BAO_0000357,,,216,1,,,Tested for inhibition against porcine 12-LO,11601,B,,CHEMBL615250,,11966,,Autocuration,,,8,H,,
,BAO_0000019,,,217,1,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,12052,B,,CHEMBL615251,,951,,Autocuration,,,8,H,,
,BAO_0000019,,,218,1,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,12052,B,,CHEMBL615252,,10997,,Autocuration,,,8,H,,
,BAO_0000019,,,219,1,,,In vitro inhibition of rat platelet 12-lipoxygenase,12052,B,,CHEMBL828340,,10193,,Expert,,,8,H,,
,BAO_0000019,,,220,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,B,,CHEMBL615253,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,221,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,12052,B,,CHEMBL615254,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,222,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,12052,B,,CHEMBL615255,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,223,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,B,,CHEMBL615256,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,224,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,12052,B,,CHEMBL615257,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,225,1,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,12052,B,,CHEMBL615258,,11087,,Autocuration,,,8,H,,
,BAO_0000219,,,226,1,,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,80007,F,621.0,CHEMBL615259,41M,15569,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,227,1,,,In vitro antitumor activity against 41M cell line.,80007,F,621.0,CHEMBL615260,41M,12989,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,228,1,,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,80007,F,621.0,CHEMBL615261,41M,16745,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,229,1,,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,80007,F,621.0,CHEMBL615262,41M,15569,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,230,1,,,In vitro antitumor activity against 41McisR cell line.,80007,F,621.0,CHEMBL615263,41M,12989,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,231,1,,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,80007,F,621.0,CHEMBL838393,41M,12989,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,232,1,,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,80007,F,621.0,CHEMBL615264,41M,16745,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000357,,,233,1,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),84,B,,CHEMBL615265,,6210,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,234,1,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,B,,CHEMBL615266,,6210,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,235,1,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,B,,CHEMBL615267,,6226,,Expert,,,8,H,,
,BAO_0000357,,,236,1,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,B,,CHEMBL615268,,17855,,Expert,,,8,H,,
,BAO_0000357,,,237,1,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,10201,B,,CHEMBL615269,,17855,,Expert,,,8,H,,
,BAO_0000357,,,238,1,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,B,,CHEMBL615270,,17855,,Expert,,,8,H,,
,BAO_0000357,,,239,1,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,B,,CHEMBL615271,,10413,,Autocuration,,,8,H,,
,BAO_0000357,,,240,1,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,B,,CHEMBL615272,,10413,562.0,Autocuration,,,8,H,Escherichia coli,
,BAO_0000357,,,241,1,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,B,,CHEMBL615103,,10413,562.0,Autocuration,,,8,H,Escherichia coli,
,BAO_0000357,,,242,1,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",11303,B,,CHEMBL615104,,10413,562.0,Autocuration,,,8,H,Escherichia coli,
,BAO_0000357,,,243,1,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,B,,CHEMBL615105,,10413,,Autocuration,,,8,H,,
,BAO_0000357,,,244,1,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",12220,B,,CHEMBL872866,,10413,,Autocuration,,,8,H,,
,BAO_0000357,,,245,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,B,,CHEMBL615106,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,246,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",11303,B,,CHEMBL615107,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,247,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",11303,B,,CHEMBL615108,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,248,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",11303,B,,CHEMBL615109,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,249,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,B,,CHEMBL615110,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,250,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,B,,CHEMBL840105,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,251,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",11303,B,,CHEMBL615111,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,252,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",11303,B,,CHEMBL615112,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,253,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",11303,B,,CHEMBL615113,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,254,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",11303,B,,CHEMBL615114,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,255,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,B,,CHEMBL615115,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,256,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,B,,CHEMBL615116,,7587,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,257,1,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",11303,B,,CHEMBL615698,,7323,,Autocuration,,,8,H,,
,BAO_0000019,,,258,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",22226,B,,CHEMBL615699,,7587,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000019,,,259,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",22226,B,,CHEMBL615700,,7587,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000357,,,260,1,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,100249,B,,CHEMBL615701,,13750,4932.0,Expert,,,8,H,Saccharomyces cerevisiae,
,BAO_0000019,,,261,1,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,B,,CHEMBL615702,,7662,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,262,1,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,B,,CHEMBL615703,,7662,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,263,1,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",22226,B,,CHEMBL615704,,7662,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,264,1,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,F,,CHEMBL615705,,12211,,Autocuration,,,6,H,,
,BAO_0000019,,,265,1,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,F,,CHEMBL615706,,12211,,Autocuration,,,6,H,,
,BAO_0000221,Ileum,,266,1,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,20033,F,,CHEMBL615707,,12211,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000019,,,267,1,,,Stimulatory activity of intragastric pressure was tested in the rat,10623,F,,CHEMBL615708,,12211,,Expert,,,8,H,,
,BAO_0000357,,,268,1,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,121,B,,CHEMBL615709,,15453,,Autocuration,,,8,H,,
,BAO_0000218,,,269,1,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),22226,F,,CHEMBL615710,,11884,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,270,1,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,12688,F,,CHEMBL615711,,7185,,Autocuration,,,8,H,,
,BAO_0000357,,,271,1,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,121,B,,CHEMBL615712,,6876,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,272,1,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,121,B,,CHEMBL836325,,6876,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,273,1,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,12198,F,,CHEMBL615713,,11863,,Autocuration,,,8,H,,
,BAO_0000357,,,274,1,,,Inhibition constant of high-affinity 5-HT uptake,12198,B,,CHEMBL615714,,11863,,Autocuration,,,8,H,,
,BAO_0000019,,,275,1,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,12198,F,,CHEMBL615715,,11863,,Autocuration,,,8,H,,
,BAO_0000019,,,276,1,,,Maximum rate was determined for high affinity transport of 5-HT,12198,F,,CHEMBL615716,,11863,,Autocuration,,,8,H,,
,BAO_0000019,,,277,1,,,Compound was tested for agonistic activity against 5-HT uptake,104714,F,,CHEMBL615717,,4639,,Autocuration,,,4,H,,
,BAO_0000019,,,278,1,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,10577,B,,CHEMBL881818,,15796,,Expert,,,8,H,,
,BAO_0000357,,,279,1,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,105,B,,CHEMBL884540,,15796,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000224,,,280,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,104744,B,,CHEMBL615718,,12801,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,281,1,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,104744,B,,CHEMBL615719,,12801,,Autocuration,,,4,H,,
,BAO_0000249,,,282,1,,Membranes,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,104744,B,,CHEMBL615720,,12120,,Autocuration,,,4,H,,
,BAO_0000249,,,283,1,,Membranes,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,104744,B,,CHEMBL615721,,12120,,Autocuration,,,4,H,,
,BAO_0000019,,,284,1,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,B,,CHEMBL615722,,11963,,Autocuration,,,4,H,,
,BAO_0000019,,,285,1,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,51,F,,CHEMBL615723,,11701,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,286,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,B,,CHEMBL615724,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,287,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,B,,CHEMBL615725,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,288,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,B,,CHEMBL615726,,9995,,Autocuration,,,8,H,,10000000.0
In vivo,BAO_0000218,,,289,1,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),10576,F,,CHEMBL615727,,16394,,Autocuration,,,8,H,,
,BAO_0000019,,,290,1,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,105570,F,,CHEMBL615728,,11574,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000219,,,291,1,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,B,449.0,CHEMBL857971,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000357,,,292,1,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL615729,,15363,,Autocuration,,,8,H,,
,BAO_0000019,,,293,1,,,Efficacy against 5-hydroxytryptamine 2A receptor,12687,F,,CHEMBL615730,,15363,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,294,1,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,12687,F,,CHEMBL615731,,15329,,Expert,,,8,H,,
,BAO_0000019,,,295,1,,,Relative potency towards 5-HT2A receptor of rat tail artery,12687,F,,CHEMBL615732,,15329,,Expert,,,8,H,,
,BAO_0000019,,,296,1,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,F,,CHEMBL615733,,15329,,Expert,,,8,H,,
,BAO_0000019,,,297,1,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,12687,F,,CHEMBL615734,,15329,,Expert,,,8,H,,
,BAO_0000019,,,298,1,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,12687,F,,CHEMBL615735,,15329,,Autocuration,,,8,H,,
,BAO_0000019,,,299,1,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,F,,CHEMBL615736,,15329,,Expert,,,8,H,,
,BAO_0000221,Ileum,,300,1,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,F,,CHEMBL615737,,273,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,301,1,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),20033,F,,CHEMBL615738,,273,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,302,1,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,F,,CHEMBL615739,,273,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000357,,,303,1,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,10623,B,,CHEMBL615278,,12092,,Autocuration,,,8,H,,
,BAO_0000019,,,304,1,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,F,,CHEMBL615279,,1317,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,305,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL615280,,12409,,Expert,,,8,H,,
,BAO_0000019,,,306,1,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,22226,B,,CHEMBL615281,,11126,9031.0,Autocuration,,,0,U,Gallus gallus,
,BAO_0000019,,,307,1,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,22226,F,,CHEMBL615282,,11126,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,308,1,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,F,,CHEMBL615283,,11126,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,309,1,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,80156,B,649.0,CHEMBL615284,HL-60,11126,9606.0,Autocuration,,,1,N,Homo sapiens,
,BAO_0000019,,,310,1,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,22226,B,,CHEMBL615285,,11126,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,311,1,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,B,,CHEMBL615286,,11126,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,312,1,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,104703,B,,CHEMBL615287,Oocytes,17807,9606.0,Autocuration,,,7,D,Homo sapiens,
,BAO_0000220,,,313,1,,,Chymotryptic inhibitory activity against 26S proteasome,100256,F,,CHEMBL615288,,16575,,Intermediate,,,2,S,,
,BAO_0000220,,,314,1,,,Inhibitory activity against 26S proteasome degradation of IkB,100256,B,,CHEMBL615289,,15407,,Intermediate,,,2,S,,
,BAO_0000219,,,315,1,,,In vitro inhibition of 2780/DOX ovarian cancer cell line,81034,F,478.0,CHEMBL615290,A2780,10797,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,316,1,,,In vitro inhibition of 2780/S ovarian cancer cell line,81034,F,478.0,CHEMBL884522,A2780,10797,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,317,1,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,22226,F,,CHEMBL615291,,3469,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000225,,,318,1,,,Association constant for binding to AATT 28-mer AATT hairpin,22222,B,,CHEMBL615292,,16037,,Intermediate,,,3,M,,
,BAO_0000225,,,319,1,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,22222,B,,CHEMBL615293,,16037,,Intermediate,,,3,M,,
,BAO_0000225,,,320,1,,,Reaction Rate Parameter for 28-mer AATT hairpin,22222,B,,CHEMBL615294,,16037,,Intermediate,,,3,M,,
,BAO_0000225,,,321,1,,,Reaction Rate Parameter for 28-mer AATT hairpin,22222,B,,CHEMBL615295,,16037,,Intermediate,,,3,M,,
,BAO_0000019,,,322,1,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),22226,F,,CHEMBL825021,,16524,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,323,1,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),22226,F,,CHEMBL615296,,16524,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,324,1,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,22226,F,,CHEMBL615297,,16524,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,325,1,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,22226,F,,CHEMBL615298,,16758,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000019,,,326,1,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,22226,F,,CHEMBL615299,,16758,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000019,,,327,1,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,22226,F,,CHEMBL615300,,16758,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000357,,,328,1,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,241,B,,CHEMBL615301,,14360,,Autocuration,,,8,H,,
,BAO_0000357,,,329,1,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,241,B,,CHEMBL615302,,14360,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,330,1,,,Selectivity ratio of ID50 in liver and heart,22226,B,,CHEMBL615303,,9964,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,331,1,,,"Selectivity, ratio of relative ID50 in liver and heart",12132,B,,CHEMBL615304,,9964,,Autocuration,,,8,H,,
,BAO_0000019,,,332,1,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,12132,B,,CHEMBL615305,,9964,,Autocuration,,,8,H,,
,BAO_0000218,,,333,1,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,B,,CHEMBL615306,,9964,,Autocuration,,,8,H,,
,BAO_0000218,,,334,1,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,B,,CHEMBL615307,,9964,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,335,1,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,B,,CHEMBL615308,,9964,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,336,1,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,F,,CHEMBL615309,,9964,,Autocuration,,,8,H,,
,BAO_0000019,,,337,1,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",22226,B,,CHEMBL615310,,9964,,Autocuration,,,0,U,,
,BAO_0000019,,,338,1,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,12132,B,,CHEMBL615311,,9964,,Autocuration,,,8,H,,
,BAO_0000019,,,339,1,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",22226,B,,CHEMBL615312,,9964,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,340,1,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,B,,CHEMBL615313,,9964,,Autocuration,,,8,H,,
,BAO_0000019,,,341,1,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,F,,CHEMBL615314,,9964,,Autocuration,,,8,H,,
,BAO_0000019,,,342,1,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",12132,B,,CHEMBL615315,,9964,,Autocuration,,,8,H,,
,BAO_0000218,,,343,1,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",22226,B,,CHEMBL615316,,9964,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,344,1,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,12132,B,,CHEMBL615317,,9964,,Autocuration,,,8,H,,
,BAO_0000218,,,345,1,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,B,,CHEMBL615318,,9964,,Autocuration,,,8,H,,
,BAO_0000218,,,346,1,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",22226,B,,CHEMBL615319,,9964,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,347,1,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,B,,CHEMBL615320,,9964,,Autocuration,,,8,H,,
,BAO_0000019,,,348,1,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,F,,CHEMBL615321,,9964,,Autocuration,,,8,H,,
,BAO_0000019,,,349,1,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",22226,B,,CHEMBL615322,,3796,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000357,,,350,1,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,B,,CHEMBL615323,,4251,562.0,Autocuration,,,8,H,Escherichia coli,
,BAO_0000357,,,351,1,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,B,,CHEMBL615407,,4251,562.0,Autocuration,,,8,H,Escherichia coli,
,BAO_0000357,,,352,1,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,B,,CHEMBL857267,,4251,562.0,Autocuration,,,8,H,Escherichia coli,
,BAO_0000357,,,353,1,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,B,,CHEMBL615408,,4251,562.0,Autocuration,,,8,H,Escherichia coli,
,BAO_0000357,,,354,1,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,19690,B,,CHEMBL615409,,166,,Autocuration,,,8,H,,
,BAO_0000357,,,355,1,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,19690,B,,CHEMBL615410,,17861,,Autocuration,,,8,H,,
,BAO_0000357,,,356,1,,,Inhibition constant against 3-dehydroquinate synthase,19690,B,,CHEMBL615411,,166,,Autocuration,,,8,H,,
,BAO_0000357,,,357,1,,,Association rate constant against 3-dehydroquinate synthase,19690,B,,CHEMBL615412,,166,,Autocuration,,,8,H,,
,BAO_0000357,,,358,1,,,Rate constant against 3-dehydroquinate synthase,19690,B,,CHEMBL615413,,166,,Autocuration,,,8,H,,
,BAO_0000019,,,359,1,,,Inhibitory activity against fuc-TVII,22226,B,,CHEMBL615414,,3548,,Autocuration,,,0,U,,
,BAO_0000251,Liver,,360,1,,Microsomes,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,B,,CHEMBL615415,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,361,1,,Microsomes,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,B,,CHEMBL615416,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,362,1,,Microsomes,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,B,,CHEMBL615417,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,363,1,,Microsomes,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,B,,CHEMBL615418,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,364,1,,Microsomes,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,B,,CHEMBL615419,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,365,1,,Microsomes,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,12236,B,,CHEMBL615420,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,366,1,,Microsomes,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,12236,B,,CHEMBL615421,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,367,1,,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,12236,B,,CHEMBL615422,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,368,1,,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,12236,B,,CHEMBL615423,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,369,1,,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,12236,B,,CHEMBL872868,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,370,1,,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,12236,B,,CHEMBL615424,,9877,10116.0,Autocuration,,,9,D,Rattus norvegicus,2107.0
,BAO_0000224,,,371,1,,,Inhibitory activity against 3-phosphoglycerate kinase.,104832,B,,CHEMBL825022,,3003,,Autocuration,,,4,H,,
,BAO_0000224,,,372,1,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,104832,B,,CHEMBL615425,,3003,,Autocuration,,,4,H,,
,BAO_0000224,,,373,1,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",104832,B,,CHEMBL615426,,3003,,Autocuration,,,4,H,,
,BAO_0000357,,,374,1,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,10612,B,,CHEMBL615427,,17185,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,375,1,,,Cytotoxicity on 3677 melanoma cells,80616,F,844.0,CHEMBL615428,3677 melanoma cell line,6072,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,376,1,,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,80616,F,844.0,CHEMBL615429,3677 melanoma cell line,6072,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,377,1,,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,80617,F,700.0,CHEMBL615430,MC-38,5018,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000019,,,378,1,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,22226,F,,CHEMBL615431,,2852,9606.0,Intermediate,,,0,U,Homo sapiens,
,BAO_0000218,,,379,1,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,22226,F,798.0,CHEMBL615432,B16,8663,,Autocuration,,,0,U,,
,BAO_0000218,,,380,1,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,22226,F,798.0,CHEMBL615433,B16,8663,,Autocuration,,,0,U,,
,BAO_0000019,,,381,1,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12464,F,,CHEMBL615434,,3245,12131.0,Expert,,,9,D,Human rhinovirus 14,
,BAO_0000218,,,382,1,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,50085,F,,CHEMBL615435,,3245,169066.0,Intermediate,,,1,N,Human rhinovirus sp.,
,BAO_0000218,,,383,1,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,50679,F,,CHEMBL615436,,3877,169066.0,Intermediate,,,1,N,human rhinovirus type 14,
,BAO_0000218,,,384,1,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,50679,F,,CHEMBL615437,,3877,169066.0,Intermediate,,,1,N,human rhinovirus type 14,
,BAO_0000019,,,385,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,F,,CHEMBL615438,,5861,12131.0,Expert,,,9,D,Human rhinovirus 14,
,BAO_0000019,,,386,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,F,,CHEMBL615439,,5861,12131.0,Expert,,,9,D,Human rhinovirus 14,
,BAO_0000019,,,387,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,F,,CHEMBL615440,,5861,12131.0,Expert,,,9,D,Human rhinovirus 14,
,BAO_0000019,,,388,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12464,F,,CHEMBL615441,,5861,12131.0,Expert,,,9,D,Human rhinovirus 14,
,BAO_0000218,,,389,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,50665,F,,CHEMBL615641,,13748,12059.0,Intermediate,,,1,N,Enterovirus,
,BAO_0000218,,,390,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,50665,F,,CHEMBL872065,,13748,12059.0,Intermediate,,,1,N,Enterovirus,
,BAO_0000218,,,391,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,50665,F,,CHEMBL825023,,13748,12059.0,Intermediate,,,1,N,Enterovirus,
,BAO_0000218,,,392,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,50665,F,,CHEMBL615642,,13748,12059.0,Intermediate,,,1,N,Enterovirus,
,BAO_0000357,,,393,1,,,Inhibition of human rhinovirus 3C protease,12464,B,,CHEMBL615643,,13748,147712.0,Expert,,,8,H,Human rhinovirus B,
,BAO_0000019,,,394,1,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,22226,B,,CHEMBL615644,,17699,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000218,,,395,1,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),80619,F,833.0,CHEMBL615645,3EM 37,7145,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,396,1,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),80619,F,833.0,CHEMBL615646,3EM 37,7145,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,397,1,,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),80619,F,833.0,CHEMBL615647,3EM 37,7145,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,398,1,,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),80619,F,833.0,CHEMBL615648,3EM 37,7145,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,399,1,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,80619,F,833.0,CHEMBL615649,3EM 37,7145,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,400,1,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,80619,F,833.0,CHEMBL615650,3EM 37,7145,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,401,1,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,F,847.0,CHEMBL615651,3LL cell line,5325,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,402,1,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,F,847.0,CHEMBL615652,3LL cell line,5325,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,403,1,,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,80620,F,847.0,CHEMBL615653,3LL cell line,5325,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,404,1,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,80620,F,847.0,CHEMBL615654,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,405,1,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,80620,F,847.0,CHEMBL615655,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,406,1,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,80620,F,847.0,CHEMBL825024,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,407,1,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,80620,F,847.0,CHEMBL615656,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,408,1,,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,80620,F,847.0,CHEMBL615657,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,409,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,80620,F,847.0,CHEMBL615658,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,410,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,80620,F,847.0,CHEMBL615659,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,411,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,80620,F,847.0,CHEMBL615660,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,412,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,F,847.0,CHEMBL615661,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,413,1,,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,80620,F,847.0,CHEMBL615662,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,414,1,,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,80620,F,847.0,CHEMBL615663,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,415,1,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,80620,F,847.0,CHEMBL615664,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,416,1,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,80620,F,847.0,CHEMBL615665,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,417,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,F,847.0,CHEMBL615666,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,418,1,,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,80620,F,847.0,CHEMBL615667,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,419,1,,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,80620,F,847.0,CHEMBL615668,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,420,1,,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,80620,F,847.0,CHEMBL615669,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,421,1,,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,80620,F,847.0,CHEMBL615670,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,422,1,,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,80620,F,847.0,CHEMBL836739,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,423,1,,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,80620,F,847.0,CHEMBL615671,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,424,1,,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,80620,F,847.0,CHEMBL615672,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,425,1,,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,80620,F,847.0,CHEMBL615791,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,426,1,,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,80620,F,847.0,CHEMBL615792,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,427,1,,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,80620,F,847.0,CHEMBL615793,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,428,1,,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,80620,F,847.0,CHEMBL615794,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,429,1,,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,80620,F,847.0,CHEMBL615795,3LL cell line,16169,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,430,1,,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,80621,F,971.0,CHEMBL615590,3LLD122,15547,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,431,1,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,22226,F,,CHEMBL615591,,8663,,Autocuration,,,0,U,,
,BAO_0000218,,,432,1,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,22226,F,,CHEMBL615592,,8663,,Autocuration,,,0,U,,
,BAO_0000218,,,433,1,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,22226,F,,CHEMBL615593,,8663,,Autocuration,,,0,U,,
,BAO_0000218,,,434,1,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,22226,F,,CHEMBL615594,,8663,,Autocuration,,,0,U,,
,BAO_0000219,,,435,1,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,F,723.0,CHEMBL615595,NIH3T3,4504,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,436,1,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,F,723.0,CHEMBL615596,NIH3T3,4504,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,437,1,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,11169,F,723.0,CHEMBL615597,NIH3T3,12695,,Expert,,,8,H,,
,BAO_0000219,,,438,1,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,80951,F,723.0,CHEMBL615598,NIH3T3,12695,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,439,1,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,80951,F,723.0,CHEMBL615599,NIH3T3,12695,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,440,1,,,Effective dose against murine 3T3 fibroblasts cells,80951,F,723.0,CHEMBL615600,NIH3T3,17642,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,441,1,,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,80951,F,723.0,CHEMBL615601,NIH3T3,17642,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,442,1,,,Cytotoxic effect on 3T3 cells,80951,F,723.0,CHEMBL615602,NIH3T3,12340,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,443,1,,,Cytotoxic effect on 3T3 cells,80951,F,723.0,CHEMBL615603,NIH3T3,12340,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,444,1,,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,80951,F,723.0,CHEMBL615604,NIH3T3,12716,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,445,1,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,F,723.0,CHEMBL615605,NIH3T3,6277,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,446,1,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,80951,F,723.0,CHEMBL615606,NIH3T3,6277,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,447,1,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,80951,F,723.0,CHEMBL884526,NIH3T3,6277,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,448,1,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,80951,F,723.0,CHEMBL615607,NIH3T3,6277,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,449,1,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,80951,F,723.0,CHEMBL615608,NIH3T3,6277,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,450,1,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,80951,F,723.0,CHEMBL615609,NIH3T3,6277,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,451,1,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,80951,F,723.0,CHEMBL615682,NIH3T3,6277,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,452,1,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,80951,F,723.0,CHEMBL615683,NIH3T3,6277,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,453,1,,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,80951,F,723.0,CHEMBL615684,NIH3T3,17780,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,454,1,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,104860,F,,CHEMBL615685,,12751,10090.0,Autocuration,,,7,D,Mus musculus,
,BAO_0000219,,,455,1,,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,80951,F,723.0,CHEMBL615686,NIH3T3,12380,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,456,1,,,Inhibitory activity against 3T3 cell line,80951,F,723.0,CHEMBL615687,NIH3T3,14892,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,457,1,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,80951,F,723.0,CHEMBL884523,NIH3T3,12695,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000019,,,458,1,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,11169,F,,CHEMBL615688,,12695,,Expert,,,8,H,,
,BAO_0000219,,,459,1,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,80951,F,723.0,CHEMBL615689,NIH3T3,12695,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,460,1,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,80951,F,723.0,CHEMBL615690,NIH3T3,12695,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000019,,,461,1,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,11169,F,,CHEMBL615691,,12695,,Expert,,,8,H,,
,BAO_0000019,,,462,1,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,11169,F,,CHEMBL615692,,12695,,Expert,,,8,H,,
,BAO_0000219,,,463,1,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,F,723.0,CHEMBL615693,NIH3T3,6277,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,464,1,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,80951,F,723.0,CHEMBL615324,NIH3T3,6277,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,465,1,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,F,723.0,CHEMBL615325,NIH3T3,4959,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,466,1,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,F,723.0,CHEMBL615490,NIH3T3,4959,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,467,1,,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,188,F,723.0,CHEMBL615491,NIH3T3,4959,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,468,1,,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),188,F,723.0,CHEMBL615492,NIH3T3,4959,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,469,1,,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,80951,F,723.0,CHEMBL615493,NIH3T3,12082,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,470,1,,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,80951,F,723.0,CHEMBL615494,NIH3T3,12082,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,471,1,,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,80951,F,723.0,CHEMBL615495,NIH3T3,12082,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,472,1,,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,80951,F,723.0,CHEMBL615496,NIH3T3,12082,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,473,1,,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,80951,F,723.0,CHEMBL615497,NIH3T3,2643,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,474,1,,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,80951,F,723.0,CHEMBL615498,NIH3T3,11926,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,475,1,,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,80951,A,723.0,CHEMBL615499,NIH3T3,15204,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,476,1,,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,80951,F,723.0,CHEMBL835522,NIH3T3,15992,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,477,1,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,80951,F,723.0,CHEMBL615500,NIH3T3,16279,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,478,1,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,F,723.0,CHEMBL615501,NIH3T3,16279,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,479,1,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,F,723.0,CHEMBL615502,NIH3T3,16279,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,480,1,,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,F,723.0,CHEMBL615503,NIH3T3,16279,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,481,1,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,F,723.0,CHEMBL615504,NIH3T3,16279,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,482,1,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,F,723.0,CHEMBL615505,NIH3T3,16279,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,483,1,,,Inhibition of swiss 3T3 mouse fibroblast proliferation,80951,F,723.0,CHEMBL615506,NIH3T3,12831,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,484,1,,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,80951,F,723.0,CHEMBL615507,NIH3T3,13497,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,485,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,F,620.0,CHEMBL615508,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000219,,,486,1,,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,80006,F,620.0,CHEMBL615509,3T3-L1,13618,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,487,1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,80006,F,620.0,CHEMBL615510,3T3-L1,11902,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,488,1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,80006,F,620.0,CHEMBL615511,3T3-L1,11902,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,489,1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,80006,F,620.0,CHEMBL615512,3T3-L1,11902,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,490,1,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",80006,F,620.0,CHEMBL615513,3T3-L1,14840,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,491,1,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",80006,F,620.0,CHEMBL615514,3T3-L1,14840,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,492,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,80006,F,620.0,CHEMBL615515,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000219,,,493,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,F,620.0,CHEMBL615516,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000219,,,494,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,F,620.0,CHEMBL615517,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000219,,,495,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,F,620.0,CHEMBL615518,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000219,,,496,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,F,620.0,CHEMBL615519,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,497,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,80006,F,620.0,CHEMBL615520,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,498,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,80006,F,620.0,CHEMBL615521,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,499,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,F,620.0,CHEMBL615522,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,500,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,F,620.0,CHEMBL615523,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,501,1,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,F,620.0,CHEMBL615524,3T3-L1,13715,,Expert,,,1,N,,
,BAO_0000218,,,502,1,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,F,620.0,CHEMBL615525,3T3-L1,13715,,Expert,,,1,N,,
,BAO_0000218,,,503,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,F,620.0,CHEMBL615526,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,504,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,F,620.0,CHEMBL615527,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,505,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,80006,F,620.0,CHEMBL615528,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,506,1,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,F,620.0,CHEMBL615529,3T3-L1,13715,,Expert,,,1,N,,
,BAO_0000218,,,507,1,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,F,620.0,CHEMBL615530,3T3-L1,13715,,Expert,,,1,N,,
,BAO_0000218,,,508,1,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,F,620.0,CHEMBL615531,3T3-L1,13715,,Expert,,,1,N,,
,BAO_0000219,,,509,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,F,620.0,CHEMBL615532,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000219,,,510,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,F,620.0,CHEMBL615533,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000219,,,511,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,F,620.0,CHEMBL615534,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,512,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,F,620.0,CHEMBL615535,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,513,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,F,620.0,CHEMBL615536,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,514,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,F,620.0,CHEMBL615537,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,515,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,F,620.0,CHEMBL615538,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000218,,,516,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,F,620.0,CHEMBL836166,3T3-L1,13715,,Intermediate,,,1,N,,
,BAO_0000219,,,517,1,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,11214,F,620.0,CHEMBL615539,3T3-L1,6411,,Expert,,,8,H,,
,BAO_0000219,,,518,1,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,80006,F,620.0,CHEMBL615540,3T3-L1,6411,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,519,1,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,11214,F,620.0,CHEMBL615541,3T3-L1,6411,,Expert,,,8,H,,
,BAO_0000219,,,520,1,,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,80006,F,620.0,CHEMBL615542,3T3-L1,3966,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,521,1,,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,80006,F,620.0,CHEMBL615543,3T3-L1,3966,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,522,1,,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,80006,F,620.0,CHEMBL615544,3T3-L1,15556,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,523,1,,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,F,620.0,CHEMBL615545,3T3-L1,5845,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,524,1,,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,F,620.0,CHEMBL615546,3T3-L1,14422,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,525,1,,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,80006,F,620.0,CHEMBL615547,3T3-L1,5845,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,526,1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,80006,F,620.0,CHEMBL615548,3T3-L1,14508,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,527,1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,80006,F,620.0,CHEMBL615549,3T3-L1,14508,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,528,1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,80006,F,620.0,CHEMBL615550,3T3-L1,14508,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,529,1,,,Inhibitory activity against rat fibroblast (3Y1) cell line,80622,F,1118.0,CHEMBL615551,3Y1 cell line,6349,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,530,1,,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,80622,F,1118.0,CHEMBL615552,3Y1 cell line,15899,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,531,1,,,Cytotoxicity in 3Y1 cells.,80622,F,1118.0,CHEMBL615553,3Y1 cell line,15899,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,532,1,,,Cytostatic effect in 3Y1 cells.,80622,F,1118.0,CHEMBL615554,3Y1 cell line,15899,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,533,1,,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",80622,F,1118.0,CHEMBL615555,3Y1 cell line,15899,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,534,1,,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,80622,F,1118.0,CHEMBL615556,3Y1 cell line,17038,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000019,,,535,1,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,22226,B,,CHEMBL615557,,12421,,Autocuration,,,0,U,,
,BAO_0000019,,,536,1,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,B,,CHEMBL615558,,12947,,Autocuration,,,0,U,,
,BAO_0000019,,,537,1,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,B,,CHEMBL872066,,12947,,Autocuration,,,0,U,,
,BAO_0000019,,,538,1,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,11607,B,,CHEMBL615559,,4896,9823.0,Expert,,,9,D,Sus scrofa,
,BAO_0000019,,,539,1,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,11607,B,,CHEMBL615560,,6148,,Autocuration,,,8,H,,
,BAO_0000019,,,540,1,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,11607,B,,CHEMBL615561,,16432,,Autocuration,,,8,H,,
,BAO_0000019,,,541,1,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,11607,B,,CHEMBL857062,,4978,,Expert,,,8,H,,
,BAO_0000019,,,542,1,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),11607,B,,CHEMBL615562,,4978,,Expert,,,8,H,,
,BAO_0000019,,,543,1,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,11607,B,,CHEMBL615563,,3723,,Autocuration,,,8,H,,
,BAO_0000357,,,544,1,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),11607,B,,CHEMBL615564,,3518,,Autocuration,,,8,H,,
,BAO_0000019,,,545,1,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,11607,B,,CHEMBL615565,,4164,,Autocuration,,,8,H,,
,BAO_0000019,,,546,1,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,11607,B,,CHEMBL615566,,3518,,Autocuration,,,8,H,,
,BAO_0000019,,,547,1,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,11607,B,,CHEMBL615567,,4164,9823.0,Expert,,,9,D,Sus scrofa,
,BAO_0000019,,,548,1,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,11607,B,,CHEMBL615568,,3518,,Autocuration,,,8,H,,
,BAO_0000357,,,549,1,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),11607,B,,CHEMBL615569,,3518,,Autocuration,,,8,H,,
,BAO_0000019,,,550,1,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,11607,B,,CHEMBL615570,,4978,,Autocuration,,,8,H,,
,BAO_0000019,,,551,1,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),11607,B,,CHEMBL615571,,4978,,Autocuration,,,8,H,,
,BAO_0000224,,,552,1,,,Binding affinity against melatonin (MT1) receptor (pC1),104733,B,,CHEMBL615572,,6455,,Autocuration,,,4,H,,
,BAO_0000019,,,553,1,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,22226,B,,CHEMBL615573,,2222,,Autocuration,,,0,U,,
,BAO_0000019,,,554,1,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,22226,B,,CHEMBL615574,,13020,,Autocuration,,,0,U,,
,BAO_0000019,,,555,1,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,22226,B,,CHEMBL615575,,13021,,Autocuration,,,0,U,,
,BAO_0000357,,,556,1,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,10619,B,,CHEMBL615576,,14532,,Autocuration,,,8,H,,
,BAO_0000357,,,557,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10619,B,,CHEMBL615577,,14118,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,558,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,51,B,,CHEMBL615578,,11884,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,559,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615579,,13969,,Expert,,,8,H,,
,BAO_0000357,,,560,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615580,,13392,,Expert,,,8,H,,
,BAO_0000019,,,561,1,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,51,B,,CHEMBL615581,,14430,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,562,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,B,,CHEMBL615582,,12248,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,563,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,B,,CHEMBL615583,,12249,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,564,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,B,,CHEMBL615584,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,565,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,B,,CHEMBL833691,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,566,1,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,B,,CHEMBL615585,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,567,1,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,B,,CHEMBL615586,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,568,1,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,B,,CHEMBL884524,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,569,1,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,B,,CHEMBL615587,,12249,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,570,1,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,B,,CHEMBL615588,,11799,,Autocuration,,,8,H,,10000000.0
,BAO_0000249,,,571,1,,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10576,B,,CHEMBL615589,,14331,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,572,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,51,B,,CHEMBL615442,,11884,9913.0,Expert,,,8,H,Bos taurus,10000000.0
,BAO_0000221,Hippocampus,,573,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,51,B,,CHEMBL615443,,14331,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,574,1,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,51,B,,CHEMBL615444,,11701,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,575,1,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,51,B,,CHEMBL615445,,11701,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,576,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,51,B,,CHEMBL615446,,12248,,Autocuration,,,8,H,,10000000.0
,BAO_0000219,,,577,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,51,B,449.0,CHEMBL615447,CHO,12248,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,578,1,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,B,,CHEMBL615448,,12248,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,579,1,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,B,,CHEMBL615449,,12249,,Expert,,,8,H,,10000000.0
,BAO_0000219,,,580,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,B,449.0,CHEMBL615450,CHO,12248,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,581,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,B,,CHEMBL615451,,11799,,Expert,,,8,H,,10000000.0
,BAO_0000357,,,582,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,B,,CHEMBL615452,,634,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,583,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,B,,CHEMBL615453,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,584,1,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,B,,CHEMBL615454,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,585,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,B,,CHEMBL615455,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,586,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,B,,CHEMBL615456,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,587,1,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,B,,CHEMBL615457,,9995,,Autocuration,,,8,H,,10000000.0
,BAO_0000218,Hippocampus,,588,1,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,51,B,,CHEMBL615458,,12210,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,589,1,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,B,,CHEMBL615459,,13311,,Expert,,,8,H,,10000000.0
,BAO_0000219,,,590,1,,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",51,B,449.0,CHEMBL615460,CHO,2331,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,591,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,51,F,,CHEMBL615461,,1375,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,592,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,51,F,,CHEMBL615462,,1375,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000221,Hippocampus,,593,1,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,51,F,,CHEMBL615463,,11574,10141.0,Autocuration,,,8,H,Cavia porcellus,10000000.0
,BAO_0000221,Ileum,,594,1,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,B,,CHEMBL615464,,12867,10141.0,Autocuration,,,8,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,595,1,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,B,,CHEMBL615465,,12867,10141.0,Autocuration,,,8,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,596,1,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,B,,CHEMBL615466,,12867,10141.0,Autocuration,,,8,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,597,1,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,B,,CHEMBL615467,,12867,10141.0,Autocuration,,,8,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,598,1,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,B,,CHEMBL615468,,12867,10141.0,Autocuration,,,8,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,599,1,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,51,B,,CHEMBL615469,,12867,10141.0,Autocuration,,,8,H,Cavia porcellus,2116.0
,BAO_0000357,,,600,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615470,,11574,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,601,1,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615471,,13114,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,602,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615472,,13181,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000221,Hippocampus,,603,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,B,,CHEMBL883242,,10639,10141.0,Autocuration,,,8,H,Cavia porcellus,10000000.0
,BAO_0000221,Hippocampus,,604,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,F,,CHEMBL615473,,10639,10141.0,Autocuration,,,8,H,Cavia porcellus,10000000.0
,BAO_0000218,,,605,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11863,B,449.0,CHEMBL615474,CHO,11883,10029.0,Autocuration,,,8,H,Cricetulus griseus,
,BAO_0000357,,,606,1,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615475,,17785,,Autocuration,,,8,H,,
,BAO_0000219,,,607,1,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,51,F,308.0,CHEMBL615476,HeLa,1558,,Autocuration,,,8,H,,
,BAO_0000219,,,608,1,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,51,F,308.0,CHEMBL615477,HeLa,1558,,Autocuration,,,8,H,,
,BAO_0000019,,,609,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,51,F,,CHEMBL615478,,15740,,Autocuration,,,8,H,,
,BAO_0000219,,,610,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,F,449.0,CHEMBL615160,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,611,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,F,449.0,CHEMBL615161,CHO,17624,,Expert,,,8,H,,
,BAO_0000219,,,612,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,51,F,449.0,CHEMBL615162,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,613,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,51,F,449.0,CHEMBL615163,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,614,1,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,B,449.0,CHEMBL615164,CHO,17624,,Expert,,,8,H,,
,BAO_0000219,,,615,1,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,B,449.0,CHEMBL615165,CHO,17624,,Expert,,,8,H,,
,BAO_0000219,,,616,1,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,51,B,449.0,CHEMBL615166,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,617,1,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,51,F,,CHEMBL615167,,14256,,Autocuration,,,8,H,,
,BAO_0000219,,,618,1,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,B,308.0,CHEMBL615168,HeLa,3445,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,619,1,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,51,B,308.0,CHEMBL615169,HeLa,3445,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,620,1,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,51,B,449.0,CHEMBL615170,CHO,17200,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,621,1,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,B,449.0,CHEMBL615171,CHO,17200,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,622,1,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,F,,CHEMBL615694,,15180,,Autocuration,,,8,H,,
,BAO_0000019,,,623,1,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,F,,CHEMBL615695,,15180,,Autocuration,,,8,H,,
,BAO_0000019,,,624,1,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,F,,CHEMBL615696,,16026,,Autocuration,,,8,H,,
,BAO_0000219,,,625,1,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,F,449.0,CHEMBL615697,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000219,,,626,1,,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,F,449.0,CHEMBL859410,CHO,2759,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,627,1,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,F,449.0,CHEMBL615841,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000219,,,628,1,,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,F,449.0,CHEMBL615842,CHO,2759,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,629,1,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,F,449.0,CHEMBL835003,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000219,,,630,1,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),51,F,449.0,CHEMBL615843,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000219,,,631,1,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,F,449.0,CHEMBL615979,CHO,2759,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,632,1,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,F,449.0,CHEMBL615980,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000219,,,633,1,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,F,449.0,CHEMBL615981,CHO,2759,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,634,1,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,51,F,,CHEMBL615982,,3445,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,635,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,F,,CHEMBL615983,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,636,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",51,F,,CHEMBL615984,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,637,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",51,F,,CHEMBL615985,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,638,1,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,F,449.0,CHEMBL615986,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,639,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,F,449.0,CHEMBL615987,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,640,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,F,449.0,CHEMBL615988,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,641,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,F,449.0,CHEMBL615989,CHO,17624,,Expert,,,8,H,,
,BAO_0000219,,,642,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,F,449.0,CHEMBL615990,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,643,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,51,F,449.0,CHEMBL615991,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,644,1,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,F,449.0,CHEMBL615992,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,645,1,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,F,449.0,CHEMBL615993,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,646,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,F,449.0,CHEMBL615994,CHO,17624,,Expert,,,8,H,,
,BAO_0000219,,,647,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,51,F,449.0,CHEMBL615995,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,648,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,F,449.0,CHEMBL615996,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,649,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,F,449.0,CHEMBL615997,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000019,,,650,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,F,,CHEMBL615998,,6563,,Autocuration,,,8,H,,
,BAO_0000019,,,651,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,F,,CHEMBL615999,,6563,,Autocuration,,,8,H,,
,BAO_0000019,,,652,1,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,F,,CHEMBL616000,,6563,,Autocuration,,,8,H,,
,BAO_0000219,,,653,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,F,722.0,CHEMBL616001,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000019,,,654,1,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",51,F,,CHEMBL616002,,6876,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,655,1,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",51,F,,CHEMBL616003,,6876,,Expert,,,8,H,,
,BAO_0000019,,,656,1,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,51,F,,CHEMBL616004,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,657,1,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,51,F,,CHEMBL616005,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,658,1,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,F,,CHEMBL616006,,5548,,Autocuration,,,8,H,,
,BAO_0000019,,,659,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",51,F,,CHEMBL616007,,5548,,Expert,,,8,H,,
,BAO_0000019,,,660,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,F,,CHEMBL616008,,5548,,Autocuration,,,8,H,,
,BAO_0000019,,,661,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,F,,CHEMBL616009,,5548,,Autocuration,,,8,H,,
,BAO_0000019,,,662,1,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",51,F,,CHEMBL616010,,5929,,Expert,,,8,H,,
,BAO_0000019,,,663,1,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",51,F,,CHEMBL616011,,5929,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,664,1,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",51,F,,CHEMBL615740,,5929,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,665,1,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",51,F,,CHEMBL615741,,16245,,Autocuration,,,8,H,,
,BAO_0000019,,,666,1,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,F,,CHEMBL615742,,5640,,Expert,,,8,H,,
,BAO_0000019,,,667,1,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",51,F,,CHEMBL615743,,5640,,Autocuration,,,8,H,,
,BAO_0000219,,,668,1,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,51,F,449.0,CHEMBL615744,CHO,14509,,Autocuration,,,8,H,,
,BAO_0000219,,,669,1,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,51,F,449.0,CHEMBL615745,CHO,14509,,Expert,,,8,H,,
,BAO_0000357,,,670,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,B,,CHEMBL615746,,15331,,Autocuration,,,8,H,,
,BAO_0000357,,,671,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,B,,CHEMBL615747,,15331,,Autocuration,,,8,H,,
,BAO_0000019,,,672,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,F,,CHEMBL615748,,6563,,Autocuration,,,8,H,,
,BAO_0000019,,,673,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",51,F,,CHEMBL615749,,6563,,Autocuration,,,8,H,,
,BAO_0000019,,,674,1,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,F,,CHEMBL615750,,6563,,Autocuration,,,8,H,,
,BAO_0000019,,,675,1,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,51,F,,CHEMBL616259,,6563,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,676,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,F,,CHEMBL616260,,6563,,Autocuration,,,8,H,,
,BAO_0000019,,,677,1,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,51,F,,CHEMBL616261,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,678,1,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,F,,CHEMBL616262,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,679,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,F,,CHEMBL616263,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,680,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,51,F,,CHEMBL616264,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,681,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,51,F,,CHEMBL616265,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,682,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,F,,CHEMBL616266,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,683,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,F,,CHEMBL616267,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,684,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,51,F,,CHEMBL616268,,5272,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,685,1,,,Inhibition of human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616269,,16146,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,686,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,B,449.0,CHEMBL884528,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,687,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,105,B,722.0,CHEMBL616270,HEK293,13706,,Expert,,,9,D,,
,BAO_0000219,,,688,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,51,B,449.0,CHEMBL616271,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000219,,,689,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,F,449.0,CHEMBL616272,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000357,,,690,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,51,B,,CHEMBL616273,,6861,,Expert,,,8,H,,
,BAO_0000357,,,691,1,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616274,,17200,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,692,1,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,51,B,449.0,CHEMBL616275,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,693,1,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,B,449.0,CHEMBL616276,CHO,17624,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,694,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,F,,CHEMBL616277,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,695,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,22226,F,,CHEMBL616278,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,696,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,22226,F,,CHEMBL616279,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,697,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,F,,CHEMBL616280,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,698,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,22226,F,,CHEMBL616281,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,699,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,F,,CHEMBL616282,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,700,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,22226,F,,CHEMBL616283,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,701,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,22226,F,,CHEMBL616284,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,702,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,22226,F,,CHEMBL616285,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,703,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,22226,F,,CHEMBL616286,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,704,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,22226,F,,CHEMBL616287,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,705,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,22226,F,,CHEMBL616288,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,706,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,22226,F,,CHEMBL616289,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,707,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,22226,F,,CHEMBL615610,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,708,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,22226,F,,CHEMBL615611,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,709,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,22226,F,,CHEMBL615612,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,710,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,22226,F,,CHEMBL615613,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,711,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,22226,F,,CHEMBL615614,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,712,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,F,,CHEMBL615615,,12058,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,713,1,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,105093,B,,CHEMBL615616,,11440,,Autocuration,,,4,H,,
,BAO_0000249,Hypothalamus,,714,1,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,11923,B,,CHEMBL615617,,6238,,Autocuration,,,8,H,,1898.0
,BAO_0000019,,,715,1,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10577,B,,CHEMBL615618,,10046,,Autocuration,,,8,H,,
,BAO_0000019,,,716,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10577,B,,CHEMBL615619,,10046,,Autocuration,,,8,H,,
,BAO_0000019,,,717,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,B,,CHEMBL615620,,10046,,Expert,,,8,H,,
,BAO_0000357,,,718,1,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",55,B,,CHEMBL615621,,167,,Autocuration,,,8,H,,
,BAO_0000357,,,719,1,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",55,B,,CHEMBL615622,,167,,Autocuration,,,8,H,,
,BAO_0000019,,,720,1,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),12166,F,,CHEMBL615623,,11520,,Autocuration,,,8,H,,
,BAO_0000019,,,721,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,F,,CHEMBL615624,,11520,,Autocuration,,,8,H,,
,BAO_0000019,,,722,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,F,,CHEMBL615625,,11520,,Autocuration,,,8,H,,
,BAO_0000019,,,723,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,F,,CHEMBL767045,,11520,,Autocuration,,,8,H,,
,BAO_0000019,,,724,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,55,F,,CHEMBL615626,,135,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,725,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,55,F,,CHEMBL615627,,135,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,726,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,55,B,,CHEMBL615628,,11311,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,727,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,B,,CHEMBL615629,,10193,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,728,1,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,55,B,,CHEMBL615630,,12281,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,729,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,B,,CHEMBL615631,,11311,,Autocuration,,,8,H,,
,BAO_0000218,,,730,1,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,F,,CHEMBL615632,,12576,,Autocuration,,,8,H,,
,BAO_0000357,,,731,1,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,17087,B,,CHEMBL615633,,12281,,Autocuration,,,8,H,,
,BAO_0000218,,,732,1,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,F,,CHEMBL615634,,12576,,Autocuration,,,8,H,,
,BAO_0000019,,,733,1,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,B,,CHEMBL615635,,11089,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000357,,,734,1,,,In vitro inhibition of rat 5-Lipoxygenase,12166,B,,CHEMBL615636,,11006,,Expert,,,8,H,,
,BAO_0000357,,,735,1,,,Inhibitory activity against 5-Lipoxygenase,12166,B,,CHEMBL615637,,11481,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,736,1,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,12166,B,702.0,CHEMBL615638,RBL-1,10864,,Expert,,,8,H,,
,BAO_0000219,,,737,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,B,702.0,CHEMBL615639,RBL-1,3595,,Autocuration,,,8,H,,
,BAO_0000219,,,738,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,12166,B,702.0,CHEMBL615640,RBL-1,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,739,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,12166,B,,CHEMBL615796,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,740,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],12166,B,,CHEMBL615845,,11311,,Autocuration,,,8,H,,
,BAO_0000357,,,741,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,B,,CHEMBL615846,,11006,,Autocuration,,,8,H,,
,BAO_0000219,,,742,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,B,702.0,CHEMBL615847,RBL-1,3595,,Autocuration,,,8,H,,
,BAO_0000357,,,743,1,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,12166,B,,CHEMBL615848,,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,744,1,,,Ratio of IC50 against 5-LO and COX,22226,B,,CHEMBL615849,,11481,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000357,,,745,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,B,,CHEMBL615850,,11006,,Autocuration,,,8,H,,
,BAO_0000357,,,746,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,12166,B,,CHEMBL615851,,11006,,Autocuration,,,8,H,,
,BAO_0000219,,,747,1,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,12166,B,,CHEMBL615852,,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,748,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,12166,F,,CHEMBL615853,,11006,,Autocuration,,,8,H,,
,BAO_0000357,Prostate gland,,749,1,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,120,B,,CHEMBL884527,,4288,,Autocuration,,,8,H,,2367.0
,BAO_0000019,,,750,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,22226,B,,CHEMBL872871,,7587,8932.0,Autocuration,,,0,U,Columba livia,
,BAO_0000019,,,751,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,22226,B,,CHEMBL615854,,7587,8932.0,Autocuration,,,0,U,Columba livia,
,BAO_0000019,,,752,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,22226,B,,CHEMBL767046,,7587,8932.0,Autocuration,,,0,U,Columba livia,
,BAO_0000357,,,753,1,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,10732,B,,CHEMBL615855,,11249,,Autocuration,,,8,H,,
,BAO_0000019,,,754,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,12198,F,,CHEMBL615856,,8003,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,755,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,F,,CHEMBL615857,,8003,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,756,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,F,,CHEMBL615858,,8003,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,757,1,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,B,,CHEMBL615859,,12416,,Expert,,,8,H,,10000000.0
,BAO_0000357,,,758,1,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,51,B,,CHEMBL615860,,16293,,Autocuration,,,8,H,,
,BAO_0000019,,,759,1,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,B,,CHEMBL615861,,13047,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000019,,,760,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,B,,CHEMBL615862,,13047,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000019,,,761,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,22226,B,,CHEMBL615863,,13047,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000019,,,762,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,22226,B,,CHEMBL615864,,13047,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000221,Hippocampus,,763,1,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,B,,CHEMBL615865,,10085,,Autocuration,,,4,H,,10000000.0
,BAO_0000221,Hippocampus,,764,1,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,B,,CHEMBL615866,,10085,,Autocuration,,,4,H,,10000000.0
,BAO_0000221,Hippocampus,,765,1,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,B,,CHEMBL615867,,10085,,Autocuration,,,4,H,,10000000.0
,BAO_0000249,,,766,1,,Membranes,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,104744,B,,CHEMBL615868,,9841,,Autocuration,,,4,H,,
,BAO_0000249,,,767,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,104744,B,,CHEMBL615869,,8822,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,768,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,104744,B,,CHEMBL615870,,9806,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,769,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,104744,B,,CHEMBL615871,,9806,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,770,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,104744,B,,CHEMBL615872,,8868,,Autocuration,,,4,H,,
,BAO_0000221,Hippocampus,,771,1,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,104744,B,,CHEMBL833492,,9036,,Autocuration,,,4,H,,10000000.0
,BAO_0000221,Hippocampus,,772,1,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,104744,B,,CHEMBL615873,,11374,,Autocuration,,,4,H,,10000000.0
,BAO_0000224,,,773,1,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,104744,B,,CHEMBL615479,,10881,,Autocuration,,,4,H,,
,BAO_0000019,,,774,1,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,104744,B,,CHEMBL615480,,8822,,Autocuration,,,4,H,,
,BAO_0000249,,,775,1,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,104744,B,,CHEMBL615481,,9806,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,776,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,B,,CHEMBL872869,,15463,,Autocuration,,,4,H,,
,BAO_0000019,,,777,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,B,,CHEMBL615482,,15463,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,778,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,B,,CHEMBL615483,,14542,,Autocuration,,,4,H,,955.0
,BAO_0000221,Brain,,779,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,B,,CHEMBL615484,,14542,,Autocuration,,,4,H,,955.0
,BAO_0000019,,,780,1,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,104744,B,,CHEMBL615485,,8569,,Autocuration,,,4,H,,
,BAO_0000224,,,781,1,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,104744,B,,CHEMBL615486,,10062,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,782,1,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,104744,B,,CHEMBL615487,,4771,,Autocuration,,,4,H,,
,BAO_0000224,,,783,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,B,,CHEMBL615488,,10062,,Autocuration,,,4,H,,
,BAO_0000224,,,784,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,B,,CHEMBL615489,,10062,,Autocuration,,,4,H,,
,BAO_0000224,,,785,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,B,,CHEMBL615389,,10062,,Autocuration,,,4,H,,
,BAO_0000019,,,786,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,B,,CHEMBL615390,,15463,,Autocuration,,,4,H,,
,BAO_0000019,,,787,1,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,B,,CHEMBL615391,,15463,,Autocuration,,,4,H,,
,BAO_0000224,,,788,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,104744,B,,CHEMBL615392,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,789,1,,,Affinity for 5-hydroxytryptamine 1 receptor,22226,B,,CHEMBL615393,,3070,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000221,Brain,,790,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,104744,B,,CHEMBL615394,,14542,,Autocuration,,,4,H,,955.0
,BAO_0000221,Brain,,791,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,B,,CHEMBL615395,,14542,,Autocuration,,,4,H,,955.0
,BAO_0000224,,,792,1,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,104744,B,,CHEMBL615396,,6398,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,793,1,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,104744,B,,CHEMBL615397,,1344,,Autocuration,,,4,H,,955.0
,BAO_0000019,,,794,1,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,B,,CHEMBL615398,,11963,,Autocuration,,,4,H,,
,BAO_0000019,,,795,1,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,22226,B,,CHEMBL615399,,8908,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,796,1,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,104744,B,,CHEMBL615400,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,797,1,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,104744,B,,CHEMBL615401,,8841,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,798,1,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,22226,B,,CHEMBL615402,,8814,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,799,1,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,104744,B,,CHEMBL615403,,11752,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,800,1,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,104744,B,,CHEMBL615404,,11642,,Autocuration,,,4,H,,955.0
,BAO_0000019,,,801,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,104744,B,,CHEMBL615781,,11642,,Autocuration,,,4,H,,
,BAO_0000220,Brain,,802,1,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,104744,B,,CHEMBL615782,,9231,,Autocuration,,,4,H,,955.0
,BAO_0000221,Brain,,803,1,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,104744,B,,CHEMBL615783,,11351,,Autocuration,,,4,H,,955.0
,BAO_0000019,,,804,1,,,Compound was tested for binding affinity against 5-HT1 receptor,22226,B,,CHEMBL873481,,4639,,Autocuration,,,0,U,,
,BAO_0000019,,,805,1,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,22226,B,,CHEMBL615784,,1205,,Autocuration,,,0,U,,
,BAO_0000357,,,806,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,B,,CHEMBL615785,,10025,,Expert,,,8,H,,
,BAO_0000249,,,807,1,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,F,,CHEMBL615786,,13241,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,808,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,F,,CHEMBL615787,,16245,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,809,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,F,,CHEMBL615788,,16245,,Autocuration,,,8,H,,
,BAO_0000019,,,810,1,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,10576,F,,CHEMBL767044,,12438,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,811,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,F,,CHEMBL615789,,16245,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,812,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,F,,CHEMBL615790,,16245,,Autocuration,,,8,H,,
,BAO_0000019,,,813,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,10576,F,,CHEMBL615813,,15740,,Autocuration,,,8,H,,
,BAO_0000219,,,814,1,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,10576,F,,CHEMBL615814,,15535,,Autocuration,,,8,H,,
,BAO_0000219,,,815,1,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,51,F,,CHEMBL615815,,15535,,Expert,,,8,H,,
,BAO_0000219,,,816,1,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,10576,F,,CHEMBL615816,,15535,,Autocuration,,,8,H,,
,BAO_0000249,,,817,1,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,10576,B,,CHEMBL615817,,9888,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,818,1,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10576,B,,CHEMBL615818,,10085,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,819,1,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10576,B,,CHEMBL615819,,10085,,Autocuration,,,8,H,,10000000.0
,BAO_0000249,,,820,1,,Membranes,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,10576,B,,CHEMBL615820,,17331,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,821,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10576,B,,CHEMBL615821,,10845,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,822,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,B,,CHEMBL615822,,10845,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,823,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL615823,,10845,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,824,1,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10576,B,,CHEMBL615824,,10845,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,825,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,B,,CHEMBL615825,,10845,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000357,,,826,1,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL615826,,13730,,Expert,,,8,H,,
,BAO_0000249,,,827,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL615827,,13508,,Expert,,,8,H,,
,BAO_0000249,Hippocampus,,828,1,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL615828,,13508,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,829,1,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL615829,,12073,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,830,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL615830,,4671,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,831,1,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10576,B,,CHEMBL615831,,13631,,Expert,,,8,H,,10000000.0
,BAO_0000357,,,832,1,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL615832,,12438,,Autocuration,,,8,H,,
,BAO_0000019,,,833,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10576,B,,CHEMBL615833,,10483,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,834,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10576,B,,CHEMBL615834,,10483,,Autocuration,,,8,H,,10000000.0
,BAO_0000249,,,835,1,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,10576,B,,CHEMBL615835,,12352,,Intermediate,,,8,H,,
,BAO_0000249,Hippocampus,,836,1,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10576,B,,CHEMBL615836,,14732,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,837,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10576,B,,CHEMBL615837,,11049,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,838,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10576,B,,CHEMBL615838,,11049,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,839,1,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",10576,B,,CHEMBL615839,,13657,,Expert,,,8,H,,
,BAO_0000019,,,840,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,10576,B,,CHEMBL884525,,11473,,Autocuration,,,8,H,,
,BAO_0000249,,,841,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,B,,CHEMBL615840,,2014,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,842,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL615405,,3086,,Expert,,,8,H,,10000000.0
,BAO_0000019,,,843,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10576,B,,CHEMBL615406,,15854,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,844,1,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,B,,CHEMBL615900,,10922,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,845,1,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10576,B,,CHEMBL615901,,13346,,Expert,,,8,H,,10000000.0
,BAO_0000357,,,846,1,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,10576,B,,CHEMBL615902,,15311,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,847,1,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,B,,CHEMBL615903,,10922,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,848,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10576,B,,CHEMBL615904,,10025,,Autocuration,,,8,H,,
,BAO_0000357,,,849,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,B,,CHEMBL615905,,10025,,Expert,,,8,H,,
,BAO_0000019,,,850,1,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,B,,CHEMBL615906,,9742,,Autocuration,,,8,H,,
,BAO_0000019,,,851,1,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,F,,CHEMBL615907,,9742,,Autocuration,,,8,H,,
,BAO_0000019,,,852,1,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,B,,CHEMBL615908,,12304,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,853,1,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10576,B,,CHEMBL615909,,15789,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,854,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",10576,B,,CHEMBL615910,,9912,,Autocuration,,,8,H,,
,BAO_0000019,,,855,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",10576,B,,CHEMBL615911,,9912,,Autocuration,,,8,H,,
,BAO_0000019,,,856,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",10576,B,,CHEMBL615912,,9912,,Autocuration,,,8,H,,
,BAO_0000019,,,857,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL615913,,16693,,Expert,,,8,H,,
,BAO_0000357,,,858,1,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,B,,CHEMBL615914,,13276,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,859,1,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,B,,CHEMBL615915,,12678,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,860,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,10576,B,,CHEMBL615916,,11825,,Autocuration,,,8,H,,
,BAO_0000357,,,861,1,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,10576,B,,CHEMBL615917,,12443,,Expert,,,8,H,,
,BAO_0000357,,,862,1,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL615918,,13830,,Expert,,,8,H,,
,BAO_0000249,Hippocampus,,863,1,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10576,B,,CHEMBL615919,,14286,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,864,1,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,B,,CHEMBL615920,,14356,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000357,,,865,1,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL615921,,15306,,Autocuration,,,8,H,,
,BAO_0000357,,,866,1,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),10576,B,,CHEMBL615922,,15306,,Expert,,,8,H,,
,BAO_0000249,,,867,1,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,F,,CHEMBL881290,,16616,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,868,1,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10576,B,,CHEMBL615923,,3651,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,869,1,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,F,,CHEMBL615924,,14331,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,870,1,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,F,,CHEMBL615925,,14331,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,871,1,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL615926,,14178,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,872,1,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL615927,,10639,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,873,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,B,,CHEMBL615928,,12306,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,874,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10576,B,,CHEMBL615929,,1348,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,875,1,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10576,B,,CHEMBL615930,,13605,,Autocuration,,,8,H,,10000000.0
,BAO_0000219,,,876,1,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,B,449.0,CHEMBL615931,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,877,1,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,F,449.0,CHEMBL615932,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000219,,,878,1,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,F,449.0,CHEMBL615933,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000357,,,879,1,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615934,,15267,,Autocuration,,,8,H,,
,BAO_0000357,,,880,1,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,51,B,,CHEMBL615935,,16532,,Autocuration,,,8,H,,
,BAO_0000019,,,881,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,F,,CHEMBL615936,,6563,,Autocuration,,,8,H,,
,BAO_0000219,,,882,1,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,51,B,449.0,CHEMBL615937,CHO,4751,,Autocuration,,,8,H,,
,BAO_0000357,,,883,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615938,,15463,,Autocuration,,,8,H,,
,BAO_0000357,,,884,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),51,B,,CHEMBL615797,,3805,,Autocuration,,,8,H,,
,BAO_0000357,,,885,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615798,,5640,,Autocuration,,,8,H,,
,BAO_0000357,,,886,1,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,51,B,,CHEMBL872870,,6563,,Autocuration,,,8,H,,
,BAO_0000357,,,887,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,51,B,,CHEMBL615799,,5548,,Autocuration,,,8,H,,
,BAO_0000357,,,888,1,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615800,,6347,,Autocuration,,,8,H,,
,BAO_0000219,,,889,1,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,F,722.0,CHEMBL615801,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000019,,,890,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,51,B,,CHEMBL615802,,13047,,Autocuration,,,8,H,,
,BAO_0000357,,,891,1,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,51,B,,CHEMBL615803,,15740,,Autocuration,,,8,H,,
,BAO_0000019,,,892,1,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,F,,CHEMBL835002,,5640,,Expert,,,8,H,,
,BAO_0000019,,,893,1,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",51,F,,CHEMBL615804,,5640,,Autocuration,,,8,H,,
,BAO_0000219,,,894,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,51,B,308.0,CHEMBL615805,HeLa,17211,,Expert,,,8,H,,
,BAO_0000219,,,895,1,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,51,B,449.0,CHEMBL615806,CHO,4751,,Autocuration,,,8,H,,
,BAO_0000357,,,896,1,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,51,B,,CHEMBL615807,,6491,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,897,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,51,B,,CHEMBL615808,,4707,,Autocuration,,,8,H,,
,BAO_0000357,,,898,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615809,,13910,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,899,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,51,B,308.0,CHEMBL615810,HeLa,16190,,Autocuration,,,8,H,,
,BAO_0000357,,,900,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615811,,16633,,Autocuration,,,8,H,,
,BAO_0000219,,,901,1,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,51,B,449.0,CHEMBL615812,CHO,11898,,Autocuration,,,8,H,,
,BAO_0000219,,,902,1,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,B,449.0,CHEMBL615751,CHO,11898,,Autocuration,,,8,H,,
,BAO_0000357,,,903,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615752,,14331,,Autocuration,,,8,H,,
,BAO_0000219,,,904,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,51,B,449.0,CHEMBL615753,CHO,17624,,Expert,,,8,H,,
,BAO_0000219,,,905,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,51,B,449.0,CHEMBL615754,CHO,17624,,Autocuration,,,8,H,,
,BAO_0000357,,,906,1,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615755,,3307,,Autocuration,,,8,H,,
,BAO_0000219,,,907,1,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,B,449.0,CHEMBL615756,CHO,6563,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,908,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615757,,14165,,Autocuration,,,8,H,,
,BAO_0000357,,,909,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,B,,CHEMBL615758,,5732,,Autocuration,,,8,H,,
,BAO_0000357,,,910,1,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,B,,CHEMBL615759,,13366,,Expert,,,8,H,,
,BAO_0000357,,,911,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615760,,17626,,Autocuration,,,8,H,,
,BAO_0000219,,,912,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,51,B,308.0,CHEMBL615761,HeLa,6588,,Expert,,,8,H,,
,BAO_0000357,,,913,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,51,B,,CHEMBL872104,,16209,,Autocuration,,,8,H,,
,BAO_0000357,,,914,1,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615762,,15463,,Autocuration,,,8,H,,
,BAO_0000357,,,915,1,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615763,,15463,,Autocuration,,,8,H,,
,BAO_0000357,,,916,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,51,B,,CHEMBL615764,,14770,,Autocuration,,,8,H,,
,BAO_0000219,,,917,1,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),51,B,1167.0,CHEMBL615765,Cell line,16245,,Autocuration,,,8,H,,
,BAO_0000019,,,918,1,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),51,B,,CHEMBL615766,,16245,,Autocuration,,,8,H,,
,BAO_0000357,,,919,1,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615767,,5548,,Autocuration,,,8,H,,
,BAO_0000357,,,920,1,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615768,,5548,,Expert,,,8,H,,
,BAO_0000357,,,921,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615769,,5548,,Autocuration,,,8,H,,
,BAO_0000357,,,922,1,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,51,B,,CHEMBL615770,,6876,,Expert,,,8,H,,
,BAO_0000357,,,923,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615771,,2598,,Autocuration,,,8,H,,
,BAO_0000357,,,924,1,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,51,B,,CHEMBL615772,,17785,,Expert,,,8,H,,
,BAO_0000357,,,925,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL615773,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,926,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615774,,5929,,Expert,,,8,H,,
,BAO_0000357,,,927,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615775,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,928,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,B,,CHEMBL615776,,1558,,Autocuration,,,8,H,,
,BAO_0000357,,,929,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL615777,,16026,,Expert,,,8,H,,
,BAO_0000219,,,930,1,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,51,B,,CHEMBL615778,,12469,,Autocuration,,,8,H,,
,BAO_0000357,,,931,1,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,B,,CHEMBL615779,,15874,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,932,1,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,B,,CHEMBL615780,,15874,,Autocuration,,,8,H,,
,BAO_0000357,,,933,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616298,,3935,,Autocuration,,,8,H,,
,BAO_0000357,,,934,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616299,,15818,,Autocuration,,,8,H,,
,BAO_0000219,,,935,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,51,B,485.0,CHEMBL616300,CHO-K1,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,936,1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,51,F,485.0,CHEMBL616301,CHO-K1,13729,,Expert,,,8,H,,
,BAO_0000019,,,937,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616302,,15413,,Autocuration,,,8,H,,
,BAO_0000019,,,938,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),51,B,,CHEMBL616117,,15413,,Autocuration,,,8,H,,
,BAO_0000019,,,939,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),51,B,,CHEMBL616118,,15413,,Autocuration,,,8,H,,
,BAO_0000019,,,940,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,51,B,,CHEMBL616119,,15413,,Autocuration,,,8,H,,
,BAO_0000219,,,941,1,,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,B,308.0,CHEMBL616120,HeLa,3445,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,942,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616121,,15740,,Autocuration,,,8,H,,
,BAO_0000357,,,943,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,51,B,,CHEMBL616122,,15740,,Autocuration,,,8,H,,
,BAO_0000357,,,944,1,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616123,,17626,,Autocuration,,,8,H,,
,BAO_0000357,,,945,1,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616124,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,946,1,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,B,,CHEMBL616125,,5640,,Expert,,,8,H,,
,BAO_0000357,,,947,1,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,51,B,,CHEMBL616126,,5272,10116.0,Expert,,,8,H,Rattus norvegicus,
,BAO_0000219,,,948,1,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,51,B,449.0,CHEMBL616127,CHO,4622,,Autocuration,,,8,H,,
,BAO_0000019,,,949,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616128,,17085,,Expert,,,8,H,,
,BAO_0000357,,,950,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,B,,CHEMBL616129,,3025,,Autocuration,,,8,H,,
,BAO_0000357,,,951,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616130,,15315,,Expert,,,8,H,,
,BAO_0000357,,,952,1,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,51,B,,CHEMBL616131,,15267,,Autocuration,,,8,H,,
,BAO_0000219,,,953,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,51,B,308.0,CHEMBL616132,HeLa,17158,,Autocuration,,,8,H,,
,BAO_0000219,,,954,1,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,51,B,308.0,CHEMBL616133,HeLa,14214,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,955,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL616134,,17133,,Autocuration,,,8,H,,
,BAO_0000357,,,956,1,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,51,B,,CHEMBL616135,,16532,,Autocuration,,,8,H,,
,BAO_0000357,,,957,1,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,51,B,,CHEMBL616136,,2391,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,958,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,51,B,,CHEMBL616137,,14447,,Autocuration,,,8,H,,
,BAO_0000019,,,959,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,51,B,,CHEMBL872105,,14447,,Autocuration,,,8,H,,
,BAO_0000357,,,960,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,51,B,,CHEMBL616138,,15086,,Autocuration,,,8,H,,
,BAO_0000357,,,961,1,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616139,,13051,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,962,1,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",51,F,,CHEMBL616140,,16026,,Autocuration,,,8,H,,
,BAO_0000019,,,963,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,51,B,,CHEMBL616141,,17085,,Expert,,,8,H,,
,BAO_0000357,,,964,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL616142,,17133,,Autocuration,,,8,H,,
,BAO_0000357,,,965,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,51,B,,CHEMBL616143,,17133,,Autocuration,,,8,H,,
,BAO_0000219,,,966,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,B,308.0,CHEMBL616144,HeLa,17211,,Autocuration,,,8,H,,
,BAO_0000219,,,967,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,51,B,308.0,CHEMBL616145,HeLa,17211,,Autocuration,,,8,H,,
,BAO_0000219,,,968,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,B,308.0,CHEMBL616012,HeLa,17211,,Autocuration,,,8,H,,
,BAO_0000219,,,969,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,B,308.0,CHEMBL616013,HeLa,17211,,Autocuration,,,8,H,,
,BAO_0000019,,,970,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,F,,CHEMBL616014,,16394,,Autocuration,,,8,H,,
,BAO_0000019,,,971,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,F,,CHEMBL616015,,16394,,Autocuration,,,8,H,,
,BAO_0000019,,,972,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,F,,CHEMBL616016,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,973,1,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,51,F,,CHEMBL616017,,16394,,Autocuration,,,8,H,,
,BAO_0000019,,,974,1,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,51,B,,CHEMBL616018,,16394,,Autocuration,,,8,H,,
,BAO_0000019,,,975,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,51,F,,CHEMBL616019,,15740,,Autocuration,,,8,H,,
,BAO_0000019,,,976,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,51,F,,CHEMBL616020,,15740,,Autocuration,,,8,H,,
,BAO_0000357,,,977,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL858018,,15740,,Autocuration,,,8,H,,
,BAO_0000219,,,978,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,F,722.0,CHEMBL616021,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000019,,,979,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",51,F,,CHEMBL616022,,5640,,Expert,,,8,H,,
,BAO_0000019,,,980,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",51,F,,CHEMBL616023,,5640,,Autocuration,,,8,H,,
,BAO_0000019,,,981,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",51,F,,CHEMBL616024,,5640,,Autocuration,,,8,H,,
,BAO_0000019,,,982,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",51,F,,CHEMBL616025,,5640,,Autocuration,,,8,H,,
,BAO_0000219,,,983,1,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,F,449.0,CHEMBL616026,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000019,,,984,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",51,F,,CHEMBL616027,,16394,,Autocuration,,,8,H,,
,BAO_0000019,,,985,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",51,F,,CHEMBL616028,,16394,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,986,1,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,51,F,,CHEMBL616029,,3445,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,987,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,51,B,449.0,CHEMBL616030,CHO,4316,,Expert,,,8,H,,
,BAO_0000019,,,988,1,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,51,B,,CHEMBL616031,,4316,,Expert,,,8,H,,
,BAO_0000019,,,989,1,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,F,,CHEMBL616032,,15180,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,990,1,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,F,,CHEMBL616033,,15180,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,991,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,F,,CHEMBL616034,,15042,,Autocuration,,,8,H,,
,BAO_0000019,,,992,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,F,,CHEMBL616035,,15042,,Autocuration,,,8,H,,
,BAO_0000019,,,993,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,F,,CHEMBL616036,,15042,,Autocuration,,,8,H,,
,BAO_0000019,,,994,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,F,,CHEMBL616037,,15042,,Autocuration,,,8,H,,
,BAO_0000019,,,995,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,F,,CHEMBL616038,,15042,,Autocuration,,,8,H,,
,BAO_0000019,,,996,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,F,,CHEMBL616039,,15042,,Autocuration,,,8,H,,
,BAO_0000019,,,997,1,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,F,,CHEMBL616040,,15042,,Autocuration,,,8,H,,
,BAO_0000219,,,998,1,,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,F,308.0,CHEMBL616041,HeLa,15180,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,999,1,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,F,308.0,CHEMBL616042,HeLa,15180,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1000,1,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,F,308.0,CHEMBL616043,HeLa,15180,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,1001,1,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",51,F,,CHEMBL616044,,16245,,Autocuration,,,8,H,,
,BAO_0000019,,,1002,1,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,F,,CHEMBL616045,,16026,,Autocuration,,,8,H,,
,BAO_0000219,,,1003,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,F,722.0,CHEMBL616046,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,1004,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,F,449.0,CHEMBL616047,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000219,,,1005,1,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,F,449.0,CHEMBL616048,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000219,,,1006,1,,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),51,F,449.0,CHEMBL616049,CHO,2759,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1007,1,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,F,449.0,CHEMBL616050,CHO,2759,,Autocuration,,,8,H,,
,BAO_0000219,,,1008,1,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,51,F,,CHEMBL616051,,15419,,Expert,,,8,H,,
,BAO_0000219,,,1009,1,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,51,F,,CHEMBL616212,,15419,,Autocuration,,,8,H,,
,BAO_0000019,,,1010,1,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,F,,CHEMBL616213,,16026,,Autocuration,,,8,H,,
In vitro,BAO_0000219,,,1011,1,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,51,B,,CHEMBL616214,,1414,,Expert,,,8,H,,
In vitro,BAO_0000219,,,1012,1,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,51,B,,CHEMBL616215,,1414,,Expert,,,8,H,,
,BAO_0000357,,,1013,1,,,Binding activity radioligand.,51,B,,CHEMBL616216,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,1014,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,51,B,,CHEMBL616217,,12861,,Autocuration,,,8,H,,
,BAO_0000357,,,1015,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616218,,5104,,Autocuration,,,8,H,,
,BAO_0000357,,,1016,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616219,,5105,,Autocuration,,,8,H,,
,BAO_0000357,,,1017,1,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616220,,16312,,Autocuration,,,8,H,,
,BAO_0000357,,,1018,1,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL833493,,15180,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1019,1,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616221,,5033,,Autocuration,,,8,H,,
,BAO_0000219,,,1020,1,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,B,449.0,CHEMBL616222,CHO,16909,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,1021,1,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,51,F,,CHEMBL616223,,2590,,Autocuration,,,8,H,,
,BAO_0000019,,,1022,1,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,F,,CHEMBL616224,,2590,,Autocuration,,,8,H,,
,BAO_0000019,,,1023,1,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,51,B,,CHEMBL616225,,16394,,Expert,,,8,H,,
,BAO_0000219,,,1024,1,,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,51,B,722.0,CHEMBL616226,HEK293,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1025,1,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,51,B,722.0,CHEMBL616227,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,1026,1,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,51,B,722.0,CHEMBL616228,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,1027,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,B,722.0,CHEMBL616229,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1028,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,51,B,722.0,CHEMBL616230,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1029,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,51,B,722.0,CHEMBL616231,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000357,,,1030,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL616232,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,1031,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,B,722.0,CHEMBL616233,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1032,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,51,B,722.0,CHEMBL857973,HEK293,4199,,Autocuration,,,8,H,,
,BAO_0000219,,,1033,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,51,B,,CHEMBL616234,,15316,,Autocuration,,,8,H,,
,BAO_0000357,,,1034,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616235,,14875,,Autocuration,,,8,H,,
,BAO_0000219,,,1035,1,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,B,308.0,CHEMBL616236,HeLa,14727,,Expert,,,8,H,,
,BAO_0000019,,,1036,1,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,B,,CHEMBL616237,,14727,,Expert,,,8,H,,
,BAO_0000219,,,1037,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,51,B,722.0,CHEMBL616238,HEK293,15146,,Autocuration,,,8,H,,
,BAO_0000219,,,1038,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,51,B,722.0,CHEMBL616239,HEK293,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,1039,1,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,51,B,,CHEMBL616240,,16429,,Autocuration,,,8,H,,
,BAO_0000219,,,1040,1,,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,51,B,308.0,CHEMBL616241,HeLa,15042,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1041,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,51,B,722.0,CHEMBL616242,HEK293,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,1042,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",51,B,722.0,CHEMBL616243,HEK293,4829,,Autocuration,,,8,H,,
,BAO_0000357,,,1043,1,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616244,,17200,,Expert,,,9,D,,
,BAO_0000357,,,1044,1,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616245,,13051,9606.0,Autocuration,,,9,D,Homo sapiens,
,BAO_0000357,,,1045,1,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,106,B,,CHEMBL616246,,5486,,Autocuration,,,8,H,,
,BAO_0000357,,,1046,1,,,Binding affinity against 5-HT1D receptor,105,B,,CHEMBL616247,,5254,,Autocuration,,,8,H,,
,BAO_0000357,,,1047,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,105,B,,CHEMBL616248,,5254,,Autocuration,,,8,H,,
,BAO_0000357,,,1048,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,107,B,,CHEMBL616249,,15331,,Autocuration,,,8,H,,
,BAO_0000357,,,1049,1,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,B,,CHEMBL616250,,13506,9606.0,Autocuration,,,8,H,Homo sapiens,
,BAO_0000357,,,1050,1,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616251,,15267,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1051,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,11863,F,,CHEMBL616252,,16616,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1052,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,11863,F,,CHEMBL616253,,16616,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1053,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,11863,F,,CHEMBL616254,,16616,,Autocuration,,,8,H,,
,BAO_0000218,,,1054,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,11863,F,,CHEMBL616255,,16616,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000218,,,1055,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,11863,F,,CHEMBL832872,,16616,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000218,,,1056,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,11863,F,,CHEMBL616256,,16616,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000218,,,1057,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,11863,F,,CHEMBL616257,,16616,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000218,,,1058,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,11863,F,,CHEMBL616258,,16616,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000218,,,1059,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,11863,F,,CHEMBL616384,,16616,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000221,Hippocampus,,1060,1,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,B,,CHEMBL616385,,10297,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1061,1,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,11863,B,,CHEMBL616386,,13704,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1062,1,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,B,,CHEMBL616387,,10297,10090.0,Expert,,,9,D,Mus musculus,10000000.0
,BAO_0000221,Hippocampus,,1063,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,B,,CHEMBL616388,,10297,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1064,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,B,,CHEMBL616389,,10297,10090.0,Expert,,,9,D,Mus musculus,10000000.0
,BAO_0000221,Hippocampus,,1065,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,B,,CHEMBL616390,,10297,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1066,1,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,11863,B,,CHEMBL616391,,217,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1067,1,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,B,,CHEMBL616392,,10297,10090.0,Expert,,,9,D,Mus musculus,10000000.0
,BAO_0000357,,,1068,1,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616393,,4921,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1069,1,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,51,B,,CHEMBL616394,,4921,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1070,1,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,51,B,,CHEMBL616395,,4996,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1071,1,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,51,B,,CHEMBL616396,,12918,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1072,1,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,B,,CHEMBL872907,,5333,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1073,1,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,B,,CHEMBL616397,,4437,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1074,1,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,51,B,,CHEMBL616398,,1742,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1075,1,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616399,,16688,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000357,,,1076,1,,,Binding activity radioligand.,51,B,,CHEMBL857065,,12861,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1077,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,B,,CHEMBL616400,,12861,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000019,,,1078,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,B,,CHEMBL616401,,12861,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1079,1,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,10624,B,,CHEMBL616402,,12490,,Expert,,,8,H,,
,BAO_0000019,,,1080,1,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616403,,11828,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000221,Hippocampus,,1081,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,51,B,,CHEMBL616404,,11866,9823.0,Autocuration,,,8,H,Sus scrofa,10000000.0
,BAO_0000249,,,1082,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,51,B,,CHEMBL616405,,12827,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1083,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,51,B,,CHEMBL616406,,12918,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1084,1,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,51,F,,CHEMBL616407,,12919,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000019,,,1085,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,51,B,,CHEMBL616408,,13047,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000249,,,1086,1,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10576,B,,CHEMBL616409,,15796,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1087,1,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10576,B,,CHEMBL616410,,3651,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000357,,,1088,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,10576,B,,CHEMBL616411,,188,,Autocuration,,,8,H,,
,BAO_0000249,,,1089,1,,Membranes,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,F,,CHEMBL616412,,16616,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,Hippocampus,,1090,1,,Membranes,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,F,,CHEMBL616413,,16616,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,1091,1,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,B,,CHEMBL616414,,12306,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1092,1,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10576,B,,CHEMBL616415,,17167,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000019,,,1093,1,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,10576,B,,CHEMBL616416,,14776,,Autocuration,,,8,H,,
,BAO_0000357,,,1094,1,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,10576,B,,CHEMBL616417,,12158,,Expert,,,8,H,,
,BAO_0000357,,,1095,1,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,10576,B,,CHEMBL616418,,13481,,Autocuration,,,8,H,,
In vitro,BAO_0000219,,,1096,1,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,10576,B,,CHEMBL616419,,13427,,Autocuration,,,8,H,,
,BAO_0000357,,,1097,1,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10576,B,,CHEMBL616420,,10210,,Autocuration,,,8,H,,
,BAO_0000249,,,1098,1,,Membranes,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,B,,CHEMBL616421,,10205,,Autocuration,,,8,H,,
,BAO_0000249,,,1099,1,,Membranes,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,B,,CHEMBL616422,,10205,,Autocuration,,,8,H,,
,BAO_0000249,,,1100,1,,Membranes,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10576,B,,CHEMBL616423,,10205,,Expert,,,8,H,,
,BAO_0000357,,,1101,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10576,B,,CHEMBL616424,,12280,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1102,1,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616425,,17386,,Expert,,,8,H,,
,BAO_0000357,,,1103,1,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,10576,B,,CHEMBL616426,,13654,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1104,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10576,B,,CHEMBL616427,,14423,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1105,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10576,B,,CHEMBL616428,,15412,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1106,1,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL616290,,12073,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1107,1,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616052,,4101,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1108,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616053,,10062,,Autocuration,,,8,H,,
,BAO_0000249,,,1109,1,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616054,,6238,,Autocuration,,,8,H,,
,BAO_0000357,,,1110,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616055,,16273,,Autocuration,,,8,H,,
,BAO_0000357,,,1111,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,10576,B,,CHEMBL616056,,11139,,Autocuration,,,8,H,,
,BAO_0000019,,,1112,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,B,,CHEMBL616057,,16796,,Expert,,,8,H,,
,BAO_0000221,Brain,,1113,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,B,,CHEMBL616058,,9548,10116.0,Expert,,,9,D,Rattus norvegicus,955.0
,BAO_0000221,Brain,,1114,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,B,,CHEMBL616059,,10381,,Autocuration,,,8,H,,955.0
,BAO_0000249,,,1115,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616060,,13408,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1116,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10576,B,,CHEMBL616061,,13825,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,1117,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10576,B,,CHEMBL616062,,11147,,Expert,,,8,H,,10000000.0
,BAO_0000249,,,1118,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616063,,10552,,Autocuration,,,8,H,,
,BAO_0000249,Striatum,,1119,1,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,B,,CHEMBL616064,,10552,,Autocuration,,,8,H,,2435.0
,BAO_0000249,,,1120,1,,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10576,B,,CHEMBL616065,,17136,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,1121,1,,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10576,B,,CHEMBL616066,,5778,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1122,1,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616067,,13481,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1123,1,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10576,B,,CHEMBL616068,,13481,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1124,1,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616069,,13630,,Intermediate,,,8,H,,10000000.0
,BAO_0000249,,,1125,1,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,B,,CHEMBL616070,,16245,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1126,1,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616071,,14509,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1127,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,B,,CHEMBL616072,,14509,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1128,1,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10576,B,,CHEMBL616073,,14509,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1129,1,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10576,B,,CHEMBL616074,,14509,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1130,1,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,10576,B,,CHEMBL616075,,14256,,Expert,,,8,H,,
,BAO_0000357,,,1131,1,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616076,,11139,,Autocuration,,,8,H,,
,BAO_0000019,,,1132,1,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10576,B,,CHEMBL616077,,11047,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1133,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10576,B,,CHEMBL616078,,11047,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1134,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10576,B,,CHEMBL616079,,11047,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,1135,1,,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,B,485.0,CHEMBL616080,CHO-K1,2395,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1136,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616081,,9699,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1137,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10576,B,,CHEMBL616082,,12028,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,1138,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10576,B,,CHEMBL616083,,12028,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1139,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,B,,CHEMBL616084,,5815,,Autocuration,,,8,H,,
,BAO_0000019,,,1140,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,10576,B,,CHEMBL616085,,16616,,Expert,,,8,H,,
,BAO_0000019,,,1141,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,10576,B,,CHEMBL616086,,5815,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1142,1,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10576,B,,CHEMBL616087,,2761,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1143,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,10576,B,,CHEMBL616088,,13133,,Expert,,,8,H,,
,BAO_0000019,,,1144,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10576,B,,CHEMBL616089,,10444,,Autocuration,,,8,H,,
,BAO_0000357,,,1145,1,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10576,B,,CHEMBL616090,,13278,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1146,1,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,10576,B,,CHEMBL616091,,15874,,Autocuration,,,8,H,,
,BAO_0000249,Striatum,,1147,1,,Membranes,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,B,,CHEMBL616092,,10552,,Autocuration,,,8,H,,2435.0
,BAO_0000357,,,1148,1,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),10576,B,,CHEMBL616093,,11130,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1149,1,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),10576,B,,CHEMBL616094,,11130,,Autocuration,,,8,H,,
,BAO_0000221,Brain,,1150,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,10576,B,,CHEMBL616095,,14542,,Autocuration,,,8,H,,955.0
,BAO_0000357,,,1151,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616096,,13670,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,1152,1,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,10576,B,,CHEMBL616097,,9888,,Expert,,,8,H,,
,BAO_0000249,,,1153,1,,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10576,B,,CHEMBL616098,,3678,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1154,1,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616099,,11332,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1155,1,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616100,,11332,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1156,1,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616101,,1185,,Expert,,,8,H,,
,BAO_0000249,,,1157,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,10576,B,,CHEMBL616102,,2014,,Expert,,,8,H,,
,BAO_0000357,,,1158,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616103,,1185,,Autocuration,,,8,H,,
,BAO_0000019,,,1159,1,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,10576,B,,CHEMBL616104,,14429,,Expert,,,8,H,,
,BAO_0000019,,,1160,1,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",10576,B,,CHEMBL616105,,16288,,Expert,,,8,H,,
,BAO_0000019,,,1161,1,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616106,,5432,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1162,1,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,10576,B,,CHEMBL616107,,14429,,Autocuration,,,8,H,,
,BAO_0000357,,,1163,1,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,10576,B,,CHEMBL616108,,13672,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1164,1,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,B,,CHEMBL616109,,11296,,Expert,,,8,H,,10000000.0
,BAO_0000357,,,1165,1,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,10576,B,,CHEMBL616110,,11296,,Autocuration,,,8,H,,
,BAO_0000219,,,1166,1,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,10576,B,449.0,CHEMBL616111,CHO,14749,,Expert,,,8,H,,
,BAO_0000019,,,1167,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,10576,B,,CHEMBL616112,,15086,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1168,1,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10576,B,,CHEMBL616113,,13462,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1169,1,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616114,,15363,,Autocuration,,,8,H,,
,BAO_0000019,,,1170,1,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616115,,15363,,Autocuration,,,8,H,,
,BAO_0000357,,,1171,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616116,,10796,,Autocuration,,,8,H,,
,BAO_0000221,Brain,,1172,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL615844,,12816,,Expert,,,8,H,,955.0
,BAO_0000221,Hippocampus,,1173,1,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL615939,,13542,,Expert,,,8,H,,10000000.0
,BAO_0000019,,,1174,1,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,10576,B,,CHEMBL615940,,13308,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1175,1,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10576,B,,CHEMBL615941,,13541,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1176,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10576,B,,CHEMBL615942,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1177,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,B,,CHEMBL615943,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1178,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10576,B,,CHEMBL615944,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1179,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10576,B,,CHEMBL615945,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1180,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10576,B,,CHEMBL615946,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1181,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10576,B,,CHEMBL615947,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1182,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10576,B,,CHEMBL615948,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1183,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10576,B,,CHEMBL615949,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1184,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10576,B,,CHEMBL615950,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1185,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10576,B,,CHEMBL615951,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1186,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10576,B,,CHEMBL615952,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1187,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10576,B,,CHEMBL615953,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1188,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10576,B,,CHEMBL615954,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1189,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,B,,CHEMBL615955,,10058,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,1190,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10576,B,,CHEMBL615956,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1191,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10576,B,,CHEMBL615957,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1192,1,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,10576,B,,CHEMBL615958,,12879,,Expert,,,8,H,,
,BAO_0000019,,,1193,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,10576,B,,CHEMBL615959,,11964,,Expert,,,8,H,,
,BAO_0000019,,,1194,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),10576,B,,CHEMBL615960,,11964,,Autocuration,,,8,H,,
,BAO_0000019,,,1195,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),10576,B,,CHEMBL615961,,11964,,Autocuration,,,8,H,,
,BAO_0000221,Brain,,1196,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,B,,CHEMBL615962,,9548,,Expert,,,8,H,,955.0
,BAO_0000019,,,1197,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,10576,B,,CHEMBL615963,,9098,,Expert,,,8,H,,
,BAO_0000019,,,1198,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,10576,B,,CHEMBL615964,,9098,,Autocuration,,,8,H,,
,BAO_0000019,,,1199,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,10576,B,,CHEMBL615965,,9098,,Autocuration,,,8,H,,
,BAO_0000219,,,1200,1,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,10576,B,449.0,CHEMBL615966,CHO,13248,,Expert,,,8,H,,
,BAO_0000249,,,1201,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,10576,B,,CHEMBL615967,,3147,,Expert,,,8,H,,
,BAO_0000019,,,1202,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,B,,CHEMBL615968,,13949,,Expert,,,8,H,,
,BAO_0000218,,,1203,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10576,B,449.0,CHEMBL615969,CHO,11883,,Autocuration,,,8,H,,
,BAO_0000218,,,1204,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),10576,B,,CHEMBL615970,,11883,,Autocuration,,,8,H,,
,BAO_0000357,,,1205,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10576,B,,CHEMBL615971,,11883,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,1206,1,,Membranes,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,B,,CHEMBL615972,,15535,,Expert,,,8,H,,
,BAO_0000249,,,1207,1,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,10576,B,,CHEMBL615973,,15535,,Autocuration,,,8,H,,
,BAO_0000249,,,1208,1,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,10576,B,,CHEMBL615974,,15535,,Autocuration,,,8,H,,
,BAO_0000219,,,1209,1,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,B,449.0,CHEMBL615975,CHO,16372,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000249,,,1210,1,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,10576,B,,CHEMBL615976,,14608,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1211,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,B,,CHEMBL872106,,4795,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000357,,,1212,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL615977,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1213,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,10576,B,,CHEMBL615978,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1214,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,10576,B,,CHEMBL616166,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1215,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,10576,B,,CHEMBL616167,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1216,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,10576,B,,CHEMBL616168,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1217,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,10576,B,,CHEMBL616169,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1218,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,10576,B,,CHEMBL616170,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1219,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,10576,B,,CHEMBL616171,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1220,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,10576,B,,CHEMBL616172,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1221,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,10576,B,,CHEMBL616173,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1222,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,10576,B,,CHEMBL616174,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1223,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,10576,B,,CHEMBL616175,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1224,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,10576,B,,CHEMBL616176,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1225,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,10576,B,,CHEMBL616177,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1226,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,10576,B,,CHEMBL616178,,13863,,Autocuration,,,8,H,,
,BAO_0000019,,,1227,1,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,10576,B,,CHEMBL616179,,9742,,Autocuration,,,8,H,,
,BAO_0000357,,,1228,1,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616180,,12073,,Autocuration,,,8,H,,
,BAO_0000357,,,1229,1,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,10576,B,,CHEMBL616181,,4101,,Autocuration,,,8,H,,
,BAO_0000019,,,1230,1,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,10576,B,,CHEMBL616182,,15360,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1231,1,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616183,,11576,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1232,1,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,10576,B,,CHEMBL615874,,5834,,Expert,,,8,H,,
,BAO_0000219,,,1233,1,,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,B,485.0,CHEMBL615875,CHO-K1,2395,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1234,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,10576,B,,CHEMBL615876,,1375,,Autocuration,,,8,H,,
,BAO_0000019,,,1235,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,10576,B,,CHEMBL615877,,1375,,Autocuration,,,8,H,,
,BAO_0000357,,,1236,1,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),10576,B,,CHEMBL615878,,3967,,Autocuration,,,8,H,,
,BAO_0000357,,,1237,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,10576,B,,CHEMBL615879,,12884,,Expert,,,8,H,,
,BAO_0000357,,,1238,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,10576,B,,CHEMBL615880,,2343,,Expert,,,8,H,,
,BAO_0000019,,,1239,1,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,B,,CHEMBL615881,,11511,,Autocuration,,,8,H,,
,BAO_0000019,,,1240,1,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,B,,CHEMBL615882,,11511,10116.0,Expert,,,9,D,Rattus norvegicus,
In vivo,BAO_0000218,,,1241,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,10576,F,,CHEMBL615883,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1242,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),10576,F,,CHEMBL615884,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1243,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),10576,F,,CHEMBL615885,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1244,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),10576,F,,CHEMBL615886,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1245,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),10576,F,,CHEMBL615887,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1246,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),10576,F,,CHEMBL615888,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1247,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),10576,F,,CHEMBL615889,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1248,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),10576,F,,CHEMBL615890,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1249,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),10576,F,,CHEMBL615891,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1250,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),10576,F,,CHEMBL615892,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1251,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),10576,F,,CHEMBL615893,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1252,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),10576,F,,CHEMBL615894,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1253,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),10576,F,,CHEMBL615895,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1254,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),10576,F,,CHEMBL615896,,16394,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,1255,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,10576,F,,CHEMBL615897,,16394,,Autocuration,,,8,H,,
,BAO_0000249,,,1256,1,,Membranes,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,F,,CHEMBL615898,,16616,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1257,1,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,10576,B,,CHEMBL615899,,16796,,Autocuration,,,8,H,,
,BAO_0000019,,,1258,1,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,B,,CHEMBL616291,,16796,,Autocuration,,,8,H,,
,BAO_0000357,,,1259,1,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,10576,B,,CHEMBL616292,,15629,,Autocuration,,,8,H,,
,BAO_0000249,,,1260,1,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,F,,CHEMBL616293,,13241,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1261,1,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL616294,,12073,,Expert,,,8,H,,10000000.0
,BAO_0000249,Hippocampus,,1262,1,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10576,B,,CHEMBL616295,,14286,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Brain,,1263,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,10576,B,,CHEMBL616296,,14542,,Autocuration,,,8,H,,955.0
,BAO_0000019,,,1264,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,F,,CHEMBL616297,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1265,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,10576,F,,CHEMBL616605,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1266,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,10576,F,,CHEMBL616606,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1267,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,F,,CHEMBL616607,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1268,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,F,,CHEMBL616608,,13630,,Expert,,,8,H,,
,BAO_0000019,,,1269,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,10576,F,,CHEMBL616609,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1270,1,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10576,F,,CHEMBL616610,,13630,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1271,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,F,,CHEMBL616611,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1272,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,10576,F,,CHEMBL616612,,13630,,Expert,,,8,H,,
,BAO_0000019,,,1273,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,10576,F,,CHEMBL616613,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1274,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,10576,F,,CHEMBL616614,,13630,,Expert,,,8,H,,
,BAO_0000019,,,1275,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,10576,F,,CHEMBL616615,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1276,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,F,,CHEMBL616616,,13630,,Expert,,,8,H,,
,BAO_0000019,,,1277,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,10576,F,,CHEMBL616617,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1278,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,F,,CHEMBL616618,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1279,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,10576,F,,CHEMBL616619,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1280,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,10576,F,,CHEMBL616620,,13630,,Expert,,,8,H,,
,BAO_0000019,,,1281,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,F,,CHEMBL616621,,13630,,Expert,,,8,H,,
,BAO_0000019,,,1282,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,10576,F,,CHEMBL616622,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1283,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,10576,F,,CHEMBL616146,,13630,,Expert,,,8,H,,
,BAO_0000019,,,1284,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,10576,F,,CHEMBL832873,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1285,1,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,10576,F,,CHEMBL616147,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1286,1,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,F,,CHEMBL872872,,13630,,Autocuration,,,8,H,,
,BAO_0000019,,,1287,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,F,,CHEMBL616148,,13630,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1288,1,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10576,B,,CHEMBL616149,,9783,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1289,1,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10576,B,,CHEMBL616150,,9783,,Expert,,,8,H,,10000000.0
,BAO_0000249,,,1290,1,,Membranes,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10576,B,,CHEMBL616151,,14331,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1291,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10576,B,,CHEMBL872873,,15260,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1292,1,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10576,B,,CHEMBL616670,,15260,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1293,1,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10576,B,,CHEMBL616671,,15260,,Autocuration,,,8,H,,10000000.0
,BAO_0000249,,,1294,1,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,F,,CHEMBL884861,,16616,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1295,1,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,10576,B,,CHEMBL616672,,15629,,Autocuration,,,8,H,,
,BAO_0000019,,,1296,1,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,B,,CHEMBL616673,,15086,,Autocuration,,,8,H,,
,BAO_0000019,,,1297,1,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,F,,CHEMBL616674,,5717,,Expert,,,8,H,,
,BAO_0000357,,,1298,1,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,B,,CHEMBL616675,,12652,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1299,1,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10576,B,,CHEMBL616676,,14608,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1300,1,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,B,,CHEMBL616677,,12306,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1301,1,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,B,,CHEMBL616678,,12306,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1302,1,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616679,,15247,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1303,1,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10576,B,,CHEMBL616680,,17529,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1304,1,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL616681,,14826,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1305,1,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL616682,,14826,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1306,1,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616683,,13241,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1307,1,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616684,,14093,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1308,1,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10576,B,,CHEMBL616685,,14093,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Brain,,1309,1,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,10576,B,,CHEMBL616686,,14442,,Autocuration,,,8,H,,955.0
,BAO_0000357,,,1310,1,,,Affinity for 5-hydroxytryptamine 1A receptor site,10576,B,,CHEMBL616687,,9919,,Autocuration,,,8,H,,
,BAO_0000357,,,1311,1,,,Affinity for 5-hydroxytryptamine 1A receptor site,10576,B,,CHEMBL616688,,9919,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1312,1,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10576,B,,CHEMBL616689,,11440,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1313,1,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,10576,B,,CHEMBL616690,,11257,,Autocuration,,,8,H,,
,BAO_0000357,,,1314,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10576,B,,CHEMBL616691,,10330,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1315,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10576,B,,CHEMBL616692,,17331,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000249,,,1316,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,10576,B,,CHEMBL616693,,16567,,Expert,,,8,H,,
,BAO_0000019,,,1317,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,B,,CHEMBL616694,,12058,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1318,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10576,B,,CHEMBL616695,,9699,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1319,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,10576,B,,CHEMBL616696,,9547,,Autocuration,,,8,H,,
,BAO_0000357,,,1320,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10576,B,,CHEMBL616697,,10330,,Autocuration,,,8,H,,
,BAO_0000357,,,1321,1,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616698,,14331,,Autocuration,,,8,H,,
,BAO_0000019,,,1322,1,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616949,,14060,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1323,1,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10576,B,,CHEMBL616950,,14744,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1324,1,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,B,,CHEMBL832875,,13506,,Autocuration,,,8,H,,
,BAO_0000221,Brain,,1325,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,B,,CHEMBL616951,,10862,,Expert,,,8,H,,955.0
,BAO_0000221,Brain,,1326,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,B,,CHEMBL616952,,10862,,Expert,,,8,H,,955.0
,BAO_0000357,,,1327,1,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10576,B,,CHEMBL616953,,10062,,Expert,,,8,H,,
,BAO_0000357,,,1328,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,10576,B,,CHEMBL616954,,12073,,Autocuration,,,8,H,,
,BAO_0000357,,,1329,1,,,GTPgammaS radioligand binding assay,106,B,,CHEMBL616955,,14875,,Autocuration,,,8,H,,
,BAO_0000357,,,1330,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,B,,CHEMBL616956,,2391,,Autocuration,,,8,H,,
,BAO_0000019,,,1331,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,106,F,,CHEMBL616957,,2391,,Autocuration,,,8,H,,
,BAO_0000019,,,1332,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,106,F,,CHEMBL616958,,2391,,Autocuration,,,8,H,,
,BAO_0000357,,,1333,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616959,,2391,,Autocuration,,,8,H,,
,BAO_0000357,,,1334,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,B,,CHEMBL616960,,2391,,Autocuration,,,8,H,,
,BAO_0000019,,,1335,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,106,F,,CHEMBL616961,,2391,,Autocuration,,,8,H,,
,BAO_0000219,,,1336,1,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,106,B,308.0,CHEMBL616962,HeLa,17211,,Expert,,,8,H,,
,BAO_0000219,,,1337,1,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,106,B,308.0,CHEMBL616963,HeLa,17211,,Autocuration,,,8,H,,
,BAO_0000357,,,1338,1,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,106,B,,CHEMBL616524,,6491,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1339,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,B,449.0,CHEMBL616525,CHO,16190,,Autocuration,,,8,H,,
,BAO_0000019,,,1340,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,106,B,,CHEMBL872908,,14165,,Autocuration,,,8,H,,
,BAO_0000019,,,1341,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,106,B,,CHEMBL616526,,14165,,Autocuration,,,8,H,,
,BAO_0000357,,,1342,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616527,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1343,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,106,B,,CHEMBL616528,,6328,,Expert,,,8,H,,
,BAO_0000357,,,1344,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,B,,CHEMBL616529,,14770,,Autocuration,,,8,H,,
,BAO_0000357,,,1345,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,106,B,,CHEMBL616530,,2598,,Autocuration,,,8,H,,
,BAO_0000357,,,1346,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616531,,6897,,Expert,,,8,H,,
,BAO_0000357,,,1347,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616532,,6897,,Autocuration,,,8,H,,
,BAO_0000357,,,1348,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616533,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,1349,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616534,,5843,,Expert,,,8,H,,
,BAO_0000357,,,1350,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,106,B,,CHEMBL616535,,14454,,Expert,,,8,H,,
,BAO_0000357,,,1351,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,106,B,,CHEMBL616536,,16209,,Autocuration,,,8,H,,
,BAO_0000357,,,1352,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616537,,3935,,Autocuration,,,8,H,,
,BAO_0000219,,,1353,1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,106,F,485.0,CHEMBL616538,CHO-K1,13729,,Expert,,,8,H,,
,BAO_0000019,,,1354,1,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,106,F,,CHEMBL616539,,14251,,Expert,,,8,H,,
,BAO_0000019,,,1355,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616540,,17085,,Expert,,,8,H,,
,BAO_0000357,,,1356,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,106,B,,CHEMBL616429,,3025,,Autocuration,,,8,H,,
,BAO_0000357,,,1357,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616430,,15315,,Expert,,,8,H,,
,BAO_0000219,,,1358,1,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,106,B,,CHEMBL616431,,14214,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1359,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616432,,3804,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1360,1,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,106,B,,CHEMBL616433,,2391,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1361,1,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616434,,4175,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1362,1,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,106,B,449.0,CHEMBL616435,CHO,17296,,Autocuration,,,8,H,,
,BAO_0000019,,,1363,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,106,B,,CHEMBL616436,,17085,,Expert,,,8,H,,
,BAO_0000219,,,1364,1,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,B,308.0,CHEMBL616437,HeLa,17211,,Autocuration,,,8,H,,
,BAO_0000219,,,1365,1,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,106,B,308.0,CHEMBL616438,HeLa,17211,,Autocuration,,,8,H,,
,BAO_0000219,,,1366,1,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,B,308.0,CHEMBL616439,HeLa,17211,,Autocuration,,,8,H,,
,BAO_0000357,,,1367,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,106,B,,CHEMBL616440,,15926,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1368,1,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,106,B,485.0,CHEMBL616441,CHO-K1,16312,,Autocuration,,,8,H,,
,BAO_0000357,,,1369,1,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,106,B,,CHEMBL616442,,5843,,Expert,,,8,H,,
,BAO_0000357,,,1370,1,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,106,B,,CHEMBL616443,,5843,,Autocuration,,,8,H,,
,BAO_0000219,,,1371,1,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,106,B,485.0,CHEMBL616444,CHO-K1,16312,,Expert,,,8,H,,
,BAO_0000357,,,1372,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616445,,15926,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1373,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616446,,15926,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1374,1,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,B,449.0,CHEMBL616447,CHO,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1375,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,106,B,,CHEMBL616448,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,1376,1,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,106,B,449.0,CHEMBL616449,CHO,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,1377,1,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,106,B,449.0,CHEMBL616450,CHO,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,1378,1,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,106,B,449.0,CHEMBL857974,CHO,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,1379,1,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,B,449.0,CHEMBL616451,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1380,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,B,449.0,CHEMBL616452,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1381,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,106,B,449.0,CHEMBL616453,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1382,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,106,B,449.0,CHEMBL616454,CHO,4199,,Autocuration,,,8,H,,
,BAO_0000357,,,1383,1,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616455,,14875,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1384,1,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,B,449.0,CHEMBL616456,CHO,15146,,Autocuration,,,8,H,,
,BAO_0000357,,,1385,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,106,B,,CHEMBL616457,,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,1386,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,B,449.0,CHEMBL616458,CHO,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,1387,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",106,B,449.0,CHEMBL616459,CHO,4829,,Autocuration,,,8,H,,
,BAO_0000019,,,1388,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,106,F,,CHEMBL616460,,14454,,Expert,,,8,H,,
,BAO_0000019,,,1389,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,106,F,,CHEMBL616461,,14454,,Expert,,,8,H,,
,BAO_0000219,,,1390,1,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,F,449.0,CHEMBL616462,CHO,14875,,Autocuration,,,8,H,,
,BAO_0000219,,,1391,1,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,F,449.0,CHEMBL616463,CHO,14875,,Autocuration,,,8,H,,
,BAO_0000019,,,1392,1,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",105,F,,CHEMBL616464,,15250,,Autocuration,,,8,H,,
,BAO_0000219,,,1393,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,105,B,449.0,CHEMBL616465,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000357,,,1394,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,17105,B,,CHEMBL832874,,15086,,Autocuration,,,8,H,,
,BAO_0000019,,,1395,1,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,106,F,,CHEMBL616184,,3025,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,,,1396,1,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,106,B,,CHEMBL616185,,14998,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,,,1397,1,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",106,B,,CHEMBL616186,,14998,9986.0,Intermediate,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,,,1398,1,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,106,B,,CHEMBL616187,,14998,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,1399,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,10577,B,,CHEMBL616188,,13969,,Expert,,,8,H,,
,BAO_0000357,,,1400,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL873475,,13392,,Intermediate,,,9,D,,
,BAO_0000019,Striatum,,1401,1,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10577,B,,CHEMBL616189,,3651,10116.0,Expert,,,9,D,Rattus norvegicus,2435.0
,BAO_0000357,,,1402,1,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,B,,CHEMBL616190,,10025,,Expert,,,8,H,,
,BAO_0000357,,,1403,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,10576,B,,CHEMBL616191,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1404,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,10576,B,,CHEMBL616192,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1405,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,10576,B,,CHEMBL616193,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1406,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,10576,B,,CHEMBL616194,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1407,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,10576,B,,CHEMBL616195,,13863,,Autocuration,,,8,H,,
,BAO_0000357,,,1408,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,10576,B,,CHEMBL616196,,13863,,Autocuration,,,8,H,,
,BAO_0000249,Hippocampus,,1409,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10576,B,,CHEMBL616197,,4622,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1410,1,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616198,,14911,,Intermediate,,,8,H,,
,BAO_0000221,Hippocampus,,1411,1,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,B,,CHEMBL616199,,12678,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1412,1,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10576,B,,CHEMBL616200,,12678,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1413,1,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616201,,14235,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1414,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,B,,CHEMBL616202,,14949,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1415,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,B,,CHEMBL616203,,14949,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1416,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10576,B,,CHEMBL616204,,14949,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1417,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10576,B,,CHEMBL616205,,14949,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1418,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10576,B,,CHEMBL616206,,14949,,Expert,,,8,H,,10000000.0
,BAO_0000249,,,1419,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,B,,CHEMBL616207,,16118,,Expert,,,8,H,,
,BAO_0000249,,,1420,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,10576,B,,CHEMBL616208,,3268,,Autocuration,,,8,H,,
,BAO_0000249,,,1421,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,10576,B,,CHEMBL616209,,3268,,Autocuration,,,8,H,,
,BAO_0000357,,,1422,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,10576,B,,CHEMBL616210,,16117,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1423,1,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10576,B,,CHEMBL616211,,9783,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1424,1,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10576,B,,CHEMBL616504,,9783,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1425,1,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616505,,14356,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000019,,,1426,1,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,10576,F,,CHEMBL616506,,15740,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1427,1,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,B,,CHEMBL872107,,12306,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1428,1,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10576,B,,CHEMBL616507,,13348,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000249,,,1429,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10576,B,,CHEMBL616303,,10394,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1430,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10576,B,,CHEMBL616304,,15260,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1431,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,B,,CHEMBL616305,,10046,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1432,1,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10576,F,,CHEMBL616306,,15260,,Intermediate,,,8,H,,10000000.0
,BAO_0000357,,,1433,1,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616307,,12851,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1434,1,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10576,B,,CHEMBL881829,,2148,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000357,,,1435,1,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,10576,B,,CHEMBL616308,,13134,,Expert,,,8,H,,
,BAO_0000019,,,1436,1,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,10576,B,,CHEMBL616309,,12462,,Autocuration,,,8,H,,
,BAO_0000019,,,1437,1,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,10576,B,,CHEMBL616310,,12462,,Expert,,,8,H,,
,BAO_0000219,,,1438,1,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,10576,B,449.0,CHEMBL616311,CHO,12462,,Autocuration,,,8,H,,
,BAO_0000357,,,1439,1,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616312,,11933,,Expert,,,8,H,,
,BAO_0000357,,,1440,1,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,10576,B,,CHEMBL616313,,11933,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1441,1,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616314,,403,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,1442,1,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL616315,,15538,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1443,1,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10576,B,,CHEMBL616567,,15538,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1444,1,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10576,B,,CHEMBL616568,,15538,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1445,1,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,10576,B,,CHEMBL616569,,12464,,Intermediate,,,8,H,,
,BAO_0000357,,,1446,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,10576,B,,CHEMBL616570,,1455,,Expert,,,8,H,,
,BAO_0000357,,,1447,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,B,,CHEMBL616571,,12652,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1448,1,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10576,B,,CHEMBL616572,,12639,,Autocuration,,,8,H,,10000000.0
,BAO_0000249,,,1449,1,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,10576,B,,CHEMBL616573,,13949,,Expert,,,8,H,,
,BAO_0000357,,,1450,1,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10576,B,,CHEMBL616574,,12463,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1451,1,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10576,B,,CHEMBL616575,,14829,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1452,1,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10576,B,,CHEMBL872108,,14829,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1453,1,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,10576,B,,CHEMBL616576,,12092,,Autocuration,,,8,H,,
,BAO_0000249,,,1454,1,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,10576,B,,CHEMBL616577,,403,,Autocuration,,,8,H,,
,BAO_0000249,,,1455,1,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,10576,B,,CHEMBL616578,,403,,Autocuration,,,8,H,,
,BAO_0000357,,,1456,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,10576,B,,CHEMBL616579,,3967,,Expert,,,8,H,,
,BAO_0000019,,,1457,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10576,B,,CHEMBL616580,,12771,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1458,1,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,B,,CHEMBL616581,,15086,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1459,1,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL616582,,14909,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1460,1,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,B,,CHEMBL616583,,14949,,Expert,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1461,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10576,B,,CHEMBL616584,,2309,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000357,,,1462,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616585,,4170,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1463,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10576,B,,CHEMBL616586,,11642,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,1464,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10576,B,,CHEMBL616587,,11642,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1465,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10576,B,,CHEMBL616588,,12953,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1466,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,B,,CHEMBL616589,,12953,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1467,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,B,,CHEMBL616590,,12953,,Expert,,,8,H,,10000000.0
,BAO_0000219,,,1468,1,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",10576,B,449.0,CHEMBL616591,CHO,12903,,Expert,,,8,H,,
,BAO_0000357,,,1469,1,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616592,,12536,,Expert,,,8,H,,
,BAO_0000357,,,1470,1,,,The inhibition activity of 5-HT1A at 1 uM,10576,B,,CHEMBL616593,,10058,,Autocuration,,,8,H,,
,BAO_0000219,,,1471,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",10576,B,485.0,CHEMBL616594,CHO-K1,12902,,Expert,,,8,H,,
,BAO_0000249,,,1472,1,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,10576,B,,CHEMBL616595,,14057,,Expert,,,8,H,,
,BAO_0000357,,,1473,1,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,10576,B,,CHEMBL616596,,11296,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1474,1,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,B,,CHEMBL616597,,11296,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1475,1,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,B,,CHEMBL616598,,11296,,Expert,,,8,H,,10000000.0
,BAO_0000249,,,1476,1,,Membranes,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10576,F,,CHEMBL616599,,16616,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,Hippocampus,,1477,1,,Membranes,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,F,,CHEMBL616600,,16616,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000019,,,1478,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,10576,B,,CHEMBL616601,,16567,,Autocuration,,,8,H,,
,BAO_0000019,,,1479,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,10576,B,,CHEMBL616602,,16567,,Autocuration,,,8,H,,
,BAO_0000019,,,1480,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,10576,B,,CHEMBL616603,,16567,,Autocuration,,,8,H,,
,BAO_0000019,,,1481,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,10576,B,,CHEMBL616604,,16567,,Autocuration,,,8,H,,
,BAO_0000249,,,1482,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,10576,B,,CHEMBL616316,,17136,,Autocuration,,,8,H,,
,BAO_0000249,,,1483,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,10576,B,,CHEMBL616317,,17136,,Autocuration,,,8,H,,
,BAO_0000019,,,1484,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10576,B,,CHEMBL616318,,16616,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,1485,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10576,B,,CHEMBL616319,,17331,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1486,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10576,B,,CHEMBL616320,,17331,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1487,1,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10576,B,,CHEMBL616321,,17167,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000019,,,1488,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,F,,CHEMBL616322,,15740,,Autocuration,,,8,H,,
,BAO_0000019,,,1489,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,10576,F,,CHEMBL616323,,15740,,Autocuration,,,8,H,,
,BAO_0000357,,,1490,1,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,10576,B,,CHEMBL616324,,4671,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1491,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,B,,CHEMBL616325,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1492,1,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,B,,CHEMBL616326,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1493,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10576,B,,CHEMBL616327,,10058,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1494,1,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616328,,12073,,Autocuration,,,8,H,,
,BAO_0000249,,,1495,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,B,,CHEMBL858110,,2759,,Autocuration,,,8,H,,
,BAO_0000249,,,1496,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,F,,CHEMBL616329,,2759,,Autocuration,,,8,H,,
,BAO_0000249,,,1497,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,B,,CHEMBL616330,,2759,,Autocuration,,,8,H,,
,BAO_0000249,,,1498,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,F,,CHEMBL616331,,2759,,Autocuration,,,8,H,,
,BAO_0000249,,,1499,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,F,,CHEMBL616332,,2759,,Autocuration,,,8,H,,
,BAO_0000249,Brain,,1500,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10576,B,,CHEMBL857063,,9737,,Autocuration,,,8,H,,955.0
,BAO_0000019,,,1501,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,10576,B,,CHEMBL616333,,9737,,Autocuration,,,8,H,,
,BAO_0000019,,,1502,1,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,10576,F,,CHEMBL616334,,5717,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1503,1,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,B,,CHEMBL616335,,12253,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1504,1,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,10576,B,,CHEMBL616336,,14025,,Autocuration,,,8,H,,
,BAO_0000249,,,1505,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10576,B,,CHEMBL616337,,10425,,Expert,,,8,H,,
,BAO_0000019,,,1506,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,10576,B,,CHEMBL616338,,14998,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1507,1,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10576,B,,CHEMBL616339,,13694,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,1508,1,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10576,B,,CHEMBL616340,,13694,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1509,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,10576,B,,CHEMBL616341,,4342,,Autocuration,,,8,H,,
,BAO_0000357,,,1510,1,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616342,,12936,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1511,1,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10576,B,,CHEMBL616343,,13144,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1512,1,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,10576,B,,CHEMBL616344,,13343,,Expert,,,8,H,,
,BAO_0000357,,,1513,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,B,,CHEMBL616345,,12132,,Expert,,,8,H,,
,BAO_0000019,,,1514,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,10576,B,,CHEMBL616346,,15419,,Expert,,,8,H,,
,BAO_0000221,Hippocampus,,1515,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,B,,CHEMBL616347,,1479,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,1516,1,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,10576,B,,CHEMBL616348,,14287,,Expert,,,8,H,,
,BAO_0000357,,,1517,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor,10576,B,,CHEMBL616349,,13116,,Expert,,,8,H,,
,BAO_0000249,,,1518,1,,Membranes,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10576,B,,CHEMBL616152,,2759,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,1519,1,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,B,,CHEMBL616153,,2759,,Autocuration,,,8,H,,
,BAO_0000019,,,1520,1,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",10576,B,,CHEMBL616154,,14748,,Expert,,,8,H,,
,BAO_0000019,,,1521,1,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,B,,CHEMBL616155,,12304,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1522,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10576,B,,CHEMBL616156,,12409,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,1523,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10576,B,,CHEMBL616157,,12409,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000221,Hippocampus,,1524,1,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10576,B,,CHEMBL616158,,13267,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1525,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,B,,CHEMBL616159,,15194,,Autocuration,,,8,H,,
,BAO_0000357,,,1526,1,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,10576,B,,CHEMBL616160,,14256,,Expert,,,8,H,,
,BAO_0000019,,,1527,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,10576,B,,CHEMBL616161,,16567,,Autocuration,,,8,H,,
,BAO_0000019,,,1528,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,F,,CHEMBL616162,,15740,,Autocuration,,,8,H,,
,BAO_0000357,,,1529,1,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,B,,CHEMBL616163,,13278,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,1530,1,,Membranes,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10626,B,,CHEMBL616164,,1970,,Expert,,,8,H,,
,BAO_0000221,Brain,,1531,1,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10576,B,,CHEMBL616165,,10034,,Autocuration,,,8,H,,955.0
,BAO_0000019,,,1532,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,51,B,,CHEMBL616355,,13348,10116.0,Autocuration,,,8,H,Rattus norvegicus,
,BAO_0000019,,,1533,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,F,,CHEMBL616356,,13630,,Autocuration,,,8,H,,
,BAO_0000221,Brain,,1534,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,B,,CHEMBL616357,,10862,,Autocuration,,,8,H,,955.0
,BAO_0000019,,,1535,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,B,,CHEMBL616358,,12058,,Autocuration,,,8,H,,
,BAO_0000357,,,1536,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616359,,4639,,Autocuration,,,8,H,,
,BAO_0000357,,,1537,1,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,51,B,,CHEMBL616360,,15453,,Expert,,,8,H,,
,BAO_0000357,,,1538,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616361,,4820,,Expert,,,8,H,,
,BAO_0000357,,,1539,1,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616362,,1089,,Autocuration,,,8,H,,
,BAO_0000249,,,1540,1,,Brain membranes,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,51,B,,CHEMBL616363,,386,,Autocuration,,,8,H,,
,BAO_0000357,,,1541,1,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,51,B,,CHEMBL616364,,6011,,Autocuration,,,8,H,,
,BAO_0000357,,,1542,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616365,,5014,,Autocuration,,,8,H,,
,BAO_0000357,,,1543,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL616366,,4402,,Expert,,,8,H,,
,BAO_0000357,,,1544,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL872906,,17066,,Expert,,,8,H,,
,BAO_0000357,,,1545,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,51,B,,CHEMBL616367,,17515,,Autocuration,,,8,H,,
,BAO_0000357,,,1546,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616368,,2474,,Autocuration,,,8,H,,
,BAO_0000357,,,1547,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,51,B,,CHEMBL616369,,4775,,Autocuration,,,8,H,,
,BAO_0000357,,,1548,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,51,B,,CHEMBL616370,,14294,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1549,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,51,B,,CHEMBL616371,,14294,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1550,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,B,449.0,CHEMBL616372,CHO,12249,,Autocuration,,,8,H,,
,BAO_0000219,,,1551,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,51,B,,CHEMBL616373,,11376,,Expert,,,8,H,,
In vivo,BAO_0000218,,,1552,1,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,B,,CHEMBL616374,,2474,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,1553,1,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,B,,CHEMBL616375,,13311,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,1554,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,51,B,,CHEMBL616376,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,1555,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,51,B,,CHEMBL857064,,1633,,Expert,,,8,H,,
,BAO_0000357,,,1556,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,B,,CHEMBL616377,,11866,,Autocuration,,,8,H,,
,BAO_0000357,,,1557,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,B,,CHEMBL616378,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,1558,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,51,B,,CHEMBL616379,,4687,,Autocuration,,,8,H,,
,BAO_0000357,,,1559,1,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616380,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,1560,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,11863,B,,CHEMBL616381,,13291,,Autocuration,,,8,H,,
,BAO_0000357,,,1561,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616382,,14159,,Autocuration,,,8,H,,
,BAO_0000357,,,1562,1,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,11863,B,,CHEMBL616383,,10812,,Autocuration,,,8,H,,
,BAO_0000219,,,1563,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,11863,B,449.0,CHEMBL616350,CHO,3032,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,1564,1,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616351,,16655,,Autocuration,,,8,H,,
,BAO_0000357,,,1565,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,11863,B,,CHEMBL616352,,14532,,Autocuration,,,8,H,,
,BAO_0000357,,,1566,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616353,,13944,,Autocuration,,,8,H,,
,BAO_0000357,,,1567,1,,,Binding affinity against serotonergic 5-HT1a receptor,11863,B,,CHEMBL616354,,13033,,Autocuration,,,8,H,,
,BAO_0000357,,,1568,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,11863,B,,CHEMBL616508,,10321,,Autocuration,,,8,H,,
,BAO_0000357,,,1569,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616559,,2968,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,1570,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616560,,13964,,Autocuration,,,8,H,,
,BAO_0000357,,,1571,1,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",11863,B,,CHEMBL616561,,15527,,Autocuration,,,8,H,,
,BAO_0000219,,,1572,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,B,449.0,CHEMBL616562,CHO,12248,,Autocuration,,,8,H,,
,BAO_0000219,,,1573,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,B,449.0,CHEMBL616563,CHO,12249,,Autocuration,,,8,H,,
,BAO_0000357,,,1574,1,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616564,,15120,,Autocuration,,,8,H,,
,BAO_0000357,,,1575,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,11863,B,,CHEMBL616565,,13313,,Autocuration,,,8,H,,
,BAO_0000218,,,1576,1,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616566,,2613,,Autocuration,,,8,H,,
,BAO_0000357,,,1577,1,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,11863,B,,CHEMBL616989,,16700,,Autocuration,,,8,H,,
,BAO_0000357,,,1578,1,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL857975,,2201,,Autocuration,,,8,H,,
,BAO_0000357,,,1579,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616990,,1274,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,1580,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,11863,B,,CHEMBL616991,,1317,,Autocuration,,,8,H,,
,BAO_0000357,,,1581,1,,,Tested against 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616992,,12146,,Autocuration,,,8,H,,
,BAO_0000357,,,1582,1,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,11863,B,,CHEMBL616993,,14059,,Autocuration,,,8,H,,
,BAO_0000019,,,1583,1,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,106,B,,CHEMBL616994,,14025,9986.0,Expert,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,,,1584,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,106,B,,CHEMBL616995,,14025,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000219,,,1585,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105571,B,722.0,CHEMBL616996,HEK293,14447,9593.0,Intermediate,,,9,D,Gorilla gorilla,
In vivo,BAO_0000218,,,1586,1,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,F,,CHEMBL616997,,3025,10141.0,Autocuration,,,8,H,Cavia porcellus,
In vivo,BAO_0000218,,,1587,1,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,F,,CHEMBL616998,,3025,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,1588,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,106,F,,CHEMBL616999,,15329,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,1589,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,106,F,,CHEMBL617000,,15329,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,1590,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,106,F,,CHEMBL617001,,15847,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,1591,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,106,F,,CHEMBL858111,,15847,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,1592,1,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,106,F,,CHEMBL617002,,14165,,Autocuration,,,8,H,,
,BAO_0000019,,,1593,1,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),106,F,,CHEMBL617003,,14214,,Autocuration,,,8,H,,
,BAO_0000019,,,1594,1,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),106,F,,CHEMBL617004,,14214,,Autocuration,,,8,H,,
,BAO_0000019,,,1595,1,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,106,F,,CHEMBL617005,,14214,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1596,1,,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,106,F,485.0,CHEMBL616623,CHO-K1,13729,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1597,1,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,106,F,449.0,CHEMBL616624,CHO,3025,,Autocuration,,,8,H,,
,BAO_0000357,,,1598,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL883243,,2391,,Autocuration,,,8,H,,
,BAO_0000019,,,1599,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,106,F,,CHEMBL616625,,2391,,Autocuration,,,8,H,,
,BAO_0000219,,,1600,1,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",106,F,449.0,CHEMBL616626,CHO,14956,,Expert,,,8,H,,
,BAO_0000219,,,1601,1,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,106,F,449.0,CHEMBL616627,CHO,2598,,Autocuration,,,8,H,,
,BAO_0000219,,,1602,1,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,106,F,449.0,CHEMBL616628,CHO,2598,,Autocuration,,,8,H,,
,BAO_0000219,,,1603,1,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,106,F,449.0,CHEMBL616629,CHO,2598,,Autocuration,,,8,H,,
,BAO_0000219,,,1604,1,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,106,F,449.0,CHEMBL616630,CHO,2598,,Autocuration,,,8,H,,
,BAO_0000019,,,1605,1,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",106,F,,CHEMBL616631,,14956,,Expert,,,8,H,,
,BAO_0000019,,,1606,1,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",106,F,,CHEMBL616632,,14956,,Autocuration,,,8,H,,
,BAO_0000357,,,1607,1,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616633,,14214,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1608,1,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,106,B,449.0,CHEMBL616634,CHO,3463,,Expert,,,8,H,,
,BAO_0000357,,,1609,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,106,B,,CHEMBL616635,,15331,,Autocuration,,,8,H,,
,BAO_0000357,,,1610,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL885358,,16146,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1611,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,B,449.0,CHEMBL616636,CHO,14159,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1612,1,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,106,B,449.0,CHEMBL616637,CHO,14158,,Expert,,,8,H,,
,BAO_0000357,,,1613,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616638,,14159,,Autocuration,,,8,H,,
,BAO_0000219,,,1614,1,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,B,449.0,CHEMBL616639,CHO,15250,,Expert,,,8,H,,
,BAO_0000219,,,1615,1,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,106,B,449.0,CHEMBL616640,CHO,15250,,Expert,,,8,H,,
,BAO_0000219,,,1616,1,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,B,449.0,CHEMBL616641,CHO,15331,,Expert,,,8,H,,
,BAO_0000219,,,1617,1,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,106,B,449.0,CHEMBL616642,CHO,15332,,Expert,,,8,H,,
,BAO_0000219,,,1618,1,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,B,449.0,CHEMBL616643,CHO,14956,,Expert,,,8,H,,
,BAO_0000357,,,1619,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),106,B,,CHEMBL616644,,3805,,Autocuration,,,8,H,,
,BAO_0000357,,,1620,1,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,106,B,,CHEMBL616645,,14875,,Autocuration,,,8,H,,
,BAO_0000019,,,1621,1,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,F,,CHEMBL616646,,14454,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,,,1622,1,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,F,,CHEMBL616647,,14454,9986.0,Expert,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,1623,1,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),105,B,,CHEMBL616509,,16288,,Autocuration,,,8,H,,
,BAO_0000357,,,1624,1,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),105,B,,CHEMBL616510,,16288,,Autocuration,,,8,H,,
,BAO_0000357,,,1625,1,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616511,,16312,,Autocuration,,,8,H,,
,BAO_0000357,,,1626,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,105,B,,CHEMBL616512,,1348,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000357,,,1627,1,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,105,B,,CHEMBL616513,,5834,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000019,Striatum,,1628,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,B,,CHEMBL616514,,13366,9913.0,Autocuration,,,8,H,Bos taurus,2435.0
,BAO_0000357,,,1629,1,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,105,B,,CHEMBL616515,,1414,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000019,,,1630,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,105,B,,CHEMBL616516,,14998,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1631,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,B,,CHEMBL616517,,11473,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1632,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,B,,CHEMBL616518,,11473,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1633,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,B,,CHEMBL616519,,10639,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1634,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,B,,CHEMBL616520,,10639,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1635,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,105,B,,CHEMBL616521,,1375,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1636,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,105,B,,CHEMBL616522,,1375,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1637,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,B,,CHEMBL884531,,16532,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1638,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,105,B,,CHEMBL616523,,11147,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000019,Striatum,,1639,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,B,,CHEMBL616731,,13366,9913.0,Autocuration,,,8,H,Bos taurus,2435.0
,BAO_0000019,,,1640,1,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,105,B,,CHEMBL616732,,10444,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1641,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,105,B,,CHEMBL616733,,16532,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1642,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,B,,CHEMBL616734,,16532,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000249,,,1643,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,105,B,,CHEMBL616735,,12827,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000249,,,1644,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,105,B,,CHEMBL616736,,12827,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000019,,,1645,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,F,,CHEMBL616737,,12919,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000019,,,1646,1,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,105,B,,CHEMBL616738,,14025,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000019,,,1647,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,F,,CHEMBL616739,,12919,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000019,,,1648,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,F,,CHEMBL616740,,12919,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000019,,,1649,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,F,,CHEMBL616741,,12919,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000219,,,1650,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105,B,722.0,CHEMBL616742,HEK293,14447,9593.0,Autocuration,,,8,H,Gorilla gorilla,
,BAO_0000019,,,1651,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,105570,B,,CHEMBL616743,,1375,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,1652,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,105570,B,,CHEMBL616744,,1375,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,1653,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,105570,F,,CHEMBL616745,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,1654,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,F,,CHEMBL616746,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,1655,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,105570,F,,CHEMBL616747,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,1656,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,105570,F,,CHEMBL616748,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,1657,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,105570,F,,CHEMBL616648,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,1658,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,105570,B,,CHEMBL616649,,11574,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,1659,1,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,105570,B,,CHEMBL616650,,1558,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000218,,,1660,1,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,F,,CHEMBL616651,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000218,,,1661,1,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,F,,CHEMBL616652,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000218,,,1662,1,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,F,,CHEMBL616653,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000218,,,1663,1,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,105570,F,,CHEMBL616654,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,1664,1,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,105570,B,,CHEMBL616655,,12253,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,1665,1,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,105570,B,,CHEMBL616656,,12936,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,1666,1,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,105,B,,CHEMBL616657,,13181,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,Striatum,,1667,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,105570,B,,CHEMBL616658,,12409,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000357,,,1668,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,105570,B,,CHEMBL616659,,10639,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,1669,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,51,B,,CHEMBL616660,,5254,,Autocuration,,,8,H,,
,BAO_0000357,,,1670,1,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,106,B,,CHEMBL616661,,13051,,Autocuration,,,8,H,,
,BAO_0000019,,,1671,1,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,105,F,,CHEMBL616662,,3463,,Expert,,,8,H,,
,BAO_0000019,,,1672,1,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,105,F,,CHEMBL616663,,15315,,Autocuration,,,8,H,,
,BAO_0000019,,,1673,1,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,105,F,,CHEMBL616664,,6011,,Autocuration,,,8,H,,
,BAO_0000219,,,1674,1,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",105,F,449.0,CHEMBL881820,CHO,14159,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1675,1,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",105,F,449.0,CHEMBL616665,CHO,14159,,Autocuration,,,8,H,,
,BAO_0000219,,,1676,1,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,B,449.0,CHEMBL616666,CHO,15250,,Expert,,,8,H,,
,BAO_0000219,,,1677,1,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,105,B,449.0,CHEMBL616667,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000219,,,1678,1,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,F,449.0,CHEMBL616668,CHO,15331,,Expert,,,8,H,,
,BAO_0000219,,,1679,1,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,F,449.0,CHEMBL616669,CHO,15332,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1680,1,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",105,F,449.0,CHEMBL617040,CHO,15332,,Expert,,,8,H,,
,BAO_0000219,,,1681,1,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",105,F,449.0,CHEMBL617041,CHO,3294,,Autocuration,,,8,H,,
,BAO_0000219,,,1682,1,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",105,F,449.0,CHEMBL617042,CHO,14158,,Expert,,,8,H,,
,BAO_0000219,,,1683,1,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",105,F,449.0,CHEMBL617043,CHO,14956,,Expert,,,8,H,,
,BAO_0000019,,,1684,1,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,105,F,,CHEMBL617044,,12469,,Autocuration,,,8,H,,
,BAO_0000219,,,1685,1,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,F,449.0,CHEMBL617045,CHO,3463,,Expert,,,8,H,,
,BAO_0000219,,,1686,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,F,449.0,CHEMBL617046,CHO,15250,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1687,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,F,449.0,CHEMBL617047,CHO,15250,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,1688,1,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",105,F,,CHEMBL617048,,14956,,Expert,,,8,H,,
,BAO_0000019,,,1689,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",105,F,,CHEMBL616897,,14159,,Autocuration,,,8,H,,
,BAO_0000019,,,1690,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",105,F,,CHEMBL616898,,14159,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1691,1,,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,105,F,449.0,CHEMBL858201,CHO,14499,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,1692,1,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,105,F,,CHEMBL616899,,15315,,Autocuration,,,8,H,,
In vitro,BAO_0000219,,,1693,1,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),105,B,,CHEMBL616900,,3294,,Autocuration,,,8,H,,
,BAO_0000219,,,1694,1,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,105,B,449.0,CHEMBL616901,CHO,3463,,Expert,,,8,H,,
,BAO_0000357,,,1695,1,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,105,B,,CHEMBL616902,,15331,,Autocuration,,,8,H,,
,BAO_0000219,,,1696,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,B,449.0,CHEMBL616903,CHO,14159,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1697,1,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,105,B,449.0,CHEMBL616904,CHO,14158,,Expert,,,8,H,,
,BAO_0000357,,,1698,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616905,,14159,,Autocuration,,,8,H,,
,BAO_0000219,,,1699,1,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,105,B,449.0,CHEMBL616906,CHO,15250,,Expert,,,8,H,,
,BAO_0000219,,,1700,1,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,B,449.0,CHEMBL616907,CHO,15250,,Expert,,,8,H,,
,BAO_0000219,,,1701,1,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,B,449.0,CHEMBL616908,CHO,15331,,Expert,,,8,H,,
,BAO_0000219,,,1702,1,,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,B,449.0,CHEMBL616909,CHO,15332,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1703,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,B,449.0,CHEMBL616910,CHO,14499,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1704,1,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,B,449.0,CHEMBL616911,CHO,15332,,Expert,,,8,H,,
,BAO_0000219,,,1705,1,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,B,449.0,CHEMBL616912,CHO,14956,,Expert,,,8,H,,
,BAO_0000357,,,1706,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),105,B,,CHEMBL616913,,3805,,Autocuration,,,8,H,,
,BAO_0000219,,,1707,1,,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,105,B,449.0,CHEMBL616914,CHO,6011,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1708,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,B,449.0,CHEMBL616915,CHO,16190,,Autocuration,,,8,H,,
,BAO_0000019,,,1709,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,105,B,,CHEMBL616916,,14165,,Autocuration,,,8,H,,
,BAO_0000357,,,1710,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616917,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1711,1,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",105,B,,CHEMBL616918,,15527,,Autocuration,,,8,H,,
,BAO_0000219,,,1712,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,105,B,,CHEMBL616919,,6328,,Expert,,,8,H,,
,BAO_0000357,,,1713,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,105,B,,CHEMBL616920,,16209,,Autocuration,,,8,H,,
,BAO_0000357,,,1714,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,105,B,,CHEMBL872914,,14770,,Autocuration,,,8,H,,
,BAO_0000357,,,1715,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,105,B,,CHEMBL616921,,2598,,Autocuration,,,8,H,,
,BAO_0000357,,,1716,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616922,,6897,,Expert,,,8,H,,
,BAO_0000357,,,1717,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616923,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,1718,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616924,,5843,,Expert,,,8,H,,
,BAO_0000357,,,1719,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,105,B,,CHEMBL875909,,14454,,Expert,,,8,H,,
,BAO_0000357,,,1720,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,105,B,,CHEMBL616925,,14454,,Autocuration,,,8,H,,
,BAO_0000357,,,1721,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,105,B,,CHEMBL616926,,14454,,Autocuration,,,8,H,,
,BAO_0000357,,,1722,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616927,,15818,,Autocuration,,,8,H,,
,BAO_0000219,,,1723,1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,105,F,485.0,CHEMBL616928,CHO-K1,13729,,Expert,,,8,H,,
In vitro,BAO_0000219,,,1724,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),105,B,,CHEMBL616929,,6011,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1725,1,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616930,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,1726,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616931,,17085,,Expert,,,8,H,,
,BAO_0000357,,,1727,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,105,B,,CHEMBL616932,,3025,,Autocuration,,,8,H,,
,BAO_0000357,,,1728,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616933,,15315,,Expert,,,8,H,,
,BAO_0000219,,,1729,1,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,105,B,,CHEMBL616934,,14214,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1730,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616935,,3804,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1731,1,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,105,B,,CHEMBL616936,,16700,,Autocuration,,,8,H,,
,BAO_0000357,,,1732,1,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,105,B,,CHEMBL616937,,2391,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1733,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616938,,4175,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,1734,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616939,,17085,,Autocuration,,,8,H,,
,BAO_0000019,,,1735,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,105,B,,CHEMBL616940,,17085,,Expert,,,8,H,,
,BAO_0000357,,,1736,1,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,105,B,,CHEMBL616941,,15926,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1737,1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,105,B,485.0,CHEMBL616942,CHO-K1,16312,,Autocuration,,,8,H,,
,BAO_0000219,,,1738,1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,105,B,485.0,CHEMBL616943,CHO-K1,16312,,Autocuration,,,8,H,,
,BAO_0000219,,,1739,1,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,104802,B,449.0,CHEMBL616944,CHO,14956,,Autocuration,,,4,H,,
,BAO_0000019,,,1740,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",105,F,,CHEMBL616945,,3294,,Autocuration,,,8,H,,
,BAO_0000357,,,1741,1,,,Binding activity radioligand.,105,B,,CHEMBL616946,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,1742,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,105,B,,CHEMBL616947,,12861,,Autocuration,,,8,H,,
,BAO_0000219,,,1743,1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,105,B,485.0,CHEMBL616948,CHO-K1,16312,,Expert,,,8,H,,
,BAO_0000357,,,1744,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616851,,5104,,Autocuration,,,8,H,,
,BAO_0000357,,,1745,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616852,,5105,,Autocuration,,,8,H,,
,BAO_0000357,,,1746,1,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616853,,14499,,Autocuration,,,8,H,,
,BAO_0000357,,,1747,1,,,Binding activity against human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616854,,15926,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1748,1,,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,B,449.0,CHEMBL616855,CHO,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1749,1,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,105,B,449.0,CHEMBL616856,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1750,1,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,105,B,449.0,CHEMBL616857,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000357,,,1751,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616858,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,1752,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,105,B,449.0,CHEMBL616859,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1753,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,105,B,449.0,CHEMBL616860,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,1754,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,B,722.0,CHEMBL616861,HEK293,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,1755,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,B,722.0,CHEMBL616541,HEK293,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,1756,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,105,B,722.0,CHEMBL616542,HEK293,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,1757,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,105,B,449.0,CHEMBL616543,CHO,4199,,Autocuration,,,8,H,,
,BAO_0000357,,,1758,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL616544,,14875,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,1759,1,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,105,B,449.0,CHEMBL616545,CHO,15146,,Autocuration,,,8,H,,
,BAO_0000357,,,1760,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,105,B,,CHEMBL616546,,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,1761,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,105,B,449.0,CHEMBL616547,CHO,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,1762,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",105,B,449.0,CHEMBL616548,CHO,4829,,Autocuration,,,8,H,,
,BAO_0000019,,,1763,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,105,F,,CHEMBL616549,,14454,,Expert,,,8,H,,
,BAO_0000019,,,1764,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,105,F,,CHEMBL616550,,14454,,Expert,,,8,H,,
,BAO_0000357,,,1765,1,,,Binding affinity against 5-HT2C receptor,108,B,,CHEMBL857066,,5254,,Autocuration,,,8,H,,
,BAO_0000357,,,1766,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,108,B,,CHEMBL616551,,5254,,Autocuration,,,8,H,,
,BAO_0000357,,,1767,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,B,,CHEMBL616552,,10639,,Autocuration,,,8,H,,
,BAO_0000019,,,1768,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,F,,CHEMBL832876,,10639,,Autocuration,,,8,H,,
,BAO_0000019,,,1769,1,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",10577,B,,CHEMBL616553,,12352,,Expert,,,8,H,,
,BAO_0000357,,,1770,1,,,Binding affinity towards 5-HT1B was determined,10577,B,,CHEMBL616554,,9098,,Autocuration,,,8,H,,
,BAO_0000019,,,1771,1,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,10577,B,,CHEMBL616555,,14430,,Expert,,,8,H,,
,BAO_0000019,,,1772,1,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",10577,B,,CHEMBL616556,,13657,,Expert,,,8,H,,
,BAO_0000019,,,1773,1,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",10577,B,,CHEMBL616557,,13657,,Autocuration,,,8,H,,
,BAO_0000019,,,1774,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10577,B,,CHEMBL616558,,15854,,Expert,,,8,H,,
,BAO_0000019,,,1775,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10577,B,,CHEMBL616749,,10639,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1776,1,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,B,,CHEMBL616750,,10025,,Autocuration,,,8,H,,
,BAO_0000357,,,1777,1,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10577,B,,CHEMBL616751,,10025,,Autocuration,,,8,H,,
,BAO_0000249,,,1778,1,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,B,,CHEMBL616752,,14286,,Autocuration,,,8,H,,
,BAO_0000019,Striatum,,1779,1,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,10577,B,,CHEMBL616753,,3651,,Autocuration,,,8,H,,2435.0
,BAO_0000357,,,1780,1,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL616754,,14178,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1781,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10577,B,,CHEMBL616755,,10639,,Autocuration,,,8,H,,
,BAO_0000019,Striatum,,1782,1,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,10577,B,,CHEMBL616756,,13605,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,1783,1,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,10577,B,,CHEMBL616757,,5834,,Autocuration,,,8,H,,2435.0
,BAO_0000357,Striatum,,1784,1,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10577,B,,CHEMBL616758,,10922,,Autocuration,,,8,H,,2435.0
,BAO_0000249,,,1785,1,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,B,,CHEMBL616759,,14286,,Autocuration,,,8,H,,
,BAO_0000357,,,1786,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,10577,B,,CHEMBL616760,,11825,,Autocuration,,,8,H,,
,BAO_0000019,Striatum,,1787,1,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,10577,B,,CHEMBL616761,,14826,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,1788,1,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,10577,B,,CHEMBL616762,,9699,,Autocuration,,,8,H,,2435.0
,BAO_0000019,,,1789,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,10577,B,,CHEMBL616763,,14423,,Autocuration,,,8,H,,
,BAO_0000357,,,1790,1,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10577,B,,CHEMBL872909,,10062,,Expert,,,8,H,,
,BAO_0000357,,,1791,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL616764,,10062,,Autocuration,,,8,H,,
,BAO_0000357,,,1792,1,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL616765,,12280,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,Striatum,,1793,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,10577,B,,CHEMBL616766,,15412,,Autocuration,,,8,H,,2435.0
,BAO_0000357,Striatum,,1794,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,10577,B,,CHEMBL616767,,15412,,Autocuration,,,8,H,,2435.0
,BAO_0000357,,,1795,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL616768,,10062,,Autocuration,,,8,H,,
,BAO_0000357,,,1796,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,B,,CHEMBL616769,,11147,,Autocuration,,,8,H,,
,BAO_0000019,,,1797,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,10577,B,,CHEMBL616770,,9547,,Autocuration,,,8,H,,
,BAO_0000019,,,1798,1,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10577,B,,CHEMBL616771,,10444,,Autocuration,,,8,H,,
,BAO_0000019,Striatum,,1799,1,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,10577,B,,CHEMBL616772,,12469,,Autocuration,,,8,H,,2435.0
,BAO_0000019,,,1800,1,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,10577,B,,CHEMBL616773,,9098,,Expert,,,8,H,,
,BAO_0000019,,,1801,1,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,10577,B,,CHEMBL616774,,9098,,Autocuration,,,8,H,,
,BAO_0000357,,,1802,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL616775,,9699,,Autocuration,,,8,H,,
,BAO_0000249,,,1803,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10577,B,,CHEMBL616776,,10394,,Autocuration,,,8,H,,
,BAO_0000357,,,1804,1,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,10577,B,,CHEMBL616777,,12092,,Autocuration,,,8,H,,
,BAO_0000357,,,1805,1,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,10577,B,,CHEMBL616778,,16700,,Autocuration,,,8,H,,
,BAO_0000249,,,1806,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10577,B,,CHEMBL616779,,403,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1807,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL616780,,12771,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1808,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,10577,B,,CHEMBL616781,,11642,,Autocuration,,,8,H,,
,BAO_0000357,,,1809,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,10577,B,,CHEMBL616782,,12953,,Autocuration,,,8,H,,
,BAO_0000357,,,1810,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,10577,B,,CHEMBL616783,,12953,,Autocuration,,,8,H,,
,BAO_0000019,Striatum,,1811,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,10577,B,,CHEMBL616784,,12953,,Expert,,,8,H,,2435.0
,BAO_0000357,,,1812,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,10577,B,,CHEMBL616785,,12953,,Autocuration,,,8,H,,
,BAO_0000249,Brain,,1813,1,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,B,,CHEMBL857067,,9737,,Autocuration,,,8,H,,955.0
,BAO_0000019,,,1814,1,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,10577,B,,CHEMBL616786,,9737,,Autocuration,,,8,H,,
,BAO_0000249,Brain,,1815,1,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,B,,CHEMBL616787,,9737,,Autocuration,,,8,H,,955.0
,BAO_0000357,,,1816,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,10577,B,,CHEMBL616788,,12827,,Autocuration,,,8,H,,
,BAO_0000357,,,1817,1,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL616789,,5033,,Autocuration,,,8,H,,
,BAO_0000019,,,1818,1,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10577,B,,CHEMBL616790,,9786,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1819,1,,,Binding affinity at 5-hydroxytryptamine 1B receptor,10577,B,,CHEMBL616791,,13116,,Expert,,,8,H,,
,BAO_0000019,,,1820,1,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,10577,B,,CHEMBL616792,,16429,,Autocuration,,,8,H,,
,BAO_0000249,,,1821,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10577,B,,CHEMBL616793,,12409,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1822,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,B,,CHEMBL616794,,15194,,Autocuration,,,8,H,,
,BAO_0000357,,,1823,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,10577,B,,CHEMBL616795,,15194,,Autocuration,,,8,H,,
,BAO_0000019,,,1824,1,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,104686,B,,CHEMBL616796,,5486,,Autocuration,,,4,H,,
,BAO_0000357,,,1825,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616797,,4639,,Autocuration,,,8,H,,
,BAO_0000249,,,1826,1,,Brain membranes,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,106,B,,CHEMBL616798,,386,,Autocuration,,,8,H,,
,BAO_0000357,,,1827,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,106,B,,CHEMBL616799,,2474,,Autocuration,,,8,H,,
,BAO_0000357,,,1828,1,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,106,B,,CHEMBL616800,,6011,,Autocuration,,,8,H,,
,BAO_0000357,,,1829,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616801,,5014,,Autocuration,,,8,H,,
,BAO_0000357,,,1830,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,106,B,,CHEMBL616802,,17515,,Autocuration,,,8,H,,
,BAO_0000357,,,1831,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,106,B,,CHEMBL616803,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,1832,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,106,B,,CHEMBL857068,,1633,,Expert,,,8,H,,
,BAO_0000357,,,1833,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,106,B,,CHEMBL616804,,1633,,Autocuration,,,8,H,,
,BAO_0000357,,,1834,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,106,B,,CHEMBL616805,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,1835,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616806,,4687,,Autocuration,,,8,H,,
,BAO_0000357,,,1836,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor,106,B,,CHEMBL616807,,11574,,Autocuration,,,8,H,,
,BAO_0000357,,,1837,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,106,B,,CHEMBL616808,,10321,,Autocuration,,,8,H,,
,BAO_0000357,,,1838,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,B,,CHEMBL616809,,15527,,Autocuration,,,8,H,,
,BAO_0000357,,,1839,1,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,106,B,,CHEMBL616810,,17200,,Autocuration,,,8,H,,
,BAO_0000224,,,1840,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,104802,B,,CHEMBL616811,,14423,,Autocuration,,,4,H,,
,BAO_0000357,,,1841,1,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,108,B,,CHEMBL616812,,5834,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,1842,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,108,B,,CHEMBL616813,,11473,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1843,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,108,B,,CHEMBL616814,,11473,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1844,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,B,,CHEMBL616815,,10639,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1845,1,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,B,,CHEMBL616816,,10639,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1846,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,108,B,,CHEMBL616817,,14331,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1847,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,108,B,,CHEMBL616818,,10796,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1848,1,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,108,B,,CHEMBL616819,,9098,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000357,,,1849,1,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,108,B,,CHEMBL616820,,14331,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000019,,,1850,1,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,108,B,,CHEMBL616821,,11828,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000357,,,1851,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,108,B,,CHEMBL616822,,11866,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,1852,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,108,B,,CHEMBL616823,,13047,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,1853,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,12689,B,,CHEMBL616824,,188,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1854,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,B,,CHEMBL616825,,11825,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1855,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,B,,CHEMBL616826,,11825,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1856,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,12689,B,,CHEMBL616827,,11624,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1857,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,12689,B,,CHEMBL616828,,11139,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1858,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,12689,B,,CHEMBL616829,,11147,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1859,1,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,12689,B,,CHEMBL616830,,10444,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1860,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,B,,CHEMBL616831,,11624,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1861,1,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,B,,CHEMBL616832,,11662,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1862,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,B,,CHEMBL616833,,11662,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1863,1,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,B,,CHEMBL616834,,11662,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1864,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,B,,CHEMBL829595,,11662,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1865,1,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,12689,B,,CHEMBL616835,,9098,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000249,,,1866,1,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,12689,B,,CHEMBL872910,,10394,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1867,1,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,12689,B,,CHEMBL616836,,11933,,Expert,,,8,H,,
,BAO_0000357,,,1868,1,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12689,B,,CHEMBL616837,,12092,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000019,,,1869,1,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12689,B,,CHEMBL616466,,12253,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000219,,,1870,1,,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12689,B,722.0,CHEMBL616467,HEK293,12253,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,1871,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,108,B,,CHEMBL616468,,1558,,Autocuration,,,8,H,,
,BAO_0000357,,,1872,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,B,,CHEMBL616469,,2474,,Autocuration,,,8,H,,
,BAO_0000357,,,1873,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,B,,CHEMBL616470,,2474,,Autocuration,,,8,H,,
,BAO_0000357,,,1874,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,B,,CHEMBL616471,,11574,,Autocuration,,,8,H,,
,BAO_0000357,,,1875,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,12689,B,,CHEMBL616472,,1558,,Autocuration,,,8,H,,
,BAO_0000357,,,1876,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,B,,CHEMBL616473,,13944,,Autocuration,,,8,H,,
,BAO_0000357,,,1877,1,,,Binding affinity against serotonergic 5-HT1c receptor,12689,B,,CHEMBL616474,,13033,,Autocuration,,,8,H,,
,BAO_0000357,,,1878,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,12689,B,,CHEMBL616475,,10321,,Autocuration,,,8,H,,
,BAO_0000357,,,1879,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,12689,B,,CHEMBL616476,,11866,,Autocuration,,,8,H,,
,BAO_0000019,,,1880,1,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,B,,CHEMBL616477,,14454,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000224,,,1881,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,104686,B,,CHEMBL616478,,11574,,Autocuration,,,4,H,,
,BAO_0000224,,,1882,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,104686,B,,CHEMBL616479,,11574,,Autocuration,,,4,H,,
,BAO_0000019,,,1883,1,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,104686,B,,CHEMBL616480,,13631,,Autocuration,,,4,H,,
,BAO_0000019,,,1884,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,104686,B,,CHEMBL616481,,9630,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000249,,,1885,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,104686,B,,CHEMBL616482,,8822,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000221,Brain,,1886,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,104686,B,,CHEMBL884713,,9064,10116.0,Autocuration,,,5,D,Rattus norvegicus,955.0
,BAO_0000224,,,1887,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,104686,B,,CHEMBL616483,,8868,,Autocuration,,,4,H,,
,BAO_0000224,,,1888,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,104686,B,,CHEMBL616484,,9064,,Autocuration,,,4,H,,
,BAO_0000019,,,1889,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,104686,B,,CHEMBL616485,,9806,,Autocuration,,,4,H,,
,BAO_0000224,,,1890,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,B,,CHEMBL616486,,9098,,Autocuration,,,4,H,,
,BAO_0000224,,,1891,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,104686,B,,CHEMBL616487,,8868,,Autocuration,,,4,H,,
,BAO_0000224,,,1892,1,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,B,,CHEMBL616488,,12765,,Autocuration,,,4,H,,
,BAO_0000019,,,1893,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,B,,CHEMBL616489,,11049,,Autocuration,,,4,H,,
,BAO_0000019,,,1894,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,B,,CHEMBL616490,,11049,,Autocuration,,,4,H,,
,BAO_0000019,,,1895,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,104686,B,,CHEMBL616491,,11049,,Autocuration,,,4,H,,
,BAO_0000019,,,1896,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,104686,B,,CHEMBL616492,,11049,,Autocuration,,,4,H,,
,BAO_0000019,,,1897,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,B,,CHEMBL616493,,11049,,Autocuration,,,4,H,,
,BAO_0000019,,,1898,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,104686,B,,CHEMBL616494,,11473,,Autocuration,,,4,H,,
,BAO_0000019,,,1899,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,104686,B,,CHEMBL616495,,11473,,Autocuration,,,4,H,,
,BAO_0000019,,,1900,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,104686,B,,CHEMBL616496,,3086,,Autocuration,,,4,H,,
,BAO_0000019,,,1901,1,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,B,,CHEMBL616497,,11049,,Autocuration,,,4,H,,
,BAO_0000019,,,1902,1,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,B,,CHEMBL616498,,11049,,Autocuration,,,4,H,,
,BAO_0000019,,,1903,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,104686,B,,CHEMBL616499,,10639,,Autocuration,,,4,H,,
,BAO_0000019,,,1904,1,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,104686,B,,CHEMBL616500,,10922,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,1905,1,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,B,,CHEMBL616501,,9064,10116.0,Autocuration,,,5,D,Rattus norvegicus,955.0
,BAO_0000221,Brain,,1906,1,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,104686,B,,CHEMBL616502,,10748,,Autocuration,,,4,H,,955.0
,BAO_0000249,,,1907,1,,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,B,,CHEMBL884529,,11614,,Autocuration,,,4,H,,
,BAO_0000249,,,1908,1,,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,B,,CHEMBL616503,,11615,,Autocuration,,,4,H,,
,BAO_0000224,,,1909,1,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL616964,,11615,,Autocuration,,,4,H,,
,BAO_0000249,,,1910,1,,Membranes,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,B,,CHEMBL616965,,11614,,Autocuration,,,4,H,,
,BAO_0000224,,,1911,1,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,104686,B,,CHEMBL616966,,11702,,Autocuration,,,4,H,,
,BAO_0000224,,,1912,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,B,,CHEMBL616967,,11702,,Autocuration,,,4,H,,
,BAO_0000224,,,1913,1,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL616968,,11702,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,1914,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,B,,CHEMBL616969,,11702,,Autocuration,,,4,H,,
,BAO_0000019,,,1915,1,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,104686,B,,CHEMBL884530,,13346,,Autocuration,,,4,H,,
,BAO_0000224,,,1916,1,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL616970,,10025,,Autocuration,,,4,H,,
,BAO_0000224,,,1917,1,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,B,,CHEMBL616971,,10025,,Autocuration,,,4,H,,
,BAO_0000224,,,1918,1,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,B,,CHEMBL616972,,10025,,Autocuration,,,4,H,,
,BAO_0000224,,,1919,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,104686,B,,CHEMBL616973,,9036,,Autocuration,,,4,H,,
,BAO_0000224,,,1920,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,104686,B,,CHEMBL616974,,9036,,Autocuration,,,4,H,,
,BAO_0000019,,,1921,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,104686,B,,CHEMBL616975,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,1922,1,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,104686,B,,CHEMBL616976,,12304,,Autocuration,,,4,H,,
,BAO_0000224,,,1923,1,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,104686,B,,CHEMBL616977,,13276,,Autocuration,,,4,H,,
,BAO_0000224,,,1924,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,B,,CHEMBL616978,,11825,,Autocuration,,,4,H,,
,BAO_0000224,,,1925,1,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,104686,B,,CHEMBL616979,,12443,,Autocuration,,,4,H,,
,BAO_0000224,,,1926,1,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL616980,,13830,,Autocuration,,,4,H,,
,BAO_0000249,,,1927,1,,Membranes,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,104686,B,,CHEMBL616981,,9592,,Autocuration,,,4,H,,
,BAO_0000249,,,1928,1,,Membranes,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,104686,B,,CHEMBL616982,,9592,,Autocuration,,,4,H,,
,BAO_0000224,,,1929,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,104686,B,,CHEMBL616983,,10881,,Autocuration,,,4,H,,
,BAO_0000019,,,1930,1,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,104686,B,,CHEMBL616984,,13605,,Autocuration,,,4,H,,
,BAO_0000224,,,1931,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL616985,,11624,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,1932,1,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,B,,CHEMBL616986,,4101,,Autocuration,,,4,H,,
,BAO_0000224,,,1933,1,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,B,,CHEMBL616987,,4101,,Autocuration,,,4,H,,
,BAO_0000019,,,1934,1,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,104686,B,,CHEMBL616988,,15360,,Autocuration,,,4,H,,
,BAO_0000019,,,1935,1,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,104686,B,,CHEMBL617243,,11576,,Autocuration,,,4,H,,
,BAO_0000019,,,1936,1,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,104686,B,,CHEMBL617244,,5834,,Autocuration,,,4,H,,
,BAO_0000219,,,1937,1,,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,B,485.0,CHEMBL617245,CHO-K1,2395,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000249,,,1938,1,,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,B,,CHEMBL617246,,11965,,Autocuration,,,4,H,,
,BAO_0000224,,,1939,1,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),104686,B,,CHEMBL617546,,3967,,Autocuration,,,4,H,,
,BAO_0000249,,,1940,1,,Brain membranes,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),104686,B,,CHEMBL617547,,11130,,Autocuration,,,4,H,,
In vitro,BAO_0000219,,,1941,1,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,B,,CHEMBL617548,,13427,,Autocuration,,,4,H,,
,BAO_0000224,,,1942,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617549,,9443,,Autocuration,,,4,H,,
,BAO_0000224,,,1943,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,B,,CHEMBL617550,,9443,,Autocuration,,,4,H,,
,BAO_0000224,,,1944,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,B,,CHEMBL617551,,11825,,Autocuration,,,4,H,,
,BAO_0000249,,,1945,1,,Membranes,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,104686,B,,CHEMBL617552,,12120,,Autocuration,,,4,H,,
,BAO_0000249,,,1946,1,,Membranes,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,104686,B,,CHEMBL617553,,12120,,Autocuration,,,4,H,,
,BAO_0000019,Thoracic aorta,,1947,1,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,104686,F,,CHEMBL617554,,11963,,Autocuration,,,4,H,,1515.0
,BAO_0000019,,,1948,1,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617555,,9069,,Autocuration,,,4,H,,
,BAO_0000224,,,1949,1,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,B,,CHEMBL617556,,8868,,Autocuration,,,4,H,,
,BAO_0000357,,,1950,1,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,10624,B,,CHEMBL617557,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,1951,1,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,10624,B,,CHEMBL617558,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,1952,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,17106,B,,CHEMBL617559,,13969,,Expert,,,8,H,,
,BAO_0000357,,,1953,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor,17106,B,,CHEMBL617560,,13392,,Expert,,,9,D,,
,BAO_0000249,,,1954,1,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,B,,CHEMBL617561,,1742,,Autocuration,,,8,H,,
,BAO_0000249,,,1955,1,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,B,,CHEMBL617562,,1742,,Autocuration,,,8,H,,
,BAO_0000357,Striatum,,1956,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,17106,B,,CHEMBL617563,,14331,,Autocuration,,,8,H,,2435.0
,BAO_0000019,,,1957,1,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,17106,F,,CHEMBL617564,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,1958,1,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,17106,B,,CHEMBL617565,,12861,,Expert,,,8,H,,
,BAO_0000357,,,1959,1,,,Binding activity radioligand.,17106,B,,CHEMBL856076,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,1960,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,17106,B,,CHEMBL617566,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,1961,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,B,,CHEMBL875911,,12861,,Expert,,,8,H,,
,BAO_0000019,,,1962,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,17106,B,,CHEMBL617567,,12861,,Autocuration,,,8,H,,
,BAO_0000249,,,1963,1,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,B,,CHEMBL617568,,675,,Autocuration,,,8,H,,
,BAO_0000019,,,1964,1,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,17106,B,,CHEMBL617569,,12490,,Expert,,,8,H,,
,BAO_0000249,,,1965,1,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,17106,B,,CHEMBL617570,,11828,,Expert,,,8,H,,
,BAO_0000357,,,1966,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,17106,B,,CHEMBL617571,,11866,,Autocuration,,,8,H,,
,BAO_0000357,,,1967,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,105,B,,CHEMBL617572,,773,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,1968,1,,,The compound was tested for intrinsic activity against 5-HT1D receptor,105,B,,CHEMBL617573,,13047,9986.0,Expert,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,,,1969,1,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,105,B,,CHEMBL617574,,13047,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,1970,1,,,The compound was tested for binding affinity against 5-HT1D receptor,105,B,,CHEMBL617575,,13047,9986.0,Expert,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,1971,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,10578,B,,CHEMBL617576,,188,,Autocuration,,,8,H,,
,BAO_0000019,,,1972,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10578,F,,CHEMBL617577,,10639,,Autocuration,,,8,H,,
,BAO_0000019,,,1973,1,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,10578,F,,CHEMBL617578,,12438,,Autocuration,,,8,H,,
,BAO_0000357,,,1974,1,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,10578,B,,CHEMBL617579,,12438,,Autocuration,,,8,H,,
,BAO_0000019,,,1975,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10578,B,,CHEMBL617580,,15854,,Expert,,,8,H,,
,BAO_0000249,,,1976,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10578,B,,CHEMBL617581,,10394,,Autocuration,,,8,H,,
,BAO_0000357,,,1977,1,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,10578,B,,CHEMBL617582,,12092,,Autocuration,,,8,H,,
,BAO_0000019,,,1978,1,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,10578,B,,CHEMBL617583,,3389,,Expert,,,8,H,,
,BAO_0000357,,,1979,1,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,105,B,,CHEMBL617584,,6011,,Autocuration,,,8,H,,
,BAO_0000357,,,1980,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL617585,,4639,,Autocuration,,,8,H,,
,BAO_0000357,,,1981,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,105,B,,CHEMBL875912,,2474,,Autocuration,,,8,H,,
,BAO_0000357,,,1982,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL617586,,5014,,Autocuration,,,8,H,,
,BAO_0000357,,,1983,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,105,B,,CHEMBL617587,,17515,,Autocuration,,,8,H,,
,BAO_0000357,,,1984,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,105,B,,CHEMBL617588,,11866,,Autocuration,,,8,H,,
,BAO_0000357,,,1985,1,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL857980,,4687,,Autocuration,,,8,H,,
,BAO_0000357,,,1986,1,,,Tested against 5-hydroxytryptamine 1D receptor,105,B,,CHEMBL617589,,12146,,Autocuration,,,8,H,,
,BAO_0000357,,,1987,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,105,B,,CHEMBL617590,,10321,,Autocuration,,,8,H,,
,BAO_0000219,,,1988,1,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,105,B,722.0,CHEMBL617591,HEK293,13267,,Autocuration,,,8,H,,
,BAO_0000357,,,1989,1,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,105,B,,CHEMBL617592,,1274,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,1990,1,,,,105,B,,CHEMBL617593,,15250,,Autocuration,,,8,H,,
,BAO_0000219,,,1991,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,106,B,485.0,CHEMBL617594,CHO-K1,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,1992,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,B,485.0,CHEMBL617595,CHO-K1,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,1993,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,105,B,722.0,CHEMBL617596,HEK293,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,1994,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,105,B,722.0,CHEMBL617597,HEK293,13706,,Autocuration,,,8,H,,
,BAO_0000019,,,1995,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,105,B,,CHEMBL617598,,13047,,Autocuration,,,8,H,,
,BAO_0000357,,,1996,1,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,105,B,,CHEMBL872916,,13366,,Autocuration,,,8,H,,
,BAO_0000357,,,1997,1,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,105,B,,CHEMBL617599,,13366,,Expert,,,8,H,,
,BAO_0000357,,,1998,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,105,B,,CHEMBL617091,,1558,,Autocuration,,,8,H,,
,BAO_0000219,,,1999,1,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",105,B,485.0,CHEMBL617092,CHO-K1,12902,,Expert,,,8,H,,
,BAO_0000219,,,2000,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,B,485.0,CHEMBL617093,CHO-K1,13706,,Autocuration,,,8,H,,
,BAO_0000019,,,2001,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,105,F,,CHEMBL617094,,13706,,Autocuration,,,8,H,,
,BAO_0000019,,,2002,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,105,F,,CHEMBL617095,,13706,,Autocuration,,,8,H,,
,BAO_0000019,,,2003,1,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,F,,CHEMBL617096,,14251,,Autocuration,,,8,H,,
,BAO_0000019,,,2004,1,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,F,,CHEMBL617097,,14251,,Autocuration,,,8,H,,
,BAO_0000019,,,2005,1,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,F,,CHEMBL617098,,14251,,Autocuration,,,8,H,,
,BAO_0000357,,,2006,1,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,105,B,,CHEMBL617301,,13313,,Autocuration,,,8,H,,
,BAO_0000357,,,2007,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,105,B,,CHEMBL617302,,13313,,Autocuration,,,8,H,,
,BAO_0000357,,,2008,1,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,105,B,,CHEMBL617303,,13366,,Autocuration,,,8,H,,
,BAO_0000357,,,2009,1,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,105,B,,CHEMBL617304,,13051,,Expert,,,8,H,,
,BAO_0000219,,,2010,1,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",105,B,449.0,CHEMBL617305,CHO,12903,,Expert,,,8,H,,
,BAO_0000219,,,2011,1,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,105,B,,CHEMBL617306,,12469,9606.0,Autocuration,,,9,D,Homo sapiens,
,BAO_0000357,,,2012,1,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,17106,B,,CHEMBL617307,,5619,,Autocuration,,,8,H,,
,BAO_0000019,,,2013,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,105,B,,CHEMBL617308,,13047,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,2014,1,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,105,B,,CHEMBL617309,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2015,1,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,B,,CHEMBL617310,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2016,1,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,B,,CHEMBL617311,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2017,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,105,B,,CHEMBL617312,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2018,1,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,105,B,,CHEMBL617313,,3269,,Autocuration,,,8,H,,
,BAO_0000357,,,2019,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,105,B,,CHEMBL617314,,12409,,Expert,,,8,H,,
,BAO_0000019,,,2020,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,F,,CHEMBL617315,,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,2021,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,106,B,722.0,CHEMBL617316,HEK293,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,2022,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,106,B,722.0,CHEMBL617317,HEK293,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,2023,1,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,B,449.0,CHEMBL617318,CHO,12903,,Autocuration,,,8,H,,
,BAO_0000019,,,2024,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,106,B,,CHEMBL617319,,13047,,Autocuration,,,8,H,,
,BAO_0000357,,,2025,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,B,,CHEMBL617320,,13366,,Expert,,,9,D,,
,BAO_0000357,,,2026,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,B,,CHEMBL617321,,13366,,Expert,,,9,D,,
,BAO_0000357,,,2027,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,B,,CHEMBL617322,,13366,,Expert,,,9,D,,
,BAO_0000357,,,2028,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,106,B,,CHEMBL616862,,13366,,Autocuration,,,8,H,,
,BAO_0000357,,,2029,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,106,B,,CHEMBL616863,,13366,,Autocuration,,,8,H,,
,BAO_0000219,,,2030,1,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,106,B,449.0,CHEMBL616864,CHO,12469,,Autocuration,,,8,H,,
,BAO_0000219,,,2031,1,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,106,B,485.0,CHEMBL616865,CHO-K1,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,2032,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,106,B,485.0,CHEMBL616866,CHO-K1,13706,,Autocuration,,,8,H,,
,BAO_0000019,,,2033,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,F,,CHEMBL616867,,13706,,Autocuration,,,8,H,,
,BAO_0000219,,,2034,1,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",106,B,485.0,CHEMBL616868,CHO-K1,12902,,Expert,,,8,H,,
,BAO_0000357,,,2035,1,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,105,B,,CHEMBL616869,,13051,,Expert,,,8,H,,
,BAO_0000219,,,2036,1,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,B,449.0,CHEMBL616870,CHO,12903,,Expert,,,8,H,,
,BAO_0000219,,,2037,1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,105,F,485.0,CHEMBL616871,CHO-K1,1558,,Autocuration,,,8,H,,
,BAO_0000219,,,2038,1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,105,F,485.0,CHEMBL616872,CHO-K1,1558,,Autocuration,,,8,H,,
,BAO_0000219,,,2039,1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,105,F,485.0,CHEMBL616873,CHO-K1,1558,,Autocuration,,,8,H,,
,BAO_0000219,,,2040,1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,105,F,485.0,CHEMBL616838,CHO-K1,1558,,Autocuration,,,8,H,,
,BAO_0000357,,,2041,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,105,B,,CHEMBL616839,,1558,,Autocuration,,,8,H,,
,BAO_0000019,,,2042,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,106,B,,CHEMBL616840,,13047,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,2043,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,105,B,,CHEMBL616841,,13313,,Autocuration,,,8,H,,
,BAO_0000357,,,2044,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,105,B,,CHEMBL616842,,13313,,Autocuration,,,8,H,,
,BAO_0000357,,,2045,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,105,B,,CHEMBL857976,,12409,,Expert,,,8,H,,
,BAO_0000219,,,2046,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,10618,B,449.0,CHEMBL616843,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000357,,,2047,1,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,10618,B,,CHEMBL616844,,1348,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2048,1,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,10618,B,,CHEMBL616845,,1348,,Autocuration,,,8,H,,
,BAO_0000357,,,2049,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,10618,B,,CHEMBL616846,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2050,1,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,10618,B,,CHEMBL616847,,16209,,Autocuration,,,8,H,,
,BAO_0000019,,,2051,1,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10618,B,,CHEMBL616848,,10444,,Autocuration,,,8,H,,
,BAO_0000357,,,2052,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,10618,B,,CHEMBL616849,,3935,,Autocuration,,,8,H,,
,BAO_0000357,,,2053,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,10618,B,,CHEMBL872911,,15818,,Autocuration,,,8,H,,
,BAO_0000019,,,2054,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,10618,B,,CHEMBL616850,,17085,,Autocuration,,,8,H,,
,BAO_0000219,,,2055,1,,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,10618,B,449.0,CHEMBL616699,CHO,12936,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2056,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,10618,B,,CHEMBL616700,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,2057,1,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,10618,B,449.0,CHEMBL616701,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2058,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,10618,B,449.0,CHEMBL616702,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2059,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,10618,B,449.0,CHEMBL616703,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000357,,,2060,1,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,10618,B,,CHEMBL616704,,13181,,Autocuration,,,8,H,,
,BAO_0000219,,,2061,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,10618,B,449.0,CHEMBL616705,CHO,4199,,Autocuration,,,8,H,,
,BAO_0000357,,,2062,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,10618,B,,CHEMBL616706,,14875,,Autocuration,,,8,H,,
,BAO_0000219,,,2063,1,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,10618,B,449.0,CHEMBL616707,CHO,15146,,Autocuration,,,8,H,,
,BAO_0000357,,,2064,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,10618,B,,CHEMBL616708,,5213,,Autocuration,,,8,H,,
,BAO_0000357,,,2065,1,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,10618,B,,CHEMBL616709,,12146,,Autocuration,,,8,H,,
,BAO_0000219,,,2066,1,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,10618,B,449.0,CHEMBL616710,CHO,13267,,Autocuration,,,8,H,,
,BAO_0000219,,,2067,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,10618,B,449.0,CHEMBL616711,CHO,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,2068,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",10618,B,449.0,CHEMBL616712,CHO,4829,,Autocuration,,,8,H,,
,BAO_0000357,,,2069,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,10618,B,,CHEMBL616713,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,2070,1,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,10618,B,,CHEMBL616714,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,2071,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,10618,B,,CHEMBL616715,,14159,,Autocuration,,,8,H,,
,BAO_0000357,,,2072,1,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,10618,B,,CHEMBL616716,,16633,,Autocuration,,,8,H,,
,BAO_0000019,,,2073,1,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",279,F,,CHEMBL616717,,17085,,Autocuration,,,8,H,,
,BAO_0000019,,,2074,1,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",279,F,,CHEMBL616718,,17085,,Expert,,,8,H,,
,BAO_0000019,,,2075,1,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,279,F,,CHEMBL875905,,16209,,Autocuration,,,8,H,,
,BAO_0000019,,,2076,1,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,279,F,,CHEMBL616719,,16209,,Autocuration,,,8,H,,
,BAO_0000019,,,2077,1,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",279,F,,CHEMBL616720,,17085,,Expert,,,8,H,,
,BAO_0000357,,,2078,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,279,B,,CHEMBL616721,,14159,,Autocuration,,,8,H,,
,BAO_0000219,,,2079,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,279,B,449.0,CHEMBL616722,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000357,,,2080,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),279,B,,CHEMBL616723,,3805,,Autocuration,,,8,H,,
,BAO_0000219,,,2081,1,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,279,B,449.0,CHEMBL616724,CHO,16190,,Autocuration,,,8,H,,
,BAO_0000357,,,2082,1,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,279,B,,CHEMBL616725,,16190,,Autocuration,,,8,H,,
,BAO_0000357,,,2083,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,279,B,,CHEMBL616726,,16209,,Autocuration,,,8,H,,
,BAO_0000357,,,2084,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,279,B,,CHEMBL616727,,16209,,Autocuration,,,8,H,,
,BAO_0000357,,,2085,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,279,B,,CHEMBL616728,,16209,,Autocuration,,,8,H,,
,BAO_0000357,,,2086,1,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,279,B,,CHEMBL616729,,6866,,Autocuration,,,8,H,,
,BAO_0000019,,,2087,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,279,B,,CHEMBL616730,,17085,,Expert,,,8,H,,
,BAO_0000357,,,2088,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,279,B,,CHEMBL617125,,16312,,Autocuration,,,8,H,,
,BAO_0000357,,,2089,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,279,B,,CHEMBL857977,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,2090,1,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,B,449.0,CHEMBL617126,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2091,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,279,B,449.0,CHEMBL617127,CHO,4199,,Autocuration,,,8,H,,
,BAO_0000357,,,2092,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,279,B,,CHEMBL617128,,14875,,Autocuration,,,8,H,,
,BAO_0000219,,,2093,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,279,B,449.0,CHEMBL617129,CHO,15146,,Autocuration,,,8,H,,
,BAO_0000357,,,2094,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,279,B,,CHEMBL617130,,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,2095,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,279,B,449.0,CHEMBL617131,CHO,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,2096,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,B,449.0,CHEMBL617132,CHO,4829,,Autocuration,,,8,H,,
,BAO_0000219,,,2097,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,B,449.0,CHEMBL617133,CHO,4829,,Autocuration,,,8,H,,
,BAO_0000357,,,2098,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,279,B,,CHEMBL617134,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,2099,1,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,279,B,,CHEMBL617135,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,2100,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,279,B,,CHEMBL617136,,5014,,Autocuration,,,8,H,,
,BAO_0000019,,,2101,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",104686,B,,CHEMBL617137,,11662,,Autocuration,,,4,H,,
,BAO_0000019,,,2102,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,B,,CHEMBL617138,,11662,,Autocuration,,,4,H,,
,BAO_0000019,,,2103,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,B,,CHEMBL617139,,11662,,Autocuration,,,4,H,,
,BAO_0000019,,,2104,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617140,,14093,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,2105,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",104686,F,,CHEMBL617141,,11200,,Autocuration,,,4,H,,
,BAO_0000019,,,2106,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,F,,CHEMBL858112,,11200,,Autocuration,,,4,H,,
,BAO_0000019,,,2107,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,17005,B,,CHEMBL617142,,12352,,Intermediate,,,8,H,,
,BAO_0000019,,,2108,1,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",22226,B,,CHEMBL617143,,13657,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,2109,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,22226,B,,CHEMBL617144,,14331,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,2110,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,22226,B,,CHEMBL617145,,14331,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,2111,1,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,22226,B,,CHEMBL617146,,14331,,Autocuration,,,0,U,,
,BAO_0000019,,,2112,1,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,104784,B,,CHEMBL617147,,12685,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,2113,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,104784,B,,CHEMBL617148,,14389,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,2114,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,104784,B,,CHEMBL617149,,14386,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000224,,,2115,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,104784,B,,CHEMBL617150,,5732,,Autocuration,,,4,H,,
,BAO_0000224,,,2116,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104784,B,,CHEMBL617151,,16293,,Autocuration,,,4,H,,
,BAO_0000224,,,2117,1,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617201,,2078,,Autocuration,,,4,H,,
,BAO_0000357,,,2118,1,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,10209,B,,CHEMBL617202,,5486,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,2119,1,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,B,,CHEMBL617203,,11820,,Autocuration,,,4,H,,
,BAO_0000019,,,2120,1,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,B,,CHEMBL617204,,10297,,Autocuration,,,4,H,,
,BAO_0000224,,,2121,1,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,104826,B,,CHEMBL617205,,13704,,Autocuration,,,4,H,,
,BAO_0000019,,,2122,1,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,104826,B,,CHEMBL617206,,10297,10090.0,Autocuration,,,5,D,Mus musculus,
In vivo,BAO_0000218,,,2123,1,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,B,,CHEMBL617207,,11820,,Autocuration,,,4,H,,
,BAO_0000019,,,2124,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,104826,B,,CHEMBL617208,,10297,10090.0,Autocuration,,,5,D,Mus musculus,
,BAO_0000224,,,2125,1,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,104826,B,,CHEMBL617209,,11555,,Autocuration,,,4,H,,
,BAO_0000224,,,2126,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,104826,B,,CHEMBL617210,,11555,,Autocuration,,,4,H,,
,BAO_0000224,,,2127,1,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,104826,B,,CHEMBL617211,,11555,,Autocuration,,,4,H,,
,BAO_0000019,,,2128,1,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,B,,CHEMBL617212,,10297,10090.0,Autocuration,,,5,D,Mus musculus,
,BAO_0000224,,,2129,1,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,104784,B,,CHEMBL617213,,16688,9823.0,Autocuration,,,4,H,Sus scrofa,
,BAO_0000224,,,2130,1,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,104784,B,,CHEMBL617214,,16688,9823.0,Autocuration,,,4,H,Sus scrofa,
,BAO_0000221,,,2131,1,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,B,,CHEMBL617215,,5333,,Autocuration,,,0,U,,
,BAO_0000221,,,2132,1,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,B,,CHEMBL617216,,4437,,Autocuration,,,0,U,,
,BAO_0000357,,,2133,1,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,17005,B,,CHEMBL617217,,5033,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,2134,1,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617218,,15267,,Autocuration,,,4,H,,
,BAO_0000019,,,2135,1,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL872913,,15267,,Autocuration,,,4,H,,
,BAO_0000019,,,2136,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,104826,B,,CHEMBL617219,,11820,,Autocuration,,,4,H,,
,BAO_0000224,,,2137,1,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL873482,,9069,,Autocuration,,,4,H,,
,BAO_0000019,,,2138,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,104686,B,,CHEMBL617220,,9162,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2139,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,104686,B,,CHEMBL617221,,9162,,Autocuration,,,4,H,,
,BAO_0000019,,,2140,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,104686,B,,CHEMBL617222,,9162,,Autocuration,,,4,H,,
,BAO_0000019,,,2141,1,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,104686,F,,CHEMBL875906,,10428,,Autocuration,,,4,H,,
,BAO_0000019,,,2142,1,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,104686,B,,CHEMBL617223,,9628,,Autocuration,,,4,H,,
,BAO_0000224,,,2143,1,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617224,,12704,,Autocuration,,,4,H,,
,BAO_0000224,,,2144,1,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104686,B,,CHEMBL617225,,15453,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2145,1,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,104686,B,,CHEMBL617226,,188,,Autocuration,,,4,H,,
,BAO_0000224,,,2146,1,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,104686,B,,CHEMBL617227,,10349,,Autocuration,,,4,H,,
,BAO_0000224,,,2147,1,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,104686,B,,CHEMBL617228,,10349,,Autocuration,,,4,H,,
,BAO_0000224,,,2148,1,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,B,,CHEMBL617229,,8868,,Autocuration,,,4,H,,
,BAO_0000224,,,2149,1,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,B,,CHEMBL617230,,10025,,Autocuration,,,4,H,,
,BAO_0000224,,,2150,1,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,B,,CHEMBL617231,,10025,,Autocuration,,,4,H,,
,BAO_0000224,,,2151,1,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,104686,B,,CHEMBL617232,,11702,,Autocuration,,,4,H,,
,BAO_0000224,,,2152,1,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617233,,11702,,Autocuration,,,4,H,,
,BAO_0000224,,,2153,1,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,B,,CHEMBL617234,,11702,,Autocuration,,,4,H,,
,BAO_0000019,,,2154,1,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,104686,F,,CHEMBL617235,,11702,,Autocuration,,,4,H,,
,BAO_0000019,,,2155,1,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,104686,F,,CHEMBL617236,,11702,,Autocuration,,,4,H,,
,BAO_0000221,Hippocampus,,2156,1,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,104686,B,,CHEMBL617237,,10085,,Autocuration,,,4,H,,10000000.0
,BAO_0000221,Hippocampus,,2157,1,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,104686,B,,CHEMBL617238,,10085,,Autocuration,,,4,H,,10000000.0
,BAO_0000221,Brain,,2158,1,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,104686,B,,CHEMBL617239,,9630,10116.0,Autocuration,,,5,D,Rattus norvegicus,955.0
,BAO_0000019,,,2159,1,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,104686,B,,CHEMBL617240,,11070,,Autocuration,,,4,H,,
,BAO_0000249,,,2160,1,,Membranes,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,B,,CHEMBL617241,,9841,,Autocuration,,,4,H,,
,BAO_0000249,,,2161,1,,Membranes,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,B,,CHEMBL875907,,9841,,Autocuration,,,4,H,,
,BAO_0000019,,,2162,1,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,104686,B,,CHEMBL617242,,13291,,Autocuration,,,4,H,,
,BAO_0000019,,,2163,1,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,104686,F,,CHEMBL617152,,10590,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,2164,1,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,B,,CHEMBL617153,,9064,10116.0,Autocuration,,,5,D,Rattus norvegicus,955.0
,BAO_0000249,,,2165,1,,Membranes,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,104686,B,,CHEMBL617154,,12268,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000221,Brain,,2166,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,104686,B,,CHEMBL617155,,13508,,Autocuration,,,4,H,,955.0
,BAO_0000019,,,2167,1,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,F,,CHEMBL617156,,11279,,Autocuration,,,4,H,,
,BAO_0000019,,,2168,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,104686,F,,CHEMBL617157,,11200,,Autocuration,,,4,H,,
,BAO_0000019,,,2169,1,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,F,,CHEMBL617158,,11200,,Autocuration,,,4,H,,
,BAO_0000019,,,2170,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,F,,CHEMBL617159,,11200,,Autocuration,,,4,H,,
,BAO_0000019,,,2171,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,F,,CHEMBL617160,,11200,,Autocuration,,,4,H,,
,BAO_0000019,,,2172,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,F,,CHEMBL858113,,11200,,Autocuration,,,4,H,,
,BAO_0000220,Brain,,2173,1,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,104686,B,,CHEMBL617247,,9231,,Autocuration,,,4,H,,955.0
,BAO_0000019,,,2174,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,B,,CHEMBL617248,,9737,,Autocuration,,,4,H,,
,BAO_0000249,Brain,,2175,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,104686,B,,CHEMBL617249,,9737,,Autocuration,,,4,H,,955.0
,BAO_0000019,,,2176,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,104686,B,,CHEMBL617250,,9737,,Autocuration,,,4,H,,
,BAO_0000019,,,2177,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,B,,CHEMBL617251,,9737,,Autocuration,,,4,H,,
,BAO_0000019,,,2178,1,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617252,,11828,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2179,1,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,104686,B,,CHEMBL617006,,12253,,Autocuration,,,4,H,,
,BAO_0000019,,,2180,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,104686,B,,CHEMBL617007,,12253,,Autocuration,,,4,H,,
,BAO_0000019,,,2181,1,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",104686,F,,CHEMBL617008,,11279,,Autocuration,,,4,H,,
,BAO_0000019,,,2182,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,104686,B,,CHEMBL617009,,11866,,Autocuration,,,4,H,,
,BAO_0000224,,,2183,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,104686,B,,CHEMBL617010,,14424,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2184,1,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL857978,,15180,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2185,1,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617011,,15180,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2186,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,104686,B,,CHEMBL617012,,9786,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2187,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,104686,B,,CHEMBL617013,,12132,,Autocuration,,,4,H,,
,BAO_0000249,,,2188,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,104686,B,,CHEMBL617014,,5486,,Autocuration,,,4,H,,
,BAO_0000019,,,2189,1,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617015,,15316,,Autocuration,,,4,H,,
,BAO_0000019,,,2190,1,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,104686,B,,CHEMBL617016,,16429,,Autocuration,,,4,H,,
,BAO_0000224,,,2191,1,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,104686,B,,CHEMBL617017,,14617,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,2192,1,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,104686,B,,CHEMBL617018,,11351,,Autocuration,,,4,H,,955.0
,BAO_0000019,,,2193,1,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,F,,CHEMBL617019,,11279,,Autocuration,,,4,H,,
,BAO_0000019,,,2194,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,B,,CHEMBL617020,,9523,,Autocuration,,,4,H,,
,BAO_0000019,,,2195,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,B,,CHEMBL617021,,9523,,Autocuration,,,4,H,,
,BAO_0000019,,,2196,1,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,B,,CHEMBL617022,,9523,,Autocuration,,,4,H,,
,BAO_0000019,,,2197,1,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,B,,CHEMBL617023,,9523,,Autocuration,,,4,H,,
,BAO_0000019,,,2198,1,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,B,,CHEMBL617024,,9523,,Autocuration,,,4,H,,
,BAO_0000019,,,2199,1,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,B,,CHEMBL617025,,9523,,Autocuration,,,4,H,,
,BAO_0000224,,,2200,1,,,Hill coefficient of compound was determined,105075,B,,CHEMBL617026,,9523,,Autocuration,,,4,H,,
,BAO_0000019,,,2201,1,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,22226,B,,CHEMBL617027,,4771,,Autocuration,,,0,U,,
,BAO_0000019,,,2202,1,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,104686,B,,CHEMBL617028,,5033,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2203,1,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,12687,B,,CHEMBL617029,,10845,,Expert,,,8,H,,
,BAO_0000019,,,2204,1,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,12687,B,,CHEMBL875908,,10845,,Expert,,,8,H,,
,BAO_0000357,,,2205,1,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),12687,B,,CHEMBL617030,,16288,,Autocuration,,,8,H,,
,BAO_0000019,,,2206,1,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),12687,B,,CHEMBL617031,,16288,,Autocuration,,,8,H,,
,BAO_0000019,,,2207,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,12687,B,,CHEMBL617032,,16190,,Autocuration,,,8,H,,
,BAO_0000224,,,2208,1,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,104686,B,,CHEMBL617033,,12463,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2209,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",104686,B,,CHEMBL617034,,9699,,Autocuration,,,4,H,,
,BAO_0000224,,,2210,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,104686,B,,CHEMBL617035,,9699,,Autocuration,,,4,H,,
,BAO_0000019,,,2211,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,B,,CHEMBL617036,,11662,,Autocuration,,,4,H,,
,BAO_0000224,,,2212,1,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617037,,1205,,Autocuration,,,4,H,,
,BAO_0000219,,,2213,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,22226,B,,CHEMBL617038,,11376,,Autocuration,,,0,U,,
,BAO_0000219,,,2214,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",104784,B,,CHEMBL617039,,11376,,Autocuration,,,4,H,,
,BAO_0000224,,,2215,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617161,,4639,,Autocuration,,,4,H,,
,BAO_0000224,,,2216,1,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617162,,2222,,Autocuration,,,4,H,,
,BAO_0000224,,,2217,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617163,,1558,,Autocuration,,,4,H,,
,BAO_0000224,,,2218,1,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617164,,1089,,Autocuration,,,4,H,,
,BAO_0000249,,,2219,1,,Brain membranes,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,104784,B,,CHEMBL617165,,386,,Autocuration,,,4,H,,
,BAO_0000224,,,2220,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,104784,B,,CHEMBL617166,,2474,,Autocuration,,,4,H,,
,BAO_0000224,,,2221,1,,,Binding affinity towards 5-HT2 receptor,104784,B,,CHEMBL617167,,17066,,Autocuration,,,4,H,,
,BAO_0000224,,,2222,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL872912,,959,,Autocuration,,,4,H,,
,BAO_0000224,,,2223,1,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,104784,B,,CHEMBL617168,,6398,,Autocuration,,,4,H,,
,BAO_0000224,,,2224,1,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,104686,B,,CHEMBL617169,,11889,,Autocuration,,,4,H,,
,BAO_0000224,,,2225,1,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617170,,4221,,Autocuration,,,4,H,,
,BAO_0000224,,,2226,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,104784,B,,CHEMBL617171,,11026,,Autocuration,,,4,H,,
,BAO_0000224,,,2227,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,104784,B,,CHEMBL617172,,11866,,Autocuration,,,4,H,,
,BAO_0000224,,,2228,1,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617173,,4221,,Autocuration,,,4,H,,
,BAO_0000019,,,2229,1,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,22226,B,,CHEMBL617174,,13950,,Autocuration,,,0,U,,
,BAO_0000224,,,2230,1,,,5-hydroxytryptamine 2 receptor binding affinity,104784,B,,CHEMBL617175,,1263,,Autocuration,,,4,H,,
,BAO_0000357,,,2231,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,17005,B,,CHEMBL617176,,13291,,Autocuration,,,8,H,,
,BAO_0000357,,,2232,1,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,17005,B,,CHEMBL617177,,10812,,Autocuration,,,8,H,,
,BAO_0000224,,,2233,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,B,,CHEMBL617178,,13020,,Autocuration,,,4,H,,
,BAO_0000224,,,2234,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,104784,B,,CHEMBL617179,,13021,,Autocuration,,,4,H,,
,BAO_0000224,,,2235,1,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,B,,CHEMBL617180,,13020,,Autocuration,,,4,H,,
,BAO_0000357,,,2236,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,17005,B,,CHEMBL617181,,14532,,Autocuration,,,8,H,,
,BAO_0000357,,,2237,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,B,,CHEMBL617182,,13944,,Autocuration,,,8,H,,
,BAO_0000357,,,2238,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,B,,CHEMBL617183,,14331,,Autocuration,,,8,H,,
,BAO_0000357,,,2239,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,17005,B,,CHEMBL617184,,14118,,Autocuration,,,8,H,,
,BAO_0000357,,,2240,1,,,Binding affinity against serotonergic 5-HT2 receptor,17005,B,,CHEMBL617185,,13033,,Autocuration,,,8,H,,
,BAO_0000357,,,2241,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,17005,B,,CHEMBL617186,,10321,,Autocuration,,,8,H,,
,BAO_0000357,,,2242,1,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,17005,B,,CHEMBL617187,,12918,,Autocuration,,,8,H,,
,BAO_0000357,,,2243,1,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,17005,B,,CHEMBL617188,,15120,,Autocuration,,,8,H,,
,BAO_0000218,,,2244,1,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,17005,B,,CHEMBL617189,,2613,,Autocuration,,,8,H,,
,BAO_0000224,,,2245,1,,,Inhibitory activity against cloned human 5-HT2 receptor,104784,B,,CHEMBL617190,,13378,9606.0,Autocuration,,,5,D,Homo sapiens,
,BAO_0000219,,,2246,1,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",104784,B,449.0,CHEMBL617191,CHO,2331,9606.0,Autocuration,,,5,D,Homo sapiens,
,BAO_0000219,,,2247,1,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",104784,B,449.0,CHEMBL617192,CHO,2331,9606.0,Autocuration,,,5,D,Homo sapiens,
,BAO_0000219,,,2248,1,,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",104784,B,449.0,CHEMBL617193,CHO,2331,9606.0,Autocuration,,,5,D,Homo sapiens,
,BAO_0000219,,,2249,1,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",104784,B,449.0,CHEMBL617194,CHO,2331,9606.0,Autocuration,,,5,D,Homo sapiens,
,BAO_0000224,,,2250,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104784,B,,CHEMBL617195,,4170,,Autocuration,,,4,H,,
,BAO_0000224,,,2251,1,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104784,B,,CHEMBL881830,,15453,,Autocuration,,,4,H,,
,BAO_0000357,,,2252,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,17005,B,,CHEMBL617196,,1479,,Autocuration,,,8,H,,
,BAO_0000224,,,2253,1,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,104686,B,,CHEMBL617197,,11139,,Autocuration,,,4,H,,
,BAO_0000357,,,2254,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,17005,B,,CHEMBL617198,,13969,,Expert,,,8,H,,
,BAO_0000357,,,2255,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,17005,B,,CHEMBL873476,,13392,,Expert,,,8,H,,
,BAO_0000019,,,2256,1,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,17005,B,,CHEMBL617199,,14430,,Expert,,,8,H,,
,BAO_0000357,,,2257,1,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617200,,13181,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,2258,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,B,,CHEMBL617484,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,2259,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,B,,CHEMBL617485,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,2260,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,B,,CHEMBL617486,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,2261,1,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,107,B,,CHEMBL858022,,13463,,Autocuration,,,8,H,,
,BAO_0000219,,,2262,1,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,B,449.0,CHEMBL617049,CHO,6347,,Autocuration,,,8,H,,
,BAO_0000219,,,2263,1,,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,107,F,449.0,CHEMBL617050,CHO,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2264,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,F,,CHEMBL617051,,4176,,Autocuration,,,8,H,,
,BAO_0000219,,,2265,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,107,F,,CHEMBL617052,,4176,,Autocuration,,,8,H,,
,BAO_0000219,,,2266,1,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,F,,CHEMBL617053,,4176,,Autocuration,,,8,H,,
,BAO_0000219,,,2267,1,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",107,B,449.0,CHEMBL617054,CHO,6347,,Autocuration,,,8,H,,
,BAO_0000219,,,2268,1,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",107,B,449.0,CHEMBL617055,CHO,6347,,Autocuration,,,8,H,,
,BAO_0000357,,,2269,1,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,107,B,,CHEMBL882924,,15331,,Autocuration,,,8,H,,
,BAO_0000357,,,2270,1,,,Inhibition of human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617056,,16146,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2271,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,B,449.0,CHEMBL617057,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000219,,,2272,1,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,107,B,,CHEMBL617058,,13631,,Expert,,,8,H,,
,BAO_0000357,,,2273,1,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),107,B,,CHEMBL617059,,3805,,Autocuration,,,8,H,,
,BAO_0000219,,,2274,1,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,107,B,449.0,CHEMBL617060,CHO,4011,,Autocuration,,,8,H,,
,BAO_0000219,,,2275,1,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,107,B,449.0,CHEMBL617061,CHO,4012,,Expert,,,8,H,,
,BAO_0000219,,,2276,1,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,107,B,307.0,CHEMBL617062,L929,6366,,Expert,,,8,H,,
,BAO_0000219,,,2277,1,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,B,449.0,CHEMBL617063,CHO,15949,,Expert,,,8,H,,
,BAO_0000019,,,2278,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,107,F,,CHEMBL617064,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2279,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,F,,CHEMBL617065,,13481,,Autocuration,,,8,H,,
,BAO_0000219,,,2280,1,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,B,449.0,CHEMBL617066,CHO,6347,,Autocuration,,,8,H,,
,BAO_0000219,,,2281,1,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,107,B,449.0,CHEMBL617067,CHO,6347,,Autocuration,,,8,H,,
,BAO_0000019,,,2282,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,107,F,,CHEMBL617068,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2283,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,107,F,,CHEMBL617069,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2284,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,F,,CHEMBL617070,,13481,,Autocuration,,,8,H,,
,BAO_0000357,,,2285,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,107,B,,CHEMBL617071,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2286,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,B,,CHEMBL872915,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2287,1,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,107,B,,CHEMBL617072,,14755,,Autocuration,,,8,H,,
,BAO_0000357,,,2288,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,107,B,,CHEMBL617073,,16441,,Autocuration,,,8,H,,
,BAO_0000357,,,2289,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,107,B,,CHEMBL617074,,14744,,Autocuration,,,8,H,,
,BAO_0000219,,,2290,1,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,B,449.0,CHEMBL617075,CHO,16659,,Expert,,,8,H,,
,BAO_0000357,,,2291,1,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617076,,3307,,Autocuration,,,8,H,,
,BAO_0000019,,,2292,1,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,107,B,,CHEMBL617077,,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2293,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,107,B,,CHEMBL617078,,5635,,Expert,,,8,H,,
,BAO_0000357,,,2294,1,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617079,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2295,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,B,,CHEMBL617080,,15527,,Autocuration,,,8,H,,
,BAO_0000219,,,2296,1,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,107,B,449.0,CHEMBL617081,CHO,6588,,Expert,,,8,H,,
,BAO_0000219,,,2297,1,,,Binding affinity towards human 5-HT2A receptor in BEK cells,107,B,,CHEMBL617082,,13631,,Expert,,,8,H,,
,BAO_0000357,,,2298,1,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617083,,17723,,Autocuration,,,8,H,,
,BAO_0000357,,,2299,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,B,,CHEMBL617084,,14770,,Autocuration,,,8,H,,
,BAO_0000357,,,2300,1,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617085,,16293,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2301,1,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,B,,CHEMBL617086,,16209,,Autocuration,,,8,H,,
,BAO_0000219,,,2302,1,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,107,B,,CHEMBL617087,,12469,,Autocuration,,,8,H,,
,BAO_0000357,,,2303,1,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617088,,15363,,Autocuration,,,8,H,,
,BAO_0000357,,,2304,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617089,,15363,,Autocuration,,,8,H,,
,BAO_0000019,,,2305,1,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",107,B,,CHEMBL617090,,16441,,Expert,,,8,H,,
,BAO_0000357,,,2306,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,107,B,,CHEMBL617513,,8,,Autocuration,,,8,H,,
,BAO_0000219,,,2307,1,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,107,B,722.0,CHEMBL617514,HEK293,4176,,Autocuration,,,8,H,,
,BAO_0000019,,,2308,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617515,,17085,,Autocuration,,,8,H,,
,BAO_0000357,,,2309,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,B,,CHEMBL617516,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,2310,1,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,B,,CHEMBL617517,,17200,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2311,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,107,B,449.0,CHEMBL617518,CHO,4013,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2312,1,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617519,,5088,,Autocuration,,,8,H,,
,BAO_0000357,,,2313,1,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617520,,5088,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2314,1,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,107,B,,CHEMBL617521,,5088,,Autocuration,,,8,H,,
,BAO_0000357,,,2315,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617522,,5088,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2316,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,107,B,,CHEMBL617523,,5088,,Autocuration,,,8,H,,
,BAO_0000357,,,2317,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,107,B,,CHEMBL617524,,5088,,Autocuration,,,8,H,,
,BAO_0000019,,,2318,1,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,104686,B,,CHEMBL617525,,9786,,Autocuration,,,4,H,,
,BAO_0000019,,,2319,1,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,104686,B,,CHEMBL617526,,9205,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2320,1,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,104686,B,,CHEMBL617527,,11257,,Autocuration,,,4,H,,
,BAO_0000019,,,2321,1,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,B,,CHEMBL617528,,9362,,Autocuration,,,4,H,,
,BAO_0000019,,,2322,1,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,B,,CHEMBL617529,,9362,,Autocuration,,,4,H,,
,BAO_0000224,,,2323,1,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,104686,B,,CHEMBL617530,,10590,,Autocuration,,,4,H,,
,BAO_0000019,,,2324,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,B,,CHEMBL617531,,10468,,Autocuration,,,4,H,,
,BAO_0000019,,,2325,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,104686,B,,CHEMBL617532,,13050,,Autocuration,,,4,H,,
,BAO_0000019,,,2326,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,104686,B,,CHEMBL617533,,11624,,Autocuration,,,4,H,,
,BAO_0000019,,,2327,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,B,,CHEMBL617534,,10468,,Autocuration,,,4,H,,
,BAO_0000224,,,2328,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,104686,B,,CHEMBL617535,,10330,,Autocuration,,,4,H,,
,BAO_0000224,,,2329,1,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,B,,CHEMBL617536,,10062,,Autocuration,,,4,H,,
,BAO_0000224,,,2330,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617537,,11642,,Autocuration,,,4,H,,
,BAO_0000224,,,2331,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617538,,10062,,Autocuration,,,4,H,,
In vitro,BAO_0000219,,,2332,1,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,B,,CHEMBL617539,,13427,,Autocuration,,,4,H,,
,BAO_0000224,,,2333,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617540,,12280,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2334,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,104686,B,,CHEMBL617541,,4101,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2335,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617542,,10062,,Autocuration,,,4,H,,
,BAO_0000224,,,2336,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,104686,B,,CHEMBL617543,,11147,,Autocuration,,,4,H,,
,BAO_0000219,,,2337,1,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,B,485.0,CHEMBL617544,CHO-K1,2395,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000219,,,2338,1,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,B,485.0,CHEMBL617545,CHO-K1,2395,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2339,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,104686,B,,CHEMBL617413,,9098,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2340,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,104686,B,,CHEMBL617414,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,2341,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,104686,B,,CHEMBL617415,,9098,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2342,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617416,,9443,,Autocuration,,,4,H,,
,BAO_0000224,,,2343,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,B,,CHEMBL617417,,9443,,Autocuration,,,4,H,,
,BAO_0000019,,,2344,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",104686,B,,CHEMBL617418,,9699,,Autocuration,,,4,H,,
,BAO_0000019,,,2345,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,104686,B,,CHEMBL617419,,9699,,Autocuration,,,4,H,,
,BAO_0000224,,,2346,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,B,,CHEMBL617420,,9098,,Autocuration,,,4,H,,
,BAO_0000224,,,2347,1,,,Affinity for 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617421,,3070,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2348,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,104686,B,,CHEMBL617422,,9547,,Autocuration,,,4,H,,
,BAO_0000019,,,2349,1,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,104686,B,,CHEMBL617423,,10444,,Autocuration,,,4,H,,
,BAO_0000019,,,2350,1,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,104686,B,,CHEMBL617424,,14617,,Autocuration,,,4,H,,
,BAO_0000019,,,2351,1,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,104686,B,,CHEMBL617425,,14617,,Autocuration,,,4,H,,
,BAO_0000224,,,2352,1,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),104686,B,,CHEMBL617426,,11130,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,2353,1,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),104686,B,,CHEMBL617427,,11130,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,2354,1,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,104686,B,,CHEMBL617428,,14542,,Autocuration,,,4,H,,955.0
,BAO_0000224,,,2355,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,104686,B,,CHEMBL617429,,2797,,Autocuration,,,4,H,,
,BAO_0000019,,,2356,1,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,B,,CHEMBL617430,,11332,,Autocuration,,,4,H,,
,BAO_0000019,,,2357,1,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,B,,CHEMBL617431,,11332,,Autocuration,,,4,H,,
,BAO_0000019,Frontal cortex,,2358,1,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,104686,B,,CHEMBL617432,,10752,,Autocuration,,,4,H,,1870.0
,BAO_0000224,,,2359,1,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617433,,1185,,Autocuration,,,4,H,,
,BAO_0000224,,,2360,1,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617434,,1185,,Autocuration,,,4,H,,
,BAO_0000224,,,2361,1,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,104686,B,,CHEMBL617435,,11624,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2362,1,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,104686,B,,CHEMBL617436,,1344,,Autocuration,,,4,H,,
,BAO_0000019,Striatum,,2363,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,104686,B,,CHEMBL617437,,15453,10116.0,Autocuration,,,5,D,Rattus norvegicus,2435.0
,BAO_0000019,,,2364,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,B,,CHEMBL617438,,11662,,Autocuration,,,4,H,,
,BAO_0000019,,,2365,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,B,,CHEMBL617439,,11662,,Autocuration,,,4,H,,
,BAO_0000224,,,2366,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617440,,10796,,Autocuration,,,4,H,,
,BAO_0000224,,,2367,1,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617441,,9069,,Autocuration,,,4,H,,
,BAO_0000019,,,2368,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,104686,B,,CHEMBL872918,,8814,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2369,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,104686,B,,CHEMBL617442,,8908,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2370,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,B,,CHEMBL617443,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,2371,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,104686,B,,CHEMBL617444,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,2372,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,B,,CHEMBL617445,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,2373,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,104686,B,,CHEMBL617446,,9098,,Autocuration,,,4,H,,
,BAO_0000249,,,2374,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,104686,B,,CHEMBL617447,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,2375,1,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,104686,B,,CHEMBL617448,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,2376,1,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,104686,B,,CHEMBL617449,,9098,,Autocuration,,,4,H,,
,BAO_0000019,,,2377,1,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,104686,B,,CHEMBL617450,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2378,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,104686,B,,CHEMBL617451,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2379,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,104686,B,,CHEMBL617452,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2380,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,104686,B,,CHEMBL617453,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2381,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,104686,B,,CHEMBL617660,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2382,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,104686,B,,CHEMBL617661,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2383,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,104686,B,,CHEMBL617662,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2384,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,104686,B,,CHEMBL872919,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2385,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,104686,B,,CHEMBL617663,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2386,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,104686,B,,CHEMBL617664,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2387,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,104686,B,,CHEMBL617665,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2388,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,104686,B,,CHEMBL617666,,9161,,Autocuration,,,4,H,,
,BAO_0000019,,,2389,1,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,104686,B,,CHEMBL617667,,12094,,Autocuration,,,4,H,,
,BAO_0000249,,,2390,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,104686,B,,CHEMBL617668,,12018,,Autocuration,,,4,H,,
,BAO_0000249,,,2391,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,104686,B,,CHEMBL617669,,10394,,Autocuration,,,4,H,,
,BAO_0000224,,,2392,1,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617670,,15260,,Autocuration,,,4,H,,
,BAO_0000224,,,2393,1,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617671,,11624,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,2394,1,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617672,,13654,,Autocuration,,,4,H,,
,BAO_0000019,,,2395,1,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,104686,B,,CHEMBL617673,,9541,,Autocuration,,,4,H,,
,BAO_0000224,,,2396,1,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,104686,B,,CHEMBL617674,,11933,,Autocuration,,,4,H,,
,BAO_0000019,,,2397,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,104686,B,,CHEMBL617675,,15538,,Autocuration,,,4,H,,
,BAO_0000019,,,2398,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,104686,B,,CHEMBL617676,,15538,,Autocuration,,,4,H,,
,BAO_0000019,,,2399,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,104686,B,,CHEMBL617677,,15538,,Autocuration,,,4,H,,
,BAO_0000019,,,2400,1,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617678,,8841,,Autocuration,,,5,D,,
,BAO_0000224,,,2401,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,104686,B,,CHEMBL617679,,1455,,Autocuration,,,4,H,,
,BAO_0000224,,,2402,1,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,104686,B,,CHEMBL617680,,1455,,Autocuration,,,4,H,,
,BAO_0000019,,,2403,1,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,104686,B,,CHEMBL617681,,11752,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,2404,1,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,104686,B,,CHEMBL617682,,11642,,Autocuration,,,4,H,,955.0
,BAO_0000224,,,2405,1,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,104686,B,,CHEMBL617683,,12092,,Autocuration,,,4,H,,
,BAO_0000224,,,2406,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,104686,B,,CHEMBL617684,,3967,,Autocuration,,,4,H,,
,BAO_0000224,,,2407,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617685,,12771,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,2408,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,104686,B,,CHEMBL617686,,11642,,Autocuration,,,4,H,,
,BAO_0000224,,,2409,1,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,104686,B,,CHEMBL617687,,11628,,Autocuration,,,4,H,,
,BAO_0000224,,,2410,1,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,B,,CHEMBL617688,,13654,,Autocuration,,,4,H,,
,BAO_0000019,,,2411,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,F,,CHEMBL617689,,11200,,Autocuration,,,4,H,,
,BAO_0000019,,,2412,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,F,,CHEMBL617690,,11200,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,2413,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,F,,CHEMBL617691,,11200,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,2414,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,F,,CHEMBL617692,,11200,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,2415,1,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,F,,CHEMBL617693,,11200,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,2416,1,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,F,,CHEMBL617694,,11200,,Autocuration,,,4,H,,
,BAO_0000221,Brain,,2417,1,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,12687,B,,CHEMBL857985,,15436,,Expert,,,8,H,,955.0
,BAO_0000019,,,2418,1,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,B,,CHEMBL617695,,15436,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2419,1,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,12687,B,,CHEMBL617696,,14025,,Autocuration,,,8,H,,
,BAO_0000357,,,2420,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,12687,B,,CHEMBL617697,,4342,,Autocuration,,,8,H,,
,BAO_0000019,,,2421,1,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,12687,B,,CHEMBL617257,,13735,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2422,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,12687,B,,CHEMBL617258,,5816,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2423,1,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,12687,B,,CHEMBL617259,,14287,,Expert,,,8,H,,
,BAO_0000357,,,2424,1,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,12687,B,,CHEMBL617260,,15738,,Autocuration,,,8,H,,
,BAO_0000357,,,2425,1,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617261,,15738,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2426,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,12687,B,,CHEMBL617262,,15026,,Autocuration,,,8,H,,
,BAO_0000019,,,2427,1,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,B,,CHEMBL617263,,16647,,Expert,,,8,H,,
,BAO_0000019,,,2428,1,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,12687,B,,CHEMBL617264,,16647,,Autocuration,,,8,H,,
,BAO_0000019,,,2429,1,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617265,,13345,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,2430,1,,Membranes,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617266,,1543,,Autocuration,,,8,H,,
,BAO_0000019,,,2431,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12687,B,,CHEMBL617267,,12444,,Autocuration,,,8,H,,
,BAO_0000019,,,2432,1,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,12687,B,,CHEMBL617268,,16404,,Expert,,,8,H,,
,BAO_0000219,,,2433,1,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,12687,B,449.0,CHEMBL617269,CHO,16404,,Autocuration,,,8,H,,
,BAO_0000357,,,2434,1,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,12687,B,,CHEMBL617323,,15577,,Expert,,,8,H,,
,BAO_0000357,,,2435,1,,,Serotonergic activity of the compound.,12687,B,,CHEMBL617324,,15577,,Autocuration,,,8,H,,
,BAO_0000249,,,2436,1,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,12687,B,,CHEMBL617325,,2495,,Autocuration,,,8,H,,
,BAO_0000019,,,2437,1,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,12687,B,,CHEMBL617326,,15042,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,2438,1,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,12687,B,,CHEMBL617327,,15026,,Expert,,,8,H,,
,BAO_0000019,,,2439,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,F,,CHEMBL617328,,12919,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2440,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,F,,CHEMBL617329,,12919,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2441,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,F,,CHEMBL617330,,12919,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2442,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,B,,CHEMBL617331,,15194,,Autocuration,,,8,H,,
,BAO_0000357,,,2443,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,12687,B,,CHEMBL617332,,15194,,Autocuration,,,8,H,,
,BAO_0000357,,,2444,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617333,,4820,,Expert,,,8,H,,
,BAO_0000357,,,2445,1,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,107,B,,CHEMBL617334,,6736,,Autocuration,,,8,H,,
,BAO_0000357,,,2446,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,107,B,,CHEMBL617335,,5163,,Autocuration,,,8,H,,
,BAO_0000357,,,2447,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,107,B,,CHEMBL617336,,5163,,Autocuration,,,8,H,,
,BAO_0000357,,,2448,1,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,107,B,,CHEMBL617337,,6011,,Autocuration,,,8,H,,
,BAO_0000357,,,2449,1,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,107,B,,CHEMBL617338,,14294,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2450,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617339,,5014,,Autocuration,,,8,H,,
,BAO_0000357,,,2451,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617340,,17066,,Expert,,,8,H,,
,BAO_0000357,,,2452,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,107,B,,CHEMBL617341,,17515,,Autocuration,,,8,H,,
,BAO_0000357,,,2453,1,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617342,,6736,,Expert,,,8,H,,
,BAO_0000357,,,2454,1,,,Affinity for 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617343,,5163,,Expert,,,8,H,,
,BAO_0000219,,,2455,1,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,107,B,723.0,CHEMBL617344,NIH3T3,16911,,Expert,,,8,H,,
,BAO_0000357,,,2456,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,107,B,,CHEMBL617345,,6841,,Expert,,,8,H,,
,BAO_0000357,,,2457,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,107,B,,CHEMBL617346,,6119,,Expert,,,8,H,,
,BAO_0000357,,,2458,1,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617347,,3962,,Autocuration,,,8,H,,
,BAO_0000357,,,2459,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,107,B,,CHEMBL617348,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,2460,1,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,107,B,,CHEMBL617349,,4373,,Autocuration,,,8,H,,
,BAO_0000019,,,2461,1,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,107,F,,CHEMBL617350,,3962,,Autocuration,,,8,H,,
,BAO_0000357,,,2462,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,107,B,,CHEMBL872339,,1633,,Expert,,,8,H,,
,BAO_0000357,,,2463,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,107,B,,CHEMBL617351,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,2464,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617352,,6576,,Expert,,,8,H,,
,BAO_0000357,,,2465,1,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617353,,4687,,Autocuration,,,8,H,,
,BAO_0000357,,,2466,1,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617354,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,2467,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617355,,14159,,Autocuration,,,8,H,,
,BAO_0000219,,,2468,1,,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,107,B,449.0,CHEMBL617356,CHO,3032,10090.0,Expert,,,8,H,Mus musculus,
,BAO_0000357,,,2469,1,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617357,,16655,,Autocuration,,,8,H,,
,BAO_0000357,,,2470,1,,,Binding affinity at 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617358,,13964,,Autocuration,,,8,H,,
,BAO_0000357,,,2471,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617359,,16989,,Expert,,,8,H,,
,BAO_0000357,,,2472,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,107,B,,CHEMBL617360,,16117,,Autocuration,,,8,H,,
,BAO_0000357,,,2473,1,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,107,B,,CHEMBL875913,,16700,,Autocuration,,,8,H,,
,BAO_0000357,,,2474,1,,,Affinity against 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617361,,3269,,Autocuration,,,8,H,,
,BAO_0000357,,,2475,1,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,107,B,,CHEMBL617362,,1274,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2476,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,107,B,,CHEMBL617363,,1317,,Autocuration,,,8,H,,
,BAO_0000357,,,2477,1,,,Tested against 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617364,,12146,,Autocuration,,,8,H,,
,BAO_0000224,,,2478,1,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,B,,CHEMBL617365,,12652,,Autocuration,,,4,H,,
,BAO_0000224,,,2479,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,105075,B,,CHEMBL617366,,12652,,Autocuration,,,4,H,,
,BAO_0000224,,,2480,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,105075,B,,CHEMBL617367,,12652,,Autocuration,,,4,H,,
,BAO_0000224,,,2481,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,B,,CHEMBL617368,,12652,,Autocuration,,,4,H,,
,BAO_0000357,,,2482,1,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),107,B,,CHEMBL617369,,16647,,Autocuration,,,8,H,,
,BAO_0000219,,,2483,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,227,B,722.0,CHEMBL617370,HEK293,15851,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2484,1,,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,227,F,449.0,CHEMBL617371,CHO,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2485,1,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),227,B,,CHEMBL617372,,3805,,Autocuration,,,8,H,,
,BAO_0000357,,,2486,1,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,227,B,,CHEMBL617373,,6491,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,2487,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,227,F,,CHEMBL617374,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2488,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,227,F,,CHEMBL617375,,13481,,Autocuration,,,8,H,,
,BAO_0000019,,,2489,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,227,F,,CHEMBL617376,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2490,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,227,F,,CHEMBL617377,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2491,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,227,F,,CHEMBL617378,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2492,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,F,,CHEMBL617379,,13481,,Autocuration,,,8,H,,
,BAO_0000357,,,2493,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,227,B,,CHEMBL617380,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2494,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,227,B,,CHEMBL617381,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2495,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,B,,CHEMBL617382,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2496,1,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617383,,12369,,Autocuration,,,8,H,,
,BAO_0000357,,,2497,1,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,107,B,,CHEMBL617384,,12369,,Expert,,,8,H,,
,BAO_0000357,,,2498,1,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,107,B,,CHEMBL617385,,12369,,Expert,,,8,H,,
,BAO_0000019,,,2499,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,107,B,,CHEMBL617386,,14447,,Autocuration,,,8,H,,
,BAO_0000019,,,2500,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,107,B,,CHEMBL617387,,14447,,Autocuration,,,8,H,,
,BAO_0000219,,,2501,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,B,723.0,CHEMBL617388,NIH3T3,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,2502,1,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,F,449.0,CHEMBL617389,CHO,6857,,Autocuration,,,8,H,,
,BAO_0000219,,,2503,1,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,F,449.0,CHEMBL617390,CHO,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000224,,,2504,1,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,104817,B,,CHEMBL617391,,5635,,Autocuration,,,4,H,,
,BAO_0000357,,,2505,1,,,Binding activity radioligand.,107,B,,CHEMBL617392,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,2506,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,107,B,,CHEMBL617393,,12861,,Autocuration,,,8,H,,
,BAO_0000219,,,2507,1,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,B,307.0,CHEMBL617394,L929,5105,,Autocuration,,,8,H,,
,BAO_0000219,,,2508,1,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,B,307.0,CHEMBL617395,L929,5104,,Expert,,,8,H,,
,BAO_0000219,,,2509,1,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,107,B,307.0,CHEMBL617396,L929,5105,,Expert,,,8,H,,
,BAO_0000219,,,2510,1,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,107,B,307.0,CHEMBL617397,L929,5105,,Autocuration,,,8,H,,
,BAO_0000357,,,2511,1,,,Binding affinity against 5-HT2A receptor,107,B,,CHEMBL617398,,5254,,Autocuration,,,8,H,,
,BAO_0000357,,,2512,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL617399,,5254,,Autocuration,,,8,H,,
,BAO_0000219,,,2513,1,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,107,B,722.0,CHEMBL617400,HEK293,13267,,Autocuration,,,8,H,,
,BAO_0000219,,,2514,1,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,107,B,722.0,CHEMBL617401,HEK293,13267,,Autocuration,,,8,H,,
,BAO_0000219,,,2515,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,107,B,722.0,CHEMBL617402,HEK293,14157,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2516,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,B,722.0,CHEMBL617403,HEK293,12936,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2517,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,107,B,,CHEMBL617404,,14068,,Expert,,,8,H,,
,BAO_0000219,,,2518,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,B,722.0,CHEMBL857981,HEK293,12936,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2519,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,B,722.0,CHEMBL617405,HEK293,12936,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2520,1,,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,107,B,722.0,CHEMBL617253,HEK293,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2521,1,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,107,B,,CHEMBL617254,,6166,,Expert,,,8,H,,
,BAO_0000219,,,2522,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,B,722.0,CHEMBL617255,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,2523,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,B,722.0,CHEMBL617256,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,2524,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,107,B,722.0,CHEMBL616874,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,2525,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,107,B,722.0,CHEMBL616875,HEK293,15779,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2526,1,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,107,B,722.0,CHEMBL616876,HEK293,14391,,Expert,,,8,H,,
,BAO_0000219,,,2527,1,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",107,B,722.0,CHEMBL616877,HEK293,15851,,Expert,,,8,H,,
,BAO_0000219,,,2528,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,107,B,722.0,CHEMBL616878,HEK293,15851,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2529,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,107,B,722.0,CHEMBL616879,HEK293,3832,,Expert,,,8,H,,
,BAO_0000219,,,2530,1,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,107,B,722.0,CHEMBL616880,HEK293,3833,,Expert,,,8,H,,
,BAO_0000219,,,2531,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,B,722.0,CHEMBL616881,HEK293,12936,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2532,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,107,B,723.0,CHEMBL616882,NIH3T3,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,2533,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,B,723.0,CHEMBL616883,NIH3T3,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,2534,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,B,723.0,CHEMBL616884,NIH3T3,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,2535,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,107,B,722.0,CHEMBL616885,HEK293,4199,,Autocuration,,,8,H,,
,BAO_0000219,,,2536,1,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,107,B,485.0,CHEMBL616886,CHO-K1,1883,,Autocuration,,,8,H,,
,BAO_0000219,,,2537,1,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,107,B,485.0,CHEMBL616887,CHO-K1,1883,,Expert,,,8,H,,
,BAO_0000357,,,2538,1,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,B,,CHEMBL616888,,14875,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2539,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,107,B,722.0,CHEMBL616889,HEK293,15146,,Autocuration,,,8,H,,
,BAO_0000219,,,2540,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,107,B,722.0,CHEMBL616890,HEK293,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,2541,1,,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,107,B,449.0,CHEMBL616891,CHO,16404,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2542,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,107,B,722.0,CHEMBL616892,HEK293,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,2543,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",107,B,722.0,CHEMBL616893,HEK293,4829,,Autocuration,,,8,H,,
,BAO_0000219,,,2544,1,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,10620,F,723.0,CHEMBL616894,NIH3T3,12652,,Autocuration,,,8,H,,
,BAO_0000219,,,2545,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,107,B,723.0,CHEMBL616895,NIH3T3,4682,,Expert,,,8,H,,
,BAO_0000019,,,2546,1,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,10620,F,,CHEMBL616896,,12652,,Autocuration,,,8,H,,
,BAO_0000357,,,2547,1,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,10621,B,,CHEMBL617099,,4921,,Autocuration,,,8,H,,
,BAO_0000357,,,2548,1,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,10621,B,,CHEMBL617100,,4921,,Autocuration,,,8,H,,
,BAO_0000357,,,2549,1,,,Binding affinity against rabbit aorta 5-HT2A receptor,107,B,,CHEMBL884532,,16312,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,2550,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,107,B,,CHEMBL617101,,14998,9986.0,Expert,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,2551,1,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,107,B,,CHEMBL617102,,14025,9986.0,Expert,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,,,2552,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,107,B,,CHEMBL617103,,13047,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,2553,1,,,The compound was tested for binding affinity against 5-HT2A receptor,107,B,,CHEMBL617104,,13047,9986.0,Expert,,,8,H,Oryctolagus cuniculus,
,BAO_0000219,,,2554,1,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,10576,B,485.0,CHEMBL857979,CHO-K1,1883,,Autocuration,,,8,H,,
,BAO_0000019,,,2555,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,12687,B,,CHEMBL857502,,13463,,Autocuration,,,8,H,,
,BAO_0000019,,,2556,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,B,,CHEMBL617105,,13463,,Autocuration,,,8,H,,
,BAO_0000019,Stomach,,2557,1,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,12687,B,,CHEMBL858021,,13463,,Autocuration,,,8,H,,945.0
,BAO_0000019,Stomach,,2558,1,,,Binding affinity for 5-HT 2A in rat stomach fundus,12687,B,,CHEMBL875910,,13463,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000019,,,2559,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,B,,CHEMBL617106,,13463,,Autocuration,,,8,H,,
,BAO_0000219,,,2560,1,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,12687,B,723.0,CHEMBL617107,NIH3T3,16326,,Expert,,,8,H,,
,BAO_0000019,,,2561,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,12687,F,,CHEMBL617108,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2562,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,12687,F,,CHEMBL617109,,14093,,Autocuration,,,8,H,,
,BAO_0000357,,,2563,1,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617110,,15740,,Autocuration,,,8,H,,
,BAO_0000357,,,2564,1,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,12687,B,,CHEMBL617111,,16633,,Autocuration,,,8,H,,
,BAO_0000019,,,2565,1,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,12687,F,,CHEMBL617112,,17200,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2566,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617113,,17133,,Autocuration,,,8,H,,
,BAO_0000357,,,2567,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617114,,17133,,Autocuration,,,8,H,,
,BAO_0000357,,,2568,1,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617115,,17133,,Autocuration,,,8,H,,
,BAO_0000219,,,2569,1,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,F,,CHEMBL617116,,17200,,Autocuration,,,8,H,,
,BAO_0000019,,,2570,1,,,Efficacy at 5-hydroxytryptamine 2A receptor,12687,F,,CHEMBL617117,,15363,,Autocuration,,,8,H,,
,BAO_0000357,,,2571,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,B,,CHEMBL617118,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,2572,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,B,,CHEMBL617119,,17200,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2573,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),12687,B,,CHEMBL617120,,17200,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,2574,1,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,F,,CHEMBL617121,,17200,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,2575,1,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,F,,CHEMBL617122,,17200,,Autocuration,,,8,H,,
,BAO_0000019,,,2576,1,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617123,,17211,,Autocuration,,,8,H,,
,BAO_0000019,,,2577,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,12687,B,,CHEMBL617124,,17331,,Expert,,,8,H,,
,BAO_0000249,,,2578,1,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,12687,B,,CHEMBL617600,,13565,,Expert,,,8,H,,
,BAO_0000357,,,2579,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,12687,B,,CHEMBL617601,,13730,,Expert,,,8,H,,
,BAO_0000019,,,2580,1,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12687,B,,CHEMBL882923,,12416,,Expert,,,8,H,,
,BAO_0000357,,,2581,1,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617602,,15295,,Autocuration,,,8,H,,
,BAO_0000019,,,2582,1,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,12687,B,,CHEMBL617603,,1742,,Autocuration,,,8,H,,
,BAO_0000357,,,2583,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617604,,15295,,Autocuration,,,8,H,,
,BAO_0000019,,,2584,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,12687,B,,CHEMBL617605,,14970,,Expert,,,8,H,,
,BAO_0000019,,,2585,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,12687,B,,CHEMBL617606,,16693,,Expert,,,8,H,,
,BAO_0000019,,,2586,1,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617607,,14776,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,2587,1,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,B,,CHEMBL617455,,14286,,Autocuration,,,8,H,,
,BAO_0000019,,,2588,1,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,B,,CHEMBL617456,,17200,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2589,1,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),12687,B,,CHEMBL617457,,15306,,Expert,,,8,H,,
,BAO_0000357,,,2590,1,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617458,,14178,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2591,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,12687,B,,CHEMBL617459,,14229,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2592,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12687,B,,CHEMBL617460,,12884,,Expert,,,8,H,,
,BAO_0000357,,,2593,1,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",12687,B,,CHEMBL617461,,13149,,Expert,,,8,H,,
,BAO_0000019,,,2594,1,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,12687,B,,CHEMBL617462,,15295,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2595,1,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,12687,B,,CHEMBL617463,,15740,,Autocuration,,,8,H,,
,BAO_0000019,,,2596,1,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",12687,B,,CHEMBL617464,,15185,,Autocuration,,,8,H,,
,BAO_0000019,,,2597,1,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",12687,B,,CHEMBL617465,,15185,,Autocuration,,,8,H,,
,BAO_0000019,,,2598,1,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,12687,B,,CHEMBL617466,,17529,,Expert,,,8,H,,
,BAO_0000019,,,2599,1,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,B,,CHEMBL617467,,14826,,Autocuration,,,8,H,,
,BAO_0000019,,,2600,1,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,12687,B,,CHEMBL617468,,17211,,Expert,,,8,H,,
,BAO_0000019,,,2601,1,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,B,,CHEMBL617469,,14826,,Autocuration,,,8,H,,
,BAO_0000019,,,2602,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617470,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2603,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,12687,B,,CHEMBL617471,,14093,,Autocuration,,,8,H,,
,BAO_0000219,,,2604,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,12687,B,723.0,CHEMBL617472,NIH3T3,13246,,Expert,,,8,H,,
,BAO_0000357,,,2605,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,12687,B,,CHEMBL617473,,13246,,Expert,,,8,H,,
,BAO_0000019,,,2606,1,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,B,,CHEMBL617474,,15436,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2607,1,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,B,,CHEMBL617475,,15436,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Brain,,2608,1,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,12687,B,,CHEMBL617476,,14442,,Autocuration,,,8,H,,955.0
,BAO_0000357,,,2609,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617477,,12457,,Expert,,,8,H,,
,BAO_0000219,,,2610,1,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12687,B,723.0,CHEMBL617478,NIH3T3,12457,,Expert,,,8,H,,
,BAO_0000221,,,2611,1,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",12687,F,,CHEMBL617479,,14755,,Autocuration,,,8,H,,
,BAO_0000357,,,2612,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,12687,B,,CHEMBL617480,,4707,,Autocuration,,,8,H,,
,BAO_0000357,,,2613,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617481,,13297,,Expert,,,8,H,,
,BAO_0000019,,,2614,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,12687,B,,CHEMBL617482,,17331,,Expert,,,8,H,,
,BAO_0000019,,,2615,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,12687,B,,CHEMBL617483,,4664,,Autocuration,,,8,H,,
,BAO_0000357,,,2616,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,B,,CHEMBL621528,,16633,,Autocuration,,,8,H,,
,BAO_0000219,,,2617,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,12687,B,723.0,CHEMBL621529,NIH3T3,4664,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2618,1,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,B,,CHEMBL621530,,16133,,Expert,,,8,H,,
,BAO_0000357,,,2619,1,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,B,,CHEMBL621531,,16133,,Expert,,,8,H,,
,BAO_0000019,,,2620,1,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL621532,,14060,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2621,1,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,B,,CHEMBL621533,,16326,,Expert,,,8,H,,
,BAO_0000219,,,2622,1,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,12687,B,449.0,CHEMBL621534,CHO,16659,,Expert,,,8,H,,
,BAO_0000019,,,2623,1,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,12687,B,,CHEMBL621535,,14776,,Autocuration,,,8,H,,
,BAO_0000357,,,2624,1,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,12687,B,,CHEMBL621536,,13481,,Autocuration,,,8,H,,
,BAO_0000357,,,2625,1,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL621537,,17386,,Autocuration,,,8,H,,
,BAO_0000357,,,2626,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL621538,,6611,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2627,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,12687,B,,CHEMBL621539,,14423,,Autocuration,,,8,H,,
,BAO_0000019,,,2628,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,12687,B,,CHEMBL621540,,15412,,Autocuration,,,8,H,,
,BAO_0000019,,,2629,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,12687,B,,CHEMBL621541,,15412,,Autocuration,,,8,H,,
,BAO_0000019,,,2630,1,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,12687,B,,CHEMBL621542,,6238,,Autocuration,,,8,H,,
,BAO_0000357,,,2631,1,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,12687,B,,CHEMBL621543,,6648,,Expert,,,8,H,,
,BAO_0000357,,,2632,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,12687,B,,CHEMBL621544,,5667,,Expert,,,8,H,,
,BAO_0000357,,,2633,1,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,12687,B,,CHEMBL621545,,6611,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2634,1,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,B,,CHEMBL621546,,13481,,Autocuration,,,8,H,,
,BAO_0000357,,,2635,1,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,12687,B,,CHEMBL621547,,13481,,Autocuration,,,8,H,,
,BAO_0000219,,,2636,1,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,12687,B,723.0,CHEMBL618692,NIH3T3,15558,,Expert,,,8,H,,
,BAO_0000357,,,2637,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL618693,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,2638,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,B,,CHEMBL872922,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2639,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,12687,B,,CHEMBL618694,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,2640,1,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,12687,B,,CHEMBL618695,,6013,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2641,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,12687,B,,CHEMBL618696,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,2642,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,12687,B,,CHEMBL618697,,6013,,Expert,,,8,H,,
,BAO_0000357,,,2643,1,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,12687,B,,CHEMBL618892,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,2644,1,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,12687,B,,CHEMBL618893,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,2645,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL618894,,16293,,Autocuration,,,8,H,,
,BAO_0000219,,,2646,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,12687,B,723.0,CHEMBL618895,NIH3T3,17175,,Expert,,,8,H,,
,BAO_0000357,,,2647,1,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,B,,CHEMBL618896,,13278,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,Caudate-putamen,,2648,1,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,12687,B,,CHEMBL618897,,3682,,Autocuration,,,8,H,,5383.0
,BAO_0000357,,,2649,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,12687,B,,CHEMBL618898,,2014,,Autocuration,,,8,H,,
,BAO_0000357,,,2650,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,12687,B,,CHEMBL618899,,2014,,Autocuration,,,8,H,,
,BAO_0000357,,,2651,1,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,12687,B,,CHEMBL618900,,4932,,Autocuration,,,8,H,,
,BAO_0000019,,,2652,1,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,12687,B,,CHEMBL618901,,4932,,Autocuration,,,8,H,,
,BAO_0000357,,,2653,1,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL618902,,3935,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,2654,1,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL618903,,5432,10116.0,Expert,,,9,D,Rattus norvegicus,10000000.0
,BAO_0000357,,,2655,1,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL618904,,15818,,Autocuration,,,8,H,,
,BAO_0000357,,,2656,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,12687,B,,CHEMBL618905,,13672,,Autocuration,,,8,H,,
,BAO_0000357,,,2657,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,12687,B,,CHEMBL618906,,13672,,Autocuration,,,8,H,,
,BAO_0000219,,,2658,1,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,12687,B,723.0,CHEMBL618907,NIH3T3,14749,,Expert,,,8,H,,
,BAO_0000019,,,2659,1,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,12687,B,,CHEMBL618908,,13462,,Autocuration,,,8,H,,
,BAO_0000357,,,2660,1,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617909,,15740,,Autocuration,,,8,H,,
,BAO_0000019,,,2661,1,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,B,,CHEMBL617910,,16647,,Expert,,,8,H,,
,BAO_0000221,Brain,,2662,1,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,12687,B,,CHEMBL617911,,13345,,Autocuration,,,8,H,,955.0
,BAO_0000249,,,2663,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,B,,CHEMBL872923,,16740,,Autocuration,,,8,H,,
,BAO_0000249,,,2664,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,B,,CHEMBL617912,,16740,,Autocuration,,,8,H,,
,BAO_0000019,,,2665,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,12687,B,,CHEMBL617913,,15535,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,2666,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,B,,CHEMBL617914,,16740,,Expert,,,8,H,,
,BAO_0000249,,,2667,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,B,,CHEMBL617915,,16740,,Autocuration,,,8,H,,
,BAO_0000249,,,2668,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,B,,CHEMBL617916,,16740,,Autocuration,,,8,H,,
,BAO_0000019,,,2669,1,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617917,,4795,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2670,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,12687,B,,CHEMBL617918,,8,,Expert,,,8,H,,
,BAO_0000019,,,2671,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,12687,B,,CHEMBL617919,,8,,Autocuration,,,8,H,,
,BAO_0000019,,,2672,1,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,B,,CHEMBL617920,,17200,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2673,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,12687,B,,CHEMBL617921,,2148,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000224,,,2674,1,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",105102,B,,CHEMBL617922,,13345,10116.0,Expert,,,5,D,Rattus norvegicus,
,BAO_0000357,,,2675,1,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,B,,CHEMBL617923,,5088,,Autocuration,,,8,H,,
,BAO_0000357,,,2676,1,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,B,,CHEMBL617924,,5088,,Autocuration,,,8,H,,
,BAO_0000357,,,2677,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,12687,B,,CHEMBL617925,,17133,,Autocuration,,,8,H,,
,BAO_0000357,,,2678,1,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,12687,B,,CHEMBL617926,,17133,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2679,1,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,12687,B,,CHEMBL617927,,16532,,Autocuration,,,8,H,,
,BAO_0000357,,,2680,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,12687,B,,CHEMBL617928,,15086,,Autocuration,,,8,H,,
,BAO_0000019,,,2681,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,B,,CHEMBL617929,,2309,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,2682,1,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12687,B,,CHEMBL617930,,12953,,Expert,,,8,H,,
,BAO_0000019,,,2683,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12687,B,,CHEMBL617931,,12953,,Autocuration,,,8,H,,
,BAO_0000019,,,2684,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12687,B,,CHEMBL617932,,12953,,Autocuration,,,8,H,,
,BAO_0000219,,,2685,1,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,12687,B,449.0,CHEMBL617933,CHO,16659,,Autocuration,,,8,H,,
,BAO_0000019,,,2686,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,B,,CHEMBL617934,,16740,,Autocuration,,,8,H,,
,BAO_0000019,,,2687,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,B,,CHEMBL617935,,16740,,Autocuration,,,8,H,,
,BAO_0000357,,,2688,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,12687,B,,CHEMBL617936,,17133,,Autocuration,,,8,H,,
,BAO_0000019,,,2689,1,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,12687,B,,CHEMBL617937,,17211,,Autocuration,,,8,H,,
,BAO_0000019,,,2690,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,12687,B,,CHEMBL617938,,17331,,Autocuration,,,8,H,,
,BAO_0000218,,,2691,1,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,12687,B,,CHEMBL617939,,16633,,Autocuration,,,8,H,,
,BAO_0000218,,,2692,1,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,12687,B,,CHEMBL617940,,16633,,Autocuration,,,8,H,,
,BAO_0000218,,,2693,1,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,12687,B,,CHEMBL617941,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2694,1,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,12687,B,,CHEMBL617942,,15026,,Expert,,,8,H,,
,BAO_0000357,,,2695,1,,,Ratio of pKi of 5-HT2A to that of D2 receptor,12687,B,,CHEMBL617943,,15026,,Expert,,,8,H,,
,BAO_0000224,,,2696,1,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,B,,CHEMBL617944,,16404,,Expert,,,4,H,,
,BAO_0000224,,,2697,1,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,B,,CHEMBL617945,,16404,,Expert,,,4,H,,
,BAO_0000224,,,2698,1,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,105075,B,,CHEMBL617946,,16404,,Expert,,,4,H,,
,BAO_0000357,,,2699,1,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,12687,B,,CHEMBL617947,,16404,,Autocuration,,,8,H,,
,BAO_0000357,,,2700,1,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,12687,B,,CHEMBL617948,,16326,,Expert,,,8,H,,
,BAO_0000019,,,2701,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,12687,F,,CHEMBL858116,,15847,,Autocuration,,,8,H,,
,BAO_0000019,,,2702,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,12687,F,,CHEMBL617949,,15847,,Autocuration,,,8,H,,
,BAO_0000019,,,2703,1,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,12687,F,,CHEMBL617950,,15329,,Autocuration,,,8,H,,
,BAO_0000019,Thoracic aorta,,2704,1,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,12687,F,,CHEMBL617951,,16404,,Expert,,,8,H,,1515.0
,BAO_0000019,Thoracic aorta,,2705,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,12687,F,,CHEMBL617952,,16404,,Expert,,,8,H,,1515.0
,BAO_0000019,Thoracic aorta,,2706,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,12687,F,,CHEMBL617953,,16404,,Autocuration,,,8,H,,1515.0
,BAO_0000357,,,2707,1,,,Binding activity radioligand.,12687,B,,CHEMBL617954,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,2708,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,B,,CHEMBL617955,,12861,,Expert,,,8,H,,
,BAO_0000019,,,2709,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12687,B,,CHEMBL857071,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,2710,1,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12687,B,,CHEMBL617270,,12490,,Expert,,,8,H,,
,BAO_0000219,,,2711,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12687,B,339.0,CHEMBL617271,N1E-115,12827,,Autocuration,,,8,H,,
,BAO_0000219,,,2712,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12687,B,339.0,CHEMBL617272,N1E-115,12827,,Autocuration,,,8,H,,
,BAO_0000019,,,2713,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12687,B,,CHEMBL617273,,12918,,Autocuration,,,8,H,,
,BAO_0000019,,,2714,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12687,F,,CHEMBL617274,,12919,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2715,1,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617275,,17723,,Autocuration,,,8,H,,
,BAO_0000357,,,2716,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617276,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,2717,1,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617277,,16293,,Autocuration,,,8,H,,
,BAO_0000019,,,2718,1,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617278,,3857,,Expert,,,8,H,,
,BAO_0000019,,,2719,1,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,108,B,,CHEMBL617279,,3857,,Expert,,,8,H,,
,BAO_0000019,,,2720,1,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617280,,3857,,Expert,,,8,H,,
,BAO_0000357,,,2721,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617281,,15363,,Autocuration,,,8,H,,
,BAO_0000357,,,2722,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617282,,15363,,Autocuration,,,8,H,,
,BAO_0000019,,,2723,1,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,108,B,,CHEMBL617283,,16441,,Expert,,,8,H,,
,BAO_0000019,,,2724,1,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,108,B,,CHEMBL617284,,16441,,Expert,,,8,H,,
,BAO_0000219,,,2725,1,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,108,B,722.0,CHEMBL617285,HEK293,4176,,Autocuration,,,8,H,,
,BAO_0000019,,,2726,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617286,,17085,,Autocuration,,,8,H,,
,BAO_0000357,,,2727,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,108,B,,CHEMBL617287,,17200,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2728,1,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,108,B,,CHEMBL617288,,5088,,Expert,,,8,H,,
,BAO_0000357,,,2729,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,108,B,,CHEMBL617289,,5088,,Autocuration,,,8,H,,
,BAO_0000357,,,2730,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,B,,CHEMBL872917,,5088,,Autocuration,,,8,H,,
,BAO_0000357,,,2731,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,108,B,,CHEMBL617290,,5088,,Autocuration,,,8,H,,
,BAO_0000219,,,2732,1,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,B,449.0,CHEMBL617291,CHO,16659,,Autocuration,,,8,H,,
,BAO_0000219,,,2733,1,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,108,B,449.0,CHEMBL617292,CHO,16659,,Autocuration,,,8,H,,
,BAO_0000219,,,2734,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,108,B,723.0,CHEMBL617293,NIH3T3,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,2735,1,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,108,F,449.0,CHEMBL617294,CHO,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,2736,1,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,B,,CHEMBL617295,,3857,,Expert,,,8,H,,
,BAO_0000357,,,2737,1,,,Binding activity radioligand.,108,B,,CHEMBL617296,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,2738,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,108,B,,CHEMBL617297,,12861,,Autocuration,,,8,H,,
,BAO_0000219,,,2739,1,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,108,B,449.0,CHEMBL617298,CHO,5104,,Expert,,,8,H,,
,BAO_0000219,,,2740,1,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,108,B,449.0,CHEMBL617299,CHO,5105,,Expert,,,8,H,,
,BAO_0000219,,,2741,1,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,108,B,449.0,CHEMBL617300,CHO,5105,,Autocuration,,,8,H,,
,BAO_0000357,,,2742,1,,,Binding affinity against 5-HT2C receptor,108,B,,CHEMBL617454,,5254,,Autocuration,,,8,H,,
,BAO_0000219,,,2743,1,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,108,B,722.0,CHEMBL617505,HEK293,13267,,Autocuration,,,8,H,,
,BAO_0000219,,,2744,1,,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,108,B,722.0,CHEMBL617506,HEK293,14157,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2745,1,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,B,722.0,CHEMBL617507,HEK293,12936,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2746,1,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,108,B,,CHEMBL617508,,14068,,Expert,,,8,H,,
,BAO_0000219,,,2747,1,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,B,722.0,CHEMBL857982,HEK293,12936,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2748,1,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,108,B,722.0,CHEMBL617509,HEK293,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2749,1,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,108,B,722.0,CHEMBL617510,HEK293,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2750,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,108,B,,CHEMBL617511,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,2751,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,108,B,722.0,CHEMBL617512,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,2752,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,108,B,722.0,CHEMBL617749,HEK293,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,2753,1,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,B,722.0,CHEMBL617750,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2754,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,B,722.0,CHEMBL617751,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2755,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,108,B,722.0,CHEMBL617752,HEK293,14391,,Expert,,,8,H,,
,BAO_0000219,,,2756,1,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",108,B,722.0,CHEMBL617753,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2757,1,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",108,B,722.0,CHEMBL617754,HEK293,15851,,Expert,,,8,H,,
,BAO_0000219,,,2758,1,,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,108,B,722.0,CHEMBL617755,HEK293,15851,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2759,1,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",108,B,722.0,CHEMBL617756,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2760,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,108,B,722.0,CHEMBL617757,HEK293,3832,,Expert,,,8,H,,
,BAO_0000219,,,2761,1,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,108,B,722.0,CHEMBL617758,HEK293,3833,,Expert,,,8,H,,
,BAO_0000219,,,2762,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,108,B,723.0,CHEMBL617759,NIH3T3,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,2763,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,108,B,722.0,CHEMBL617760,HEK293,4199,,Autocuration,,,8,H,,
,BAO_0000219,,,2764,1,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,108,B,485.0,CHEMBL617761,CHO-K1,1883,,Expert,,,8,H,,
,BAO_0000357,,,2765,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617762,,4321,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2766,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617763,,14875,,Autocuration,,,8,H,,
,BAO_0000219,,,2767,1,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,108,B,722.0,CHEMBL857983,HEK293,15146,,Autocuration,,,8,H,,
,BAO_0000219,,,2768,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,108,B,722.0,CHEMBL617764,HEK293,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,2769,1,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,108,B,308.0,CHEMBL617765,HeLa,16404,,Autocuration,,,8,H,,
,BAO_0000019,,,2770,1,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,108,F,,CHEMBL617766,,13267,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,2771,1,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,108,F,,CHEMBL617767,,13267,,Autocuration,,,8,H,,10000000.0
,BAO_0000219,,,2772,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,108,B,722.0,CHEMBL617768,HEK293,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,2773,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",108,B,722.0,CHEMBL617769,HEK293,4829,,Autocuration,,,8,H,,
,BAO_0000357,,,2774,1,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,11864,B,,CHEMBL858023,,13463,,Autocuration,,,8,H,,
,BAO_0000019,Stomach,,2775,1,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,11864,B,,CHEMBL617770,,13463,,Autocuration,,,8,H,,945.0
,BAO_0000019,Stomach,,2776,1,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,11864,B,,CHEMBL617771,,13463,,Autocuration,,,8,H,,945.0
,BAO_0000219,,,2777,1,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,11864,F,625.0,CHEMBL617772,A9,12652,,Autocuration,,,8,H,,
,BAO_0000219,,,2778,1,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,B,723.0,CHEMBL617773,NIH3T3,4682,,Autocuration,,,8,H,,
,BAO_0000219,,,2779,1,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,11864,B,723.0,CHEMBL617850,NIH3T3,4682,,Autocuration,,,8,H,,
,BAO_0000219,,,2780,1,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,B,723.0,CHEMBL617851,NIH3T3,4682,,Autocuration,,,8,H,,
,BAO_0000019,,,2781,1,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,11864,F,,CHEMBL617852,,12652,,Autocuration,,,8,H,,
,BAO_0000019,Stomach,,2782,1,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,12689,B,,CHEMBL858024,,13463,10090.0,Autocuration,,,8,H,Mus musculus,945.0
,BAO_0000019,Stomach,,2783,1,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,12689,B,,CHEMBL617853,,13463,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000357,,,2784,1,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,108,B,,CHEMBL617854,,13969,,Expert,,,8,H,,
,BAO_0000357,,,2785,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL873477,,13392,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000357,,,2786,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617855,,13392,,Expert,,,8,H,,
,BAO_0000019,,,2787,1,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,108,B,,CHEMBL617856,,14430,,Expert,,,8,H,,
,BAO_0000019,,,2788,1,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,108,B,,CHEMBL617857,,1742,,Autocuration,,,8,H,,
,BAO_0000249,,,2789,1,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,108,B,,CHEMBL617858,,14286,,Autocuration,,,8,H,,
,BAO_0000357,,,2790,1,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617859,,5619,,Autocuration,,,8,H,,
,BAO_0000357,,,2791,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617860,,15086,,Autocuration,,,8,H,,
,BAO_0000357,,,2792,1,,,Binding activity radioligand.,108,B,,CHEMBL617861,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,2793,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,108,B,,CHEMBL617862,,12861,,Expert,,,8,H,,
,BAO_0000019,,,2794,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,108,B,,CHEMBL617863,,12861,,Autocuration,,,8,H,,
,BAO_0000249,,,2795,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,108,B,,CHEMBL617864,,12827,,Autocuration,,,8,H,,
,BAO_0000249,,,2796,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,108,B,,CHEMBL617649,,12827,,Autocuration,,,8,H,,
,BAO_0000019,,,2797,1,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,F,,CHEMBL617650,,12919,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000019,,,2798,1,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,F,,CHEMBL617651,,12919,9823.0,Expert,,,8,H,Sus scrofa,
,BAO_0000357,,,2799,1,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,108,B,,CHEMBL617652,,16429,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,2800,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,108,B,,CHEMBL857072,,773,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,2801,1,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617653,,5033,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,2802,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,B,,CHEMBL617654,,12861,,Autocuration,,,8,H,,
,BAO_0000019,,,2803,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,12689,F,,CHEMBL617655,,14093,,Autocuration,,,8,H,,
,BAO_0000357,,,2804,1,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,12689,B,,CHEMBL617656,,14970,,Expert,,,8,H,,
,BAO_0000357,,,2805,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,12689,B,,CHEMBL617657,,14970,,Autocuration,,,8,H,,
,BAO_0000357,,,2806,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,12689,B,,CHEMBL617658,,14970,,Autocuration,,,8,H,,
,BAO_0000357,,,2807,1,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL617659,,14178,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2808,1,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL617838,,14178,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,,,2809,1,,Brain membranes,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,12689,B,,CHEMBL617839,,14229,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2810,1,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,12689,B,,CHEMBL617840,,16532,,Autocuration,,,8,H,,
,BAO_0000019,,,2811,1,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,12689,B,,CHEMBL617841,,14826,,Autocuration,,,8,H,,
,BAO_0000019,,,2812,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,12689,B,,CHEMBL875915,,17211,,Autocuration,,,8,H,,
In vitro,BAO_0000219,,,2813,1,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,12689,B,,CHEMBL617842,,17211,,Expert,,,8,H,,
,BAO_0000219,,,2814,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,12689,B,723.0,CHEMBL617843,NIH3T3,13246,,Expert,,,8,H,,
,BAO_0000357,,,2815,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,12689,B,,CHEMBL617844,,13246,,Expert,,,8,H,,
,BAO_0000357,,,2816,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL617845,,12457,,Expert,,,8,H,,
,BAO_0000219,,,2817,1,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12689,B,723.0,CHEMBL617846,NIH3T3,12457,,Expert,,,8,H,,
,BAO_0000357,,,2818,1,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,12689,B,,CHEMBL617847,,4707,,Autocuration,,,8,H,,
,BAO_0000357,,,2819,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL617848,,13297,,Expert,,,8,H,,
,BAO_0000357,,,2820,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,B,,CHEMBL617849,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2821,1,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,B,,CHEMBL621507,,16133,,Expert,,,8,H,,
,BAO_0000357,,,2822,1,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,12689,B,,CHEMBL621508,,16326,,Expert,,,8,H,,
,BAO_0000019,,,2823,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,12689,B,,CHEMBL621509,,14423,,Autocuration,,,8,H,,
,BAO_0000019,,,2824,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,12689,B,,CHEMBL621510,,15412,,Autocuration,,,8,H,,
,BAO_0000019,,,2825,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,12689,B,,CHEMBL621511,,15412,,Autocuration,,,8,H,,
,BAO_0000219,,,2826,1,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,12689,B,625.0,CHEMBL621512,A9,15558,,Expert,,,8,H,,
,BAO_0000357,,,2827,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,B,,CHEMBL621513,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2828,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,12689,B,,CHEMBL621514,,6013,,Expert,,,8,H,,
In vitro,BAO_0000219,,,2829,1,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,12689,B,,CHEMBL621515,,17175,,Expert,,,8,H,,
,BAO_0000219,,,2830,1,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12689,B,,CHEMBL621516,,12469,,Autocuration,,,8,H,,
,BAO_0000019,Caudate-putamen,,2831,1,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,12689,B,,CHEMBL621517,,3682,,Autocuration,,,8,H,,5383.0
,BAO_0000357,,,2832,1,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,12689,B,,CHEMBL621518,,4932,,Autocuration,,,8,H,,
,BAO_0000019,,,2833,1,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,12689,B,,CHEMBL621519,,4932,,Autocuration,,,8,H,,
,BAO_0000357,,,2834,1,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL621520,,3935,,Autocuration,,,8,H,,
,BAO_0000357,,,2835,1,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL621521,,15818,,Autocuration,,,8,H,,
,BAO_0000357,,,2836,1,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL621522,,15818,,Autocuration,,,8,H,,
,BAO_0000219,,,2837,1,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,12689,B,,CHEMBL621523,,14749,,Expert,,,8,H,,
,BAO_0000357,,,2838,1,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL621524,,15740,,Autocuration,,,8,H,,
,BAO_0000357,,,2839,1,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,12689,B,,CHEMBL621525,,17133,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2840,1,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,12689,B,,CHEMBL872921,,16532,,Autocuration,,,8,H,,
,BAO_0000357,,,2841,1,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL621526,,12369,,Autocuration,,,8,H,,
,BAO_0000219,,,2842,1,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12689,B,,CHEMBL621527,,12369,,Expert,,,8,H,,
,BAO_0000019,,,2843,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,12689,B,,CHEMBL617865,,2309,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2844,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL617866,,12953,,Autocuration,,,8,H,,
,BAO_0000019,,,2845,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12689,B,,CHEMBL617867,,12953,,Autocuration,,,8,H,,
,BAO_0000357,,,2846,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12689,B,,CHEMBL617487,,12953,,Autocuration,,,8,H,,
,BAO_0000357,,,2847,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,12689,B,,CHEMBL617488,,12953,,Expert,,,8,H,,
,BAO_0000357,,,2848,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,12689,B,,CHEMBL617489,,17133,,Autocuration,,,8,H,,
,BAO_0000019,,,2849,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,12689,B,,CHEMBL617490,,17211,,Autocuration,,,8,H,,
,BAO_0000019,,,2850,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,12689,B,,CHEMBL617491,,17211,,Autocuration,,,8,H,,
,BAO_0000019,,,2851,1,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,12689,B,,CHEMBL617492,,14025,,Autocuration,,,8,H,,
,BAO_0000019,,,2852,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,12689,B,,CHEMBL617493,,14998,,Autocuration,,,8,H,,
,BAO_0000357,,,2853,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,12689,B,,CHEMBL617494,,4342,,Autocuration,,,8,H,,
,BAO_0000019,,,2854,1,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,12689,B,,CHEMBL617495,,13735,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,2855,1,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,12689,B,,CHEMBL617496,,13181,,Autocuration,,,8,H,,
,BAO_0000219,,,2856,1,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,12689,B,485.0,CHEMBL617497,CHO-K1,1883,,Autocuration,,,8,H,,
,BAO_0000357,,,2857,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,B,,CHEMBL617498,,15194,,Autocuration,,,8,H,,
,BAO_0000357,,,2858,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,12689,B,,CHEMBL617499,,15194,,Autocuration,,,8,H,,
,BAO_0000019,,,2859,1,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,12689,F,,CHEMBL617500,,14579,,Autocuration,,,8,H,,
,BAO_0000357,,,2860,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617501,,4639,,Autocuration,,,8,H,,
,BAO_0000357,,,2861,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617502,,4820,,Expert,,,8,H,,
,BAO_0000357,,,2862,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,227,B,,CHEMBL617503,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2863,1,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,227,B,,CHEMBL617504,,14755,,Autocuration,,,8,H,,
,BAO_0000357,,,2864,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,227,B,,CHEMBL617406,,14744,,Autocuration,,,8,H,,
,BAO_0000019,,,2865,1,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,227,B,,CHEMBL617407,,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2866,1,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,227,B,,CHEMBL617408,,16209,,Autocuration,,,8,H,,
,BAO_0000357,,,2867,1,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,B,,CHEMBL617409,,15363,,Autocuration,,,8,H,,
,BAO_0000357,,,2868,1,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,B,,CHEMBL617410,,15363,,Autocuration,,,8,H,,
,BAO_0000357,,,2869,1,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,227,B,,CHEMBL617411,,15363,,Autocuration,,,8,H,,
,BAO_0000019,,,2870,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,227,B,,CHEMBL617412,,17085,,Autocuration,,,8,H,,
,BAO_0000357,,,2871,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,227,B,,CHEMBL617774,,17200,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2872,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,B,722.0,CHEMBL617775,HEK293,15851,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2873,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,B,722.0,CHEMBL617776,HEK293,15851,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2874,1,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,F,449.0,CHEMBL617777,CHO,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2875,1,,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,F,449.0,CHEMBL617778,CHO,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2876,1,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,B,722.0,CHEMBL617779,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2877,1,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,227,B,722.0,CHEMBL617780,HEK293,15851,,Expert,,,8,H,,
,BAO_0000219,,,2878,1,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",227,B,722.0,CHEMBL617781,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2879,1,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,227,B,722.0,CHEMBL617782,HEK293,14157,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2880,1,,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,227,B,722.0,CHEMBL617783,HEK293,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2881,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,227,B,,CHEMBL617784,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,2882,1,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,227,B,722.0,CHEMBL617785,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,2883,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,227,B,722.0,CHEMBL857984,HEK293,14391,,Expert,,,8,H,,
,BAO_0000219,,,2884,1,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,227,B,722.0,CHEMBL617786,HEK293,3832,,Expert,,,8,H,,
,BAO_0000219,,,2885,1,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,227,B,722.0,CHEMBL617787,HEK293,3833,,Expert,,,8,H,,
,BAO_0000219,,,2886,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,227,B,722.0,CHEMBL617788,HEK293,15851,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2887,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,227,B,722.0,CHEMBL617789,HEK293,15851,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2888,1,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,227,B,722.0,CHEMBL617790,HEK293,4199,,Autocuration,,,8,H,,
,BAO_0000219,,,2889,1,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,227,B,485.0,CHEMBL617791,CHO-K1,1883,,Expert,,,8,H,,
,BAO_0000357,,,2890,1,,,Binding affinity against 5-hydroxytryptamine 2B receptor,227,B,,CHEMBL617608,,4321,,Expert,,,8,H,,
,BAO_0000219,,,2891,1,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,227,B,722.0,CHEMBL617609,HEK293,15146,,Autocuration,,,8,H,,
,BAO_0000219,,,2892,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,227,B,722.0,CHEMBL617610,HEK293,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,2893,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,227,B,722.0,CHEMBL617611,HEK293,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,2894,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,B,722.0,CHEMBL617612,HEK293,4829,,Autocuration,,,8,H,,
,BAO_0000219,,,2895,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,B,722.0,CHEMBL617613,HEK293,4829,,Autocuration,,,8,H,,
,BAO_0000019,,,2896,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,227,B,,CHEMBL617614,,14025,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,Stomach,,2897,1,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,12688,B,,CHEMBL617615,,13463,,Expert,,,8,H,,945.0
,BAO_0000357,Stomach,,2898,1,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,12688,B,,CHEMBL858114,,7259,,Expert,,,8,H,,945.0
,BAO_0000357,Stomach,,2899,1,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,12688,B,,CHEMBL617616,,7259,,Autocuration,,,8,H,,945.0
,BAO_0000019,Stomach,,2900,1,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,12688,F,,CHEMBL617617,,7185,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000019,,,2901,1,,,Antagonistic against 5-hydroxytryptamine 2B receptor,12688,F,,CHEMBL875914,,7185,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,Stomach,,2902,1,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,12688,F,,CHEMBL617618,,13267,,Autocuration,,,8,H,,945.0
,BAO_0000357,Stomach,,2903,1,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,12688,B,,CHEMBL617619,,13735,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000019,,,2904,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,12688,F,,CHEMBL617620,,15738,,Autocuration,,,8,H,,
,BAO_0000019,,,2905,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,12688,F,,CHEMBL617621,,15738,,Autocuration,,,8,H,,
,BAO_0000019,,,2906,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,12688,F,,CHEMBL617622,,15738,,Autocuration,,,8,H,,
,BAO_0000357,Stomach,,2907,1,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,B,,CHEMBL617623,,12936,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000357,Stomach,,2908,1,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,B,,CHEMBL617624,,12936,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000357,Stomach,,2909,1,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,B,,CHEMBL617625,,12936,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000357,Stomach,,2910,1,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,B,,CHEMBL617626,,12936,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000019,Stomach,,2911,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,F,,CHEMBL617627,,16404,,Autocuration,,,8,H,,945.0
,BAO_0000019,Stomach,,2912,1,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,F,,CHEMBL617628,,16404,,Expert,,,8,H,,945.0
,BAO_0000019,Stomach,,2913,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,12688,F,,CHEMBL617629,,16404,,Autocuration,,,8,H,,945.0
,BAO_0000019,Stomach,,2914,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,12688,F,,CHEMBL858115,,16404,,Autocuration,,,8,H,,945.0
,BAO_0000019,Stomach,,2915,1,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,12688,F,,CHEMBL617630,,16404,10116.0,Expert,,,9,D,Rattus norvegicus,945.0
,BAO_0000019,Thoracic aorta,,2916,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,12688,F,,CHEMBL617631,,16404,,Autocuration,,,8,H,,1515.0
,BAO_0000357,,,2917,1,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,B,,CHEMBL617632,,7483,,Autocuration,,,8,H,,
,BAO_0000357,,,2918,1,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,12688,B,,CHEMBL617633,,7483,,Expert,,,8,H,,
,BAO_0000357,,,2919,1,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,B,,CHEMBL617634,,7483,,Autocuration,,,8,H,,
,BAO_0000357,,,2920,1,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,12688,B,,CHEMBL617635,,7483,,Autocuration,,,8,H,,
,BAO_0000019,Stomach,,2922,1,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,F,,CHEMBL617637,,16404,10116.0,Autocuration,,,9,D,Rattus norvegicus,945.0
,BAO_0000357,,,2923,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,227,B,,CHEMBL617638,,6347,,Autocuration,,,8,H,,
,BAO_0000357,,,2924,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,227,B,,CHEMBL617639,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,2925,1,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,227,B,,CHEMBL617640,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,2926,1,,,Evaluated for the binding affinity to 5-HT 2B receptor,227,B,,CHEMBL617641,,4687,,Autocuration,,,8,H,,
,BAO_0000357,,,2927,1,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,227,B,,CHEMBL617642,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,2928,1,,,Binding affinities against 5-hydroxytryptamine 2B receptor,227,B,,CHEMBL617643,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2929,1,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,227,B,,CHEMBL617644,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2930,1,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,227,B,,CHEMBL617645,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,2931,1,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,B,,CHEMBL617646,,15026,,Expert,,,8,H,,
,BAO_0000357,,,2932,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,B,,CHEMBL617647,,15738,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,2933,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,108,B,,CHEMBL617648,,15738,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,2934,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,108,B,,CHEMBL617875,,15738,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,2935,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,108,B,,CHEMBL617876,,15738,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,2936,1,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,108,B,,CHEMBL617877,,16404,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000357,,,2937,1,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,B,,CHEMBL617878,,15026,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000357,,,2938,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,B,,CHEMBL617879,,15738,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000019,,,2939,1,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,108,B,,CHEMBL617880,,16312,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,Striatum,,2940,1,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,20033,B,,CHEMBL617881,,5486,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000357,,,2941,1,,,Binding affinity against 5-HT1A receptor,51,B,,CHEMBL857073,,5254,,Autocuration,,,8,H,,
,BAO_0000219,,,2942,1,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,108,F,449.0,CHEMBL617882,CHO,3857,,Expert,,,8,H,,
,BAO_0000219,,,2943,1,,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,108,F,449.0,CHEMBL617883,CHO,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,2944,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,108,F,,CHEMBL617884,,4176,,Autocuration,,,8,H,,
,BAO_0000219,,,2945,1,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,108,B,449.0,CHEMBL617885,CHO,6347,,Autocuration,,,8,H,,
,BAO_0000219,,,2946,1,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",108,B,449.0,CHEMBL617886,CHO,6347,,Autocuration,,,8,H,,
,BAO_0000357,,,2947,1,,,Inhibition of human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617887,,16146,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2948,1,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),108,B,,CHEMBL617888,,3805,,Autocuration,,,8,H,,
,BAO_0000019,,,2949,1,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,B,,CHEMBL617889,,3857,,Autocuration,,,8,H,,
,BAO_0000357,,,2950,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL617890,,5635,,Autocuration,,,8,H,,
,BAO_0000357,,,2951,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,B,,CHEMBL617891,,5635,,Autocuration,,,8,H,,
,BAO_0000357,,,2952,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,B,,CHEMBL617892,,5635,,Autocuration,,,8,H,,
,BAO_0000219,,,2953,1,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,108,B,449.0,CHEMBL617893,CHO,4012,,Expert,,,8,H,,
,BAO_0000219,,,2954,1,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,108,B,449.0,CHEMBL617894,CHO,6366,,Expert,,,8,H,,
,BAO_0000219,,,2955,1,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,B,449.0,CHEMBL617895,CHO,15949,,Expert,,,8,H,,
,BAO_0000219,,,2956,1,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,108,B,449.0,CHEMBL617896,CHO,17211,,Autocuration,,,8,H,,
,BAO_0000357,,,2957,1,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,108,B,,CHEMBL617897,,6491,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,2958,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,108,F,,CHEMBL617898,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2959,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,108,F,,CHEMBL617899,,13481,,Autocuration,,,8,H,,
,BAO_0000219,,,2960,1,,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,108,B,449.0,CHEMBL617900,CHO,6347,10116.0,Expert,,,8,H,Rattus norvegicus,
,BAO_0000019,,,2961,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,108,F,,CHEMBL617901,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2962,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,108,F,,CHEMBL617902,,14093,,Autocuration,,,8,H,,
,BAO_0000019,,,2963,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,F,,CHEMBL617903,,13481,,Autocuration,,,8,H,,
,BAO_0000357,,,2964,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,108,B,,CHEMBL617904,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2965,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,108,B,,CHEMBL617905,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2966,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,108,B,,CHEMBL617906,,14442,,Autocuration,,,8,H,,
,BAO_0000357,,,2967,1,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,108,B,,CHEMBL617907,,14755,,Autocuration,,,8,H,,
,BAO_0000357,,,2968,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,108,B,,CHEMBL617908,,14744,,Autocuration,,,8,H,,
,BAO_0000219,,,2969,1,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,B,449.0,CHEMBL620617,CHO,16659,,Expert,,,8,H,,
,BAO_0000019,,,2970,1,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,108,B,,CHEMBL620618,,6857,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2971,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,108,B,,CHEMBL620619,,5635,,Expert,,,8,H,,
,BAO_0000357,,,2972,1,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL620620,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,2973,1,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,108,B,,CHEMBL620621,,16209,,Autocuration,,,8,H,,
,BAO_0000249,,,2974,1,,Membranes,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,104698,B,,CHEMBL872920,,5778,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000223,,,2975,1,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,104698,B,,CHEMBL620622,,5094,,Autocuration,,,6,H,,
,BAO_0000019,,,2976,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,104698,B,,CHEMBL620623,,809,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,2977,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,104698,B,,CHEMBL620624,,1578,,Autocuration,,,6,H,,
,BAO_0000019,,,2978,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,104698,B,,CHEMBL620625,,809,,Autocuration,,,6,H,,
,BAO_0000219,,,2979,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,104698,B,,CHEMBL620626,,12469,,Autocuration,,,6,H,,
,BAO_0000019,,,2980,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,104698,B,,CHEMBL621307,,14290,,Autocuration,,,6,H,,
,BAO_0000019,,,2981,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,104698,B,,CHEMBL621308,,14290,,Autocuration,,,6,H,,
,BAO_0000223,,,2982,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,104698,B,,CHEMBL621309,,10609,,Autocuration,,,6,H,,
,BAO_0000223,,,2983,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,104698,B,,CHEMBL621310,,10609,,Autocuration,,,6,H,,
,BAO_0000223,,,2984,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,104698,B,,CHEMBL621311,,10609,,Autocuration,,,6,H,,
,BAO_0000249,,,2985,1,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,B,,CHEMBL621502,,15253,,Autocuration,,,6,H,,
,BAO_0000249,,,2986,1,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,B,,CHEMBL621503,,15253,,Autocuration,,,6,H,,
,BAO_0000249,,,2987,1,,Membranes,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,104698,B,,CHEMBL621504,,11683,,Autocuration,,,6,H,,
,BAO_0000223,,,2988,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL621505,,12092,,Autocuration,,,6,H,,
,BAO_0000019,,,2989,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,B,,CHEMBL621506,,1946,,Autocuration,,,6,H,,
,BAO_0000223,,,2990,1,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,104698,B,,CHEMBL619781,,11623,,Autocuration,,,6,H,,
,BAO_0000223,,,2991,1,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,104698,B,,CHEMBL619782,,11623,,Autocuration,,,6,H,,
,BAO_0000019,,,2992,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,104698,B,,CHEMBL619783,,14788,,Autocuration,,,6,H,,
,BAO_0000019,,,2993,1,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,104698,B,,CHEMBL619784,,5432,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000249,,,2994,1,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,B,,CHEMBL619785,,14826,,Autocuration,,,6,H,,
,BAO_0000223,,,2995,1,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL619786,,2222,,Autocuration,,,6,H,,
,BAO_0000019,,,2996,1,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,104698,B,,CHEMBL619787,,11963,,Autocuration,,,6,H,,
,BAO_0000019,,,2997,1,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,104698,B,,CHEMBL872925,,14145,,Autocuration,,,6,H,,
,BAO_0000019,,,2998,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,104698,B,,CHEMBL619788,,17819,,Autocuration,,,6,H,,
,BAO_0000249,,,2999,1,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,B,,CHEMBL619789,,10394,,Autocuration,,,6,H,,
,BAO_0000249,,,3000,1,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,B,,CHEMBL619790,,10394,,Autocuration,,,6,H,,
,BAO_0000019,,,3001,1,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,B,,CHEMBL619791,,15034,,Autocuration,,,6,H,,
,BAO_0000019,,,3002,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,B,,CHEMBL619792,,691,,Autocuration,,,6,H,,
,BAO_0000249,,,3003,1,,Membranes,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,104698,B,,CHEMBL619793,,12092,,Autocuration,,,6,H,,
,BAO_0000223,,,3004,1,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL619794,,11752,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000221,Brain,,3005,1,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,104698,B,,CHEMBL619795,,11752,,Autocuration,,,6,H,,955.0
,BAO_0000019,,,3006,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,104698,B,,CHEMBL619796,,301,,Autocuration,,,6,H,,
,BAO_0000223,,,3007,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,104698,B,,CHEMBL620448,,16532,,Autocuration,,,6,H,,
,BAO_0000223,,,3008,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,B,,CHEMBL620449,,16532,,Autocuration,,,6,H,,
,BAO_0000223,,,3009,1,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,104698,B,,CHEMBL620450,,12092,,Autocuration,,,6,H,,
,BAO_0000223,,,3010,1,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,104698,B,,CHEMBL620451,,11684,,Autocuration,,,6,H,,
,BAO_0000223,,,3011,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,104698,B,,CHEMBL620631,,11684,,Autocuration,,,6,H,,
,BAO_0000019,,,3012,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,104698,B,,CHEMBL620632,,12953,,Autocuration,,,6,H,,
,BAO_0000019,,,3013,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,104698,B,,CHEMBL620633,,12953,,Autocuration,,,6,H,,
,BAO_0000223,,,3014,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,104698,B,,CHEMBL620634,,12953,,Autocuration,,,6,H,,
,BAO_0000019,,,3015,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,104698,B,,CHEMBL620635,,12861,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3016,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,F,,CHEMBL620636,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3017,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,104698,F,,CHEMBL620637,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3018,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,104698,F,,CHEMBL620638,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3019,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,104698,F,,CHEMBL620639,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3020,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,F,,CHEMBL620640,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3021,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,104698,F,,CHEMBL620641,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3022,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,104698,F,,CHEMBL620642,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3023,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,104698,F,,CHEMBL620643,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3024,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,104698,F,,CHEMBL620644,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3025,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,F,,CHEMBL620645,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3026,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,104698,F,,CHEMBL620646,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3027,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,104698,F,,CHEMBL620647,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3028,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,104698,F,,CHEMBL620648,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3029,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,F,,CHEMBL620649,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3030,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,104698,F,,CHEMBL620650,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3031,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,104698,F,,CHEMBL620651,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3032,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,104698,F,,CHEMBL872875,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3033,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,104698,F,,CHEMBL620652,,11454,,Autocuration,,,6,H,,
,BAO_0000019,,,3034,1,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,104698,F,,CHEMBL620653,,10609,,Autocuration,,,6,H,,
,BAO_0000019,,,3035,1,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,104698,B,,CHEMBL857076,,12861,,Autocuration,,,6,H,,
,BAO_0000019,,,3036,1,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL620654,,12861,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000223,,,3037,1,,,Binding activity radioligand.,104698,B,,CHEMBL620655,,12861,,Autocuration,,,6,H,,
,BAO_0000249,,,3038,1,,Brain membranes,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,104698,B,,CHEMBL620656,,10728,,Autocuration,,,6,H,,
,BAO_0000249,,,3039,1,,Brain membranes,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,104698,B,,CHEMBL620657,,10728,,Autocuration,,,6,H,,
,BAO_0000357,,,3040,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,108,B,,CHEMBL620658,,5163,,Autocuration,,,8,H,,
,BAO_0000357,,,3041,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,108,B,,CHEMBL620659,,5163,,Autocuration,,,8,H,,
,BAO_0000357,,,3042,1,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,108,B,,CHEMBL620660,,6011,,Autocuration,,,8,H,,
,BAO_0000357,,,3043,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL620661,,5014,,Autocuration,,,8,H,,
,BAO_0000357,,,3044,1,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL620662,,5635,,Autocuration,,,8,H,,
,BAO_0000357,,,3045,1,,,Affinity for 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL620663,,5163,,Expert,,,8,H,,
,BAO_0000357,,,3046,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,B,,CHEMBL620664,,6841,,Autocuration,,,8,H,,
,BAO_0000357,,,3047,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,108,B,,CHEMBL620665,,6119,,Expert,,,8,H,,
,BAO_0000357,,,3048,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,108,B,,CHEMBL620666,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,3049,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,108,B,,CHEMBL620667,,1633,,Autocuration,,,8,H,,
,BAO_0000357,,,3050,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,108,B,,CHEMBL620668,,1633,,Expert,,,8,H,,
,BAO_0000357,,,3051,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,108,B,,CHEMBL620669,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,3052,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL620670,,6576,,Expert,,,8,H,,
,BAO_0000357,,,3053,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL620671,,4687,,Autocuration,,,8,H,,
,BAO_0000357,,,3054,1,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,108,B,,CHEMBL620672,,12146,,Autocuration,,,8,H,,
,BAO_0000357,,,3055,1,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,108,B,,CHEMBL620673,,12146,,Autocuration,,,8,H,,
,BAO_0000357,,,3056,1,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL620674,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,3057,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL620675,,14159,,Autocuration,,,8,H,,
,BAO_0000357,,,3058,1,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,108,B,,CHEMBL620676,,16700,,Autocuration,,,8,H,,
,BAO_0000357,,,3059,1,,,Affinity against 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL621382,,3269,,Autocuration,,,8,H,,
,BAO_0000357,,,3060,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL621383,,1274,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3061,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,108,B,,CHEMBL621384,,1317,,Autocuration,,,8,H,,
,BAO_0000357,,,3062,1,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,144,B,,CHEMBL621385,,5834,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000357,,,3063,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,144,B,,CHEMBL617989,,11147,9913.0,Autocuration,,,8,H,Bos taurus,
,BAO_0000019,,,3064,1,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,104714,F,,CHEMBL617990,,14145,10141.0,Expert,,,4,H,Cavia porcellus,
,BAO_0000221,Ileum,,3065,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,B,,CHEMBL875085,,10561,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000019,,,3066,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,104714,F,,CHEMBL617991,,15847,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3067,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,104714,F,,CHEMBL617992,,15847,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000221,Ileum,,3068,1,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,B,,CHEMBL617993,,10561,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3069,1,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,104714,B,,CHEMBL617994,,11454,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000019,,,3070,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,104714,F,,CHEMBL617995,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3071,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,104714,F,,CHEMBL617996,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3072,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,104714,F,,CHEMBL617997,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3073,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,104714,F,,CHEMBL617998,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3074,1,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,104714,F,,CHEMBL617999,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3075,1,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,104714,F,,CHEMBL618000,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000221,Ileum,,3076,1,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",104714,F,,CHEMBL617815,,15253,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3077,1,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",104714,F,,CHEMBL617816,,15253,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3078,1,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,104714,F,,CHEMBL617817,,11963,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3079,1,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,104714,B,,CHEMBL617818,,1946,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3080,1,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,104714,B,,CHEMBL617819,,1946,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000223,,,3081,1,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,104714,B,,CHEMBL617820,,12045,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000221,Ileum,,3082,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,B,,CHEMBL617821,,1559,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3083,1,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,F,,CHEMBL617822,,273,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3084,1,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),104714,F,,CHEMBL617823,,273,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3085,1,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,104714,F,,CHEMBL617824,,188,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3086,1,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,104714,F,,CHEMBL617825,,12919,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3087,1,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,104714,F,,CHEMBL617826,,12918,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3088,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,B,,CHEMBL617827,,1559,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3089,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,F,,CHEMBL617828,,273,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3090,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,B,,CHEMBL617829,,1559,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3091,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,104714,B,,CHEMBL617830,,1559,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3092,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,104714,B,,CHEMBL617831,,1559,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3093,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,104714,B,,CHEMBL617832,,14424,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000019,,,3094,1,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,22226,B,,CHEMBL617833,,13181,10141.0,Autocuration,,,0,U,Cavia porcellus,
,BAO_0000357,,,3095,1,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,51,B,,CHEMBL617834,,5486,,Autocuration,,,8,H,,
,BAO_0000223,,,3096,1,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,104714,B,,CHEMBL617835,,6491,9606.0,Expert,,,5,D,Homo sapiens,
,BAO_0000223,,,3097,1,,,Binding affinity towards 5-HT3 receptor,104714,B,,CHEMBL617836,,6013,,Autocuration,,,4,H,,
,BAO_0000223,,,3098,1,,,Binding activity radioligand.,104714,B,,CHEMBL617837,,12861,,Autocuration,,,4,H,,
,BAO_0000019,,,3099,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,104714,B,,CHEMBL620392,,12861,,Autocuration,,,4,H,,
,BAO_0000223,,,3100,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,B,,CHEMBL620393,,5104,,Autocuration,,,4,H,,
,BAO_0000223,,,3101,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,B,,CHEMBL620394,,5105,,Autocuration,,,4,H,,
,BAO_0000223,,,3102,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,104714,B,,CHEMBL620395,,5104,,Autocuration,,,4,H,,
,BAO_0000019,,,3103,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,22226,B,,CHEMBL620396,,3935,,Autocuration,,,0,U,,
,BAO_0000219,,,3104,1,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,105030,B,433.0,CHEMBL620582,NG108-15,13657,,Expert,,,4,H,,
In vivo,BAO_0000218,,,3105,1,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",105030,B,,CHEMBL620583,,10369,,Autocuration,,,4,H,,
,BAO_0000019,,,3106,1,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,B,,CHEMBL620584,,10369,,Autocuration,,,4,H,,
,BAO_0000224,,,3107,1,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,105030,B,,CHEMBL620585,,12918,,Autocuration,,,4,H,,
,BAO_0000224,,,3108,1,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,105030,B,,CHEMBL620586,,12918,,Autocuration,,,4,H,,
,BAO_0000019,,,3109,1,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,B,,CHEMBL620587,,10369,,Autocuration,,,4,H,,
,BAO_0000019,,,3110,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,105030,B,,CHEMBL620588,,773,,Autocuration,,,4,H,,
,BAO_0000218,,,3111,1,,,5-hydroxytryptamine 3 receptor agonism in mouse,105030,F,,CHEMBL620589,,12918,,Autocuration,,,4,H,,
,BAO_0000219,,,3112,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,105030,B,,CHEMBL620590,,10561,,Autocuration,,,4,H,,
,BAO_0000019,,,3113,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,B,,CHEMBL617956,,12827,,Autocuration,,,4,H,,
,BAO_0000019,,,3114,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,B,,CHEMBL617957,,12827,,Autocuration,,,4,H,,
,BAO_0000224,,,3115,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,105030,B,,CHEMBL617958,,12918,,Autocuration,,,4,H,,
,BAO_0000219,,,3116,1,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,B,,CHEMBL617959,,273,,Autocuration,,,4,H,,
,BAO_0000219,,,3117,1,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,B,,CHEMBL617960,,273,,Autocuration,,,4,H,,
,BAO_0000224,,,3118,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,105030,B,,CHEMBL617961,,10561,,Autocuration,,,4,H,,
In vitro,BAO_0000219,,,3119,1,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,105030,B,,CHEMBL617962,,5033,,Autocuration,,,4,H,,
,BAO_0000219,,,3120,1,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,105030,B,339.0,CHEMBL617963,N1E-115,16429,,Autocuration,,,4,H,,
,BAO_0000019,,,3121,1,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,11765,B,,CHEMBL617964,,10322,,Autocuration,,,8,H,,
,BAO_0000219,,,3122,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,11765,B,,CHEMBL617965,,14331,,Autocuration,,,8,H,,
,BAO_0000357,,,3123,1,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10630,B,,CHEMBL617966,,13462,10090.0,Autocuration,,,9,D,Mus musculus,
,BAO_0000019,,,3124,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,B,,CHEMBL857074,,12861,,Autocuration,,,8,H,,
,BAO_0000357,,,3125,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,144,B,,CHEMBL617967,,15086,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000357,,,3126,1,,,Binding activity radioligand.,144,B,,CHEMBL617968,,12861,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000223,,,3127,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,104714,B,,CHEMBL617969,,10561,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000223,,,3128,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,104714,B,,CHEMBL617970,,10561,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000223,,,3129,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,104714,B,,CHEMBL617971,,10561,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000019,,,3130,1,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104714,B,,CHEMBL617972,,10561,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000019,,,3131,1,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,F,,CHEMBL617973,,273,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000019,,,3132,1,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,F,,CHEMBL617974,,273,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000221,Ileum,,3133,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,F,,CHEMBL617975,,273,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,2116.0
,BAO_0000019,,,3134,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,F,,CHEMBL617976,,273,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000019,,,3135,1,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,F,,CHEMBL617977,,273,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000019,,,3136,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,F,,CHEMBL617978,,273,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000019,,,3137,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,F,,CHEMBL617979,,273,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000219,,,3138,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,104714,B,449.0,CHEMBL617980,CHO,13047,9986.0,Autocuration,,,4,H,Oryctolagus cuniculus,
,BAO_0000019,,,3139,1,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL617981,,1650,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3140,1,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),12020,B,,CHEMBL617982,,16288,,Autocuration,,,8,H,,
,BAO_0000357,,,3141,1,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),12020,B,,CHEMBL617983,,16288,,Autocuration,,,8,H,,
,BAO_0000019,,,3142,1,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,104698,B,,CHEMBL617984,,10254,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3143,1,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",104698,B,,CHEMBL617985,,14532,,Autocuration,,,6,H,,
In vivo,BAO_0000218,Heart,,3144,1,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,F,,CHEMBL617986,,13392,,Autocuration,,,6,H,,948.0
,BAO_0000019,Heart,,3145,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,F,,CHEMBL617987,,13392,,Autocuration,,,6,H,,948.0
,BAO_0000019,Heart,,3146,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,F,,CHEMBL617988,,13392,,Autocuration,,,6,H,,948.0
,BAO_0000019,Heart,,3147,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",104698,F,,CHEMBL617792,,13392,,Autocuration,,,6,H,,948.0
,BAO_0000019,Heart,,3148,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,F,,CHEMBL617793,,13392,,Autocuration,,,6,H,,948.0
,BAO_0000019,,,3149,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",104698,F,,CHEMBL617794,,13392,,Autocuration,,,6,H,,
,BAO_0000019,,,3150,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,F,,CHEMBL617795,,13392,,Autocuration,,,6,H,,
,BAO_0000019,,,3151,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,F,,CHEMBL617796,,13392,,Autocuration,,,6,H,,
,BAO_0000019,,,3152,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",104698,F,,CHEMBL617797,,13392,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3153,1,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),104698,F,,CHEMBL617798,,1089,10116.0,Autocuration,,,7,D,Rattus norvegicus,
In vivo,BAO_0000218,,,3154,1,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),104698,F,,CHEMBL617799,,1089,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3155,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617800,,11454,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3156,1,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,104698,F,,CHEMBL617801,,11454,10116.0,Autocuration,,,7,D,Rattus norvegicus,
In vivo,BAO_0000218,,,3157,1,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,104698,F,,CHEMBL617802,,12205,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3158,1,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),104698,F,,CHEMBL617803,,1089,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3159,1,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,B,,CHEMBL617804,,5094,,Autocuration,,,6,H,,
,BAO_0000019,,,3160,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL617805,,2622,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000223,,,3161,1,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL617806,,245,,Autocuration,,,6,H,,
,BAO_0000019,,,3162,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,104698,B,,CHEMBL617807,,14788,,Autocuration,,,6,H,,
,BAO_0000019,,,3163,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,104698,B,,CHEMBL617808,,14788,,Autocuration,,,6,H,,
,BAO_0000249,,,3164,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,104698,B,,CHEMBL617809,,3020,,Autocuration,,,6,H,,
,BAO_0000019,,,3165,1,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,104698,B,,CHEMBL617810,,1742,,Autocuration,,,6,H,,
,BAO_0000249,Brain,,3166,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,104698,B,,CHEMBL617811,,17394,,Autocuration,,,6,H,,955.0
,BAO_0000221,Brain,,3167,1,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,104698,B,,CHEMBL617812,,17394,,Autocuration,,,6,H,,955.0
,BAO_0000249,,,3168,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,B,,CHEMBL617813,,17394,,Autocuration,,,6,H,,
,BAO_0000249,,,3169,1,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,B,,CHEMBL617814,,14286,,Autocuration,,,6,H,,
,BAO_0000019,,,3170,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,104698,B,,CHEMBL617698,,14178,,Autocuration,,,6,H,,
,BAO_0000019,,,3171,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,104698,B,,CHEMBL617699,,14178,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3172,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,104698,B,,CHEMBL617700,,14178,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000223,,,3173,1,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL617701,,14178,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3174,1,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,B,,CHEMBL617702,,15034,,Autocuration,,,6,H,,
,BAO_0000249,,,3175,1,,Membranes,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",104698,B,,CHEMBL617703,,1089,,Autocuration,,,6,H,,
,BAO_0000019,,,3176,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,104698,B,,CHEMBL617704,,1089,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000223,,,3177,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,B,,CHEMBL617705,,16532,,Autocuration,,,6,H,,
,BAO_0000223,,,3178,1,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL617706,,12801,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000219,,,3179,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),104698,B,433.0,CHEMBL617707,NG108-15,15194,,Autocuration,,,6,H,,
,BAO_0000219,,,3180,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,104698,B,433.0,CHEMBL617708,NG108-15,15194,,Autocuration,,,6,H,,
,BAO_0000019,,,3181,1,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,104698,B,,CHEMBL617709,,15194,,Autocuration,,,6,H,,
,BAO_0000019,,,3182,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,104698,B,,CHEMBL617710,,15194,,Autocuration,,,6,H,,
,BAO_0000019,,,3183,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,104698,B,,CHEMBL882925,,15194,,Autocuration,,,6,H,,
,BAO_0000019,,,3184,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,104698,B,,CHEMBL617711,,15194,,Autocuration,,,6,H,,
,BAO_0000019,,,3185,1,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,104698,F,,CHEMBL617712,,10610,,Autocuration,,,6,H,,
,BAO_0000019,,,3186,1,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,104698,F,,CHEMBL617713,,10355,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3187,1,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",104698,F,,CHEMBL617714,,691,,Autocuration,,,6,H,,
,BAO_0000218,,,3188,1,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,104698,F,,CHEMBL617715,,10611,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3189,1,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,104698,F,,CHEMBL617716,,12801,,Autocuration,,,6,H,,
,BAO_0000218,,,3190,1,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,104698,F,,CHEMBL617717,,10609,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3191,1,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617718,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3192,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617719,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3193,1,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),104698,F,,CHEMBL617720,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3194,1,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617721,,11454,10116.0,Autocuration,,,7,D,Rattus norvegicus,
In vivo,BAO_0000218,,,3195,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617722,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3196,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,104698,F,,CHEMBL617723,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3197,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617724,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3198,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617725,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3199,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617726,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3200,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617727,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3201,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617728,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3202,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617729,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3203,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617730,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3204,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617731,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3205,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617732,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3206,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617733,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3207,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617734,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3208,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,104698,F,,CHEMBL872874,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3209,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,104698,F,,CHEMBL617735,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3210,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,104698,F,,CHEMBL617736,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3211,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,104698,F,,CHEMBL617737,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3212,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,104698,F,,CHEMBL617738,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3213,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617739,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3214,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617740,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3215,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617741,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3216,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617742,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3217,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617743,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3218,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617744,,11454,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3219,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,104698,F,,CHEMBL617745,,11454,,Autocuration,,,6,H,,
,BAO_0000218,,,3220,1,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",104698,F,,CHEMBL617746,,670,,Autocuration,,,6,H,,
,BAO_0000218,,,3221,1,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",104698,F,,CHEMBL617747,,670,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3222,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,104698,F,,CHEMBL617748,,10321,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3223,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,104698,F,,CHEMBL618909,,10321,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3224,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,104698,F,,CHEMBL618910,,10321,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3225,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,104698,F,,CHEMBL618911,,10321,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3226,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,104698,F,,CHEMBL618912,,10321,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,3227,1,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),104698,F,,CHEMBL618913,,10322,,Autocuration,,,6,H,,
,BAO_0000019,,,3228,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,F,,CHEMBL618914,,15412,,Autocuration,,,6,H,,
,BAO_0000019,,,3229,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,F,,CHEMBL618915,,15412,,Autocuration,,,6,H,,
,BAO_0000223,,,3230,1,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL618916,,15412,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3231,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,104698,F,,CHEMBL618917,,15412,,Autocuration,,,6,H,,
,BAO_0000221,Hippocampus,,3232,1,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,104698,B,,CHEMBL618918,,15412,,Intermediate,,,7,D,,10000000.0
,BAO_0000019,,,3233,1,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,104698,B,,CHEMBL618919,,15412,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3234,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL618920,,17394,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000223,,,3235,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL618921,,12457,,Autocuration,,,6,H,,
,BAO_0000019,,,3236,1,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL618922,,12457,,Autocuration,,,6,H,,
,BAO_0000019,,,3237,1,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,104698,B,,CHEMBL618923,,12205,,Autocuration,,,6,H,,
,BAO_0000019,,,3238,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,104698,B,,CHEMBL618924,,14532,,Autocuration,,,6,H,,
,BAO_0000019,,,3239,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,104698,B,,CHEMBL618925,,1122,,Autocuration,,,6,H,,
,BAO_0000019,,,3240,1,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,B,,CHEMBL618926,,5094,,Autocuration,,,6,H,,
,BAO_0000221,Ileum,,3241,1,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,20033,F,,CHEMBL618927,,809,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3242,1,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,20033,F,,CHEMBL618928,,809,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3243,1,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",20033,F,,CHEMBL618929,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3244,1,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",20033,F,,CHEMBL618930,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3245,1,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,F,,CHEMBL618931,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3246,1,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,F,,CHEMBL619594,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3247,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",20033,F,,CHEMBL619595,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3248,1,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,20033,F,,CHEMBL619596,,13961,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3249,1,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,20033,F,,CHEMBL619755,,13961,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3250,1,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,20033,F,,CHEMBL619756,,809,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3251,1,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,20033,F,,CHEMBL619757,,809,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3252,1,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,20033,F,,CHEMBL619758,,809,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3253,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",20033,F,,CHEMBL619759,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3254,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",20033,F,,CHEMBL619760,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3255,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",20033,F,,CHEMBL619761,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3256,1,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,20033,F,,CHEMBL619762,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3257,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,F,,CHEMBL619763,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3258,1,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,F,,CHEMBL617868,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000357,,,3259,1,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,B,,CHEMBL617869,,15034,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000249,Striatum,,3260,1,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,B,,CHEMBL882926,,5094,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000249,Striatum,,3261,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,B,,CHEMBL617870,,5094,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000357,Striatum,,3262,1,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,20033,B,,CHEMBL617871,,5399,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000357,Striatum,,3263,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,B,,CHEMBL617872,,17394,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000357,Striatum,,3264,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,B,,CHEMBL617873,,17394,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000357,Striatum,,3265,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,B,,CHEMBL617874,,17394,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000221,Ileum,,3266,1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,20033,F,,CHEMBL619067,,13961,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3267,1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,20033,F,,CHEMBL619068,,13961,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3268,1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,F,,CHEMBL619069,,13961,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000357,,,3269,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,20033,B,,CHEMBL619070,,16946,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3270,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,20033,B,,CHEMBL619071,,16946,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,3271,1,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,20033,F,,CHEMBL619072,,15034,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,3272,1,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,20033,F,,CHEMBL619073,,15034,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,3273,1,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,20033,F,,CHEMBL619074,,12918,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3274,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,20033,B,,CHEMBL619075,,16946,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,Striatum,,3275,1,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,B,,CHEMBL619076,,17394,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000357,Striatum,,3276,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,20033,B,,CHEMBL619077,,15034,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000249,Striatum,,3277,1,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,B,,CHEMBL619078,,5094,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000249,Striatum,,3278,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,B,,CHEMBL619079,,5094,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000221,Ileum,,3279,1,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,20033,B,,CHEMBL619080,,17358,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000357,,,3280,1,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,20033,B,,CHEMBL619081,,12953,10141.0,Expert,,,9,D,Cavia porcellus,
,BAO_0000357,,,3281,1,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,B,,CHEMBL619082,,12953,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3282,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,20033,B,,CHEMBL619083,,12953,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3283,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,B,,CHEMBL619084,,12953,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000221,Ileum,,3284,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,F,,CHEMBL859397,,273,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3285,1,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,20033,F,,CHEMBL619085,,12918,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3286,1,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,20033,F,,CHEMBL619086,,12919,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3287,1,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,20033,F,,CHEMBL619087,,273,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3288,1,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,F,,CHEMBL619088,,273,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000357,,,3289,1,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,20033,B,,CHEMBL619089,,13181,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3290,1,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,168,B,,CHEMBL619090,,13181,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,3291,1,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,20033,F,,CHEMBL619091,,15034,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3292,1,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,B,,CHEMBL619092,,5033,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000019,,,3293,1,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,20033,B,,CHEMBL619093,,1980,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000219,,,3294,1,,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,168,B,722.0,CHEMBL619094,HEK293,13181,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,3295,1,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,20033,B,,CHEMBL619095,,14287,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3296,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,20033,B,,CHEMBL857988,,1317,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3297,1,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,20033,B,,CHEMBL619096,,15316,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,Striatum,,3298,1,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,20033,B,,CHEMBL619097,,16429,10141.0,Intermediate,,,9,D,Cavia porcellus,2435.0
,BAO_0000221,Hippocampus,,3299,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,20033,B,,CHEMBL619098,,14818,10141.0,Intermediate,,,9,D,Cavia porcellus,10000000.0
,BAO_0000357,,,3300,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,20033,B,,CHEMBL619751,,15194,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000357,,,3301,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,20033,B,,CHEMBL619752,,15194,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000221,Ileum,,3302,1,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,F,,CHEMBL875096,,13961,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000357,,,3303,1,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,108,B,,CHEMBL619004,,5486,,Autocuration,,,8,H,,
,BAO_0000357,,,3304,1,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,168,B,,CHEMBL619005,,16209,,Autocuration,,,8,H,,
,BAO_0000019,,,3305,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL619006,,17085,,Autocuration,,,8,H,,
,BAO_0000219,,,3306,1,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,168,B,308.0,CHEMBL619007,HeLa,4199,,Autocuration,,,8,H,,
,BAO_0000357,,,3307,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL619008,,15146,,Autocuration,,,8,H,,
,BAO_0000357,,,3308,1,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL619009,,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,3309,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",168,B,308.0,CHEMBL619010,HeLa,4829,,Autocuration,,,8,H,,
,BAO_0000357,,,3310,1,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,10622,B,,CHEMBL619011,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3311,1,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,10622,B,,CHEMBL619012,,17358,,Autocuration,,,8,H,,
,BAO_0000219,,,3312,1,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,10622,B,,CHEMBL619013,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,3313,1,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,10622,B,,CHEMBL619014,,17358,,Autocuration,,,8,H,,
,BAO_0000019,Cardiac atrium,,3314,1,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,11249,F,,CHEMBL857503,,268,,Autocuration,,,8,H,,2081.0
,BAO_0000019,Cardiac atrium,,3315,1,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,11249,F,,CHEMBL619015,,268,,Autocuration,,,8,H,,2081.0
,BAO_0000357,,,3316,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,11249,B,,CHEMBL619016,,15086,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,3317,1,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,11249,B,,CHEMBL619017,,14875,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,3318,1,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,168,B,,CHEMBL619018,,13267,9823.0,Autocuration,,,8,H,Sus scrofa,10000000.0
,BAO_0000019,,,3319,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,168,B,,CHEMBL619019,,13047,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000357,,,3320,1,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10623,B,,CHEMBL619020,,1650,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,3321,1,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,F,,CHEMBL619021,,567,,Autocuration,,,8,H,,
,BAO_0000357,,,3322,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,10623,B,,CHEMBL619022,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3323,1,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,10623,B,,CHEMBL619023,,188,,Autocuration,,,8,H,,
,BAO_0000019,,,3324,1,,,lntrinsic activity relative to 5-HT receptor,10623,F,,CHEMBL619024,,670,,Autocuration,,,8,H,,
,BAO_0000019,,,3325,1,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,10623,F,,CHEMBL619025,,204,,Autocuration,,,8,H,,
,BAO_0000019,,,3326,1,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,10623,F,,CHEMBL619026,,1946,,Expert,,,8,H,,
,BAO_0000019,,,3327,1,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,10623,F,,CHEMBL619027,,6398,,Autocuration,,,8,H,,
,BAO_0000019,,,3328,1,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,10623,F,,CHEMBL619028,,6398,,Autocuration,,,8,H,,
,BAO_0000019,,,3329,1,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,10623,F,,CHEMBL619029,,17358,,Autocuration,,,8,H,,
,BAO_0000019,,,3330,1,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,10623,F,,CHEMBL619030,,6398,,Autocuration,,,8,H,,
,BAO_0000357,,,3331,1,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,10623,B,,CHEMBL619031,,11752,,Expert,,,8,H,,
,BAO_0000019,,,3332,1,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,10623,F,,CHEMBL619032,,809,,Autocuration,,,8,H,,
,BAO_0000357,,,3333,1,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10623,B,,CHEMBL619033,,14178,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3334,1,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,B,,CHEMBL619034,,567,,Autocuration,,,8,H,,
,BAO_0000357,,,3335,1,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,10623,B,,CHEMBL619035,,1946,,Autocuration,,,8,H,,
,BAO_0000357,,,3336,1,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,10623,B,,CHEMBL619036,,1946,,Autocuration,,,8,H,,
,BAO_0000019,,,3337,1,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10623,B,,CHEMBL619037,,13961,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,Striatum,,3338,1,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,10623,B,,CHEMBL619038,,6238,,Autocuration,,,8,H,,2435.0
,BAO_0000249,,,3339,1,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,10623,B,,CHEMBL619039,,14290,,Autocuration,,,8,H,,
,BAO_0000249,,,3340,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,10623,B,,CHEMBL619040,,14290,,Expert,,,8,H,,
,BAO_0000019,Striatum,,3341,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,B,,CHEMBL619041,,809,10116.0,Expert,,,9,D,Rattus norvegicus,2435.0
,BAO_0000019,Striatum,,3342,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,B,,CHEMBL619042,,1578,,Autocuration,,,8,H,,2435.0
,BAO_0000249,Striatum,,3343,1,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,10623,B,,CHEMBL619043,,16709,,Expert,,,8,H,,2435.0
,BAO_0000019,Striatum,,3344,1,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,10623,B,,CHEMBL619044,,1946,,Expert,,,8,H,,2435.0
,BAO_0000249,Striatum,,3345,1,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,10623,B,,CHEMBL619045,,15253,,Expert,,,8,H,,2435.0
,BAO_0000249,Striatum,,3346,1,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,B,,CHEMBL619046,,4535,,Expert,,,8,H,,2435.0
,BAO_0000249,,,3347,1,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,10623,B,,CHEMBL619047,,13961,,Expert,,,8,H,,
,BAO_0000221,Brain,,3348,1,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,10623,F,,CHEMBL619048,,17358,,Autocuration,,,8,H,,955.0
,BAO_0000019,,,3349,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,10623,F,,CHEMBL859398,,15847,,Autocuration,,,8,H,,
,BAO_0000019,,,3350,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,10623,F,,CHEMBL619049,,15847,,Autocuration,,,8,H,,
,BAO_0000019,,,3351,1,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,10623,F,,CHEMBL857886,,670,,Autocuration,,,8,H,,
,BAO_0000019,,,3352,1,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,10623,F,,CHEMBL619050,,670,,Autocuration,,,8,H,,
,BAO_0000019,,,3353,1,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,F,,CHEMBL620591,,1317,,Autocuration,,,8,H,,
,BAO_0000357,,,3354,1,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10623,B,,CHEMBL620592,,12936,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000249,Striatum,,3355,1,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,B,,CHEMBL620593,,4535,,Expert,,,8,H,,2435.0
,BAO_0000019,,,3356,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10623,F,,CHEMBL620594,,14424,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,3357,1,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,10623,F,,CHEMBL875079,,14424,,Expert,,,8,H,,
,BAO_0000019,,,3358,1,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,F,,CHEMBL620595,,14424,,Expert,,,8,H,,
,BAO_0000019,,,3359,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10623,F,,CHEMBL620596,,14424,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,3360,1,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,10623,F,,CHEMBL620597,,14424,,Autocuration,,,8,H,,
,BAO_0000019,,,3361,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,10623,F,,CHEMBL620598,,14424,,Expert,,,8,H,,
,BAO_0000218,,,3362,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),10623,F,,CHEMBL620599,,14424,,Expert,,,8,H,,
,BAO_0000019,,,3363,1,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,F,,CHEMBL620600,,14424,,Autocuration,,,8,H,,
,BAO_0000019,,,3364,1,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,168,F,,CHEMBL620601,,1980,10116.0,Autocuration,,,8,H,Rattus norvegicus,
,BAO_0000019,,,3365,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,168,F,,CHEMBL620602,,4639,,Autocuration,,,8,H,,
,BAO_0000357,,,3366,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL620603,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3367,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,168,B,,CHEMBL620604,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3368,1,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,168,B,,CHEMBL620605,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3369,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL620606,,1558,,Autocuration,,,8,H,,
,BAO_0000019,,,3370,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,F,,CHEMBL620607,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3371,1,,,In vitro binding affinity towards 5-HT4 receptor was determined,168,B,,CHEMBL620608,,16117,,Autocuration,,,8,H,,
,BAO_0000019,,,3372,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,F,,CHEMBL620609,,17358,,Autocuration,,,8,H,,
,BAO_0000019,,,3373,1,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,168,F,,CHEMBL620610,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3374,1,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL620611,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3375,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,168,B,,CHEMBL620612,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3376,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,168,B,,CHEMBL620613,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3377,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,168,B,,CHEMBL620614,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3378,1,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,168,B,,CHEMBL620615,,1274,,Expert,,,8,H,,
,BAO_0000249,,,3379,1,,Brain membranes,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,104698,B,,CHEMBL857075,,10728,,Autocuration,,,6,H,,
,BAO_0000249,,,3380,1,,Brain membranes,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,104698,B,,CHEMBL620616,,11695,,Autocuration,,,6,H,,
,BAO_0000249,,,3381,1,,Brain membranes,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,104698,B,,CHEMBL619411,,11695,,Autocuration,,,6,H,,
,BAO_0000019,,,3382,1,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,104698,B,,CHEMBL619412,,12490,,Autocuration,,,6,H,,
,BAO_0000019,,,3383,1,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL619413,,11828,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000221,Hippocampus,,3384,1,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,104698,B,,CHEMBL619414,,12253,,Autocuration,,,6,H,,10000000.0
,BAO_0000019,,,3385,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104698,B,,CHEMBL619415,,10561,,Autocuration,,,6,H,,
,BAO_0000019,,,3386,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,104698,B,,CHEMBL619416,,10561,,Autocuration,,,6,H,,
,BAO_0000019,,,3387,1,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,104698,F,,CHEMBL619417,,14432,,Autocuration,,,6,H,,
,BAO_0000223,,,3388,1,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL619418,,12936,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000223,,,3389,1,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,104698,B,,CHEMBL619419,,1274,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3390,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,104698,B,,CHEMBL619420,,1980,,Autocuration,,,6,H,,
,BAO_0000249,,,3391,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,104698,B,,CHEMBL619421,,670,,Autocuration,,,6,H,,
,BAO_0000019,,,3392,1,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,104698,B,,CHEMBL619422,,968,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000019,,,3393,1,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,104698,B,,CHEMBL619423,,14287,,Autocuration,,,6,H,,
,BAO_0000019,,,3394,1,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,104698,B,,CHEMBL875080,,567,,Autocuration,,,6,H,,
,BAO_0000019,,,3395,1,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,104698,B,,CHEMBL619424,,13267,,Autocuration,,,6,H,,
,BAO_0000249,,,3396,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,104698,B,,CHEMBL619425,,14826,,Autocuration,,,6,H,,
,BAO_0000223,,,3397,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,104698,B,,CHEMBL619426,,15194,,Autocuration,,,6,H,,
,BAO_0000223,,,3398,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,104698,B,,CHEMBL619427,,15194,,Autocuration,,,6,H,,
,BAO_0000223,,,3399,1,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL619645,,10394,10116.0,Autocuration,,,7,D,Rattus norvegicus,
,BAO_0000249,,,3400,1,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",10576,B,,CHEMBL619646,,13657,,Expert,,,9,D,,
,BAO_0000221,Brain,,3401,1,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,12020,F,,CHEMBL619647,,1879,,Autocuration,,,8,H,,955.0
,BAO_0000019,,,3402,1,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,12020,F,,CHEMBL619648,,1879,,Autocuration,,,8,H,,
,BAO_0000019,,,3403,1,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,12020,F,,CHEMBL619165,,1879,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,3404,1,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,12020,F,,CHEMBL620719,,204,,Autocuration,,,8,H,,
,BAO_0000019,,,3405,1,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,B,,CHEMBL872924,,1879,,Autocuration,,,8,H,,
,BAO_0000357,,,3406,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,12020,B,,CHEMBL620720,,1879,,Autocuration,,,8,H,,
,BAO_0000019,,,3407,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,B,,CHEMBL620721,,1879,,Autocuration,,,8,H,,
,BAO_0000019,,,3408,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,12020,B,,CHEMBL620722,,1879,,Autocuration,,,8,H,,
,BAO_0000019,,,3409,1,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",104698,B,,CHEMBL620723,,10641,,Autocuration,,,6,H,,
,BAO_0000019,,,3410,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,12020,B,,CHEMBL620724,,773,,Autocuration,,,8,H,,
,BAO_0000249,,,3411,1,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,104698,B,,CHEMBL620725,,11952,,Autocuration,,,6,H,,
,BAO_0000019,,,3412,1,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,12020,F,,CHEMBL620726,,14145,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3413,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,144,B,,CHEMBL620727,,17066,,Expert,,,8,H,,
,BAO_0000223,,,3414,1,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,104714,B,,CHEMBL620728,,6398,,Autocuration,,,4,H,,
,BAO_0000019,,,3415,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,22226,B,,CHEMBL620729,,10321,,Autocuration,,,0,U,,
,BAO_0000019,,,3416,1,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,104714,F,,CHEMBL858288,,511,,Autocuration,,,4,H,,
,BAO_0000223,,,3417,1,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,104714,B,,CHEMBL620730,,4639,,Autocuration,,,4,H,,
,BAO_0000223,,,3418,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,B,,CHEMBL620731,,4639,,Autocuration,,,4,H,,
,BAO_0000019,,,3419,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,104714,F,,CHEMBL620732,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3420,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,F,,CHEMBL618042,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3421,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,104714,F,,CHEMBL618043,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000223,,,3422,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,104714,B,,CHEMBL618044,,1558,,Autocuration,,,4,H,,
,BAO_0000019,,,3423,1,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,104714,F,,CHEMBL618045,,268,,Autocuration,,,4,H,,
,BAO_0000223,,,3424,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,104714,B,,CHEMBL618046,,2474,,Autocuration,,,4,H,,
,BAO_0000019,,,3425,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,104714,F,,CHEMBL618047,,5067,,Autocuration,,,4,H,,
,BAO_0000019,,,3426,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,104714,F,,CHEMBL875084,,5067,,Autocuration,,,4,H,,
,BAO_0000019,,,3427,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,104714,F,,CHEMBL618048,,5067,,Autocuration,,,4,H,,
,BAO_0000223,,,3428,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,104714,B,,CHEMBL618049,,5067,,Autocuration,,,4,H,,
,BAO_0000019,,,3429,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,104714,F,,CHEMBL619764,,5067,,Autocuration,,,4,H,,
,BAO_0000019,,,3430,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,104714,F,,CHEMBL619765,,5067,,Autocuration,,,4,H,,
,BAO_0000019,,,3431,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,104714,F,,CHEMBL619766,,5067,,Autocuration,,,4,H,,
,BAO_0000223,,,3432,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,104714,B,,CHEMBL619767,,5067,,Autocuration,,,4,H,,
,BAO_0000223,,,3433,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,104714,B,,CHEMBL619768,,5067,,Autocuration,,,4,H,,
,BAO_0000019,,,3434,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,104714,F,,CHEMBL619769,,5067,,Autocuration,,,4,H,,
,BAO_0000223,,,3435,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,104714,B,,CHEMBL619770,,5067,,Autocuration,,,4,H,,
,BAO_0000223,,,3436,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,B,,CHEMBL619771,,5067,,Autocuration,,,4,H,,
,BAO_0000219,,,3437,1,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,104714,B,,CHEMBL619772,,14331,,Autocuration,,,4,H,,
,BAO_0000223,,,3438,1,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,104714,B,,CHEMBL619773,,5067,,Autocuration,,,4,H,,
,BAO_0000219,,,3439,1,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,104714,B,433.0,CHEMBL619774,NG108-15,6179,,Autocuration,,,4,H,,
,BAO_0000019,,,3440,1,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,104714,B,,CHEMBL875083,,4265,,Autocuration,,,4,H,,
,BAO_0000219,,,3441,1,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,104714,B,433.0,CHEMBL620718,NG108-15,4265,,Autocuration,,,4,H,,
,BAO_0000223,,,3442,1,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,104714,B,,CHEMBL618127,,17358,,Autocuration,,,4,H,,
,BAO_0000223,,,3443,1,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,104714,B,,CHEMBL618128,,17358,,Autocuration,,,4,H,,
In vitro,BAO_0000219,,,3444,1,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,104714,B,,CHEMBL618129,,13628,,Autocuration,,,4,H,,
,BAO_0000223,,,3445,1,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,104714,B,,CHEMBL618130,,4612,,Autocuration,,,4,H,,
,BAO_0000019,,,3446,1,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,104714,F,,CHEMBL618131,,17358,,Autocuration,,,4,H,,
,BAO_0000019,,,3447,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,104714,F,,CHEMBL618132,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3448,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,104714,F,,CHEMBL618133,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3449,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,104714,F,,CHEMBL618134,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3450,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,F,,CHEMBL618135,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000223,,,3451,1,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,104714,B,,CHEMBL618136,,511,,Autocuration,,,4,H,,
,BAO_0000223,,,3452,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,B,,CHEMBL618137,,1479,,Autocuration,,,4,H,,
,BAO_0000223,,,3453,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,104714,B,,CHEMBL618138,,1317,,Autocuration,,,4,H,,
,BAO_0000223,,,3454,1,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,104714,B,,CHEMBL618139,,12146,,Autocuration,,,4,H,,
,BAO_0000223,,,3455,1,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,104714,B,,CHEMBL618140,,12146,,Autocuration,,,4,H,,
,BAO_0000223,,,3456,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,104714,B,,CHEMBL618141,,13969,,Autocuration,,,4,H,,
,BAO_0000357,,,3457,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,108,B,,CHEMBL873478,,13392,,Expert,,,8,H,,
,BAO_0000223,,,3458,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104698,B,,CHEMBL618142,,13392,,Autocuration,,,6,H,,
,BAO_0000357,,,3459,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,144,B,,CHEMBL618143,,14159,,Autocuration,,,8,H,,
,BAO_0000357,,,3460,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,144,B,,CHEMBL618144,,1558,,Autocuration,,,8,H,,
,BAO_0000357,,,3461,1,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,144,B,,CHEMBL618145,,16655,,Autocuration,,,8,H,,
,BAO_0000223,,,3462,1,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,B,,CHEMBL618146,,13020,,Autocuration,,,4,H,,
,BAO_0000223,,,3463,1,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,104714,B,,CHEMBL618147,,13021,,Autocuration,,,4,H,,
,BAO_0000223,,,3464,1,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,B,,CHEMBL618148,,13020,,Autocuration,,,4,H,,
,BAO_0000019,,,3465,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,144,B,,CHEMBL618149,,10321,,Autocuration,,,8,H,,
,BAO_0000357,,,3466,1,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,B,,CHEMBL872927,,15818,,Autocuration,,,8,H,,
,BAO_0000357,,,3467,1,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,B,,CHEMBL618150,,15818,,Autocuration,,,8,H,,
,BAO_0000357,,,3468,1,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,144,B,,CHEMBL618151,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3469,1,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,144,B,,CHEMBL875094,,2222,,Autocuration,,,8,H,,
,BAO_0000019,,,3470,1,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,144,B,,CHEMBL618152,,10322,,Autocuration,,,8,H,,
,BAO_0000357,,,3471,1,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,144,B,,CHEMBL618153,,16117,,Autocuration,,,8,H,,
,BAO_0000357,,,3472,1,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,144,B,,CHEMBL618888,,17200,,Autocuration,,,8,H,,
,BAO_0000019,,,3473,1,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,144,F,,CHEMBL618889,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3474,1,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,144,B,,CHEMBL618890,,16700,,Autocuration,,,8,H,,
,BAO_0000019,,,3475,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,144,B,,CHEMBL618891,,1980,,Autocuration,,,8,H,,
,BAO_0000019,,,3476,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,144,B,,CHEMBL619054,,1980,,Autocuration,,,8,H,,
,BAO_0000223,,,3477,1,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,104714,B,,CHEMBL619055,,12409,,Autocuration,,,4,H,,
,BAO_0000357,,,3478,1,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,B,,CHEMBL619056,,4365,,Autocuration,,,8,H,,
,BAO_0000019,,,3479,1,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,144,F,,CHEMBL619057,,4365,,Autocuration,,,8,H,,
,BAO_0000357,,,3480,1,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,B,,CHEMBL619058,,4365,,Autocuration,,,8,H,,
,BAO_0000219,,,3481,1,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,12020,F,,CHEMBL619059,Oocytes,6769,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3482,1,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,12020,F,,CHEMBL619060,Oocytes,6769,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3483,1,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,12020,F,,CHEMBL875095,Oocytes,6769,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000221,Ileum,,3484,1,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,20033,F,,CHEMBL619061,,809,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3485,1,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,20033,F,,CHEMBL619062,,809,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000019,,,3486,1,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,20033,F,,CHEMBL619063,,14290,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000221,Ileum,,3487,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,20033,B,,CHEMBL619064,,17358,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000357,,,3488,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,20033,B,,CHEMBL619065,,17358,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000221,Ileum,,3489,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,20033,B,,CHEMBL619066,,17358,10141.0,Intermediate,,,9,D,Cavia porcellus,2116.0
,BAO_0000221,Ileum,,3490,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,10209,B,,CHEMBL619775,,17386,,Autocuration,,,8,H,,2116.0
,BAO_0000357,,,3491,1,,,Affinity against 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL619776,,3269,,Autocuration,,,8,H,,
,BAO_0000224,,,3492,1,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,B,,CHEMBL619777,,7721,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000224,,,3493,1,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,B,,CHEMBL619778,,7721,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000221,Ileum,,3494,1,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,104841,B,,CHEMBL619779,,9117,10141.0,Autocuration,,,4,H,Cavia porcellus,2116.0
,BAO_0000224,,,3495,1,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,B,,CHEMBL619780,,7721,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000224,,,3496,1,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,B,,CHEMBL619166,,7721,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3497,1,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,F,,CHEMBL619167,,15796,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000019,,,3498,1,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,F,,CHEMBL619168,,15796,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000219,Cardiac atrium,,3499,1,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,168,B,,CHEMBL619169,,15650,9606.0,Expert,,,9,D,Homo sapiens,2081.0
,BAO_0000219,Cardiac atrium,,3500,1,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,168,B,,CHEMBL619170,,15650,9606.0,Expert,,,9,D,Homo sapiens,2081.0
,BAO_0000019,,,3501,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",104841,F,,CHEMBL619171,,6866,9606.0,Autocuration,,,5,D,Homo sapiens,
,BAO_0000219,Cardiac atrium,,3502,1,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",168,F,,CHEMBL619172,,15650,9606.0,Expert,,,9,D,Homo sapiens,2081.0
,BAO_0000019,,,3503,1,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,22226,B,,CHEMBL619173,,10063,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000019,,,3504,1,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,22226,B,,CHEMBL619174,,12665,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000019,,,3505,1,,,5-hydroxytryptamine receptor binding affinity was determined in rats,104705,B,,CHEMBL619175,,7504,,Autocuration,,,4,H,,
,BAO_0000224,,,3506,1,,,Binding affinity at rat 5-hydroxytryptamine receptor.,104705,B,,CHEMBL619176,,7504,,Autocuration,,,4,H,,
,BAO_0000019,,,3507,1,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,104705,B,,CHEMBL619177,,7038,,Autocuration,,,4,H,,
,BAO_0000224,,,3508,1,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,104705,B,,CHEMBL619178,,7626,,Autocuration,,,4,H,,
,BAO_0000224,,,3509,1,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,104705,B,,CHEMBL619179,,7626,,Autocuration,,,4,H,,
,BAO_0000019,Stomach,,3510,1,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,104705,F,,CHEMBL619180,,7185,,Autocuration,,,4,H,,945.0
,BAO_0000019,Stomach,,3511,1,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,104705,F,,CHEMBL619181,,7185,,Autocuration,,,4,H,,945.0
,BAO_0000019,,,3512,1,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,104705,F,,CHEMBL619182,,7185,,Autocuration,,,4,H,,
,BAO_0000224,,,3513,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,104705,B,,CHEMBL619183,,6960,,Autocuration,,,4,H,,
,BAO_0000224,,,3514,1,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",104705,B,,CHEMBL619184,,6960,,Autocuration,,,4,H,,
,BAO_0000221,Hippocampus,,3515,1,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,B,,CHEMBL619185,,12416,,Autocuration,,,8,H,,10000000.0
,BAO_0000357,,,3516,1,,,Binding affinity for rat 5-hydroxytryptamine transporter.,12198,B,,CHEMBL619186,,15753,,Expert,,,8,H,,
,BAO_0000019,,,3517,1,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,104705,B,,CHEMBL619187,,8062,,Autocuration,,,4,H,,
,BAO_0000019,,,3518,1,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,104705,B,,CHEMBL619188,,9036,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,3519,1,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,104705,B,,CHEMBL619189,,15067,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,Brain,,3520,1,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,12198,F,,CHEMBL619190,,15753,10116.0,Expert,,,9,D,Rattus norvegicus,955.0
,BAO_0000221,Cerebellum,,3521,1,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,12198,F,,CHEMBL619191,,15753,10116.0,Expert,,,9,D,Rattus norvegicus,2037.0
,BAO_0000019,,,3522,1,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,104705,B,,CHEMBL619192,,15295,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,3523,1,,,Percent binding affinity against 5-hydroxytryptamine receptor,104705,B,,CHEMBL619193,,6347,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,,,3524,1,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,22226,B,,CHEMBL619194,,6763,,Autocuration,,,0,U,,
,BAO_0000224,,,3525,1,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,104705,B,,CHEMBL619195,,12092,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000224,,,3526,1,,,Affinity against 5-hydroxytryptamine receptor was determined,104705,B,,CHEMBL619196,,1579,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000019,Stomach,,3527,1,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,104705,B,,CHEMBL619197,,1579,10116.0,Autocuration,,,5,D,Rattus norvegicus,945.0
In vitro,BAO_0000219,,,3528,1,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,B,,CHEMBL619198,,5963,9606.0,Expert,,,9,D,Homo sapiens,
In vitro,BAO_0000219,,,3529,1,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,B,,CHEMBL875081,,5963,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3530,1,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,18065,B,,CHEMBL884712,,5030,,Autocuration,,,8,H,,
,BAO_0000357,,,3531,1,,,Inhibition of 5-hydroxytryptamine reuptake,121,B,,CHEMBL884710,,15796,,Expert,,,8,H,,
,BAO_0000019,,,3532,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",18065,F,,CHEMBL619199,,15413,,Autocuration,,,8,H,,
,BAO_0000019,,,3533,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",18065,F,,CHEMBL619200,,15413,,Autocuration,,,8,H,,
,BAO_0000019,,,3534,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",18065,F,,CHEMBL619201,,15413,,Autocuration,,,8,H,,
,BAO_0000019,,,3535,1,,,Tested for 5-hydroxytryptamine receptor uptake,18065,F,,CHEMBL619202,,12409,,Autocuration,,,8,H,,
,BAO_0000219,,,3536,1,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,B,449.0,CHEMBL619203,CHO,16909,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,3537,1,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,51,F,,CHEMBL619204,,16909,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000249,,,3538,1,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,10576,B,,CHEMBL619205,,15629,9606.0,Autocuration,,,8,H,Homo sapiens,
,BAO_0000357,,,3539,1,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,10576,B,,CHEMBL619206,,15629,,Autocuration,,,8,H,,
,BAO_0000249,,,3540,1,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,10576,B,,CHEMBL619207,,15629,,Expert,,,8,H,,
,BAO_0000019,Striatum,,3541,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10825,F,,CHEMBL619208,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3542,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10825,F,,CHEMBL619209,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3543,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10825,F,,CHEMBL619210,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3544,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,F,,CHEMBL619211,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3545,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10825,F,,CHEMBL619212,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3546,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10825,F,,CHEMBL620681,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3547,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10825,F,,CHEMBL620682,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3548,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10825,F,,CHEMBL620683,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3549,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10825,F,,CHEMBL620684,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3550,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,F,,CHEMBL620685,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Striatum,,3551,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10825,F,,CHEMBL620686,,10034,,Autocuration,,,8,H,,2435.0
,BAO_0000019,Limbic system,,3552,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10825,F,,CHEMBL620687,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000019,Limbic system,,3553,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,F,,CHEMBL620688,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000019,Limbic system,,3554,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10825,F,,CHEMBL620689,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000019,Limbic system,,3555,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10825,F,,CHEMBL620690,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000019,Limbic system,,3556,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10825,F,,CHEMBL620691,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000019,Limbic system,,3557,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10825,F,,CHEMBL620692,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000019,Limbic system,,3558,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10825,F,,CHEMBL620693,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000357,,,3559,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL620694,,1274,,Expert,,,8,H,,
,BAO_0000019,,,3560,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,F,,CHEMBL857986,,17358,,Autocuration,,,8,H,,
,BAO_0000357,,,3561,1,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,168,B,,CHEMBL620695,,14532,,Autocuration,,,8,H,,
,BAO_0000357,,,3562,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL620696,,16989,,Expert,,,8,H,,
,BAO_0000357,,,3563,1,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,168,B,,CHEMBL620697,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,3564,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,168,B,,CHEMBL620698,,15779,,Autocuration,,,8,H,,
,BAO_0000357,,,3565,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,B,,CHEMBL620699,,15779,,Autocuration,,,8,H,,
,BAO_0000357,,,3566,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,B,,CHEMBL620700,,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3567,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,168,B,643.0,CHEMBL620701,COS-7,15650,,Autocuration,,,8,H,,
,BAO_0000219,,,3568,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,168,B,643.0,CHEMBL875082,COS-7,15650,,Autocuration,,,8,H,,
,BAO_0000219,,,3569,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,168,B,643.0,CHEMBL620702,COS-7,15650,,Autocuration,,,8,H,,
,BAO_0000219,,,3570,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,168,B,643.0,CHEMBL620703,COS-7,15650,,Autocuration,,,8,H,,
,BAO_0000219,,,3571,1,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,B,673.0,CHEMBL620704,C6,17046,,Autocuration,,,8,H,,
,BAO_0000219,,,3572,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,B,673.0,CHEMBL620705,C6,17046,,Expert,,,8,H,,
,BAO_0000219,,,3573,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,168,B,673.0,CHEMBL620706,C6,15650,,Expert,,,8,H,,
,BAO_0000219,,,3574,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,168,B,673.0,CHEMBL620707,C6,17046,,Expert,,,8,H,,
,BAO_0000357,,,3575,1,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,10624,B,,CHEMBL620708,,17066,,Expert,,,8,H,,
,BAO_0000357,,,3576,1,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,105,B,,CHEMBL620709,,17200,,Autocuration,,,8,H,,
,BAO_0000357,,,3577,1,,,Binding affinity against 5-hydroxytryptamine 5A receptor,10624,B,,CHEMBL620710,,16146,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3578,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,10624,B,449.0,CHEMBL620711,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000357,,,3579,1,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,10624,B,,CHEMBL620712,,6491,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3580,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,B,,CHEMBL620713,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3581,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,10624,B,,CHEMBL620714,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3582,1,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,10624,B,,CHEMBL620715,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3583,1,,,Binding affinity towards 5-HT5A receptor,10624,B,,CHEMBL620716,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,3584,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,10624,B,,CHEMBL620717,,17175,,Expert,,,8,H,,
,BAO_0000357,,,3585,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,B,,CHEMBL618072,,15818,,Autocuration,,,8,H,,
,BAO_0000357,,,3586,1,,,Binding affinity towards cloned human 5-HT5A receptor was determined,10624,B,,CHEMBL857987,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,3587,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10624,B,722.0,CHEMBL618073,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3588,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10624,B,722.0,CHEMBL618074,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3589,1,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),10624,B,722.0,CHEMBL618075,HEK293,5213,,Autocuration,,,8,H,,
,BAO_0000357,,,3590,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10625,B,,CHEMBL618076,,17066,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,3591,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10625,B,,CHEMBL618077,,17066,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,3592,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10625,B,,CHEMBL618078,,17066,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,3593,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10625,B,,CHEMBL881821,,17066,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,3594,1,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10625,B,,CHEMBL618079,,17066,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,3595,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,10625,B,,CHEMBL618080,,17175,,Expert,,,8,H,,
,BAO_0000219,,,3596,1,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10576,B,722.0,CHEMBL618081,HEK293,16190,,Autocuration,,,8,H,,
,BAO_0000219,,,3597,1,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10626,B,722.0,CHEMBL618082,HEK293,16190,,Autocuration,,,8,H,,
,BAO_0000357,,,3598,1,,,Binding affinity towards 5-HT5a receptor,10624,B,,CHEMBL618083,,4820,,Expert,,,8,H,,
,BAO_0000357,,,3599,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,10624,B,,CHEMBL618084,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3600,1,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,10624,B,,CHEMBL618085,,17066,,Expert,,,8,H,,
,BAO_0000357,,,3601,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,10624,B,,CHEMBL618086,,17175,,Expert,,,8,H,,
,BAO_0000357,,,3602,1,,,Binding affinities against 5-hydroxytryptamine 5A receptor,10624,B,,CHEMBL875092,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,3603,1,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,10624,B,,CHEMBL618087,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,3604,1,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,10624,B,,CHEMBL872926,,16700,,Autocuration,,,8,H,,
,BAO_0000019,,,3605,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,104714,F,,CHEMBL618088,,4639,10141.0,Autocuration,,,4,H,Cavia porcellus,
,BAO_0000223,,,3606,1,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,104714,B,,CHEMBL618089,,5486,,Autocuration,,,4,H,,
,BAO_0000357,,,3607,1,,,Inhibition of human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618090,,16146,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3608,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,10627,B,,CHEMBL618091,,17273,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3609,1,,,Inhibition against human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618092,,17687,,Autocuration,,,8,H,,
,BAO_0000357,,,3610,1,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,10627,B,,CHEMBL618093,,6491,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3611,1,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,10627,B,308.0,CHEMBL618094,HeLa,16190,,Expert,,,8,H,,
,BAO_0000357,,,3612,1,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618095,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3613,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL875093,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3614,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,10627,B,,CHEMBL618096,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3615,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,10627,B,,CHEMBL618118,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3616,1,,,Binding affinity against 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618119,,3555,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3617,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618120,,5808,,Expert,,,8,H,,
,BAO_0000357,,,3618,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618121,,6013,,Autocuration,,,8,H,,
,BAO_0000219,,,3619,1,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",10627,B,722.0,CHEMBL618122,HEK293,15818,,Expert,,,8,H,,
,BAO_0000357,,,3620,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,10627,B,,CHEMBL618123,,16209,,Autocuration,,,8,H,,
,BAO_0000219,,,3621,1,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,10627,B,722.0,CHEMBL618124,HEK293,3935,,Expert,,,8,H,,
,BAO_0000357,,,3622,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618125,,15818,,Autocuration,,,8,H,,
,BAO_0000219,,,3623,1,,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,B,722.0,CHEMBL618126,HEK293,3805,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,3624,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,10627,B,,CHEMBL618236,,16441,,Expert,,,8,H,,
,BAO_0000019,,,3625,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10627,B,,CHEMBL618237,,16441,,Expert,,,8,H,,
,BAO_0000219,,,3626,1,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,10627,B,643.0,CHEMBL618238,COS-7,6786,,Expert,,,8,H,,
,BAO_0000357,,,3627,1,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618239,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,3628,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL618240,,17085,,Autocuration,,,8,H,,
,BAO_0000357,,,3629,1,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,10627,B,,CHEMBL618241,,17200,,Autocuration,,,8,H,,
,BAO_0000219,,,3630,1,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,B,722.0,CHEMBL859399,HEK293,17451,,Autocuration,,,8,H,,
,BAO_0000019,,,3631,1,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,10627,F,,CHEMBL618242,,3935,,Autocuration,,,8,H,,
,BAO_0000357,,,3632,1,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL857991,,5033,,Autocuration,,,8,H,,
,BAO_0000357,,,3633,1,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL619951,,4540,,Expert,,,8,H,,
,BAO_0000219,,,3634,1,,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,B,308.0,CHEMBL619952,HeLa,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3635,1,,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,B,308.0,CHEMBL619953,HeLa,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3636,1,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,10627,B,308.0,CHEMBL619954,HeLa,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,3637,1,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,B,308.0,CHEMBL619955,HeLa,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,3638,1,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,B,308.0,CHEMBL619956,HeLa,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,3639,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,10627,B,449.0,CHEMBL619957,CHO,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3640,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10627,B,722.0,CHEMBL619958,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3641,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,10627,B,722.0,CHEMBL620627,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3642,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10627,B,722.0,CHEMBL620628,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3643,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,10627,B,308.0,CHEMBL620629,HeLa,15779,,Autocuration,,,8,H,,
,BAO_0000357,,,3644,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620630,,6166,,Autocuration,,,8,H,,
,BAO_0000219,,,3645,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,10627,B,308.0,CHEMBL620782,HeLa,17451,,Autocuration,,,8,H,,
,BAO_0000357,,,3646,1,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620783,,15316,,Autocuration,,,8,H,,
,BAO_0000357,,,3647,1,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620784,,4199,,Expert,,,8,H,,
,BAO_0000219,,,3648,1,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,10627,B,308.0,CHEMBL620785,HeLa,15146,,Expert,,,8,H,,
,BAO_0000357,,,3649,1,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),10627,B,,CHEMBL857992,,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,3650,1,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,10627,B,,CHEMBL620786,,16429,,Autocuration,,,8,H,,
,BAO_0000219,,,3651,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,10627,B,308.0,CHEMBL620787,HeLa,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,3652,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",10627,B,308.0,CHEMBL620788,HeLa,4829,,Autocuration,,,8,H,,
,BAO_0000219,,,3653,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",10627,B,308.0,CHEMBL620789,HeLa,4829,,Autocuration,,,8,H,,
,BAO_0000219,,,3654,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",10627,B,308.0,CHEMBL620790,HeLa,4829,,Autocuration,,,8,H,,
,BAO_0000219,,,3655,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,10628,B,449.0,CHEMBL620791,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000019,,,3656,1,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,10628,B,,CHEMBL620792,,14423,,Autocuration,,,8,H,,
,BAO_0000357,,,3657,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,10628,B,,CHEMBL620793,,15086,,Autocuration,,,8,H,,
,BAO_0000357,,,3658,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,10628,B,,CHEMBL620794,,4342,,Autocuration,,,8,H,,
,BAO_0000219,,,3659,1,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,10627,B,308.0,CHEMBL620795,HeLa,16190,9606.0,Autocuration,,,9,D,Homo sapiens,
,BAO_0000357,,,3660,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620796,,4820,,Expert,,,8,H,,
,BAO_0000357,,,3661,1,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,10627,B,,CHEMBL620797,,4639,,Autocuration,,,8,H,,
,BAO_0000019,,,3662,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,F,,CHEMBL620798,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3663,1,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,10627,B,,CHEMBL620799,,6011,,Autocuration,,,8,H,,
,BAO_0000357,,,3664,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620800,,17066,,Expert,,,8,H,,
,BAO_0000357,,,3665,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,10627,B,,CHEMBL620801,,17515,,Autocuration,,,8,H,,
,BAO_0000357,,,3666,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL875100,,5014,,Autocuration,,,8,H,,
,BAO_0000357,,,3667,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,10627,B,,CHEMBL620802,,4373,,Autocuration,,,8,H,,
,BAO_0000019,,,3668,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,10627,F,,CHEMBL620803,,17066,,Expert,,,8,H,,
,BAO_0000019,,,3669,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,F,,CHEMBL620804,,17066,,Expert,,,8,H,,
,BAO_0000357,,,3670,1,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,10627,B,,CHEMBL620805,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,3671,1,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620806,,4687,,Autocuration,,,8,H,,
,BAO_0000357,,,3672,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,10627,B,,CHEMBL620807,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,3673,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,10627,B,,CHEMBL620808,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,3674,1,,,Binding affinities against 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620809,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,3675,1,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620810,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,3676,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620811,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3677,1,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,10627,B,,CHEMBL620812,,16700,,Autocuration,,,8,H,,
,BAO_0000357,,,3678,1,,,Affinity against 5-hydroxytryptamine 6 receptor,10627,B,,CHEMBL620813,,3269,,Autocuration,,,8,H,,
,BAO_0000357,,,3679,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],10627,B,,CHEMBL620814,,5486,,Autocuration,,,8,H,,
,BAO_0000357,,,3680,1,,,Inhibition of human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL620815,,16146,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3681,1,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,10209,B,722.0,CHEMBL620816,HEK293,5014,,Autocuration,,,8,H,,
,BAO_0000357,,,3682,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL620817,,15463,,Autocuration,,,8,H,,
,BAO_0000357,,,3683,1,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),10209,B,,CHEMBL620818,,3805,,Autocuration,,,8,H,,
,BAO_0000219,,,3684,1,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,10209,B,722.0,CHEMBL620819,HEK293,5014,,Expert,,,8,H,,
,BAO_0000357,,,3685,1,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,10209,B,,CHEMBL620820,,6491,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3686,1,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,10209,B,449.0,CHEMBL620821,CHO,16190,,Autocuration,,,8,H,,
,BAO_0000357,,,3687,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL620822,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3688,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL620823,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3689,1,,,Binding affinity against 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL620824,,3555,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3690,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,10209,B,449.0,CHEMBL620825,CHO,6588,,Expert,,,8,H,,
,BAO_0000357,,,3691,1,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,10209,B,,CHEMBL872930,,15463,,Autocuration,,,8,H,,
,BAO_0000357,,,3692,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL620826,,6013,,Autocuration,,,8,H,,
,BAO_0000357,,,3693,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,10209,B,,CHEMBL620827,,16209,,Autocuration,,,8,H,,
,BAO_0000357,,,3694,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL620828,,3935,,Autocuration,,,8,H,,
,BAO_0000357,,,3695,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL620829,,15818,,Autocuration,,,8,H,,
,BAO_0000219,,,3696,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,10209,B,722.0,CHEMBL620830,HEK293,5014,,Expert,,,8,H,,
,BAO_0000019,,,3697,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,10209,B,,CHEMBL620831,,16441,,Expert,,,8,H,,
,BAO_0000019,,,3698,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10209,B,,CHEMBL620832,,16441,,Expert,,,8,H,,
,BAO_0000357,,,3699,1,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL621548,,4234,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,3700,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL621549,,17085,,Autocuration,,,8,H,,
,BAO_0000357,,,3701,1,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,10209,B,,CHEMBL621550,,17200,,Autocuration,,,8,H,,
,BAO_0000219,,,3702,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,10209,B,449.0,CHEMBL621551,CHO,17451,,Autocuration,,,8,H,,
,BAO_0000019,,,3703,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,10209,B,,CHEMBL621552,,17085,,Autocuration,,,8,H,,
,BAO_0000357,,,3704,1,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL857077,,5104,,Autocuration,,,8,H,,
,BAO_0000357,,,3705,1,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,10209,B,,CHEMBL618158,,5104,,Autocuration,,,8,H,,
,BAO_0000219,,,3706,1,,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,B,643.0,CHEMBL618159,COS-7,5033,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3707,1,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,B,643.0,CHEMBL875101,COS-7,5486,,Autocuration,,,8,H,,
,BAO_0000219,,,3708,1,,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,10209,B,722.0,CHEMBL618160,HEK293,4540,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3709,1,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,10209,B,,CHEMBL618161,,6166,,Expert,,,8,H,,
,BAO_0000219,,,3710,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,10209,B,722.0,CHEMBL618162,HEK293,17342,,Expert,,,8,H,,
,BAO_0000357,,,3711,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,10209,B,,CHEMBL618163,,17342,,Expert,,,8,H,,
,BAO_0000357,,,3712,1,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,10209,B,,CHEMBL618164,,17296,,Autocuration,,,8,H,,
,BAO_0000219,,,3713,1,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,10209,B,,CHEMBL618165,,16429,,Expert,,,8,H,,
,BAO_0000219,,,3714,1,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,10209,B,722.0,CHEMBL618166,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3715,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,B,722.0,CHEMBL857989,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3716,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,B,722.0,CHEMBL619888,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3717,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,B,722.0,CHEMBL619889,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3718,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,10209,B,722.0,CHEMBL619890,HEK293,15779,,Autocuration,,,8,H,,
,BAO_0000219,,,3719,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,10209,B,449.0,CHEMBL619891,CHO,17451,,Autocuration,,,8,H,,
,BAO_0000219,,,3720,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),10209,B,722.0,CHEMBL619892,HEK293,4199,,Autocuration,,,8,H,,
,BAO_0000219,,,3721,1,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,10209,B,722.0,CHEMBL619893,HEK293,4199,,Expert,,,9,D,,
,BAO_0000219,,,3722,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),10209,B,722.0,CHEMBL619894,HEK293,4199,,Autocuration,,,8,H,,
,BAO_0000219,,,3723,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,10209,B,722.0,CHEMBL619895,HEK293,3680,,Intermediate,,,9,D,,
,BAO_0000357,,,3724,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,10209,B,,CHEMBL619896,,3680,,Intermediate,,,9,D,,
,BAO_0000219,,,3725,1,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,10209,B,643.0,CHEMBL619897,COS-7,15316,,Autocuration,,,8,H,,
,BAO_0000219,,,3726,1,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,10209,B,722.0,CHEMBL619898,HEK293,15146,,Autocuration,,,8,H,,
,BAO_0000219,,,3727,1,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,10209,B,722.0,CHEMBL619899,HEK293,5213,,Expert,,,8,H,,
,BAO_0000219,,,3728,1,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),10209,B,722.0,CHEMBL619900,HEK293,5213,,Autocuration,,,8,H,,
,BAO_0000219,,,3729,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,10209,B,722.0,CHEMBL619901,HEK293,14818,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,3730,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,10209,B,722.0,CHEMBL620580,HEK293,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,3731,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,10209,B,722.0,CHEMBL620581,HEK293,14818,,Autocuration,,,8,H,,
,BAO_0000219,,,3732,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",10209,B,722.0,CHEMBL620733,HEK293,4829,,Autocuration,,,8,H,,
,BAO_0000357,,,3733,1,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,10209,B,,CHEMBL620734,,17200,9606.0,Autocuration,,,9,D,Homo sapiens,
,BAO_0000357,,,3734,1,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10022,B,,CHEMBL620735,,17066,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000019,,,3735,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,10209,B,,CHEMBL620736,,14025,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000219,,,3736,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,11923,B,449.0,CHEMBL620737,CHO,15250,,Autocuration,,,8,H,,
,BAO_0000219,,,3737,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,11923,B,449.0,CHEMBL620738,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3738,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,11923,B,449.0,CHEMBL620739,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3739,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,11923,B,449.0,CHEMBL620740,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3740,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,11923,B,449.0,CHEMBL620741,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3741,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,11923,B,449.0,CHEMBL620742,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3742,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,11923,B,449.0,CHEMBL620743,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3743,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,11923,B,449.0,CHEMBL620744,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3744,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,11923,B,449.0,CHEMBL620745,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3745,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,11923,B,449.0,CHEMBL620746,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3746,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,11923,B,449.0,CHEMBL620747,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3747,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,11923,B,449.0,CHEMBL620748,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3748,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,11923,B,449.0,CHEMBL620749,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000357,,,3749,1,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,11923,B,,CHEMBL620750,,17066,,Expert,,,8,H,,
,BAO_0000357,,,3750,1,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,11923,B,,CHEMBL620751,,17066,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3751,1,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,11923,B,,CHEMBL620752,,17386,,Expert,,,8,H,,
,BAO_0000019,,,3752,1,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,11923,B,,CHEMBL872929,,14423,,Autocuration,,,8,H,,
,BAO_0000357,,,3753,1,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,11923,B,,CHEMBL620753,,15874,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3754,1,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,11923,B,,CHEMBL620754,,15874,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3755,1,,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,11923,B,449.0,CHEMBL620755,CHO,16372,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3756,1,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,11923,B,,CHEMBL620756,,4622,,Autocuration,,,8,H,,
,BAO_0000357,,,3757,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,11923,B,,CHEMBL620757,,15086,,Autocuration,,,8,H,,
,BAO_0000219,,,3758,1,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",11923,B,449.0,CHEMBL620758,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3759,1,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",11923,B,449.0,CHEMBL620759,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3760,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,11923,B,449.0,CHEMBL620760,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000219,,,3761,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,11923,B,449.0,CHEMBL620761,CHO,16372,,Autocuration,,,8,H,,
,BAO_0000221,Ileum,,3762,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,11923,F,,CHEMBL620762,,17386,,Autocuration,,,8,H,,2116.0
,BAO_0000221,Ileum,,3763,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,11923,F,,CHEMBL620763,,17386,,Autocuration,,,8,H,,2116.0
,BAO_0000221,Ileum,,3764,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,11923,F,,CHEMBL620764,,17386,,Autocuration,,,8,H,,2116.0
,BAO_0000249,,,3765,1,,Membranes,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,11923,B,,CHEMBL857990,,5831,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3766,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,11923,B,,CHEMBL620765,,4342,,Autocuration,,,8,H,,
,BAO_0000357,,,3767,1,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,11923,B,,CHEMBL620766,,17319,,Expert,,,8,H,,
,BAO_0000019,Hypothalamus,,3768,1,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,11923,B,,CHEMBL620767,,17342,,Expert,,,8,H,,1898.0
,BAO_0000357,,,3769,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,11923,B,,CHEMBL620768,,17342,,Autocuration,,,8,H,,
,BAO_0000249,Hypothalamus,,3770,1,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,11923,B,,CHEMBL619051,,3680,,Expert,,,8,H,,1898.0
,BAO_0000357,,,3771,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,11923,B,,CHEMBL619052,,3680,,Expert,,,8,H,,
,BAO_0000219,,,3772,1,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,11923,F,722.0,CHEMBL619053,HEK293,17319,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3773,1,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,11923,F,722.0,CHEMBL619703,HEK293,17319,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3774,1,,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,11923,F,722.0,CHEMBL619704,HEK293,17319,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3775,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL619851,,4820,,Expert,,,8,H,,
,BAO_0000357,,,3776,1,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,10209,B,,CHEMBL619852,,4639,,Autocuration,,,8,H,,
,BAO_0000357,,,3777,1,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,10209,B,,CHEMBL619853,,6011,,Autocuration,,,8,H,,
,BAO_0000357,,,3778,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL619854,,17066,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3779,1,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL619855,,17066,,Expert,,,8,H,,
,BAO_0000357,,,3780,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,10209,B,,CHEMBL619856,,17515,,Autocuration,,,8,H,,
,BAO_0000357,,,3781,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,B,,CHEMBL619857,,4373,,Autocuration,,,8,H,,
,BAO_0000019,,,3782,1,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,10209,F,,CHEMBL619858,,17066,,Expert,,,8,H,,
,BAO_0000357,,,3783,1,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,10209,B,,CHEMBL619859,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,3784,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,B,,CHEMBL619860,,4373,,Autocuration,,,8,H,,
,BAO_0000357,,,3785,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL619861,,4687,,Autocuration,,,8,H,,
,BAO_0000357,,,3786,1,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL619862,,17342,,Expert,,,8,H,,
,BAO_0000357,,,3787,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,10209,B,,CHEMBL619863,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,3788,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,10209,B,,CHEMBL619864,,16946,,Autocuration,,,8,H,,
,BAO_0000357,,,3789,1,,,Binding affinities against 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL872928,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,3790,1,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL619865,,16633,,Autocuration,,,8,H,,
,BAO_0000357,,,3791,1,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,10209,B,,CHEMBL619866,,17066,,Expert,,,8,H,,
,BAO_0000357,,,3792,1,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,10209,B,,CHEMBL619867,,16700,,Autocuration,,,8,H,,
,BAO_0000221,Ileum,,3793,1,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,10209,B,,CHEMBL619868,,17386,,Autocuration,,,8,H,,2116.0
,BAO_0000019,,,3794,1,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,55,F,,CHEMBL619869,,14080,,Autocuration,,,8,H,,
,BAO_0000019,,,3795,1,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,55,F,,CHEMBL619870,,14080,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3796,1,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,55,B,,CHEMBL619871,,409,,Autocuration,,,8,H,,
,BAO_0000357,,,3797,1,,,In vitro inhibition of human recombinant lipoxygenase enzyme,55,B,,CHEMBL619872,,409,,Autocuration,,,8,H,,
,BAO_0000357,,,3798,1,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,55,B,,CHEMBL619873,,409,,Autocuration,,,8,H,,
,BAO_0000357,Blood,,3799,1,,,Inhibition of 5-lipoxygenase in human whole blood.,55,B,,CHEMBL619874,,11090,,Expert,,,8,H,,178.0
,BAO_0000357,Blood,,3800,1,,,Inhibition of 5-lipoxygenase in human whole blood.,55,B,,CHEMBL619875,,11090,,Expert,,,8,H,,178.0
,BAO_0000357,,,3801,1,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,55,B,,CHEMBL619876,,948,,Autocuration,,,8,H,,
,BAO_0000357,,,3802,1,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),55,B,,CHEMBL619877,,948,,Autocuration,,,8,H,,
,BAO_0000219,,,3803,1,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,55,F,,CHEMBL619878,,13622,,Expert,,,8,H,,
,BAO_0000019,Blood,,3804,1,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,55,F,,CHEMBL619879,,13622,,Autocuration,,,8,H,,178.0
,BAO_0000357,,,3805,1,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,55,B,,CHEMBL619880,,9637,,Autocuration,,,8,H,,
,BAO_0000357,,,3806,1,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),55,B,,CHEMBL619881,,11320,,Autocuration,,,8,H,,
,BAO_0000357,,,3807,1,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,55,B,,CHEMBL619882,,11320,,Expert,,,8,H,,
,BAO_0000357,,,3808,1,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,55,B,,CHEMBL619883,,6838,,Autocuration,,,8,H,,
,BAO_0000357,Blood,,3809,1,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),55,B,,CHEMBL619884,,17667,9606.0,Expert,,,9,D,Homo sapiens,178.0
,BAO_0000357,,,3810,1,,,In vitro potency against human 5-Lipoxygenase,55,B,,CHEMBL619885,,12703,,Autocuration,,,8,H,,
,BAO_0000019,,,3811,1,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,55,F,,CHEMBL619886,,14312,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,Blood,,3812,1,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,55,F,,CHEMBL619887,,14312,,Autocuration,,,8,H,,178.0
,BAO_0000019,,,3813,1,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,F,,CHEMBL875097,,5364,,Autocuration,,,8,H,,
,BAO_0000219,,,3814,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,55,B,,CHEMBL618001,,951,,Autocuration,,,8,H,,
,BAO_0000219,,,3815,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,55,B,,CHEMBL618002,,951,,Autocuration,,,8,H,,
,BAO_0000219,,,3816,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,55,B,,CHEMBL618003,,951,,Autocuration,,,8,H,,
,BAO_0000219,,,3817,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,55,B,,CHEMBL618004,,951,,Autocuration,,,8,H,,
,BAO_0000219,,,3818,1,,,Inhibition of human 5-lipoxygenase in human cells,55,B,,CHEMBL618005,,12365,,Autocuration,,,8,H,,
,BAO_0000357,,,3819,1,,,Inhibition of human neutrophil 5-lipoxygenase,55,B,,CHEMBL618006,,10603,,Expert,,,8,H,,
,BAO_0000019,,,3820,1,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,55,B,,CHEMBL875086,,10501,,Autocuration,,,8,H,,
,BAO_0000357,Blood,,3821,1,,,Inhibition of 5-lipoxygenase from human whole blood,55,B,,CHEMBL618007,,12281,,Expert,,,8,H,,178.0
,BAO_0000357,,,3822,1,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,B,,CHEMBL618008,,2567,,Autocuration,,,8,H,,
,BAO_0000219,,,3823,1,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,55,B,,CHEMBL618009,,2567,,Autocuration,,,8,H,,
,BAO_0000357,,,3824,1,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,55,B,,CHEMBL618010,,10193,,Expert,,,8,H,,
,BAO_0000357,,,3825,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,B,,CHEMBL618011,,10193,,Autocuration,,,8,H,,
,BAO_0000357,,,3826,1,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,55,B,,CHEMBL618012,,13623,,Expert,,,8,H,,
,BAO_0000357,,,3827,1,,,Tested against 5-lipoxygenase,55,B,,CHEMBL882927,,12780,,Autocuration,,,8,H,,
,BAO_0000357,,,3828,1,,,Tested for activity against 5-Lipoxygenase (5-LO),55,B,,CHEMBL618013,,12780,,Autocuration,,,8,H,,
,BAO_0000357,,,3829,1,,,Tested for activity against 5-lipoxygenase,55,B,,CHEMBL618014,,12780,,Autocuration,,,8,H,,
,BAO_0000357,,,3830,1,,,Tested for inhibition of 5-HPETE production by human 5-LO,55,B,,CHEMBL618015,,11966,,Autocuration,,,8,H,,
,BAO_0000019,,,3831,1,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,F,,CHEMBL618016,,5364,,Autocuration,,,8,H,,
,BAO_0000357,,,3832,1,,,Inhibition of Human 5-lipoxygenase,55,B,,CHEMBL618017,,13165,,Expert,,,8,H,,
,BAO_0000019,,,3833,1,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,55,B,,CHEMBL618018,,5364,,Autocuration,,,8,H,,
,BAO_0000219,,,3834,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,B,,CHEMBL875087,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,3835,1,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],55,B,,CHEMBL618019,,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,3836,1,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,55,B,,CHEMBL618020,,14863,,Autocuration,,,8,H,,
,BAO_0000019,,,3837,1,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,55,B,,CHEMBL618021,,14863,,Autocuration,,,8,H,,
,BAO_0000357,Blood,,3838,1,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),55,B,,CHEMBL618022,,11087,,Autocuration,,,8,H,,178.0
,BAO_0000357,,,3839,1,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,55,B,,CHEMBL618023,,455,,Autocuration,,,8,H,,
,BAO_0000357,,,3840,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,B,,CHEMBL618024,,13183,,Autocuration,,,8,H,,
,BAO_0000019,,,3841,1,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,55,B,,CHEMBL873950,,10319,,Expert,,,8,H,,
,BAO_0000357,,,3842,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,B,,CHEMBL618025,,10193,,Autocuration,,,8,H,,
,BAO_0000219,,,3843,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,55,B,,CHEMBL618026,,951,,Autocuration,,,8,H,,
,BAO_0000219,,,3844,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,55,B,,CHEMBL618027,,951,,Autocuration,,,8,H,,
,BAO_0000219,,,3845,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,55,B,,CHEMBL618028,,951,,Autocuration,,,8,H,,
,BAO_0000219,,,3846,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,55,B,,CHEMBL618029,,951,,Autocuration,,,8,H,,
,BAO_0000357,,,3847,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,55,B,,CHEMBL618030,,9859,,Expert,,,8,H,,
,BAO_0000357,,,3848,1,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,55,B,,CHEMBL618031,,9859,,Expert,,,8,H,,
,BAO_0000357,,,3849,1,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,55,B,,CHEMBL618032,,9859,,Autocuration,,,8,H,,
,BAO_0000357,,,3850,1,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,B,,CHEMBL618033,,2567,,Autocuration,,,8,H,,
,BAO_0000357,,,3851,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,55,B,,CHEMBL618034,,10193,,Autocuration,,,8,H,,
,BAO_0000357,,,3852,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,B,,CHEMBL875088,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,3853,1,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,55,B,,CHEMBL618035,,949,,Autocuration,,,8,H,,
,BAO_0000019,,,3854,1,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,55,B,,CHEMBL618036,,949,,Autocuration,,,8,H,,
,BAO_0000357,,,3855,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,55,B,,CHEMBL618037,,10603,,Expert,,,8,H,,
,BAO_0000357,,,3856,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,B,,CHEMBL618038,,10603,,Expert,,,8,H,,
,BAO_0000019,,,3857,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,F,,CHEMBL618761,,10603,,Autocuration,,,8,H,,
,BAO_0000357,,,3858,1,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,55,B,,CHEMBL618762,,10603,,Expert,,,8,H,,
,BAO_0000357,,,3859,1,,,Inhibition of lipoxygenase at the concentration of 1 uM,55,B,,CHEMBL618763,,10603,,Expert,,,8,H,,
,BAO_0000357,,,3860,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,55,B,,CHEMBL618764,,10193,,Autocuration,,,8,H,,
,BAO_0000357,,,3861,1,,,Inhibition of 5-Lipoxygenase (5-LOX),55,B,,CHEMBL618765,,14580,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000357,,,3862,1,,,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,B,,CHEMBL618766,,11090,,Expert,,,8,H,,
,BAO_0000357,,,3863,1,,,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,B,,CHEMBL618767,,11090,,Expert,,,8,H,,
,BAO_0000357,,,3864,1,,,Inhibitory activity against lipoxygenase-2 in mice,17087,B,,CHEMBL619380,,6339,,Autocuration,,,8,H,,
,BAO_0000357,,,3865,1,,,Inhibitory activity against murine lipoxygenase-2.,17087,B,,CHEMBL619381,,6339,,Expert,,,8,H,,
,BAO_0000357,,,3866,1,,,Inhibition of 5-lipoxygenase from mouse macrophage,17087,B,,CHEMBL619382,,12281,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,3867,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,17087,B,,CHEMBL619383,,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,3868,1,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,B,,CHEMBL619384,,11089,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,3869,1,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,55,B,,CHEMBL619385,,10091,9823.0,Autocuration,,,8,H,Sus scrofa,
,BAO_0000019,,,3870,1,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,55,B,,CHEMBL882928,,14352,9986.0,Autocuration,,,8,H,Oryctolagus cuniculus,
,BAO_0000019,,,3871,1,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,12166,B,,CHEMBL619386,,13329,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,3872,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",12166,B,,CHEMBL619387,,13329,,Autocuration,,,8,H,,
,BAO_0000019,,,3873,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,B,,CHEMBL619388,,13329,,Autocuration,,,8,H,,
,BAO_0000019,,,3874,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",12166,B,,CHEMBL619389,,13329,,Autocuration,,,8,H,,
,BAO_0000019,,,3875,1,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),12166,B,,CHEMBL619390,,13329,,Expert,,,8,H,,
,BAO_0000019,,,3876,1,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",12166,B,,CHEMBL619391,,13329,,Expert,,,8,H,,
,BAO_0000019,,,3877,1,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,12166,B,,CHEMBL619392,,13329,,Autocuration,,,8,H,,
,BAO_0000019,,,3878,1,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),12166,B,,CHEMBL619393,,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,3879,1,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,12166,B,,CHEMBL619394,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,3880,1,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,B,702.0,CHEMBL619395,RBL-1,105,,Autocuration,,,8,H,,
,BAO_0000219,,,3881,1,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,B,702.0,CHEMBL619396,RBL-1,105,,Autocuration,,,8,H,,
,BAO_0000357,,,3882,1,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),12166,B,,CHEMBL619397,,9138,,Autocuration,,,8,H,,
,BAO_0000357,,,3883,1,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",12166,B,,CHEMBL619398,,9138,,Autocuration,,,8,H,,
,BAO_0000357,,,3884,1,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",12166,B,,CHEMBL619399,,9138,,Autocuration,,,8,H,,
,BAO_0000357,,,3885,1,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,B,,CHEMBL619400,,14427,,Autocuration,,,8,H,,
,BAO_0000019,,,3886,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,B,,CHEMBL619401,,13329,,Autocuration,,,8,H,,
,BAO_0000019,,,3887,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",12166,B,,CHEMBL619402,,13329,,Autocuration,,,8,H,,
,BAO_0000219,,,3888,1,,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,12166,B,663.0,CHEMBL619403,RBL-2H3,14427,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3889,1,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,B,,CHEMBL619404,,14427,,Autocuration,,,8,H,,
,BAO_0000357,,,3890,1,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,12166,B,,CHEMBL619405,,14427,,Autocuration,,,8,H,,
,BAO_0000219,,,3891,1,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,12166,B,702.0,CHEMBL619406,RBL-1,10293,,Expert,,,8,H,,
,BAO_0000219,,,3892,1,,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,12166,B,702.0,CHEMBL619407,RBL-1,338,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,3893,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),12166,B,,CHEMBL619408,,303,,Autocuration,,,8,H,,
,BAO_0000219,,,3894,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,12166,B,702.0,CHEMBL619409,RBL-1,303,,Autocuration,,,8,H,,
,BAO_0000219,,,3895,1,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,12166,B,702.0,CHEMBL619410,RBL-1,9247,,Expert,,,8,H,,
,BAO_0000219,,,3896,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,B,702.0,CHEMBL619753,RBL-1,9247,,Autocuration,,,8,H,,
,BAO_0000219,,,3897,1,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,12166,B,702.0,CHEMBL619754,RBL-1,137,,Autocuration,,,8,H,,
,BAO_0000357,,,3898,1,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,12166,B,,CHEMBL619903,,11481,,Expert,,,8,H,,
,BAO_0000357,,,3899,1,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",12166,B,,CHEMBL619904,,11481,,Expert,,,8,H,,
,BAO_0000357,,,3900,1,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,12166,B,,CHEMBL619905,,9029,,Expert,,,8,H,,
,BAO_0000019,,,3901,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,12166,B,,CHEMBL619906,,1701,,Autocuration,,,8,H,,
,BAO_0000019,,,3902,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,12166,B,,CHEMBL619907,,1701,,Autocuration,,,8,H,,
,BAO_0000019,,,3903,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,12166,B,,CHEMBL619908,,1701,,Autocuration,,,8,H,,
,BAO_0000019,,,3904,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,12166,B,,CHEMBL619909,,1701,,Autocuration,,,8,H,,
,BAO_0000219,,,3905,1,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,12166,F,702.0,CHEMBL619910,RBL-1,13358,,Expert,,,8,H,,
,BAO_0000219,,,3906,1,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,12166,B,702.0,CHEMBL882929,RBL-1,1175,,Expert,,,8,H,,
,BAO_0000219,,,3907,1,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,12166,B,702.0,CHEMBL619911,RBL-1,8797,,Expert,,,8,H,,
,BAO_0000019,,,3908,1,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,12166,B,,CHEMBL619912,,8797,,Autocuration,,,8,H,,
,BAO_0000357,,,3909,1,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,12166,B,,CHEMBL619913,,577,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3910,1,,,In vitro inhibitory activity against RBL-1 5-LO,12166,B,702.0,CHEMBL619914,RBL-1,9295,,Expert,,,8,H,,
,BAO_0000219,,,3911,1,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),12166,B,702.0,CHEMBL619915,RBL-1,9295,,Autocuration,,,8,H,,
,BAO_0000219,,,3912,1,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),12166,B,702.0,CHEMBL619916,RBL-1,9295,,Autocuration,,,8,H,,
,BAO_0000218,,,3913,1,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,12166,B,,CHEMBL619917,,9295,,Autocuration,,,8,H,,
,BAO_0000357,,,3914,1,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,12166,B,,CHEMBL619918,,9295,,Autocuration,,,8,H,,
,BAO_0000218,,,3915,1,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,12166,B,,CHEMBL619919,,216,,Autocuration,,,8,H,,
,BAO_0000219,,,3916,1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,12166,B,702.0,CHEMBL883710,RBL-1,11090,,Autocuration,,,8,H,,
,BAO_0000019,Blood,,3917,1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,12166,B,,CHEMBL619920,,11090,,Autocuration,,,8,H,,178.0
,BAO_0000357,,,3918,1,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,12166,B,,CHEMBL619921,,10091,,Expert,,,8,H,,
,BAO_0000019,,,3919,1,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,12166,F,,CHEMBL619922,,10274,,Autocuration,,,8,H,,
,BAO_0000219,,,3920,1,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,12166,F,,CHEMBL619923,,13622,,Autocuration,,,8,H,,
,BAO_0000219,,,3921,1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,12166,B,702.0,CHEMBL619924,RBL-1,12118,,Expert,,,8,H,,
,BAO_0000357,,,3922,1,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,12166,B,,CHEMBL619925,,12576,,Expert,,,8,H,,
,BAO_0000219,,,3923,1,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,12166,B,702.0,CHEMBL619926,RBL-1,9546,,Expert,,,8,H,,
,BAO_0000219,,,3924,1,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,12166,B,702.0,CHEMBL619927,RBL-1,9521,,Autocuration,,,8,H,,
,BAO_0000219,,,3925,1,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,12166,B,702.0,CHEMBL619928,RBL-1,10626,,Expert,,,8,H,,
,BAO_0000219,,,3926,1,,,In vitro inhibition of RBL-1 5-lipoxygenase,12166,B,702.0,CHEMBL619929,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3927,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,12166,B,702.0,CHEMBL875089,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3928,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,12166,B,702.0,CHEMBL619930,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3929,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,12166,B,702.0,CHEMBL619931,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3930,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,12166,B,702.0,CHEMBL619932,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3931,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,12166,B,702.0,CHEMBL619933,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3932,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,12166,B,702.0,CHEMBL619934,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3933,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,12166,B,702.0,CHEMBL619935,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3934,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,12166,B,702.0,CHEMBL619936,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3935,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,12166,B,702.0,CHEMBL619937,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3936,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,12166,B,702.0,CHEMBL619938,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3937,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,12166,B,702.0,CHEMBL619939,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3938,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,12166,B,702.0,CHEMBL619940,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3939,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,12166,B,702.0,CHEMBL875090,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3940,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,12166,B,702.0,CHEMBL619941,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3941,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,12166,B,702.0,CHEMBL619942,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3942,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,12166,B,702.0,CHEMBL883711,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3943,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,12166,B,702.0,CHEMBL619943,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3944,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,12166,B,702.0,CHEMBL619944,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3945,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,12166,B,702.0,CHEMBL619945,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3946,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,12166,B,702.0,CHEMBL619946,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3947,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,12166,B,702.0,CHEMBL619947,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3948,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,12166,B,702.0,CHEMBL619948,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000219,,,3949,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,12166,B,702.0,CHEMBL619949,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000019,,,3950,1,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,12166,B,,CHEMBL619950,,9401,,Expert,,,8,H,,
,BAO_0000019,,,3951,1,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,12166,B,,CHEMBL618050,,10325,,Autocuration,,,8,H,,
,BAO_0000219,,,3952,1,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,12166,F,663.0,CHEMBL875091,RBL-2H3,1556,,Expert,,,8,H,,
,BAO_0000219,,,3953,1,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,12166,F,663.0,CHEMBL618051,RBL-2H3,1556,,Expert,,,8,H,,
,BAO_0000219,,,3954,1,,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,12166,B,702.0,CHEMBL618052,RBL-1,961,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,3955,1,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,12166,B,,CHEMBL618053,,6838,,Autocuration,,,8,H,,
,BAO_0000019,,,3956,1,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),12166,B,,CHEMBL618054,,10325,,Expert,,,8,H,,
,BAO_0000219,,,3957,1,,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,B,702.0,CHEMBL618055,RBL-1,9209,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3958,1,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,12166,B,702.0,CHEMBL618056,RBL-1,11520,,Expert,,,8,H,,
,BAO_0000357,,,3959,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined,12166,B,,CHEMBL618057,,137,,Autocuration,,,8,H,,
,BAO_0000219,,,3960,1,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,12166,B,702.0,CHEMBL618058,RBL-1,4717,,Autocuration,,,8,H,,
,BAO_0000219,,,3961,1,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,12166,B,702.0,CHEMBL618059,RBL-1,10636,,Expert,,,8,H,,
,BAO_0000019,,,3962,1,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,12166,F,,CHEMBL618060,,14312,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3963,1,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,12166,B,702.0,CHEMBL618061,RBL-1,1203,,Autocuration,,,8,H,,
,BAO_0000019,,,3964,1,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,12166,B,,CHEMBL618062,,1203,,Autocuration,,,8,H,,
,BAO_0000219,,,3965,1,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,12166,B,702.0,CHEMBL618063,RBL-1,13622,,Expert,,,8,H,,
,BAO_0000357,,,3966,1,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,12166,B,,CHEMBL618064,,9793,,Autocuration,,,8,H,,
,BAO_0000219,,,3967,1,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,12166,B,702.0,CHEMBL618065,RBL-1,1143,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3968,1,,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,12166,B,702.0,CHEMBL618066,RBL-1,11854,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3969,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,B,702.0,CHEMBL618067,RBL-1,3595,,Autocuration,,,8,H,,
,BAO_0000219,,,3970,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,B,702.0,CHEMBL618068,RBL-1,3595,,Autocuration,,,8,H,,
,BAO_0000219,,,3971,1,,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,12166,B,702.0,CHEMBL618069,RBL-1,10501,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,3972,1,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,B,702.0,CHEMBL618070,RBL-1,12526,,Expert,,,8,H,,
,BAO_0000019,Limbic system,,3973,1,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,10825,F,,CHEMBL618071,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000019,Limbic system,,3974,1,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,F,,CHEMBL619247,,10034,,Autocuration,,,8,H,,349.0
,BAO_0000019,,,3975,1,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,10825,F,,CHEMBL619248,,10034,,Autocuration,,,8,H,,
,BAO_0000221,Hippocampus,,3976,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,B,,CHEMBL619249,,10046,,Autocuration,,,8,H,,10000000.0
,BAO_0000221,Hippocampus,,3977,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,B,,CHEMBL619250,,10046,,Autocuration,,,8,H,,10000000.0
,BAO_0000019,,,3978,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,B,,CHEMBL619251,,10046,,Autocuration,,,8,H,,
,BAO_0000019,Blood,,3979,1,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,55,F,,CHEMBL619252,,12079,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
,BAO_0000019,Blood,,3980,1,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,55,F,,CHEMBL619253,,12079,,Autocuration,,,8,H,,178.0
,BAO_0000219,,,3981,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,B,,CHEMBL619254,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,3982,1,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,17140,B,,CHEMBL619255,,12338,,Expert,,,8,H,,
,BAO_0000219,,,3983,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,17140,B,,CHEMBL619256,,12143,,Expert,,,8,H,,
,BAO_0000219,,,3984,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),17140,B,,CHEMBL875418,,12143,,Autocuration,,,8,H,,
,BAO_0000219,,,3985,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,B,,CHEMBL619257,,12143,,Expert,,,8,H,,
,BAO_0000219,,,3986,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,B,,CHEMBL619258,,12143,,Autocuration,,,8,H,,
,BAO_0000357,,,3987,1,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,17140,B,,CHEMBL619259,,12365,,Expert,,,8,H,,
,BAO_0000357,,,3988,1,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,17140,B,,CHEMBL619260,,13500,,Expert,,,8,H,,
In vivo,BAO_0000218,Blood,,3989,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619261,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3990,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619263,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3991,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619264,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3992,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619265,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3993,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619266,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3994,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619902,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3995,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620058,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3996,1,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620059,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3997,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620060,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3998,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620061,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,3999,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",55,F,,CHEMBL620062,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4000,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620063,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4001,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",55,F,,CHEMBL620064,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4002,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620065,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4003,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",55,F,,CHEMBL620066,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4004,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620067,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4005,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",55,F,,CHEMBL620068,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4006,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620069,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4007,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",55,F,,CHEMBL620070,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4008,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620071,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4009,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",55,F,,CHEMBL620072,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4010,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620036,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4011,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",55,F,,CHEMBL857702,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4012,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620037,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4013,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",55,F,,CHEMBL620038,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4014,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620039,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4015,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",55,F,,CHEMBL620040,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4016,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620041,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4017,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",55,F,,CHEMBL620042,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4018,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620043,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4019,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",55,F,,CHEMBL620044,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4020,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620045,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4021,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",55,F,,CHEMBL620046,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4022,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620047,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4023,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",55,F,,CHEMBL620048,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4024,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",55,F,,CHEMBL857703,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4025,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",55,F,,CHEMBL620049,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4026,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620050,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4027,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL620051,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4028,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619213,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4029,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619214,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4030,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619804,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4031,1,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619805,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4032,1,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619806,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4033,1,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619807,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,4034,1,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,F,,CHEMBL619808,,12832,9615.0,Autocuration,,,8,H,Canis lupus familiaris,178.0
,BAO_0000218,,,4035,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,55,B,,CHEMBL619809,,3595,9615.0,Autocuration,,,8,H,Canis lupus familiaris,
,BAO_0000218,,,4036,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,55,B,,CHEMBL619810,,3595,9615.0,Autocuration,,,8,H,Canis lupus familiaris,
,BAO_0000218,,,4037,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,55,B,,CHEMBL619811,,3595,9615.0,Autocuration,,,8,H,Canis lupus familiaris,
,BAO_0000218,,,4038,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,55,B,,CHEMBL620769,,3595,9615.0,Autocuration,,,8,H,Canis lupus familiaris,
,BAO_0000218,,,4039,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,55,B,,CHEMBL620770,,3595,9615.0,Autocuration,,,8,H,Canis lupus familiaris,
,BAO_0000218,,,4040,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,55,B,,CHEMBL620771,,3595,9615.0,Autocuration,,,8,H,Canis lupus familiaris,
,BAO_0000218,,,4041,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,55,B,,CHEMBL620772,,3595,9615.0,Autocuration,,,8,H,Canis lupus familiaris,
,BAO_0000218,,,4042,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,55,B,,CHEMBL620773,,3595,9615.0,Autocuration,,,8,H,Canis lupus familiaris,
,BAO_0000357,,,4043,1,,,Ability to inhibit 5-lipoxygenase in guinea pig,55,B,,CHEMBL620774,,9203,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4044,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),55,B,,CHEMBL620775,,82,10141.0,Expert,,,8,H,Cavia porcellus,
,BAO_0000357,,,4045,1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,55,B,,CHEMBL620776,,11090,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000218,Blood,,4046,1,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",55,B,,CHEMBL620777,,12832,10141.0,Autocuration,,,8,H,Cavia porcellus,178.0
,BAO_0000357,,,4047,1,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,55,B,,CHEMBL620778,,1065,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4048,1,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,55,B,,CHEMBL620779,,1065,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,4049,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,55,B,,CHEMBL621500,,12832,10141.0,Expert,,,8,H,Cavia porcellus,
,BAO_0000019,,,4050,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,B,,CHEMBL621501,,12832,10141.0,Expert,,,8,H,Cavia porcellus,
,BAO_0000019,,,4051,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,B,,CHEMBL618098,,12832,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,4052,1,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,B,,CHEMBL618099,,10504,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4053,1,,,Inhibitory activity against 5-lipoxygenase,55,B,,CHEMBL618100,,7788,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4054,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,55,B,,CHEMBL618101,,10001,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4055,1,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,55,B,,CHEMBL618102,,10193,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4056,1,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,55,B,,CHEMBL618103,,13243,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4057,1,,,Inhibitory activity uM,55,B,,CHEMBL618104,,13243,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000219,,,4058,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,55,B,,CHEMBL883712,,969,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4059,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM,55,B,,CHEMBL618105,,10001,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4060,1,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,B,,CHEMBL618106,,7788,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4061,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,55,B,,CHEMBL618107,,10001,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4062,1,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,B,,CHEMBL618108,,10193,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4063,1,,,Inhibitory activity uM,55,B,,CHEMBL618109,,13243,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4064,1,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,55,B,,CHEMBL618110,,13243,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4065,1,,,Inhibitory activity uM,55,B,,CHEMBL618111,,13243,10141.0,Expert,,,8,H,Cavia porcellus,
,BAO_0000019,,,4066,1,,,Inhibitory activity uM,55,F,,CHEMBL618112,,13243,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000019,,,4067,1,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,B,,CHEMBL618113,,10504,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000357,,,4068,1,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,B,,CHEMBL618114,,7788,10141.0,Autocuration,,,8,H,Cavia porcellus,
,BAO_0000221,Ileum,,4069,1,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,55,F,,CHEMBL620871,,10546,10141.0,Expert,,,8,H,Cavia porcellus,2116.0
,BAO_0000357,,,4070,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,B,,CHEMBL620872,,13183,,Autocuration,,,8,H,,
,BAO_0000357,,,4071,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,B,,CHEMBL620873,,13183,,Autocuration,,,8,H,,
,BAO_0000357,,,4072,1,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),55,B,,CHEMBL620874,,2578,,Autocuration,,,8,H,,
,BAO_0000357,,,4073,1,,,In vitro inhibition of human 5-Lipoxygenase.,55,B,,CHEMBL620875,,12780,,Expert,,,8,H,,
,BAO_0000251,Liver,,4074,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,B,,CHEMBL620876,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4075,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,B,,CHEMBL620877,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4076,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,B,,CHEMBL857854,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4077,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,22226,B,,CHEMBL620878,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4078,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,B,,CHEMBL620879,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4079,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,B,,CHEMBL620880,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4080,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,B,,CHEMBL620881,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4081,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,B,,CHEMBL620882,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4082,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,B,,CHEMBL620883,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4083,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,B,,CHEMBL620884,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4084,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,B,,CHEMBL620885,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4085,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,22226,B,,CHEMBL620886,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4086,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,B,,CHEMBL620887,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4087,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,B,,CHEMBL618039,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4088,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,B,,CHEMBL618040,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4089,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,22226,B,,CHEMBL618041,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4090,1,,Microsomes,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,B,,CHEMBL618216,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4091,1,,Microsomes,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,B,,CHEMBL618217,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4092,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,22226,B,,CHEMBL618218,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4093,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,22226,B,,CHEMBL618219,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4094,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,22226,B,,CHEMBL618220,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4095,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,22226,B,,CHEMBL618221,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4096,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,22226,B,,CHEMBL618222,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4097,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,B,,CHEMBL618223,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4098,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,B,,CHEMBL618224,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4099,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,22226,B,,CHEMBL618225,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4100,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,22226,B,,CHEMBL618226,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4101,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,B,,CHEMBL618227,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4102,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,B,,CHEMBL618228,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4103,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,B,,CHEMBL618229,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4104,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,B,,CHEMBL618230,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4105,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,B,,CHEMBL618231,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4106,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,B,,CHEMBL618232,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4107,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,B,,CHEMBL618233,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4108,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,B,,CHEMBL618234,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4109,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,B,,CHEMBL618235,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4110,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,B,,CHEMBL618115,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4111,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,B,,CHEMBL618116,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4112,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,B,,CHEMBL618117,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4113,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,B,,CHEMBL619968,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4114,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,B,,CHEMBL619969,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4115,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,B,,CHEMBL619970,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4116,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,22226,B,,CHEMBL619971,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4117,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,22226,B,,CHEMBL619972,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4118,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,22226,B,,CHEMBL619973,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4119,1,,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,22226,B,,CHEMBL619974,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4120,1,,Microsomes,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,B,,CHEMBL619975,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,,,4121,1,,Microsomes,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,22226,B,,CHEMBL619976,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000251,Liver,,4122,1,,Microsomes,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,B,,CHEMBL619977,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4123,1,,Microsomes,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,B,,CHEMBL619978,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4124,1,,Microsomes,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",22226,B,,CHEMBL619979,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4125,1,,Microsomes,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,B,,CHEMBL619980,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4126,1,,Microsomes,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,B,,CHEMBL619981,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000219,,,4127,1,,,In vitro inhibition of 7226/S myeloma cancer cell line,80433,F,741.0,CHEMBL619982,RPMI-8226,10797,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4128,1,,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),80698,F,993.0,CHEMBL619983,BEL-7404 tumor cell line,6881,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4129,1,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,F,391.0,CHEMBL620031,786-0,3838,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4130,1,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,F,391.0,CHEMBL620032,786-0,3838,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4131,1,,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,81264,F,505.0,CHEMBL620033,V79,12981,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,4132,1,,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,81264,F,505.0,CHEMBL620034,V79,12981,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,4133,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,80635,F,1119.0,CHEMBL620035,7800C1 cell line,7653,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,4134,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,80635,F,1119.0,CHEMBL618318,7800C1 cell line,7653,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,4135,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,80635,F,1119.0,CHEMBL618319,7800C1 cell line,7653,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,4136,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,80635,F,1119.0,CHEMBL618320,7800C1 cell line,7653,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,4137,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,80635,F,1119.0,CHEMBL618321,7800C1 cell line,7653,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,4138,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,80635,F,1119.0,CHEMBL883118,7800C1 cell line,7653,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,4139,1,,,In vitro antitumor activity against renal 786-0 tumor cell lines,80640,F,391.0,CHEMBL883795,786-0,17229,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4140,1,,,Cytotoxic activity against 786-0 Renal cancer cell line,80640,F,391.0,CHEMBL618322,786-0,12858,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4141,1,,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,80640,F,391.0,CHEMBL618323,786-0,16325,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4142,1,,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,80640,F,391.0,CHEMBL618324,786-0,16325,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4143,1,,,In vitro antitumor activity against human renal 786-0 cell line,80640,F,391.0,CHEMBL618325,786-0,5858,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4144,1,,,Inhibition of Renal cancer in 786-0 cancer cell lines,80640,F,391.0,CHEMBL875416,786-0,16325,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4145,1,,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,80640,F,391.0,CHEMBL618326,786-0,14696,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4146,1,,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,80640,F,391.0,CHEMBL618327,786-0,3786,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4147,1,,,inhibition of the growth of renal cancer(786-0) cell line,80640,F,391.0,CHEMBL619215,786-0,14696,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4148,1,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,F,391.0,CHEMBL619216,786-0,14769,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4149,1,,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,80640,F,391.0,CHEMBL619217,786-0,15354,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4150,1,,,The IC50 value was measured on 786-0 cell line in ovarian tumor,80640,F,391.0,CHEMBL619218,786-0,14255,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4151,1,,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,80640,F,391.0,CHEMBL619219,786-0,14255,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4152,1,,,The IC50 value was measured on 786-0 cell line in renal tumor type.,80640,F,391.0,CHEMBL619220,786-0,14255,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4153,1,,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,80640,F,391.0,CHEMBL619221,786-0,14696,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4154,1,,,Tested for cytotoxic activity against renal cancer 786-0 cell line,80640,F,391.0,CHEMBL619222,786-0,12016,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4155,1,,,Compound was tested for growth inhibitory activity against 786-0 cell line,80640,F,391.0,CHEMBL857454,786-0,2597,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4156,1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,12166,B,702.0,CHEMBL619223,RBL-1,12526,,Autocuration,,,8,H,,
,BAO_0000219,,,4157,1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,12166,B,702.0,CHEMBL619224,RBL-1,12526,,Autocuration,,,8,H,,
,BAO_0000019,,,4158,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,B,,CHEMBL619225,,14799,,Autocuration,,,8,H,,
,BAO_0000219,,,4159,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,B,702.0,CHEMBL619226,RBL-1,3595,,Expert,,,8,H,,
,BAO_0000219,,,4160,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,B,702.0,CHEMBL619227,RBL-1,3595,,Expert,,,8,H,,
,BAO_0000357,,,4161,1,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,12166,B,,CHEMBL619228,,12767,,Autocuration,,,8,H,,
,BAO_0000219,,,4162,1,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,12166,B,,CHEMBL619229,,10997,,Autocuration,,,8,H,,
,BAO_0000219,,,4163,1,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,12166,B,702.0,CHEMBL619230,RBL-1,11388,,Autocuration,,,8,H,,
,BAO_0000357,,,4164,1,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,12166,B,,CHEMBL619231,,167,,Autocuration,,,8,H,,
,BAO_0000357,,,4165,1,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",12166,B,,CHEMBL619232,,167,,Autocuration,,,8,H,,
,BAO_0000357,,,4166,1,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,12166,B,,CHEMBL619233,,13744,,Expert,,,8,H,,
,BAO_0000357,,,4167,1,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,12166,B,,CHEMBL619234,,1630,,Autocuration,,,8,H,,
,BAO_0000357,,,4168,1,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),12166,B,,CHEMBL619235,,1630,,Autocuration,,,8,H,,
,BAO_0000019,,,4169,1,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",12166,B,,CHEMBL619236,,969,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,4170,1,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,12166,B,702.0,CHEMBL619237,RBL-1,13621,,Autocuration,,,8,H,,
,BAO_0000357,,,4171,1,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,12166,B,,CHEMBL619238,,10089,,Autocuration,,,8,H,,
,BAO_0000357,,,4172,1,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,12166,B,,CHEMBL619239,,10193,,Expert,,,8,H,,
,BAO_0000357,,,4173,1,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,12166,B,,CHEMBL619240,,11966,,Autocuration,,,8,H,,
,BAO_0000019,,,4174,1,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,B,,CHEMBL875417,,12251,,Autocuration,,,8,H,,
,BAO_0000219,,,4175,1,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),12166,B,702.0,CHEMBL619241,RBL-1,211,,Autocuration,,,8,H,,
,BAO_0000019,,,4176,1,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,F,,CHEMBL619242,,12251,,Expert,,,8,H,,
,BAO_0000219,,,4177,1,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,12166,B,702.0,CHEMBL883796,RBL-1,12495,,Autocuration,,,8,H,,
,BAO_0000357,,,4178,1,,,Tested for its inhibitory activity against 5-lipoxygenase,12166,B,,CHEMBL619243,,414,,Autocuration,,,8,H,,
,BAO_0000357,,,4179,1,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,12166,B,,CHEMBL619244,,414,,Autocuration,,,8,H,,
,BAO_0000019,,,4180,1,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",12166,B,,CHEMBL619245,,10325,,Expert,,,8,H,,
,BAO_0000019,,,4181,1,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,B,,CHEMBL619246,,11966,,Expert,,,8,H,,
,BAO_0000219,,,4182,1,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,B,702.0,CHEMBL619984,RBL-1,165,,Expert,,,8,H,,
,BAO_0000219,,,4183,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,12166,B,702.0,CHEMBL619985,RBL-1,165,,Autocuration,,,8,H,,
,BAO_0000219,,,4184,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,B,702.0,CHEMBL619986,RBL-1,165,,Autocuration,,,8,H,,
,BAO_0000219,,,4185,1,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,B,702.0,CHEMBL619987,RBL-1,165,,Expert,,,8,H,,
,BAO_0000218,,,4186,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,12166,B,,CHEMBL619988,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4187,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,12166,B,702.0,CHEMBL619989,RBL-1,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4188,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,B,702.0,CHEMBL619990,RBL-1,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4189,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,B,,CHEMBL619991,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4190,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),12166,B,,CHEMBL619992,,11311,,Autocuration,,,8,H,,
In vivo,BAO_0000218,,,4191,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),12166,B,,CHEMBL619993,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4192,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,12166,F,663.0,CHEMBL619994,RBL-2H3,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4193,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,12166,F,663.0,CHEMBL619995,RBL-2H3,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,4194,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],12166,B,,CHEMBL619996,,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,4195,1,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,12166,B,,CHEMBL619997,,11732,,Autocuration,,,8,H,,
,BAO_0000019,,,4196,1,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,12166,B,,CHEMBL619998,,11732,,Expert,,,8,H,,
,BAO_0000019,,,4197,1,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,12166,B,,CHEMBL619999,,11087,,Expert,,,8,H,,
,BAO_0000019,,,4198,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,12166,B,,CHEMBL620000,,11087,,Autocuration,,,8,H,,
,BAO_0000219,,,4199,1,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,12166,B,702.0,CHEMBL620001,RBL-1,11087,,Autocuration,,,8,H,,
,BAO_0000357,,,4200,1,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,12166,B,,CHEMBL620002,,11087,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,4201,1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,12166,B,702.0,CHEMBL620003,RBL-1,496,,Autocuration,,,8,H,,
,BAO_0000219,,,4202,1,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,12166,F,702.0,CHEMBL620004,RBL-1,13986,,Expert,,,8,H,,
,BAO_0000357,,,4203,1,,,Compound was evaluated for the inhibition of 5-lipoxygenase,12166,B,,CHEMBL874063,,11520,,Autocuration,,,8,H,,
,BAO_0000219,,,4204,1,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,12166,B,702.0,CHEMBL620005,RBL-1,10293,,Autocuration,,,8,H,,
,BAO_0000219,,,4205,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,12166,B,702.0,CHEMBL620006,RBL-1,303,,Autocuration,,,8,H,,
,BAO_0000219,,,4206,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,12166,B,702.0,CHEMBL620007,RBL-1,303,,Autocuration,,,8,H,,
,BAO_0000219,,,4207,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,12166,B,702.0,CHEMBL620008,RBL-1,9247,,Autocuration,,,8,H,,
,BAO_0000219,,,4208,1,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,12166,B,702.0,CHEMBL620009,RBL-1,9247,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,4209,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,B,702.0,CHEMBL620010,RBL-1,9247,,Autocuration,,,8,H,,
,BAO_0000219,,,4210,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,12166,B,702.0,CHEMBL620011,RBL-1,9247,,Autocuration,,,8,H,,
,BAO_0000219,,,4211,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,12166,B,702.0,CHEMBL620677,RBL-1,9247,,Autocuration,,,8,H,,
,BAO_0000219,,,4212,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,12166,B,702.0,CHEMBL620678,RBL-1,9247,,Autocuration,,,8,H,,
,BAO_0000219,,,4213,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,12166,B,702.0,CHEMBL620679,RBL-1,9247,,Autocuration,,,8,H,,
,BAO_0000219,,,4214,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,12166,B,702.0,CHEMBL620680,RBL-1,9247,,Autocuration,,,8,H,,
,BAO_0000357,,,4215,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM,12166,B,,CHEMBL620838,,11481,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,4216,1,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,12166,B,,CHEMBL620839,,105,,Autocuration,,,8,H,,
,BAO_0000357,,,4217,1,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,12166,B,,CHEMBL620840,,9029,,Expert,,,8,H,,
,BAO_0000219,,,4218,1,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,12166,B,702.0,CHEMBL620841,RBL-1,1175,,Expert,,,8,H,,
,BAO_0000219,,,4219,1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,12166,B,702.0,CHEMBL620842,RBL-1,12118,,Autocuration,,,8,H,,
,BAO_0000219,,,4220,1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,12166,B,702.0,CHEMBL620843,RBL-1,12118,,Autocuration,,,8,H,,
,BAO_0000219,,,4221,1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,12166,B,702.0,CHEMBL620844,RBL-1,12118,,Autocuration,,,8,H,,
,BAO_0000219,,,4222,1,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,12166,B,702.0,CHEMBL620845,RBL-1,9225,,Autocuration,,,8,H,,
,BAO_0000019,,,4223,1,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,12166,B,,CHEMBL620846,,9401,,Autocuration,,,8,H,,
,BAO_0000357,,,4224,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,B,,CHEMBL873951,,137,,Autocuration,,,8,H,,
,BAO_0000357,,,4225,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,B,,CHEMBL620847,,137,,Autocuration,,,8,H,,
,BAO_0000219,,,4226,1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,B,702.0,CHEMBL620848,RBL-1,4717,,Autocuration,,,8,H,,
,BAO_0000219,,,4227,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,B,702.0,CHEMBL620849,RBL-1,3595,,Autocuration,,,8,H,,
,BAO_0000219,,,4228,1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,12166,B,702.0,CHEMBL620850,RBL-1,10501,,Autocuration,,,8,H,,
,BAO_0000219,,,4229,1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,12166,B,702.0,CHEMBL620851,RBL-1,10501,,Autocuration,,,8,H,,
,BAO_0000219,,,4230,1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,12166,B,702.0,CHEMBL620852,RBL-1,10501,,Autocuration,,,8,H,,
,BAO_0000219,,,4231,1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,B,702.0,CHEMBL875098,RBL-1,12526,,Autocuration,,,8,H,,
,BAO_0000219,,,4232,1,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,12166,B,702.0,CHEMBL620853,RBL-1,14799,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,4233,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,12166,B,,CHEMBL620854,,14799,,Autocuration,,,8,H,,
,BAO_0000219,,,4234,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,B,702.0,CHEMBL620855,RBL-1,3595,,Autocuration,,,8,H,,
,BAO_0000219,,,4235,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,B,702.0,CHEMBL839884,RBL-1,3595,,Expert,,,8,H,,
,BAO_0000219,,,4236,1,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,B,702.0,CHEMBL620856,RBL-1,12526,,Autocuration,,,8,H,,
,BAO_0000219,,,4237,1,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,B,702.0,CHEMBL620857,RBL-1,12526,,Autocuration,,,8,H,,
,BAO_0000019,,,4238,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,B,,CHEMBL620858,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,4239,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,B,,CHEMBL620859,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,4240,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,B,,CHEMBL620860,,10193,,Autocuration,,,8,H,,
,BAO_0000019,,,4241,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,12166,B,,CHEMBL620861,,10193,,Autocuration,,,8,H,,
,BAO_0000357,,,4242,1,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),12166,B,,CHEMBL620862,,9138,,Expert,,,8,H,,
,BAO_0000357,,,4243,1,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,12166,B,,CHEMBL620863,,9138,,Autocuration,,,8,H,,
,BAO_0000019,,,4244,1,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,B,,CHEMBL620864,,11966,,Autocuration,,,8,H,,
,BAO_0000219,,,4245,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,12166,B,702.0,CHEMBL620865,RBL-1,165,,Autocuration,,,8,H,,
,BAO_0000219,,,4246,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,12166,B,702.0,CHEMBL620866,RBL-1,165,,Autocuration,,,8,H,,
,BAO_0000219,,,4247,1,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,12166,B,663.0,CHEMBL620867,RBL-2H3,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4248,1,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,B,663.0,CHEMBL620868,RBL-2H3,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4249,1,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,F,663.0,CHEMBL620869,RBL-2H3,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,4250,1,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,12166,F,,CHEMBL873952,,11311,,Autocuration,,,8,H,,
,BAO_0000357,,,4251,1,,,The compound was tested for inhibition of isolated 5-lipoxygenase,12166,B,,CHEMBL875099,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4252,1,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,12166,F,663.0,CHEMBL620870,RBL-2H3,11311,,Autocuration,,,8,H,,
,BAO_0000019,,,4253,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,12166,B,,CHEMBL618261,,11087,,Autocuration,,,8,H,,
,BAO_0000019,,,4254,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,12166,B,,CHEMBL618262,,11087,,Autocuration,,,8,H,,
,BAO_0000019,,,4255,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,12166,B,,CHEMBL619428,,11087,,Autocuration,,,8,H,,
,BAO_0000019,,,4256,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,B,,CHEMBL619429,,11087,,Autocuration,,,8,H,,
,BAO_0000019,,,4257,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,B,,CHEMBL619430,,11087,,Autocuration,,,8,H,,
,BAO_0000219,,,4258,1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,12166,B,702.0,CHEMBL620017,RBL-1,496,,Autocuration,,,8,H,,
,BAO_0000219,,,4259,1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,12166,B,702.0,CHEMBL620018,RBL-1,496,,Autocuration,,,8,H,,
,BAO_0000219,,,4260,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,12166,F,702.0,CHEMBL620019,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000219,,,4261,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,12166,F,702.0,CHEMBL620020,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000219,,,4262,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,12166,F,702.0,CHEMBL620021,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000219,,,4263,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,12166,F,702.0,CHEMBL620022,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000219,,,4264,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,12166,F,702.0,CHEMBL620023,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000219,,,4265,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,12166,F,702.0,CHEMBL620024,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000219,,,4266,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,12166,F,702.0,CHEMBL620025,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000219,,,4267,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,12166,F,702.0,CHEMBL620026,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000219,,,4268,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,12166,F,702.0,CHEMBL620027,RBL-1,13986,,Autocuration,,,8,H,,
,BAO_0000019,,,4269,1,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,12166,F,,CHEMBL620028,,13986,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000357,,,4270,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,12166,B,,CHEMBL620029,,10193,,Autocuration,,,8,H,,
,BAO_0000357,,,4271,1,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,12166,B,,CHEMBL620030,,9295,,Autocuration,,,8,H,,
,BAO_0000219,,,4272,1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,12166,B,702.0,CHEMBL875415,RBL-1,4717,,Autocuration,,,8,H,,
,BAO_0000219,,,4273,1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,B,702.0,CHEMBL618256,RBL-1,4717,,Autocuration,,,8,H,,
,BAO_0000219,,,4274,1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,12166,B,702.0,CHEMBL618257,RBL-1,11854,,Autocuration,,,8,H,,
,BAO_0000219,,,4275,1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,12166,B,702.0,CHEMBL618258,RBL-1,11854,,Autocuration,,,8,H,,
,BAO_0000219,,,4276,1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,12166,B,702.0,CHEMBL618259,RBL-1,11854,,Autocuration,,,8,H,,
,BAO_0000019,,,4277,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,B,,CHEMBL618260,,10193,,Autocuration,,,8,H,,
,BAO_0000219,,,4278,1,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,12166,B,702.0,CHEMBL618215,RBL-1,9295,,Autocuration,,,8,H,,
,BAO_0000219,,,4279,1,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,12166,B,702.0,CHEMBL618390,RBL-1,9295,,Autocuration,,,8,H,,
,BAO_0000219,,,4280,1,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,12166,B,702.0,CHEMBL618391,RBL-1,9295,,Autocuration,,,8,H,,
,BAO_0000219,,,4281,1,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,12166,B,702.0,CHEMBL618392,RBL-1,9295,,Autocuration,,,8,H,,
,BAO_0000219,,,4282,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,12166,B,702.0,CHEMBL618393,RBL-1,165,,Autocuration,,,8,H,,
,BAO_0000219,,,4283,1,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,12166,B,,CHEMBL618394,,11311,,Autocuration,,,8,H,,
,BAO_0000219,,,4284,1,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,B,702.0,CHEMBL618395,RBL-1,10489,9606.0,Expert,,,8,H,Homo sapiens,
,BAO_0000219,,,4285,1,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,B,702.0,CHEMBL618396,RBL-1,10489,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,4286,1,,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),12166,B,702.0,CHEMBL858253,RBL-1,10489,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,4287,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,B,,CHEMBL618397,,14799,10116.0,Autocuration,,,9,D,Rattus norvegicus,
,BAO_0000357,,,4288,1,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),12054,B,,CHEMBL618398,,9295,3847.0,Autocuration,,,8,H,Glycine max,
,BAO_0000019,,,4289,1,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",22226,B,,CHEMBL618399,,16811,,Autocuration,,,0,U,,
,BAO_0000357,,,4290,1,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,55,B,,CHEMBL618400,,168,,Expert,,,8,H,,
,BAO_0000357,,,4291,1,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,55,B,,CHEMBL618401,,6309,,Autocuration,,,8,H,,
,BAO_0000357,,,4292,1,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,55,B,,CHEMBL618402,,6309,,Autocuration,,,8,H,,
,BAO_0000219,,,4293,1,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,55,B,702.0,CHEMBL876400,RBL-1,3092,,Autocuration,,,8,H,,
,BAO_0000357,,,4294,1,,,Inhibitory activity against 5-lipoxygenase.,55,B,,CHEMBL618403,,168,,Expert,,,8,H,,
,BAO_0000357,,,4295,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,55,B,,CHEMBL618404,,168,,Autocuration,,,8,H,,
,BAO_0000357,,,4296,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,55,B,,CHEMBL618405,,168,,Autocuration,,,8,H,,
,BAO_0000357,,,4297,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,55,B,,CHEMBL618406,,168,,Autocuration,,,8,H,,
,BAO_0000019,,,4298,1,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,55,F,,CHEMBL618407,,12338,,Expert,,,8,H,,
,BAO_0000357,,,4299,1,,,Tested for the inhibitory activity against 5-lipoxygenase,55,B,,CHEMBL618408,,4501,,Autocuration,,,8,H,,
,BAO_0000357,,,4300,1,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,55,B,,CHEMBL618409,,1132,,Autocuration,,,8,H,,
,BAO_0000357,,,4301,1,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,55,B,,CHEMBL618410,,2117,,Autocuration,,,8,H,,
,BAO_0000357,,,4302,1,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,55,B,,CHEMBL618411,,168,,Autocuration,,,8,H,,
,BAO_0000357,,,4303,1,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,55,B,,CHEMBL618412,,168,,Autocuration,,,8,H,,
,BAO_0000219,,,4304,1,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,12166,B,702.0,CHEMBL618413,RBL-1,13575,,Autocuration,,,8,H,,
,BAO_0000357,,,4305,1,,,,12166,B,,CHEMBL618414,,11089,,Autocuration,,,8,H,,
,BAO_0000357,,,4306,1,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),10102,B,,CHEMBL618415,,216,,Autocuration,,,8,H,,
,BAO_0000019,,,4307,1,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,10102,B,,CHEMBL618416,,13165,,Autocuration,,,8,H,,
,BAO_0000357,,,4308,1,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,10102,B,,CHEMBL876401,,3278,,Autocuration,,,8,H,,
,BAO_0000357,,,4309,1,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,10102,B,,CHEMBL618417,,3278,,Expert,,,8,H,,
,BAO_0000357,,,4310,1,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,10102,B,,CHEMBL618418,,11966,,Autocuration,,,8,H,,
,BAO_0000357,,,4311,1,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",10102,B,,CHEMBL618419,,175,,Autocuration,,,8,H,,
,BAO_0000357,,,4312,1,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",10102,B,,CHEMBL618420,,175,,Autocuration,,,8,H,,
,BAO_0000357,,,4313,1,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,10102,B,,CHEMBL618421,,13449,,Autocuration,,,8,H,,
,BAO_0000019,,,4314,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,11238,B,,CHEMBL618422,,12014,,Autocuration,,,8,H,,
,BAO_0000019,,,4315,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),11238,B,,CHEMBL618423,,12014,,Autocuration,,,8,H,,
,BAO_0000019,,,4316,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),11238,B,,CHEMBL618424,,12014,,Autocuration,,,8,H,,
,BAO_0000220,,,4317,1,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,100284,B,,CHEMBL618425,,99,,Intermediate,,,2,S,,
,BAO_0000019,,,4318,1,,,The dark toxicity against 543 human galactophore carcinoma cells,22226,F,,CHEMBL618426,,4349,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,4319,1,,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,80623,F,390.0,CHEMBL618427,Panel (56 tumour cell lines),4071,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4320,1,,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,80008,F,345.0,CHEMBL618428,5637,17589,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4321,1,,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,80008,F,345.0,CHEMBL618429,5637,15002,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4322,1,,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",80008,F,345.0,CHEMBL618430,5637,13958,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4323,1,,,Growth inhibition against human 5637 cell lines,80008,F,345.0,CHEMBL618431,5637,17589,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4324,1,,,Antitumor activity against human bladder carcinoma 5637 cells.,80008,F,345.0,CHEMBL883799,5637,16748,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4325,1,,,Antitumor activity against human bladder carcinoma 5637 cells,80008,F,345.0,CHEMBL618432,5637,16747,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4326,1,,,Antitumor activity against human bladder carcinoma 5637 cells,80008,F,345.0,CHEMBL618433,5637,16747,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000357,,,4327,1,,,In vitro inhibition of bovine trypsin(Trp).,10443,B,,CHEMBL618434,,15285,9913.0,Expert,,,9,D,Bos taurus,
,BAO_0000219,,,4328,1,,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,240,B,407.0,CHEMBL618435,CV-1,3726,9527.0,Expert,,,8,H,Cercopithecidae,
,BAO_0000357,,,4329,1,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,10577,B,,CHEMBL876402,,5033,,Autocuration,,,8,H,,
,BAO_0000019,,,4330,1,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,104698,F,,CHEMBL618436,,11756,,Autocuration,,,6,H,,
In vivo,BAO_0000218,,,4331,1,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,22226,F,,CHEMBL618437,,11953,,Autocuration,,,0,U,,
,BAO_0000357,,,4332,1,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,20033,B,,CHEMBL618438,,5033,10141.0,Intermediate,,,9,D,Cavia porcellus,
,BAO_0000251,,,4333,1,,Microsomes,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,A,,CHEMBL883800,,11347,10116.0,Expert,,,8,H,Rattus norvegicus,
,BAO_0000251,,,4334,1,,Microsomes,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,A,,CHEMBL618439,,11347,10116.0,Expert,,,8,H,Rattus norvegicus,
,BAO_0000019,,,4335,1,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,F,,CHEMBL618440,,1229,,Intermediate,,,0,U,,
,BAO_0000019,,,4336,1,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,F,,CHEMBL618441,,1229,,Intermediate,,,0,U,,
,BAO_0000019,,,4337,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,11938,B,,CHEMBL618442,,17588,5691.0,Expert,,,8,H,Trypanosoma brucei,
,BAO_0000019,,,4338,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,11938,B,,CHEMBL618443,,17588,5691.0,Autocuration,,,8,H,Trypanosoma brucei,
,BAO_0000019,,,4339,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,11938,B,,CHEMBL619158,,17588,9940.0,Expert,,,8,H,Ovis aries,
,BAO_0000019,,,4340,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,11938,B,,CHEMBL620974,,17588,9940.0,Autocuration,,,8,H,Ovis aries,
,BAO_0000357,,,4341,1,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,11938,B,,CHEMBL620975,,16485,,Autocuration,,,8,H,,
,BAO_0000019,,,4342,1,,,Average inhibitory concentration against 60 human cell lines was reported,22226,F,,CHEMBL620976,,4337,9606.0,Intermediate,,,0,U,Homo sapiens,
,BAO_0000019,,,4343,1,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,22226,F,,CHEMBL620977,,4112,9606.0,Expert,,,0,U,Homo sapiens,
,BAO_0000219,,,4344,1,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,80315,F,542.0,CHEMBL620978,Panel NCI-60 (60 carcinoma cell lines),16160,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4345,1,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,80315,F,542.0,CHEMBL620979,Panel NCI-60 (60 carcinoma cell lines),16160,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4346,1,,,In vitro mean growth inhibitory activity against 60-cell panel,80315,F,542.0,CHEMBL620980,Panel NCI-60 (60 carcinoma cell lines),17376,,Expert,,,1,N,,
,BAO_0000219,,,4347,1,,,In vitro mean growth lethal concentration against 60-cell panel,80315,F,542.0,CHEMBL620981,Panel NCI-60 (60 carcinoma cell lines),17376,,Expert,,,1,N,,
,BAO_0000219,,,4348,1,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,80315,F,542.0,CHEMBL620982,Panel NCI-60 (60 carcinoma cell lines),17376,,Expert,,,1,N,,
,BAO_0000219,,,4349,1,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,80315,F,542.0,CHEMBL620983,Panel NCI-60 (60 carcinoma cell lines),17376,,Expert,,,1,N,,
,BAO_0000019,,,4350,1,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,F,,CHEMBL620984,,3241,,Autocuration,,,4,H,,
,BAO_0000019,,,4351,1,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,F,,CHEMBL620985,,3241,,Autocuration,,,4,H,,
,BAO_0000357,,,4352,1,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,275,B,,CHEMBL620986,,3725,,Expert,,,8,H,,
,BAO_0000218,,,4353,1,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,50425,F,,CHEMBL620987,,10805,5833.0,Expert,,,1,N,Plasmodium falciparum,
,BAO_0000218,,,4354,1,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,50425,F,,CHEMBL620988,,10805,5833.0,Expert,,,1,N,Plasmodium falciparum,
,BAO_0000218,,,4355,1,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,50425,F,,CHEMBL620989,,10805,5833.0,Expert,,,1,N,Plasmodium falciparum,
,BAO_0000218,,,4356,1,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,50425,F,,CHEMBL620990,,10805,5833.0,Expert,,,1,N,Plasmodium falciparum,
,BAO_0000218,,,4357,1,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,50425,F,,CHEMBL620991,,10805,5833.0,Intermediate,,,1,N,Plasmodium falciparum,
,BAO_0000218,,,4358,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,80628,F,850.0,CHEMBL620992,6C3HED,10144,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4359,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,80628,F,850.0,CHEMBL620993,6C3HED,10144,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4360,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,80628,F,850.0,CHEMBL620994,6C3HED,10144,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4361,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,80628,F,850.0,CHEMBL620995,6C3HED,10144,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4362,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,80628,F,850.0,CHEMBL620996,6C3HED,10144,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4363,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,80628,F,850.0,CHEMBL875581,6C3HED,10144,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4364,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,22224,F,,CHEMBL620997,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4365,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,22224,F,,CHEMBL620998,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4366,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),22224,F,,CHEMBL620999,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4367,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,22224,F,,CHEMBL621000,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4368,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,22224,F,,CHEMBL621001,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4369,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,22224,F,,CHEMBL621002,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4370,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,22224,F,,CHEMBL621003,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4371,1,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",22224,F,,CHEMBL621004,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4372,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),22224,F,,CHEMBL621005,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4373,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),22224,F,,CHEMBL621006,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,4374,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,22224,F,,CHEMBL621007,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4375,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,22224,F,,CHEMBL621008,,10144,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4376,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,22224,F,,CHEMBL621009,,10144,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4377,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,22224,F,,CHEMBL857705,,10144,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4378,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,22224,F,,CHEMBL619828,,10144,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4379,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,22224,F,,CHEMBL619829,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4380,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,22224,F,,CHEMBL619830,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4381,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,22224,F,,CHEMBL619831,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4382,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,22224,F,,CHEMBL619832,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4383,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,22224,A,,CHEMBL619833,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4384,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,22224,A,,CHEMBL619834,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4385,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,22224,A,,CHEMBL619835,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4386,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,22224,A,,CHEMBL619836,,10685,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000218,,,4387,1,,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",80628,F,850.0,CHEMBL619837,6C3HED,8831,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4388,1,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,22224,F,,CHEMBL619838,,11704,,Autocuration,,,0,U,,
,BAO_0000218,,,4389,1,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,50594,A,,CHEMBL619839,,11704,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4390,1,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,80628,F,850.0,CHEMBL619840,6C3HED,10685,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4391,1,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,80628,F,850.0,CHEMBL619841,6C3HED,10685,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4392,1,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),80628,F,850.0,CHEMBL857704,6C3HED,11368,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000218,,,4393,1,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),80628,F,850.0,CHEMBL619842,6C3HED,11368,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4394,1,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),80628,F,850.0,CHEMBL619843,6C3HED,11368,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000019,,,4395,1,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",22226,B,,CHEMBL619844,,17763,1280.0,Autocuration,,,0,U,Staphylococcus aureus,
,BAO_0000251,Liver,,4396,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,22226,B,,CHEMBL857855,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4397,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,B,,CHEMBL619845,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4398,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,22226,B,,CHEMBL619846,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4399,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,22226,B,,CHEMBL619847,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4400,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,22226,B,,CHEMBL619848,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4401,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,22226,B,,CHEMBL620893,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4402,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,22226,B,,CHEMBL620894,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4403,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,22226,B,,CHEMBL620895,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4404,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,B,,CHEMBL620896,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4405,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,B,,CHEMBL620897,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4406,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,B,,CHEMBL620898,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
,BAO_0000251,Liver,,4407,1,,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,B,,CHEMBL620899,,7411,10116.0,Autocuration,,,0,U,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Plasma,,4408,1,,,The apparent total plasma clearance in monkey,22224,A,,CHEMBL620900,,347,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,,,4409,1,,,Compound was evaluated for Hepatic clearance in monkey,22224,A,,CHEMBL620901,,3341,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4410,1,,,Lower clearance in monkey (i.v.) at 0.5 mpk,22224,A,,CHEMBL620902,,17853,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4411,1,,,Plasma clearance in rhesus monkey,22224,A,,CHEMBL620903,,4514,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4412,1,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,22224,A,,CHEMBL620904,,6062,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4413,1,,,Plasma clearance of compound was determined in monkey,22224,A,,CHEMBL620905,,6821,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4414,1,,,Plasma clearance was calculated in rhesus monkey,22224,A,,CHEMBL620906,,6057,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4415,1,,,Plasma clearance in rhesus monkey,22224,A,,CHEMBL875420,,5145,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4416,1,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,A,,CHEMBL620907,,6641,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4417,1,,,Plasma clearance was evaluated in rhesus,22224,A,,CHEMBL620908,,5472,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4418,1,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,22224,A,,CHEMBL620909,,4257,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4419,1,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,A,,CHEMBL620910,,5546,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4420,1,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,A,,CHEMBL620911,,5334,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4421,1,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,A,,CHEMBL620912,,5334,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4422,1,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,22224,A,,CHEMBL620913,,17509,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4423,1,,,Cmax in monkey after administration of 1 mg/kg iv,22224,A,,CHEMBL620914,,6535,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4424,1,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,22224,A,,CHEMBL620915,,5668,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4425,1,,,Cmax in cynomolgus monkey by iv administration,22224,A,,CHEMBL620916,,5922,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4426,1,,,Cmax in cynomolgus monkey by po administration,22224,A,,CHEMBL620917,,5922,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4427,1,,,Cmax value evaluated in monkey,22224,A,,CHEMBL620918,,6078,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4428,1,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,A,,CHEMBL620919,,2661,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,Plasma,,4429,1,,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,22224,A,,CHEMBL620920,,3249,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,Plasma,,4430,1,,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,22224,A,,CHEMBL620921,,3249,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,Plasma,,4431,1,,,Maximal plasma concentration in squirrel monkeys,22224,A,,CHEMBL620922,,5553,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,,,4432,1,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,A,,CHEMBL620923,,1916,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,Plasma,,4433,1,,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,22224,A,,CHEMBL620924,,6227,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,,,4434,1,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,A,,CHEMBL620925,,4809,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4435,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,A,,CHEMBL620926,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4436,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,A,,CHEMBL620927,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4437,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,22224,A,,CHEMBL620928,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4438,1,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,22224,A,,CHEMBL620929,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,Plasma,,4439,1,,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,22224,A,,CHEMBL620930,,6221,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
,BAO_0000218,,,4440,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,22224,A,,CHEMBL620931,,167,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,4441,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,22224,A,,CHEMBL620932,,167,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4442,1,,,Absolute bioavailability was evaluated in monkey,22224,A,,CHEMBL620933,,4257,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4443,1,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,22224,A,,CHEMBL620934,,6221,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4444,1,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,22224,A,,CHEMBL620935,,17667,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4445,1,,,Bioavailability of compound was determined in rhesus monkey,22224,A,,CHEMBL620936,,17267,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4446,1,,,Bioavailability determined after oral administration in marmoset,22224,A,,CHEMBL620937,,4256,38020.0,Autocuration,,,0,U,marmosets,
In vivo,BAO_0000218,,,4447,1,,,Oral bioavailability in cynomolgus monkey,22224,A,,CHEMBL620938,,4256,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,4448,1,,,Bioavailability in monkey (p.o.) at 2.0 mpk,22224,A,,CHEMBL620939,,17853,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4449,1,,,Bioavailability was evaluated after oral administration in monkey,22224,A,,CHEMBL620940,,16365,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4450,1,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,A,,CHEMBL620941,,1916,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,4451,1,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,A,,CHEMBL620942,,5334,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4452,1,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,A,,CHEMBL620943,,5334,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4453,1,,,Bioavailability of the compound was determined in monkey,22224,A,,CHEMBL620944,,17592,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4454,1,,,Bioavailability in squirrel monkey (dose 5 mg/kg),22224,A,,CHEMBL620945,,1399,9521.0,Autocuration,,,0,U,Saimiri sciureus,
In vivo,BAO_0000218,,,4455,1,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,A,,CHEMBL620946,,4809,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4456,1,,,Oral bioavailability in monkey,22224,A,,CHEMBL620947,,3341,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4457,1,,,Compound was tested for bioavailability in squirrel monkey,22224,A,,CHEMBL620948,,64,9521.0,Autocuration,,,0,U,Saimiri sciureus,
In vivo,BAO_0000218,,,4458,1,,,Oral bioavailability in Rhesus monkey,22224,A,,CHEMBL620949,,5005,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4459,1,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),22224,A,,CHEMBL620950,,5005,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4460,1,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,22224,A,,CHEMBL620951,,5237,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,4461,1,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,22224,A,,CHEMBL620952,,5237,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,4462,1,,,Oral bioavailability in monkey (dose 5 mg/kg),22224,A,,CHEMBL875421,,5302,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4463,1,,,Oral bioavailability of compound at 5 mg/kg in monkey,22224,A,,CHEMBL620953,,17667,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4464,1,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,A,,CHEMBL873491,,6161,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,4465,1,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,50588,A,,CHEMBL620954,,6161,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,4466,1,,,Plasma half life determined,50588,A,,CHEMBL620955,,3854,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,4467,1,,,Plasma half life in dog,50588,A,,CHEMBL618097,,993,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,4468,1,,,Plasma half-life in Beagle dogs,50588,A,,CHEMBL618268,,4514,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,4469,1,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,A,,CHEMBL618269,,5334,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,4470,1,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),50588,A,,CHEMBL618270,,5334,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,4471,1,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,50588,A,,CHEMBL618271,,1466,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,4472,1,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,50588,A,,CHEMBL873493,,1466,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,4473,1,,,Tested for the half life period in dog,50588,A,,CHEMBL621031,,5313,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,4474,1,,,Tested for the half life period in dog at dosage of 10 mpk,50588,A,,CHEMBL621032,,5313,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,4475,1,,,The compound was tested for half life in dog,50588,A,,CHEMBL621033,,3880,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,4476,1,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",50588,A,,CHEMBL621034,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,4477,1,,,The half life was determined,50588,A,,CHEMBL621035,,3880,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,4478,1,,,The plasma half-life in dogs,50588,A,,CHEMBL621036,,3918,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,4479,1,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,50588,A,,CHEMBL621037,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,4480,1,,,Half life in dog,50588,A,,CHEMBL619812,,17796,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,4481,1,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,A,,CHEMBL619813,,5983,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,4482,1,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,50588,A,,CHEMBL873335,,1466,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,4483,1,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,A,,CHEMBL619814,,16456,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,4484,1,,,Cmax in ferrets after 30 mg/kg oral dose,50506,A,,CHEMBL619815,,6113,9669.0,Expert,,,1,N,Mustela putorius furo,
In vivo,BAO_0000218,,,4485,1,,,Emesis in ferrets at 30 mg/kg oral dose,50506,F,,CHEMBL619816,,6113,9669.0,Expert,,,1,N,Mustela putorius furo,
In vivo,BAO_0000218,,,4486,1,,,Bioavailability in cynomolgus monkey,22224,A,,CHEMBL619817,,17796,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,4487,1,,,Volume of distribution in cynomolgus,100710,A,,CHEMBL619818,,17796,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,Plasma,,4488,1,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,22224,A,,CHEMBL619819,,5308,10141.0,Autocuration,,,0,U,Cavia porcellus,1969.0
,BAO_0000218,,,4489,1,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,A,,CHEMBL619820,,4877,10141.0,Autocuration,,,0,U,Cavia porcellus,
,BAO_0000218,,,4490,1,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",22224,A,,CHEMBL875419,,4876,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,Plasma,,4491,1,,,AUC in guinea pig after 3mg/kg oral dose,22224,A,,CHEMBL619821,,4878,10141.0,Autocuration,,,0,U,Cavia porcellus,1969.0
In vivo,BAO_0000218,,,4492,1,,,Bioavailability in guinea pig was tested,22224,A,,CHEMBL619822,,5308,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4493,1,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,22224,A,,CHEMBL619823,,4877,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4494,1,,,Tested for the oral bioavailability of the compound,22224,A,,CHEMBL619824,,4876,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4495,1,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,22224,A,,CHEMBL619825,,4876,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4496,1,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,22224,A,,CHEMBL619826,,5308,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,Lung,,4497,1,,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,A,,CHEMBL619827,,4877,10141.0,Autocuration,,,0,U,Cavia porcellus,2048.0
In vivo,BAO_0000218,,,4498,1,,,Cmax in guinea pig after 3mg/kg oral dose,22224,A,,CHEMBL618167,,4878,10141.0,Autocuration,,,0,U,Cavia porcellus,
,BAO_0000019,Blood,,4499,1,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,22224,A,,CHEMBL618168,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,178.0
,BAO_0000019,Brain,,4500,1,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,22224,A,,CHEMBL618169,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,955.0
,BAO_0000019,,,4501,1,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,22224,A,,CHEMBL618170,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,
,BAO_0000019,Intestine,,4502,1,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,22224,A,,CHEMBL618171,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,160.0
,BAO_0000019,Kidney,,4503,1,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,22224,A,,CHEMBL618172,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,2113.0
,BAO_0000019,Liver,,4504,1,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,22224,A,,CHEMBL618173,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,2107.0
,BAO_0000019,,,4505,1,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,22224,A,,CHEMBL618174,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,
,BAO_0000019,Spleen,,4506,1,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,22224,A,,CHEMBL875408,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,2106.0
In vivo,BAO_0000218,,,4507,1,,,Elimination T1/2 in Guinea pig (PO dose),22224,A,,CHEMBL839827,,14465,10141.0,Autocuration,,,0,U,Cavia porcellus,
,BAO_0000019,,,4508,1,,,Partition coefficient was measured as -log (counts per min ),22224,A,,CHEMBL618175,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4509,1,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,A,,CHEMBL618176,,611,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4510,1,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,A,,CHEMBL618177,,611,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4511,1,,,Elimination T1/2 in Guinea pig (PO dose),22224,A,,CHEMBL618178,,14465,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4512,1,,,"Tested for the half life period of the compound, intravenously",22224,A,,CHEMBL618179,,4876,10141.0,Autocuration,,,0,U,Cavia porcellus,
,BAO_0000019,,,4513,1,,,Half-life was measured,22224,A,,CHEMBL873489,,5689,10141.0,Autocuration,,,0,U,Cavia porcellus,
,BAO_0000019,,,4514,1,,,The time required for onset of inotropy after addition of a single dose of delta F75,22224,A,,CHEMBL618180,,7515,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4515,1,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,22224,A,,CHEMBL618181,,17667,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4516,1,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,22224,A,,CHEMBL618182,,17667,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,4517,1,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,A,,CHEMBL618183,,4727,10029.0,Autocuration,,,0,U,Cricetulus griseus,
In vivo,BAO_0000218,,,4518,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL618184,,10107,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4519,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,A,,CHEMBL618185,,10107,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4520,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL618186,,10107,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4521,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL618187,,10107,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4522,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,50594,A,,CHEMBL618188,,10107,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4523,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL875409,,10107,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4524,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL618189,,10107,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Blood,,4525,1,,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618190,,3655,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,4526,1,,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618191,,3655,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,4527,1,,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,50594,A,,CHEMBL618192,,3655,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Bone,,4528,1,,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618193,,3655,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,4529,1,,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618194,,3655,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,4530,1,,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,50594,A,,CHEMBL618195,,3655,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Brain,,4531,1,,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618196,,3655,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,4532,1,,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618197,,3655,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,4533,1,,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,50594,A,,CHEMBL618198,,3655,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Heart,,4534,1,,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618199,,3655,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,4535,1,,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618200,,3655,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,4536,1,,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,50594,A,,CHEMBL618201,,3655,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Intestine,,4537,1,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618202,,3655,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Intestine,,4538,1,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618203,,3655,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Intestine,,4539,1,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,50594,A,,CHEMBL618204,,3655,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Kidney,,4540,1,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618205,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,4541,1,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618206,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,4542,1,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,50594,A,,CHEMBL618207,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,4543,1,,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618208,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,4544,1,,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618932,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,4545,1,,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,50594,A,,CHEMBL618933,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Lung,,4546,1,,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618934,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,4547,1,,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618935,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,4548,1,,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,50594,A,,CHEMBL618936,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Muscle tissue,,4549,1,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL618937,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,4550,1,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL618938,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,4551,1,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,50594,A,,CHEMBL619104,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Spleen,,4552,1,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL619105,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,4553,1,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL619106,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,4554,1,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,50594,A,,CHEMBL619107,,3655,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Stomach,,4555,1,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,50594,A,,CHEMBL875410,,3655,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,4556,1,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,50594,A,,CHEMBL619108,,3655,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,4557,1,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,50594,A,,CHEMBL619109,,3655,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,,,4558,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,A,,CHEMBL619110,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4559,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,F,,CHEMBL619111,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4560,1,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,50594,A,,CHEMBL619112,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4561,1,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,50594,A,,CHEMBL619113,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4562,1,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,50594,A,,CHEMBL619114,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4563,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,F,,CHEMBL619115,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,4564,1,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,81034,F,478.0,CHEMBL619116,A2780,3830,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4565,1,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,81034,F,478.0,CHEMBL619117,A2780,3829,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4566,1,,,Compound was evaluated for cytotoxicity against A2780 cell lines.,81034,F,478.0,CHEMBL619118,A2780,2040,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4567,1,,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,81034,F,478.0,CHEMBL619119,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4568,1,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,F,478.0,CHEMBL619120,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4569,1,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,F,478.0,CHEMBL619121,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4570,1,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,F,478.0,CHEMBL619122,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4571,1,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,F,478.0,CHEMBL619123,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4572,1,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,F,478.0,CHEMBL619124,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4573,1,,,Compound was evaluated for cytotoxicity against A2780 cell line,81034,F,478.0,CHEMBL619125,A2780,2859,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4574,1,,,In vitro inhibitory activity against human tumor cell line A2780,81034,F,478.0,CHEMBL875411,A2780,5618,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4575,1,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,81034,F,478.0,CHEMBL619126,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4576,1,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,F,478.0,CHEMBL619127,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4577,1,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,F,478.0,CHEMBL619128,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4578,1,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,F,478.0,CHEMBL619129,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4579,1,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,81034,F,478.0,CHEMBL619130,A2780,2113,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4580,1,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,81034,F,478.0,CHEMBL619131,A2780,2113,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4581,1,,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,81034,F,478.0,CHEMBL619132,A2780,16745,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,4582,1,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,F,478.0,CHEMBL619133,A2780,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4583,1,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,F,478.0,CHEMBL619134,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4584,1,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,F,478.0,CHEMBL619135,A2780,15684,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4585,1,,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,81034,F,478.0,CHEMBL619136,A2780,2040,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4586,1,,,Relative resistance factor in A2780 cisplatin-resistant line,81034,F,478.0,CHEMBL619137,A2780,2040,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4587,1,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,81034,F,478.0,CHEMBL883713,A2780,16165,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4588,1,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,81034,F,478.0,CHEMBL875412,A2780,16165,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,4589,1,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,F,478.0,CHEMBL619138,A2780,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000218,,,4590,1,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,F,478.0,CHEMBL619262,A2780,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4591,1,,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,81034,F,478.0,CHEMBL619139,A2780,3992,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4592,1,,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,81034,F,478.0,CHEMBL619140,A2780,10553,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4593,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,81034,F,478.0,CHEMBL619141,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4594,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,81034,F,478.0,CHEMBL619142,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4595,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,81034,F,478.0,CHEMBL619143,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4596,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,81034,F,478.0,CHEMBL619144,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4597,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,81034,F,478.0,CHEMBL619145,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4598,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,81034,F,478.0,CHEMBL619146,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4599,1,,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,81034,F,478.0,CHEMBL619147,A2780,15569,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4600,1,,,Antiproliferative effect of compound on A2780/DX cell line,81034,F,478.0,CHEMBL619148,A2780,17420,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4601,1,,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,81034,F,478.0,CHEMBL619149,A2780,17420,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4602,1,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),81034,F,478.0,CHEMBL619150,A2780,15099,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4603,1,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),81034,F,478.0,CHEMBL619151,A2780,15099,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4604,1,,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,81034,F,478.0,CHEMBL883794,A2780,17672,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4605,1,,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,81034,F,478.0,CHEMBL619152,A2780,17672,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4606,1,,,In vitro cytotoxicity against A2780ADR cell line,81034,F,478.0,CHEMBL619153,A2780,17270,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4607,1,,,In vitro cytotoxicity against A2780CIS cell line,81034,F,478.0,CHEMBL619154,A2780,17270,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4608,1,,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,81034,F,478.0,CHEMBL619155,A2780,5574,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4609,1,,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,81034,F,478.0,CHEMBL619156,A2780,2113,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4610,1,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,F,478.0,CHEMBL619157,A2780,16913,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4611,1,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,F,478.0,CHEMBL619797,A2780,16913,9606.0,Intermediate,,,1,N,Homo sapiens,
In vivo,BAO_0000218,,,4612,1,,,Oral bioavailability of compound in rhesus macaques,22224,A,,CHEMBL619798,,17839,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4613,1,,,Oral bioavailability in monkey,22224,A,,CHEMBL619799,,6821,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4614,1,,,Oral bioavailability evaluated in monkey,22224,A,,CHEMBL619800,,6078,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4615,1,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),22224,A,,CHEMBL619801,,6535,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4616,1,,,Oral bioavailability in Rhesus monkey,22224,A,,CHEMBL619802,,4449,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4617,1,,,Oral bioavailability was calculated in rhesus monkey,22224,A,,CHEMBL619803,,6057,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4618,1,,,Oral bioavailability in cynomolgus monkey,22224,A,,CHEMBL619965,,5922,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,4619,1,,,Oral bioavailability in monkey,22224,A,,CHEMBL619966,,5940,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4620,1,,,Oral bioavailability in monkey,22224,A,,CHEMBL619967,,6265,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4621,1,,,Oral bioavailability in monkey (dose 1 mg/kg),22224,A,,CHEMBL620073,,6265,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4622,1,,,Oral bioavailability in monkey (dose 5 mg/kg),22224,A,,CHEMBL620074,,6265,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4623,1,,,Oral bioavailability in monkey,22224,A,,CHEMBL620075,,5940,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4624,1,,,Oral bioavailability in monkey,22224,A,,CHEMBL620076,,5940,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4625,1,,,Oral bioavailability in rhesus monkey,22224,A,,CHEMBL620077,,4514,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4626,1,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,22224,A,,CHEMBL620078,,5546,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4627,1,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,22224,A,,CHEMBL620079,,5553,9521.0,Autocuration,,,0,U,Saimiri sciureus,
In vivo,BAO_0000218,,,4628,1,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,A,,CHEMBL620080,,6641,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4629,1,,,Oral bioavailability in Rhesus monkey,22224,A,,CHEMBL620081,,5472,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4630,1,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),22224,A,,CHEMBL620082,,5668,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4631,1,,,Oral bioavailability in monkey at 10 mg/kg of the compound,22224,A,,CHEMBL620083,,5711,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,4632,1,,,Bioavailability in Rhesus monkey,22224,A,,CHEMBL620084,,5145,9544.0,Autocuration,,,0,U,Macaca mulatta,
,BAO_0000218,,,4633,1,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL620085,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,4634,1,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL874595,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4635,1,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,22224,A,,CHEMBL873352,,3249,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4636,1,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,22224,A,,CHEMBL620086,,3249,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4637,1,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,22224,A,,CHEMBL620087,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4638,1,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,A,,CHEMBL620088,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4639,1,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,A,,CHEMBL620089,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4640,1,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,A,,CHEMBL620090,,4809,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4641,1,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,A,,CHEMBL620091,,4809,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000251,,,4642,1,,Microsomes,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),22224,A,,CHEMBL620092,,14294,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000251,,,4643,1,,Microsomes,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),22224,A,,CHEMBL620093,,14294,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000251,,,4644,1,,Microsomes,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),22224,A,,CHEMBL620094,,14294,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000251,,,4645,1,,Microsomes,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),22224,A,,CHEMBL620095,,14294,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4646,1,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL620096,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4647,1,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL620097,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4648,1,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,22224,A,,CHEMBL620098,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,4649,1,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL620099,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,4650,1,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL620100,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4651,1,,,Elimination Half-life of compound was determined in monkey,22224,A,,CHEMBL620101,,6821,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4652,1,,,Half life of compound was determined in rhesus monkey,22224,A,,CHEMBL620102,,17267,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000366,Plasma,,4653,1,,,Half life in monkey plasma,22224,A,,CHEMBL620103,,5819,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
,BAO_0000366,Plasma,,4654,1,,,Half life in monkey plasma; Not detected,22224,A,,CHEMBL620104,,5819,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,,,4655,1,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,A,,CHEMBL874596,,1916,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4656,1,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,22224,A,,CHEMBL873490,,17509,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4657,1,,,Terminal half life of the compound.,22224,A,,CHEMBL620105,,1399,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4658,1,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,A,,CHEMBL620780,,1916,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4659,1,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,A,,CHEMBL620781,,4809,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,4660,1,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,A,,CHEMBL620956,,5546,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,Urine,,4661,1,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL620957,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,1088.0
,BAO_0000218,Urine,,4662,1,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL620958,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,1088.0
In vivo,BAO_0000218,,,4663,1,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,22224,A,,CHEMBL620959,,4257,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4664,1,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,22224,A,,CHEMBL620960,,6221,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4665,1,,,Volume of distribution was evaluated in rhesus,22224,A,,CHEMBL620961,,5472,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4666,1,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,A,,CHEMBL620962,,4727,10029.0,Autocuration,,,0,U,Cricetulus griseus,
In vivo,BAO_0000218,,,4667,1,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,22224,A,,CHEMBL620963,,4727,10029.0,Autocuration,,,0,U,Cricetulus griseus,
In vivo,BAO_0000218,,,4668,1,,,Bioavailability in hamster was determined,22224,A,,CHEMBL620964,,4727,10029.0,Autocuration,,,0,U,Cricetulus griseus,
In vivo,BAO_0000218,,,4669,1,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,22224,A,,CHEMBL620965,,4727,10029.0,Autocuration,,,0,U,Cricetulus griseus,
In vivo,BAO_0000218,,,4670,1,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,22224,A,,CHEMBL620966,,4727,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000221,Blood,,4671,1,,,Half life of compound was determined in hamster blood,22224,A,,CHEMBL620967,,4727,10029.0,Autocuration,,,0,U,Cricetulus griseus,178.0
,BAO_0000019,,,4672,1,,,Michaelis-Menten constant of the compound.,22224,A,,CHEMBL620968,,1452,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000019,,,4673,1,,,Vmax value was measured at 0 uM concentration of silyl ether.,22224,A,,CHEMBL874597,,1452,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000019,,,4674,1,,,Vmax value was measured at 10 uM concentration of silyl ether.,22224,A,,CHEMBL620969,,1452,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000019,,,4675,1,,,Vmax value was measured at 5 uM concentration of silyl ether.,22224,A,,CHEMBL620970,,1452,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000357,,,4676,1,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,235,B,,CHEMBL620971,,11706,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000218,,,4677,1,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,22224,A,,CHEMBL620972,,1916,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4678,1,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),22224,A,,CHEMBL620973,,17791,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4679,1,,,Active metabolite of ifosfamide determined in humans; A-Active,22224,A,,CHEMBL618243,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4680,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,22224,A,,CHEMBL618244,,6567,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4681,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,22224,A,,CHEMBL618245,,6567,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4682,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,22224,A,,CHEMBL618246,,6567,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4683,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,22224,A,,CHEMBL618247,,6567,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000218,,,4684,1,,,Compound was evaluated for oral bioavailability in human,22224,A,,CHEMBL618248,,17791,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,Urine,,4685,1,,,Metabolite of ifosfamide determined in urine; NF-Not found,22224,A,,CHEMBL618249,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,,,4686,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),22224,A,,CHEMBL618250,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4687,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,22224,A,,CHEMBL874598,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4688,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,22224,A,,CHEMBL618251,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4689,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,22224,A,,CHEMBL618252,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4690,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,22224,A,,CHEMBL618253,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4691,1,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),22224,A,,CHEMBL618254,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4692,1,,,Percent of compound in healthy individuals (Group D),22224,A,,CHEMBL618255,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,Liver,,4693,1,,Microsomes,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,A,,CHEMBL618983,,4397,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000019,,,4694,1,,,Binding towards human plasma protein at 10 uM,22224,A,,CHEMBL618984,,17409,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4695,1,,,Binding towards human plasma protein at 100 uM,22224,A,,CHEMBL618985,,17409,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4696,1,,,Human plasma protein binding activity was determined,22224,A,,CHEMBL618986,,17176,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4697,1,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,A,,CHEMBL618987,,15444,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4698,1,,,Percent binding of compound towards human plasma protein was determined,22224,A,,CHEMBL618988,,17267,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,Liver,,4699,1,,Microsomes,Plasma clearance in human liver microsomes,22224,A,,CHEMBL618989,,5944,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vitro,BAO_0000251,Liver,,4700,1,,Microsomes,In vitro intrinsic clearance in human liver microsome,22224,A,,CHEMBL618990,,5668,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vitro,BAO_0000251,Liver,,4701,1,,Microsomes,In vitro intrinsic clearance in human liver microsome,22224,A,,CHEMBL618991,,5669,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vitro,BAO_0000251,,,4702,1,,Microsomes,In vitro microsome metabolism clearance in human was determined,22224,A,,CHEMBL876725,,5041,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,,,4703,1,,Microsomes,In vitro microsome metabolism clearance in human was determined; High,22224,A,,CHEMBL618992,,5041,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,,,4704,1,,Microsomes,In vitro microsome metabolism clearance in human was determined; ND denotes no data,22224,A,,CHEMBL618993,,5041,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,Liver,,4705,1,,Microsomes,Pharmacokinetic property (clearance) in human liver microsome,22224,A,,CHEMBL618994,,5676,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vitro,BAO_0000251,Liver,,4706,1,,Microsomes,Plasma clearance in human liver microsomes,22224,A,,CHEMBL618995,,5944,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vitro,BAO_0000251,Liver,,4707,1,,Microsomes,In vitro clearance in human liver microsomes,22224,A,,CHEMBL618996,,17538,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vitro,BAO_0000251,Liver,,4708,1,,Microsomes,Intrinsic clearance in human liver microsomes was determined,22224,A,,CHEMBL618997,,6331,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vitro,BAO_0000251,Liver,,4709,1,,Microsomes,Intrinsic clearance in human liver microsomes was determined,22224,A,,CHEMBL618998,,5948,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vivo,BAO_0000218,,,4710,1,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,22224,A,,CHEMBL618999,,5965,9606.0,Autocuration,,,0,U,Homo sapiens,
In vivo,BAO_0000218,,,4711,1,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,22224,A,,CHEMBL620223,,1916,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000218,,,4712,1,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,22224,A,,CHEMBL620224,,5965,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4713,1,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,22224,A,,CHEMBL620225,,1299,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4714,1,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,22224,A,,CHEMBL620226,,1299,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,Urine,,4715,1,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,A,,CHEMBL620227,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4716,1,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,A,,CHEMBL876726,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4717,1,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,A,,CHEMBL620228,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4718,1,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,A,,CHEMBL620229,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
In vivo,BAO_0000218,,,4719,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,F,,CHEMBL620230,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4720,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,F,,CHEMBL620231,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4721,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,F,,CHEMBL620232,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4722,1,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,50594,F,,CHEMBL620233,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4723,1,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),50594,A,,CHEMBL620234,,14294,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4724,1,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),50594,A,,CHEMBL620235,,14294,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4725,1,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),50594,A,,CHEMBL620236,,14294,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Liver,,4726,1,,,In vitro metabolic potential in mouse liver microsomes,50594,A,,CHEMBL620237,,6251,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,,,4727,1,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,50594,A,,CHEMBL620238,,17582,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Adrenal gland,,4728,1,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),50594,A,,CHEMBL620239,,17811,10090.0,Intermediate,,,1,N,Mus musculus,2369.0
,BAO_0000218,Brain,,4729,1,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,50594,A,,CHEMBL620240,,17811,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Brain,,4730,1,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,50594,A,,CHEMBL620241,,17811,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,,,4731,1,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),50594,A,,CHEMBL876727,,17811,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Kidney,,4732,1,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),50594,A,,CHEMBL620242,,17811,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
,BAO_0000218,,,4733,1,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),50594,A,,CHEMBL620243,,17811,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4734,1,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,50594,A,,CHEMBL620244,,5288,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Serum,,4735,1,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,50594,A,,CHEMBL620245,,2717,10090.0,Intermediate,,,1,N,Mus musculus,1977.0
,BAO_0000218,Serum,,4736,1,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,50594,A,,CHEMBL620246,,2717,10090.0,Intermediate,,,1,N,Mus musculus,1977.0
,BAO_0000218,Serum,,4737,1,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,50594,A,,CHEMBL620247,,2717,10090.0,Intermediate,,,1,N,Mus musculus,1977.0
In vivo,BAO_0000218,Plasma,,4738,1,,,Half life of compound was determined in plasma of mice at 24 mg/Kg,50594,A,,CHEMBL620248,,17753,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,4739,1,,,Half life of compound was determined in plasma of mice at 40 mg/Kg,50594,A,,CHEMBL873497,,17753,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,4740,1,,,Half life of compound was determined in plasma of mice at 5 mg/Kg,50594,A,,CHEMBL620249,,17753,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,,,4741,1,,,Half life after intraperitoneal administration in mice at 18 uM/kg,50594,F,,CHEMBL620250,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4742,1,,,Half life after intraperitoneal administration in mice at 23 uM/kg,50594,F,,CHEMBL620251,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4743,1,,,Half life after intraperitoneal administration in mice at 25 uM/kg,50594,F,,CHEMBL620252,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4744,1,,,Half life after intraperitoneal administration in mice at 26 uM/kg,50594,F,,CHEMBL620253,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4745,1,,,Half life after intravenous administration in mice at 23 uM/kg,50594,F,,CHEMBL620254,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4746,1,,,Half life after intravenous administration in mice at 24 uM/kg,50594,A,,CHEMBL620255,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4747,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,A,,CHEMBL620256,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4748,1,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,50594,A,,CHEMBL876728,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4749,1,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,50594,A,,CHEMBL620257,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4750,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,A,,CHEMBL620258,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4751,1,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",50594,A,,CHEMBL620259,,4890,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4752,1,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,50594,A,,CHEMBL620260,,429,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Blood,,4753,1,,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,50594,A,,CHEMBL620261,,17837,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,,,4754,1,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,50594,A,,CHEMBL620262,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4755,1,,,Half life at a dose of 10 mg/kg peroral administration in mice.,50594,A,,CHEMBL620263,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4756,1,,,Half life in ob/ob mice,50594,A,,CHEMBL620264,,6619,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4757,1,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,50594,A,,CHEMBL620265,,4066,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4758,1,,,Half-life was measured in mouse,50594,A,,CHEMBL620266,,4239,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4759,1,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,50594,A,,CHEMBL620267,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4760,1,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,50594,A,,CHEMBL619364,,8999,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4761,1,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,50594,A,,CHEMBL619365,,8999,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Brain,,4762,1,,,T2 in brain of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL619366,,17641,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Kidney,,4763,1,,,T2 in kidney of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL619367,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
,BAO_0000218,Liver,,4764,1,,,T2 in liver of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL619368,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Lung,,4765,1,,,T2 in lungs of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL619369,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Spleen,,4766,1,,,T2 in spleen of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL876729,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,,,4767,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,A,,CHEMBL619370,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4768,1,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",50594,A,,CHEMBL619371,,4890,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4769,1,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,50594,A,,CHEMBL619372,,429,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4770,1,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,50594,A,,CHEMBL620012,,429,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4771,1,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,50594,A,,CHEMBL620013,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,4772,1,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,F,478.0,CHEMBL620014,A2780,16913,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4773,1,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,F,478.0,CHEMBL620015,A2780,16913,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4774,1,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,F,478.0,CHEMBL621010,A2780,16913,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4775,1,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,F,478.0,CHEMBL621011,A2780,16913,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4776,1,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,F,478.0,CHEMBL621012,A2780,16913,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4777,1,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,F,478.0,CHEMBL621013,A2780,16913,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4778,1,,,In vitro cytotoxicity against A2780TAX cell line,81034,F,478.0,CHEMBL621014,A2780,17270,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4779,1,,,In vitro inhibitory activity against human tumor cell line A2780cis,80017,F,481.0,CHEMBL618154,A2780cisR,5618,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4780,1,,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,81034,F,478.0,CHEMBL618155,A2780,17777,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4781,1,,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,80017,F,481.0,CHEMBL618156,A2780cisR,16112,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4782,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,F,481.0,CHEMBL618157,A2780cisR,15748,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4783,1,,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,81034,F,478.0,CHEMBL618328,A2780,6633,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4784,1,,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,81034,F,478.0,CHEMBL618329,A2780,16930,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4785,1,,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,81034,F,478.0,CHEMBL618330,A2780,17496,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4786,1,,,In vitro antitumor activity against A2780cisR cell line.,81034,F,478.0,CHEMBL618331,A2780,12989,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4787,1,,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),81034,F,478.0,CHEMBL618332,A2780,4840,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4788,1,,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,81034,F,478.0,CHEMBL618333,A2780,12989,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4789,1,,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,80017,F,481.0,CHEMBL618334,A2780cisR,16745,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4790,1,,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,81034,F,478.0,CHEMBL618335,A2780,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000019,,,4791,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,11736,B,,CHEMBL618336,,16547,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,4792,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,F,,CHEMBL618337,,16547,,Expert,,,8,H,,
,BAO_0000019,,,4793,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,F,,CHEMBL618338,,16547,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000219,,,4794,1,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,278,F,722.0,CHEMBL618339,HEK293,15856,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,4795,1,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,278,F,722.0,CHEMBL618340,HEK293,15856,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,4796,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,11831,B,,CHEMBL618341,,16547,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000019,,,4797,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,F,,CHEMBL618342,,16547,,Expert,,,8,H,,
,BAO_0000019,,,4798,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,F,,CHEMBL618343,,16547,10090.0,Expert,,,9,D,Mus musculus,
,BAO_0000357,,,4799,1,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,280,B,,CHEMBL621038,,17402,,Expert,,,8,H,,
,BAO_0000219,,,4800,1,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),22226,F,574.0,CHEMBL621039,T-cells,11746,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,4801,1,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,22226,F,574.0,CHEMBL621040,T-cells,11746,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,4802,1,,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,80018,F,455.0,CHEMBL621041,A-375,5455,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4803,1,,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,80018,F,455.0,CHEMBL621042,A-375,2068,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4804,1,,,In vitro antitumor activity against A375cell line extracted form melanoma,80018,F,455.0,CHEMBL621043,A-375,2683,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4805,1,,,Inhibition of cell growth in (A375) melan cell line,80018,F,455.0,CHEMBL621044,A-375,15313,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4806,1,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,80018,F,455.0,CHEMBL621045,A-375,13739,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4807,1,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,80018,F,455.0,CHEMBL621046,A-375,13739,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4808,1,,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,80018,F,455.0,CHEMBL621047,A-375,14750,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4809,1,,,Antiproliferative activity measured against A427 human lung carcinoma,80019,F,797.0,CHEMBL621048,A-427,14777,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4810,1,,,Antiproliferative activity measured against A427 human lung carcinoma,80019,F,797.0,CHEMBL883798,A-427,14777,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4811,1,,,Cytotoxicity against lung carcinoma A427 tumor cell lines,80019,F,797.0,CHEMBL621049,A-427,17672,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4812,1,,,Inhibition of large cell lung carcinoma (A427),80019,F,797.0,CHEMBL621050,A-427,14368,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4813,1,,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,80019,F,797.0,CHEMBL621051,A-427,14368,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4814,1,,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80019,F,797.0,CHEMBL621052,A-427,13866,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4815,1,,,Inhibitory concentration in human lung carcinoma A427 cell line,80019,F,797.0,CHEMBL621053,A-427,2545,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4816,1,,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,80019,F,797.0,CHEMBL621054,A-427,2545,9606.0,Intermediate,,,1,N,Homo sapiens,
In vivo,BAO_0000218,,,4817,1,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,A,,CHEMBL621055,,6062,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4818,1,,,Tested for volume of distribution upon iv administration to african green monkey,22224,A,,CHEMBL876398,,4578,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4819,1,,,Volume of distribution in monkey,22224,A,,CHEMBL621056,,17592,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4820,1,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,A,,CHEMBL621057,,5005,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4821,1,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,A,,CHEMBL621058,,5005,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,4822,1,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,22224,A,,CHEMBL621059,,5922,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4823,1,,,The distribution volume after intravenous administration in cynomolgus monkeys,22224,A,,CHEMBL621060,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4824,1,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,22224,A,,CHEMBL621061,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4825,1,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,22224,A,,CHEMBL621062,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4826,1,,,Volume displacement was calculated in rhesus monkey,22224,A,,CHEMBL621063,,6057,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4827,1,,,Volume of distribution in steady state was determined in rhesus monkey,22224,A,,CHEMBL621064,,5145,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4828,1,,,Volume of distribution of compound was determined in monkey,22224,A,,CHEMBL621065,,6821,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4829,1,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,A,,CHEMBL621066,,5334,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4830,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,A,,CHEMBL621067,,5334,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4831,1,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,A,,CHEMBL621068,,6641,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4832,1,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,A,,CHEMBL876399,,2661,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4833,1,,,Volume distribution in monkey after administration of 1 mg/kg iv,22224,A,,CHEMBL621069,,6535,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4834,1,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,A,,CHEMBL621070,,4809,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4835,1,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,A,,CHEMBL621071,,6062,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4836,1,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL621072,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4837,1,,,Oral systemic bioavailability upon iv administration to african green monkey,22224,A,,CHEMBL618209,,4578,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4838,1,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,A,,CHEMBL618210,,4809,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4839,1,,,Baboon plasma free fraction. ,22224,A,,CHEMBL618211,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,4840,1,,,Area under the curve was calculated in rhesus monkey after iv administration,22224,A,,CHEMBL618212,,6057,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4841,1,,,Area under the curve was calculated in rhesus monkey after peroral administration,22224,A,,CHEMBL618213,,6057,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4842,1,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,22224,A,,CHEMBL618214,,17853,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4843,1,,,Half life period in monkey after 5 mg/kg dose,22224,A,,CHEMBL873492,,5302,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4844,1,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,22224,A,,CHEMBL618272,,4257,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4845,1,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,22224,A,,CHEMBL618273,,4257,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,Plasma,,4846,1,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,A,,CHEMBL618274,,13501,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,,,4847,1,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,22224,A,,CHEMBL618275,,5394,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4848,1,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,A,,CHEMBL618276,,2661,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4849,1,,,Compound was evaluated for terminal half life in monkey,22224,A,,CHEMBL618277,,3341,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4850,1,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,22224,A,,CHEMBL618278,,3045,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,Plasma,,4851,1,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,A,,CHEMBL618279,,5005,9544.0,Autocuration,,,0,U,Macaca mulatta,1969.0
,BAO_0000019,,,4852,1,,,Half life of compound was determined in squirrel monkey,22224,A,,CHEMBL618280,,4847,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4853,1,,,Half life after iv administration in cynomolgus monkey,22224,A,,CHEMBL618281,,4256,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,Plasma,,4854,1,,,Half life in monkey plasma after administration of 1 mg/kg iv,22224,A,,CHEMBL618282,,6535,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
,BAO_0000019,,,4855,1,,,Half life was calculated in rhesus monkey,22224,A,,CHEMBL618283,,6057,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4856,1,,,Half life in monkey,22224,A,,CHEMBL618284,,17592,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4857,1,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,A,,CHEMBL618285,,6641,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4858,1,,,Half life was evaluated in rhesus,22224,A,,CHEMBL618286,,5472,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4859,1,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,22224,A,,CHEMBL618287,,6221,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4860,1,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,22224,A,,CHEMBL618288,,5668,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4861,1,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,A,,CHEMBL876393,,4809,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4862,1,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,A,,CHEMBL618289,,5546,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4863,1,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,22224,A,,CHEMBL618290,,5553,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4864,1,,,Half-life was calculated in monkey,22224,A,,CHEMBL618291,,6078,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4865,1,,,Half-life in Squirrel monkey,22224,A,,CHEMBL618292,,5147,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,4866,1,,,Half-life in rhesus monkey,22224,A,,CHEMBL618293,,5145,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4867,1,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,22224,A,,CHEMBL618294,,6062,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4868,1,,,Half-life period after intravenous administration in cynomolgus monkeys,22224,A,,CHEMBL618295,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4869,1,,,Half-life period after oral administration in cynomolgus monkeys,22224,A,,CHEMBL618296,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,4870,1,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,22224,A,,CHEMBL618297,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,Urine,,4871,1,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,A,,CHEMBL618298,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4872,1,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,A,,CHEMBL618299,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4873,1,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,A,,CHEMBL618300,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4874,1,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,A,,CHEMBL618301,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4875,1,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,A,,CHEMBL618302,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4876,1,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,A,,CHEMBL876394,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4877,1,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,A,,CHEMBL618303,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,4878,1,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,A,,CHEMBL618304,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
In vivo,BAO_0000218,,,4879,1,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,22224,A,,CHEMBL618305,,1916,9606.0,Autocuration,,,0,U,Homo sapiens,
In vivo,BAO_0000218,,,4880,1,,,Oral bioavailability in human,22224,A,,CHEMBL618306,,16643,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4881,1,,,Compound was tested for human plasma protein binding,22224,A,,CHEMBL618307,,17248,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4882,1,,,Compound was tested for human plasma protein binding; Not determined,22224,A,,CHEMBL618308,,17248,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4883,1,,,Protein binding activity of compound in human plasma; % Free,22224,A,,CHEMBL618309,,6241,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4884,1,,,Unbound fraction (plasma),22224,A,,CHEMBL618310,,17716,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000366,Plasma,,4885,1,,,Half life for the hydrolysis of compound in human blood serum,22224,A,,CHEMBL873353,,17605,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,4886,1,,,Half life period in human plasma using phosphate buffer (0.08 M),22224,A,,CHEMBL618311,,17625,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,4887,1,,,Half life period in human plasma using phosphate buffer (0.1 M),22224,A,,CHEMBL618312,,17625,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,4888,1,,,Half-life in human plasma was determined,22224,A,,CHEMBL618313,,17747,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,,,4889,1,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,22224,A,,CHEMBL618314,,15613,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4890,1,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),22224,A,,CHEMBL618315,,354,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4891,1,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,A,,CHEMBL618316,,3741,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4892,1,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,A,,CHEMBL618317,,3741,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4893,1,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,A,,CHEMBL620138,,3741,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4894,1,,,Partition coefficient (logP),22224,A,,CHEMBL858280,,17599,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4895,1,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,22224,A,,CHEMBL620139,,5486,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,,,4896,1,,Microsomes,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,22224,A,,CHEMBL620140,,5600,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4897,1,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),22224,A,,CHEMBL620141,,14294,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4898,1,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),22224,A,,CHEMBL620142,,14294,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4899,1,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),22224,A,,CHEMBL620143,,14294,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,,,4900,1,,Microsomes,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),22224,A,,CHEMBL620144,,14294,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,,,4901,1,,Microsomes,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),22224,A,,CHEMBL620145,,14294,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,,,4902,1,,Microsomes,Metabolism of compound in human microsomes; Trace,22224,A,,CHEMBL620146,,14294,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,Liver,,4903,1,,Microsomes,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,22224,A,,CHEMBL620147,,6260,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000251,,,4904,1,,Microsomes,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,22224,A,,CHEMBL620148,,6187,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,Liver,,4905,1,,Microsomes,In vitro metabolic potential in human liver microsomes,22224,A,,CHEMBL620149,,6251,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000019,,,4906,1,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,22224,A,,CHEMBL876412,,3246,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4907,1,,,Tested for human plasma protein binding of the compound; Not tested,22224,A,,CHEMBL619352,,17313,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4908,1,,,Compound was tested for percent protein binding (PB) in human,22224,A,,CHEMBL619353,,6227,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,Plasma,,4909,1,,,Protein binding in human plasma,22224,A,,CHEMBL619354,,5530,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,,,4910,1,,,Permeability coefficient (B to A) in Caco-2 cell,22224,A,,CHEMBL619355,,6108,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4911,1,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,22224,A,,CHEMBL619356,,6108,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4912,1,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),22224,A,,CHEMBL619357,,2774,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4913,1,,,In vitro rate of absorption observed as Caco-2 permeability in humans,22224,A,,CHEMBL619358,,16643,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,4914,1,,,Cellular permeability of compound was determined in Caco-2 cells; High,22224,A,495.0,CHEMBL619359,Caco-2,17582,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,4915,1,,,Permeability in Caco-2 cells of compound,22224,A,495.0,CHEMBL619360,Caco-2,6838,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4916,1,,,Permeability coefficient (A to B) in Caco-2 cell,22224,A,,CHEMBL619361,,6108,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4917,1,,,Permeability coefficient (B to A) in Caco-2 cell,22224,A,,CHEMBL619362,,6108,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4918,1,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),22224,A,,CHEMBL619363,,6108,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4919,1,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,22224,A,,CHEMBL618942,,2146,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4920,1,,,Compound was tested for protein binding in human plasma,22224,A,,CHEMBL618943,,4514,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,4921,1,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,22224,A,,CHEMBL618944,,6108,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,Urine,,4922,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,22224,A,,CHEMBL618945,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
In vivo,BAO_0000218,,,4923,1,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,50594,A,,CHEMBL618946,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4924,1,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,A,,CHEMBL876413,,3277,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4925,1,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,A,,CHEMBL618947,,3802,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Plasma,,4926,1,,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,50594,A,,CHEMBL618948,,2862,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,4927,1,,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,A,,CHEMBL618949,,6348,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,,,4928,1,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,50594,F,,CHEMBL618950,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4929,1,,,Tmax after oral administration at 30 mg/kg in ICR mouse,50594,A,,CHEMBL618951,,5781,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4930,1,,,Tmax after peroral administration in mice at 2.4 uM/kg,50594,A,,CHEMBL618952,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4931,1,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,50594,A,,CHEMBL618953,,4066,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Brain,,4932,1,,,Tmax in brain of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL618954,,17641,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Kidney,,4933,1,,,Tmax in kidney of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL618955,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,4934,1,,,Tmax in liver of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL618956,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Lung,,4935,1,,,Tmax in lungs of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL618957,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,,,4936,1,,,Tmax in mice at 18 uM/kg i.p. administration,50594,F,,CHEMBL618958,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4937,1,,,Tmax in mice at 23 uM/kg i.v. administration,50594,F,,CHEMBL618959,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4938,1,,,Tmax in mice at 25 uM/kg i.p. administration,50594,F,,CHEMBL618960,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4939,1,,,Tmax in mice at 26 uM/kg i.p. administration,50594,F,,CHEMBL876723,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Spleen,,4940,1,,,Tmax in spleen of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL618961,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,,,4941,1,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,A,,CHEMBL618962,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4942,1,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,50594,A,,CHEMBL618963,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4943,1,,,Tmax value in IRC mice,50594,A,,CHEMBL618964,,5951,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4944,1,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,A,,CHEMBL618965,,5506,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4945,1,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,A,,CHEMBL618966,,5506,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Urine,,4946,1,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),50594,A,,CHEMBL618967,,429,10090.0,Intermediate,,,1,N,Mus musculus,1088.0
,BAO_0000218,Urine,,4947,1,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),50594,A,,CHEMBL618968,,429,10090.0,Intermediate,,,1,N,Mus musculus,1088.0
,BAO_0000218,Urine,,4948,1,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),50594,A,,CHEMBL618969,,4066,10090.0,Intermediate,,,1,N,Mus musculus,1088.0
,BAO_0000218,,,4949,1,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,A,,CHEMBL618970,,17734,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,4950,1,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,A,,CHEMBL618971,,17734,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4951,1,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,A,,CHEMBL618972,,6062,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4952,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,50594,A,,CHEMBL618973,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4953,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,50594,A,,CHEMBL618974,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4954,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,A,,CHEMBL618975,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4955,1,,,Vd in mice,50594,A,,CHEMBL618976,,5980,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4956,1,,,Volume of distribution in mouse,50594,A,,CHEMBL618977,,17592,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4957,1,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,A,,CHEMBL876724,,6348,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4958,1,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,50594,A,,CHEMBL618978,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4959,1,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,50594,A,,CHEMBL618979,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4960,1,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,50594,A,,CHEMBL618980,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4961,1,,,Pharmacokinetic property (vdss) was measured in mouse,50594,A,,CHEMBL618981,,4239,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4962,1,,,Value distribution upon iv administration in mouse,50594,A,,CHEMBL618982,,2862,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4963,1,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,A,,CHEMBL620150,,17734,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4964,1,,,Volume of distribution was evaluated in mice after intravenous administration,50594,A,,CHEMBL620151,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4965,1,,,Volume of distribution was evaluated in mice after oral administration,50594,A,,CHEMBL620152,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4966,1,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,50594,A,,CHEMBL620153,,17837,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4967,1,,,Steady state volume of distribution was determined in mice,50594,A,,CHEMBL876395,,5727,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4968,1,,,Volume distribution (steady state) of compound was determined in mouse,50594,A,,CHEMBL620154,,17852,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4969,1,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,50594,A,,CHEMBL620155,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4970,1,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,50594,A,,CHEMBL620156,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,4971,1,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,A,,CHEMBL620157,,6062,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Kidney,,4972,1,,,Biodistribution of compound (oxidized form) in in kidney tissue,50594,A,,CHEMBL620158,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Blood,,4973,1,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,A,,CHEMBL620159,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,4974,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,A,,CHEMBL620160,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,4975,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL620161,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000219,,,4976,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,80019,F,797.0,CHEMBL620162,A-427,10708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4977,1,,,Inhibition of A431 human squamous cell carcinoma cell proliferation,80852,F,500.0,CHEMBL620163,A-431,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4978,1,,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,80852,F,500.0,CHEMBL620833,A-431,16062,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4979,1,,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,80852,F,500.0,CHEMBL876396,A-431,16062,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4980,1,,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,80852,F,500.0,CHEMBL620834,A-431,16958,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4981,1,,,Inhibition of A431 human carcinoma cell proliferation,80852,F,500.0,CHEMBL620835,A-431,6700,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4982,1,,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,80852,F,500.0,CHEMBL620836,A-431,17226,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4983,1,,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,80852,F,500.0,CHEMBL620837,A-431,6828,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4984,1,,,In vitro cytotoxicity against epidermoid carcinoma cell line,80852,F,500.0,CHEMBL621017,A-431,12314,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,4985,1,,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9,F,500.0,CHEMBL621018,A-431,13412,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,4986,1,,,Antiproliferative activity of compound was measured on human tumor cell line A431.,80852,F,500.0,CHEMBL621019,A-431,13299,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4987,1,,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,80852,F,500.0,CHEMBL621020,A-431,17420,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4988,1,,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,80852,F,500.0,CHEMBL621021,A-431,13678,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4989,1,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,9,F,500.0,CHEMBL621022,A-431,14171,,Expert,,,8,H,,
,BAO_0000219,,,4990,1,,,Tested for antiproliferative activity against human A431 cells,80852,F,500.0,CHEMBL621023,A-431,6333,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4991,1,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9,F,500.0,CHEMBL621024,A-431,2356,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,4992,1,,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,80852,F,500.0,CHEMBL621025,A-431,15578,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4993,1,,,Inhibition of A431 cell proliferation,80852,F,500.0,CHEMBL621026,A-431,5126,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4994,1,,,Cytotoxic effect on A431 human epidermoid carcinoma cells,80852,F,500.0,CHEMBL621027,A-431,6844,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4995,1,,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),80852,F,500.0,CHEMBL876397,A-431,6844,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,4996,1,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,80852,F,500.0,CHEMBL883797,A-431,4925,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4997,1,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,80852,F,500.0,CHEMBL621028,A-431,4925,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4998,1,,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,80852,F,500.0,CHEMBL621029,A-431,13978,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,4999,1,,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,80852,F,500.0,CHEMBL621030,A-431,16786,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5000,1,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,9,F,500.0,CHEMBL621147,A-431,13412,,Expert,,,8,H,,
,BAO_0000218,,,5001,1,,,In vivo antiproliferative activity against A431 cell line,80852,F,500.0,CHEMBL621148,A-431,17824,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5002,1,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9,F,500.0,CHEMBL621149,A-431,12751,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5003,1,,,Inhibition of A431 human epidermoid carcinoma cell proliferation,80852,F,500.0,CHEMBL621150,A-431,12380,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5004,1,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9,F,500.0,CHEMBL621151,A-431,4959,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5005,1,,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),80852,F,500.0,CHEMBL621152,A-431,6333,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5006,1,,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),80852,F,500.0,CHEMBL621153,A-431,6333,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5007,1,,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),80852,F,500.0,CHEMBL884000,A-431,6333,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,5008,1,,,Inhibition of EGFR overexpressing A431 cell proliferation,9,F,,CHEMBL621154,,5296,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5009,1,,,Inhibition of A431 cell proliferation,80852,F,500.0,CHEMBL621155,A-431,12624,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5010,1,,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9,F,500.0,CHEMBL621156,A-431,14926,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5011,1,,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9,F,500.0,CHEMBL621157,A-431,14926,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5012,1,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),9,F,500.0,CHEMBL621158,A-431,14926,,Expert,,,8,H,,
,BAO_0000219,,,5013,1,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,F,500.0,CHEMBL621159,A-431,15144,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5014,1,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,F,500.0,CHEMBL621160,A-431,15144,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5015,1,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,80852,F,500.0,CHEMBL621161,A-431,5245,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5016,1,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,80852,F,500.0,CHEMBL621162,A-431,5245,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5017,1,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,F,500.0,CHEMBL621163,A-431,5245,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5018,1,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,80852,F,500.0,CHEMBL621164,A-431,5245,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5019,1,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,80852,F,500.0,CHEMBL621165,A-431,5245,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,5020,1,,,Half-life period in cynomolgus monkey,22224,A,,CHEMBL619159,,5922,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vitro,BAO_0000366,Plasma,,5021,1,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",22224,A,,CHEMBL619160,,1116,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,,,5022,1,,,Longer half-life in monkey (i.v.) at 0.5 mpk,22224,A,,CHEMBL619161,,17853,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000366,Plasma,,5023,1,,,Plasma half life in monkey,22224,A,,CHEMBL619162,,993,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
,BAO_0000366,Plasma,,5024,1,,,Plasma half-life in rhesus monkey,22224,A,,CHEMBL619163,,4514,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,Plasma,,5025,1,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,A,,CHEMBL619164,,5334,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,Plasma,,5026,1,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,A,,CHEMBL619320,,5334,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,,,5027,1,,,Tested for half life upon iv administration to african green monkey,22224,A,,CHEMBL619321,,4578,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,5028,1,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,A,,CHEMBL873336,,2661,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,5029,1,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,A,,CHEMBL619322,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,5030,1,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,A,,CHEMBL619323,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,5031,1,,,The time for peak concentration value after oral administration in cynomolgus monkeys,22224,A,,CHEMBL619324,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5032,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,22224,A,,CHEMBL619325,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5033,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,22224,A,,CHEMBL876411,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5034,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,22224,A,,CHEMBL619326,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5035,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,22224,A,,CHEMBL619327,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5036,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,22224,A,,CHEMBL619328,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5037,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,22224,A,,CHEMBL619329,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5038,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,22224,A,,CHEMBL619330,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5039,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,22224,A,,CHEMBL619331,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5040,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,22224,A,,CHEMBL619332,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5041,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,22224,A,,CHEMBL619333,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5042,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,22224,A,,CHEMBL619334,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5043,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,22224,A,,CHEMBL619335,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5044,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,22224,A,,CHEMBL619336,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5045,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,22224,A,,CHEMBL619337,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5046,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,22224,A,,CHEMBL619338,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,5047,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,22224,A,,CHEMBL619339,,11271,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,5048,1,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,A,,CHEMBL619340,,5809,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,5049,1,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,A,,CHEMBL873496,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,5050,1,,,AUC value in rat after IV administration at a dose of 10 mg/kg,50597,A,,CHEMBL619341,,3546,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,5051,1,,,AUC value in rat after oral administration at a dose of 10 mg/kg,50597,A,,CHEMBL619342,,3546,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,5052,1,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,50597,A,,CHEMBL619343,,3546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,5053,1,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,50597,A,,CHEMBL619344,,3546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,5054,1,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,50597,A,,CHEMBL619345,,3546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,5055,1,,,Vc value in rat after IV administration at a dose of 10 mg/kg,50597,A,,CHEMBL619346,,3546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,5056,1,,,Half life period in rat after IV administration at a dose of 10 mg/kg,50597,A,,CHEMBL619347,,3546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000019,,,5057,1,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,A,,CHEMBL619348,,10625,9557.0,Autocuration,,,0,U,Papio hamadryas,
,BAO_0000019,,,5058,1,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),22224,A,,CHEMBL619349,,10625,9557.0,Autocuration,,,0,U,Papio hamadryas,
,BAO_0000019,,,5059,1,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),22224,A,,CHEMBL619350,,10625,9557.0,Autocuration,,,0,U,Papio hamadryas,
,BAO_0000019,,,5060,1,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,22224,A,,CHEMBL619351,,10625,9557.0,Autocuration,,,0,U,Papio hamadryas,
,BAO_0000019,,,5061,1,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,22224,A,,CHEMBL875953,,10625,9557.0,Autocuration,,,0,U,Papio hamadryas,
,BAO_0000019,,,5062,1,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,22224,A,,CHEMBL621716,,10625,9557.0,Autocuration,,,0,U,Papio hamadryas,
,BAO_0000019,,,5063,1,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,22224,A,,CHEMBL621717,,10625,9557.0,Autocuration,,,0,U,Papio hamadryas,
,BAO_0000019,,,5064,1,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,A,,CHEMBL621718,,10625,9557.0,Autocuration,,,0,U,Papio hamadryas,
,BAO_0000019,,,5065,1,,,Area under curve after 1 mpk peroral administration to beagles,22224,A,,CHEMBL621719,,3510,9615.0,Autocuration,,,0,U,beagle,
,BAO_0000019,,,5066,1,,,Area under curve after 2 mpk peroral administration to beagles,22224,A,,CHEMBL621720,,3510,9615.0,Autocuration,,,0,U,beagle,
In vivo,BAO_0000218,,,5067,1,,,Cmax value after 1 mpk peroral administration to beagles,22224,A,,CHEMBL621721,,3510,9615.0,Autocuration,,,0,U,beagle,
,BAO_0000019,Urine,,5068,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,22224,A,,CHEMBL621722,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,5069,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,22224,A,,CHEMBL621723,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,5070,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,22224,A,,CHEMBL621724,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,5071,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,22224,A,,CHEMBL623443,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,5072,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,22224,A,,CHEMBL623444,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,5073,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,22224,A,,CHEMBL623445,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000019,Urine,,5074,1,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,22224,A,,CHEMBL623446,,7766,9606.0,Autocuration,,,0,U,Homo sapiens,1088.0
,BAO_0000251,Liver,,5075,1,,Microsomes,Metabolic stability observed at 30 min after administration in human liver microsomes,22224,A,,CHEMBL623447,,16643,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000019,,,5076,1,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,22224,A,,CHEMBL623448,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5077,1,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,22224,A,,CHEMBL623449,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5078,1,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,22224,A,,CHEMBL623450,,6852,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,Liver,,5079,1,,Microsomes,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",22224,A,,CHEMBL623451,,6567,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000019,,,5080,1,,,Metabolic stability (% remaining at 30 mins) in human S9.,22224,A,,CHEMBL623452,,6570,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5081,1,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,22224,A,,CHEMBL623453,,6570,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,Liver,,5082,1,,Microsomes,Percent parent compound remaining after 20 min incubation with human liver microsomes,22224,A,,CHEMBL623454,,5237,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000251,Liver,,5083,1,,Microsomes,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,22224,A,,CHEMBL623455,,5237,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000251,Liver,,5084,1,,Microsomes,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,22224,A,,CHEMBL624371,,5237,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000218,,,5085,1,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,22224,A,,CHEMBL624372,,5202,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5086,1,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,22224,A,,CHEMBL624373,,5481,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5087,1,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,22224,A,,CHEMBL624374,,5481,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5088,1,,,The percent remaining in human plasma after 30 min was determined,22224,A,,CHEMBL624556,,3956,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000366,Plasma,,5089,1,,,Conversion rate of the prodrug in human plasma,22224,A,,CHEMBL624557,,5074,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5090,1,,,Conversion rate of the prodrug in human plasma; ND means no data,22224,A,,CHEMBL624558,,5074,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000221,Blood,,5091,1,,,Half life of compound was determined in human blood,22224,A,,CHEMBL624559,,4727,9606.0,Autocuration,,,0,U,Homo sapiens,178.0
,BAO_0000019,,,5092,1,,,Half life of compound was determined in man with once daily dosing,22224,A,,CHEMBL624560,,5965,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,,,5093,1,,Microsomes,Half life in human microsomes,22224,A,,CHEMBL624561,,5732,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000366,Plasma,,5094,1,,,Half life in human plasma,22224,A,,CHEMBL624562,,5819,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5095,1,,,Half life in human plasma; Not detected,22224,A,,CHEMBL624563,,5819,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vivo,BAO_0000218,,,5096,1,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,22224,A,,CHEMBL624564,,1916,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,Liver,,5097,1,,Microsomes,Half-life for oxidative metabolic stability was determined using rat liver microsomes,22224,A,,CHEMBL624565,,6597,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000366,Plasma,,5098,1,,,Half-life in human plasma,22224,A,,CHEMBL875152,,5229,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5099,1,,,Half-life of the parent prodrug in plasma,22224,A,,CHEMBL624566,,5229,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vitro,BAO_0000366,Plasma,,5100,1,,,In vitro half life in human plasma was determined,22224,A,,CHEMBL873805,,2192,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vitro,BAO_0000251,Liver,,5101,1,,Microsomes,The compound was tested In Vitro for half life in human liver microsomes.,22224,A,,CHEMBL624567,,3032,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vivo,BAO_0000218,,,5102,1,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,22224,A,,CHEMBL624568,,1916,9606.0,Autocuration,,,0,U,Homo sapiens,
In vivo,BAO_0000218,,,5103,1,,,Observed volume of distribution,22224,A,,CHEMBL624569,,17716,9606.0,Autocuration,,,0,U,Homo sapiens,
In vivo,BAO_0000218,,,5104,1,,,Oral bioavailability in human,22224,A,,CHEMBL624570,,15778,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5105,1,,,Tested for human plasma protein binding of the compound,22224,A,,CHEMBL624571,,17313,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5106,1,,,"First order rate constant, k was determined in human plasma",22224,A,,CHEMBL624572,,4231,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5107,1,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,A,,CHEMBL624573,,4755,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5108,1,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,A,,CHEMBL875153,,4755,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,Liver,,5109,1,,Microsomes,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,22224,A,,CHEMBL624574,,16907,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000019,,,5110,1,,,The compound was tested for the plasma binding in human,22224,A,,CHEMBL624575,,10839,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5111,1,,,Plasma protein binding (human),22224,A,,CHEMBL624576,,10839,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,Liver,,5112,1,,Microsomes,Compound was evaluated for half-life in human liver microsomes,22224,A,,CHEMBL624577,,3199,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
In vitro,BAO_0000221,Blood,,5113,1,,,Half life measured in vitro for its stability in human blood,22224,A,,CHEMBL624578,,1345,9606.0,Autocuration,,,0,U,Homo sapiens,178.0
,BAO_0000019,Serum,,5114,1,,,Half life in human serum,22224,A,,CHEMBL622796,,4297,9606.0,Autocuration,,,0,U,Homo sapiens,1977.0
,BAO_0000019,Serum,,5115,1,,,Half life in human serum; ND=not determined,22224,A,,CHEMBL622797,,4297,9606.0,Autocuration,,,0,U,Homo sapiens,1977.0
,BAO_0000019,,,5116,1,,,Half life were determined in CEM-SS cell extract in decomposition step 1,22224,A,,CHEMBL622798,,4297,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5117,1,,,Half life were determined in CEM-SS cell extract in decomposition step 2,22224,A,,CHEMBL622799,,4297,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000366,Plasma,,5118,1,,,Half life of the in human plasma,22224,A,,CHEMBL622800,,4231,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vitro,BAO_0000220,,,5119,1,,S9,Half life period in human hepatic S9 fraction was determined,22224,A,,CHEMBL622801,,5633,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,Liver,,5120,1,,Microsomes,Half life period in human liver microsome was determined,22224,A,,CHEMBL622802,,5633,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000019,,,5121,1,,,Half life period was determined; 6-7,22224,A,,CHEMBL622803,,17791,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5122,1,,,Half life period was evaluated in human,22224,A,,CHEMBL875154,,17791,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000366,Plasma,,5123,1,,,Half life time in human plasma,22224,A,,CHEMBL622804,,3160,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vivo,BAO_0000218,Brain,,5124,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622805,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Heart,,5125,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622611,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,5126,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622612,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Kidney,,5127,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL875160,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,5128,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,A,,CHEMBL622613,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,5129,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622614,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,5130,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622615,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,5131,1,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,A,,CHEMBL622616,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,5132,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622617,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Spleen,,5133,1,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,A,,CHEMBL622618,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,5134,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,A,,CHEMBL622619,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,5135,1,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622620,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Brain,,5136,1,,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL622621,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Blood,,5137,1,,,Biodistribution of compound (oxidized form) in blood tissue,50594,A,,CHEMBL622622,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,5138,1,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622623,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,5139,1,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,A,,CHEMBL622624,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,5140,1,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL622625,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,5141,1,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622626,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,5142,1,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,A,,CHEMBL622627,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Brain,,5143,1,,,Biodistribution of compound (oxidized form) in brain tissue of mice,50594,A,,CHEMBL622628,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,5144,1,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622629,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,5145,1,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL622630,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,5146,1,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622631,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,5147,1,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,A,,CHEMBL622632,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,5148,1,,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,A,,CHEMBL622633,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Heart,,5149,1,,,Biodistribution of compound (oxidized form) in heart tissue of mice,50594,A,,CHEMBL622634,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,5150,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL622635,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,5151,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL875161,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,5152,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL622636,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,5153,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL623335,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,5154,1,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,A,,CHEMBL623336,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Kidney,,5155,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL623337,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,5156,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,A,,CHEMBL623338,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,5157,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL623339,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,5158,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL623524,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,5159,1,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,A,,CHEMBL623525,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,5160,1,,,Biodistribution of compound (oxidized form) in liver tissue,50594,A,,CHEMBL623526,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,5161,1,,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL623527,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,5162,1,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL623528,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000219,,,5163,1,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,80852,F,500.0,CHEMBL624615,A-431,5245,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5164,1,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,F,500.0,CHEMBL621672,A-431,5245,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,5165,1,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",80852,F,500.0,CHEMBL621673,A-431,16289,,Expert,,,1,N,,
,BAO_0000218,,,5166,1,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",80852,F,500.0,CHEMBL621674,A-431,16289,,Expert,,,1,N,,
,BAO_0000219,,,5167,1,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,F,500.0,CHEMBL884002,A-431,16093,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5168,1,,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",80852,F,500.0,CHEMBL621850,A-431,16825,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5169,1,,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,80852,F,500.0,CHEMBL621851,A-431,4848,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5170,1,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9,F,500.0,CHEMBL621852,A-431,14827,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5171,1,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9,F,500.0,CHEMBL621853,A-431,14827,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000218,,,5172,1,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",80852,F,500.0,CHEMBL621854,A-431,16289,,Expert,,,1,N,,
,BAO_0000218,,,5173,1,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,F,500.0,CHEMBL621855,A-431,16289,,Expert,,,1,N,,
,BAO_0000218,,,5174,1,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,F,500.0,CHEMBL623724,A-431,16289,,Expert,,,1,N,,
,BAO_0000218,,,5175,1,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",80852,F,500.0,CHEMBL623725,A-431,16289,,Expert,,,1,N,,
,BAO_0000218,,,5176,1,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",80852,F,500.0,CHEMBL623726,A-431,16289,,Expert,,,1,N,,
,BAO_0000219,,,5177,1,,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9,F,500.0,CHEMBL623727,A-431,16289,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5178,1,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,9,F,500.0,CHEMBL623728,A-431,16289,,Expert,,,8,H,,
,BAO_0000218,,,5179,1,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",80852,F,500.0,CHEMBL623729,A-431,16289,,Expert,,,1,N,,
,BAO_0000218,,,5180,1,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,F,500.0,CHEMBL623730,A-431,16289,,Expert,,,1,N,,
,BAO_0000218,,,5181,1,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,F,500.0,CHEMBL623731,A-431,16289,,Expert,,,1,N,,
,BAO_0000218,,,5182,1,,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,F,500.0,CHEMBL623732,A-431,14555,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000218,,,5183,1,,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,F,500.0,CHEMBL623733,A-431,14555,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000218,,,5184,1,,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,F,500.0,CHEMBL623734,A-431,14555,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000218,,,5185,1,,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,F,500.0,CHEMBL623735,A-431,14555,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,5186,1,,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,80852,F,500.0,CHEMBL623736,A-431,1937,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5187,1,,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,80852,F,500.0,CHEMBL623737,A-431,13739,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5188,1,,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,80852,F,500.0,CHEMBL623738,A-431,3558,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5189,1,,,Dose giving a 50% decrease in the living cell number (A437 cells),80852,F,500.0,CHEMBL875168,A-431,3558,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5190,1,,,In vitro inhibitory concentration against proliferation of A459 cell line.,80682,F,646.0,CHEMBL623739,A549,17686,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5191,1,,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,80682,F,646.0,CHEMBL623740,A549,5305,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5192,1,,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,80682,F,646.0,CHEMBL624424,A549,3614,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5193,1,,,In vitro antitumor activity against renal A498 tumor cell lines,80021,F,624.0,CHEMBL624425,A498,17229,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5194,1,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",80021,F,624.0,CHEMBL624426,A498,15935,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5195,1,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",80021,F,624.0,CHEMBL624427,A498,15935,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5196,1,,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,80021,F,624.0,CHEMBL624428,A498,15560,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5197,1,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,80021,F,624.0,CHEMBL624429,A498,13891,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5198,1,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,80021,F,624.0,CHEMBL624620,A498,13891,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5199,1,,,Cytotoxicity on kidney carcinoma (A-498) cell line,80021,F,624.0,CHEMBL624621,A498,13788,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5200,1,,,Compound was evaluated against Human cell line renal A498,80021,F,624.0,CHEMBL624622,A498,15403,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5201,1,,,Compound was tested for inhibition of A498 human renal cancer cell line,80021,F,624.0,CHEMBL624623,A498,1009,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5202,1,,,Growth inhibitory activity against A498 human cancer cell line,80021,F,624.0,CHEMBL874365,A498,1043,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5203,1,,,In vitro antitumor activity against human renal A498 cell line,80021,F,624.0,CHEMBL624624,A498,5858,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5204,1,,,In vitro cytotoxic activity against renal (A498) cell line,80021,F,624.0,CHEMBL624625,A498,5958,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5205,1,,,In vitro cytotoxic activity against human renal cancer (A498) cell line,80021,F,624.0,CHEMBL624626,A498,5506,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5206,1,,,Tested for cytostatic activity against renal A498 cell line,80021,F,624.0,CHEMBL624627,A498,12781,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5207,1,,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,80021,F,624.0,CHEMBL883157,A498,14399,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5208,1,,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,80021,F,624.0,CHEMBL624628,A498,5958,9606.0,Expert,,,1,N,Homo sapiens,
In vivo,BAO_0000218,,,5209,1,,,Cmax value after 2 mpk peroral administration to beagles,22224,A,,CHEMBL624629,,3510,9615.0,Autocuration,,,0,U,beagle,
In vivo,BAO_0000218,,,5210,1,,,Bioavailability,22224,A,,CHEMBL623551,,3510,9615.0,Autocuration,beagle,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,5211,1,,,Bioavailability after 1 mpk peroral administration to beagles,22224,A,,CHEMBL623552,,3510,9615.0,Autocuration,beagle,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,5212,1,,,Bioavailability after 2 mpk peroral administration to beagles,22224,A,,CHEMBL623553,,3510,9615.0,Autocuration,beagle,,0,U,Canis lupus familiaris,
,BAO_0000019,,,5213,1,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,22224,A,,CHEMBL623554,,3085,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5214,1,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,22224,A,,CHEMBL623555,,3085,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5215,1,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,22224,A,,CHEMBL623556,,3085,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5216,1,,,Solubility against bovine alpha-chymotrypsin,22224,A,,CHEMBL623557,,9372,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5217,1,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,A,,CHEMBL623558,,3085,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5218,1,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,A,,CHEMBL623559,,3085,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000221,Spleen,,5219,1,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,22224,A,,CHEMBL623560,,1469,9913.0,Autocuration,,,0,U,Bos taurus,2106.0
,BAO_0000019,,,5220,1,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,22224,A,,CHEMBL623561,,4297,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5221,1,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,22224,A,,CHEMBL623562,,4297,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5222,1,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,22224,A,,CHEMBL623563,,17585,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000221,Spleen,,5223,1,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,22224,A,,CHEMBL623564,,1336,9913.0,Autocuration,,,0,U,Bos taurus,2106.0
,BAO_0000019,,,5224,1,,,Half life in presence of 2 mg/mL BSA at pH 8.8,22224,A,,CHEMBL873806,,3085,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5225,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,22224,A,,CHEMBL623565,,2857,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5226,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,22224,A,,CHEMBL623566,,2857,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5227,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,22224,A,,CHEMBL623567,,2857,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000019,,,5228,1,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),22224,A,,CHEMBL623568,,1540,9913.0,Autocuration,,,0,U,Bos taurus,
,BAO_0000218,Plasma,,5229,1,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,50588,A,,CHEMBL623569,,6316,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,5230,1,,,AUC after administration at 100 mg/kg/day in dogs,50588,A,,CHEMBL623570,,17594,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,5231,1,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,50588,A,,CHEMBL624254,,4953,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,5232,1,,,AUC value after 15 mg/kg iv dose in Dogs,50588,A,,CHEMBL624255,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,5233,1,,,AUC value after 30 mg/kg po dose in Dogs,50588,A,,CHEMBL624256,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,5234,1,,,AUC value after administration of 4 mg/Kg oral dose in dog,50588,A,,CHEMBL624257,,2959,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,5235,1,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,50588,A,,CHEMBL624258,,17594,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,5236,1,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,50588,A,,CHEMBL875277,,5356,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5237,1,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,50588,A,,CHEMBL622667,,16807,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5238,1,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,50588,A,,CHEMBL622668,,4527,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5239,1,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,50588,A,,CHEMBL622669,,4527,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5240,1,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,50588,A,,CHEMBL622670,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5241,1,,,Area under curve determined in dogs after oral administration of 10 mg/kg,50588,A,,CHEMBL622671,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5242,1,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,A,,CHEMBL622672,,5802,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5243,1,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,A,,CHEMBL622673,,3598,9615.0,Expert,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5244,1,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,50588,A,,CHEMBL622674,,3598,9615.0,Expert,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5245,1,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,A,,CHEMBL622675,,5944,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5246,1,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,50588,A,,CHEMBL622676,,5944,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5247,1,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,A,,CHEMBL622677,,5944,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5248,1,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,50588,A,,CHEMBL622678,,5944,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5249,1,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,50588,A,,CHEMBL622679,,4186,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5250,1,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,A,,CHEMBL622680,,5007,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5251,1,,,Area under curve was determine after peroral administration at 10 mpk in dog,50588,A,,CHEMBL622681,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5252,1,,,Area under curve was determine after peroral administration at 5 mpk in dog,50588,A,,CHEMBL875278,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5253,1,,,Area under curve was determined,50588,A,,CHEMBL622682,,5006,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5254,1,,,Area under curve in dogs,50588,A,,CHEMBL622683,,5006,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5255,1,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,50588,A,,CHEMBL622684,,3771,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5256,1,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),50588,A,,CHEMBL622685,,3771,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5257,1,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,50588,A,,CHEMBL622686,,3771,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5258,1,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,A,,CHEMBL618344,,1916,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5259,1,,,Area under curve value in dog at a dose of 5 mg/kg,50588,A,,CHEMBL875582,,5302,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5260,1,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,50588,A,,CHEMBL618345,,5600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5261,1,,,Area under curve was determined after 0.3 mg/kg po administration in dog,50588,A,,CHEMBL618346,,5600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5262,1,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,50588,A,,CHEMBL618347,,17764,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5263,1,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,50588,A,,CHEMBL618348,,4368,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000019,,,5264,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,22224,A,,CHEMBL618349,,5318,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5265,1,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,A,,CHEMBL618350,,5318,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5266,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,22224,A,,CHEMBL618351,,5318,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5267,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,22224,A,,CHEMBL618352,,5318,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000221,Blood,,5268,1,,,Time taken to reduce 50% of the concentration of compound in blood plasma,22224,A,,CHEMBL873494,,14518,9606.0,Autocuration,,,0,U,Homo sapiens,178.0
,BAO_0000366,Plasma,,5269,1,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,A,,CHEMBL618353,,2209,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5270,1,,,Half life in human plasma,22224,A,,CHEMBL618354,,6787,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5271,1,,,Half life in human plasma was reported,22224,A,,CHEMBL875583,,4898,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,Serum,,5272,1,,,Half life in human serum,22224,A,,CHEMBL618355,,6072,9606.0,Autocuration,,,0,U,Homo sapiens,1977.0
,BAO_0000366,Plasma,,5273,1,,,Half life upon exposure to human plasma,22224,A,,CHEMBL618356,,16907,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vitro,BAO_0000251,,,5274,1,,Microsomes,t1/2 in human microsomes,22224,A,,CHEMBL618357,,5656,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000366,Plasma,,5275,1,,,Half life period in 80% human plasma at 37 degree Centigrade,22224,A,,CHEMBL618358,,4755,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000221,Zone of skin,,5276,1,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),22224,A,,CHEMBL618359,,17503,9606.0,Autocuration,,,0,U,Homo sapiens,14.0
In vitro,BAO_0000366,Plasma,,5277,1,,,Half-life measured in in vitro Cathepsin B assay in human plasma,22224,A,,CHEMBL618360,,12357,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,,,5278,1,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,22224,A,,CHEMBL618361,,3076,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000251,Liver,,5279,1,,Microsomes,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,22224,A,,CHEMBL618362,,6410,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000366,Plasma,,5280,1,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,A,,CHEMBL618363,,3741,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5281,1,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,A,,CHEMBL618364,,3741,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5282,1,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,A,,CHEMBL875584,,3741,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,,,5283,1,,,Half-life in the CEM cell extracts,22224,A,,CHEMBL618365,,1540,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000366,Plasma,,5284,1,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,22224,A,,CHEMBL873495,,2905,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5285,1,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,22224,A,,CHEMBL618366,,2905,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,,,5286,1,,,Half-life was determined,22224,A,,CHEMBL618367,,5523,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000221,Blood,,5287,1,,,Half-life (human blood stability),22224,A,,CHEMBL618368,,1499,9606.0,Autocuration,,,0,U,Homo sapiens,178.0
,BAO_0000221,Blood,,5288,1,,,Half-life (human blood stability); no data,22224,A,,CHEMBL618369,,1499,9606.0,Autocuration,,,0,U,Homo sapiens,178.0
,BAO_0000366,Plasma,,5289,1,,,Half-life in human plasma,22224,A,,CHEMBL618370,,17065,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,,,5290,1,,,CYP3A4 metabolism half-life (t1/2),22224,A,,CHEMBL618371,,6861,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000221,Blood,,5291,1,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),22224,A,,CHEMBL618372,,1499,9606.0,Autocuration,,,0,U,Homo sapiens,178.0
In vitro,BAO_0000366,Plasma,,5292,1,,,In vitro half life in human plasma,22224,A,,CHEMBL618373,,530,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vitro,BAO_0000366,Plasma,,5293,1,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",22224,A,,CHEMBL618374,,1116,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vitro,BAO_0000366,Plasma,,5294,1,,,In vitro hydrolysis in human plasma,22224,A,,CHEMBL618375,,6695,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vitro,BAO_0000366,Plasma,,5295,1,,,In vitro hydrolysis in human plasma; no data,22224,A,,CHEMBL618376,,6695,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
In vitro,BAO_0000251,Liver,,5296,1,,Microsomes,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,22224,A,,CHEMBL618377,,10,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000366,Plasma,,5297,1,,,Plasma half life in human,22224,A,,CHEMBL618378,,993,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5298,1,,,Stability after incubation with human plasma (at 37 degree C),22224,A,,CHEMBL618379,,15429,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5299,1,,,T1/2 was evaluated in human plasma,22224,A,,CHEMBL618380,,1675,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5300,1,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,A,,CHEMBL618381,,2209,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5301,1,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",22224,A,,CHEMBL618382,,2209,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,,,5302,1,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,A,,CHEMBL618383,,5318,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000019,,,5303,1,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,22224,A,,CHEMBL618384,,2412,9606.0,Autocuration,,,0,U,Homo sapiens,
In vitro,BAO_0000019,,,5304,1,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,22224,A,,CHEMBL618385,,2412,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000366,Plasma,,5305,1,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,22224,A,,CHEMBL619099,,2906,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000366,Plasma,,5306,1,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,22224,A,,CHEMBL619100,,2906,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000019,,,5307,1,,,Time taken for 50% to be consumed by serum PON1 was determined,22224,A,,CHEMBL619101,,5495,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000019,,,5308,1,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,22224,A,,CHEMBL619102,,5495,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000251,Liver,,5309,1,,Microsomes,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,A,,CHEMBL619103,,4397,9606.0,Autocuration,,,0,U,Homo sapiens,2107.0
,BAO_0000218,,,5310,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,A,,CHEMBL619268,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5311,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL619269,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5312,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,A,,CHEMBL619270,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5313,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL619271,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5314,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,A,,CHEMBL875585,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5315,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,A,,CHEMBL619272,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000219,,,5316,1,,,Compound tested for growth inhibition of renal cancer cell line 786-0,80640,F,391.0,CHEMBL619273,786-0,6058,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5317,1,,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,80640,F,391.0,CHEMBL619274,786-0,17708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5318,1,,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,80640,F,391.0,CHEMBL619275,786-0,14017,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5319,1,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",80640,F,391.0,CHEMBL619276,786-0,16818,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5320,1,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",80640,F,391.0,CHEMBL619277,786-0,16818,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5321,1,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",80640,F,391.0,CHEMBL619278,786-0,16818,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5322,1,,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,80640,F,391.0,CHEMBL619279,786-0,11970,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5323,1,,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,80640,F,391.0,CHEMBL858458,786-0,12400,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5324,1,,,Cytotoxic effect on renal cancer line 786-0,80640,F,391.0,CHEMBL619280,786-0,12888,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5325,1,,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,80640,F,391.0,CHEMBL619281,786-0,15300,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5326,1,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,F,391.0,CHEMBL619282,786-0,14769,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5327,1,,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",80640,F,391.0,CHEMBL619283,786-0,15895,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5328,1,,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,80640,F,391.0,CHEMBL619284,786-0,17376,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5329,1,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80640,F,391.0,CHEMBL619285,786-0,14882,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5330,1,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),80640,F,391.0,CHEMBL619286,786-0,14882,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5331,1,,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,80640,F,391.0,CHEMBL619287,786-0,15176,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5332,1,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80640,F,391.0,CHEMBL857455,786-0,12696,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5333,1,,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),80640,F,391.0,CHEMBL883801,786-0,2496,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5334,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,80641,F,972.0,CHEMBL619288,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5335,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),80641,F,972.0,CHEMBL619289,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5336,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,80641,F,972.0,CHEMBL619290,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5337,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),80641,F,972.0,CHEMBL619291,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5338,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),80641,F,972.0,CHEMBL619292,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5339,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,F,972.0,CHEMBL619293,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5340,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),80641,F,972.0,CHEMBL619294,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5341,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),80641,F,972.0,CHEMBL619295,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5342,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),80641,F,972.0,CHEMBL619296,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5343,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,F,972.0,CHEMBL619297,791T cell line,11831,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5344,1,,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,80640,F,391.0,CHEMBL619298,786-0,12782,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,5345,1,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,22226,F,,CHEMBL619299,,1229,,Intermediate,,,0,U,,
,BAO_0000219,,,5346,1,,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,80433,F,741.0,CHEMBL619300,RPMI-8226,15313,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5347,1,,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,80433,F,741.0,CHEMBL619301,RPMI-8226,15313,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5348,1,,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,80433,F,741.0,CHEMBL619302,RPMI-8226,11544,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5349,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,F,741.0,CHEMBL619303,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5350,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,F,741.0,CHEMBL619304,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5351,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,F,741.0,CHEMBL857706,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5352,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,F,741.0,CHEMBL619305,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5353,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,F,741.0,CHEMBL619306,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5354,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,F,741.0,CHEMBL619307,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5355,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,F,741.0,CHEMBL619308,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5356,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,F,741.0,CHEMBL619309,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5357,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,F,741.0,CHEMBL619310,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5358,1,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,F,624.0,CHEMBL619311,A498,14769,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5359,1,,,Compound was tested for the growth inhibition of A498 renal tumor cell line,80021,F,624.0,CHEMBL619312,A498,15354,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5360,1,,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),80021,F,624.0,CHEMBL619313,A498,17445,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5361,1,,,In vitro inhibitory concentration against renal cancer cell line A498,80021,F,624.0,CHEMBL619314,A498,4337,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5362,1,,,Cytotoxicity against A 498 tumor cell line,80021,F,624.0,CHEMBL619959,A498,15277,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5363,1,,,In vitro antitumor activity against A498 human cancer cell line,80021,F,624.0,CHEMBL619960,A498,4812,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5364,1,,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),80021,F,624.0,CHEMBL619961,A498,4812,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5365,1,,,Inhibitory dose required against A498 human tumor cell lines,80021,F,624.0,CHEMBL619962,A498,4995,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5366,1,,,Anticancer activity against one renal cancer (A498 cell line),80021,F,624.0,CHEMBL875586,A498,5847,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5367,1,,,In vitro cytotoxicity against melanoma A498 cell line,80021,F,624.0,CHEMBL619963,A498,6557,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5368,1,,,Compound was tested for growth inhibitory activity against A498 cell line,80021,F,624.0,CHEMBL619964,A498,2597,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5369,1,,,Compound tested for growth inhibition of renal cancer cell line A498,80021,F,624.0,CHEMBL620108,A498,6058,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5370,1,,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,80021,F,624.0,CHEMBL620109,A498,17708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5371,1,,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,80021,F,624.0,CHEMBL620110,A498,15176,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5372,1,,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,80021,F,624.0,CHEMBL620111,A498,15300,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5373,1,,,Tested for cytotoxicity against A498 cell lines in renal cancer,80021,F,624.0,CHEMBL620112,A498,11970,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5374,1,,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,80021,F,624.0,CHEMBL620113,A498,12400,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5375,1,,,Cytotoxic effect on renal cancer lines A498,80021,F,624.0,CHEMBL620114,A498,12888,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5376,1,,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,80021,F,624.0,CHEMBL620115,A498,3030,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5377,1,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,F,624.0,CHEMBL620116,A498,14769,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5378,1,,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,80021,F,624.0,CHEMBL620117,A498,17376,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5379,1,,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,80021,F,624.0,CHEMBL620118,A498,16558,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5380,1,,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,80021,F,624.0,CHEMBL620119,A498,5194,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5381,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,80021,F,624.0,CHEMBL620120,A498,10708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5382,1,,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,80682,F,646.0,CHEMBL620121,A549,16880,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5383,1,,,Antitumor activity against A549 human lung carcinoma cell line,80682,F,646.0,CHEMBL620122,A549,10196,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5384,1,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,80682,F,646.0,CHEMBL620123,A549,10196,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5385,1,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,80682,F,646.0,CHEMBL620124,A549,10196,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5386,1,,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",80682,F,646.0,CHEMBL620125,A549,12083,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5387,1,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,80682,F,646.0,CHEMBL620126,A549,16464,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5388,1,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,F,646.0,CHEMBL883027,A549,16464,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5389,1,,,In vitro cytotoxic activity against human lung A549 cell line,80682,F,646.0,CHEMBL620127,A549,16470,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5390,1,,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),80682,F,646.0,CHEMBL620128,A549,16470,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5391,1,,,In vitro cytotoxic activity against human lung A549 cell line),80682,F,646.0,CHEMBL620129,A549,16470,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5392,1,,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,80682,F,646.0,CHEMBL620130,A549,16470,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5393,1,,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,80682,F,646.0,CHEMBL620131,A549,16582,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5394,1,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",80682,F,646.0,CHEMBL620132,A549,15935,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5395,1,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",80682,F,646.0,CHEMBL620133,A549,15935,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5396,1,,,Inhibition of A549 human lung carcinoma cell proliferation,80682,F,646.0,CHEMBL620134,A549,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5397,1,,,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,F,646.0,CHEMBL620135,A549,17376,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5398,1,,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,80682,F,646.0,CHEMBL620136,A549,16496,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5399,1,,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,80682,F,646.0,CHEMBL620137,A549,16152,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5400,1,,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,80682,F,646.0,CHEMBL620268,A549,16152,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5401,1,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,F,646.0,CHEMBL620269,A549,16464,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5402,1,,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,80682,F,646.0,CHEMBL620270,A549,2288,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5403,1,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,F,646.0,CHEMBL620271,A549,17350,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5404,1,,,Inhibition of A549 cancer cell proliferation,80682,F,646.0,CHEMBL620272,A549,4090,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5405,1,,,Inhibition of A549 cancer cell proliferation (Not tested),80682,F,646.0,CHEMBL620273,A549,4090,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5406,1,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,F,646.0,CHEMBL620274,A549,17350,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5407,1,,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,80682,F,646.0,CHEMBL620275,A549,4197,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5408,1,,,Antiproliferative potency determined as inhibitory concentration against A549 cells,80682,F,646.0,CHEMBL620276,A549,17072,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5409,1,,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,80682,F,646.0,CHEMBL620277,A549,17072,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5410,1,,,Cytotoxicity against Renal cell lines A549 was determined,80682,F,646.0,CHEMBL620278,A549,5194,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,5411,1,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,50588,A,,CHEMBL620279,,4257,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5412,1,,,Area under curve was determined in dog after oral administration at 1 mg/kg,50588,A,,CHEMBL620280,,6123,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5413,1,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,A,,CHEMBL620281,,1337,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5414,1,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,A,,CHEMBL620282,,1337,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5415,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),50588,A,,CHEMBL621134,,8833,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5416,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),50588,A,,CHEMBL621135,,8833,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5417,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),50588,A,,CHEMBL621136,,8833,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5418,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),50588,A,,CHEMBL621137,,8833,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,5419,1,,,Area under plasma concentration time curve in dog upon oral administration,50588,A,,CHEMBL621138,,17657,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,5420,1,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,50588,A,,CHEMBL875587,,17650,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,5421,1,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,50588,A,,CHEMBL621139,,1977,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5422,1,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,50588,A,,CHEMBL621140,,1977,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5423,1,,,Area under the curve for the compound was obtained when tested in dog,50588,A,,CHEMBL621141,,3132,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5424,1,,,Area under the curve at a dose of 1 mg/kg,50588,A,,CHEMBL621142,,5473,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5425,1,,,Area under the curve at a dose of 1 mg/kg (oral),50588,A,,CHEMBL621143,,5474,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5426,1,,,Area under the curve at i.v. dose of 0.2 mg/kg,50588,A,,CHEMBL621144,,5474,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5427,1,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,50588,A,,CHEMBL621145,,6062,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5428,1,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,50588,A,,CHEMBL621146,,4709,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5429,1,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,50588,A,,CHEMBL622567,,2652,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5430,1,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,50588,A,,CHEMBL622568,,2652,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5431,1,,,Compound was evaluated for area under the curve in dog blood.,50588,A,,CHEMBL622569,,2877,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5432,1,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,50588,A,,CHEMBL622570,,5444,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,5433,1,,,AUC in dog after oral dose (1 mg/kg),50588,A,,CHEMBL622571,,5130,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,5434,1,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,50588,A,,CHEMBL622572,,6265,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5435,1,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",50588,A,,CHEMBL622573,,4657,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5436,1,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,50588,A,,CHEMBL622574,,16367,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5437,1,,,Pharmacokinetic parameter AUC after oral administration to dogs,50588,A,,CHEMBL622575,,16367,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5438,1,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,50588,A,,CHEMBL622576,,9579,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5439,1,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,50588,A,,CHEMBL622577,,9579,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5440,1,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,A,,CHEMBL622578,,5983,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5441,1,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,50588,A,,CHEMBL622579,,6241,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5442,1,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",50588,A,,CHEMBL622580,,5313,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5443,1,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",50588,A,,CHEMBL622581,,5313,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5444,1,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,A,,CHEMBL622582,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5445,1,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,A,,CHEMBL622583,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5446,1,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,A,,CHEMBL622584,,6641,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5447,1,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,A,,CHEMBL622585,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5448,1,,,Compound was evaluated for oral bioavailability in dog; 90-100,50588,A,,CHEMBL622586,,17791,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5449,1,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,50588,A,,CHEMBL623281,,17655,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5450,1,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,50588,A,,CHEMBL623282,,17655,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5451,1,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,50588,A,,CHEMBL623283,,6596,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5452,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623284,,3880,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5453,1,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,50588,A,,CHEMBL623285,,16367,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,5454,1,,,Plasma protein binding towards dog plasma at 10 uM,50588,A,,CHEMBL623463,,17409,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,5455,1,,,Plasma protein binding towards dog plasma at 100 uM,50588,A,,CHEMBL875952,,17409,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,5456,1,,,Bioavailability in dog (dose 4 mg/kg p.o.),50588,A,,CHEMBL621705,,2959,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5457,1,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,50588,A,,CHEMBL621706,,13501,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5458,1,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,50588,A,,CHEMBL621707,,4527,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5459,1,,,Bioavailability in dogs,50588,A,,CHEMBL621708,,15145,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5460,1,,,Bioavailability,50588,A,,CHEMBL621709,,4219,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5461,1,,,Oral bioavailability in dog (dose 10 mg/kg),50588,A,,CHEMBL621710,,17538,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5462,1,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,50588,A,,CHEMBL621711,,17538,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5463,1,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),50588,A,,CHEMBL621712,,1466,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5464,1,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,50588,A,,CHEMBL621713,,17650,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5465,1,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,50588,A,,CHEMBL621714,,3132,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5466,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL621715,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,Liver,,5467,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,A,,CHEMBL623717,,2413,10095.0,Autocuration,,,0,U,Mus sp.,2107.0
,BAO_0000218,Liver,,5468,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,A,,CHEMBL623718,,2413,10095.0,Autocuration,,,0,U,Mus sp.,2107.0
,BAO_0000218,Liver,,5469,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL623719,,2413,10095.0,Autocuration,,,0,U,Mus sp.,2107.0
,BAO_0000218,,,5470,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,A,,CHEMBL623720,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5471,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL623721,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,Muscle tissue,,5472,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,A,,CHEMBL623722,,2413,10095.0,Autocuration,,,0,U,Mus sp.,2385.0
,BAO_0000218,Muscle tissue,,5473,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,A,,CHEMBL623723,,2413,10095.0,Autocuration,,,0,U,Mus sp.,2385.0
,BAO_0000218,Muscle tissue,,5474,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL618543,,2413,10095.0,Autocuration,,,0,U,Mus sp.,2385.0
,BAO_0000218,Spleen,,5475,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,A,,CHEMBL618544,,2413,10095.0,Autocuration,,,0,U,Mus sp.,2106.0
,BAO_0000218,Spleen,,5476,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL875155,,2413,10095.0,Autocuration,,,0,U,Mus sp.,2106.0
,BAO_0000218,,,5477,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,A,,CHEMBL618545,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5478,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,A,,CHEMBL618546,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5479,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL623529,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5480,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,A,,CHEMBL623530,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000218,,,5481,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,A,,CHEMBL621764,,2413,10095.0,Autocuration,,,0,U,Mus sp.,
,BAO_0000019,,,5482,1,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,A,,CHEMBL621765,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,Cerebellum,,5483,1,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,A,,CHEMBL621766,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,2037.0
,BAO_0000019,Frontal cortex,,5484,1,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,A,,CHEMBL621767,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,1870.0
,BAO_0000019,,,5485,1,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),22224,A,,CHEMBL621768,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,Striatum,,5486,1,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),22224,A,,CHEMBL621769,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,2435.0
,BAO_0000019,,,5487,1,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,A,,CHEMBL621770,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,Cerebellum,,5488,1,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,A,,CHEMBL621771,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,2037.0
,BAO_0000019,Frontal cortex,,5489,1,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,A,,CHEMBL621772,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,1870.0
,BAO_0000019,,,5490,1,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),22224,A,,CHEMBL621773,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,Striatum,,5491,1,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),22224,A,,CHEMBL621774,,17827,9527.0,Autocuration,,,0,U,Cercopithecidae,2435.0
,BAO_0000218,,,5492,1,,,Compound was evaluated for oral bioavailability in rats,22224,A,,CHEMBL621775,,17791,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,Plasma,,5493,1,,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,22224,A,,CHEMBL621776,,17667,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
,BAO_0000019,,,5494,1,,,Half life period was evaluated in monkey,22224,A,,CHEMBL621777,,17791,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,5495,1,,,Half-life in rhesus monkeys by intravenous administration of dose,22224,A,,CHEMBL875162,,110,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,Plasma,,5496,1,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,50594,A,,CHEMBL621778,,5781,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,Plasma,,5497,1,,,AUC after intraperitoneal administration of 100 mg/kg in mice,50594,A,,CHEMBL621779,,17734,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,Plasma,,5498,1,,,AUC value was determined after oral administration,50594,A,,CHEMBL622479,,17718,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,,,5499,1,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,A,,CHEMBL622480,,4573,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5500,1,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,A,,CHEMBL622481,,3277,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5501,1,,,Area under curve by ioral administration in mouse,50594,A,,CHEMBL622482,,2862,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5502,1,,,Area under curve by iv administration in mouse,50594,A,,CHEMBL622483,,2862,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5503,1,,,Area under curve at 0-8 hr in IRC mice after peroral administration,50594,A,,CHEMBL622484,,5951,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5504,1,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,50594,A,,CHEMBL622641,,17729,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5505,1,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,50594,A,,CHEMBL622642,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5506,1,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,50594,A,,CHEMBL622643,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5507,1,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,50594,A,,CHEMBL622644,,17729,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,5508,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,F,741.0,CHEMBL622645,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5509,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,F,741.0,CHEMBL622646,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5510,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,F,741.0,CHEMBL621238,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5511,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,F,741.0,CHEMBL621239,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5512,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,F,741.0,CHEMBL621240,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5513,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,F,741.0,CHEMBL621241,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5514,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,F,741.0,CHEMBL621242,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5515,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,F,741.0,CHEMBL620350,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5516,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,F,741.0,CHEMBL620351,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5517,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,F,741.0,CHEMBL620352,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5518,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,F,741.0,CHEMBL620353,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5519,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,F,741.0,CHEMBL620354,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5520,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,F,741.0,CHEMBL620355,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5521,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,F,741.0,CHEMBL620356,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5522,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,F,741.0,CHEMBL620357,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5523,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,F,741.0,CHEMBL620358,RPMI-8226,9424,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5524,1,,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,80433,F,741.0,CHEMBL620359,RPMI-8226,9424,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5525,1,,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,80433,F,741.0,CHEMBL620360,RPMI-8226,11544,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5526,1,,,Cytotoxicity of compound against 8226/DOX1V cells,80433,F,741.0,CHEMBL620361,RPMI-8226,17378,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5527,1,,,Cytotoxicity of compound against 8226/S cells,80433,F,741.0,CHEMBL620362,RPMI-8226,17378,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5528,1,,,Inhibitory concentration against 8226 myeloma cancer cell line,80433,F,741.0,CHEMBL620363,RPMI-8226,17079,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5529,1,,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,80433,F,741.0,CHEMBL620364,RPMI-8226,17079,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5530,1,,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,80647,F,854.0,CHEMBL620365,833K,13466,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5531,1,,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',80647,F,854.0,CHEMBL620366,833K,13466,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5532,1,,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,80647,F,854.0,CHEMBL620367,833K,2392,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5533,1,,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,80647,F,854.0,CHEMBL620368,833K,2392,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,5534,1,,,Inhibitory activity against caspase-1,22226,B,,CHEMBL620369,,6608,,Autocuration,,,0,U,,
,BAO_0000357,,,5535,1,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,45,B,,CHEMBL620370,,10199,1351.0,Autocuration,,,8,H,Enterococcus faecalis,
,BAO_0000219,,,5536,1,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,80648,F,705.0,CHEMBL620371,8701-BC,17749,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5537,1,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,80648,F,705.0,CHEMBL620372,8701-BC,17749,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,5538,1,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,22226,F,,CHEMBL876492,,1229,,Intermediate,,,0,U,,
,BAO_0000019,,,5539,1,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,22226,F,,CHEMBL620373,,1229,,Intermediate,,,0,U,,
,BAO_0000019,,,5540,1,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,22226,F,,CHEMBL620374,,1229,,Intermediate,,,0,U,,
,BAO_0000019,,,5541,1,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,22226,B,,CHEMBL620375,,6390,,Autocuration,,,0,U,,
,BAO_0000019,,,5542,1,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,F,,CHEMBL857902,,16219,1314.0,Autocuration,,,0,U,Streptococcus pyogenes,
,BAO_0000019,,,5543,1,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,F,,CHEMBL620376,,16219,1314.0,Autocuration,,,0,U,Streptococcus pyogenes,
,BAO_0000357,,,5544,1,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,11922,B,,CHEMBL620377,,17043,,Autocuration,,,8,H,,
,BAO_0000219,,,5545,1,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,F,324.0,CHEMBL620378,KB ,6929,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5546,1,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,A,324.0,CHEMBL620379,KB ,6929,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5547,1,,,In vitro cytotoxicity of compound was tested against 9KB cells.,22226,F,,CHEMBL620380,,7083,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,5548,1,,,Cytotoxic concentration against 9L cells was determined on day 3,80653,F,392.0,CHEMBL884006,9L,12446,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,5549,1,,,Tested in vitro for anticancer activity against 9L cells,80653,F,392.0,CHEMBL620381,9L,15345,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,5550,1,,,Tested in vitro for anticancer activity against 9L cells; Not determined,80653,F,392.0,CHEMBL620382,9L,15345,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,5551,1,,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,80682,F,646.0,CHEMBL620383,A549,6301,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5552,1,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,80682,F,646.0,CHEMBL876493,A549,4833,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5553,1,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,80682,F,646.0,CHEMBL620384,A549,4833,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5554,1,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,80682,F,646.0,CHEMBL620385,A549,4833,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5555,1,,,Cytotoxicity against human lung carcinoma A549 cell line,80682,F,646.0,CHEMBL620386,A549,13330,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5556,1,,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,25,F,646.0,CHEMBL620387,A549,17517,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5557,1,,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",25,F,646.0,CHEMBL621404,A549,17517,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5558,1,,,"In vitro growth inhibition of A549, lung carcinoma",80682,F,646.0,CHEMBL621405,A549,14425,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5559,1,,,"In vitro growth inhibition of A549, lung carcinoma.",80682,F,646.0,CHEMBL621406,A549,14425,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5560,1,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,F,646.0,CHEMBL621407,A549,5228,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5561,1,,,Cytotoxic activity against human lung cancer A549 cell line was determined,80682,F,646.0,CHEMBL621408,A549,5351,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5562,1,,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,80682,F,646.0,CHEMBL885345,A549,12198,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5563,1,,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,80682,F,646.0,CHEMBL621409,A549,13891,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5564,1,,,Cytotoxicity in A549 (human carcinoma) cell line.,80682,F,646.0,CHEMBL876034,A549,5677,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5565,1,,,Cytotoxicity on lung carcinoma (A-549) cell line,80682,F,646.0,CHEMBL621410,A549,13788,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5566,1,,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,80682,F,646.0,CHEMBL621411,A549,13384,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5567,1,,,Effective dose of compound against replication of A549 cell line was evaluated,80682,F,646.0,CHEMBL621412,A549,6726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5568,1,,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,80682,F,646.0,CHEMBL621413,A549,3455,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5569,1,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),80682,F,646.0,CHEMBL621414,A549,5726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5570,1,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,80682,F,646.0,CHEMBL621415,A549,5726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5571,1,,,The compound was evaluated for antiproliferative activity against A549 cell line,80682,F,646.0,CHEMBL621416,A549,3936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5572,1,,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,80682,F,646.0,CHEMBL621417,A549,14991,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5573,1,,,Concentration required for growth inhibition of human lung carcinoma cell line A549,80682,F,646.0,CHEMBL621418,A549,5243,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5574,1,,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,80682,F,646.0,CHEMBL621419,A549,12858,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5575,1,,,Growth inhibition against A549 cell line was evaluated,80682,F,646.0,CHEMBL621420,A549,6776,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5576,1,,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,80682,F,646.0,CHEMBL875823,A549,16558,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5577,1,,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,80682,F,646.0,CHEMBL621421,A549,4583,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5578,1,,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,80682,F,646.0,CHEMBL621422,A549,13514,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5579,1,,,Chemosensitivity against DT-diaphorase rich A549 cell lines,80682,F,646.0,CHEMBL884014,A549,15166,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5580,1,,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,F,646.0,CHEMBL621423,A549,13873,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5581,1,,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,80682,F,646.0,CHEMBL621424,A549,6447,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5582,1,,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,80682,F,646.0,CHEMBL621425,A549,2068,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5583,1,,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,80682,F,646.0,CHEMBL621426,A549,1863,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5584,1,,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,80682,F,646.0,CHEMBL621427,A549,13873,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5585,1,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,F,646.0,CHEMBL621428,A549,13873,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5586,1,,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,F,646.0,CHEMBL621429,A549,13873,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5587,1,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),80682,F,646.0,CHEMBL621430,A549,579,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5588,1,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,80682,F,646.0,CHEMBL621431,A549,579,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5589,1,,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,80682,F,646.0,CHEMBL621432,A549,4584,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5590,1,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,80682,F,646.0,CHEMBL621433,A549,5421,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5591,1,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,F,646.0,CHEMBL875824,A549,5421,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5592,1,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,F,646.0,CHEMBL621434,A549,5421,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5593,1,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,80682,F,646.0,CHEMBL621435,A549,5421,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5594,1,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,80682,F,646.0,CHEMBL621436,A549,14188,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5595,1,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,80682,F,646.0,CHEMBL621437,A549,14188,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5596,1,,,Compound was tested for the growth inhibition of A549 lung tumor cell line,80682,F,646.0,CHEMBL621438,A549,15354,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5597,1,,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,80682,F,646.0,CHEMBL621439,A549,14253,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5598,1,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,F,646.0,CHEMBL621440,A549,13873,9606.0,Intermediate,,,1,N,Homo sapiens,
In vivo,BAO_0000218,,,5599,1,,,Oral bioavailability in dog (conscious),50588,A,,CHEMBL621441,,3043,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5600,1,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,50588,A,,CHEMBL621442,,3045,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5601,1,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,50588,A,,CHEMBL621443,,3022,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5602,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621444,,4453,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5603,1,,,Oral bioavailability in dog,50588,A,,CHEMBL625133,,1696,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5604,1,,,Oral bioavailability in dog,50588,A,,CHEMBL625134,,5045,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5605,1,,,Oral bioavailability in dog (fasted),50588,A,,CHEMBL625135,,5356,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5606,1,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,50588,A,,CHEMBL625136,,17764,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5607,1,,,Oral bioavailability in dog,50588,A,,CHEMBL625137,,6448,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5608,1,,,Oral bioavailability in dog,50588,A,,CHEMBL625138,,1475,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5609,1,,,Percent bioavailability in dog,50588,A,,CHEMBL625139,,3788,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5610,1,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,50588,A,,CHEMBL872264,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5611,1,,,Oral bioavailability in dog,50588,A,,CHEMBL625140,,13397,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5612,1,,,The compound was evaluated for bioavailability in dogs; 34-44,50588,A,,CHEMBL624436,,2137,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5613,1,,,Bioavailability in dog (dose 4 mg/kg p.o.),50588,A,,CHEMBL624437,,2959,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5614,1,,,Oral bioavailability in dog,50588,A,,CHEMBL872261,,6448,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5615,1,,,8 hour trough Blood level in dog was measured after administration of compound,50588,A,,CHEMBL624438,,6084,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,5616,1,,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,50588,A,,CHEMBL624439,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,5617,1,,,C24 after oral administration at 5 mg/kg,50588,A,,CHEMBL624440,,6316,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5618,1,,,Clearance after oral and iv dosing in dogs,50588,A,,CHEMBL624441,,5238,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,5619,1,,,Clearance of the drug was measured in the plasma of dog,50588,A,,CHEMBL624442,,17796,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,5620,1,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,50588,A,,CHEMBL624443,,2652,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5621,1,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,A,,CHEMBL624444,,5654,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5622,1,,,Clearance of compound was determined in dogs,50588,A,,CHEMBL624445,,6621,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5623,1,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,50588,A,,CHEMBL624446,,6505,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5624,1,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,A,,CHEMBL624447,,5802,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5625,1,,,Plasma clearance in dog was determined,50588,A,,CHEMBL624448,,17267,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5626,1,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,A,,CHEMBL624449,,4521,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5627,1,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,50588,A,,CHEMBL624450,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5628,1,,,Plasma clearance in dog after administration of 1 mg/kg iv,50588,A,,CHEMBL875942,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5629,1,,,Plasma clearance in dogs,50588,A,,CHEMBL624451,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5630,1,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,50588,A,,CHEMBL624452,,5542,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5631,1,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,A,,CHEMBL624453,,5199,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5632,1,,,Plasma clearance after 15 mg/kg iv dose in Dogs,50588,A,,CHEMBL624454,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5633,1,,,Plasma clearance after 30 mg/kg po dose in Dogs,50588,A,,CHEMBL624455,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5634,1,,,Plasma administration to dogs,50588,A,,CHEMBL624456,,16367,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5635,1,,,Plasma clearance was determined,50588,A,,CHEMBL624457,,5505,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5636,1,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,50588,A,,CHEMBL624458,,6215,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5637,1,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,50588,A,,CHEMBL624459,,1466,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vitro,BAO_0000251,Liver,,5638,1,,Microsomes,Intrinsic clearance in human liver microsomes,102164,A,,CHEMBL624460,,5007,9606.0,Intermediate,,,2,S,Homo sapiens,2107.0
In vitro,BAO_0000251,Liver,,5639,1,,Microsomes,Intrinsic clearance in human liver microsomes,102164,A,,CHEMBL624461,,5007,9606.0,Intermediate,,,2,S,Homo sapiens,2107.0
In vivo,BAO_0000218,,,5640,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,A,,CHEMBL875943,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5641,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,A,,CHEMBL624462,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5642,1,,,Clearance in dog (dose 1 mg/kg i.v.),50588,A,,CHEMBL624463,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5643,1,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,50588,A,,CHEMBL624464,,6221,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5644,1,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,A,,CHEMBL624465,,5007,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5645,1,,,Plasma clearance after peroral administration at 10 mpk in dog,50588,A,,CHEMBL624466,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5646,1,,,Plasma clearance after peroral administration at 5 mpk in dog,50588,A,,CHEMBL624467,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5647,1,,,Plasma clearance after peroral administration at 5 mg/kg in dog,50588,A,,CHEMBL624468,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5648,1,,,Plasma clearance was measured in dog,50588,A,,CHEMBL624469,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5649,1,,,Plasma clearance was measured in dog,50588,A,,CHEMBL624470,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5650,1,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,A,,CHEMBL624471,,5983,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5651,1,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,50588,A,,CHEMBL624472,,5600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5652,1,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,50588,A,,CHEMBL622775,,17764,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5653,1,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,50588,A,,CHEMBL622776,,6039,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5654,1,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,50588,A,,CHEMBL622777,,6039,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5655,1,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,50588,A,,CHEMBL622778,,6039,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5656,1,,,Clearance by intravenous administration of 1.2 mg/kg in dog,50588,A,,CHEMBL622779,,4368,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5657,1,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,50588,A,,CHEMBL622780,,4305,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,5658,1,,,Clearance value was evaluated in dog plasma,50588,A,,CHEMBL622781,,1918,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,5659,1,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,A,,CHEMBL622782,,6005,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,5660,1,,,Compound was tested for plasma clearance in dog,50588,A,,CHEMBL622783,,4839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,5661,1,,,Pharmacokinetic property (Plasma clearance) was measured in dog,50588,A,,CHEMBL622784,,4239,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,5662,1,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,50594,A,,CHEMBL622785,,17729,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5663,1,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,50594,A,,CHEMBL622786,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5664,1,,,Area under curve value in mouse at a dose of 10 mg/kg,50594,A,,CHEMBL622787,,5302,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5665,1,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,A,,CHEMBL875949,,5506,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5666,1,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,A,,CHEMBL622788,,5506,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5667,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,F,,CHEMBL622789,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5668,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,F,,CHEMBL622790,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5669,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,F,,CHEMBL622791,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5670,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,F,,CHEMBL622792,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5671,1,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,50594,A,,CHEMBL622793,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5672,1,,,Area under curve was determined for the compound at 24 mg/Kg,50594,A,,CHEMBL622794,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5673,1,,,Area under curve was determined for the compound at 40 mg/Kg,50594,A,,CHEMBL622795,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5674,1,,,Area under curve was determined for the compound at 5 mg/Kg,50594,A,,CHEMBL621803,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5675,1,,,Area under the curve for the compound is obtained at dose 25 mg/kg,50594,A,,CHEMBL621804,,3132,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5676,1,,,Area under the curve for the compound was obtained when tested in mouse,50594,A,,CHEMBL621805,,3132,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5677,1,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,50594,A,,CHEMBL621806,,17837,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5678,1,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,50594,A,,CHEMBL621807,,17837,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5679,1,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,50594,A,,CHEMBL621808,,6062,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5680,1,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,50594,A,,CHEMBL621809,,4066,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5681,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,A,,CHEMBL621810,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5682,1,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,A,,CHEMBL875164,,14239,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5683,1,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,A,,CHEMBL621811,,14239,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5684,1,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",50594,A,,CHEMBL621812,,4890,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5685,1,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),50594,A,,CHEMBL621813,,429,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5686,1,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),50594,A,,CHEMBL621814,,429,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5687,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,50594,A,,CHEMBL621815,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5688,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,50594,A,,CHEMBL621816,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5689,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,A,,CHEMBL621817,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5690,1,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,50594,A,,CHEMBL621818,,6091,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5691,1,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,50594,A,,CHEMBL621819,,6091,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5692,1,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,50594,A,,CHEMBL621820,,6091,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5693,1,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,50594,A,,CHEMBL621821,,6091,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5694,1,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,50594,A,,CHEMBL621822,,6178,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5695,1,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,50594,A,,CHEMBL619474,,6178,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5696,1,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,A,,CHEMBL619475,,6619,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5697,1,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,A,,CHEMBL619476,,6619,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5698,1,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",50594,A,,CHEMBL619477,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5699,1,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",50594,A,,CHEMBL619478,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5700,1,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",50594,A,,CHEMBL619479,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5701,1,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",50594,A,,CHEMBL619480,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5702,1,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,50594,A,,CHEMBL619481,,3192,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5703,1,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,50594,A,,CHEMBL619482,,3192,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5704,1,,,Area under the curve was evaluated in mice after intravenous administration,50594,A,,CHEMBL619483,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5705,1,,,Area under the curve was evaluated in mice after oral administration,50594,A,,CHEMBL619484,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Plasma,,5706,1,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,50594,A,,CHEMBL619485,,16597,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,Plasma,,5707,1,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,50594,A,,CHEMBL619486,,16597,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,,,5708,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,A,,CHEMBL619487,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,5709,1,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,50594,A,,CHEMBL619488,,17734,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Blood,,5710,1,,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,50594,A,,CHEMBL620106,,7767,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000219,,,5711,1,,,The compound was tested in vitro for anticancer activity against 9L cells,80653,F,392.0,CHEMBL620107,9L,15345,,Intermediate,,,1,N,,
,BAO_0000019,,,5712,1,,,Anti proliferation activity determined; Weak effect,22226,F,,CHEMBL620283,,2181,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000219,,,5713,1,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,22226,F,,CHEMBL875176,,2181,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000219,,,5714,1,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,22226,F,,CHEMBL620284,,2181,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000219,,,5715,1,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,22226,F,,CHEMBL623515,,2181,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,5716,1,,,The cytotoxic activity was in vitro tested by 9PS assay method,22226,F,,CHEMBL623516,,10486,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000019,,,5717,1,,,The cytotoxic activity was in vitro tested by 9PS assay method.,22226,F,,CHEMBL623517,,10486,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000019,,,5718,1,,,Partition coefficient (logD6.5),22224,A,,CHEMBL857878,,15508,,Autocuration,,,0,U,,
,BAO_0000219,,,5719,1,,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,81034,F,478.0,CHEMBL623518,A2780,5242,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5720,1,,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),80018,F,455.0,CHEMBL624195,A-375,16167,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5721,1,,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,80852,F,500.0,CHEMBL624196,A-431,4782,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5722,1,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,F,500.0,CHEMBL624197,A-431,16093,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,5723,1,,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,80021,F,624.0,CHEMBL624198,A498,2596,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5724,1,,,in vitro cytotoxicity against A 498 cancer cell line,80021,F,624.0,CHEMBL621287,A498,2596,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5725,1,,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,80021,F,624.0,CHEMBL621288,A498,3239,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5726,1,,,Cytotoxic activity against A 498 renal cancer cell lines.,80021,F,624.0,CHEMBL876496,A498,1847,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5727,1,,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,80021,F,624.0,CHEMBL621289,A498,10553,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,5728,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,F,,CHEMBL621290,,16219,1280.0,Autocuration,,,0,U,Staphylococcus aureus,
,BAO_0000019,,,5729,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,F,,CHEMBL621291,,16219,1280.0,Autocuration,,,0,U,Staphylococcus aureus,
,BAO_0000019,,,5730,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,F,,CHEMBL621292,,16219,1280.0,Autocuration,,,0,U,Staphylococcus aureus,
,BAO_0000019,,,5731,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,F,,CHEMBL621293,,16219,1280.0,Autocuration,,,0,U,Staphylococcus aureus,
,BAO_0000219,,,5732,1,,,Inhibitory concentration required against A 549 lung cancer cell line,80682,F,646.0,CHEMBL621294,A549,4782,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5733,1,,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,80682,F,646.0,CHEMBL621295,A549,11805,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5734,1,,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,80682,F,646.0,CHEMBL884007,A549,11805,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5735,1,,,In vitro cytotoxicity against lung cancer A 549 cell lines,80682,F,646.0,CHEMBL621296,A549,2007,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5736,1,,,Compound was tested for its cytotoxicity against A 549 cell line,80682,F,646.0,CHEMBL621297,A549,4594,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5737,1,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",80682,F,646.0,CHEMBL839828,A549,6018,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5738,1,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",80682,F,646.0,CHEMBL620397,A549,6018,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5739,1,,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,80682,F,646.0,CHEMBL620398,A549,3599,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5740,1,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,F,646.0,CHEMBL620399,A549,2551,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5741,1,,,In vitro inhibition of A549 (human lung cancer) cell growth.,80682,F,646.0,CHEMBL620400,A549,16132,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5742,1,,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,80682,F,646.0,CHEMBL620401,A549,16132,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5743,1,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,F,646.0,CHEMBL620402,A549,2551,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5744,1,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),80682,F,646.0,CHEMBL620403,A549,2551,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000218,,,5745,1,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,22226,F,,CHEMBL620404,,11913,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,5746,1,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,104694,F,,CHEMBL620405,,12621,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,5747,1,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,104694,F,,CHEMBL620406,,12621,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,5748,1,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,104694,F,,CHEMBL620407,,12621,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,5749,1,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,104694,F,,CHEMBL620408,,12621,,Autocuration,,,4,H,,
In vivo,BAO_0000218,,,5750,1,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,104694,F,,CHEMBL620409,,12621,,Autocuration,,,4,H,,
,BAO_0000219,,,5751,1,,,Inhibition of A-498 human Renal cell proliferation,80021,F,624.0,CHEMBL620410,A498,3600,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000019,,,5752,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",22226,F,,CHEMBL620411,,1796,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,5753,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",22226,F,,CHEMBL620412,,1796,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000019,,,5754,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",22226,F,,CHEMBL876596,,1796,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000219,,,5755,1,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,80012,F,622.0,CHEMBL620413,A 172,16464,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5756,1,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,F,622.0,CHEMBL620414,A 172,16464,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5757,1,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,F,622.0,CHEMBL620415,A 172,16464,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5758,1,,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,80682,F,646.0,CHEMBL620416,A549,13617,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5759,1,,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,80682,F,646.0,CHEMBL620417,A549,4584,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5760,1,,,Cytotoxic activity evaluated against A549 tumor cells,80682,F,646.0,CHEMBL620418,A549,13799,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5761,1,,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,80682,F,646.0,CHEMBL620419,A549,16726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5762,1,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,80682,F,646.0,CHEMBL620420,A549,16109,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5763,1,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,80682,F,646.0,CHEMBL620421,A549,16109,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5764,1,,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,80682,F,646.0,CHEMBL620422,A549,15474,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5765,1,,,Cytotoxicity of compound against A549 cell line,80682,F,646.0,CHEMBL620423,A549,6851,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5766,1,,,Cytotoxicity against human lung cell carcinoma A549 cell line,80682,F,646.0,CHEMBL620424,A549,17534,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5767,1,,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,80682,F,646.0,CHEMBL620425,A549,2621,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5768,1,,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,80682,F,646.0,CHEMBL620426,A549,830,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5769,1,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,80682,F,646.0,CHEMBL620427,A549,14255,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5770,1,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,80682,F,646.0,CHEMBL620428,A549,14255,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5771,1,,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,80682,F,646.0,CHEMBL620429,A549,1590,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5772,1,,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,80682,F,646.0,CHEMBL620430,A549,6146,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5773,1,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,F,646.0,CHEMBL839887,A549,17427,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5774,1,,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,80682,F,646.0,CHEMBL620431,A549,5280,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5775,1,,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,80682,F,646.0,CHEMBL884010,A549,16786,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5776,1,,,In vitro cytotoxicity against A549 (human lung cancer),80682,F,646.0,CHEMBL620538,A549,5895,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5777,1,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,F,646.0,CHEMBL620539,A549,14297,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000218,,,5778,1,,,In vivo antiproliferative activity against A549 cell line,80682,F,646.0,CHEMBL623373,A549,17824,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5779,1,,,Inhibition of non-small-cell lung adenocarcinoma (A549),80682,F,646.0,CHEMBL623374,A549,14368,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5780,1,,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,80682,F,646.0,CHEMBL623375,A549,14368,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5781,1,,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,80682,F,646.0,CHEMBL623376,A549,14254,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5782,1,,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),80682,F,646.0,CHEMBL623377,A549,15897,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5783,1,,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80682,F,646.0,CHEMBL623378,A549,13866,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5784,1,,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,80682,F,646.0,CHEMBL623379,A549,13370,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5785,1,,,Inhibitory activity against A549 lung cancer cell line,80682,F,646.0,CHEMBL623380,A549,4862,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5786,1,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,80682,F,646.0,CHEMBL623381,A549,4862,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5787,1,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,80682,F,646.0,CHEMBL623382,A549,4862,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5788,1,,,Inhibitory concentration against A549 (lung cancer) cell line,80682,F,646.0,CHEMBL623383,A549,15970,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5789,1,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,F,646.0,CHEMBL623384,A549,17713,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5790,1,,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,80682,F,646.0,CHEMBL623385,A549,4833,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5791,1,,,Activity against A549 cancer cell line.,80682,F,646.0,CHEMBL623386,A549,13736,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5792,1,,,The compound was evaluated for cytotoxicity against A549 cell line,80682,F,646.0,CHEMBL884105,A549,4312,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5793,1,,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,80682,F,646.0,CHEMBL623387,A549,5421,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5794,1,,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,F,646.0,CHEMBL621568,A549,5421,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5795,1,,,Growth inhibitory activity was measured for human A549 tumor cell line.,80682,F,646.0,CHEMBL621569,A549,14717,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5796,1,,,Inhibitory activity against A549 lung cancer cell line,80682,F,646.0,CHEMBL621570,A549,4634,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5797,1,,,Inhibitory activity against A549 cell line; inactive,80682,F,646.0,CHEMBL621571,A549,1149,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5798,1,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,F,646.0,CHEMBL621572,A549,5421,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5799,1,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,F,646.0,CHEMBL621573,A549,5421,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5800,1,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,F,646.0,CHEMBL621574,A549,5421,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5801,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),80682,F,646.0,CHEMBL621575,A549,3320,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5802,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),80682,F,646.0,CHEMBL621576,A549,3320,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5803,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),80682,F,646.0,CHEMBL621577,A549,3320,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5804,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),80682,F,646.0,CHEMBL621578,A549,3320,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5805,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),80682,F,646.0,CHEMBL621579,A549,3320,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5806,1,,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,80682,F,646.0,CHEMBL621580,A549,5726,9606.0,Intermediate,,,1,N,Homo sapiens,
In vivo,BAO_0000218,,,5807,1,,,Plasma clearance (in vivo) in mongrel dogs was determined,50588,A,,CHEMBL621581,,17800,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5808,1,,,Plasma clearance was measured in dog,50588,A,,CHEMBL621582,,5985,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5809,1,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,A,,CHEMBL621583,,5530,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5810,1,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,A,,CHEMBL621584,,5530,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,5811,1,,,Tested for plasma clearance in dog,50588,A,,CHEMBL621585,,4839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,5812,1,,,The compound was tested for clearance in dog plasma.,50588,A,,CHEMBL621586,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5813,1,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",50588,A,,CHEMBL875835,,4838,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5814,1,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,50588,A,,CHEMBL621587,,4137,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,5815,1,,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,A,,CHEMBL621588,,5017,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vitro,BAO_0000218,Liver,,5816,1,,Microsomes,In vitro clearance in dog liver microsomes,50588,A,,CHEMBL621589,,17538,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2107.0
In vivo,BAO_0000218,,,5817,1,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,A,,CHEMBL621590,,6161,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5818,1,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,50588,A,,CHEMBL621591,,6161,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5819,1,,,Plasma clearance in dog,50588,A,,CHEMBL621592,,1696,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5820,1,,,Clearance rate in dog,50588,A,,CHEMBL621593,,6762,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,5821,1,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,A,,CHEMBL621594,,5932,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,5822,1,,,Clearance in dogs,50588,A,,CHEMBL621595,,6305,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5823,1,,,Plasma clearance in dogs,50588,A,,CHEMBL621596,,4942,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5824,1,,,Plasma clearance was determined,50588,A,,CHEMBL621597,,4219,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5825,1,,,Lower clearance in dog (i.v.) at 0.5 mpk,50588,A,,CHEMBL621598,,17853,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5826,1,,,Plasma clearance in Beagle dogs,50588,A,,CHEMBL621599,,4514,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5827,1,,,Plasma clearance (Clp) in dog,50588,A,,CHEMBL875836,,6448,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5828,1,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,50588,A,,CHEMBL621600,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5829,1,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,50588,A,,CHEMBL621601,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5830,1,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,50588,A,,CHEMBL618474,,6062,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5831,1,,,Plasma clearance of compound was determined in dog,50588,A,,CHEMBL618475,,6821,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5832,1,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,50588,A,,CHEMBL624524,,4709,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5833,1,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,A,,CHEMBL624525,,4521,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5834,1,,,Plasma clearance in dog was determined,50588,A,,CHEMBL624526,,5374,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5835,1,,,Plasma clearance was calculated in dog,50588,A,,CHEMBL624527,,6057,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5836,1,,,Plasma clearance at the dose of 2 mg/kg in dog,50588,A,,CHEMBL624528,,4727,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5837,1,,,Plasma clearance in dog,50588,A,,CHEMBL624529,,5145,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5838,1,,,Plasma clearance in dog,50588,A,,CHEMBL624530,,17657,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5839,1,,,Plasma clearance in dog; Unable to calculate,50588,A,,CHEMBL624531,,17657,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5840,1,,,Plasma clearance in rhesus monkey,50588,A,,CHEMBL624532,,5145,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5841,1,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,A,,CHEMBL624533,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5842,1,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,A,,CHEMBL624534,,6641,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5843,1,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,A,,CHEMBL624535,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5844,1,,,Plasma clearance was evaluated in dog,50588,A,,CHEMBL624536,,5472,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5845,1,,,Plasma clearance was evaluated in dog; Not tested,50588,A,,CHEMBL624537,,5472,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5846,1,,,Plasma clearance was evaluated in rhesus,50588,A,,CHEMBL624538,,5472,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5847,1,,,Plasma clearance was evaluated in rhesus; Not tested,50588,A,,CHEMBL624539,,5472,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5848,1,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,50588,A,,CHEMBL624540,,4257,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5849,1,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,A,,CHEMBL624541,,6679,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5850,1,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,A,,CHEMBL624542,,5546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5851,1,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,A,,CHEMBL624543,,6348,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5852,1,,,Clearance value at a dose of 0.2 mg/kg i.v.,50588,A,,CHEMBL624544,,5474,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,5853,1,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,50588,A,,CHEMBL624545,,6316,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,5854,1,,,Cmax after oral dose of compound at 3 mg/kg in dogs,50588,A,,CHEMBL624546,,17594,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5855,1,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,50588,A,,CHEMBL875957,,17594,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5856,1,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,A,,CHEMBL624547,,5802,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5857,1,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,A,,CHEMBL624548,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5858,1,,,Cmax in dog after administration of 1 mg/kg iv,50588,A,,CHEMBL624549,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,5859,1,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,50588,A,,CHEMBL624550,,1466,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,5860,1,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,50588,A,,CHEMBL621613,,6505,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5861,1,,,Cmax was determine after peroral administration at 10 mpk in dog,50588,A,,CHEMBL621614,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5862,1,,,Cmax was determine after peroral administration at 5 mpk in dog,50588,A,,CHEMBL623431,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5863,1,,,Cmax was determine after peroral administration at 5 mg/kg in dog,50588,A,,CHEMBL623432,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5864,1,,,Cmax after 0.3 mg/kg po administration in dog,50588,A,,CHEMBL623433,,5600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5865,1,,,Cmax after peroral administration in dogs at 2.4 uM/kg,50588,A,,CHEMBL623434,,17764,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5866,1,,,Cmax in dog after oral administration at 1 mg/kg,50588,A,,CHEMBL623435,,6123,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5867,1,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,50588,A,,CHEMBL623436,,6123,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5868,1,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,50588,A,,CHEMBL875958,,6757,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5869,1,,,Cmax value after 15 mg/kg iv dose in Dogs,50588,A,,CHEMBL623437,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Blood,,5870,1,,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623438,,7767,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,5871,1,,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623439,,7767,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Bone,,5872,1,,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623440,,7767,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,5873,1,,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623441,,7767,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,5874,1,,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623442,,7767,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,,,5875,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623469,,7767,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,5876,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623470,,7767,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,5877,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623471,,7767,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Heart,,5878,1,,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623472,,7767,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,5879,1,,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623473,,7767,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,5880,1,,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623474,,7767,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Kidney,,5881,1,,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623475,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,5882,1,,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623476,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,5883,1,,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL623477,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Intestine,,5884,1,,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL621896,,7767,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Intestine,,5885,1,,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL621897,,7767,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Intestine,,5886,1,,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL621898,,7767,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Liver,,5887,1,,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL621899,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,5888,1,,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL621900,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,5889,1,,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL621901,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Lung,,5890,1,,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL621902,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,5891,1,,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL621903,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,5892,1,,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL622587,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Muscle tissue,,5893,1,,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620285,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,5894,1,,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL875285,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,5895,1,,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620286,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,,,5896,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620287,,7767,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,5897,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620288,,7767,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,5898,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620289,,7767,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Intestine,,5899,1,,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620290,,7767,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Intestine,,5900,1,,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620291,,7767,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Intestine,,5901,1,,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620292,,7767,10090.0,Intermediate,,,1,N,Mus musculus,160.0
In vivo,BAO_0000218,Spleen,,5902,1,,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620293,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,5903,1,,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL620294,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,5904,1,,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL618614,,7767,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Stomach,,5905,1,,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL618615,,7767,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,5906,1,,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL618616,,7767,10090.0,Intermediate,,,1,N,Mus musculus,945.0
,BAO_0000219,,,5907,1,,,Cytotoxicity against A-172 human tumor cell lines,80012,F,622.0,CHEMBL618617,A 172,2036,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5908,1,,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,80012,F,622.0,CHEMBL618618,A 172,2357,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5909,1,,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,80014,F,623.0,CHEMBL618619,A204,1457,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5910,1,,,Tested for antiproliferative activity against A-2780 tumoral cell line,81034,F,478.0,CHEMBL618620,A2780,4379,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5911,1,,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,80018,F,455.0,CHEMBL618621,A-375,1093,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5912,1,,,Tested in vitro against A-375 cell line human melanoma,80018,F,455.0,CHEMBL618622,A-375,12152,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5913,1,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,80019,F,797.0,CHEMBL618623,A-427,16464,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5914,1,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,F,797.0,CHEMBL618624,A-427,16464,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5915,1,,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,80019,F,797.0,CHEMBL618625,A-427,16582,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5916,1,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,F,797.0,CHEMBL618626,A-427,16464,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5917,1,,,Antitumor activity on A-427 lung carcinoma cell lines,80019,F,797.0,CHEMBL618627,A-427,10413,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5918,1,,,Cytotoxic activity against human A-427 lung tumor cell line,80019,F,797.0,CHEMBL618628,A-427,6418,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5919,1,,,In vitro antitumor effects against human A-427 cell lines.,80019,F,797.0,CHEMBL618629,A-427,17134,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5920,1,,,In vitro inhibition of A-427 (human lung cancer) cell growth.,80019,F,797.0,CHEMBL618630,A-427,16132,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5921,1,,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,80019,F,797.0,CHEMBL618631,A-427,16132,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5922,1,,,Cytotoxic activity of compound against A-427 lung human tumor cell line,80019,F,797.0,CHEMBL618632,A-427,16780,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5923,1,,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,80852,F,500.0,CHEMBL618633,A-431,4085,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5924,1,,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,80021,F,624.0,CHEMBL619315,A498,1276,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5925,1,,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,80021,F,624.0,CHEMBL619316,A498,3498,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5926,1,,,Cytotoxicity against human kidney carcinoma A-498cell lines,80021,F,624.0,CHEMBL619317,A498,1169,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5927,1,,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,80021,F,624.0,CHEMBL619318,A498,4450,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5928,1,,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,80021,F,624.0,CHEMBL619319,A498,3311,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5929,1,,,Antitumor cytotoxic activity against A-498 cell line was determined,80021,F,624.0,CHEMBL619739,A498,4461,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5930,1,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,80021,F,624.0,CHEMBL619740,A498,3311,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5931,1,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,80021,F,624.0,CHEMBL883158,A498,3311,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5932,1,,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,80021,F,624.0,CHEMBL884012,A498,1457,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5933,1,,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,80021,F,624.0,CHEMBL619741,A498,3664,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5934,1,,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",80021,F,624.0,CHEMBL619742,A498,15895,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5935,1,,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,80682,F,646.0,CHEMBL876610,A549,11843,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5936,1,,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,80682,F,646.0,CHEMBL619743,A549,11843,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5937,1,,,In vitro antiproliferative activity against human A-549 NSCL cell line,80682,F,646.0,CHEMBL619744,A549,17705,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5938,1,,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,80682,F,646.0,CHEMBL619745,A549,17705,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5939,1,,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,80682,F,646.0,CHEMBL619746,A549,4369,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5940,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,80682,F,646.0,CHEMBL619747,A549,4369,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5941,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,80682,F,646.0,CHEMBL619748,A549,4369,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5942,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,80682,F,646.0,CHEMBL619749,A549,4369,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5943,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,80682,F,646.0,CHEMBL619750,A549,4369,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5944,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,80682,F,646.0,CHEMBL624014,A549,4369,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5945,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,80682,F,646.0,CHEMBL624015,A549,4369,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5946,1,,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,80682,F,646.0,CHEMBL885344,A549,4787,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5947,1,,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,80682,F,646.0,CHEMBL623224,A549,4787,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5948,1,,,Cytotoxic activity against A-549 cell line,80682,F,646.0,CHEMBL623225,A549,6513,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5949,1,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,80682,F,646.0,CHEMBL622698,A549,6690,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5950,1,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,80682,F,646.0,CHEMBL622699,A549,6690,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5951,1,,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",80682,F,646.0,CHEMBL622700,A549,12263,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5952,1,,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),80682,F,646.0,CHEMBL622701,A549,1054,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5953,1,,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),80682,F,646.0,CHEMBL622702,A549,1359,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5954,1,,,Cytotoxic activity against human lung carcinoma (A-549) cell line,80682,F,646.0,CHEMBL622703,A549,3547,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5955,1,,,Cytotoxic activity towards A-549 cells,80682,F,646.0,CHEMBL622704,A549,5771,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5956,1,,,"In vitro percent inhibition of A549, lung carcinoma.",80682,F,646.0,CHEMBL622705,A549,14425,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5957,1,,,"In vitro percent inhibition of A549, lung carcinoma",80682,F,646.0,CHEMBL622706,A549,14425,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5958,1,,,"In vitro percent inhibition of A549, lung carcinoma.",80682,F,646.0,CHEMBL622707,A549,14425,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5959,1,,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",80682,F,646.0,CHEMBL622708,A549,14425,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5960,1,,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,80682,F,646.0,CHEMBL622709,A549,5280,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5961,1,,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,80682,F,646.0,CHEMBL622710,A549,15176,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5962,1,,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,80682,F,646.0,CHEMBL622711,A549,15300,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,5963,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,F,646.0,CHEMBL622712,A549,17824,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,5964,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,F,646.0,CHEMBL622713,A549,17824,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,5965,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,F,646.0,CHEMBL622714,A549,17824,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,5966,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,F,646.0,CHEMBL622715,A549,17824,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,5967,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,F,646.0,CHEMBL622716,A549,17824,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5968,1,,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",80682,F,646.0,CHEMBL622717,A549,17824,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,5969,1,,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),80682,F,646.0,CHEMBL622718,A549,17528,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5970,1,,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,80682,F,646.0,CHEMBL622719,A549,6870,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5971,1,,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,F,646.0,CHEMBL622720,A549,6870,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5972,1,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,80682,F,646.0,CHEMBL622721,A549,6870,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5973,1,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,F,646.0,CHEMBL622722,A549,6870,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5974,1,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,F,646.0,CHEMBL876030,A549,16726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5975,1,,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",80682,F,646.0,CHEMBL620206,A549,6170,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5976,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,80682,F,646.0,CHEMBL620207,A549,6583,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5977,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,80682,F,646.0,CHEMBL620208,A549,6583,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5978,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,80682,F,646.0,CHEMBL620209,A549,6583,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5979,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,80682,F,646.0,CHEMBL620210,A549,6583,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5980,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,80682,F,646.0,CHEMBL621639,A549,6583,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5981,1,,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,80682,F,646.0,CHEMBL621640,A549,17321,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5982,1,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,80682,F,646.0,CHEMBL621641,A549,17528,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5983,1,,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,80682,F,646.0,CHEMBL621642,A549,12888,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,5984,1,,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,80682,F,646.0,CHEMBL621643,A549,4312,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5985,1,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,80682,F,646.0,CHEMBL621644,A549,4312,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5986,1,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,80682,F,646.0,CHEMBL621645,A549,4312,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,5987,1,,,In vitro antiproliferative activity against A549 cell line,80682,F,646.0,CHEMBL621646,A549,17737,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,5988,1,,,Synergism with indomethacin in A549 cells,80682,F,646.0,CHEMBL621647,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,5989,1,,,Synergism with tolmetin in A549 cells,80682,F,646.0,CHEMBL621648,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,5990,1,,,Synergism with sulindac in A549 cells,80682,F,646.0,CHEMBL621649,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,5991,1,,,Antagonism of indomethacin in A549 cells,80682,F,646.0,CHEMBL621650,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,5992,1,,,Antagonism of sulindac in A549 cells,80682,F,646.0,CHEMBL621651,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,5993,1,,,Antagonism of tolmetin in A549 cells,80682,F,646.0,CHEMBL621652,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,5994,1,,,Synergism with indomethacin in A549 cells,80682,F,646.0,CHEMBL621653,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,5995,1,,,Synergism with sulindac in A549 cells,80682,F,646.0,CHEMBL621654,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,5996,1,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,80682,F,646.0,CHEMBL621655,A549,6630,,Intermediate,,,1,N,,
In vivo,BAO_0000218,,,5997,1,,,Cmax value after 30 mg/kg po dose in Dogs,50588,A,,CHEMBL621656,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5998,1,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,A,,CHEMBL621657,,5944,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,5999,1,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,50588,A,,CHEMBL621658,,5944,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6000,1,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,A,,CHEMBL621659,,5944,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6001,1,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,50588,A,,CHEMBL621660,,5944,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6002,1,,,Cmax value after administration of 4 mg/Kg oral dose in dog,50588,A,,CHEMBL621661,,2959,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6003,1,,,Cmax value in dog,50588,A,,CHEMBL621662,,6241,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6004,1,,,Cmax value in dogs after oral administration at 1 mg/kg,50588,A,,CHEMBL621663,,6241,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6005,1,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,50588,A,,CHEMBL621664,,2652,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6006,1,,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,50588,A,,CHEMBL621665,,1806,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6007,1,,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,50588,A,,CHEMBL621666,,1806,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6008,1,,,Concentration maxima after oral dosing in dogs,50588,A,,CHEMBL621667,,1021,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6009,1,,,Concentration maxima after oral dosing in dogs; not available,50588,A,,CHEMBL876738,,1021,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6010,1,,,Concentration maxima after oral dosing in dogs; not available,50588,A,,CHEMBL621668,,1021,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6011,1,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,50588,A,,CHEMBL621669,,5444,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6012,1,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,50588,A,,CHEMBL621670,,5444,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6013,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,50588,A,,CHEMBL621671,,5444,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6014,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,50588,A,,CHEMBL622360,,5444,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6015,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,50588,A,,CHEMBL622361,,5444,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6016,1,,,Cmax in dog plasma after oral dose (1 mg/kg),50588,A,,CHEMBL622362,,5130,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6017,1,,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,50588,A,,CHEMBL622363,,3249,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6018,1,,,Maximal plasma concentration at a dose of 1 mg/kg,50588,A,,CHEMBL622364,,5473,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6019,1,,,Maximal plasma concentration at a dose of 1 mg/kg (oral),50588,A,,CHEMBL622365,,5474,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6020,1,,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,50588,A,,CHEMBL622533,,4657,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6021,1,,,Maximum concentration of compound in dog was evaluated.,50588,A,,CHEMBL622534,,3031,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6022,1,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,50588,A,,CHEMBL622535,,4527,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6023,1,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,50588,A,,CHEMBL876739,,4186,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6024,1,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,A,,CHEMBL622536,,5007,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6025,1,,,Maximum concentration obtained in dog plasma was determined,50588,A,,CHEMBL622537,,3132,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6026,1,,,Maximum concentration was determined,50588,A,,CHEMBL622538,,5006,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6027,1,,,Maximum concentration at the dose of 2 mg/kg in dog,50588,A,,CHEMBL627867,,4727,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6028,1,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,A,,CHEMBL627868,,1916,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6029,1,,,Maximum concentration was evaluated in dog plasma,50588,A,,CHEMBL627869,,1918,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6030,1,,,Maximum concentration was evaluated after 75 min after administration in dog,50588,A,,CHEMBL627870,,3045,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6031,1,,,Maximum plasma concentration determined in dog after oral administration of 17b,50588,A,,CHEMBL627871,,9579,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6032,1,,,Maximum plasma concentration determined in dog after oral administration of 2b,50588,A,,CHEMBL627872,,9579,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6033,1,,,Maximum plasma concentration in dog,50588,A,,CHEMBL627873,,933,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6034,1,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,50588,A,,CHEMBL627874,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6035,1,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,50588,A,,CHEMBL627875,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6036,1,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,50588,A,,CHEMBL627876,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6037,1,,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,50588,A,,CHEMBL627877,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6038,1,,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,A,,CHEMBL627878,,6348,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6039,1,,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,50588,A,,CHEMBL627879,,16367,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6040,1,,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,A,,CHEMBL875355,,1337,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6041,1,,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,A,,CHEMBL627880,,1337,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6042,1,,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,A,,CHEMBL627881,,5199,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6043,1,,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,A,,CHEMBL627882,,17650,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6044,1,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50588,A,,CHEMBL627883,,6679,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6045,1,,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,50588,A,,CHEMBL628526,,5356,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6046,1,,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,50588,A,,CHEMBL628527,,5356,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6047,1,,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,50588,A,,CHEMBL628528,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6048,1,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,50588,A,,CHEMBL628529,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6049,1,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,50588,A,,CHEMBL628530,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6050,1,,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,50588,A,,CHEMBL625243,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6051,1,,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,A,,CHEMBL625244,,3598,9615.0,Expert,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6052,1,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,50588,A,,CHEMBL625245,,4368,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6053,1,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,50588,A,,CHEMBL625246,,6265,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Stomach,,6054,1,,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,A,,CHEMBL625247,,7767,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Urine,,6055,1,,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,A,,CHEMBL625248,,7767,10090.0,Intermediate,,,1,N,Mus musculus,1088.0
In vivo,BAO_0000218,Urine,,6056,1,,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,50594,A,,CHEMBL625249,,7767,10090.0,Intermediate,,,1,N,Mus musculus,1088.0
In vivo,BAO_0000218,Urine,,6057,1,,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,50594,A,,CHEMBL625250,,7767,10090.0,Intermediate,,,1,N,Mus musculus,1088.0
,BAO_0000218,,,6058,1,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,50594,A,,CHEMBL625251,,17811,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6059,1,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,50594,A,,CHEMBL875356,,17811,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6060,1,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),50594,A,,CHEMBL625252,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Blood,,6061,1,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,A,,CHEMBL625253,,17827,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000218,,,6062,1,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),50594,A,,CHEMBL625254,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6063,1,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),50594,A,,CHEMBL625255,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6064,1,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),50594,A,,CHEMBL625256,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Blood,,6065,1,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,A,,CHEMBL625257,,17827,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000218,Blood,,6066,1,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),50594,A,,CHEMBL625258,,17827,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000218,,,6067,1,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),50594,A,,CHEMBL625259,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6068,1,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,50594,A,,CHEMBL625260,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6069,1,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,A,,CHEMBL625261,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6070,1,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,A,,CHEMBL625262,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6071,1,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,A,,CHEMBL622639,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6072,1,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,50594,A,,CHEMBL622640,,17257,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6073,1,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,50594,A,,CHEMBL622812,,17257,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6074,1,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,50594,A,,CHEMBL622813,,17257,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6075,1,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,50594,A,,CHEMBL622814,,17257,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6076,1,,,Time at maximum activity in mice (Radiolabeled compound),50594,A,,CHEMBL622815,,17827,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6077,1,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,50594,A,,CHEMBL625342,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6078,1,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,50594,A,,CHEMBL625343,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6079,1,,,Binding towards mouse plasma protein at 10 uM,50594,A,,CHEMBL877591,,17409,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6080,1,,,Binding towards mouse plasma protein at 100 uM,50594,A,,CHEMBL625344,,17409,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6081,1,,,Bioavailability was evaluated in mice after intravenous administration,50594,A,,CHEMBL625345,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6082,1,,,Bioavailability was evaluated in mice after oral administration,50594,A,,CHEMBL625346,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6083,1,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,50594,A,,CHEMBL625347,,3132,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6084,1,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,50594,A,,CHEMBL625348,,3132,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6085,1,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,50594,A,,CHEMBL625349,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6086,1,,,Oral bioavailability in mouse,50594,A,,CHEMBL625350,,2862,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6087,1,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,50594,A,,CHEMBL882952,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Brain,,6088,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL625351,,846,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,6089,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL625352,,846,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,6090,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL877592,,846,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,6091,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL625353,,846,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,6092,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL625354,,846,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,6093,1,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL626019,,846,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Heart,,6094,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL626020,,846,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,6095,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL626021,,846,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,6096,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL626022,,846,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,6097,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL626192,,846,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000219,,,6098,1,,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),80682,F,646.0,CHEMBL626193,A549,1276,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6099,1,,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,80682,F,646.0,CHEMBL626194,A549,3498,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6100,1,,,Cytotoxicity against human lung carcinoma A-549 cell lines,80682,F,646.0,CHEMBL626195,A549,1169,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6101,1,,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,80682,F,646.0,CHEMBL626196,A549,4450,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6102,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549,80682,F,646.0,CHEMBL626197,A549,358,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6103,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,80682,F,646.0,CHEMBL626198,A549,358,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6104,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,80682,F,646.0,CHEMBL626199,A549,358,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6105,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,80682,F,646.0,CHEMBL626200,A549,358,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6106,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,80682,F,646.0,CHEMBL626201,A549,358,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6107,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,80682,F,646.0,CHEMBL626202,A549,358,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6108,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,80682,F,646.0,CHEMBL626203,A549,358,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6109,1,,,In vitro cytotoxicity against A-549 human lung cancer cells,80682,F,646.0,CHEMBL626204,A549,15167,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6110,1,,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,80682,F,646.0,CHEMBL624701,A549,4139,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6111,1,,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,80682,F,646.0,CHEMBL624702,A549,833,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6112,1,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,F,646.0,CHEMBL624703,A549,15718,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6113,1,,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,80682,F,646.0,CHEMBL624704,A549,12373,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6114,1,,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,80682,F,646.0,CHEMBL624705,A549,637,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6115,1,,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,80682,F,646.0,CHEMBL624706,A549,14867,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6116,1,,,Antitumor cytotoxic activity against A-549 cell line was determined,80682,F,646.0,CHEMBL624707,A549,4461,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6117,1,,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",80682,F,646.0,CHEMBL624708,A549,5406,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6118,1,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,F,646.0,CHEMBL624709,A549,4457,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6119,1,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,F,646.0,CHEMBL884107,A549,1386,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6120,1,,,Antitumoral activity was assayed against A-549 cell line,80682,F,646.0,CHEMBL624710,A549,3265,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6121,1,,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,80682,F,646.0,CHEMBL624711,A549,2359,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6122,1,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,F,646.0,CHEMBL624712,A549,4457,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6123,1,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,F,646.0,CHEMBL624713,A549,12454,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6124,1,,,Compound was tested for inhibition of cell growth of A-549 cells,80682,F,646.0,CHEMBL624714,A549,1481,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6125,1,,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,80682,F,646.0,CHEMBL624715,A549,1750,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6126,1,,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,80682,F,646.0,CHEMBL624716,A549,5065,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6127,1,,,In vitro cytotoxicity against A549-human lung carcinoma cells.,80682,F,646.0,CHEMBL619505,A549,808,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6128,1,,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,80682,F,646.0,CHEMBL619506,A549,16364,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6129,1,,,Cytotoxic activity against A-549 cell lines.,80682,F,646.0,CHEMBL619507,A549,1847,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6130,1,,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,80682,F,646.0,CHEMBL619508,A549,1747,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6131,1,,,Cytotoxicity against human A549 non small cell lung cell lines,80682,F,646.0,CHEMBL619509,A549,1003,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6132,1,,,Inhibition of cell growth in (A-549) lung cell line,80682,F,646.0,CHEMBL619510,A549,15313,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6133,1,,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,80682,F,646.0,CHEMBL619511,A549,3122,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6134,1,,,In vitro antitumor activity against A-549 tumor cells.,80682,F,646.0,CHEMBL619512,A549,16049,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6135,1,,,In vitro antitumor effects against human A-549 cell lines.,80682,F,646.0,CHEMBL619513,A549,17134,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6136,1,,,In vitro cytotoxic activity of compound against A-549 cell line,80682,F,646.0,CHEMBL619514,A549,6406,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6137,1,,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,80682,F,646.0,CHEMBL619515,A549,627,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6138,1,,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,80682,F,646.0,CHEMBL619516,A549,12307,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6139,1,,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,80682,F,646.0,CHEMBL884005,A549,17861,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6140,1,,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,80682,F,646.0,CHEMBL619517,A549,6682,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6141,1,,,Inhibitory concentration of compound against A-549 cell line,80682,F,646.0,CHEMBL619518,A549,6663,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6142,1,,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,80682,F,646.0,CHEMBL619519,A549,2454,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6143,1,,,cytotoxic activity against leukemia (A-549) cancer cell line,80682,F,646.0,CHEMBL876489,A549,14709,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6144,1,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,F,646.0,CHEMBL619520,A549,15718,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6145,1,,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,80682,F,646.0,CHEMBL619521,A549,15718,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6146,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),80682,F,646.0,CHEMBL619522,A549,17130,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6147,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),80682,F,646.0,CHEMBL619523,A549,17130,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6148,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),80682,F,646.0,CHEMBL619524,A549,17130,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6149,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),80682,F,646.0,CHEMBL619525,A549,17130,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6150,1,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,80682,F,646.0,CHEMBL619526,A549,6630,,Intermediate,,,1,N,,
,BAO_0000219,,,6151,1,,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,80682,F,646.0,CHEMBL619527,A549,16726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6152,1,,,Cytotoxicity against A549 cells; No cytotoxicity,80682,F,646.0,CHEMBL619528,A549,17846,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6153,1,,,Cytotoxicity against human lung carcinoma (A549) cell lines,80682,F,646.0,CHEMBL619529,A549,3415,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6154,1,,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,80682,F,646.0,CHEMBL619530,A549,3415,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6155,1,,,In vitro anticancer activity against human lung (A549) cell line,80682,F,646.0,CHEMBL876490,A549,5609,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6156,1,,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,80682,F,646.0,CHEMBL619531,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6157,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619532,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6158,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619533,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6159,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619534,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6160,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL620164,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6161,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL620165,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6162,1,,,Inhibition of A549 human lung tumor cell proliferation,80682,F,646.0,CHEMBL620166,A549,16295,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6163,1,,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",80682,F,646.0,CHEMBL620167,A549,16825,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6164,1,,,In vitro cytotoxicity against human tumor cell line A549,80682,F,646.0,CHEMBL620168,A549,3439,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6165,1,,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,80682,F,646.0,CHEMBL620338,A549,10870,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6166,1,,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,80682,F,646.0,CHEMBL620339,A549,4845,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6167,1,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,80682,F,646.0,CHEMBL620340,A549,5822,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6168,1,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,80682,F,646.0,CHEMBL620341,A549,5822,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6169,1,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,80682,F,646.0,CHEMBL876491,A549,5822,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6170,1,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,F,646.0,CHEMBL620342,A549,16381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6171,1,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,F,646.0,CHEMBL620343,A549,16381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6172,1,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,F,646.0,CHEMBL620344,A549,16381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6173,1,,,In vitro anticancer activity against human lung (A549) cell line,80682,F,646.0,CHEMBL620345,A549,5609,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6174,1,,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,80682,F,646.0,CHEMBL620346,A549,4644,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6175,1,,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,80682,F,646.0,CHEMBL620347,A549,4644,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6176,1,,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,80682,F,646.0,CHEMBL620348,A549,4644,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6177,1,,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,80682,F,646.0,CHEMBL620349,A549,4644,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6178,1,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,80682,F,646.0,CHEMBL618667,A549,5822,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6179,1,,,Percentage inhibition of human lung carcinoma (A549) cell lines,80682,F,646.0,CHEMBL618668,A549,3415,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6180,1,,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,80682,F,646.0,CHEMBL876031,A549,16726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6181,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",80682,F,646.0,CHEMBL618759,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6182,1,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,F,646.0,CHEMBL618760,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6183,1,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,F,646.0,CHEMBL619000,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6184,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",80682,F,646.0,CHEMBL619001,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6185,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",80682,F,646.0,CHEMBL619002,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6186,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",80682,F,646.0,CHEMBL619003,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6187,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",80682,F,646.0,CHEMBL619597,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6188,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",80682,F,646.0,CHEMBL619598,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6189,1,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,80682,F,646.0,CHEMBL619599,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6190,1,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,80682,F,646.0,CHEMBL619600,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6191,1,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,F,646.0,CHEMBL619601,A549,16726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6192,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619602,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6193,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619603,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6194,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619604,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6195,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619605,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
In vivo,BAO_0000218,,,6196,1,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,50588,A,,CHEMBL619606,,6084,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6197,1,,,Pharmacokinetic activity (Cmax) in dog,50588,A,,CHEMBL876032,,6084,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6198,1,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,A,,CHEMBL619607,,4809,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6199,1,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,50588,A,,CHEMBL619608,,5983,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6200,1,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,50588,A,,CHEMBL619609,,6251,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6201,1,,,Cmax in dog plasma after 30mg/kg oral dose,50588,A,,CHEMBL619610,,5932,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Blood,,6202,1,,,Tested for the peak blood level in dog,50588,A,,CHEMBL619611,,4273,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,,,6203,1,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",50588,A,,CHEMBL619612,,5313,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6204,1,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",50588,A,,CHEMBL619613,,5313,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Blood,,6205,1,,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,50588,A,,CHEMBL619614,,6221,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
,BAO_0000218,,,6206,1,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,50588,A,,CHEMBL619615,,4709,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6207,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,50588,A,,CHEMBL619616,,167,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,6208,1,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,50588,A,,CHEMBL619617,,6241,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,6209,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,50588,A,,CHEMBL619618,,344,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6210,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,50588,A,,CHEMBL876033,,344,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6211,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,50588,A,,CHEMBL619619,,344,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6212,1,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,50588,A,,CHEMBL619620,,2189,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Urine,,6213,1,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,50588,A,,CHEMBL619621,,2189,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1088.0
,BAO_0000218,Urine,,6214,1,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,50588,A,,CHEMBL619622,,2189,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1088.0
,BAO_0000218,Urine,,6215,1,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,50588,A,,CHEMBL618874,,2189,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1088.0
In vivo,BAO_0000218,,,6216,1,,,Absolute bioavailability was evaluated in dog,50588,A,,CHEMBL618875,,4257,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6217,1,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,50588,A,,CHEMBL618876,,6221,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6218,1,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,50588,A,,CHEMBL618877,,6215,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6219,1,,,Bioavailability in dog,50588,A,,CHEMBL618878,,17267,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6220,1,,,Bioavailability in dog,50588,A,,CHEMBL618879,,6621,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6221,1,,,Bioavailability after intravenous administration in dogs,50588,A,,CHEMBL618880,,3854,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6222,1,,,Bioavailability after peroral administration in dogs,50588,A,,CHEMBL618881,,3854,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6223,1,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,A,,CHEMBL618882,,5007,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6224,1,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,50588,A,,CHEMBL624226,,4333,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6225,1,,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,50588,A,,CHEMBL624227,,4333,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6226,1,,,Bioavailability,50588,A,,CHEMBL624228,,5006,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6227,1,,,Bioavailability,50588,A,,CHEMBL624229,,5199,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6228,1,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,50588,A,,CHEMBL624230,,4368,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6229,1,,,Bioavailability in dog,50588,A,,CHEMBL624231,,3771,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6230,1,,,Bioavailability in dog,50588,A,,CHEMBL624232,,4953,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6231,1,,,Bioavailability in dog,50588,A,,CHEMBL625127,,5064,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6232,1,,,Bioavailability in dog,50588,A,,CHEMBL625128,,17657,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6233,1,,,Bioavailability in dog,50588,A,,CHEMBL621675,,17796,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6234,1,,,Bioavailability in dog (p.o.) at 2.0 mpk,50588,A,,CHEMBL621676,,17853,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6235,1,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),50588,A,,CHEMBL621677,,4521,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6236,1,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,A,,CHEMBL621678,,4521,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6237,1,,,Bioavailability in dog,50588,A,,CHEMBL621679,,5006,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6238,1,,,Bioavailability was evaluated after oral administration in dog,50588,A,,CHEMBL621680,,16365,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6239,1,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,A,,CHEMBL621681,,1916,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6240,1,,,Bioavailability was evaluated in dog,50588,A,,CHEMBL876740,,1918,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6241,1,,,Bioavailability in dog,50588,A,,CHEMBL621682,,4239,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6242,1,,,Bioavailability in dog,50588,A,,CHEMBL621683,,6505,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6243,1,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,A,,CHEMBL621684,,5334,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6244,1,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,A,,CHEMBL621685,,5334,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6245,1,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,A,,CHEMBL621686,,4809,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6246,1,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,A,,CHEMBL621687,,6348,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6247,1,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,50588,A,,CHEMBL621688,,6005,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6248,1,,,Bioavailability of compound in dog was determined after peroral administration,50588,A,,CHEMBL621689,,17804,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6249,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621690,,3184,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6250,1,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,50588,A,,CHEMBL621691,,1806,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6251,1,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,50588,A,,CHEMBL875941,,1806,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6252,1,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,50588,A,,CHEMBL621692,,1806,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6253,1,,,Bioavailability in dog,50588,A,,CHEMBL621693,,4839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6254,1,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),50588,A,,CHEMBL621694,,5017,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Heart,,6255,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL621695,,846,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,6256,1,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL621696,,846,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Kidney,,6257,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL621697,,846,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,6258,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL621698,,846,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,6259,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623420,,846,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,6260,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623421,,846,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,6261,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623422,,846,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,6262,1,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623423,,846,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,6263,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623424,,846,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,6264,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623425,,846,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,6265,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623426,,846,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,6266,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623427,,846,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,6267,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623428,,846,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,6268,1,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL875947,,846,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Lung,,6269,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623429,,846,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,6270,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL623430,,846,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,6271,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL622588,,846,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,6272,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL622589,,846,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,6273,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL622751,,846,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,6274,1,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,A,,CHEMBL622752,,846,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,,,6275,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL622753,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6276,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL622647,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6277,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL875163,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6278,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL622648,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6279,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL622649,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Brain,,6280,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL622650,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Brain,,6281,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL622651,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Brain,,6282,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL622652,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Brain,,6283,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL622653,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Brain,,6284,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL622654,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Heart,,6285,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL622655,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Heart,,6286,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL622656,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Heart,,6287,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL622657,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Heart,,6288,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL622658,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Heart,,6289,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL622659,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Kidney,,6290,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL624630,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
,BAO_0000218,Kidney,,6291,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL624631,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
,BAO_0000218,Kidney,,6292,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL624632,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
,BAO_0000219,,,6293,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,80682,F,646.0,CHEMBL624633,A549,17130,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6294,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,80682,F,646.0,CHEMBL624634,A549,17130,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6295,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),80682,F,646.0,CHEMBL624635,A549,17130,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6296,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),80682,F,646.0,CHEMBL624636,A549,17130,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6297,1,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,F,646.0,CHEMBL857055,A549,3263,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6298,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,80682,F,646.0,CHEMBL624637,A549,6663,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6299,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,80682,F,646.0,CHEMBL624638,A549,6663,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6300,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,80682,F,646.0,CHEMBL874366,A549,6663,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6301,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,80682,F,646.0,CHEMBL624639,A549,6663,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6302,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,80682,F,646.0,CHEMBL624640,A549,6663,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6303,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,80682,F,646.0,CHEMBL624641,A549,6663,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6304,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,80682,F,646.0,CHEMBL624642,A549,6663,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6305,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,80682,F,646.0,CHEMBL624643,A549,6663,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6306,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,80682,F,646.0,CHEMBL624644,A549,6663,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6307,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,80682,F,646.0,CHEMBL624645,A549,6663,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6308,1,,,The compound was evaluated for its cytotoxic potency against A-549 cell line,80682,F,646.0,CHEMBL619445,A549,3983,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6309,1,,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,80682,F,646.0,CHEMBL839886,A549,11141,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6310,1,,,Cytotoxic activity of compound against A-549 tumor cell line.,80682,F,646.0,CHEMBL619446,A549,5076,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6311,1,,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,80682,F,646.0,CHEMBL619447,A549,3311,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6312,1,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,80682,F,646.0,CHEMBL619448,A549,3311,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6313,1,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,80682,F,646.0,CHEMBL619449,A549,3311,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6314,1,,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,80682,F,646.0,CHEMBL619450,A549,5076,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6315,1,,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),80682,F,646.0,CHEMBL619451,A549,4150,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6316,1,,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,80682,F,646.0,CHEMBL619452,A549,2150,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6317,1,,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,80682,F,646.0,CHEMBL619453,A549,4644,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6318,1,,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,80682,F,646.0,CHEMBL874367,A549,263,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6319,1,,,Cytotoxic concentration against A-549 tumor cells.,80682,F,646.0,CHEMBL619454,A549,11333,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6320,1,,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,80682,F,646.0,CHEMBL619455,A549,11333,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6321,1,,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",80682,F,646.0,CHEMBL619456,A549,15895,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,6322,1,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,50191,F,,CHEMBL619457,,16677,470.0,Expert,,,1,N,Acinetobacter baumannii,
,BAO_0000218,,,6323,1,,,Activity against Acinetobacter calcoaceticus (AC54),50192,F,,CHEMBL619458,,10624,471.0,Intermediate,,,1,N,Acinetobacter calcoaceticus,
,BAO_0000218,,,6324,1,,,In vitro antifungal activity against Aspergillus flavus CM74,50274,F,,CHEMBL619459,,16717,5059.0,Expert,,,1,N,Aspergillus flavus,
,BAO_0000218,,,6325,1,,,In vitro antifungal activity against Aspergillus flavus CM74,50274,F,,CHEMBL619460,,16717,5059.0,Expert,,,1,N,Aspergillus flavus,
,BAO_0000218,,,6326,1,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,50416,F,,CHEMBL619461,,5513,746128.0,Intermediate,,,1,N,Aspergillus fumigatus,
,BAO_0000218,,,6327,1,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),50416,F,,CHEMBL619462,,15962,746128.0,Intermediate,,,1,N,Aspergillus fumigatus,
,BAO_0000218,,,6328,1,,,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,F,,CHEMBL620388,,15962,746128.0,Intermediate,,,1,N,Aspergillus fumigatus,
,BAO_0000218,,,6329,1,,,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,F,,CHEMBL620389,,15962,746128.0,Intermediate,,,1,N,Aspergillus fumigatus,
,BAO_0000218,,,6330,1,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),50416,F,,CHEMBL620390,,15962,746128.0,Intermediate,,,1,N,Aspergillus fumigatus,
,BAO_0000218,,,6331,1,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,F,,CHEMBL620391,,16717,746128.0,Expert,,,1,N,Aspergillus fumigatus,
,BAO_0000218,,,6332,1,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,F,,CHEMBL621073,,16717,746128.0,Expert,,,1,N,Aspergillus fumigatus,
,BAO_0000218,,,6333,1,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,50296,F,,CHEMBL621074,,8117,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6334,1,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,50366,F,,CHEMBL621075,,8117,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6335,1,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,F,,CHEMBL619554,,15472,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000218,,,6336,1,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,F,,CHEMBL619555,,15472,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000218,,,6337,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,50169,F,,CHEMBL619556,,16443,714.0,Intermediate,,,1,N,Aggregatibacter actinomycetemcomitans,
,BAO_0000218,,,6338,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,50169,F,,CHEMBL619557,,16443,714.0,Intermediate,,,1,N,Aggregatibacter actinomycetemcomitans,
,BAO_0000218,,,6339,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,50169,F,,CHEMBL619558,,16443,714.0,Intermediate,,,1,N,Aggregatibacter actinomycetemcomitans,
,BAO_0000219,,,6340,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619559,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6341,1,,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619560,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6342,1,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,F,646.0,CHEMBL619561,A549,16381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6343,1,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,F,646.0,CHEMBL619562,A549,16381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6344,1,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,F,646.0,CHEMBL619563,A549,16381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6345,1,,,GI values against A549 cells (lung cancer),80682,F,646.0,CHEMBL857457,A549,16381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6346,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,80682,F,646.0,CHEMBL619564,A549,17206,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6347,1,,,Inhibitory activity against A549 human adenocarcinoma,80682,F,646.0,CHEMBL619565,A549,16325,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,6348,1,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,80682,F,646.0,CHEMBL619566,A549,10708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,6349,1,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,80682,F,646.0,CHEMBL619567,A549,10708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6350,1,,,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,F,646.0,CHEMBL619568,A549,17376,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6351,1,,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,80682,F,646.0,CHEMBL619569,A549,17376,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6352,1,,,Cytotoxicity against human A549 lung cells,80682,F,646.0,CHEMBL619570,A549,17488,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,6353,1,,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,80682,F,646.0,CHEMBL619571,A549,17404,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6354,1,,,Growth inhibition of A549 (human lung carcinoma) cell line.,80682,F,646.0,CHEMBL619572,A549,10958,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6355,1,,,Effective dose required for inhibitory activity against A549 human tumor cell line.,80682,F,646.0,CHEMBL619573,A549,17099,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6356,1,,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,80682,F,646.0,CHEMBL619574,A549,17099,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6357,1,,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,80682,F,646.0,CHEMBL619575,A549,4096,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6358,1,,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,80682,F,646.0,CHEMBL619576,A549,4096,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6359,1,,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,80682,F,646.0,CHEMBL619577,A549,4096,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6360,1,,,In vitro inhibitory activity against A549 tumor cell culture,80682,F,646.0,CHEMBL619578,A549,2525,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6361,1,,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,80682,F,646.0,CHEMBL884009,A549,2525,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6362,1,,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),80682,F,646.0,CHEMBL619579,A549,5302,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6363,1,,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,80682,F,646.0,CHEMBL619580,A549,16325,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6364,1,,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,80682,F,646.0,CHEMBL619581,A549,16939,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6365,1,,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,80682,F,646.0,CHEMBL619582,A549,17229,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6366,1,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,80682,F,646.0,CHEMBL619583,A549,17380,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6367,1,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,80682,F,646.0,CHEMBL876502,A549,17380,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6368,1,,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,80682,F,646.0,CHEMBL619584,A549,1903,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6369,1,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,F,646.0,CHEMBL619585,A549,3838,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6370,1,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,F,646.0,CHEMBL619586,A549,14696,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6371,1,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,F,646.0,CHEMBL619587,A549,3838,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6372,1,,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,80682,F,646.0,CHEMBL619588,A549,1522,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6373,1,,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,80682,F,646.0,CHEMBL619589,A549,12400,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6374,1,,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,F,646.0,CHEMBL619590,A549,14696,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6375,1,,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),80682,F,646.0,CHEMBL619591,A549,14769,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6376,1,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,80682,F,646.0,CHEMBL619592,A549,14696,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6377,1,,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,80682,F,646.0,CHEMBL619593,A549,1888,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6378,1,,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,80682,F,646.0,CHEMBL620217,A549,12016,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6379,1,,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,80682,F,646.0,CHEMBL620218,A549,6058,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6380,1,,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,80682,F,646.0,CHEMBL620219,A549,17708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6381,1,,,Antitumor activity against A549/ATCC cell line,80682,F,646.0,CHEMBL620220,A549,12301,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6382,1,,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,80682,F,646.0,CHEMBL625141,A549,11970,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6383,1,,,In vitro cytotoxicity against A549/ATCC cell line.,80682,F,646.0,CHEMBL625142,A549,11818,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6384,1,,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,80682,F,646.0,CHEMBL625143,A549,12400,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6385,1,,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,80682,F,646.0,CHEMBL625144,A549,3381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6386,1,,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,80682,F,646.0,CHEMBL622474,A549,17376,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6387,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,80682,F,646.0,CHEMBL884104,A549,10708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6388,1,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,22226,F,,CHEMBL622475,,2964,9606.0,Autocuration,,,0,U,Homo sapiens,
In vivo,BAO_0000218,,,6389,1,,,Compound was tested for oral bioavailability in dogs,22224,A,,CHEMBL622476,,5005,9615.0,Intermediate,,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,6390,1,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,50588,A,,CHEMBL875831,,6229,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6391,1,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,50588,A,,CHEMBL622477,,6229,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6392,1,,,Oral bioavailability in dog,50588,A,,CHEMBL622478,,5374,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6393,1,,,Compound was tested for the oral bioavailability in dog; No availability,50588,A,,CHEMBL623172,,5374,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6394,1,,,Oral bioavailability in dog (dose 5 mg/kg),50588,A,,CHEMBL623173,,6265,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6395,1,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,A,,CHEMBL623174,,5654,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6396,1,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,A,,CHEMBL623175,,5654,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6397,1,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),50588,A,,CHEMBL623340,,16456,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6398,1,,,Oral bioavailability in dog (dose 5 mg/kg),50588,A,,CHEMBL623341,,5302,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6399,1,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),50588,A,,CHEMBL623342,,3624,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6400,1,,,Oral bioavailability of active FTIs in dogs,50588,A,,CHEMBL623343,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6401,1,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,A,,CHEMBL623344,,5802,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6402,1,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,A,,CHEMBL623345,,3598,9615.0,Expert,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6403,1,,,Oral bioavailability in dog,50588,A,,CHEMBL875832,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6404,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623346,,6762,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6405,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623347,,6821,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6406,1,,,Oral bioavailability of compound was determined in dog; Not tested,50588,A,,CHEMBL623348,,6821,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6407,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623349,,5210,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6408,1,,,Oral bioavailability (10 mg/kg) was determined in dog,50588,A,,CHEMBL623350,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6409,1,,,Oral bioavailability,50588,A,,CHEMBL623351,,761,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6410,1,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),50588,A,,CHEMBL623352,,761,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6411,1,,,Oral bioavailability administered in solution in rats,50588,A,,CHEMBL623353,,761,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6412,1,,,Oral bioavailability after 30 mg/kg po dose in Dogs,50588,A,,CHEMBL875833,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6413,1,,,Oral bioavailability at a dose of 1 mg/kg in dogs,50588,A,,CHEMBL623354,,5474,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6414,1,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),50588,A,,CHEMBL623355,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6415,1,,,Oral bioavailability in Dog; ND = not determined,50588,A,,CHEMBL623356,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6416,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623357,,3352,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6417,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623358,,6168,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6418,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623359,,5988,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6419,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623360,,4942,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6420,1,,,Oral bioavailability in dogs; No data,50588,A,,CHEMBL623361,,4942,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6421,1,,,Oral bioavailability measured in dogs,50588,A,,CHEMBL623362,,14541,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6422,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623363,,4449,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6423,1,,,Oral bioavailability was calculated in dog,50588,A,,CHEMBL623364,,6057,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6424,1,,,Oral bioavailability after 0.3 mg/kg po administration in dog,50588,A,,CHEMBL875834,,5600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6425,1,,,Oral bioavailability in dog (i.v. dosing),50588,A,,CHEMBL623365,,5542,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6426,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623366,,5542,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6427,1,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,50588,A,,CHEMBL623367,,5546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6428,1,,,Oral bioavailability in Beagle dogs,50588,A,,CHEMBL623368,,4514,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6429,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623369,,3624,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6430,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623370,,3854,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6431,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623371,,5836,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6432,1,,,Oral bioavailability in dog,50588,A,,CHEMBL623372,,5940,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6433,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621351,,6168,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6434,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621352,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6435,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621353,,6251,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6436,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621354,,6448,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6437,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621355,,6647,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6438,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621356,,5940,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6439,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621357,,933,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6440,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621358,,5210,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6441,1,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),50588,A,,CHEMBL621359,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6442,1,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,A,,CHEMBL621360,,6641,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6443,1,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,A,,CHEMBL621361,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6444,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621362,,5472,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6445,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621363,,5985,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6446,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621364,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6447,1,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),50588,A,,CHEMBL621166,,5530,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6448,1,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),50588,A,,CHEMBL621167,,5530,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6449,1,,,Oral bioavailability (F) in dogs,50588,A,,CHEMBL621168,,6305,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6450,1,,,Oral bioavailability in dog,50588,A,,CHEMBL621169,,5210,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6451,1,,,Bioavailability in dog,50588,A,,CHEMBL875950,,5238,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6452,1,,,Oral bioavailability in dog (dose 10 mg/kg),50588,A,,CHEMBL621170,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6453,1,,,Oral bioavailability after peroral administration at 5 mpk in Dog,50588,A,,CHEMBL621171,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6454,1,,,Oral bioavailability in dog (dose 5 mg/kg),50588,A,,CHEMBL621172,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6455,1,,,Oral bioavailability in dog (dose 10 mg/kg),50588,A,,CHEMBL621173,,6084,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Kidney,,6456,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL621174,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
,BAO_0000218,Kidney,,6457,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL621175,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
,BAO_0000218,Liver,,6458,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL621176,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Liver,,6459,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL621177,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Liver,,6460,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL621178,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Liver,,6461,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL621179,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Liver,,6462,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL621180,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Lung,,6463,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL875951,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Lung,,6464,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL621181,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Lung,,6465,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL621182,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Lung,,6466,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL621183,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Lung,,6467,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL621184,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,,,6468,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL621185,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6469,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL621186,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6470,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL621187,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6471,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL621188,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6472,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL621189,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Spleen,,6473,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL621190,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
,BAO_0000218,Spleen,,6474,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL618520,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
,BAO_0000218,Spleen,,6475,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL621739,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
,BAO_0000218,Spleen,,6476,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL621740,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
,BAO_0000218,Spleen,,6477,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL621741,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
,BAO_0000218,,,6478,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL621742,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6479,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL621743,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6480,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL621744,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6481,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL621745,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6482,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL621746,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6483,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL621747,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6484,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL621748,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6485,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL621749,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6486,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL621750,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6487,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL621751,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Heart,,6488,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL621752,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Heart,,6489,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL621753,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Heart,,6490,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL875955,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Heart,,6491,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL621754,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Heart,,6492,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL621755,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,948.0
,BAO_0000218,Liver,,6493,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL621756,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Liver,,6494,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL624199,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Liver,,6495,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL624200,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Liver,,6496,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL624375,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Liver,,6497,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL624376,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Lung,,6498,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL624377,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Lung,,6499,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL624378,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,,,6500,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,F,,CHEMBL857901,,12269,107673.0,Intermediate,,,1,N,aeinetobacter anitrotap,
,BAO_0000218,,,6501,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,F,,CHEMBL875274,,12269,107673.0,Intermediate,,,1,N,Acinetobacter calcoaceticus subsp. anitratus,
,BAO_0000218,,,6502,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,F,,CHEMBL624379,,12269,107673.0,Intermediate,,,1,N,Acinetobacter calcoaceticus subsp. anitratus,
,BAO_0000218,,,6503,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,F,,CHEMBL624380,,12269,107673.0,Intermediate,,,1,N,aeinetobacter anitrotap,
,BAO_0000218,,,6504,1,,,Activity against Acinetobacter calcoaceticus (AC54),50192,F,,CHEMBL624381,,10624,471.0,Intermediate,,,1,N,Acinetobacter calcoaceticus,
,BAO_0000218,,,6505,1,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,50714,F,,CHEMBL624382,,17216,28377.0,Intermediate,,,1,N,Anolis carolinensis,
,BAO_0000218,,,6506,1,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,50714,F,,CHEMBL624383,,17216,28377.0,Intermediate,,,1,N,Anolis carolinensis,
,BAO_0000218,,,6507,1,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,50296,F,,CHEMBL624384,,9560,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6508,1,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,50296,F,,CHEMBL624385,,9560,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6509,1,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,50296,F,,CHEMBL624386,,9560,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6510,1,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,50296,F,,CHEMBL624387,,9560,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6511,1,,,Plaque bactericidal index against Actinomyces naeslundii 631,50296,F,,CHEMBL624388,,9560,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6512,1,,,Plaque bactericidal index against Actinomyces naeslundii N/9,50296,F,,CHEMBL624389,,9560,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6513,1,,,Plaque bactericidal index against Actinomyces naeslundii B74,50296,F,,CHEMBL624390,,9560,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6514,1,,,Plaque bactericidal index against Actinomyces naeslundii N/3,50296,F,,CHEMBL875275,,9560,1655.0,Intermediate,,,1,N,Actinomyces naeslundii,
,BAO_0000218,,,6515,1,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,50056,F,,CHEMBL624391,,114,85549.0,Intermediate,,,1,N,Artemia salina,
,BAO_0000218,,,6516,1,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",50056,F,,CHEMBL623636,,114,85549.0,Intermediate,,,1,N,Artemia salina,
,BAO_0000218,,,6517,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,F,,CHEMBL623637,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6518,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,F,,CHEMBL623638,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6519,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,F,,CHEMBL623639,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6520,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,F,,CHEMBL623640,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6521,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,F,,CHEMBL623641,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6522,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,50532,F,,CHEMBL623642,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6523,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,F,,CHEMBL623643,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6524,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,F,,CHEMBL623644,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6525,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,F,,CHEMBL623645,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6526,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,F,,CHEMBL623646,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6527,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,F,,CHEMBL623647,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6528,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,50532,F,,CHEMBL623648,,10841,6253.0,Intermediate,,,1,N,Ascaris suum,
,BAO_0000218,,,6529,1,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,F,,CHEMBL623649,,8117,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6530,1,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,F,,CHEMBL623650,,8117,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6531,1,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,50366,F,,CHEMBL623651,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6532,1,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,50366,F,,CHEMBL623652,,9560,1656.0,Expert,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6533,1,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,50366,F,,CHEMBL623653,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6534,1,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,50366,F,,CHEMBL623654,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6535,1,,,Plaque bactericidal index against Actinomyces viscosus 8A06,50366,F,,CHEMBL623655,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6536,1,,,Plaque bactericidal index against Actinomyces viscosus M-100,50366,F,,CHEMBL623656,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6537,1,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,50366,F,,CHEMBL623657,,9560,1656.0,Expert,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6538,1,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,F,,CHEMBL623658,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6539,1,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,F,,CHEMBL623659,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6540,1,,,Plaque bactericidal index against Actinomyces viscosus 626,50366,F,,CHEMBL623660,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6541,1,,,Plaque bactericidal index against Actinomyces viscosus T14V,50366,F,,CHEMBL623661,,9560,1656.0,Intermediate,,,1,N,Actinomyces viscosus,
,BAO_0000218,,,6542,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,50535,F,,CHEMBL875281,,10986,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000218,,,6543,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,50535,F,,CHEMBL623662,,10986,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000218,,,6544,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,50535,F,,CHEMBL623663,,10986,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000218,,,6545,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,50535,F,,CHEMBL623664,,10986,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000218,,,6546,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,50535,F,,CHEMBL623665,,10986,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000219,,,6547,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,80023,F,165.0,CHEMBL621856,A673,10708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6548,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,80661,F,645.0,CHEMBL620432,A704,10708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6549,1,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,22226,F,,CHEMBL620433,,416,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000219,,,6550,1,,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,F,625.0,CHEMBL620434,A9,14354,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,6551,1,,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,F,625.0,CHEMBL620435,A9,14354,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,6552,1,,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,80024,F,625.0,CHEMBL620436,A9,5116,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6553,1,,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,80024,F,625.0,CHEMBL876597,A9,5116,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6554,1,,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,81037,F,874.0,CHEMBL620437,Human ovarian carcinoma cell line,15694,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6555,1,,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",80024,F,625.0,CHEMBL620438,A9,13038,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,6556,1,,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,80024,F,625.0,CHEMBL620439,A9,13038,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,6557,1,,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,80024,F,625.0,CHEMBL619657,A9,10923,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,6558,1,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,80024,F,625.0,CHEMBL619658,A9,10923,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,6559,1,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,80024,F,625.0,CHEMBL619659,A9,10923,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000019,,,6560,1,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",10649,F,,CHEMBL619660,,10923,,Expert,,,8,H,,
,BAO_0000219,,,6561,1,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,80024,F,625.0,CHEMBL619661,A9,10923,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,6562,1,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,80024,F,625.0,CHEMBL619662,A9,10923,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,6563,1,,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,80663,F,975.0,CHEMBL619663,AA6,8158,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6564,1,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,22226,F,,CHEMBL619664,,15494,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,6565,1,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",22226,F,,CHEMBL619665,,15494,9606.0,Autocuration,,,0,U,Homo sapiens,
,BAO_0000219,,,6566,1,,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),80662,F,974.0,CHEMBL883244,AA5,12348,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6567,1,,,Cytotoxicity was measured against AA5/HIV-1(IIIB),80662,F,974.0,CHEMBL884011,AA5,12348,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6568,1,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,80662,F,974.0,CHEMBL619666,AA5,2726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6569,1,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,80566,F,379.0,CHEMBL619667,U-937,2726,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6570,1,,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,80578,F,274.0,CHEMBL619668,UV4,10747,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6571,1,,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",80089,F,185.0,CHEMBL619669,CHO-AA8,11005,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6572,1,,,Average intracellular compound concentration when the hypoxic SER=1.6,80089,F,185.0,CHEMBL876608,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6573,1,,,Average intracellular compound concentration when the hypoxic SER=1.6.,80089,F,185.0,CHEMBL619670,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6574,1,,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,80089,F,185.0,CHEMBL619671,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6575,1,,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,80089,F,185.0,CHEMBL619672,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6576,1,,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,80089,F,185.0,CHEMBL619673,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6577,1,,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",80089,F,185.0,CHEMBL619674,CHO-AA8,13436,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6578,1,,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",80089,F,185.0,CHEMBL619675,CHO-AA8,13435,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6579,1,,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,80089,F,185.0,CHEMBL619676,CHO-AA8,13302,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6580,1,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,F,185.0,CHEMBL619677,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6581,1,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,A,185.0,CHEMBL619678,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6582,1,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,80089,A,185.0,CHEMBL619679,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6583,1,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,80089,A,185.0,CHEMBL619680,CHO-AA8,12878,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6584,1,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,80089,A,185.0,CHEMBL621457,CHO-AA8,12878,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6585,1,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,80089,F,185.0,CHEMBL876609,CHO-AA8,14367,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6586,1,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,80089,F,185.0,CHEMBL621458,CHO-AA8,14367,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6587,1,,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,80089,F,185.0,CHEMBL621459,CHO-AA8,12398,36483.0,Expert,,,1,N,hampster,
,BAO_0000219,,,6588,1,,,Aerobic growth inhibition in Chinese hamster cell line AA8,80089,F,185.0,CHEMBL621460,CHO-AA8,12878,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6589,1,,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,80089,F,185.0,CHEMBL621461,CHO-AA8,13820,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6590,1,,,Inhibition of growth under aerobic conditions in AA8 cells,80089,F,185.0,CHEMBL621462,CHO-AA8,13436,10029.0,Expert,,,1,N,Cricetulus griseus,
In vivo,BAO_0000218,,,6591,1,,,Oral bioavailability in dog (dose 10 mg/kg),50588,A,,CHEMBL621463,,6084,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6592,1,,,Oral bioavailability in dog at 10 mg/kg of the compound,50588,A,,CHEMBL621464,,5711,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6593,1,,,Oral bioavailability in dog (dose 5 uM/kg),50588,A,,CHEMBL621465,,4353,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6594,1,,,Oral bioavailability in dog (dose 5 uM/kg),50588,A,,CHEMBL621466,,4353,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6595,1,,,Oral bioavailability in dog (mongrel),50588,A,,CHEMBL621467,,17800,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6596,1,,,Oral bioavailability in dog (dose 10 mg/kg),50588,A,,CHEMBL621468,,3994,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6597,1,,,Oral bioavailability in dog (dose 10 mg/kg),50588,F,,CHEMBL876734,,3994,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6598,1,,,Bioavailability in dog,50588,A,,CHEMBL618476,,5145,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6599,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),50588,A,,CHEMBL618477,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6600,1,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),50588,A,,CHEMBL618478,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6601,1,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,50588,A,,CHEMBL618479,,5983,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6602,1,,,Bioavailability in dog,50588,A,,CHEMBL618480,,4273,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6603,1,,,Bioavailability in dog (dose 3-10 mg/kg),50588,A,,CHEMBL618481,,12500,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6604,1,,,The compound was tested for bioavailability of compound in plasma of dog; Complete,50588,A,,CHEMBL618482,,12500,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6605,1,,,Oral bioavailability in dog,50588,A,,CHEMBL618483,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6606,1,,,Oral bioavailability in dog,50588,A,,CHEMBL618484,,3880,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6607,1,,,Bioavailability in dog,50588,A,,CHEMBL618485,,4838,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6608,1,,,oral bioavailability was measured in dogs,50588,A,,CHEMBL618486,,15600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6609,1,,,Compound was tested for plasma protein binding in dog; Not determined,50588,A,,CHEMBL618487,,17248,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6610,1,,,Compound was tested for plasma protein binding of dog,50588,A,,CHEMBL618488,,17248,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6611,1,,,Compound was tested for plasma protein binding of dog; Not determined,50588,A,,CHEMBL876735,,17248,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6612,1,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,50588,A,,CHEMBL618489,,17443,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6613,1,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,50588,A,,CHEMBL618490,,4186,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6614,1,,,Half life was determined,50588,A,,CHEMBL618491,,3749,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6615,1,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,50588,A,,CHEMBL618492,,3249,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6616,1,,,Half life was evaluated in dog,50588,A,,CHEMBL873354,,3022,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6617,1,,,Half life was determined,50588,A,,CHEMBL618493,,3749,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6618,1,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,A,,CHEMBL618494,,2517,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Heart,,6619,1,,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,A,,CHEMBL618495,,2517,9615.0,Intermediate,,,1,N,Canis lupus familiaris,948.0
In vivo,BAO_0000218,Kidney,,6620,1,,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,A,,CHEMBL618496,,2517,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2113.0
In vivo,BAO_0000218,Liver,,6621,1,,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,A,,CHEMBL618497,,2517,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2107.0
In vivo,BAO_0000218,Lung,,6622,1,,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,A,,CHEMBL618498,,2517,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2048.0
In vivo,BAO_0000218,Spleen,,6623,1,,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,A,,CHEMBL618499,,2517,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2106.0
,BAO_0000218,,,6624,1,,,LogP in dog,50588,A,,CHEMBL876736,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6625,1,,,Partition coefficient (logP),50588,A,,CHEMBL618500,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6626,1,,,Partition coefficient in dog,50588,A,,CHEMBL857831,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6627,1,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,50588,A,,CHEMBL618501,,17764,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6628,1,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),50588,A,,CHEMBL618502,,4809,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6629,1,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,50588,A,,CHEMBL618503,,5600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6630,1,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),50588,A,,CHEMBL618504,,14294,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6631,1,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),50588,A,,CHEMBL618505,,14294,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6632,1,,,Metabolism of compound in dog S9 microsomes; Trace,50588,A,,CHEMBL618506,,14294,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Liver,,6633,1,,,In vitro metabolic potential in dog liver microsomes,50588,A,,CHEMBL618507,,6251,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2107.0
In vivo,BAO_0000218,,,6634,1,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,50588,A,,CHEMBL876737,,3748,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6635,1,,,Oral bioavailability in dog,50588,A,,CHEMBL618508,,2713,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6636,1,,,Oral bioavailability in dog,50588,A,,CHEMBL618509,,6512,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6637,1,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,A,,CHEMBL618510,,6679,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6638,1,,,The compound was tested for bioavailability in dogs,50588,A,,CHEMBL618511,,3749,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6639,1,,,The compound was tested for oral bioavailability in dogs,50588,A,,CHEMBL618512,,3749,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6640,1,,,Oral bioavailability in dog,50588,A,,CHEMBL618513,,6742,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6641,1,,,Compound was tested for percent protein binding (PB) in dog,50588,A,,CHEMBL618514,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6642,1,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,50588,A,,CHEMBL620052,,6874,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6643,1,,,Compound was evaluated for plasma clearance.,50588,A,,CHEMBL620053,,2877,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6644,1,,,The compound was tested for plasma clearance in dog,50588,A,,CHEMBL620054,,12500,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6645,1,,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,50588,A,,CHEMBL620055,,12500,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,6646,1,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,50588,A,,CHEMBL620056,,4709,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Liver,,6647,1,,,In vitro relative rate of metabolism was determined in dog liver microsomes,50588,A,,CHEMBL620057,,5542,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2107.0
In vivo,BAO_0000218,,,6648,1,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,50588,A,,CHEMBL618939,,17594,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6649,1,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,A,,CHEMBL618940,,2652,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6650,1,,,Half life after intravenous administration in dogs at 1.2 uM/kg,50588,A,,CHEMBL618941,,17764,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Lung,,6651,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL624473,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Lung,,6652,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL624474,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Lung,,6653,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL624475,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,,,6654,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,50594,A,42.0,CHEMBL624476,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6655,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,50594,A,42.0,CHEMBL623478,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6656,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,50594,A,42.0,CHEMBL623479,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6657,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,50594,A,42.0,CHEMBL623480,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6658,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,50594,A,42.0,CHEMBL623481,CCRF S-180,6599,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Brain,,6659,1,,,C2 in brain of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623482,,17641,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Kidney,,6660,1,,,C2 in kidney of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623483,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
,BAO_0000218,Liver,,6661,1,,,C2 in liver of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623484,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
,BAO_0000218,Lung,,6662,1,,,C2 in lungs of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623485,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000218,Spleen,,6663,1,,,C2 in spleen of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623486,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,,,6664,1,,,Plasma clearance in mouse,50594,A,,CHEMBL623487,,17852,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6665,1,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,50594,A,,CHEMBL623488,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6666,1,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,50594,A,,CHEMBL623489,,17837,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6667,1,,,Clearance was evaluated in mice after intravenous administration,50594,A,,CHEMBL875157,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6668,1,,,Clearance was evaluated in mice after oral administration,50594,A,,CHEMBL623490,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6669,1,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,50594,A,,CHEMBL623491,,4239,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6670,1,,,Plasma clearance of compound was determined at 40 mg/Kg,50594,A,,CHEMBL623492,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6671,1,,,Plasma clearance of at 24 mg/Kg,50594,A,,CHEMBL623493,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6672,1,,,Plasma clearance at 24 mg/Kg,50594,A,,CHEMBL623494,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6673,1,,,Plasma clearance at 5 mg/Kg,50594,A,,CHEMBL623495,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6674,1,,,Plasma clearance in mice,50594,A,,CHEMBL623496,,5727,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6675,1,,,Plasma clearance value upon iv administration in mouse,50594,A,,CHEMBL623497,,2862,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Plasma,,6676,1,,,Total plasma clearance in mice,50594,A,,CHEMBL623498,,5980,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,,,6677,1,,,Clearance in mouse,50594,A,,CHEMBL623499,,17592,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6678,1,,,Clearance value was determined,50594,A,,CHEMBL623500,,17718,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6679,1,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,50594,A,,CHEMBL623501,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000100,,,6680,1,,,Calculated partition coefficient (clogP),22229,P,,CHEMBL875158,,17384,,Intermediate,,,0,U,,
In vivo,BAO_0000218,,,6681,1,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,50594,A,,CHEMBL623502,,6062,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6682,1,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,50594,A,,CHEMBL623503,,17734,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6683,1,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,A,,CHEMBL623504,,6348,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6684,1,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,50594,A,,CHEMBL623505,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6685,1,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,50594,A,,CHEMBL623506,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6686,1,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,A,,CHEMBL623507,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6687,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,50594,A,,CHEMBL623508,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6688,1,,,Cmax after oral administration at 30 mg/kg in ICR mouse,50594,A,,CHEMBL623509,,5781,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6689,1,,,Cmax after peroral administration in mice at 2.4 uM/kg,50594,A,,CHEMBL875159,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Brain,,6690,1,,,Cmax in brain of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623510,,17641,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Kidney,,6691,1,,,Cmax in kidney of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623511,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,6692,1,,,Cmax in liver of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623512,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Lung,,6693,1,,,Cmax in lungs of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL623513,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,,,6694,1,,,Cmax in mice at 18 uM/kg i.p. administration,50594,F,,CHEMBL623514,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6695,1,,,Cmax in mice at 23 uM/kg i.v. administration,50594,F,,CHEMBL622609,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6696,1,,,Cmax in mice at 24 uM/kg i.p. administration,50594,F,,CHEMBL622610,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6697,1,,,Cmax in mice at 25 uM/kg i.p. administration,50594,F,,CHEMBL621823,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6698,1,,,Cmax in mice at 26 uM/kg i.p. administration,50594,F,,CHEMBL621824,,17764,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Spleen,,6699,1,,,Cmax in spleen of mice at the oral dose of 50 mg/kg,50594,A,,CHEMBL621825,,17641,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,,,6700,1,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,A,,CHEMBL621826,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6701,1,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,50594,A,,CHEMBL621827,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6702,1,,,Cmax value was determined,50594,A,,CHEMBL621828,,5727,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6703,1,,,Cmax value in IRC mice,50594,A,,CHEMBL621829,,5951,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6704,1,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,A,,CHEMBL621830,,5506,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6705,1,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,A,,CHEMBL621831,,5506,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Plasma,,6706,1,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,A,,CHEMBL621832,,14239,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6707,1,,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",50594,A,,CHEMBL624579,,4890,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,,,6708,1,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,50594,A,,CHEMBL624580,,429,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6709,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,50535,F,,CHEMBL624581,,10986,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000218,,,6710,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,50535,F,,CHEMBL624582,,10986,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000218,,,6711,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,50535,F,,CHEMBL624583,,10986,6277.0,Intermediate,,,1,N,Acanthocheilonema viteae,
,BAO_0000219,,,6712,1,,,Inhibitory activity against human tumor cell line A0375 melanoma.,80018,F,455.0,CHEMBL624584,A-375,13227,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000249,,,6713,1,,Brain membranes,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,12512,B,,CHEMBL624585,,4481,10116.0,Expert,,,9,D,Rattus norvegicus,
,BAO_0000019,,,6714,1,,,Forskolin-induced cAMP production at human A1 adenosine receptor,114,F,,CHEMBL875165,,16931,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,6715,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,114,F,449.0,CHEMBL619490,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6716,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,F,449.0,CHEMBL619491,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6717,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,114,F,449.0,CHEMBL619492,CHO,3850,,Expert,,,8,H,,
,BAO_0000219,,,6718,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,114,F,449.0,CHEMBL619493,CHO,3850,,Expert,,,8,H,,
,BAO_0000219,,,6719,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,114,F,449.0,CHEMBL619494,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6720,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,114,F,449.0,CHEMBL619495,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6721,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,114,F,449.0,CHEMBL619496,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6722,1,,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,F,449.0,CHEMBL619497,CHO,3850,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000219,,,6723,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,114,F,449.0,CHEMBL619498,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6724,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,114,F,449.0,CHEMBL619499,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6725,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,114,F,449.0,CHEMBL619500,CHO,3850,,Expert,,,8,H,,
,BAO_0000219,,,6726,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,114,F,449.0,CHEMBL619501,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6727,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,114,F,449.0,CHEMBL619502,CHO,3850,,Expert,,,8,H,,
,BAO_0000219,,,6728,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,114,F,449.0,CHEMBL619503,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6729,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,F,449.0,CHEMBL619504,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6730,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,114,F,449.0,CHEMBL621298,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6731,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,114,F,449.0,CHEMBL621299,CHO,3850,,Expert,,,8,H,,
,BAO_0000219,,,6732,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,114,F,449.0,CHEMBL621300,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6733,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,114,F,449.0,CHEMBL621301,CHO,3850,,Autocuration,,,8,H,,
,BAO_0000219,,,6734,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,F,449.0,CHEMBL621302,CHO,3850,,Expert,,,8,H,,
,BAO_0000219,,,6735,1,,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,80013,F,164.0,CHEMBL621303,A10,12680,9986.0,Intermediate,,,1,N,Oryctolagus cuniculus,
,BAO_0000219,,,6736,1,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,22226,F,164.0,CHEMBL621304,A10,1313,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000219,,,6737,1,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,22226,F,164.0,CHEMBL621305,A10,1313,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000219,,,6738,1,,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,80013,F,164.0,CHEMBL621306,A10,17567,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,6739,1,,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,80013,F,164.0,CHEMBL618444,A10,17567,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,6740,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,80013,F,164.0,CHEMBL618445,A10,11819,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,6741,1,,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,80089,F,185.0,CHEMBL618446,CHO-AA8,13436,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6742,1,,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,80089,F,185.0,CHEMBL618447,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6743,1,,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,80089,F,185.0,CHEMBL618448,CHO-AA8,12651,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6744,1,,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,80089,F,185.0,CHEMBL618449,CHO-AA8,13300,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6745,1,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,80089,F,185.0,CHEMBL618637,CHO-AA8,15296,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6746,1,,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",80089,F,185.0,CHEMBL618638,CHO-AA8,15328,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6747,1,,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),80089,F,185.0,CHEMBL618639,CHO-AA8,13302,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6748,1,,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",80089,F,185.0,CHEMBL618640,CHO-AA8,14367,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6749,1,,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,80089,F,185.0,CHEMBL618641,CHO-AA8,17002,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6750,1,,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,80089,F,185.0,CHEMBL618642,CHO-AA8,13436,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6751,1,,,Inhibitory activity against aerobic growth of AA8 cells.,80089,F,185.0,CHEMBL618643,CHO-AA8,13435,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6752,1,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,A,185.0,CHEMBL884013,CHO-AA8,10503,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6753,1,,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,F,185.0,CHEMBL622723,CHO-AA8,10503,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6754,1,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,F,185.0,CHEMBL622724,CHO-AA8,10503,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6755,1,,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,80089,F,185.0,CHEMBL622725,CHO-AA8,15090,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6756,1,,,Cytotoxicity against AA8 cell line,80089,F,185.0,CHEMBL622726,CHO-AA8,10368,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6757,1,,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),80089,F,185.0,CHEMBL622727,CHO-AA8,12651,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6758,1,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,A,185.0,CHEMBL622728,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6759,1,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,F,185.0,CHEMBL622729,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6760,1,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,A,185.0,CHEMBL622730,CHO-AA8,12687,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6761,1,,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,80089,F,185.0,CHEMBL622731,CHO-AA8,1890,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6762,1,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,F,185.0,CHEMBL622732,CHO-AA8,10747,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6763,1,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,F,185.0,CHEMBL622733,CHO-AA8,10747,10029.0,Intermediate,,,1,N,Cricetulus griseus,
,BAO_0000218,,,6764,1,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),22224,F,,CHEMBL622734,,11616,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6765,1,,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,80089,F,185.0,CHEMBL622735,CHO-AA8,11616,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6766,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,22224,F,185.0,CHEMBL618746,CHO-AA8,3471,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6767,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,22224,F,185.0,CHEMBL618747,CHO-AA8,3471,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6768,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,22224,F,185.0,CHEMBL620540,CHO-AA8,3471,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6769,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,22224,F,185.0,CHEMBL620541,CHO-AA8,3471,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6770,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,22224,F,185.0,CHEMBL620542,CHO-AA8,3471,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6771,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,22224,F,185.0,CHEMBL620543,CHO-AA8,3471,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6772,1,,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,22224,F,185.0,CHEMBL618832,CHO-AA8,3471,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6773,1,,,Concentration required to reduce AA8 cell survival by 10%,80089,F,185.0,CHEMBL618833,CHO-AA8,11616,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6774,1,,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",22224,F,185.0,CHEMBL618834,CHO-AA8,2656,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6775,1,,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,F,185.0,CHEMBL618835,CHO-AA8,10518,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6776,1,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,F,185.0,CHEMBL618836,CHO-AA8,10518,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6777,1,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,22224,F,185.0,CHEMBL618837,CHO-AA8,10518,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6778,1,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,22224,F,185.0,CHEMBL618838,CHO-AA8,10518,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6779,1,,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,22224,F,185.0,CHEMBL618839,CHO-AA8,16156,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6780,1,,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,22224,F,185.0,CHEMBL618840,CHO-AA8,2656,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000019,,,6781,1,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",22224,F,,CHEMBL618841,,11005,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6782,1,,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,22224,F,185.0,CHEMBL618842,CHO-AA8,11942,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6783,1,,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,22224,F,185.0,CHEMBL618843,CHO-AA8,2128,10029.0,Autocuration,,,0,U,Cricetulus griseus,
In vivo,BAO_0000218,,,6784,1,,,Half life period after 15 mg/kg iv dose in Dogs,50588,A,,CHEMBL618844,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6785,1,,,Half life period after 30 mg/kg po dose in Dogs,50588,A,,CHEMBL618845,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6786,1,,,Half life was measured after oral 2b administration (tested in 6 dogs),50588,A,,CHEMBL618846,,9579,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6787,1,,,Half life was measured in dog after oral 17b administration,50588,A,,CHEMBL618847,,9579,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6788,1,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,50588,A,,CHEMBL618848,,9579,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6789,1,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,50588,A,,CHEMBL618849,,9579,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6790,1,,,Tmax value after 15 mg/kg iv dose in Dogs,50588,A,,CHEMBL618850,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6791,1,,,Tmax value after 30 mg/kg po dose in Dogs,50588,A,,CHEMBL618851,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6792,1,,,Compound was evaluated for its half life when administered intravenously in dog,50588,A,,CHEMBL873815,,3184,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6793,1,,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,A,,CHEMBL618852,,5017,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,6794,1,,,Elimination Half-life of compound was determined in dog,50588,A,,CHEMBL618853,,6821,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6795,1,,,Half life of compound in dog following oral administration,50588,A,,CHEMBL618854,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6796,1,,,Half life of compound was determined in dog,50588,A,,CHEMBL618855,,17267,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Blood,,6797,1,,,Half life of compound was determined in dog blood,50588,A,,CHEMBL618856,,4727,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,,,6798,1,,,Half life after oral and iv dosing in dogs,50588,A,,CHEMBL875827,,5238,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6799,1,,,Half life in dogs in hours,50588,A,,CHEMBL618857,,4942,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6800,1,,,Half life on i.v. administration of 2 mg/kg was measured in dog,50588,A,,CHEMBL618858,,6505,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6801,1,,,t1/2 in dog after oral dose (1 mg/kg),50588,A,,CHEMBL618859,,5130,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6802,1,,,Half life was evaluated in dog,50588,A,,CHEMBL618860,,1475,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6803,1,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,50588,A,,CHEMBL618861,,17804,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6804,1,,,Half life period of compound was determined after peroral administration at 2 mg/kg,50588,A,,CHEMBL622539,,17804,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6805,1,,,Half life period (10 mg/kg) was determined in dog,50588,A,,CHEMBL622540,,6084,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6806,1,,,Half life period (10 mg/kg) was determined in dog,50588,A,,CHEMBL873803,,6084,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6807,1,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,50588,A,,CHEMBL873804,,5542,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6808,1,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,50588,A,,CHEMBL624311,,5542,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6809,1,,,Half life period in dog,50588,A,,CHEMBL624312,,6084,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6810,1,,,Half life period in dogs after oral administration at 1 mg/kg,50588,A,,CHEMBL624313,,6241,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6811,1,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,A,,CHEMBL624314,,1916,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6812,1,,,Half-life of compound was determined in dogs,50588,A,,CHEMBL624315,,6621,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,6813,1,,,Half-life in dog plasma,50588,A,,CHEMBL624316,,1696,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,6814,1,,,Half-life in mongrel dogs was determined,50588,A,,CHEMBL624317,,17800,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6815,1,,,Half-life in dog upon oral administration,50588,A,,CHEMBL624318,,17657,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6816,1,,,Half-life in dog upon oral administration; Unable to calculate,50588,A,,CHEMBL624319,,17657,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6817,1,,,Half-life was measured in dog,50588,A,,CHEMBL624496,,4239,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6818,1,,,Half-life was measured in dog,50588,A,,CHEMBL624497,,5985,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6819,1,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,50588,A,,CHEMBL624498,,9932,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6820,1,,,Oral half life was determined,50588,A,,CHEMBL624499,,5199,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6821,1,,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,50588,A,,CHEMBL624500,,5199,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,6822,1,,,Plasma half life was evaluated,50588,A,,CHEMBL624501,,1475,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,6823,1,,,Plasma half life was evaluated in Dog,50588,A,,CHEMBL623666,,1475,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,6824,1,,,Plasma half life was evaluated in dog,50588,A,,CHEMBL623667,,1475,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6825,1,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,50588,A,,CHEMBL623668,,6316,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6826,1,,,Tested for the half life value in dog,50588,A,,CHEMBL623669,,4883,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6827,1,,,Maximum time at the dose of 2 mg/kg in dog,50588,A,,CHEMBL623670,,4727,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6828,1,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,A,,CHEMBL623671,,1916,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Blood,,6829,1,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,A,,CHEMBL875945,,1337,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,6830,1,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,A,,CHEMBL623672,,1337,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,,,6831,1,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,50588,A,,CHEMBL623673,,6265,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6832,1,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,A,,CHEMBL623674,,4809,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6833,1,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,A,,CHEMBL623675,,5983,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6834,1,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",50588,A,,CHEMBL872526,,5313,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6835,1,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",50588,A,,CHEMBL623676,,5313,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6836,1,,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,A,,CHEMBL623677,,17650,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,6837,1,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,A,,CHEMBL623678,,5199,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,6838,1,,,Time taken for maximum plasma concentration in dog,50588,A,,CHEMBL623679,,933,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6839,1,,,Time to reach Cmax after oral administration to dogs,50588,A,,CHEMBL623680,,16367,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,6840,1,,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,A,,CHEMBL623681,,6348,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,6841,1,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,50588,A,,CHEMBL623682,,6316,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6842,1,,,Tmax after peroral administration (1 mg/kg) was determined in dog,50588,A,,CHEMBL623683,,6215,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6843,1,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,A,,CHEMBL623684,,3598,9615.0,Expert,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6844,1,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,50588,A,,CHEMBL622745,,4527,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6845,1,,,Tmax after peroral administration in dogs at 2.4 uM/kg,50588,A,,CHEMBL622746,,17764,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6846,1,,,In vivo Cmax in mice at dose of 100 mg/kg,50594,A,,CHEMBL622747,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6847,1,,,In vivo Cmax in mice at dose of 50 mg/kg,50594,A,,CHEMBL622748,,5969,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6848,1,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,A,,CHEMBL622749,,4573,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Plasma,,6849,1,,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,A,,CHEMBL622750,,3277,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6850,1,,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,50594,A,,CHEMBL623411,,17734,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6851,1,,,Maximum concentration obtained in mouse plasma was determined,50594,A,,CHEMBL875946,,3132,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6852,1,,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,50594,A,,CHEMBL623412,,3132,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6853,1,,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,A,,CHEMBL623413,,6348,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6854,1,,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,50594,A,,CHEMBL623414,,17729,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6855,1,,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,50594,A,,CHEMBL623415,,17729,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6856,1,,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,50594,A,,CHEMBL623416,,17729,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6857,1,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,50594,A,,CHEMBL623417,,17728,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6858,1,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,50594,A,,CHEMBL623418,,17728,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6859,1,,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,50594,A,,CHEMBL623419,,17728,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,,,6860,1,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,50594,A,,CHEMBL622816,,4066,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6861,1,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,50594,A,,CHEMBL623313,,6178,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6862,1,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,50594,A,,CHEMBL623314,,6178,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6863,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,50594,A,,CHEMBL876788,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6864,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,50594,A,,CHEMBL623315,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6865,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,50594,A,,CHEMBL623316,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6866,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,50594,A,,CHEMBL623317,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6868,1,,,Cmax in male mice after 2 mg/kg oral dose,50594,A,,CHEMBL623319,,5961,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6869,1,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,50594,A,,CHEMBL623320,,6137,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,6870,1,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,A,,CHEMBL623321,,3802,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6871,1,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,50594,A,,CHEMBL623322,,3535,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6872,1,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,50594,A,,CHEMBL623323,,3535,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6873,1,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,50594,A,,CHEMBL623324,,3535,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6874,1,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,50594,A,,CHEMBL623325,,3535,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6875,1,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,50594,A,,CHEMBL623326,,3535,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6876,1,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,50594,A,,CHEMBL623327,,3535,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Plasma,,6877,1,,,Maximum concentration in plasma upon oral administration in mouse,50594,A,,CHEMBL623328,,2862,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,Plasma,,6878,1,,,Maximum plasma concentration was evaluated in mice after oral administration,50594,A,,CHEMBL623329,,2675,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,6879,1,,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,50594,A,,CHEMBL623330,,2675,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,,,6880,1,,,Dose at which the compound induced fecal excretion in mice,50594,A,,CHEMBL876789,,5399,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,6893,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,80013,F,164.0,CHEMBL623333,A10,11819,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,6894,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,80013,F,164.0,CHEMBL623334,A10,11819,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,6895,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,80013,F,164.0,CHEMBL627536,A10,11819,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,6896,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,80013,F,164.0,CHEMBL627537,A10,11819,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000219,,,6897,1,,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),80013,F,164.0,CHEMBL627538,A10,16361,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000219,,,6898,1,,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,80655,F,393.0,CHEMBL884106,A121,2288,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6899,1,,,Anticancer activity against human ovarian carcinoma A121 cells,80655,F,393.0,CHEMBL625294,A121,10404,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6900,1,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,80655,F,393.0,CHEMBL625295,A121,14790,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6901,1,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,80655,F,393.0,CHEMBL625296,A121,14790,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6902,1,,,Growth inhibition of human ovarian carcinoma (A121) cell line,80655,F,393.0,CHEMBL625297,A121,14253,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6903,1,,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,80655,F,393.0,CHEMBL625298,A121,13617,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6904,1,,,Cytotoxicity against human A121 ovarian cells,80655,F,393.0,CHEMBL625960,A121,1003,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6905,1,,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,80655,F,393.0,CHEMBL625961,A121,830,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6906,1,,,In vitro cytotoxicity against human ovarian carcinoma A21,80655,F,393.0,CHEMBL625962,A121,12307,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6907,1,,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,80655,F,393.0,CHEMBL624717,A121,14254,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6908,1,,,Inhibitory activity of compound against human A121 ovarian cell line.,80655,F,393.0,CHEMBL624718,A121,13370,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6909,1,,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,80655,F,393.0,CHEMBL624719,A121,14790,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6910,1,,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,80655,F,393.0,CHEMBL624720,A121,3614,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6911,1,,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,80012,F,622.0,CHEMBL624721,A 172,2664,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6912,1,,,In vitro cytotoxicity against A172 human tumor cell lines.,80012,F,622.0,CHEMBL624722,A 172,2037,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6913,1,,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,80012,F,622.0,CHEMBL877597,A 172,14539,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6914,1,,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,80012,F,622.0,CHEMBL624723,A 172,2836,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6915,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,80012,F,622.0,CHEMBL624724,A 172,10708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000224,,,6916,1,,,Association constant against A2 adenosine receptor,104729,B,,CHEMBL624725,,8975,9615.0,Autocuration,,,4,H,Canis lupus familiaris,
,BAO_0000219,,,6917,1,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,80656,F,1085.0,CHEMBL624726,A2,7645,,Intermediate,,,1,N,fish,
,BAO_0000224,,,6918,1,,,Ratio of Ki for adenosine A2 and A1 receptor binding,104713,B,,CHEMBL857535,,11377,10116.0,Autocuration,,,5,D,Rattus norvegicus,
,BAO_0000219,,,6919,1,,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,80014,F,623.0,CHEMBL624727,A204,13528,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6920,1,,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,80014,F,623.0,CHEMBL624728,A204,10160,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6921,1,,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,80015,F,404.0,CHEMBL624729,A2058,15144,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6922,1,,,Growth inhibition against Human squamous cell line(A 253),80657,F,973.0,CHEMBL624730,A253 cell line,13160,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6923,1,,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,80657,F,973.0,CHEMBL624731,A253 cell line,12898,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6924,1,,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,80657,F,973.0,CHEMBL624732,A253 cell line,13069,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6925,1,,,Growth inhibition of A253 cell lines.,80657,F,973.0,CHEMBL883245,A253 cell line,15984,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6926,1,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),80657,F,973.0,CHEMBL624733,A253 cell line,15564,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6927,1,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,F,973.0,CHEMBL624734,A253 cell line,15564,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6928,1,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,F,973.0,CHEMBL624735,A253 cell line,15564,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6929,1,,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,81034,F,478.0,CHEMBL621780,A2780,4720,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6930,1,,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,81034,F,478.0,CHEMBL877598,A2780,16112,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6931,1,,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,81034,F,478.0,CHEMBL621781,A2780,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6932,1,,,Cytotoxicity against human cancer cell lines A2780 (ovarian),81034,F,478.0,CHEMBL621782,A2780,16378,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6933,1,,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,81034,F,478.0,CHEMBL621783,A2780,16085,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6934,1,,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,81034,F,478.0,CHEMBL621784,A2780,16317,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6935,1,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,F,478.0,CHEMBL621785,A2780,15748,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6936,1,,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,81034,F,478.0,CHEMBL621968,A2780,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6937,1,,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,81034,F,478.0,CHEMBL621969,A2780,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6938,1,,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,81034,F,478.0,CHEMBL621970,A2780,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6939,1,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,81034,F,478.0,CHEMBL621971,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6940,1,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,81034,F,478.0,CHEMBL621972,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6941,1,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,81034,F,478.0,CHEMBL884108,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,6942,1,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,22224,F,,CHEMBL623826,,15296,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6943,1,,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,22224,A,185.0,CHEMBL623827,CHO-AA8,10251,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6944,1,,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,22224,F,185.0,CHEMBL623828,CHO-AA8,10251,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6945,1,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,22224,F,185.0,CHEMBL623829,CHO-AA8,10251,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6946,1,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),22224,F,185.0,CHEMBL623830,CHO-AA8,10251,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000019,,,6947,1,,,Growth inhibition against CHO-derived cell line AA8,22224,F,,CHEMBL623831,,11858,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6948,1,,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],22224,F,185.0,CHEMBL623832,CHO-AA8,11858,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6949,1,,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,80089,F,185.0,CHEMBL623833,CHO-AA8,11616,36483.0,Expert,,,1,N,hampster,
,BAO_0000219,,,6950,1,,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,80089,F,185.0,CHEMBL623834,CHO-AA8,11616,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000219,,,6951,1,,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,22224,F,185.0,CHEMBL623835,CHO-AA8,10518,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6952,1,,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,22224,F,185.0,CHEMBL623836,CHO-AA8,11396,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6953,1,,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,22224,F,185.0,CHEMBL623837,CHO-AA8,10518,10029.0,Autocuration,,,0,U,Cricetulus griseus,
,BAO_0000219,,,6954,1,,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,80089,F,185.0,CHEMBL623838,CHO-AA8,11616,10029.0,Expert,,,1,N,Cricetulus griseus,
,BAO_0000019,,,6955,1,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,12675,F,,CHEMBL623839,,14837,,Autocuration,,,8,H,,
,BAO_0000019,,,6956,1,,,Number of binding sites (n) of isolated serum protein AAG,12675,F,,CHEMBL623840,,14837,,Autocuration,,,8,H,,
,BAO_0000225,,,6957,1,,,Association constant for binding to AATT duplex,22222,B,,CHEMBL623841,,16037,,Intermediate,,,3,M,,
,BAO_0000219,,,6958,1,,,Inhibition of ABAE human fibroblast cell proliferation,100090,F,416.0,CHEMBL623842,ABAE,16597,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000218,,,6959,1,,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",80668,F,1064.0,CHEMBL623843,AC755,8831,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,6960,1,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,102444,F,,CHEMBL618669,,13419,9986.0,Expert,,,9,D,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,6961,1,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,102444,F,,CHEMBL618670,,13419,9986.0,Expert,,,9,D,Oryctolagus cuniculus,
,BAO_0000357,,,6962,1,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,69,B,,CHEMBL618671,,15778,,Autocuration,,,8,H,,
,BAO_0000357,,,6963,1,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,69,B,,CHEMBL618672,,15778,,Autocuration,,,8,H,,
,BAO_0000219,,,6964,1,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,80669,F,978.0,CHEMBL618673,ACH-2 cell line,12988,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6965,1,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),80669,F,978.0,CHEMBL618674,ACH-2 cell line,12988,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6966,1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,22224,F,998.0,CHEMBL618675,T cell line,12988,11676.0,Autocuration,,,0,U,Human immunodeficiency virus 1,
,BAO_0000219,,,6967,1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),22224,F,998.0,CHEMBL618676,T cell line,12988,11676.0,Autocuration,,,0,U,Human immunodeficiency virus 1,
,BAO_0000219,,,6968,1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),22224,F,998.0,CHEMBL618677,T cell line,12988,11676.0,Autocuration,,,0,U,Human immunodeficiency virus 1,
,BAO_0000219,,,6969,1,,,Inhibition of growth of renal cancer ACHN cell line,80025,F,626.0,CHEMBL618678,ACHN,11843,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6970,1,,,Inhibition of growth of ACHN renal cancer cell line,80025,F,626.0,CHEMBL618679,ACHN,16939,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6971,1,,,Inhibitory concentration required against ACHN renal cancer cell line,80025,F,626.0,CHEMBL618680,ACHN,4782,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6972,1,,,Concentration required to inhibit growth of human renal (ACHN) cell line,80025,F,626.0,CHEMBL618681,ACHN,6310,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6973,1,,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,80025,F,626.0,CHEMBL618682,ACHN,6310,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6974,1,,,Cytotoxic activity against ACHN Renal cancer cell line,80025,F,626.0,CHEMBL618683,ACHN,12858,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6975,1,,,Cytotoxicity evaluation against ACHN renal cancer cells,80025,F,626.0,CHEMBL618684,ACHN,17380,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6976,1,,,In vitro antitumor activity against human renal ACHN cell line,80025,F,626.0,CHEMBL618685,ACHN,5858,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6977,1,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,F,626.0,CHEMBL876499,ACHN,3838,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6978,1,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,F,626.0,CHEMBL618686,ACHN,3838,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6979,1,,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",80025,F,626.0,CHEMBL618687,ACHN,5406,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6980,1,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,F,626.0,CHEMBL618688,ACHN,4071,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6981,1,,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,F,626.0,CHEMBL618689,ACHN,4071,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,6982,1,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,80025,F,626.0,CHEMBL618690,ACHN,4071,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6983,1,,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,80025,F,626.0,CHEMBL618691,ACHN,15002,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6984,1,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,F,626.0,CHEMBL619373,ACHN,14769,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6985,1,,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",80025,F,626.0,CHEMBL884008,ACHN,13958,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6986,1,,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,80025,F,626.0,CHEMBL619374,ACHN,1665,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6987,1,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,80025,F,626.0,CHEMBL619375,ACHN,15354,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6988,1,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,80025,F,626.0,CHEMBL619376,ACHN,15354,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6989,1,,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,80025,F,626.0,CHEMBL619377,ACHN,13978,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,6990,1,,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,80025,F,626.0,CHEMBL619378,ACHN,6798,9606.0,Intermediate,,,1,N,Homo sapiens,
In vivo,BAO_0000218,,,6991,1,,,Tmax value after administration of 4 mg/Kg oral dose in dog,50588,A,,CHEMBL872527,,2959,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6992,1,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",50588,A,,CHEMBL876500,,9932,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,6993,1,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,A,,CHEMBL619379,,5546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6994,1,,,Volume distribution after 15 mg/kg iv dose in Dogs,50588,A,,CHEMBL619538,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6995,1,,,Volume distribution after 30 mg/kg po dose in Dogs,50588,A,,CHEMBL619539,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6996,1,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,50588,A,,CHEMBL619540,,4257,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6997,1,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,50588,A,,CHEMBL619541,,4305,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6998,1,,,Volume of distribution was evaluated in dog,50588,A,,CHEMBL619542,,5472,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,6999,1,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,A,,CHEMBL619543,,6062,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7000,1,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,A,,CHEMBL619544,,3598,9615.0,Expert,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7001,1,,,The compound was tested for volume of distribution in dog,50588,A,,CHEMBL619545,,12500,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7002,1,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,50588,A,,CHEMBL619546,,12500,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7003,1,,,Vd (1 mg/kg) was determined in dog (in vivo),50588,A,,CHEMBL619547,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7004,1,,,Vd in dog,50588,A,,CHEMBL619548,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7005,1,,,Volume distribution was determined,50588,A,,CHEMBL619549,,4219,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7006,1,,,Volume of distribution in dog,50588,A,,CHEMBL619550,,1696,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7007,1,,,Volume of distribution by as 4 fold increase by iv administration in dogs,50588,A,,CHEMBL876501,,5542,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7008,1,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,A,,CHEMBL619551,,5199,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7009,1,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,A,,CHEMBL619552,,6348,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7010,1,,,Volume distribution at the dose of 2 mg/kg in dog,50588,A,,CHEMBL619553,,4727,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7011,1,,,Steady state volume of distribution was determined,50588,A,,CHEMBL618722,,16367,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7012,1,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,50588,A,,CHEMBL618723,,2652,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7013,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,A,,CHEMBL618724,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7014,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,A,,CHEMBL618725,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7015,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),50588,A,,CHEMBL618726,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7016,1,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,A,,CHEMBL618727,,5334,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7017,1,,,Pharmacokinetic property (vdss) was measured in dog,50588,A,,CHEMBL624233,,4239,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7018,1,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,50588,A,,CHEMBL624234,,4709,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7019,1,,,Vdss was determined after iv 0.1 mg/kg administration in dog,50588,A,,CHEMBL624235,,5600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7020,1,,,Volume displacement was calculated in dog,50588,A,,CHEMBL624236,,6057,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7021,1,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,A,,CHEMBL624237,,5654,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7022,1,,,Volume distribution constant was determined,50588,A,,CHEMBL624238,,5505,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7023,1,,,Volume distribution at a dose of 1 uM/kg in dog was determined,50588,A,,CHEMBL624239,,4527,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7024,1,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,A,,CHEMBL875829,,4521,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7025,1,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,A,,CHEMBL624240,,4521,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7026,1,,,Volume distribution (Vdss) was measured in dog,50588,A,,CHEMBL624241,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7027,1,,,Volume distribution (Vdss) was measured in dog,50588,A,,CHEMBL624242,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7028,1,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,A,,CHEMBL624243,,6679,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7029,1,,,Volume of distribution in steady state was determined in dog,50588,A,,CHEMBL624244,,5145,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7030,1,,,Volume of distribution of compound was determined in dog,50588,A,,CHEMBL624245,,6821,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7031,1,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,50588,A,,CHEMBL624246,,4137,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7032,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,A,,CHEMBL624247,,5334,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7033,1,,,Volume of distribution (Vdss) was measured in dog,50588,A,,CHEMBL624248,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7034,1,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,A,,CHEMBL624249,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7035,1,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,A,,CHEMBL624250,,6641,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7036,1,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,A,,CHEMBL624251,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7037,1,,,Maximum rate of depolarization of the upstroke of the action potential,50588,A,,CHEMBL624252,,11659,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7038,1,,,Steady state volume distribution in dog,50588,A,,CHEMBL624253,,6448,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7039,1,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,50588,A,,CHEMBL624950,,5474,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7040,1,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,50588,A,,CHEMBL624951,,1466,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7041,1,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,A,,CHEMBL875830,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7042,1,,,Volume distribution in dog after administration of 1 mg/kg iv,50588,A,,CHEMBL624952,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7043,1,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,50588,A,,CHEMBL624953,,17764,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7044,1,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,50588,A,,CHEMBL624954,,6215,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7045,1,,,Vss on i.v. administration of 2 mg/kg was measured in dog,50588,A,,CHEMBL624955,,6505,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7046,1,,,Vss was determined,50588,A,,CHEMBL624956,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7047,1,,,Vss in dog,50588,A,,CHEMBL625129,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7048,1,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,A,,CHEMBL625130,,6062,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7049,1,,,Volume distribution in dogs,50588,A,,CHEMBL625131,,4942,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7050,1,,,Volume of distribution in dog,50588,A,,CHEMBL625132,,17796,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7051,1,,,Tested for the oral bioavailability in dog,50588,A,,CHEMBL872263,,4883,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7060,1,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,50594,A,,CHEMBL624336,,17837,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7061,1,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,50594,A,,CHEMBL624337,,17729,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7062,1,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,50594,A,,CHEMBL624338,,17729,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7063,1,,,Bioavailability was measured in mouse,50594,A,,CHEMBL624339,,4239,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7064,1,,,Bioavailability in mouse,50594,A,,CHEMBL624340,,17592,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7065,1,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,A,,CHEMBL624341,,6348,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7066,1,,,Bioavailability in mouse,50594,A,,CHEMBL624342,,2801,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7067,1,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,50594,A,,CHEMBL624343,,2801,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7068,1,,,Oral bioavailability in mouse,50594,A,,CHEMBL624344,,17718,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7069,1,,,Oral availability at 50 mg/kg po in male mice,50594,A,,CHEMBL624345,,5727,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7070,1,,,Oral bioavailability in mouse (dose 10 mg/kg),50594,A,,CHEMBL624346,,5302,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7071,1,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,50594,A,,CHEMBL624347,,3598,10090.0,Expert,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7072,1,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",50594,A,,CHEMBL624348,,5961,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7074,1,,,Oral bioavailability in mouse,50594,A,,CHEMBL622754,,6091,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7075,1,,,Oral bioavailability in vivo in mice;ND=Not determined,50594,A,,CHEMBL622755,,6091,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7076,1,,,Oral bioavailability in mouse at 10 mg/kg of the compound,50594,A,,CHEMBL622756,,5711,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7077,1,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),50594,A,,CHEMBL622757,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7078,1,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),50594,A,,CHEMBL622758,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7079,1,,,Tested for bioavailability of the compound,50594,A,,CHEMBL622759,,3802,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,7080,1,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,50594,A,,CHEMBL622760,,3802,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Plasma,,7081,1,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,50594,A,,CHEMBL622761,,14029,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,Plasma,,7082,1,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,50594,A,,CHEMBL622762,,14029,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,Plasma,,7083,1,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,50594,A,,CHEMBL622763,,14029,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,Plasma,,7084,1,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,50594,A,,CHEMBL622764,,14029,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,Plasma,,7085,1,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,50594,A,,CHEMBL622765,,14029,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,,,7086,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,50594,F,,CHEMBL622766,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7087,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,50594,A,,CHEMBL622767,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7088,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,50594,A,,CHEMBL622768,,17753,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Blood,,7089,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL875948,,10107,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,7090,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,A,,CHEMBL622769,,10107,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,7091,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL622770,,10107,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,7092,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL622771,,10107,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,7093,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL622772,,10107,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,7094,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL622773,,10107,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,7095,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL622774,,10107,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Bone,,7096,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL621725,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,7097,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,A,,CHEMBL621726,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
,BAO_0000219,,,7098,1,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,81034,F,478.0,CHEMBL621727,A2780,15608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7099,1,,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,81034,F,478.0,CHEMBL622413,A2780,3290,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7100,1,,,Compound was evaluated for cytotoxicity against A2780 cell line,81034,F,478.0,CHEMBL622414,A2780,2859,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7101,1,,,Inhibition of A2780 cell clonogenic assay,81034,F,478.0,CHEMBL622415,A2780,15688,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7102,1,,,Cytotoxic effect on ovarian cancer cell line (A2780),81034,F,478.0,CHEMBL884001,A2780,5642,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7103,1,,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,81034,F,478.0,CHEMBL622416,A2780,6633,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7104,1,,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",81034,F,478.0,CHEMBL622417,A2780,3906,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7105,1,,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,81034,F,478.0,CHEMBL622590,A2780,6788,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7106,1,,,Antiproliferative activity against human A2780 cells,81034,F,478.0,CHEMBL622591,A2780,17582,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7107,1,,,Inhibition of human A2780 cell proliferation,81034,F,478.0,CHEMBL622592,A2780,17764,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7108,1,,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,81034,F,478.0,CHEMBL622593,A2780,17764,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7109,1,,,Inhibition of human A2780 cell proliferation (No data),81034,F,478.0,CHEMBL622594,A2780,17764,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7110,1,,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,81034,F,478.0,CHEMBL622595,A2780,2815,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7111,1,,,Compound was evaluated against human Ovarian carcinoma cell line A2780,81034,F,478.0,CHEMBL622596,A2780,16930,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7112,1,,,Growth inhibition against A2780 wild-type ovarian cell lines,81034,F,478.0,CHEMBL622597,A2780,17777,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7113,1,,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,81034,F,478.0,CHEMBL622598,A2780,17777,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,7114,1,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,104766,F,,CHEMBL622599,,16936,9606.0,Autocuration,,,5,D,Homo sapiens,
,BAO_0000219,,,7115,1,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,F,478.0,CHEMBL622600,A2780,13759,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7116,1,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,F,478.0,CHEMBL622601,A2780,13759,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7117,1,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,F,478.0,CHEMBL622602,A2780,13759,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7118,1,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,F,478.0,CHEMBL622603,A2780,13759,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7119,1,,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,F,478.0,CHEMBL622604,A2780,15292,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7120,1,,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,F,478.0,CHEMBL622605,A2780,15292,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7121,1,,,In vitro inhibition of human ovarian cell line A2780,81034,F,478.0,CHEMBL622606,A2780,15069,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7122,1,,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",81034,F,478.0,CHEMBL619463,A2780,15069,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7123,1,,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),81034,F,478.0,CHEMBL619464,A2780,14073,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7124,1,,,Concentration required to inhibit A2780-cell growth by 50%,81034,F,478.0,CHEMBL619465,A2780,14553,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7125,1,,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,81034,F,478.0,CHEMBL619466,A2780,13040,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7126,1,,,Cytotoxic effect on human ovarian (A2780) cancer cell line,81034,F,478.0,CHEMBL619467,A2780,6891,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7127,1,,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,81034,F,478.0,CHEMBL619468,A2780,15569,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7128,1,,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,81034,F,478.0,CHEMBL619469,A2780,14190,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7129,1,,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,F,478.0,CHEMBL619470,A2780,15014,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7130,1,,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,F,478.0,CHEMBL619471,A2780,15014,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7131,1,,,Cytotoxicity against human ovarian carcinoma A2780 cell line,81034,F,478.0,CHEMBL619472,A2780,17496,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7132,1,,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",81034,F,478.0,CHEMBL619473,A2780,13617,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7133,1,,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",81034,F,478.0,CHEMBL874368,A2780,13617,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7134,1,,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",81034,F,478.0,CHEMBL884003,A2780,13617,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7135,1,,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",81034,F,478.0,CHEMBL622690,A2780,13617,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7136,1,,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,81034,F,478.0,CHEMBL622691,A2780,17672,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7137,1,,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,F,478.0,CHEMBL622692,A2780,4544,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7138,1,,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,F,478.0,CHEMBL623406,A2780,4544,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7139,1,,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",81034,F,478.0,CHEMBL884004,A2780,16317,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7140,1,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,81034,F,478.0,CHEMBL623407,A2780,15099,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7141,1,,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,81034,F,478.0,CHEMBL623408,A2780,13978,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7142,1,,,In vitro antitumor activity against A2780 cell line.,81034,F,478.0,CHEMBL623409,A2780,12989,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7143,1,,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,81034,F,478.0,CHEMBL623410,A2780,5574,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7144,1,,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,81034,F,478.0,CHEMBL623576,A2780,13528,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7145,1,,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,80025,F,626.0,CHEMBL623577,ACHN,12782,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7146,1,,,The IC50 value was measured on ACHN cell line in renal tumor type.,80025,F,626.0,CHEMBL623578,ACHN,14255,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7147,1,,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,80025,F,626.0,CHEMBL623579,ACHN,16364,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7148,1,,,In vitro lethal concentration against most sensitive ACHN cell line,80025,F,626.0,CHEMBL623580,ACHN,17376,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7149,1,,,Tested for cytotoxic activity against renal cancer ACHN cell line,80025,F,626.0,CHEMBL623581,ACHN,12016,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7150,1,,,Compound tested for growth inhibition of renal cancer cell line ACHN,80025,F,626.0,CHEMBL857456,ACHN,6058,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7151,1,,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,80025,F,626.0,CHEMBL623582,ACHN,17708,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7152,1,,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,80025,F,626.0,CHEMBL623583,ACHN,15176,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7153,1,,,In vitro anticancer activity against ACHN renal cancer cell line,80025,F,626.0,CHEMBL623584,ACHN,2806,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7154,1,,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,80025,F,626.0,CHEMBL623585,ACHN,15300,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7155,1,,,Percent selectivity was evaluated in renal ACHN cell lines,80025,F,626.0,CHEMBL623586,ACHN,16364,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7156,1,,,In vitro inhibitory activity against renal ACHN cancer cell line,80025,F,626.0,CHEMBL623587,ACHN,13859,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7157,1,,,Tested for cytotoxicity against ACHN cell lines in renal cancer,80025,F,626.0,CHEMBL875279,ACHN,11970,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7158,1,,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,80025,F,626.0,CHEMBL623588,ACHN,2450,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7159,1,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80025,F,626.0,CHEMBL623589,ACHN,12696,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7160,1,,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,80025,F,626.0,CHEMBL623590,ACHN,12400,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7161,1,,,Cytotoxic effect on renal cancer line ACHN,80025,F,626.0,CHEMBL623591,ACHN,12888,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7162,1,,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,80025,F,626.0,CHEMBL623592,ACHN,3156,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7163,1,,,In vitro inhibition of Renal Cancer ACHN cell lines,80025,F,626.0,CHEMBL623593,ACHN,3381,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7164,1,,,Antitumor activity against human renal adenocarcinoma ACHN cells,80025,F,626.0,CHEMBL623594,ACHN,16747,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7165,1,,,Antitumor activity against human renal adenocarcinoma ACHN cells.,80025,F,626.0,CHEMBL621833,ACHN,16748,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7166,1,,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,80025,F,626.0,CHEMBL621834,ACHN,12062,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7167,1,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,F,626.0,CHEMBL621835,ACHN,14769,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7168,1,,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",80025,F,626.0,CHEMBL621836,ACHN,15895,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7169,1,,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,80025,F,626.0,CHEMBL621837,ACHN,17376,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7170,1,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80025,F,626.0,CHEMBL875280,ACHN,14882,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7171,1,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,80025,F,626.0,CHEMBL621838,ACHN,14882,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7172,1,,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,80025,F,626.0,CHEMBL621839,ACHN,15661,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000019,,,7173,1,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,A,,CHEMBL621840,,9680,,Autocuration,,,0,U,,
,BAO_0000019,,,7174,1,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,10647,F,,CHEMBL621841,,14579,,Autocuration,,,8,H,,
,BAO_0000218,,,7175,1,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,50529,F,468.0,CHEMBL622979,HEL,17290,10358.0,Expert,,,1,N,Cytomegalovirus,
,BAO_0000218,,,7176,1,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,50529,F,,CHEMBL876595,,17290,10358.0,Intermediate,,,1,N,Cytomegalovirus,
,BAO_0000357,,,7177,1,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),12159,B,,CHEMBL620221,,15891,,Autocuration,,,8,H,,
,BAO_0000357,,,7178,1,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),12159,B,,CHEMBL620222,,15890,,Autocuration,,,8,H,,
,BAO_0000219,,,7179,1,,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,80670,F,979.0,CHEMBL620506,ADDP cell line,3801,9913.0,Intermediate,,,1,N,Bos taurus,
,BAO_0000219,,,7180,1,,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,F,980.0,CHEMBL620507,ADJ/PC6,9222,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,7181,1,,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,F,980.0,CHEMBL620508,ADJ/PC6,9222,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,7182,1,,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",80671,F,980.0,CHEMBL620509,ADJ/PC6,7257,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,7183,1,,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,80671,F,980.0,CHEMBL620510,ADJ/PC6,7257,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,7184,1,,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,80671,A,980.0,CHEMBL620511,ADJ/PC6,7257,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,7185,1,,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,80671,F,980.0,CHEMBL620512,ADJ/PC6,8084,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000019,,,7186,1,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,22224,F,,CHEMBL620513,,14943,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000019,,,7187,1,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,22224,F,,CHEMBL620514,,14943,10090.0,Autocuration,,,0,U,Mus musculus,
,BAO_0000019,,,7188,1,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,22224,F,,CHEMBL620515,,14943,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,7189,1,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),22224,A,,CHEMBL620516,,10524,1423.0,Autocuration,,,0,U,Bacillus subtilis,
,BAO_0000218,Plasma,,7190,1,,,AUC value in dog after IV administration at a dose of 5 mg/kg,50588,A,,CHEMBL620517,,3546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,7191,1,,,AUC value in dog after oral administration at a dose of 5 mg/kg,50588,A,,CHEMBL620518,,3546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,7192,1,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,50588,A,,CHEMBL620519,,3546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7193,1,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,50588,A,,CHEMBL621386,,3546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7194,1,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,50588,A,,CHEMBL621387,,3546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7195,1,,,Compound was evaluated for its clearance when administered intravenously in dog,50588,A,,CHEMBL621388,,3184,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7196,1,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,A,,CHEMBL621389,,16456,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7197,1,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,A,,CHEMBL621390,,4809,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000100,,,7198,1,,,Calculated partition coefficient (clogP),22229,P,,CHEMBL621391,,4219,,Intermediate,,,0,U,,
,BAO_0000218,,,7199,1,,,Half life in dog,50588,A,,CHEMBL621392,,3748,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7200,1,,,Time taken for EC90 was determined when tested in dog,50588,A,,CHEMBL621393,,3132,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7201,1,,,Half life (iv) was determined,50588,A,,CHEMBL621394,,4219,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Liver,,7202,1,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,50588,A,,CHEMBL621395,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2107.0
,BAO_0000218,,,7203,1,,,Area under the curve was calculated in dog after iv administration,50588,A,,CHEMBL621396,,6057,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7204,1,,,Area under the curve was calculated in dog after peroral administration,50588,A,,CHEMBL621397,,6057,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7205,1,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,50588,A,,CHEMBL621398,,17853,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7206,1,,,pKa was evaluated in dog,50588,A,,CHEMBL618818,,3639,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7207,1,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,50588,A,,CHEMBL618819,,14541,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7208,1,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,A,,CHEMBL618820,,16456,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7209,1,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,A,,CHEMBL873810,,16456,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7210,1,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,A,,CHEMBL876606,,2652,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7211,1,,,Compound was evaluated for the half-life (t 1/2) in hours,50588,A,,CHEMBL618821,,3624,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Blood,,7212,1,,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,A,,CHEMBL618822,,1337,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,7213,1,,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,A,,CHEMBL618823,,1337,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,,,7214,1,,,Half life after intravenous administration of 1 mg/kg in dog,50588,A,,CHEMBL618824,,4709,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7215,1,,,Half life was measured in dog,50588,A,,CHEMBL618825,,15660,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7216,1,,,Half life period in dog after 5 mg/kg dose,50588,A,,CHEMBL618826,,5302,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7217,1,,,Half life period was evaluated in dog; 4-4.8,50588,A,,CHEMBL618827,,17791,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7218,1,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,A,,CHEMBL618828,,6348,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7219,1,,,Half-life was determined in dog after a3 mg/kg of iv dose,50588,A,,CHEMBL618829,,4257,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7220,1,,,Half-life was determined,50588,A,,CHEMBL618830,,3771,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7221,1,,,Half life in dogs,50588,A,,CHEMBL618831,,6305,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,7222,1,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,50588,A,,CHEMBL619489,,13501,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,7223,1,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,50588,A,,CHEMBL619649,,17594,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7224,1,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,50588,A,,CHEMBL876607,,3045,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7225,1,,,Compound was evaluated for the half life period after oral administration in conscious dog.,50588,A,,CHEMBL619650,,3043,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7226,1,,,Compound was tested for half life in dog,50588,A,,CHEMBL619651,,4839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7227,1,,,Compound was tested for its half life in dog,50588,A,,CHEMBL619652,,4839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7228,1,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,A,,CHEMBL619653,,5802,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7229,1,,,Half life of compound in dog was determined,50588,A,,CHEMBL619654,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7230,1,,,Half life (iv) was determined,50588,A,,CHEMBL619655,,4219,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Blood,,7231,1,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),50588,A,,CHEMBL619656,,13966,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Plasma,,7232,1,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,A,,CHEMBL873812,,3994,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,7233,1,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,F,,CHEMBL621365,,3994,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,7234,1,,,Half life in dog,50588,A,,CHEMBL621366,,4453,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,7235,1,,,Half life in dog plasma,50588,A,,CHEMBL621367,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,7236,1,,,Half life in dog plasma after administration of 0.25 mg/kg iv,50588,A,,CHEMBL621368,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,7237,1,,,Half life in dog plasma after administration of 1 mg/kg iv,50588,A,,CHEMBL621369,,6535,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,7238,1,,,Half life in dog plasma was determined at dose 10 mg/kg,50588,A,,CHEMBL621370,,3132,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,7239,1,,,Half life in dog was determined,50588,A,,CHEMBL621371,,5374,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7240,1,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,A,,CHEMBL621372,,5007,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,7241,1,,,Half life upon exposure to human plasma,50588,A,,CHEMBL621373,,16907,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,7242,1,,,Half life was calculated in dog,50588,A,,CHEMBL621374,,6057,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7243,1,,,Half life was determined,50588,A,,CHEMBL621375,,5006,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7244,1,,,Half life was determined,50588,A,,CHEMBL621376,,5473,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7245,1,,,Half life by intravenous administration of 1.2 mg/kg in dog,50588,A,,CHEMBL619624,,4368,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7246,1,,,Half life in dog,50588,A,,CHEMBL875840,,6448,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7247,1,,,Half life in dog after intra venous administration of the compound,50588,A,,CHEMBL619625,,4353,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7248,1,,,Half life in dog after intra venous administration of the compound; ND means Not determined,50588,A,,CHEMBL619626,,4353,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7249,1,,,Half life in dog after po administration of the compound,50588,A,,CHEMBL619627,,4353,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7250,1,,,Half life in dog after po administration of the compound; ND means Not determined,50588,A,,CHEMBL873817,,4353,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7251,1,,,Half life in dog at the single oral dose of 1 mg/kg,50588,A,,CHEMBL619628,,6265,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7252,1,,,Half life in dogs,50588,A,,CHEMBL619629,,5006,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7253,1,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,50588,A,,CHEMBL619630,,5356,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7254,1,,,Half life in rat,50588,A,,CHEMBL619631,,405,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7255,1,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,A,,CHEMBL619632,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Bone,,7256,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL619633,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,7257,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL875841,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,7258,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL619634,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,7259,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL619635,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Bone,,7260,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL619636,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000001.0
In vivo,BAO_0000218,Gut,,7261,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL619637,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000004.0
In vivo,BAO_0000218,Gut,,7262,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,A,,CHEMBL619638,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000004.0
In vivo,BAO_0000218,Gut,,7263,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL619639,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000004.0
In vivo,BAO_0000218,Gut,,7264,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL619640,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000004.0
In vivo,BAO_0000218,Gut,,7265,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL619641,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000004.0
In vivo,BAO_0000218,Gut,,7266,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL619642,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000004.0
In vivo,BAO_0000218,Gut,,7267,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL619643,,10107,10090.0,Intermediate,,,1,N,Mus musculus,10000004.0
In vivo,BAO_0000218,Heart,,7268,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL619644,,10107,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,7269,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,A,,CHEMBL621112,,10107,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,7270,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL621113,,10107,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,7271,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL621114,,10107,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,7272,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL621115,,10107,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,7273,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL621116,,10107,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,7274,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL621117,,10107,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Kidney,,7275,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL621118,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,7276,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,A,,CHEMBL621119,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,7277,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL621120,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,7278,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL621757,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,7279,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL621758,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,7280,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL621759,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,7281,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL621760,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,7282,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL621761,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,7283,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,A,,CHEMBL621762,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,7284,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL621763,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,7285,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL624502,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,7286,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL624503,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,7287,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL624504,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,7288,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL624505,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Lung,,7289,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL624506,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
,BAO_0000219,,,7290,1,,,In vitro cytotoxicity against A2780 (human ovarian cancer),81034,F,478.0,CHEMBL624507,A2780,5895,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7291,1,,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,81034,F,478.0,CHEMBL624508,A2780,6338,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7292,1,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,81034,F,478.0,CHEMBL624509,A2780,15163,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7293,1,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,81034,F,478.0,CHEMBL624510,A2780,15163,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7294,1,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,81034,F,478.0,CHEMBL875956,A2780,15000,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7295,1,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,81034,F,478.0,CHEMBL839885,A2780,15000,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7296,1,,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,81034,F,478.0,CHEMBL624511,A2780,14729,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7297,1,,,In vitro cytotoxicity against A2780 cell line,81034,F,478.0,CHEMBL624512,A2780,17270,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7298,1,,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,81034,F,478.0,CHEMBL624513,A2780,5685,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7299,1,,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,81034,F,478.0,CHEMBL624514,A2780,3563,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,7300,1,,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,81034,F,478.0,CHEMBL618547,A2780,17753,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7301,1,,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",81034,F,478.0,CHEMBL618548,A2780,16317,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7302,1,,,Inhibition of tubulin polymerization in analogy of ca.,81034,F,478.0,CHEMBL618549,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7303,1,,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,81034,F,478.0,CHEMBL618550,A2780,3801,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7304,1,,,Cytotoxic effect in ovarian cancer cell line (A2780),81034,F,478.0,CHEMBL618551,A2780,6181,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7305,1,,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,81034,F,478.0,CHEMBL618552,A2780,5318,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7306,1,,,Tested for the cytotoxicity in A2780 ovarian cell line,81034,F,478.0,CHEMBL618553,A2780,4840,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7307,1,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,F,478.0,CHEMBL618554,A2780,15748,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7308,1,,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,81034,F,478.0,CHEMBL618555,A2780,15748,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7309,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,80017,F,481.0,CHEMBL618556,A2780cisR,15748,,Intermediate,,,1,N,,
,BAO_0000219,,,7310,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,F,481.0,CHEMBL618557,A2780cisR,15748,,Intermediate,,,1,N,,
,BAO_0000219,,,7311,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,80017,F,481.0,CHEMBL618558,A2780cisR,15748,,Intermediate,,,1,N,,
,BAO_0000219,,,7312,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),80017,F,481.0,CHEMBL618559,A2780cisR,15748,,Intermediate,,,1,N,,
,BAO_0000218,,,7313,1,,,In vivo log of cells killed after administration of compound in A2780 cell line,81034,F,478.0,CHEMBL618560,A2780,17753,9606.0,Intermediate,,,1,N,Homo sapiens,
In vivo,BAO_0000218,,,7314,1,,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,81034,F,478.0,CHEMBL618561,A2780,17753,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7315,1,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,81034,F,478.0,CHEMBL618562,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7316,1,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,81034,F,478.0,CHEMBL618563,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7317,1,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,81034,F,478.0,CHEMBL618564,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7318,1,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,81034,F,478.0,CHEMBL618565,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,7319,1,,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),81034,F,478.0,CHEMBL618566,A2780,17528,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7320,1,,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,81034,F,478.0,CHEMBL618567,A2780,6633,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7321,1,,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,81034,F,478.0,CHEMBL618568,A2780,15000,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7322,1,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,81034,F,478.0,CHEMBL618569,A2780,17528,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7323,1,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,81034,F,478.0,CHEMBL621857,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7324,1,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,81034,F,478.0,CHEMBL621858,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7325,1,,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,81034,F,478.0,CHEMBL621859,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7326,1,,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",81034,F,478.0,CHEMBL621860,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7327,1,,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),81034,F,478.0,CHEMBL621861,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7328,1,,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",81034,F,478.0,CHEMBL621862,A2780,16936,9606.0,Expert,,,1,N,Homo sapiens,
,BAO_0000219,,,7329,1,,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,F,478.0,CHEMBL621863,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7330,1,,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,F,478.0,CHEMBL621864,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7331,1,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,F,478.0,CHEMBL621865,A2780,16936,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7332,1,,,In vitro antiproliferative activity against A2780 cell line,81034,F,478.0,CHEMBL621866,A2780,17737,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000219,,,7333,1,,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,81034,F,478.0,CHEMBL621867,A2780,17764,10090.0,Expert,,,1,N,Mus musculus,
,BAO_0000219,,,7334,1,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,81034,F,478.0,CHEMBL621868,A2780,3830,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000219,,,7335,1,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,81034,F,478.0,CHEMBL875282,A2780,3829,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000218,,,7336,1,,,Vc value in dog after IV administration at a dose of 5 mg/kg,50588,A,,CHEMBL621869,,3546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7337,1,,,Half life period in dog after IV administration at a dose of 5 mg/kg,50588,A,,CHEMBL621870,,3546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000019,,,7338,1,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,22224,A,,CHEMBL621871,,5668,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,Plasma,,7339,1,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL621243,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
,BAO_0000218,Plasma,,7340,1,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL621244,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,1969.0
In vivo,BAO_0000218,,,7341,1,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,A,,CHEMBL621245,,4256,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,7342,1,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,22224,A,,CHEMBL621246,,4256,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,7343,1,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,22224,A,,CHEMBL621247,,4256,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,7344,1,,,Oral Bioavailability in rat,22224,A,,CHEMBL618386,,4256,10116.0,Autocuration,,,0,U,Rattus norvegicus,
,BAO_0000218,,,7345,1,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,A,,CHEMBL618387,,1916,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7346,1,,,Area under curve value in monkey at a dose of 5 mg/kg,22224,A,,CHEMBL618388,,5302,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7347,1,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,22224,A,,CHEMBL618389,,4257,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,7348,1,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,22224,A,,CHEMBL618574,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,7349,1,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,22224,A,,CHEMBL618575,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,7350,1,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,22224,A,,CHEMBL618576,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7351,1,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,22224,A,,CHEMBL618577,,6078,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7352,1,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,22224,A,,CHEMBL876487,,6078,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7353,1,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,22224,A,,CHEMBL618578,,6062,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7354,1,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,A,,CHEMBL618579,,2661,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,7355,1,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,A,,CHEMBL618580,,2661,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7356,1,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,22224,A,,CHEMBL618581,,5394,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7357,1,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,22224,A,,CHEMBL618582,,4397,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7358,1,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,22224,A,,CHEMBL618583,,17509,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7359,1,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,22224,A,,CHEMBL618584,,17509,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7360,1,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),22224,A,,CHEMBL618585,,6641,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000218,,,7361,1,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),22224,A,,CHEMBL618586,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7362,1,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL618587,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7363,1,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,A,,CHEMBL618588,,3443,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,7364,1,,,Binding towards monkey plasma protein at 10 uM,22224,A,,CHEMBL618589,,17409,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,7365,1,,,Binding towards monkey plasma protein at 100 uM,22224,A,,CHEMBL618590,,17409,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7366,1,,,Apparent bioavailability in squirrel monkey was determined,22224,A,,CHEMBL872262,,1052,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7367,1,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,A,,CHEMBL618591,,13501,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7368,1,,,Bioavailability in monkey (dose 2 mg/kg),22224,A,,CHEMBL618592,,17509,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,7369,1,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,22224,A,,CHEMBL876488,,5394,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7370,1,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,A,,CHEMBL618593,,2661,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7371,1,,,Bioavailability in monkey (i.d. dosing),22224,A,,CHEMBL618594,,11219,9443.0,Autocuration,,,0,U,monkey,
In vivo,BAO_0000218,,,7372,1,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,22224,A,,CHEMBL618595,,3045,9527.0,Autocuration,,,0,U,Cercopithecidae,
,BAO_0000019,,,7373,1,,,Clearance of the drug was measured in cynomolgus,22224,A,,CHEMBL621469,,17796,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7374,1,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,22224,A,,CHEMBL621470,,1399,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7375,1,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,A,,CHEMBL621471,,2661,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,Plasma,,7376,1,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,A,,CHEMBL621472,,5005,9544.0,Autocuration,,,0,U,Macaca mulatta,1969.0
In vivo,BAO_0000218,,,7377,1,,,Plasma clearance in rhesus monkey was determined,22224,A,,CHEMBL621473,,17267,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7378,1,,,Plasma clearance in monkey after administration of 1 mg/kg iv,22224,A,,CHEMBL621474,,6535,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7379,1,,,Plasma clearance in cynomolgus monkey,22224,A,,CHEMBL621475,,5922,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7380,1,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,22224,A,,CHEMBL621476,,6221,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7381,1,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,22224,A,,CHEMBL624290,,5668,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7382,1,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,22224,A,,CHEMBL624291,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7383,1,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,A,,CHEMBL624292,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7384,1,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,A,,CHEMBL624293,,5355,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7385,1,,,Tested for Clearance upon iv administration to african green monkey,22224,A,,CHEMBL624294,,4578,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7386,1,,,Clearance in monkey,22224,A,,CHEMBL624295,,17592,9527.0,Autocuration,,,0,U,Cercopithecidae,
In vivo,BAO_0000218,,,7387,1,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,A,,CHEMBL624296,,6641,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7388,1,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,A,,CHEMBL624297,,6642,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7389,1,,,Half life was evaluated after intravenous administration to dogs,50588,A,,CHEMBL624298,,16367,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7390,1,,,Half life was evaluated in dog,50588,A,,CHEMBL624299,,5472,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7391,1,,,Half life was evaluated in dog,50588,A,,CHEMBL624300,,5474,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7392,1,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,A,,CHEMBL624301,,5654,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7393,1,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),50588,A,,CHEMBL624302,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7394,1,,,Half life period after intravenous administration in dog,50588,A,,CHEMBL876026,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7395,1,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,50588,A,,CHEMBL624303,,6221,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7396,1,,,Half life period at a dose of 1 uM/kg in dog was determined,50588,A,,CHEMBL624304,,4527,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7397,1,,,Half life period was determine after peroral administration at 10 mpk in dog,50588,A,,CHEMBL624305,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7398,1,,,Half life period was determine after peroral administration at 5 mpk in dog,50588,A,,CHEMBL624306,,5668,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7399,1,,,Half life period was determined,50588,A,,CHEMBL624307,,3854,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7400,1,,,Half life period was determined,50588,A,,CHEMBL624308,,5505,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7401,1,,,Half life period by iv administration in dog at a dose of 6 mg/kg,50588,A,,CHEMBL624309,,6251,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7402,1,,,Half life period was evaluated in dog,50588,A,,CHEMBL624310,,1918,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7403,1,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,A,,CHEMBL625003,,5546,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7404,1,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,A,,CHEMBL625004,,4809,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7405,1,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,50588,A,,CHEMBL625005,,6215,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7406,1,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,50588,A,,CHEMBL873813,,4527,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7407,1,,,Half-life after oral dose of compound at 3 mg/kg in dogs,50588,A,,CHEMBL625006,,17594,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7408,1,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,50588,A,,CHEMBL625007,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7409,1,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,50588,A,,CHEMBL876027,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7410,1,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,50588,A,,CHEMBL625008,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7411,1,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,50588,A,,CHEMBL625009,,17839,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,7412,1,,,Half-life of compound in plasma of dog was determined,50588,A,,CHEMBL625010,,5210,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,7413,1,,,Half-life of compound was determined in dogs,50588,A,,CHEMBL625011,,5210,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7414,1,,,Half-life after administration of 4 mg/Kg oral dose in dog,50588,A,,CHEMBL621553,,2959,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7415,1,,,Half-life after intravenous administration of 1 mg/kg/h in dog,50588,A,,CHEMBL621554,,4137,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7416,1,,,Half-life in Dog,50588,A,,CHEMBL621555,,5064,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7417,1,,,Half-life in Dog,50588,A,,CHEMBL621556,,5147,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7418,1,,,Half-life in dog,50588,A,,CHEMBL621557,,5145,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7419,1,,,Half-life in dog after oral administration at 1 mg/kg,50588,A,,CHEMBL621558,,6123,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7420,1,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,50588,A,,CHEMBL621559,,6123,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7421,1,,,Half-life in dogs,50588,A,,CHEMBL621560,,4333,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7422,1,,,Half-life in dogs; ND indicates not determined,50588,A,,CHEMBL876028,,4333,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,Plasma,,7423,1,,,Half-life in plasma of dog,50588,A,,CHEMBL621561,,12500,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,7424,1,,,Half-life in plasma of dog at dose of 3-10 mgkg,50588,A,,CHEMBL621562,,12500,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,7425,1,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,A,,CHEMBL621563,,6005,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7426,1,,,Half-life was measured in dog after an iv dose of 1 mg/kg,50588,A,,CHEMBL621564,,6062,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7427,1,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,50588,A,,CHEMBL621565,,17650,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7428,1,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,A,,CHEMBL621566,,5530,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7429,1,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,A,,CHEMBL621567,,5530,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7430,1,,,Half-life of the compound after 0.3 mg/kg po administration in dog,50588,A,,CHEMBL622978,,5600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7431,1,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,50588,A,,CHEMBL873814,,6039,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7432,1,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,50588,A,,CHEMBL623219,,6039,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7433,1,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,50588,A,,CHEMBL624477,,6039,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7434,1,,,t1/2 in dog,50588,A,,CHEMBL624478,,6227,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7435,1,,,Half-life period measured in dogs,50588,A,,CHEMBL624479,,14541,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7436,1,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,A,,CHEMBL624480,,4521,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7437,1,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,A,,CHEMBL623595,,4521,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7438,1,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,A,,CHEMBL623596,,6679,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vitro,BAO_0000218,Plasma,,7439,1,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",50588,A,,CHEMBL623597,,1116,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,7440,1,,,In vivo half life period was calculated at 1 mg/kg in dog,50588,A,,CHEMBL623598,,5444,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7441,1,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,50588,A,,CHEMBL623599,,5444,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7442,1,,,Longer half-life in dog (i.v.) at 0.5 mpk,50588,A,,CHEMBL623600,,17853,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7443,1,,,Oral bioavailability in dog (dose 5 uM/kg),50588,A,,CHEMBL623601,,4353,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7444,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,A,,CHEMBL623602,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7445,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,A,,CHEMBL623603,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,7446,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),50588,A,,CHEMBL623604,,16452,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Lung,,7447,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,A,,CHEMBL623605,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,7448,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL623606,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,7449,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL623607,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,7450,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL623608,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,7451,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL623609,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,7452,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL623610,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Muscle tissue,,7453,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL623611,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,7454,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,A,,CHEMBL623612,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,7455,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL623613,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,7456,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL623614,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,7457,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL623615,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,7458,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL623616,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,7459,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL623617,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Zone of skin,,7460,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL875944,,10107,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,7461,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,A,,CHEMBL623618,,10107,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,7462,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL623619,,10107,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,7463,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL623620,,10107,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,7464,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL623621,,10107,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,7465,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL623622,,10107,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,7466,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL623623,,10107,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Spleen,,7467,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL623624,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,7468,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,A,,CHEMBL618521,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,7469,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL618522,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,7470,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL618523,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,7471,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL618524,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,7472,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL618525,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,7473,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL624586,,10107,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Stomach,,7474,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,A,,CHEMBL624587,,10107,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,7475,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,A,,CHEMBL624588,,10107,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,7476,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,A,,CHEMBL624589,,10107,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,7477,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,A,,CHEMBL624590,,10107,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,7478,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,A,,CHEMBL624591,,10107,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,7479,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,A,,CHEMBL624592,,10107,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,Stomach,,7480,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,A,,CHEMBL624593,,10107,10090.0,Intermediate,,,1,N,Mus musculus,945.0
In vivo,BAO_0000218,,,7481,1,,,Oral bioavailability in rat,50597,A,,CHEMBL624594,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7482,1,,,Tested for the bioavailability in rat,50597,A,,CHEMBL624595,,4950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7483,1,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,A,,CHEMBL624596,,5328,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7484,1,,,Bioavailability in rat,50597,A,,CHEMBL624597,,406,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7485,1,,,Bioavailability in rat,50597,A,,CHEMBL624598,,12500,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7486,1,,,Bioavailability in rat (dose 3-10 mg/kg),50597,A,,CHEMBL624599,,12500,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7487,1,,,Bioavailability in rat,50597,A,,CHEMBL875166,,5247,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7488,1,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,A,,CHEMBL624600,,4186,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7489,1,,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,A,,CHEMBL624601,,4186,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7490,1,,,Half life after oral administration was determined in rats at 6 mg/kg,50597,A,,CHEMBL624602,,6647,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7491,1,,,Half life was determined,50597,A,,CHEMBL624603,,6484,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7492,1,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,50597,A,,CHEMBL624604,,3249,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7493,1,,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,50597,A,,CHEMBL624605,,6281,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,7494,1,,,Half life in rats,50597,A,,CHEMBL624606,,3307,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Blood,,7495,1,,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,50597,A,,CHEMBL624607,,12058,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,,,7496,1,,,Hill coefficient of the compound,50597,A,,CHEMBL624608,,8833,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Blood,,7497,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,50597,A,,CHEMBL624609,,3193,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,7498,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,50597,A,,CHEMBL624610,,3193,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,7499,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,50597,A,,CHEMBL624611,,3193,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,7500,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,50597,A,,CHEMBL624612,,3193,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,7501,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,50597,A,,CHEMBL875167,,3193,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,7502,1,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,50597,A,,CHEMBL624613,,3193,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,7503,1,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",50597,A,,CHEMBL624614,,3193,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,,,7504,1,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,A,,CHEMBL624392,,5960,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Brain,,7505,1,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624393,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,7506,1,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624394,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,7507,1,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624395,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,7508,1,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624396,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,7509,1,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624397,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Thyroid gland,,7510,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624398,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,7511,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624399,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,7512,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624400,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,7513,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624401,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,7514,1,,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,50597,A,,CHEMBL624402,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Blood,,7515,1,,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,A,,CHEMBL624403,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7516,1,,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,50597,A,,CHEMBL624404,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7517,1,,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,50597,A,,CHEMBL624405,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Bone,,7518,1,,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,A,,CHEMBL624406,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7519,1,,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,50597,A,,CHEMBL624407,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7520,1,,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,50597,A,,CHEMBL624408,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Heart,,7521,1,,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,A,,CHEMBL618644,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7522,1,,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,50597,A,,CHEMBL618645,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7523,1,,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,50597,A,,CHEMBL618646,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Kidney,,7524,1,,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,A,,CHEMBL618647,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7525,1,,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,50597,A,,CHEMBL618648,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7526,1,,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,50597,A,,CHEMBL618649,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Liver,,7527,1,,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,A,,CHEMBL618650,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7528,1,,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,50597,A,,CHEMBL618651,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7529,1,,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,50597,A,,CHEMBL876497,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Lung,,7530,1,,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,A,,CHEMBL618652,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,7531,1,,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,50597,A,,CHEMBL618653,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,7532,1,,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,50597,A,,CHEMBL618654,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,,,7533,1,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,50597,A,,CHEMBL618655,,6351,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7534,1,,,Compound was tested for solubility in water,50597,A,,CHEMBL618656,,1465,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000100,,,7535,1,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),22229,P,,CHEMBL618657,,5182,,Intermediate,,,0,U,,
,BAO_0000218,,,7536,1,,,Solubility was determined,50597,A,,CHEMBL618658,,17847,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7537,1,,,solubility in water (ug/mL) at 37 degree C.,50597,A,,CHEMBL618659,,15339,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7538,1,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,50597,A,,CHEMBL618660,,5202,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7539,1,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,50597,A,,CHEMBL618661,,1088,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7540,1,,,Half life in rats,50597,A,,CHEMBL873807,,3169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7541,1,,,Half life in Dawley rat,50597,A,,CHEMBL618662,,5353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7542,1,,,Half life period after 3 mg/kg iv administration,50597,A,,CHEMBL618663,,2864,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7543,1,,,Half life period after 3 mg/kg iv administration in rat,50597,A,,CHEMBL618664,,2864,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7544,1,,,Half life period after 3 mg/kg iv administration in the rat,50597,A,,CHEMBL618665,,2864,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7545,1,,,Half life period in female Sprague-Dawley rats,50597,A,,CHEMBL876498,,6362,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7546,1,,,Half life period in rat,50597,A,,CHEMBL618666,,6249,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7547,1,,,Half-life in rats was determined,50597,A,,CHEMBL620440,,3169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7548,1,,,Half-life in rats with metabolic oxidation,50597,A,,CHEMBL620441,,3169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7549,1,,,Half-life in rats,50597,A,,CHEMBL620442,,3169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7550,1,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,A,,CHEMBL620443,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7551,1,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,A,,CHEMBL620444,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7552,1,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,A,,CHEMBL620445,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7553,1,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,A,,CHEMBL620446,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7554,1,,,Biological half-life measured in plasma of rat,50597,A,,CHEMBL620447,,2879,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7555,1,,,Biological half-life measured in plasma of rat; 22-25,50597,A,,CHEMBL621129,,2879,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7556,1,,,Biological half-life measured in plasma of rat; 9-16,50597,A,,CHEMBL621130,,2879,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7557,1,,,Compound was evaluated for its half life when administered intravenously in rat,50597,A,,CHEMBL873808,,3184,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7558,1,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,50597,A,,CHEMBL876598,,4891,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7559,1,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,50597,A,,CHEMBL621131,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7560,1,,,Half life (T1/2) after oral administration in rat,50597,A,,CHEMBL621132,,5656,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7561,1,,,Half life of compound after iv administration of 20 mg/kg dose in rat,50597,A,,CHEMBL621133,,4413,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7562,1,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,A,,CHEMBL621312,,3598,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7563,1,,,Half life of compound was determined in rat,50597,A,,CHEMBL621313,,17267,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Blood,,7564,1,,,Half life of compound was determined in rat blood,50597,A,,CHEMBL621314,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,,,7565,1,,,Half life at 1 mg/kg was determined in rat,50597,A,,CHEMBL621315,,17651,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7566,1,,,Half life at 10 mg/kg was determined in rat,50597,A,,CHEMBL621316,,17651,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7567,1,,,Half life in rats,50597,A,,CHEMBL621317,,401,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7568,1,,,Half life in rats in hours,50597,A,,CHEMBL621318,,4942,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7569,1,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,A,,CHEMBL621319,,17735,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7570,1,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,50597,A,,CHEMBL621377,,6056,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7571,1,,,Half life was determined,50597,A,,CHEMBL621378,,5213,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7572,1,,,Half life after i.v. administration,50597,A,,CHEMBL876599,,6616,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7573,1,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,50597,A,,CHEMBL621379,,5937,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7574,1,,,Half life in rat plasma,50597,A,,CHEMBL621380,,5819,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7575,1,,,Half life in rat plasma; Not detected,50597,A,,CHEMBL621381,,5819,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,7576,1,,,Half life in rats,50597,A,,CHEMBL618515,,6803,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7577,1,,,Half life period of compound was determined after peroral administration,50597,A,,CHEMBL618516,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7578,1,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,50597,A,,CHEMBL618517,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7579,1,,,Half life period in rat,50597,A,,CHEMBL618518,,5948,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7580,1,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,A,,CHEMBL618519,,1916,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7581,1,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,A,,CHEMBL618698,,1916,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7582,1,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,50597,A,,CHEMBL618862,,1916,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7583,1,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL618863,,4890,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7584,1,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,50597,A,,CHEMBL618864,,17764,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7585,1,,,Half life time in rat the dose of 2 mg/kg,50597,A,,CHEMBL618865,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7586,1,,,Half-life 24 hr after 10 mg/kg iv administration in rats,50597,A,,CHEMBL618866,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7587,1,,,Half-life 24 hr after 2 mg/kg iv administration in rats,50597,A,,CHEMBL618867,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7588,1,,,Half-life consistent with the observed metabolic steady state in rats,50597,A,,CHEMBL875828,,6597,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7589,1,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,A,,CHEMBL618868,,17735,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7590,1,,,Half-life for oxidative metabolic stability was determined using male human,50597,A,,CHEMBL618869,,6597,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7591,1,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",50597,A,,CHEMBL618870,,17670,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7592,1,,,Half-life in rat plasma,50597,A,,CHEMBL618871,,1696,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7593,1,,,Half-life in rat plasma was determined,50597,A,,CHEMBL618872,,1742,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,7594,1,,,Half-life in rats was determined,50597,A,,CHEMBL873816,,17800,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7595,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,22224,A,,CHEMBL618873,,12923,,Autocuration,,,0,U,,
,BAO_0000019,,,7596,1,,,Area under curve after oral dose of 0.1 mg//kg,22224,A,,CHEMBL621602,,11954,,Autocuration,,,0,U,,
,BAO_0000218,,,7597,1,,,Area under curve after oral dose of 0.3 mg/kg,22224,A,,CHEMBL621603,,11954,,Autocuration,,,0,U,,
,BAO_0000218,,,7598,1,,,Area under curve after oral dose of 1 mg/kg,22224,A,,CHEMBL621604,,11954,,Autocuration,,,0,U,,
,BAO_0000218,,,7599,1,,,Area under curve after oral dose of 10 mg/kg,22224,A,,CHEMBL621605,,11954,,Autocuration,,,0,U,,
,BAO_0000218,,,7600,1,,,Area under curve after oral dose of 23.4 mg/kg,22224,A,,CHEMBL621606,,11954,,Autocuration,,,0,U,,
,BAO_0000218,,,7601,1,,,Area under curve after oral dose of 3 mg/kg,22224,A,,CHEMBL621607,,11954,,Autocuration,,,0,U,,
,BAO_0000218,,,7602,1,,,Area under curve after oral dose of 3.87 mg/kg,22224,A,,CHEMBL621608,,11954,,Autocuration,,,0,U,,
,BAO_0000019,,,7603,1,,,Area under curve was determined,22224,A,,CHEMBL621609,,5237,,Autocuration,,,0,U,,
,BAO_0000218,,,7604,1,,,Area under curve at a dose of 10 mg/kg,22224,A,,CHEMBL621610,,4026,,Autocuration,,,0,U,,
,BAO_0000218,,,7605,1,,,Area under curve was determined; ND=No data,50597,A,,CHEMBL621611,,5237,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7606,1,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,A,,CHEMBL621612,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7607,1,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,A,,CHEMBL622308,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7608,1,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,A,,CHEMBL622309,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7609,1,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,A,,CHEMBL622310,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7610,1,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,A,,CHEMBL622311,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7611,1,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,50597,A,,CHEMBL622312,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7612,1,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,A,,CHEMBL622931,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7613,1,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,50597,A,,CHEMBL622932,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7614,1,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,A,,CHEMBL622736,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7615,1,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,A,,CHEMBL622737,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7616,1,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,A,,CHEMBL622738,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7617,1,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,A,,CHEMBL622739,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7618,1,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,A,,CHEMBL622740,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7619,1,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,50597,A,,CHEMBL622741,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7620,1,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,A,,CHEMBL622742,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7621,1,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,50597,A,,CHEMBL622743,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7622,1,,,AUC in mice,50594,A,,CHEMBL622744,,11637,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000019,,,7623,1,,,Area under curve was measured from the graph obtained from concentration Vs time,22224,A,,CHEMBL624134,,11149,,Autocuration,,,0,U,,
,BAO_0000019,,,7624,1,,,Area under curve value of compound per hour after oral administration,22224,A,,CHEMBL624135,,10016,,Autocuration,,,0,U,,
,BAO_0000218,,,7625,1,,,Area under curve was determined after oral administration in rats,50597,A,,CHEMBL624136,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7626,1,,,Area under curve was determined after oral administration in rats; No data,50597,A,,CHEMBL624137,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7627,1,,,Area under curve was determined after oral administration in rats;No data,50597,A,,CHEMBL624320,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7628,1,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,A,,CHEMBL624321,,12923,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7629,1,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,50597,A,,CHEMBL624322,,15372,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7630,1,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,50597,A,,CHEMBL624323,,15372,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7631,1,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,50597,A,,CHEMBL624324,,15372,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7632,1,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,50597,A,,CHEMBL624325,,15372,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7633,1,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,50597,A,,CHEMBL624326,,15372,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7634,1,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,50597,A,,CHEMBL624327,,15372,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7635,1,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,50597,A,,CHEMBL624328,,15372,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7636,1,,,Area under curve was determined in Dogs after peroral administration,50588,A,,CHEMBL627848,,14169,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7637,1,,,Area under curve was determined in Rats after peroral administration,50597,A,,CHEMBL627849,,14169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7638,1,,,Area under curve was determined in carotid blood of rat when administered intradermally,50597,A,,CHEMBL627850,,14258,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7639,1,,,Area under curve was determined in portal blood of rat when administered intradermally,50597,A,,CHEMBL627851,,14258,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7640,1,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,A,,CHEMBL627852,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7641,1,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,A,,CHEMBL627853,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7642,1,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,A,,CHEMBL627854,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7643,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,A,,CHEMBL627855,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7644,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,A,,CHEMBL627856,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7645,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,A,,CHEMBL875339,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7646,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),50594,A,,CHEMBL627857,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Spleen,,7647,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,50597,A,,CHEMBL627858,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Blood,,7648,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,50597,A,,CHEMBL627859,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Brain,,7649,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,50597,A,,CHEMBL627860,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Heart,,7650,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,50597,A,,CHEMBL627019,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Liver,,7651,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,50597,A,,CHEMBL627020,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Lung,,7652,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,50597,A,,CHEMBL627021,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Muscle tissue,,7653,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,50597,A,,CHEMBL627022,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,,,7654,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,50597,A,,CHEMBL627023,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Spleen,,7655,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,50597,A,,CHEMBL627024,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Thyroid gland,,7656,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,50597,A,,CHEMBL627025,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Kidney,,7657,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,50597,A,,CHEMBL627026,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Blood,,7658,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,50597,A,,CHEMBL627027,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Brain,,7659,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,50597,A,,CHEMBL627028,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Heart,,7660,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,50597,A,,CHEMBL627029,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Kidney,,7661,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,50597,A,,CHEMBL627030,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Liver,,7662,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,50597,A,,CHEMBL627031,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Lung,,7663,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,50597,A,,CHEMBL627032,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Muscle tissue,,7664,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,50597,A,,CHEMBL627033,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,,,7665,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,50597,A,,CHEMBL627034,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Spleen,,7666,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,50597,A,,CHEMBL627035,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Thyroid gland,,7667,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,50597,A,,CHEMBL627036,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Blood,,7668,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,50597,A,,CHEMBL875340,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Heart,,7669,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,50597,A,,CHEMBL627037,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Kidney,,7670,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,50597,A,,CHEMBL627038,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Liver,,7671,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,50597,A,,CHEMBL627039,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Muscle tissue,,7672,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,50597,A,,CHEMBL627040,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Spleen,,7673,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,50597,A,,CHEMBL624663,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Thyroid gland,,7674,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,50597,A,,CHEMBL625963,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Brain,,7675,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,50597,A,,CHEMBL876799,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Lung,,7676,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,50597,A,,CHEMBL626133,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,,,7677,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,50597,A,,CHEMBL626134,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7678,1,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,A,,CHEMBL626135,,6295,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7679,1,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,A,,CHEMBL626136,,6296,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7680,1,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,50597,A,,CHEMBL626137,,6296,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7681,1,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,A,,CHEMBL626138,,6295,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7682,1,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,A,,CHEMBL626139,,6296,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7683,1,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,A,,CHEMBL626140,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7684,1,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,A,,CHEMBL626141,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7685,1,,,C24h in rat p.o. at 20 mg/kg concentration,50597,A,,CHEMBL626142,,17686,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Muscle tissue,,7686,1,,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,A,,CHEMBL627930,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,7687,1,,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,50597,A,,CHEMBL627931,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,7688,1,,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,50597,A,,CHEMBL627932,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Spleen,,7689,1,,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,A,,CHEMBL627933,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,7690,1,,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,50597,A,,CHEMBL627934,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,7691,1,,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,50597,A,,CHEMBL627935,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Blood,,7692,1,,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,A,,CHEMBL627936,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7693,1,,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,50597,A,,CHEMBL627937,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7694,1,,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,A,,CHEMBL627938,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7695,1,,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,50597,A,,CHEMBL627939,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7696,1,,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,50597,A,,CHEMBL627940,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7697,1,,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,A,,CHEMBL627941,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7698,1,,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,A,,CHEMBL876800,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7699,1,,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,50597,A,,CHEMBL627942,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7700,1,,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,A,,CHEMBL627943,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7701,1,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,50597,A,,CHEMBL627944,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7702,1,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,50597,A,,CHEMBL627945,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7703,1,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,50597,A,,CHEMBL628584,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7704,1,,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,50597,A,,CHEMBL628585,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7705,1,,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,50597,A,,CHEMBL628586,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7706,1,,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,50597,A,,CHEMBL628587,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7707,1,,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,50597,A,,CHEMBL628588,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7708,1,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,50597,A,,CHEMBL628589,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7709,1,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,50597,A,,CHEMBL625304,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7710,1,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,50597,A,,CHEMBL625305,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7711,1,,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,50597,A,,CHEMBL625306,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7712,1,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,50597,A,,CHEMBL625307,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7713,1,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,50597,A,,CHEMBL625308,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7714,1,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,50597,A,,CHEMBL627740,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7715,1,,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,50597,A,,CHEMBL627741,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7716,1,,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,A,,CHEMBL627742,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7717,1,,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,50597,A,,CHEMBL627743,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,7718,1,,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,50597,A,,CHEMBL627744,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Bone,,7719,1,,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,50597,A,,CHEMBL627745,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7720,1,,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,A,,CHEMBL627746,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7721,1,,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,A,,CHEMBL627747,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7722,1,,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,50597,A,,CHEMBL876810,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7723,1,,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,50597,A,,CHEMBL627748,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7724,1,,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,A,,CHEMBL627749,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7725,1,,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,A,,CHEMBL627750,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7726,1,,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,50597,A,,CHEMBL618728,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7727,1,,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,A,,CHEMBL618729,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7728,1,,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,50597,A,,CHEMBL618730,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7729,1,,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,50597,A,,CHEMBL618731,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7730,1,,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,50597,A,,CHEMBL618732,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7731,1,,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,50597,A,,CHEMBL618733,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7732,1,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,50597,A,,CHEMBL618734,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7733,1,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,50597,A,,CHEMBL618735,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7734,1,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,50597,A,,CHEMBL876602,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7735,1,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,50597,A,,CHEMBL618736,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7736,1,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,50597,A,,CHEMBL618737,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7737,1,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,50597,A,,CHEMBL618738,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7738,1,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,50597,A,,CHEMBL618739,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7739,1,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,50597,A,,CHEMBL618740,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7740,1,,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,A,,CHEMBL618741,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7741,1,,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,50597,A,,CHEMBL618742,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,7742,1,,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,50597,A,,CHEMBL618743,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Plasma,,7743,1,,,Half-life from rat plasma at a single oral dose of 25 mg/kg,50597,A,,CHEMBL618744,,17752,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,7744,1,,,Half-life in male rat,50597,A,,CHEMBL618745,,5610,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7745,1,,,Half-life in rat after peroral administration at 10 mg/kg concentration,50597,A,,CHEMBL620479,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7746,1,,,Half-life in rat after peroral administration at 5 mg/kg concentration,50597,A,,CHEMBL620480,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7747,1,,,Half-life in rat at a dose of 3 mg/kg,50597,A,,CHEMBL620481,,17771,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7748,1,,,Half-life was evaluated in rats,50597,A,,CHEMBL620482,,1974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7749,1,,,Half-life was measured in rat,50597,A,,CHEMBL876603,,4239,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7750,1,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,50597,A,,CHEMBL620483,,6681,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7751,1,,,Half-life period in rats after intravenous administration at 5 mg/kg,50597,A,,CHEMBL620484,,17752,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7752,1,,,Half-life period in rat at 10 mg/kg,50597,A,,CHEMBL620485,,6046,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7753,1,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",50597,A,,CHEMBL620486,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7754,1,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",50597,A,,CHEMBL620487,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7755,1,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",50597,A,,CHEMBL620488,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7756,1,,,Half-life time in rat the dose of 2 mg/kg,50597,A,,CHEMBL620489,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7757,1,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,50597,A,,CHEMBL620490,,1088,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7758,1,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,50597,A,,CHEMBL620491,,5610,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7759,1,,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,A,,CHEMBL876604,,3032,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7760,1,,,Oral half life was determined,50597,A,,CHEMBL620492,,5199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7761,1,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",50597,A,,CHEMBL620493,,14941,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7762,1,,,Pharmacokinetic property (t1/2) in rat,50597,A,,CHEMBL620494,,4408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7763,1,,,Plasma elimination half-life was determined,50597,A,,CHEMBL620495,,2552,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7764,1,,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,A,,CHEMBL620496,,5199,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7765,1,,,Plasma half life was observed after intravenous administration in rat,50597,A,,CHEMBL620497,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7766,1,,,Plasma half-life was determined,50597,A,,CHEMBL620498,,1465,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7767,1,,,Plasma half-life following oral administration in Fisher rats,50597,A,,CHEMBL620499,,1446,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7768,1,,,Plasma half-life in rat,50597,A,,CHEMBL620500,,6824,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7769,1,,,Plasmatic Half-life after intravenous administration to rat,50597,A,,CHEMBL873809,,17533,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7770,1,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,A,,CHEMBL620501,,5979,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7771,1,,,Terminal half life after intravenous administration (1 mg/kg) in rat,50597,A,,CHEMBL620502,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7772,1,,,Terminal half life in Rat at a oral dose of 5 mg/kg,50597,A,,CHEMBL620503,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7773,1,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,A,,CHEMBL620504,,2463,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7774,1,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,50597,A,,CHEMBL876605,,4883,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7775,1,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,50597,A,,CHEMBL620505,,4883,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7776,1,,,plasma half life was observed after intravenous administration in rat,50597,A,,CHEMBL873811,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7777,1,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,A,,CHEMBL624016,,3598,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7778,1,,,Half life of compound determined in rat,50597,A,,CHEMBL624017,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7779,1,,,Mean residence time determined in rat,50597,A,,CHEMBL624018,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7780,1,,,Plasma half life determined in rat,50597,A,,CHEMBL624019,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Brain,,7781,1,,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,50597,A,,CHEMBL624020,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,,,7782,1,,,Compound was evaluated for pharmacokinetic parameter maximum time period,50597,A,,CHEMBL624201,,4891,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7783,1,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,A,,CHEMBL872528,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7784,1,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL624202,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7785,1,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL624203,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7786,1,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL624350,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7787,1,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL621320,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7788,1,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,A,,CHEMBL621321,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7789,1,,,Maximum time (Tmax) required to reach Cmax in rats,50597,A,,CHEMBL621322,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7790,1,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL621323,,4890,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7791,1,,,Maximum time of clearance of compound in rats after peroral administration,50597,A,,CHEMBL621324,,6571,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7792,1,,,Maximum time at the dose of 2 mg/kg in rat,50597,A,,CHEMBL621325,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7793,1,,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,50597,A,,CHEMBL875837,,17651,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7794,1,,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,50597,A,,CHEMBL621326,,17651,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7795,1,,,Tmax in Guinea pig (PO dose),50597,A,,CHEMBL621327,,14465,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7796,1,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",50597,A,,CHEMBL621328,,14941,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7797,1,,,Pharmacokinetic parameter (Tmax) in rat,50597,A,,CHEMBL621329,,5960,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7798,1,,,Pharmacokinetic parameter (Tmax) was estimated,50597,A,,CHEMBL621330,,5022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7799,1,,,Pharmacokinetic property (Tmax) in rat,50597,A,,CHEMBL621331,,4408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7800,1,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,A,,CHEMBL621332,,5983,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7801,1,,,T max in Rat at a oral dose of 5 mg/kg,50597,A,,CHEMBL621333,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7802,1,,,T max was determined at 10 mg/kg po dose in rats,50597,A,,CHEMBL621334,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7803,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,A,,CHEMBL621335,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7804,1,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,50588,A,,CHEMBL621336,,14180,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7805,1,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,50597,A,,CHEMBL621337,,14180,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7806,1,,,Area under curve was measured after i.v. administration into Beagle dog.,50588,A,,CHEMBL621338,,14599,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7807,1,,,Area under curve was measured after iv administration into Beagle dog,50588,A,,CHEMBL875838,,14599,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7808,1,,,Area under curve was measured after po administration into Beagle dog,50588,A,,CHEMBL621339,,14599,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7809,1,,,Area under curve was measured after po administration into Beagle dog.,50588,A,,CHEMBL621340,,14599,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7810,1,,,Area under curve was measured at peroral dose of 3 mg/kg,22224,A,,CHEMBL621341,,15675,,Autocuration,,,0,U,,
,BAO_0000019,,,7811,1,,,Area under curve was measured by using concentration Vs time,22224,A,,CHEMBL621342,,12706,,Autocuration,,,0,U,,
,BAO_0000019,,,7812,1,,,Area under curve was measured by using concentration Vs time; not tested,22224,A,,CHEMBL621343,,12706,,Autocuration,,,0,U,,
,BAO_0000218,,,7813,1,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),50594,A,,CHEMBL621344,,9750,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7814,1,,,Area under curve(AUC) was measured in mice after oral administration.,50594,A,,CHEMBL621345,,9750,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000019,,,7815,1,,,Area under curve(AUC) value of the compound,22224,A,,CHEMBL621346,,14691,,Autocuration,,,0,U,,
,BAO_0000218,,,7816,1,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,22224,A,,CHEMBL621347,,14691,,Autocuration,,,0,U,,
,BAO_0000218,,,7817,1,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,50588,A,,CHEMBL621348,,14691,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000019,Blood,,7818,1,,,Area under curve(carotid artery) was determined by the availability in blood,22224,A,,CHEMBL621349,,2939,,Autocuration,,,0,U,,178.0
,BAO_0000019,Blood,,7819,1,,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,22224,A,,CHEMBL621350,,2939,,Autocuration,,,0,U,,178.0
,BAO_0000019,Blood,,7820,1,,,Area under curve(carotid artery) was determined by the availability in blood; No data,22224,A,,CHEMBL875839,,2939,,Autocuration,,,0,U,,178.0
,BAO_0000019,Blood,,7821,1,,,Area under curve(portal vein) was determined by the availability in blood,22224,A,,CHEMBL620211,,2939,,Autocuration,,,0,U,,178.0
,BAO_0000019,Blood,,7822,1,,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,22224,A,,CHEMBL620212,,2939,,Autocuration,,,0,U,,178.0
,BAO_0000019,Blood,,7823,1,,,Area under curve(portal vein) was determined by the availability in blood; No data,22224,A,,CHEMBL620213,,2939,,Autocuration,,,0,U,,178.0
,BAO_0000218,Plasma,,7824,1,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,A,,CHEMBL620214,,9552,9544.0,Intermediate,,,1,N,Macaca mulatta,1969.0
,BAO_0000218,Plasma,,7825,1,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,A,,CHEMBL620215,,9552,9544.0,Intermediate,,,1,N,Macaca mulatta,1969.0
,BAO_0000218,Plasma,,7826,1,,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,50797,A,,CHEMBL620216,,9552,9544.0,Intermediate,,,1,N,Macaca mulatta,1969.0
,BAO_0000218,Plasma,,7827,1,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",50588,A,,CHEMBL620888,,9552,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,7828,1,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",50588,A,,CHEMBL620889,,9552,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000019,Plasma,,7829,1,,,Area under plasma concentration vs time curve observed in rats for 0-3 h,22224,A,,CHEMBL620890,,9552,,Autocuration,,,0,U,,1969.0
,BAO_0000218,Plasma,,7830,1,,,Area under plasma time curve determined in male rat,50597,A,,CHEMBL620891,,11911,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000019,,,7831,1,,,Area under the MAP curve measured over 5 min.,22224,A,,CHEMBL620892,,16618,,Autocuration,,,0,U,,
,BAO_0000218,,,7832,1,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,50594,A,,CHEMBL621079,,14387,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7833,1,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,50594,A,,CHEMBL621080,,14387,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,7834,1,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,50588,A,,CHEMBL621081,,12836,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7835,1,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,100712,A,,CHEMBL621082,,12836,10026.0,Intermediate,,,1,N,Cricetinae,
,BAO_0000218,,,7836,1,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,50597,A,,CHEMBL621083,,12836,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7837,1,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,50588,A,,CHEMBL621084,,14339,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7838,1,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,50588,A,,CHEMBL621085,,14339,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7839,1,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,50588,A,,CHEMBL621086,,14339,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7840,1,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50588,A,,CHEMBL621087,,10524,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7841,1,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),50588,A,,CHEMBL622607,,9994,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7842,1,,,Serum AUC in marmosets (IV dose),50588,A,,CHEMBL622608,,11325,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000019,,,7843,1,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,22224,A,,CHEMBL624481,,12536,,Autocuration,,,0,U,,
,BAO_0000019,,,7844,1,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,22224,A,,CHEMBL624482,,12536,,Autocuration,,,0,U,,
,BAO_0000019,,,7845,1,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,22224,A,,CHEMBL624483,,12536,,Autocuration,,,0,U,,
,BAO_0000019,,,7846,1,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,22224,A,,CHEMBL624484,,12536,,Autocuration,,,0,U,,
,BAO_0000019,,,7847,1,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,22224,A,,CHEMBL624485,,12536,,Autocuration,,,0,U,,
,BAO_0000218,,,7848,1,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,50597,A,,CHEMBL624486,,15556,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000019,,,7849,1,,,Area under the curve for the compound was calculated.,22224,A,,CHEMBL624487,,2809,,Autocuration,,,0,U,,
,BAO_0000019,,,7850,1,,,Area under the curve in concentration/ time,22224,A,,CHEMBL624488,,9511,,Autocuration,,,0,U,,
,BAO_0000218,,,7851,1,,,Area under the curve administered intraintestinal in rats.,50597,A,,CHEMBL624489,,12818,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7852,1,,,Area under the curve administered intravenously in rats.,50597,A,,CHEMBL625184,,12818,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000019,,,7853,1,,,Area under the curve during intravenous administration,22224,A,,CHEMBL625185,,15118,,Autocuration,,,0,U,,
,BAO_0000019,,,7854,1,,,Area under the curve during intravenous administration; Not determined,22224,A,,CHEMBL875954,,15118,,Autocuration,,,0,U,,
,BAO_0000019,,,7855,1,,,Area under the curve during systemic administration,22224,A,,CHEMBL625186,,15118,,Autocuration,,,0,U,,
,BAO_0000019,,,7856,1,,,Area under the curve during systemic administration; Not determined,22224,A,,CHEMBL625187,,15118,,Autocuration,,,0,U,,
,BAO_0000019,,,7857,1,,,Area under the curve was calculated for the compound.,22224,A,,CHEMBL625188,,2632,,Autocuration,,,0,U,,
,BAO_0000218,,,7858,1,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,50588,A,,CHEMBL625189,,14346,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7859,1,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,50588,A,,CHEMBL625190,,14346,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,7860,1,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,50597,A,,CHEMBL621733,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7861,1,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,50597,A,,CHEMBL621734,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7862,1,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,50597,A,,CHEMBL621735,,11149,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7863,1,,,Clearance of the drug was measured in the plasma of rat; No data,50597,A,,CHEMBL621736,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7864,1,,,The pharmacokinetic parameter plasma clearance in vivo in rats,50597,A,,CHEMBL621737,,5247,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,7865,1,,,Plasma clearance at the dose of 2 mg/kg in rat,50597,A,,CHEMBL621738,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7866,1,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,A,,CHEMBL622806,,5654,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7867,1,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,A,,CHEMBL623519,,5654,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7868,1,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,A,,CHEMBL623520,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7869,1,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,A,,CHEMBL623521,,17065,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7870,1,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,A,,CHEMBL623522,,17671,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7871,1,,,Clearance rate in rat,50597,A,,CHEMBL623523,,6672,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7872,1,,,Clearance rate in rat,50597,A,,CHEMBL623690,,6673,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7873,1,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL623691,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7874,1,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL623692,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7875,1,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL623693,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7876,1,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL623694,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7877,1,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,50597,A,,CHEMBL623695,,4413,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7878,1,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,50597,A,,CHEMBL623696,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7879,1,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,50597,A,,CHEMBL623697,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7880,1,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,A,,CHEMBL623698,,5005,9544.0,Intermediate,,,0,U,Macaca mulatta,1969.0
In vivo,BAO_0000218,Plasma,,7881,1,,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,22224,A,,CHEMBL623699,,5005,10116.0,Intermediate,,,0,U,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7882,1,,,Mean (%CV) PK parameters for CL(mL/min/kg).,50597,A,,CHEMBL623700,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7883,1,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,50597,A,,CHEMBL623701,,3747,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7884,1,,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,50597,A,,CHEMBL623702,,16366,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7885,1,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,50597,A,,CHEMBL623703,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7886,1,,,Plasma clearance in rat was determined,50597,A,,CHEMBL623704,,17267,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7887,1,,,Plasma clearance in rat after administration of 2 mg/kg iv,50597,A,,CHEMBL623705,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7888,1,,,Plasma clearance in rat after administration of 2 mg/kg iv,50597,A,,CHEMBL623706,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7889,1,,,Plasma clearance was determined,50597,A,,CHEMBL623707,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7890,1,,,Plasma clearance in rat,50597,A,,CHEMBL623708,,5960,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7891,1,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,50597,A,,CHEMBL623709,,5937,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7892,1,,,Plasma clearance in rat by iv administration,50597,A,,CHEMBL623710,,5871,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7893,1,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,50597,A,,CHEMBL623711,,5874,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7894,1,,,Plasma clearance in rat p.o.,50597,A,,CHEMBL623712,,6504,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7895,1,,,Plasma clearance in rats,50597,A,,CHEMBL623713,,6803,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7896,1,,,Plasma clearance was determined; ND denotes no data,50597,A,,CHEMBL623714,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7897,1,,,Plasma clearance was determined; ND denotes not determined,50597,A,,CHEMBL623715,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7898,1,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,A,,CHEMBL623716,,1916,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7899,1,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,A,,CHEMBL622980,,5199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7900,1,,,Plasma administration to rats,50597,A,,CHEMBL622981,,16367,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7901,1,,,Plasma clearance of the compound in female Sprague-Dawley rats,50597,A,,CHEMBL622982,,6362,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7902,1,,,Plasma clearance was observed after intravenous administration in rat,50597,A,,CHEMBL622983,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7903,1,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,50597,A,,CHEMBL622984,,6215,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7904,1,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,50597,A,,CHEMBL622985,,1466,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7905,1,,,plasma clearance was observed after intravenous administration in rat,50597,A,,CHEMBL623631,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7906,1,,,In vivo CL/F determined,50597,A,,CHEMBL623632,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7907,1,,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,50597,A,,CHEMBL623633,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7908,1,,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,50597,A,,CHEMBL623634,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7909,1,,,Compound was tested for the lower blood clearance in rat,50597,A,,CHEMBL623635,,5213,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7910,1,,,Evaluated for the low clearance in rat (in vivo),50597,A,,CHEMBL621195,,4687,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7911,1,,,Pharmacokinetic property (CLb)of the compound was determined in rat,50597,A,,CHEMBL621196,,3371,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7912,1,,,Rapid clearance after intravenous administration in rat was determined,50597,A,,CHEMBL875287,,4690,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7913,1,,,Clearance measured in rat,50597,A,,CHEMBL621197,,5702,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,7914,1,,,Compound was evaluated for plasma clearance in rat,50597,A,,CHEMBL621198,,740,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7915,1,,,Low plasma clearance was calculated in rat,50597,A,,CHEMBL621199,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7916,1,,,Pharmacokinetic property (Clp) in rat,50597,A,,CHEMBL621200,,5789,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7917,1,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,50597,A,,CHEMBL621201,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7918,1,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,50597,A,,CHEMBL621202,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7919,1,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,50597,A,,CHEMBL621203,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7920,1,,,Plasma clearance after IV dosing at 1 mg/kg in rat,50597,A,,CHEMBL621204,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Heart,,7921,1,,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,50597,A,,CHEMBL621205,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7922,1,,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,50597,A,,CHEMBL621206,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7923,1,,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,A,,CHEMBL621207,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7924,1,,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,50597,A,,CHEMBL621208,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7925,1,,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,50597,A,,CHEMBL621209,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7926,1,,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,50597,A,,CHEMBL876484,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7927,1,,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,A,,CHEMBL621210,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7928,1,,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,50597,A,,CHEMBL621211,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7929,1,,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,A,,CHEMBL621212,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7930,1,,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,50597,A,,CHEMBL621213,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7931,1,,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,50597,A,,CHEMBL621214,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7932,1,,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,50597,A,,CHEMBL621215,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7933,1,,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,50597,A,,CHEMBL621216,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7934,1,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,50597,A,,CHEMBL621217,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7935,1,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,50597,A,,CHEMBL621218,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7936,1,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,50597,A,,CHEMBL621219,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7937,1,,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,50597,A,,CHEMBL621220,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7938,1,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,50597,A,,CHEMBL621221,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7939,1,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,50597,A,,CHEMBL621222,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7940,1,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,50597,A,,CHEMBL621223,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7941,1,,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,50597,A,,CHEMBL876485,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7942,1,,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,A,,CHEMBL621224,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7943,1,,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,50597,A,,CHEMBL621225,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,7944,1,,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,50597,A,,CHEMBL621226,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Kidney,,7945,1,,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,50597,A,,CHEMBL621227,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7946,1,,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,A,,CHEMBL621228,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7947,1,,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,A,,CHEMBL621229,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7948,1,,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,50597,A,,CHEMBL621230,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7949,1,,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,A,,CHEMBL621231,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7950,1,,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,A,,CHEMBL621232,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7951,1,,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,A,,CHEMBL621233,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7952,1,,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,50597,A,,CHEMBL621234,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7953,1,,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,A,,CHEMBL621235,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7954,1,,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,A,,CHEMBL621236,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7955,1,,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,50597,A,,CHEMBL621237,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,7956,1,,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,50597,A,,CHEMBL876486,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Intestine,,7957,1,,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,50597,A,,CHEMBL622436,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,7958,1,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,50597,A,,CHEMBL622437,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,7959,1,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,50597,A,,CHEMBL622438,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Liver,,7960,1,,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,50597,A,,CHEMBL622439,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7961,1,,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,50597,A,,CHEMBL622440,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7962,1,,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,50597,A,,CHEMBL622441,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7963,1,,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,A,,CHEMBL622442,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7964,1,,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,50597,A,,CHEMBL622443,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7965,1,,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,A,,CHEMBL622444,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7966,1,,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,50597,A,,CHEMBL622445,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7967,1,,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,A,,CHEMBL622446,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7968,1,,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,A,,CHEMBL622447,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7969,1,,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,50597,A,,CHEMBL622448,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7970,1,,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,A,,CHEMBL622449,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7971,1,,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,50597,A,,CHEMBL622450,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7972,1,,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,50597,A,,CHEMBL622451,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7973,1,,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,50597,A,,CHEMBL622452,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7974,1,,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,50597,A,,CHEMBL622453,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7975,1,,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,50597,A,,CHEMBL622454,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7976,1,,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,50597,A,,CHEMBL622455,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,7977,1,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,50597,A,,CHEMBL876024,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,,,7978,1,,,T max was determined at 3 mg/kg po dose in rats,50597,A,,CHEMBL622456,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7979,1,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL622457,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7980,1,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL622458,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7981,1,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,50597,A,,CHEMBL622459,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7982,1,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,50597,A,,CHEMBL873343,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,7983,1,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,50597,A,,CHEMBL622460,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7984,1,,,Time for maximum plasma concentration determined in rat,50597,A,,CHEMBL622461,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7985,1,,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,A,,CHEMBL622462,,6681,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7986,1,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,50597,A,,CHEMBL622463,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7987,1,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,50597,A,,CHEMBL622464,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7988,1,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,50597,A,,CHEMBL622465,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7989,1,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,50597,A,,CHEMBL622466,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,7990,1,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,50597,A,,CHEMBL622467,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7991,1,,,Time of maximum plasma concentration in rat,50597,A,,CHEMBL622468,,6824,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7992,1,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,A,,CHEMBL876025,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7993,1,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,A,,CHEMBL622469,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,7994,1,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,A,,CHEMBL622470,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,7995,1,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,50597,A,,CHEMBL622471,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,7996,1,,,Time required to reach maximum concentration in rat plasma,50597,A,,CHEMBL622472,,1742,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7997,1,,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,A,,CHEMBL622473,,2774,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7998,1,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,A,,CHEMBL624282,,5199,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,7999,1,,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,A,,CHEMBL624283,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8000,1,,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,A,,CHEMBL624284,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8001,1,,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,A,,CHEMBL624285,,1916,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8002,1,,,Time to reach Cmax after oral administration to rats,50597,A,,CHEMBL624286,,16367,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8003,1,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,50597,A,,CHEMBL624287,,16366,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8004,1,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,50597,A,,CHEMBL624288,,216,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8005,1,,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,50597,A,,CHEMBL624289,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8006,1,,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,50597,A,,CHEMBL873344,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8007,1,,,Tmax after peroral administration (10 mg/kg) was determined in rat,50597,A,,CHEMBL619623,,6215,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8008,1,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,A,,CHEMBL621399,,3598,10116.0,Expert,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8009,1,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,50597,A,,CHEMBL621400,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8010,1,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",50597,A,,CHEMBL621401,,17670,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8011,1,,,Tmax was determined,50597,A,,CHEMBL621402,,1465,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8012,1,,,Tmax was determined,50597,A,,CHEMBL621403,,2552,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8013,1,,,Tmax after oral administration in rat,50597,A,,CHEMBL621121,,5656,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8014,1,,,Tmax after peroral administration in rats at 2.4 uM/kg,50597,A,,CHEMBL872525,,17764,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8015,1,,,Tmax in male rat,50597,A,,CHEMBL621122,,5610,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8016,1,,,Tmax in rat at 10 mg/kg,50597,A,,CHEMBL621123,,6046,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8017,1,,,Tmax in rat by po administration at a dose of 40 mg/kg,50597,A,,CHEMBL621124,,5874,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8018,1,,,Tmax in rats,50597,A,,CHEMBL621125,,17596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8019,1,,,Tmax was measured in rats after peroral administration at 5 mg/kg,50597,A,,CHEMBL621126,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8020,1,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,50597,A,,CHEMBL621127,,1908,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8021,1,,,Tmax value after administration of 20 mg/Kg oral dose in rat,50597,A,,CHEMBL621128,,2959,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8022,1,,,Tmax value at a dose of 10 mg/kg in male SD rats,50597,A,,CHEMBL618263,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8023,1,,,Tmax value at a dose of 100 mg/kg in male SD rats,50597,A,,CHEMBL618264,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8024,1,,,Tmax value at a dose of 50 mg/kg in male SD rats,50597,A,,CHEMBL618265,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8025,1,,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,A,,CHEMBL618266,,4186,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8026,1,,,time required to reach maximum concentration (Cmax) after oral administration in rat,50597,A,,CHEMBL618267,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Urine,,8027,1,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),50597,A,,CHEMBL618450,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Urine,,8028,1,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),50597,A,,CHEMBL618451,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,,,8029,1,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,A,,CHEMBL618452,,5546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Urine,,8030,1,,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,50597,A,,CHEMBL618453,,3173,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Urine,,8031,1,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,50597,A,,CHEMBL618454,,3173,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Urine,,8032,1,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,50597,A,,CHEMBL618455,,3173,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
In vivo,BAO_0000218,,,8033,1,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,50597,A,,CHEMBL618456,,4257,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8034,1,,,Compound distribution in rat tissues was determined,50597,A,,CHEMBL618457,,6011,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8035,1,,,Volume of distribution was evaluated in rat,50597,A,,CHEMBL618458,,5472,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8036,1,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,50597,A,,CHEMBL618459,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8037,1,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,50597,A,,CHEMBL876733,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8038,1,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,50588,A,,CHEMBL618460,,14346,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,8039,1,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,50597,A,,CHEMBL618461,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000019,,,8040,1,,,Area under the curve was determined after oral administration (300 uM/Kg),22224,A,,CHEMBL618462,,15469,,Autocuration,,,0,U,,
,BAO_0000218,,,8041,1,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,50597,A,,CHEMBL618463,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8042,1,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,50597,A,,CHEMBL618464,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8043,1,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,50597,A,,CHEMBL618465,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8044,1,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,50597,A,,CHEMBL618466,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8045,1,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,50597,A,,CHEMBL618467,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8046,1,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,50597,A,,CHEMBL618468,,15372,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,8047,1,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,50588,A,,CHEMBL618469,,12935,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,8048,1,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,50588,A,,CHEMBL618470,,12935,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,,,8049,1,,,Plasma drug AUC in rat (PO dose),22224,A,,CHEMBL618471,,14813,,Autocuration,,,0,U,,
,BAO_0000218,,,8050,1,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,50594,A,,CHEMBL618472,,15792,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8051,1,,,Area under was determined at a dose of 30 mg/kg,22224,A,,CHEMBL618473,,3579,,Autocuration,,,0,U,,
,BAO_0000218,,,8052,1,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,50506,A,,CHEMBL621699,,12487,9669.0,Intermediate,,,1,N,Mustela putorius furo,
,BAO_0000218,,,8053,1,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,50597,A,,CHEMBL621700,,12487,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8054,1,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,50597,A,,CHEMBL621701,,12487,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8055,1,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,50506,A,,CHEMBL621702,,12487,9669.0,Intermediate,,,1,N,Mustela putorius furo,
,BAO_0000218,,,8056,1,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,50588,A,,CHEMBL621703,,12487,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,8057,1,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,50588,A,,CHEMBL621704,,12487,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,8058,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",50597,A,,CHEMBL624259,,12902,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8059,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",50597,A,,CHEMBL624260,,12902,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8060,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",50597,A,,CHEMBL624430,,12902,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8061,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",50597,A,,CHEMBL624431,,12902,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8062,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",50597,A,,CHEMBL624432,,12902,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8063,1,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",50597,A,,CHEMBL624433,,12902,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8064,1,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",50597,A,,CHEMBL624434,,12902,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8065,1,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",50597,A,,CHEMBL624435,,12902,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8066,1,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,50594,A,,CHEMBL618570,,12745,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8067,1,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,A,,CHEMBL618571,,12745,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8068,1,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,50594,A,,CHEMBL618572,,12745,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8069,1,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,A,,CHEMBL618573,,12745,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8070,1,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,50594,A,,CHEMBL619267,,12745,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8071,1,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,A,,CHEMBL619431,,12745,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8072,1,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,50594,A,,CHEMBL619432,,12745,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8073,1,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,A,,CHEMBL619433,,12745,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Plasma,,8074,1,,,AUC in mice after oral dose (50 mg/kg),22224,A,,CHEMBL619434,,13298,,Autocuration,,,0,U,,1969.0
,BAO_0000218,Serum,,8075,1,,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,50594,A,,CHEMBL619435,,12226,10090.0,Intermediate,,,1,N,Mus musculus,1977.0
,BAO_0000019,Plasma,,8076,1,,,AUC (0-4 hr) ug/ml/h,22224,A,,CHEMBL619436,,12634,,Autocuration,,,0,U,,1969.0
,BAO_0000218,,,8077,1,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,50597,A,,CHEMBL619437,,14810,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8078,1,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,22224,A,,CHEMBL619438,,13889,,Autocuration,,,0,U,,
,BAO_0000218,,,8079,1,,,Compound was evaluated for Area under curve in mice,50594,A,,CHEMBL619439,,10018,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8080,1,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,A,,CHEMBL619440,,8758,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8081,1,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,22224,F,,CHEMBL619441,,8758,,Autocuration,,,0,U,,
,BAO_0000218,,,8082,1,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,A,,CHEMBL619442,,8758,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000019,,,8083,1,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,22224,A,,CHEMBL875156,,2249,,Autocuration,,,0,U,,
,BAO_0000019,,,8084,1,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,22224,A,,CHEMBL619443,,2249,,Autocuration,,,0,U,,
,BAO_0000019,,,8085,1,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,22224,A,,CHEMBL619444,,2249,,Autocuration,,,0,U,,
,BAO_0000019,,,8086,1,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,22224,A,,CHEMBL623464,,2249,,Autocuration,,,0,U,,
,BAO_0000218,,,8087,1,,,Compound was evaluated for area under curve when administered through oral route in mouse,50594,A,,CHEMBL623465,,15115,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8088,1,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,50597,A,,CHEMBL623466,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8089,1,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,50597,A,,CHEMBL623467,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8090,1,,,Plasma clearance in rat,50597,A,,CHEMBL623468,,6249,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8091,1,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,A,,CHEMBL622660,,2463,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8092,1,,,Plasma clearance rate in Sprague-Dawley rats,50597,A,,CHEMBL622661,,4969,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8093,1,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,F,,CHEMBL622662,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8094,1,,,Pharmacokinetic property (total body clearance) in rat,50597,A,,CHEMBL622663,,3457,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8095,1,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,50597,A,,CHEMBL622664,,5983,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8096,1,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,A,,CHEMBL622665,,6295,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8097,1,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,A,,CHEMBL622666,,6296,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8098,1,,,Cl in rat i.v. at 2 mg/kg concentration,50597,A,,CHEMBL621615,,17686,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8099,1,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,50597,A,,CHEMBL621616,,17764,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8100,1,,,Clearance was determined,50597,A,,CHEMBL621617,,5503,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8101,1,,,Clearance by intravenous administration of 3.4 mg/kg in rat,50597,A,,CHEMBL621618,,4368,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8102,1,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,A,,CHEMBL621619,,6005,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8103,1,,,Clearance rate after i.v. administration in rats,50597,A,,CHEMBL621620,,5031,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8104,1,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL621786,,4890,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8105,1,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,A,,CHEMBL621787,,5182,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8106,1,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,50597,A,,CHEMBL621788,,5979,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8107,1,,,Clearance (Cl) after oral administration in rat,50597,A,,CHEMBL621789,,5656,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8108,1,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,50597,A,,CHEMBL621790,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8109,1,,,Compound was tested for plasma clearance in rat,50597,A,,CHEMBL621791,,4839,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vitro,BAO_0000218,,,8110,1,,Microsomes,In vitro microsome metabolism clearance in rat was determined,50597,A,,CHEMBL621792,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,,,8111,1,,Microsomes,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,50597,A,,CHEMBL621793,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8112,1,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL621794,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8113,1,,,In vivo plasma clearance was determined,50597,A,,CHEMBL621795,,5496,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8114,1,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,50597,A,,CHEMBL621796,,5739,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Liver,,8115,1,,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,50597,A,401.0,CHEMBL621797,Hepatocyte,5676,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,,,8116,1,,,Pharmacokinetic property (Plasma clearance) was measured in rat,50597,A,,CHEMBL621798,,4239,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8117,1,,,Pharmacokinetic property (clearance) in rat i.v.,50597,A,,CHEMBL621799,,5676,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8118,1,,,"Plasma Clearance was evaluated in rats, iv",50597,A,,CHEMBL621800,,1918,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8119,1,,,Plasma clearance (in vivo) in rats was determined,50597,A,,CHEMBL621801,,17800,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8120,1,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,50597,A,,CHEMBL621802,,6056,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8121,1,,,Plasma clearance was determined,50597,A,,CHEMBL618596,,5496,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8122,1,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,50597,A,,CHEMBL618597,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8123,1,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,50597,A,,CHEMBL618598,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8124,1,,,Plasma clearance in rats,50597,A,,CHEMBL618599,,17752,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8125,1,,,Plasma clearance rate determined in rat,50597,A,,CHEMBL618600,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8126,1,,,Plasma clearance was determined in rat,50597,A,,CHEMBL618601,,6011,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8127,1,,,Plasma clearance was determined,50597,A,,CHEMBL618602,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8128,1,,,Plasma clearance value in rat,50597,A,,CHEMBL618603,,5948,10116.0,Intermediate,,,1,N,Rattus norvegicus,
Ex vivo,BAO_0000218,Liver,,8129,1,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,50597,A,,CHEMBL618604,,6125,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,,,8130,1,,,Clearance in rat,50597,A,,CHEMBL618605,,4839,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8131,1,,,Total body clearance in rat i.v. at 2 mg/kg concentration,50597,A,,CHEMBL618606,,17686,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8132,1,,,Clearance of compound in rats after intravenous administration,50597,A,,CHEMBL618607,,6571,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8133,1,,,Clearance after iv administration to rats,50597,A,,CHEMBL618608,,3364,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8134,1,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,A,,CHEMBL618609,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8135,1,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,A,,CHEMBL618610,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8136,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,50597,A,,CHEMBL618611,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8137,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,A,,CHEMBL618612,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8138,1,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,A,,CHEMBL618613,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8139,1,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,A,,CHEMBL621076,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8140,1,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,A,,CHEMBL621077,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8141,1,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",50597,A,,CHEMBL621078,,17670,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8142,1,,,Clearance in rat,50597,A,,CHEMBL621251,,5970,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8143,1,,,Clearance in rat after oral administration at 10 mg/kg,50597,A,,CHEMBL621252,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8144,1,,,Clearance in rat.,50597,A,,CHEMBL621253,,4590,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8145,1,,,Clearance rate following an oral dose of 20 mg/kg in rats,50597,A,,CHEMBL621254,,6193,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8146,1,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,50597,A,,CHEMBL621255,,2832,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8147,1,,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,50597,A,,CHEMBL621256,,1052,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Liver,,8148,1,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,50597,A,,CHEMBL621257,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8149,1,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,50597,A,,CHEMBL621258,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8150,1,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,50597,A,,CHEMBL621259,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8151,1,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,50597,A,,CHEMBL621260,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8152,1,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,50597,A,,CHEMBL876494,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8153,1,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,50597,A,,CHEMBL621261,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8154,1,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,50597,A,,CHEMBL621262,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8155,1,,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,A,,CHEMBL621263,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8156,1,,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,50597,A,,CHEMBL621264,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Muscle tissue,,8157,1,,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,50597,A,,CHEMBL621265,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8158,1,,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,50597,A,,CHEMBL621266,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8159,1,,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,50597,A,,CHEMBL621267,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8160,1,,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,50597,A,,CHEMBL621268,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8161,1,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,50597,A,,CHEMBL621269,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8162,1,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,50597,A,,CHEMBL621270,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8163,1,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,50597,A,,CHEMBL621271,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8164,1,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,50597,A,,CHEMBL621272,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8165,1,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,50597,A,,CHEMBL621273,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8166,1,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,50597,A,,CHEMBL621274,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8167,1,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,50597,A,,CHEMBL876495,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8168,1,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,50597,A,,CHEMBL621275,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8169,1,,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,50597,A,,CHEMBL621276,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8170,1,,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,50597,A,,CHEMBL621277,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Intestine,,8171,1,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,50597,A,,CHEMBL621278,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,8172,1,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,50597,A,,CHEMBL621279,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,8173,1,,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),50597,A,,CHEMBL621280,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Spleen,,8174,1,,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,50597,A,,CHEMBL621281,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8175,1,,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,50597,A,,CHEMBL621282,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8176,1,,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,A,,CHEMBL621283,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8177,1,,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,50597,A,,CHEMBL621284,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8178,1,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,50597,A,,CHEMBL621285,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8179,1,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,50597,A,,CHEMBL621286,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8180,1,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,50597,A,,CHEMBL623220,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8181,1,,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,50597,A,,CHEMBL623221,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8182,1,,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,50597,A,,CHEMBL876029,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Stomach,,8183,1,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,50597,A,,CHEMBL623222,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,8184,1,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,50597,A,,CHEMBL623223,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,8185,1,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,50597,A,,CHEMBL621445,,9866,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Blood,,8186,1,,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621446,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8187,1,,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621447,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8188,1,,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619681,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8189,1,,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619682,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8190,1,,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619683,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Brain,,8191,1,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619684,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,8192,1,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619685,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,8193,1,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619686,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,8194,1,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619687,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,8195,1,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619688,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Heart,,8196,1,,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619689,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,8197,1,,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619690,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,8198,1,,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619691,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,,,8199,1,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,A,,CHEMBL619692,,6062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8200,1,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,A,,CHEMBL619693,,3598,10116.0,Expert,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8201,1,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,50597,A,,CHEMBL619694,,1908,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8202,1,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,50597,A,,CHEMBL619695,,17596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8203,1,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,50597,A,,CHEMBL619696,,4891,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8204,1,,,Compound was evaluated for volume of distribution in rat,50597,A,,CHEMBL619697,,740,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8205,1,,,Steady state volume distribution was determined; steady state(ss),50597,A,,CHEMBL619698,,16366,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8206,1,,,Steady state volume of distribution after iv administration to rats,50597,A,,CHEMBL619699,,3364,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8207,1,,,Steady state volume of distribution dosing at 3 mg/kg iv,50597,A,,CHEMBL619700,,2552,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8208,1,,,The compound was evaluated for volume of distribution in rat,50597,A,,CHEMBL619701,,406,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8209,1,,,The compound was tested for volume of distribution in rat,50597,A,,CHEMBL619702,,12500,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8210,1,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,50597,A,,CHEMBL620335,,12500,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8211,1,,,Volume distribution (VD) after oral administration in rat,50597,A,,CHEMBL620336,,5656,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8212,1,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,A,,CHEMBL620337,,17671,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8213,1,,,Volume distribution in rat,50597,A,,CHEMBL620520,,1094,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8214,1,,,Volume distribution in rat,50597,A,,CHEMBL620521,,5833,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8215,1,,,Volume distribution in rat after peroral administration at 10 mg/kg,50597,A,,CHEMBL875825,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8216,1,,,Volume distribution in rat after peroral administration at 5 mg/kg,50597,A,,CHEMBL620522,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8217,1,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,A,,CHEMBL620523,,6005,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8218,1,,,Volume of distribution in rat.,50597,A,,CHEMBL620524,,1696,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8219,1,,,Volume of distribution in rat,50597,A,,CHEMBL620525,,6672,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8220,1,,,Volume of distribution in rat,50597,A,,CHEMBL620526,,6673,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8221,1,,,Volume of distribution in rat by iv administration,50597,A,,CHEMBL620527,,5871,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8222,1,,,Volume of distribution in rats,50597,A,,CHEMBL620528,,6803,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8223,1,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,A,,CHEMBL620529,,5199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8224,1,,,Volume distribution at the dose of 2 mg/kg in rat,50597,A,,CHEMBL620530,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8225,1,,,Steady state volume of distribution was determined,50597,A,,CHEMBL620531,,16367,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8226,1,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,A,,CHEMBL620532,,5005,9544.0,Intermediate,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,8227,1,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,22224,A,,CHEMBL620533,,5005,10116.0,Intermediate,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,8228,1,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,22224,A,,CHEMBL620534,,5005,10116.0,Intermediate,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,8229,1,,,Mean (%CV) PK parameters for Vdss(mL/kg).,50597,A,,CHEMBL620535,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8230,1,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,50597,A,,CHEMBL875826,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8231,1,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,50597,A,,CHEMBL620536,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8232,1,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,A,,CHEMBL620537,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8233,1,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,50597,A,,CHEMBL618526,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8234,1,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,50597,A,,CHEMBL618527,,5739,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8235,1,,,Pharmacokinetic property (Vdss) in rat,50597,A,,CHEMBL618528,,5789,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8236,1,,,Pharmacokinetic property (vdss) was measured in rat,50597,A,,CHEMBL618529,,4239,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8237,1,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,50597,A,,CHEMBL618530,,4709,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8238,1,,,Volume of distribution in rat,50597,A,,CHEMBL618531,,6642,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8239,1,,,The pharmacokinetic parameter volume of distribution in vivo in rats,50597,A,,CHEMBL618532,,5247,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8240,1,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,F,,CHEMBL618533,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8241,1,,,Vdss in rat i.v. at 2 mg/kg concentration,50597,A,,CHEMBL618534,,17686,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8242,1,,,Volume distribution after intravenous administration (1 mg/kg) in rat,50597,A,,CHEMBL618535,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8243,1,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,A,,CHEMBL618536,,5654,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8244,1,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,A,,CHEMBL618537,,5654,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8245,1,,,Volume distribution at a dose of 10 uM/kg in rat was determined,50597,A,,CHEMBL618538,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8246,1,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,A,,CHEMBL618539,,4521,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8247,1,,,Volume distribution was calculated in rat,50597,A,,CHEMBL618540,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8248,1,,,Volume distribution was determined,50597,A,,CHEMBL618541,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8249,1,,,Volume of distribution after intravenous administration was evaluated in rat,50597,A,,CHEMBL618542,,2938,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8250,1,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,A,,CHEMBL622544,,6679,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8251,1,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",50597,A,,CHEMBL622545,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8252,1,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,A,,CHEMBL622546,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8253,1,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",50597,A,,CHEMBL622547,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8254,1,,,Volume of distribution in steady state was determined in rat,50597,A,,CHEMBL622548,,5145,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8255,1,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,50597,A,,CHEMBL622549,,6467,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8256,1,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,A,,CHEMBL622550,,6467,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8257,1,,,Compound was evaluated for area under curve when administered through oral route to mouse,50594,A,,CHEMBL622551,,15115,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8258,1,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,A,,CHEMBL622552,,8758,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8259,1,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,A,,CHEMBL622553,,8758,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8260,1,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,22224,F,,CHEMBL622554,,8267,,Autocuration,,,0,U,,
,BAO_0000218,,,8261,1,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,50588,A,,CHEMBL622555,,8267,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,8262,1,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,A,,CHEMBL622556,,14239,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8263,1,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,A,,CHEMBL622557,,14239,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Blood,,8264,1,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,50594,A,,CHEMBL622558,,10754,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000218,Blood,,8265,1,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,50594,A,,CHEMBL622559,,10754,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000218,,,8266,1,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,50588,A,,CHEMBL622560,,10754,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,8267,1,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,A,,CHEMBL622561,,14681,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8268,1,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,50597,A,,CHEMBL622562,,14681,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8269,1,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,A,,CHEMBL622563,,14681,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000019,,,8270,1,,,Concentration of compound in Central nervous system,22224,A,,CHEMBL622564,,13118,,Autocuration,,,0,U,,
,BAO_0000019,,,8271,1,,,Concentration of compound in Central nervous system; Not detectable,22224,A,,CHEMBL622565,,13118,,Autocuration,,,0,U,,
,BAO_0000218,,,8272,1,,,"Concentration of diester in the blood, following oral administration in mice",50594,A,,CHEMBL622566,,13318,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8273,1,,,"Concentration of monoester in the blood, following oral administration in mice",50594,A,,CHEMBL624515,,13318,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8274,1,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,50594,A,,CHEMBL624516,,13318,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000019,,,8275,1,,,Evaluated for Pharmacokinetic property: Area under the curve,22224,A,,CHEMBL624517,,15692,,Autocuration,,,0,U,,
,BAO_0000218,,,8276,1,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,50594,A,,CHEMBL624518,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8277,1,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,100710,A,,CHEMBL624519,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8278,1,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,100710,A,,CHEMBL624520,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8279,1,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,100710,A,,CHEMBL624521,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8280,1,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,100710,A,,CHEMBL624522,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8281,1,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,100710,A,,CHEMBL624523,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8282,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,A,,CHEMBL624409,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8283,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",100710,A,,CHEMBL624410,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8284,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,A,,CHEMBL624411,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8285,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",100710,A,,CHEMBL623531,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8286,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",100710,A,,CHEMBL623532,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8287,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",100710,A,,CHEMBL623533,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8288,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,A,,CHEMBL623534,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
,BAO_0000218,,,8289,1,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,50594,A,,CHEMBL623535,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8290,1,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,50594,A,,CHEMBL623536,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8291,1,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,50594,A,,CHEMBL623537,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8292,1,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,50594,A,,CHEMBL623538,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8293,1,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,50594,A,,CHEMBL623539,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8294,1,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,50594,A,,CHEMBL623540,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8295,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",50594,A,,CHEMBL623541,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8296,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",50594,A,,CHEMBL623542,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8297,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",50594,A,,CHEMBL623543,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8298,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",50594,A,,CHEMBL623544,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8299,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",50594,A,,CHEMBL623545,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8300,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",50594,A,,CHEMBL623546,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Plasma,,8301,1,,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL623547,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8302,1,,,High i.v. clearance in Dawley rats,50597,A,,CHEMBL623548,,6827,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,Liver,,8303,1,,Microsomes,In vitro clearance in rat liver microsomes,50597,A,,CHEMBL623549,,17538,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vitro,BAO_0000218,Liver,,8304,1,,Microsomes,Intrinsic clearance in rat liver microsomes was determined,50597,A,,CHEMBL623550,,6331,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vitro,BAO_0000218,Liver,,8305,1,,,Intrinsic clearance in rat hepatocytes was determined,50597,A,401.0,CHEMBL875276,Hepatocyte,5948,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,,,8306,1,,,Plasma Clearance was determined,50597,A,,CHEMBL621872,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8307,1,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,50597,A,,CHEMBL621873,,6647,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8308,1,,,Plasma clearance in rat.,50597,A,,CHEMBL621874,,1696,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8309,1,,,Plasma clearance in rats,50597,A,,CHEMBL621875,,6597,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8310,1,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,50597,A,,CHEMBL621876,,347,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8311,1,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,50597,A,,CHEMBL621877,,16423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8312,1,,,Plasma clearance was measured in rat,50597,A,,CHEMBL621878,,2879,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8313,1,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,A,,CHEMBL621879,,4883,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8314,1,,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",50597,A,,CHEMBL621880,,5328,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8315,1,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,50597,A,,CHEMBL621881,,5160,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8316,1,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,A,,CHEMBL621882,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8317,1,,,Total clearance at 1 mg/kg was determined in rat,50597,A,,CHEMBL875283,,17651,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8318,1,,,Total clearance at 10 mg/kg was determined in rat,50597,A,,CHEMBL621883,,17651,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8319,1,,,Clearance in rat,50597,A,,CHEMBL621884,,6596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8320,1,,,Plasma clearance rate determined in rats,50597,A,,CHEMBL621885,,4796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8321,1,,,Clearance of compound in rat was evaluated,50597,A,,CHEMBL621886,,6850,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8322,1,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,50597,A,,CHEMBL621887,,5932,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8323,1,,,Pharmacokinetic property (blood clearance) in rat,50597,A,,CHEMBL621888,,3371,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8324,1,,,Plasma clearance in rat,50597,A,,CHEMBL621889,,2083,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8325,1,,,Plasma clearance in rats,50597,A,,CHEMBL621890,,4942,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,Liver,,8326,1,,Microsomes,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,50597,A,,CHEMBL621891,,6838,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,,,8327,1,,,Clearance in Dawley rat,50597,A,,CHEMBL621892,,5353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8328,1,,,Clearance rat,50597,A,,CHEMBL621893,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8329,1,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),50597,A,,CHEMBL621894,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8330,1,,,Clearance rat; Not determined,50597,A,,CHEMBL621895,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8331,1,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,50597,A,,CHEMBL875284,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8332,1,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,A,,CHEMBL618699,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8333,1,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,A,,CHEMBL618700,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8334,1,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,A,,CHEMBL618701,,6211,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8335,1,,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,A,,CHEMBL876600,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8336,1,,,Clearance of compound in rat after 1 mg/kg i.v. administration,50597,A,,CHEMBL618702,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8337,1,,,Compound was evaluated for Hepatic clearance in rat,50597,A,,CHEMBL618703,,3341,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8338,1,,,In vivo clearance after 5 mg/kg dose,50597,A,,CHEMBL618704,,4891,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8339,1,,,Compound was tested for plasma clearance in rats,50597,A,,CHEMBL618705,,1094,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8340,1,,,Hepatic clearance after intravenous administration was evaluated in rat,50597,A,,CHEMBL618706,,2938,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8341,1,,,Lower clearance in rat (i.v.) at 0.5 mpk,50597,A,,CHEMBL618707,,17853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8342,1,,,Pharmacokinetic parameter expressed as plasma clearance in rat,50597,A,,CHEMBL618708,,6049,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8343,1,,,Pharmacokinetic property (Clp) in rat,50597,A,,CHEMBL618709,,5789,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8344,1,,,Plasma clearance in Sprague-Dawley rats,50597,A,,CHEMBL618710,,4514,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8345,1,,,Plasma clearance (Clp) in rat,50597,A,,CHEMBL618711,,6448,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8346,1,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,50597,A,,CHEMBL618712,,6062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8347,1,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,50597,A,,CHEMBL618713,,5710,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8348,1,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,50597,A,,CHEMBL618714,,4709,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8349,1,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,A,,CHEMBL618715,,4521,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8350,1,,,Plasma clearance in rat was determined,50597,A,,CHEMBL618716,,1742,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8351,1,,,Plasma clearance measured in rat,50597,A,,CHEMBL876601,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8352,1,,,Plasma clearance was calculated in rat,50597,A,,CHEMBL618717,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8353,1,,,Plasma clearance in rat,50597,A,,CHEMBL618718,,5145,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8354,1,,,Plasma clearance in rat,50597,A,,CHEMBL618719,,5833,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8355,1,,,Plasma clearance in rat,50597,A,,CHEMBL618720,,6453,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8356,1,,,Plasma clearance in rat,50597,A,,CHEMBL618721,,6640,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8357,1,,,Plasma clearance in rats,50597,A,,CHEMBL621477,,6305,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8358,1,,,Plasma clearance in rat,50597,A,,CHEMBL621478,,6642,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8359,1,,,Plasma clearance was evaluated in rat,50597,A,,CHEMBL621479,,5472,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8360,1,,,Plasma clearance was evaluated in rat; Not tested,50597,A,,CHEMBL621480,,5472,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8361,1,,,Plasma clearance rate was determined for the compound in rat,50597,A,,CHEMBL621481,,5144,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8362,1,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",50597,A,,CHEMBL621482,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8363,1,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,A,,CHEMBL621483,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8364,1,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",50597,A,,CHEMBL621484,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Heart,,8365,1,,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621485,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,8366,1,,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621486,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Intestine,,8367,1,,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621487,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,8368,1,,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621488,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,8369,1,,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621489,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,8370,1,,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621490,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,8371,1,,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621491,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Kidney,,8372,1,,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621492,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,8373,1,,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621493,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,8374,1,,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621494,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,8375,1,,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621495,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,8376,1,,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621496,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Liver,,8377,1,,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621497,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8378,1,,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621498,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8379,1,,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL621499,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8380,1,,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL618634,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8381,1,,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL618635,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Lung,,8382,1,,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL618636,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,8383,1,,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619737,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,8384,1,,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL619738,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,8385,1,,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL624329,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,8386,1,,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL624330,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Muscle tissue,,8387,1,,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL624331,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8388,1,,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL624332,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8389,1,,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL624333,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8390,1,,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL624334,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8391,1,,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL624335,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Spleen,,8392,1,,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620016,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8393,1,,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620169,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8394,1,,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620170,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8395,1,,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620171,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,8396,1,,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620172,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Stomach,,8397,1,,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620173,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,8398,1,,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620174,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,8399,1,,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620175,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,8400,1,,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620176,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,8401,1,,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620177,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
,BAO_0000218,Cerebellum,,8402,1,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620178,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2037.0
,BAO_0000218,Cerebellum,,8403,1,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620179,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2037.0
,BAO_0000218,,,8404,1,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620180,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8405,1,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,50597,A,,CHEMBL620181,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8406,1,,,Volume of distribution of compound in rats after intravenous administration,50597,A,,CHEMBL620182,,6571,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8407,1,,,Volume of distribution in rat,50597,A,,CHEMBL620183,,6453,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8408,1,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,50597,A,,CHEMBL620184,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8409,1,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,A,,CHEMBL620185,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8410,1,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,A,,CHEMBL620186,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8411,1,,,Volume of distribution was determined in Dawley rat,50597,A,,CHEMBL620187,,5353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8412,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,A,,CHEMBL620188,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8413,1,,,Volume of distribution was reported in Sprague-Dawley rat,50597,A,,CHEMBL620189,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8414,1,,,Volumes of distribution in rat after peroral administration,50597,A,,CHEMBL620190,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8415,1,,,Volumes of distribution in rat after po administration,50597,A,,CHEMBL620191,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8416,1,,,Volumes of distribution in rat after po administration; Not determined,50597,A,,CHEMBL620192,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8417,1,,,Pharmacokinetic property (Volume) in rat i.v.,50597,A,,CHEMBL620193,,5676,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8418,1,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,50597,A,,CHEMBL620194,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8419,1,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",50597,A,,CHEMBL876730,,17670,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8420,1,,,Volume distribution in rat after oral administration at 10 mg/kg,50597,A,,CHEMBL620195,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8421,1,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL620196,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8422,1,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,A,,CHEMBL620197,,4883,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8423,1,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,50597,A,,CHEMBL620198,,6647,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8424,1,,,Volume of distribution in rats,50597,A,,CHEMBL620199,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8425,1,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,50597,A,,CHEMBL620200,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8426,1,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,50597,A,,CHEMBL620201,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8427,1,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL620202,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8428,1,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL620203,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8429,1,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,50597,A,,CHEMBL620204,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8430,1,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL620205,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8431,1,,,Pharmacokinetic parameter (Vss) in rat,50597,A,,CHEMBL624664,,5960,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8432,1,,,Pharmacokinetic property (Volume) in rat i.v.,50597,A,,CHEMBL624665,,5676,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8433,1,,,Pharmacokinetic property (Vss) in rat,50597,A,,CHEMBL624666,,5948,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8434,1,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,A,,CHEMBL624667,,5979,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8435,1,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL624668,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8436,1,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL624669,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8437,1,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL624670,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8438,1,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL624671,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8439,1,,,Steady state volume distribution in rat,50597,A,,CHEMBL624672,,6448,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8440,1,,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",50597,A,,CHEMBL624673,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8441,1,,,Steady state volume of distribution determined in rat,50597,A,,CHEMBL624674,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8442,1,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,A,,CHEMBL624675,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8443,1,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,50597,A,,CHEMBL621728,,1466,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8444,1,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,50597,A,,CHEMBL621729,,5182,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8445,1,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,50597,A,,CHEMBL621730,,5182,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8446,1,,,Volume distribution in rat after administration of 2 mg/kg iv,50597,A,,CHEMBL621731,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8447,1,,,Volume distribution in rat after administration of 2 mg/kg iv,50597,A,,CHEMBL621732,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8448,1,,,Volume in steady state distribution value was determined,50597,A,,CHEMBL621908,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8449,1,,,Volume in steady state distribution value was determined; ND denotes no data,50597,A,,CHEMBL875347,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8450,1,,,Volume in steady state distribution value was determined; ND denotes not determined,50597,A,,CHEMBL621909,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8451,1,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,A,,CHEMBL621910,,17065,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8452,1,,,Volume of distribution at steady state was evaluated in rats,50597,A,,CHEMBL621911,,6597,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8453,1,,,Volume of distribution at steady state was observed after intravenous administration in rat,50597,A,,CHEMBL621912,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8454,1,,,Volume of distribution in steady state was determined in rat,50597,A,,CHEMBL621913,,6485,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8455,1,,,Volume of distribution in steady state was determined in rat,50597,A,,CHEMBL621914,,17655,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8456,1,,,Volume of distribution after i.v. administration,50597,A,,CHEMBL621915,,6616,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8457,1,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,A,,CHEMBL621916,,1916,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Liver,,8458,1,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,A,,CHEMBL621917,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,8459,1,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL621918,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Spleen,,8460,1,,,Biodistribution of compound (oxidized form) in spleen tissue,50594,A,,CHEMBL621919,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8461,1,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL621920,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8462,1,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,A,,CHEMBL621921,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8463,1,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL622401,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8464,1,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,A,,CHEMBL875348,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8465,1,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,A,,CHEMBL622402,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Blood,,8466,1,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,50594,A,,CHEMBL622403,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,8467,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL622404,,16438,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Brain,,8468,1,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,50594,A,,CHEMBL622405,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,8469,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,A,,CHEMBL622406,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,8470,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL622407,,16438,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Heart,,8471,1,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,50594,A,,CHEMBL622408,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,8472,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,A,,CHEMBL622409,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,8473,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL622410,,16438,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Kidney,,8474,1,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,50594,A,,CHEMBL622411,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,8475,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,A,,CHEMBL627864,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,8476,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL627865,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,8477,1,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,50594,A,,CHEMBL627866,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,8478,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL627751,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Spleen,,8479,1,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,50594,A,,CHEMBL627752,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8480,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,A,,CHEMBL627753,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8481,1,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,A,,CHEMBL627754,,16438,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
,BAO_0000218,,,8482,1,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,50594,A,,CHEMBL627755,,12467,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Brain,,8483,1,,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627756,,17208,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,8484,1,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627757,,17208,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,8485,1,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627758,,17208,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,8486,1,,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627759,,17208,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,8487,1,,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627760,,17208,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Brain,,8488,1,,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627761,,17208,10090.0,Intermediate,,,1,N,Mus musculus,955.0
In vivo,BAO_0000218,Heart,,8489,1,,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL876811,,17208,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,8490,1,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627762,,17208,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,8491,1,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627763,,17208,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,8492,1,,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627764,,17208,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,8493,1,,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627765,,17208,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Heart,,8494,1,,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627766,,17208,10090.0,Intermediate,,,1,N,Mus musculus,948.0
In vivo,BAO_0000218,Kidney,,8495,1,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627767,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,8496,1,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627768,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,8497,1,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL628422,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,8498,1,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL628423,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,,,8499,1,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,50597,A,,CHEMBL628424,,5089,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8500,1,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,50597,A,,CHEMBL628425,,5089,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8501,1,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,50597,A,,CHEMBL628426,,4257,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8502,1,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,A,,CHEMBL628427,,6679,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8503,1,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,A,,CHEMBL626938,,5546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8504,1,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,A,,CHEMBL626939,,6141,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8505,1,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,A,,CHEMBL626940,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8506,1,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,A,,CHEMBL626941,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8507,1,,,Plasma clearance was reported in Sprague-Dawley rat,50597,A,,CHEMBL626942,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8508,1,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,50597,A,,CHEMBL876812,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8509,1,,,Plasma clearance of compound in rats was evaluated,50597,A,,CHEMBL626943,,6848,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8510,1,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,50597,A,,CHEMBL626944,,6848,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8511,1,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,50597,A,,CHEMBL626945,,6467,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8512,1,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,A,,CHEMBL626946,,6467,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8513,1,,,Plasma clearance rate in Sprague-Dawley rats,50597,A,,CHEMBL626856,,4956,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8514,1,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),50597,A,,CHEMBL626857,,5529,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8515,1,,,The compound was evaluated for plasma clearance in rat,50597,A,,CHEMBL626858,,406,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8516,1,,,Total plasma clearance in rat,50597,A,,CHEMBL627018,,17655,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Blood,,8517,1,,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,50597,A,,CHEMBL625331,,3293,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8518,1,,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,50597,A,,CHEMBL625332,,4075,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,,,8519,1,,,C max was determined at 10 mg/kg po dose in rats,50597,A,,CHEMBL877590,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8520,1,,,C max was determined at 3 mg/kg po dose in rats,50597,A,,CHEMBL625333,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8521,1,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,50597,A,,CHEMBL625334,,17594,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8522,1,,,Cmax after single intravenous bolus of 1 mg/kg in rats,50597,A,,CHEMBL625335,,17594,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8523,1,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,50597,A,,CHEMBL625336,,4762,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8524,1,,,Cmax 24 hr after 10 mg/kg oral administration in rats,50597,A,,CHEMBL625337,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8525,1,,,Cmax 24 hr after 2 mg/kg oral administration in rats,50597,A,,CHEMBL625338,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8526,1,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,50597,A,,CHEMBL625339,,1466,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8527,1,,,Cmax in rat after administration of 2 mg/kg iv,50597,A,,CHEMBL625340,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8528,1,,,Cmax in rat after administration of 2 mg/kg iv,50597,A,,CHEMBL625341,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8529,1,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,50597,A,,CHEMBL622687,,3169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8530,1,,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,50597,A,,CHEMBL622688,,6515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Blood,,8531,1,,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,50597,A,,CHEMBL622689,,11149,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8532,1,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,50597,A,,CHEMBL620295,,11149,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,,,8533,1,,,Cmax after 10 mg/kg oral administration in rat,50597,A,,CHEMBL620296,,17858,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8534,1,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,50597,A,,CHEMBL620297,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8535,1,,,Cmax after IV dosing at 1 mg/kg in rat; no data,50597,A,,CHEMBL620298,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8536,1,,,Cmax after oral administration at 20 mpk in rats,50597,A,,CHEMBL620299,,4426,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8537,1,,,Cmax after oral administration at 20 mpk in rats; Not performed.,50597,A,,CHEMBL620300,,4426,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8538,1,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,50597,A,,CHEMBL620301,,4426,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8539,1,,,Cmax after oral administration in rat,50597,A,,CHEMBL620302,,5656,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8540,1,,,Cmax after oral administration at a dose of 2 mg/kg in rat,50597,A,,CHEMBL620303,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8541,1,,,Cmax after oral administration at a dose of 4 mg/kg in rat,50597,A,,CHEMBL620304,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8542,1,,,Cmax in rats after 20 mg/kg oral dose,50597,A,,CHEMBL620305,,6113,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8543,1,,,Cmax after peroral administration in rats at 2.4 uM/kg,50597,A,,CHEMBL620306,,17764,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8544,1,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,50597,A,,CHEMBL620307,,4756,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8545,1,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,50597,A,,CHEMBL620308,,4756,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8546,1,,,Cmax by administering at 20 mg/kg p.o. in rats,50597,A,,CHEMBL620309,,6402,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8547,1,,,Cmax in male rat,50597,A,,CHEMBL620310,,5610,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8548,1,,,Cmax in rat,50597,A,,CHEMBL620311,,5207,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8549,1,,,Cmax in rat,50597,A,,CHEMBL620312,,6011,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8550,1,,,Cmax in rat,50597,A,,CHEMBL620313,,6504,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8551,1,,,Cmax in rat at 10 mg/kg,50597,A,,CHEMBL620314,,6046,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8552,1,,,Cmax in rat at the dose of 1 mg/kg i.v.,50597,A,,CHEMBL620315,,6504,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8553,1,,,Cmax in rat by po administration at a dose of 40 mg/kg,50597,A,,CHEMBL620316,,5874,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8554,1,,,Cmax in rat p.o. at 20 mg/kg concentration,50597,A,,CHEMBL620317,,17686,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8555,1,,,Cmax in rats,50597,A,,CHEMBL620318,,5836,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8556,1,,,Cmax in rats,50597,A,,CHEMBL620319,,17596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8557,1,,,Cmax was evaluated after 20 uM/kg of peroral administration,50597,A,,CHEMBL620320,,16423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8558,1,,,Cmax was measured in rats after peroral administration at 3 mg/kg,50597,A,,CHEMBL620321,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8559,1,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,50597,A,,CHEMBL620322,,1908,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8560,1,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620323,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Frontal cortex,,8561,1,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620324,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,1870.0
,BAO_0000218,Frontal cortex,,8562,1,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620325,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,1870.0
,BAO_0000218,Hippocampus,,8563,1,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620326,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000000.0
,BAO_0000218,Hippocampus,,8564,1,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620327,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000000.0
,BAO_0000218,,,8565,1,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620328,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8566,1,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620329,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Midbrain,,8567,1,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620330,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,1891.0
,BAO_0000218,Midbrain,,8568,1,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL875286,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,1891.0
,BAO_0000218,,,8569,1,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620331,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8570,1,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620332,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Striatum,,8571,1,,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620333,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2435.0
,BAO_0000218,Striatum,,8572,1,,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,A,,CHEMBL620334,,13950,10116.0,Intermediate,,,1,N,Rattus norvegicus,2435.0
,BAO_0000218,Blood,,8573,1,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL621015,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8574,1,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL621016,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8575,1,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL621191,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8576,1,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL621192,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8577,1,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL621193,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8578,1,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL621194,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8579,1,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL624204,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8580,1,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL624205,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8581,1,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL624206,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8582,1,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL624207,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8583,1,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL624208,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8584,1,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL624209,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8585,1,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL624210,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8586,1,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL624211,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8587,1,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL624212,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8588,1,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL624213,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8589,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL876611,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8590,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL624214,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8591,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL624215,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8592,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL624216,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8593,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL624217,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8594,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL624218,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8595,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL624219,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8596,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL624220,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8597,1,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL624221,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,,,8598,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL624222,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8599,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL624223,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8600,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL624224,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8601,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL624225,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8602,1,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,50597,A,,CHEMBL622420,,17764,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8603,1,,,Volume of steady state distribution after i.v. administration in rats,50597,A,,CHEMBL622421,,5031,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8604,1,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,50597,A,,CHEMBL622422,,6215,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8605,1,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,A,,CHEMBL622423,,17671,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8606,1,,,Vss was determined,50597,A,,CHEMBL622424,,17752,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8607,1,,,Vss in rat,50597,A,,CHEMBL622425,,6596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8608,1,,,Vss was evaluated after 10 uM/kg of intra arterial administration,50597,A,,CHEMBL876612,,16423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8609,1,,,volume of distribution at steady state was observed after intravenous administration in rat,50597,A,,CHEMBL622426,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8610,1,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,A,,CHEMBL622427,,6062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8611,1,,,Pharmacokinetic (PK) parameter Vz in rat,50597,A,,CHEMBL622428,,5874,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8612,1,,,Volume distribution in rats,50597,A,,CHEMBL622429,,4942,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8613,1,,,Volume of distribution in rat; No data,50597,A,,CHEMBL622430,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8614,1,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL622431,,4890,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Ileum,,8615,1,,,% absorption predicted from in vitro rat ileum transport studies,50597,A,,CHEMBL622432,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,2116.0
In vivo,BAO_0000218,,,8616,1,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,A,,CHEMBL622433,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8617,1,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,A,,CHEMBL622434,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8618,1,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,50597,A,,CHEMBL622435,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8619,1,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),50597,A,,CHEMBL618748,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8620,1,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,A,,CHEMBL618749,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8621,1,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,A,,CHEMBL618750,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8622,1,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,A,,CHEMBL618751,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8623,1,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,A,,CHEMBL618752,,13569,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8624,1,,,Oral bioavailability in rat,50597,A,,CHEMBL618753,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8625,1,,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,50597,A,,CHEMBL618754,,750,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8626,1,,,Oral bioavailability in rat,50597,A,,CHEMBL618755,,750,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8627,1,,,Oral bioavailability in rat,50597,A,,CHEMBL618756,,4590,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8628,1,,,Oral bioavailability in rat,50597,A,,CHEMBL618757,,1716,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8629,1,,,Bioavailability in rat,50597,A,,CHEMBL618758,,1974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8630,1,,,Oral bioavailability in rat (dose 30 mg/kg),50597,A,,CHEMBL621088,,4502,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8631,1,,,Pharmacokinetic property (cLogP) in rat,50597,A,,CHEMBL621089,,3371,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Blood,,8632,1,,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,50597,F,,CHEMBL621090,,9099,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,8633,1,,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,50597,F,,CHEMBL621091,,9099,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,,,8634,1,,,Clearance in rat.,50597,A,,CHEMBL876731,,4590,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8635,1,,,Compound was evaluated for its clearance when administered intravenously in rat,50597,A,,CHEMBL621092,,3184,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8636,1,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,A,,CHEMBL621093,,16456,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8637,1,,,Blood: Brain distribution ratio is determined in rat,50597,A,,CHEMBL621094,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8638,1,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,50597,A,,CHEMBL621095,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8639,1,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,50597,A,,CHEMBL621096,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Kidney,,8640,1,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL621097,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,,,8641,1,,,Percent dose excreted in 0-48 hours administered ip to male rat,50597,F,,CHEMBL621098,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Cerebellum,,8642,1,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621099,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2037.0
,BAO_0000218,Cerebellum,,8643,1,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621100,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2037.0
,BAO_0000218,Cerebellum,,8644,1,,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL621101,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2037.0
,BAO_0000218,Cerebellum,,8645,1,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621102,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2037.0
,BAO_0000218,Cerebellum,,8646,1,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL876732,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2037.0
,BAO_0000218,,,8647,1,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621103,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8648,1,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621104,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8649,1,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL621105,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8650,1,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621106,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8651,1,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621107,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8652,1,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621108,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8653,1,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621109,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Kidney,,8654,1,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL621110,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Kidney,,8655,1,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL621111,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2113.0
In vivo,BAO_0000218,Liver,,8656,1,,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL622541,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,8657,1,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL622542,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,8658,1,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL622543,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,8659,1,,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624412,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,8660,1,,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624413,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Liver,,8661,1,,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624414,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2107.0
In vivo,BAO_0000218,Lung,,8662,1,,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624415,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,8663,1,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624416,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,8664,1,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624417,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,8665,1,,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624418,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,8666,1,,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624419,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Lung,,8667,1,,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624420,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2048.0
In vivo,BAO_0000218,Muscle tissue,,8668,1,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624421,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8669,1,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624422,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8670,1,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL624423,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8671,1,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL625123,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8672,1,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL625124,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8673,1,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL625125,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2385.0
In vivo,BAO_0000218,Zone of skin,,8674,1,,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL625126,,17208,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,8675,1,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626947,,17208,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,8676,1,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626948,,17208,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,8677,1,,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626949,,17208,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,8678,1,,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626950,,17208,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Zone of skin,,8679,1,,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626951,,17208,10090.0,Intermediate,,,1,N,Mus musculus,14.0
In vivo,BAO_0000218,Spleen,,8680,1,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626952,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8681,1,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626953,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8682,1,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626954,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8683,1,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626955,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8684,1,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626956,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Spleen,,8685,1,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626957,,17208,10090.0,Intermediate,,,1,N,Mus musculus,2106.0
In vivo,BAO_0000218,Blood,,8686,1,,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626958,,17208,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,8687,1,,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626959,,17208,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,8688,1,,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626960,,17208,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,8689,1,,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL626961,,17208,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,8690,1,,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627589,,17208,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,8691,1,,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),50594,A,,CHEMBL627590,,17208,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000218,,,8692,1,,,Time taken for EC90 was determined when tested in mouse,50594,A,,CHEMBL627591,,3132,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8693,1,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,50594,A,,CHEMBL627592,,3132,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8694,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,A,,CHEMBL627593,,16597,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8695,1,,,Half life in mice,50594,A,,CHEMBL627594,,5727,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8696,1,,,Half life period in mouse after 10 mg/Kg dose,50594,A,,CHEMBL876813,,5302,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8697,1,,,Half life period in mouse after 10 mg/kg dose,50594,A,,CHEMBL627595,,5302,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8698,1,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,A,,CHEMBL627596,,6348,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8699,1,,,Cmax value at 5 mg/kg po was determined in rat,50597,A,,CHEMBL627597,,5964,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8700,1,,,Cmax value evaluated in rat,50597,A,,CHEMBL627598,,6078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Brain,,8701,1,,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,50597,A,,CHEMBL627599,,5206,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,,,8702,1,,,Cmax value after administration of 20 mg/Kg oral dose in rat,50597,A,,CHEMBL627600,,2959,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8703,1,,,Cmax value at 1 mg/kg po in rat,50597,A,,CHEMBL627601,,5964,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8704,1,,,Cmax value at 5 mg/kg po in rat,50597,A,,CHEMBL627776,,5964,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8705,1,,,Cmax value at a dose of 10 mg/kg in male SD rats,50597,A,,CHEMBL627777,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8706,1,,,Cmax value at a dose of 100 mg/kg in male SD rats,50597,A,,CHEMBL627778,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8707,1,,,Cmax value at a dose of 50 mg/kg in male SD rats,50597,A,,CHEMBL627779,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8708,1,,,Cmax value in rats at 10 mg/kg,50597,A,,CHEMBL876814,,17617,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8709,1,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,50597,A,,CHEMBL627780,,1445,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8710,1,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,50597,A,,CHEMBL627781,,6082,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8711,1,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,A,,CHEMBL627782,,1446,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8712,1,,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,50597,A,,CHEMBL627783,,5407,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8713,1,,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,50597,A,,CHEMBL627784,,2690,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8714,1,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,50597,A,,CHEMBL627785,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8715,1,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,50597,A,,CHEMBL627786,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8716,1,,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,50597,A,,CHEMBL627787,,4891,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8717,1,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,50597,A,,CHEMBL627788,,2807,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8718,1,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,50597,A,,CHEMBL626579,,2807,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8719,1,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,50597,A,,CHEMBL626580,,2807,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8720,1,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,50597,A,,CHEMBL876815,,3634,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8721,1,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,50597,A,,CHEMBL626581,,1881,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8722,1,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,50597,A,,CHEMBL626582,,1881,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8723,1,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,50597,A,,CHEMBL626583,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8724,1,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL626205,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8725,1,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL626206,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8726,1,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL626207,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8727,1,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL623882,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8728,1,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,50597,A,,CHEMBL623883,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8729,1,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,50597,A,,CHEMBL623884,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8730,1,,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,A,,CHEMBL623885,,3032,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8731,1,,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,50597,A,,CHEMBL623886,,6295,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8732,1,,,Maximal concentration in rat was determined,50597,A,,CHEMBL623887,,6619,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8733,1,,,Maximal concentration after i.v. administration,50597,A,,CHEMBL623888,,6616,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8734,1,,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,50597,A,,CHEMBL623889,,3249,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8735,1,,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,50597,A,,CHEMBL623890,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8736,1,,,Cmax in rat plasma after oral dose (50 mg/Kg),50597,A,,CHEMBL623891,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8737,1,,,Maximal plasma concentration was determined.,50597,A,,CHEMBL623892,,1360,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8738,1,,,Maximal plasma drug concentration was determined,50597,A,,CHEMBL623893,,2552,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8739,1,,,Maximal concentration in rats after peroral administration,50597,A,,CHEMBL877616,,6571,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8740,1,,,Maximum concentration in rat after 2 mg/kg peroral administration,50597,A,,CHEMBL623894,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8741,1,,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,50597,A,,CHEMBL623895,,6567,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8742,1,,,Maximum concentration of compound in rat was evaluated.,50597,A,,CHEMBL623896,,3031,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8743,1,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,50597,A,,CHEMBL623897,,3436,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8744,1,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,50597,A,,CHEMBL623898,,3436,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8745,1,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,A,,CHEMBL623899,,2083,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8746,1,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,50597,A,,CHEMBL623900,,3436,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8747,1,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,50597,A,,CHEMBL623901,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8748,1,,,Maximum concentration was evaluated in rats,50597,A,,CHEMBL623902,,1974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Cerebrospinal fluid,,8749,1,,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,50597,A,,CHEMBL623903,,3307,10116.0,Intermediate,,,1,N,Rattus norvegicus,1359.0
In vivo,BAO_0000218,Plasma,,8750,1,,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,50597,A,,CHEMBL623904,,3307,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8751,1,,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,A,,CHEMBL877617,,1916,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8752,1,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,50597,A,,CHEMBL623905,,1500,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8753,1,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,50597,A,,CHEMBL623906,,1500,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8754,1,,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,A,,CHEMBL623907,,4186,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,8755,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL623908,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8756,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL623909,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8757,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL623910,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8758,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL623911,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8759,1,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL623912,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8760,1,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL624616,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8761,1,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL624617,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8762,1,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL624618,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8763,1,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL624619,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8764,1,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL624794,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8765,1,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL624795,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8766,1,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL623921,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8767,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL623922,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8768,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL623923,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8769,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL623924,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8770,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL623925,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8771,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL623926,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8772,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL623927,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8773,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL623928,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8774,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL623929,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8775,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL623930,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Brain,,8776,1,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL623931,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8777,1,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL622165,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8778,1,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL621249,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8779,1,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL621250,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8780,1,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL621448,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8781,1,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL621449,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8782,1,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL621450,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8783,1,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL621451,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8784,1,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL621452,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8785,1,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL621453,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8786,1,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL621454,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8787,1,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL621455,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8788,1,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL621456,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8789,1,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL625145,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8790,1,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL875847,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8791,1,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL625146,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8792,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL625147,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8793,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL625148,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8794,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL625149,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8795,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL625150,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8796,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL625151,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8797,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL625152,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8798,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL625153,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8799,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL625154,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,8800,1,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL625155,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,,,8801,1,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL625156,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,8802,1,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624354,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Hippocampus,,8803,1,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624355,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000000.0
,BAO_0000218,Hippocampus,,8804,1,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624356,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000000.0
,BAO_0000218,Hippocampus,,8805,1,,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624357,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000000.0
,BAO_0000218,Hippocampus,,8806,1,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624358,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000000.0
,BAO_0000218,Striatum,,8807,1,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624359,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2435.0
,BAO_0000218,Striatum,,8808,1,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624360,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2435.0
,BAO_0000218,Striatum,,8809,1,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL624361,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2435.0
,BAO_0000218,Striatum,,8810,1,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624362,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2435.0
,BAO_0000218,Striatum,,8811,1,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624363,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2435.0
In vivo,BAO_0000218,Blood,,8812,1,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624364,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8813,1,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624365,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8814,1,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624366,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8815,1,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624367,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Brain,,8816,1,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624368,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,8817,1,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL624369,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,8818,1,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL624370,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,8819,1,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625069,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,8820,1,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625070,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Heart,,8821,1,,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL626051,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,8822,1,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL626052,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,8823,1,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL626053,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,8824,1,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL626054,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,8825,1,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL626055,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Kidney,,8826,1,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL626056,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,8827,1,,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL626057,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,8828,1,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625193,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,8829,1,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625194,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Liver,,8830,1,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625195,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8831,1,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625196,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8832,1,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL625197,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8833,1,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625198,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,8834,1,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL627929,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Lung,,8835,1,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL627074,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,8836,1,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL627075,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,8837,1,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL627076,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,8838,1,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL627077,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,8839,1,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL627078,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Muscle tissue,,8840,1,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL627079,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,,,8841,1,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,A,,CHEMBL873824,,4573,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Plasma,,8842,1,,,Half life in mouse plasma was determined at dose 25 mg/kg,50594,A,,CHEMBL627080,,3132,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,,,8843,1,,,Half life was determined,50594,A,,CHEMBL627081,,17718,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8844,1,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,A,,CHEMBL627082,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8845,1,,,Half-life in male mice after 1 mg/kg intravenous dose,50594,A,,CHEMBL627083,,5961,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Plasma,,8847,1,,,Half life in mice plasma,50594,A,,CHEMBL627085,,17731,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,,,8848,1,,,Half life in mouse,50594,A,,CHEMBL627086,,17592,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Plasma,,8849,1,,,Half life in mouse plasma at dose 25 mg/kg,50594,A,,CHEMBL627087,,3132,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,,,8850,1,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,50594,A,,CHEMBL627088,,17729,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8851,1,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,50594,A,,CHEMBL627089,,17729,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8852,1,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,50594,A,,CHEMBL627090,,17729,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8853,1,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,A,,CHEMBL627091,,3277,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8854,1,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",50594,A,,CHEMBL627092,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8855,1,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",50594,A,,CHEMBL876785,,3760,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8856,1,,,Half-life by iv administration in mouse,50594,A,,CHEMBL627093,,2862,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8857,1,,,Half-life by oral administration in mouse,50594,A,,CHEMBL627094,,2862,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8858,1,,,Half-life in mice,50594,A,,CHEMBL627095,,5980,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Brain,,8859,1,,,Half-life using mouse brain homogenate,50594,A,,CHEMBL627096,,6159,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,,,8860,1,,,Half-life was measured in mice,50594,A,,CHEMBL627097,,6254,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8861,1,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,50594,A,,CHEMBL627098,,6062,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,Blood,,8862,1,,,Half-life period was determined in mouse blood,50594,A,,CHEMBL627099,,1574,10090.0,Intermediate,,,1,N,Mus musculus,178.0
,BAO_0000218,Brain,,8863,1,,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",50594,A,,CHEMBL627100,,56,10090.0,Intermediate,,,1,N,Mus musculus,955.0
,BAO_0000218,Plasma,,8864,1,,,Plasma half life in mouse,50594,A,,CHEMBL627101,,993,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
,BAO_0000218,,,8865,1,,,Stability of the peptide in the presence of mouse serum,50594,A,,CHEMBL627102,,6652,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8866,1,,,Terminal half life of compound was determined in mouse,50594,A,,CHEMBL627103,,17852,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8867,1,,,Terminal half life was evaluated in mice after intravenous administration,50594,A,,CHEMBL627104,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8868,1,,,Terminal half life was evaluated in mice after oral administration,50594,A,,CHEMBL627105,,2675,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8869,1,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,50594,A,,CHEMBL876786,,499,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8870,1,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,50594,A,,CHEMBL873825,,499,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8871,1,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,50594,A,,CHEMBL627106,,499,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8872,1,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,50594,A,,CHEMBL626336,,14239,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8873,1,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",50594,A,,CHEMBL877462,,5506,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8874,1,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",50594,A,,CHEMBL626337,,5506,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,8875,1,,,Half life after intraperitoneal administration of 100 mg/kg in mice,50594,A,,CHEMBL626338,,17734,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8876,1,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,50594,A,,CHEMBL626339,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8877,1,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,A,,CHEMBL626340,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8878,1,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,50594,A,,CHEMBL625377,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8879,1,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,50594,A,,CHEMBL625378,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,8880,1,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,50594,A,,CHEMBL625379,,17728,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000251,,,8881,1,,Microsomes,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),22224,A,,CHEMBL625380,,14294,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000251,,,8882,1,,Microsomes,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),22224,A,,CHEMBL625381,,14294,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000019,,,8883,1,,,Stability to porcine renal DHP-I,22224,A,,CHEMBL625382,,6056,9823.0,Autocuration,,,0,U,Sus scrofa,
In vivo,BAO_0000218,,,8884,1,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,22224,A,,CHEMBL873828,,1317,9823.0,Autocuration,,,0,U,Sus scrofa,
In vivo,BAO_0000218,,,8885,1,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,22224,A,,CHEMBL625383,,1317,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000019,,,8886,1,,,Half-life of the parent prodrug in porcine esterase solution,22224,A,,CHEMBL625384,,5229,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000019,,,8887,1,,,"First order rate constant, k was determined in in pig liver Esterase",22224,A,,CHEMBL625385,,4231,9823.0,Autocuration,,,0,U,Sus scrofa,
,BAO_0000221,Liver,,8888,1,,,Half life of the in pig liver Esterase,22224,A,,CHEMBL625386,,4231,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
,BAO_0000221,Liver,,8889,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,22224,A,,CHEMBL623571,,5318,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
,BAO_0000221,Liver,,8890,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,22224,A,,CHEMBL623572,,5318,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
,BAO_0000221,Liver,,8891,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,22224,A,,CHEMBL623573,,5318,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
,BAO_0000221,Liver,,8892,1,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,22224,A,,CHEMBL623574,,3305,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
,BAO_0000221,Liver,,8893,1,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,22224,A,,CHEMBL623575,,3305,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
,BAO_0000221,Liver,,8894,1,,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,22224,A,,CHEMBL623749,,2842,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
,BAO_0000221,Liver,,8895,1,,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,22224,A,,CHEMBL623750,,2842,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
In vitro,BAO_0000221,Liver,,8896,1,,,Half-life in vitro in pig liver,22224,A,,CHEMBL623751,,889,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
,BAO_0000221,Liver,,8897,1,,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,22224,A,,CHEMBL623752,,1904,9823.0,Autocuration,,,0,U,Sus scrofa,2107.0
In vivo,BAO_0000218,Plasma,,8898,1,,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,A,,CHEMBL623753,,4186,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8899,1,,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,A,,CHEMBL623754,,2774,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8900,1,,,Maximum concentration in rat plasma was determined,50597,A,,CHEMBL623755,,1742,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8901,1,,,Maximum concentration in rats,50597,A,,CHEMBL623756,,3169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8902,1,,,Maximum concentration in rats at 1-2 hours,50597,A,,CHEMBL623757,,3169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8903,1,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,50597,A,,CHEMBL623758,,2081,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Brain,,8904,1,,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,50597,A,,CHEMBL623759,,3307,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,,,8905,1,,,Maximum concentration at the dose of 2 mg/kg in rat,50597,A,,CHEMBL623760,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,8906,1,,,Maximum concentration was evaluated in rats,50597,A,,CHEMBL623761,,6597,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8907,1,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,50597,A,,CHEMBL623762,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8908,1,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,50597,A,,CHEMBL877594,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8909,1,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,50597,A,,CHEMBL623763,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8910,1,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,50597,A,,CHEMBL623764,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8911,1,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,50597,A,,CHEMBL623765,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Blood,,8912,1,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,50597,A,,CHEMBL623766,,2591,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8913,1,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,50597,A,,CHEMBL623767,,2591,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,8914,1,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,50597,A,,CHEMBL623768,,2591,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Plasma,,8915,1,,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,50597,A,,CHEMBL623769,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8916,1,,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,50597,A,,CHEMBL623770,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8917,1,,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,50597,A,,CHEMBL623771,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8918,1,,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,50597,A,,CHEMBL623772,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8919,1,,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,A,,CHEMBL623773,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8920,1,,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,A,,CHEMBL623774,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8921,1,,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,A,,CHEMBL623775,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,8922,1,,,Cmax in rat (PO dose),50597,A,,CHEMBL623776,,14465,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,8923,1,,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL622191,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8924,1,,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL622192,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8925,1,,,Maximum plasma concentration determined in rat,50597,A,,CHEMBL622193,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8926,1,,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,A,,CHEMBL622194,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8927,1,,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,A,,CHEMBL622195,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8928,1,,,Maximum plasma concentration in rat,50597,A,,CHEMBL622196,,6824,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8929,1,,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,A,,CHEMBL622197,,17065,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8930,1,,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,50597,A,,CHEMBL622198,,2932,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8931,1,,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,50597,A,,CHEMBL622199,,2932,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8932,1,,,Maximum plasma concentration of compound was measured in rat,50597,A,,CHEMBL622200,,2879,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8933,1,,,Maximum plasma concentration after 20 mg/kg oral administration in rat,50597,A,,CHEMBL622201,,2864,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8934,1,,,Maximum plasma concentration after oral administration to rats,50597,A,,CHEMBL623990,,16367,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8935,1,,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,A,,CHEMBL623991,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8936,1,,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",50597,A,,CHEMBL623992,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8937,1,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,A,,CHEMBL623993,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8938,1,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,50597,A,,CHEMBL623994,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8939,1,,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,F,,CHEMBL623995,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8940,1,,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,F,,CHEMBL623996,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8941,1,,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,F,,CHEMBL623997,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8942,1,,,Maximum plasma concentration dosed orally in rats,50597,A,,CHEMBL623998,,4516,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8943,1,,,Maximum plasma concentration dosed orally in rats after 6 hours,50597,A,,CHEMBL623999,,4516,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8944,1,,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,50597,A,,CHEMBL624000,,4516,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8945,1,,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,A,,CHEMBL624001,,5199,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8946,1,,,Maximum plasma concentration in rat after po administration,50597,A,,CHEMBL624002,,17538,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8947,1,,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",50597,A,,CHEMBL624003,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,8948,1,,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",50597,A,,CHEMBL624004,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Heart,,8949,1,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL624005,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8950,1,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL624006,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8951,1,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL624007,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8952,1,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL624008,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8953,1,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL624009,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8954,1,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL874387,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8955,1,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL624010,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8956,1,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL624011,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8957,1,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL624012,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8958,1,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL624013,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8959,1,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL624736,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8960,1,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL624737,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8961,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL624738,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8962,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL624739,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8963,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL624740,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8964,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL624896,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8965,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL624897,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8966,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL624108,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8967,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL624109,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8968,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL624110,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8969,1,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL624111,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8970,1,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL624112,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8971,1,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL624113,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8972,1,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL619709,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,8973,1,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL619710,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Kidney,,8974,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL619711,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8975,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL619712,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8976,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL619713,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8977,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL619714,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8978,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL619715,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8979,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL619716,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8980,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL619717,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8981,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL619718,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8982,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL619719,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8983,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL875329,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8984,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL619720,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8985,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL619721,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8986,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL619722,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8987,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL619723,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8988,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL619724,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8989,1,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL619725,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8990,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL619726,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8991,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL619727,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8992,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL619728,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,8993,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL619729,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Muscle tissue,,8994,1,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL619730,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8995,1,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL619731,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8996,1,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL619732,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8997,1,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL619733,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,8998,1,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL619734,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Zone of skin,,8999,1,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL619735,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,9000,1,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL875330,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,9001,1,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL628465,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,9002,1,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL628466,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,9003,1,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL628467,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Spleen,,9004,1,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL628468,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,9005,1,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL628469,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,9006,1,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL628470,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,9007,1,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL628471,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,9008,1,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL628472,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Thyroid gland,,9009,1,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625191,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,9010,1,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL625192,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,9011,1,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,A,,CHEMBL875337,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,9012,1,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL626341,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,9013,1,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL626342,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Liver,,9014,1,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,A,,CHEMBL621943,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,9015,1,,,Half life in rats,50597,A,,CHEMBL621944,,3748,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9016,1,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,50597,A,,CHEMBL621945,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9017,1,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),50597,A,,CHEMBL621946,,4871,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9018,1,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,A,,CHEMBL621947,,4871,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9019,1,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),50597,A,,CHEMBL621948,,4872,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9020,1,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,A,,CHEMBL621949,,4872,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9021,1,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),50597,A,,CHEMBL621950,,5413,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9022,1,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,50597,A,,CHEMBL621951,,5413,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Blood,,9023,1,,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,50597,A,,CHEMBL621952,,15272,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Liver,,9024,1,,,Stability (%) in rat liver microsomes,50597,A,,CHEMBL621953,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,9025,1,,,Area under curve was calculated after intravenous administration,50597,A,,CHEMBL621954,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9026,1,,,Area under the curve was calculated after iv administration in rat,50597,A,,CHEMBL621955,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9027,1,,,Area under the curve was calculated in rat after peroral administration,50597,A,,CHEMBL621956,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9028,1,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,A,,CHEMBL621957,,6211,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9029,1,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,50597,A,,CHEMBL621958,,5710,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9030,1,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,50597,A,,CHEMBL621959,,5710,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9031,1,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,50597,A,,CHEMBL621960,,17853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9032,1,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,50597,A,,CHEMBL621961,,17853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9033,1,,,p value of the compound,50597,A,,CHEMBL621962,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9034,1,,,p value of the compound,50597,F,,CHEMBL876787,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9035,1,,,p value of the compound,50597,A,,CHEMBL621963,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Stomach,,9036,1,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,A,,CHEMBL622637,,6175,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
,BAO_0000218,Stomach,,9037,1,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,A,,CHEMBL622638,,6175,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
,BAO_0000218,Stomach,,9038,1,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,A,,CHEMBL626561,,6175,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
,BAO_0000019,,,9039,1,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),22224,F,,CHEMBL626562,,7991,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000218,,,9040,1,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),22224,A,,CHEMBL626563,,429,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000218,,,9041,1,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),22224,A,,CHEMBL626564,,429,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9042,1,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,A,,CHEMBL626565,,6253,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9043,1,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,A,,CHEMBL626566,,6253,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9044,1,,,Clearance rate in rabbits,22224,A,,CHEMBL626567,,3615,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9045,1,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,A,,CHEMBL626568,,4059,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9046,1,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,A,,CHEMBL626569,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9047,1,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,A,,CHEMBL626570,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9048,1,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,A,,CHEMBL626571,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9049,1,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,22224,A,,CHEMBL626572,,429,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,Plasma,,9050,1,,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,A,,CHEMBL626573,,4059,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,1969.0
,BAO_0000251,Liver,,9051,1,,Microsomes,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,22224,A,,CHEMBL626574,,9659,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,2107.0
,BAO_0000251,Liver,,9052,1,,Microsomes,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,22224,A,,CHEMBL626575,,9659,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,2107.0
,BAO_0000218,,,9053,1,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,22224,A,,CHEMBL626576,,3639,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000218,,,9054,1,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,22224,A,,CHEMBL626577,,3639,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9055,1,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,22224,A,,CHEMBL626578,,3639,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9056,1,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,A,,CHEMBL625263,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9057,1,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,A,,CHEMBL625264,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9058,1,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,A,,CHEMBL625265,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000251,,,9059,1,,Microsomes,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),22224,A,,CHEMBL625266,,14294,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000251,,,9060,1,,Microsomes,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),22224,A,,CHEMBL876796,,14294,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9061,1,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,22224,A,,CHEMBL625267,,429,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,Plasma,,9062,1,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,A,,CHEMBL625268,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,1969.0
In vivo,BAO_0000218,Plasma,,9063,1,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,A,,CHEMBL625269,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,1969.0
In vivo,BAO_0000218,Plasma,,9064,1,,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,A,,CHEMBL624689,,5124,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,1969.0
In vivo,BAO_0000218,,,9065,1,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,22224,A,,CHEMBL624690,,429,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000218,Urine,,9066,1,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),22224,A,,CHEMBL624691,,429,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,1088.0
,BAO_0000218,Urine,,9067,1,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),22224,A,,CHEMBL624692,,429,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,1088.0
In vivo,BAO_0000218,,,9068,1,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,A,,CHEMBL624693,,4059,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,,,9069,1,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,22224,A,,CHEMBL624694,,4137,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vitro,BAO_0000221,,,9070,1,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,22224,A,,CHEMBL877596,,11672,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000019,,,9071,1,,,Time within which only 10% of the drug was degraded,22224,A,,CHEMBL624695,,12886,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000221,Liver,,9072,1,,,Half life period in rabbit liver homogenate,22224,A,,CHEMBL624696,,3853,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,2107.0
,BAO_0000019,,,9073,1,,,Half life value in rabbits,22224,A,,CHEMBL624697,,3615,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
In vivo,BAO_0000218,Blood,,9074,1,,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,A,,CHEMBL624698,,6253,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,178.0
In vivo,BAO_0000218,Blood,,9075,1,,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,A,,CHEMBL624699,,6253,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,178.0
In vivo,BAO_0000218,,,9076,1,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,22224,A,,CHEMBL624700,,6077,9986.0,Autocuration,,,0,U,Oryctolagus cuniculus,
,BAO_0000218,Plasma,,9077,1,,,AUC 0-8 hr value in rats at 10 mg/kg,50597,A,,CHEMBL622903,,17617,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9078,1,,,AUC after administration at 2000 mg/kg/day in rats,50597,A,,CHEMBL622904,,17594,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9079,1,,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,50597,A,,CHEMBL622905,,6149,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9080,1,,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,A,,CHEMBL622906,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9081,1,,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,A,,CHEMBL622907,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9082,1,,,AUC in rat after oral administration at 10.5 mg/kg dose,50597,A,,CHEMBL622908,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9083,1,,,AUC in rat after oral administration at 11.2 mg/kg dose,50597,A,,CHEMBL622909,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9084,1,,,AUC in rat after oral administration at 9.7 mg/kg dose,50597,A,,CHEMBL622910,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Brain,,9085,1,,,AUC in rat brain after oral administration at 10 mg/kg,50597,A,,CHEMBL622911,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Plasma,,9086,1,,,AUC in rat p.o.,50597,A,,CHEMBL622912,,6504,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9087,1,,,AUC in rat p.o. at 20 mg/kg concentration,50597,A,,CHEMBL622913,,17686,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9088,1,,,AUC in rat plasma after oral administration at 10 mg/kg,50597,A,,CHEMBL622914,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9089,1,,,AUC in rats,50597,A,,CHEMBL622915,,216,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9090,1,,,AUC value after IV dose at a dose of 5 mg/kg in rats.,50597,A,,CHEMBL622916,,1908,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9091,1,,,AUC value after oral dose at a dose of 10 mg/kg in rats.,50597,A,,CHEMBL622917,,1908,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9092,1,,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,A,,CHEMBL622918,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9093,1,,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,50597,A,,CHEMBL622919,,216,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9094,1,,,Maximum plasma concentration was evaluated in rat,50597,A,,CHEMBL622920,,6049,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9095,1,,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,A,,CHEMBL622921,,2463,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9096,1,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50597,A,,CHEMBL622922,,6679,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9097,1,,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,A,,CHEMBL622923,,6681,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9098,1,,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL877604,,4890,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9099,1,,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,50597,A,,CHEMBL622924,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9100,1,,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,50597,A,,CHEMBL622925,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9101,1,,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,50597,A,,CHEMBL622926,,16366,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9102,1,,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,50597,A,,CHEMBL623625,,6227,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9103,1,,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,A,,CHEMBL623626,,3598,10116.0,Expert,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9104,1,,,Maximum plasma drug concentration was determined,50597,A,,CHEMBL623627,,1465,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9105,1,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,50597,A,,CHEMBL623628,,4368,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9106,1,,,Mean peak plasma concentration was observed after intravenous administration in rat,50597,A,,CHEMBL623629,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9107,1,,,Mean peak plasma concentration was observed after oral administration in rat,50597,A,,CHEMBL623630,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9108,1,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,50597,A,,CHEMBL623804,,5355,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9109,1,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,50597,A,,CHEMBL623805,,5355,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9110,1,,,Peak oral plasma concentration was determined in rats by oral administration,50597,A,,CHEMBL623806,,1567,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9111,1,,,Peak plasma concentration (Cmax) was determined,50597,A,,CHEMBL623807,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9112,1,,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,50597,A,,CHEMBL623808,,6193,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9113,1,,,Peak plasma concentration (Cmax) in rats,50597,A,,CHEMBL623809,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9114,1,,,Peak plasma concentration at 1 mg/kg peroral administration,50597,A,,CHEMBL623810,,6485,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9115,1,,,Peak plasma concentration in rat,50597,A,,CHEMBL623811,,17655,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9116,1,,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",50597,A,,CHEMBL623812,,14941,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9117,1,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,50597,A,,CHEMBL877605,,5394,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9118,1,,,Pharmacokinetic property (Cmax) in rat,50597,A,,CHEMBL623813,,4408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9119,1,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,A,,CHEMBL623814,,5983,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9120,1,,,Cmax in rat after 3mg/kg oral dose,50597,A,,CHEMBL623815,,4878,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9121,1,,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,50597,A,,CHEMBL623816,,5862,10116.0,Intermediate,Sprague-Dawley,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9122,1,,,Cmax in rats after 20 mg/kg oral dose,50597,A,,CHEMBL623145,,4517,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9123,1,,,Cmax in rat plasma after 30mg/kg oral dose,50597,A,,CHEMBL623146,,5932,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9124,1,,,Plasma concentration after oral administration of 100 mg/kg to rats,50597,A,,CHEMBL623147,,5436,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Brain,,9125,1,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,A,,CHEMBL623042,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,,,9126,1,,,Tested for the Cmax in rat at 10 mg/kg per orally,50597,A,,CHEMBL623043,,4950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9127,1,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL623044,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9128,1,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL623045,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9129,1,,,Bioavailability as oral Cmax in rats at 30 mins,50597,A,,CHEMBL623046,,3360,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9130,1,,,Bioavailability as oral Cmax in rats at 6hr,50597,A,,CHEMBL623226,,3360,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9131,1,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,50597,A,,CHEMBL623227,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9132,1,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,50597,A,,CHEMBL623228,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9133,1,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,50597,A,,CHEMBL623229,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9134,1,,,The maximum plasma levels for the compounds were determined by LC-MS.,50597,A,,CHEMBL623230,,5160,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9135,1,,,mean peak plasma concentration was observed after intravenous administration in rat,50597,A,,CHEMBL623231,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9136,1,,,mean peak plasma concentration was observed after oral administration in rat,50597,A,,CHEMBL623232,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9137,1,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,50597,A,,CHEMBL623233,,4709,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9138,1,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,50597,A,,CHEMBL623234,,3535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9139,1,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,50597,A,,CHEMBL623235,,3535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9140,1,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,50597,A,,CHEMBL623236,,3535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9141,1,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,50597,A,,CHEMBL623237,,3535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9142,1,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,50597,A,,CHEMBL623238,,3535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9143,1,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,50597,A,,CHEMBL623239,,3535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9144,1,,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,22224,A,,CHEMBL623240,,5005,10116.0,Intermediate,,,0,U,Rattus norvegicus,1969.0
,BAO_0000218,Hypothalamus,,9145,1,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",50597,A,,CHEMBL623241,,6326,10116.0,Intermediate,,,1,N,Rattus norvegicus,1898.0
,BAO_0000218,Hypothalamus,,9146,1,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",50597,A,,CHEMBL623242,,6326,10116.0,Intermediate,,,1,N,Rattus norvegicus,1898.0
,BAO_0000218,,,9147,1,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",50597,A,,CHEMBL874394,,6326,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9148,1,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",50597,A,,CHEMBL623243,,6326,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9149,1,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL623244,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Kidney,,9150,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL623245,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9151,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL623246,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9152,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL623247,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9153,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL623248,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9154,1,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL623249,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Liver,,9155,1,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL625072,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9156,1,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL625073,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9157,1,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL625074,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9158,1,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL625075,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9159,1,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL625076,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9160,1,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL625077,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9161,1,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL625078,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9162,1,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL874395,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9163,1,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL625079,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9164,1,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL625080,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9165,1,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL625081,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9166,1,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL625082,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9167,1,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL625083,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9168,1,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL625084,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9169,1,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL625085,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9170,1,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL625086,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9171,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL625087,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9172,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL625088,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9173,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL622205,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9174,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL622206,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9175,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL622207,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9176,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL622366,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9177,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL622367,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9178,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL875331,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9179,1,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL622368,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Lung,,9180,1,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL622369,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9181,1,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL622370,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9182,1,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL622371,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9183,1,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL622372,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9184,1,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL622373,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9185,1,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL622374,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9186,1,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL622375,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9187,1,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL622376,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9188,1,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL622377,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9189,1,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL622378,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9190,1,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL622379,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9191,1,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL622380,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9192,1,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL622381,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9193,1,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL622382,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9194,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL622383,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Stomach,,9195,1,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,A,,CHEMBL875332,,6175,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
,BAO_0000218,Stomach,,9196,1,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,A,,CHEMBL622384,,6175,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
,BAO_0000218,Stomach,,9197,1,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,A,,CHEMBL622385,,6175,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
,BAO_0000218,Stomach,,9198,1,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,A,,CHEMBL622386,,6175,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
,BAO_0000218,,,9199,1,,,The compound was tested for the plasma binding in rat,50597,A,,CHEMBL622387,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9200,1,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",50597,A,,CHEMBL622388,,16459,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9201,1,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",50597,A,,CHEMBL622389,,16459,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9202,1,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",50597,A,,CHEMBL622390,,16459,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9203,1,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),50597,A,,CHEMBL622391,,16459,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9204,1,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),50597,A,,CHEMBL622392,,16459,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9205,1,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),50597,A,,CHEMBL622393,,16459,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9206,1,,,Plasma level at 2 hr after administration of the compound,50597,A,,CHEMBL622394,,3278,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9207,1,,,plasma level at 2 hr after administration of the compound,50597,A,,CHEMBL622395,,3278,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Serum,,9208,1,,,Stability in rat serum measured as % recovery at 1 min,50597,A,,CHEMBL622396,,4684,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,Serum,,9209,1,,,Stability in rat serum measured as % recovery at 10 min,50597,A,,CHEMBL624894,,4684,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,Serum,,9210,1,,,Stability in rat serum measured as % recovery at 10 mins,50597,A,,CHEMBL624895,,4684,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,Serum,,9211,1,,,Stability in rat serum measured as % recovery at 2 hr,50597,A,,CHEMBL624058,,4684,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,Serum,,9212,1,,,Stability in rat serum measured as % recovery at 3 min,50597,A,,CHEMBL624059,,4684,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,Serum,,9213,1,,,Stability in rat serum measured as % recovery at 3 mins,50597,A,,CHEMBL624060,,4684,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,Serum,,9214,1,,,Stability in rat serum measured as % recovery at 5 min,50597,A,,CHEMBL624061,,4684,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,Serum,,9215,1,,,Stability in rat serum measured as % recovery at 5 mins,50597,A,,CHEMBL624062,,4684,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
In vivo,BAO_0000218,,,9216,1,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,A,,CHEMBL624063,,16456,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9217,1,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,A,,CHEMBL624064,,16456,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9218,1,,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,50597,A,,CHEMBL624065,,723,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9219,1,,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,50597,A,,CHEMBL624066,,723,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9220,1,,,Half life tested in mature male rat at a dose of 30 mg/kg,50597,A,,CHEMBL877490,,5160,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9221,1,,,Half life after intravenous administration of 1 mg/kg in rat,50597,A,,CHEMBL874442,,4709,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9222,1,,,Half life period after administration (30 mg/kg) in rat,50597,A,,CHEMBL626890,,5633,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9223,1,,,Half life period in rat after 5 mg/Kg dose,50597,A,,CHEMBL626891,,5302,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9224,1,,,Half life period in rat after 5 mg/kg dose,50597,A,,CHEMBL626892,,5302,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9225,1,,,Half life period was determined,50597,A,,CHEMBL626893,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9226,1,,,Half life period was evaluated in rat,50597,A,,CHEMBL626894,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9227,1,,,Half life period was evaluated in rat; 0.5-1.0,50597,A,,CHEMBL626895,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9228,1,,,Half life period was evaluated in rat; 5.9-7.5,50597,A,,CHEMBL626896,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9229,1,,,Half-life in rat plasma,50597,A,,CHEMBL626897,,14512,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9230,1,,,Half-life time in rat was determined,50597,A,,CHEMBL626898,,6230,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9231,1,,,Terminal half-life after iv administration to rats,50597,A,,CHEMBL626899,,3364,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9232,1,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,50597,A,,CHEMBL626900,,6874,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9233,1,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,50597,A,,CHEMBL626901,,857,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9234,1,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),50597,A,,CHEMBL626902,,858,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9235,1,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),50597,A,,CHEMBL626903,,858,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9236,1,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,50597,A,,CHEMBL874443,,5355,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9237,1,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,50597,A,,CHEMBL626904,,5355,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9238,1,,,Half life in rats,50597,A,,CHEMBL626905,,6305,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9239,1,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,A,,CHEMBL873830,,13501,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9240,1,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,50597,A,,CHEMBL626906,,17594,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9241,1,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,A,,CHEMBL631076,,4186,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9242,1,,,Biological half-life was measured in plasma of rats,50597,A,,CHEMBL631077,,2932,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9243,1,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,A,,CHEMBL631078,,17065,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9244,1,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,50597,A,,CHEMBL631079,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9245,1,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,50597,A,,CHEMBL631080,,2713,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9246,1,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,50597,A,,CHEMBL631081,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9247,1,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,50597,A,,CHEMBL631239,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9248,1,,,Compound was evaluated for plasma half life in rat,50597,A,,CHEMBL631240,,740,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9249,1,,,AUC value at a dose of 5 mg/kg (p.o.) in rats,50597,A,,CHEMBL631241,,6597,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9250,1,,,AUC value after administration of 20 mg/Kg oral dose in rat,50597,A,,CHEMBL631242,,2959,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9251,1,,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,50597,A,,CHEMBL631243,,17594,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9252,1,,,AUC0-96 after administration at 50 mg/kg,50597,A,,CHEMBL874444,,17596,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9253,1,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,50597,A,,CHEMBL631244,,17594,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9254,1,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",50597,A,,CHEMBL631245,,3293,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9255,1,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,50597,A,,CHEMBL627162,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9256,1,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,50597,A,,CHEMBL627163,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9257,1,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,50597,A,,CHEMBL627164,,6757,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Kidney,,9258,1,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,50597,A,,CHEMBL627165,,5979,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,,,9259,1,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,50597,A,,CHEMBL627166,,5979,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9260,1,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,50597,A,,CHEMBL627167,,5979,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9261,1,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,50597,A,,CHEMBL627822,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9262,1,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,A,,CHEMBL627823,,5355,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9263,1,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,50597,A,,CHEMBL627824,,5355,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9264,1,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,A,,CHEMBL627825,,5355,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9265,1,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,50597,A,,CHEMBL627826,,5633,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9266,1,,,Area under curve (Pharmacokinetic property) was determined,50597,A,,CHEMBL627827,,1716,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9267,1,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,50597,A,,CHEMBL627828,,1716,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9268,1,,,Area under curve after intravenous administration (1 mg/kg) in rat,50597,A,,CHEMBL627829,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9269,1,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,50597,A,,CHEMBL627830,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9270,1,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,50597,A,,CHEMBL627831,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9271,1,,,Area under curve in male SD rats was observed after oral administration in rat,50597,A,,CHEMBL627832,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9272,1,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,50597,A,,CHEMBL627833,,4413,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9273,1,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,A,,CHEMBL627834,,3598,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9274,1,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,50597,A,,CHEMBL628004,,3598,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9275,1,,,Area under curve at 5 mg/kg po was determined in rat,50597,A,,CHEMBL628005,,5964,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9276,1,,,Area under curve in Rat at a oral dose of 5 mg/kg,50597,A,,CHEMBL628006,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9277,1,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,A,,CHEMBL628007,,4186,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9278,1,,,Area under curve was determined,50597,A,,CHEMBL625676,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9279,1,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,50597,A,,CHEMBL631309,,17858,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9280,1,,,Area under curve after intravenous administration at 3 mg/kg,50597,A,,CHEMBL631310,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9281,1,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,50597,A,,CHEMBL631311,,6106,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9282,1,,,Area under curve at 4 hr in rat,50597,A,,CHEMBL631312,,5964,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9283,1,,,Area under curve at a dose of 30 mg/kg,50597,A,,CHEMBL631313,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9284,1,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,50597,A,,CHEMBL631314,,4756,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9285,1,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,50597,A,,CHEMBL631315,,4756,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9286,1,,,Area under curve for a 2-mpk po dose in SD rats,50597,A,,CHEMBL631316,,5862,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9287,1,,,Area under curve in SD rats,50597,A,,CHEMBL631317,,5862,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9288,1,,,Area under curve in rat after oral administration at 13 mg/kg dose,50597,A,,CHEMBL874471,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9289,1,,,Area under curve in rat by po administration at 0-24 hr,50597,A,,CHEMBL631318,,5871,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9290,1,,,Area under curve in rat plasma,50597,A,,CHEMBL631319,,5919,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9291,1,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,50597,A,,CHEMBL631320,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9292,1,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,50597,A,,CHEMBL631321,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9293,1,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,50597,A,,CHEMBL631322,,10,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9294,1,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,50597,A,,CHEMBL631323,,11149,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9295,1,,,Area under curve value in rat at a dose of 5 mg/kg,50597,A,,CHEMBL631324,,5302,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9296,1,,,Area under curve was determined after oral administration in rats,50597,A,,CHEMBL631325,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9297,1,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL631326,,4890,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9298,1,,,Area under curve was determined after peroral administration in rat,50597,A,,CHEMBL631327,,6011,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9299,1,,,Area under curve was determined at a dose 30 mpk administered orally.,50597,A,,CHEMBL631328,,5375,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9300,1,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,50597,A,,CHEMBL631329,,17764,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9301,1,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,50597,A,,CHEMBL627217,,4368,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9302,1,,,Area under curve was determined in male rat,50597,A,,CHEMBL626352,,5610,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9303,1,,,Area under curve was determined in rat after PO administration,50597,A,,CHEMBL626353,,5833,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9304,1,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,50597,A,,CHEMBL626354,,4257,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9305,1,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,50597,A,,CHEMBL626355,,5937,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9306,1,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,50597,A,,CHEMBL626356,,5932,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9307,1,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,50597,A,,CHEMBL626357,,5932,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9308,1,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL626358,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9309,1,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL626359,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9310,1,,,Peak plasma concentration in rat at a dose of 3 mg/kg,50597,A,,CHEMBL626360,,17771,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9311,1,,,Plasma concentration at 2 hr in rats was evaluated.,50597,A,,CHEMBL626361,,1628,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9312,1,,,Plasma concentration at 2 hr in rats was evaluated; Not available,50597,A,,CHEMBL626362,,1628,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9313,1,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL626363,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9314,1,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,A,,CHEMBL626970,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9315,1,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,A,,CHEMBL626971,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9316,1,,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,A,,CHEMBL626972,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9317,1,,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,A,,CHEMBL626973,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9318,1,,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,A,,CHEMBL626974,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9319,1,,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,A,,CHEMBL874592,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9320,1,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,50597,A,,CHEMBL626975,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9321,1,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,50597,A,,CHEMBL626976,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9322,1,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,50597,A,,CHEMBL626977,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9323,1,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,50597,A,,CHEMBL626978,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9324,1,,,PK study was carried to determine the relative absorption ranking in rat.,50597,A,,CHEMBL626979,,16427,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9325,1,,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,50597,A,,CHEMBL626980,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Blood,,9326,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",50597,A,,CHEMBL626981,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,9327,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",50597,A,,CHEMBL626982,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,9328,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",50597,A,,CHEMBL626983,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,9329,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",50597,A,,CHEMBL622522,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,9330,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",50597,A,,CHEMBL622523,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,9331,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",50597,A,,CHEMBL622524,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Brain,,9332,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",50597,A,,CHEMBL622525,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,9333,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",50597,A,,CHEMBL622526,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,9334,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",50597,A,,CHEMBL619849,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,9335,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",50597,A,,CHEMBL619850,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,9336,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",50597,A,,CHEMBL623864,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,9337,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",50597,A,,CHEMBL623865,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Heart,,9338,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",50597,A,,CHEMBL623866,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,9339,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",50597,A,,CHEMBL623867,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,9340,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",50597,A,,CHEMBL877615,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,9341,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",50597,A,,CHEMBL623868,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,9342,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",50597,A,,CHEMBL623869,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,9343,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",50597,A,,CHEMBL623870,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Lung,,9344,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL623871,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9345,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL623872,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9346,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL622129,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9347,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL622130,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9348,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL622131,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9349,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL622132,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9350,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL622133,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9351,1,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL622134,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9352,1,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL622135,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9353,1,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL622136,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Muscle tissue,,9354,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL622137,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9355,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL622138,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9356,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL623017,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9357,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL623018,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9358,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL623019,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9359,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL623020,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9360,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL623021,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9361,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL623022,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9362,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL623023,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9363,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL623024,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9364,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL623025,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9365,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL620545,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9366,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL620546,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9367,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL620547,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9368,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL620548,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9369,1,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL620549,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9370,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL620550,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9371,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL620551,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9372,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL620552,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9373,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL620553,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9374,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL620554,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9375,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL875845,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9376,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL620555,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9377,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL620556,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9378,1,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL620557,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,,,9379,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL620558,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9380,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL620559,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9381,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL622939,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9382,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL622940,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9383,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL622941,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9384,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL622942,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9385,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL622943,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9386,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL622944,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9387,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL622945,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9388,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL622946,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9389,1,,,Compound was evaluated for terminal half life in rat,50597,A,,CHEMBL622947,,3341,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9390,1,,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,50597,A,,CHEMBL622948,,3634,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9391,1,,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,50597,A,,CHEMBL622949,,3634,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9392,1,,,Compound was tested for its half life in rat,50597,A,,CHEMBL622950,,4839,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9393,1,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,A,,CHEMBL622951,,5005,9544.0,Intermediate,,,0,U,Macaca mulatta,1969.0
,BAO_0000366,Plasma,,9394,1,,,Compound was tested for its plasma half life in Sprague Dawley rats,22224,A,,CHEMBL622952,,5005,10116.0,Intermediate,,,0,U,Rattus norvegicus,1969.0
,BAO_0000366,Plasma,,9395,1,,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,22224,A,,CHEMBL622953,,5005,10116.0,Intermediate,,,0,U,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9396,1,,,Compound was tested for plasma half-life period in rat,50597,A,,CHEMBL873818,,1094,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9397,1,,,Elimination half life after i.v. administration of compound in rats,50597,A,,CHEMBL622954,,5031,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9398,1,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,50597,A,,CHEMBL622955,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9399,1,,,Elimination half-life after IV dosing at 1 mg/kg in rat,50597,A,,CHEMBL875229,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9400,1,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,50597,A,,CHEMBL622956,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9401,1,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,50597,A,,CHEMBL622957,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Brain,,9402,1,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,A,,CHEMBL622958,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Plasma,,9403,1,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,A,,CHEMBL622959,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Brain,,9404,1,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,A,,CHEMBL622960,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Plasma,,9405,1,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,A,,CHEMBL622961,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9406,1,,,Evaluated for the half life in rat (in vivo),50597,A,,CHEMBL622962,,4687,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9407,1,,,Hafl life in rat,50597,A,,CHEMBL622963,,6640,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9408,1,,,Hafl life rat,50597,A,,CHEMBL622964,,6640,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9409,1,,,Hafl life rat,50597,A,,CHEMBL622965,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9410,1,,,Hafl life rat; Not determined,50597,A,,CHEMBL622966,,6640,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9411,1,,,Hafl life rat; Not determined,50597,A,,CHEMBL622967,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Kidney,,9412,1,,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL622968,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Liver,,9413,1,,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL622969,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Lung,,9414,1,,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL875327,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,,,9415,1,,,Half life in rat after 1 mg/kg i.v. administration,50597,A,,CHEMBL628638,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9416,1,,,Half life in rat after 2 mg/kg peroral administration,50597,A,,CHEMBL628639,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9417,1,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL625840,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9418,1,,,Half life of 10 mg/kg oral dose determined in rats,50597,A,,CHEMBL625841,,4722,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9419,1,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL625842,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9420,1,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL625843,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9421,1,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL625844,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9422,1,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL873822,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9423,1,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL625845,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9424,1,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL627059,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9425,1,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL627060,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9426,1,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL627061,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9427,1,,,Half life of compound at 5 mg/kg after po administration was determined in rat,50597,A,,CHEMBL627709,,4762,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9428,1,,,Half life of compound determined after intravenous administration to rat,50597,A,,CHEMBL627710,,5327,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9429,1,,,Half life of compound was determined in rat,50597,A,,CHEMBL627711,,4847,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9430,1,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,A,,CHEMBL627712,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9431,1,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL627713,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9432,1,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL627714,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9433,1,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,A,,CHEMBL627889,,4256,9541.0,Intermediate,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,9434,1,,,Half life determined in rat by intravenous administration,22224,A,,CHEMBL627890,,4256,10116.0,Intermediate,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,9435,1,,,Half life determined in rats after iv administration,50597,A,,CHEMBL627891,,4722,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9436,1,,,Half life in rat plasma after administration of 2 mg/kg iv,50597,A,,CHEMBL627892,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9437,1,,,Half life in rat plasma after administration of 2 mg/kg iv,50597,A,,CHEMBL627893,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9438,1,,,Half life in rat plasma was determined,50597,A,,CHEMBL627894,,1435,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9439,1,,,Half life in rat plasma was determined; NA means not applicable,50597,A,,CHEMBL627895,,1435,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9440,1,,,Half life in rat was tested,50597,A,,CHEMBL627896,,5206,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9441,1,,,Half life measured in rat plasma,50597,A,,CHEMBL627897,,6080,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9442,1,,,Half life recorded in rats,50597,A,,CHEMBL627898,,4449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9443,1,,,Half life was calculated,50597,A,,CHEMBL627899,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9444,1,,,Half life was calculated in rat,50597,A,,CHEMBL873823,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9445,1,,,Half life was determined,50597,A,,CHEMBL627900,,3747,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9446,1,,,Half life after 10 mg/kg oral administration in rat,50597,A,,CHEMBL627901,,17858,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9447,1,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,50597,A,,CHEMBL627902,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9448,1,,,Half life after administering orally a dose of 30 mg/kg,50597,A,,CHEMBL627903,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9449,1,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,50597,A,,CHEMBL627904,,5031,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9450,1,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,50597,A,,CHEMBL627905,,4722,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9451,1,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,50597,A,,CHEMBL627906,,6078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9452,1,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,50597,A,,CHEMBL627907,,6078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9453,1,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,50597,A,,CHEMBL876783,,6078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9454,1,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,50597,A,,CHEMBL627908,,6078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9455,1,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,A,,CHEMBL627909,,17065,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9456,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,50597,A,,CHEMBL627910,,1353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9457,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),50597,A,,CHEMBL627911,,1353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9458,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),50597,A,,CHEMBL627912,,1353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9459,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),50597,A,,CHEMBL627913,,1353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9460,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),50597,A,,CHEMBL627914,,1353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9461,1,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,50597,A,,CHEMBL627915,,16423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9462,1,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,50597,A,,CHEMBL627916,,16423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9463,1,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,50597,A,,CHEMBL627917,,6062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9464,1,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,50597,A,,CHEMBL627918,,6056,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9465,1,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,50597,A,,CHEMBL627919,,5182,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9466,1,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,50597,A,,CHEMBL627920,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9467,1,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,50597,A,,CHEMBL627921,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9468,1,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL627922,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9469,1,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL876784,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9470,1,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL627923,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9471,1,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL626208,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9472,1,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL626209,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9473,1,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL626210,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9474,1,,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,A,,CHEMBL627994,,2463,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9475,1,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,50597,A,,CHEMBL627995,,4709,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9476,1,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,50597,A,,CHEMBL627996,,4075,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9477,1,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,50597,A,,CHEMBL627997,,5394,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9478,1,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,50597,A,,CHEMBL627998,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9479,1,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,50597,A,,CHEMBL628640,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9480,1,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,50597,A,,CHEMBL628641,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9481,1,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,50597,A,,CHEMBL628642,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9482,1,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),50597,A,,CHEMBL628643,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9483,1,,,Compound was tested for area under curve in rat,50597,A,,CHEMBL628644,,2591,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9484,1,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,50597,A,,CHEMBL628645,,6567,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9485,1,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,A,,CHEMBL628646,,6211,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9486,1,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),50597,A,,CHEMBL628647,,5529,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9487,1,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,A,,CHEMBL628648,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9488,1,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,A,,CHEMBL625358,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9489,1,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,A,,CHEMBL625359,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9490,1,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,A,,CHEMBL625360,,5408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9491,1,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),50597,A,,CHEMBL625361,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9492,1,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),50597,A,,CHEMBL625362,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9493,1,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),50597,A,,CHEMBL625363,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9494,1,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,A,,CHEMBL625364,,4796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9495,1,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL625365,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9496,1,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL625366,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9497,1,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL625367,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Kidney,,9498,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",50597,A,,CHEMBL625368,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9499,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",50597,A,,CHEMBL625369,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9500,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",50597,A,,CHEMBL625370,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9501,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",50597,A,,CHEMBL625371,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9502,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",50597,A,,CHEMBL625372,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9503,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",50597,A,,CHEMBL625373,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Liver,,9504,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",50597,A,,CHEMBL625374,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9505,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",50597,A,,CHEMBL877593,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9506,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",50597,A,,CHEMBL625375,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9507,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",50597,A,,CHEMBL625376,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9508,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",50597,A,,CHEMBL621973,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9509,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",50597,A,,CHEMBL621974,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Lung,,9510,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",50597,A,,CHEMBL621975,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9511,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",50597,A,,CHEMBL622166,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9512,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",50597,A,,CHEMBL622167,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9513,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",50597,A,,CHEMBL622168,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9514,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",50597,A,,CHEMBL622169,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,9515,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",50597,A,,CHEMBL622170,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Thyroid gland,,9516,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",50597,A,,CHEMBL622171,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9517,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",50597,A,,CHEMBL622172,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9518,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",50597,A,,CHEMBL622173,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9519,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",50597,A,,CHEMBL622174,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9520,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",50597,A,,CHEMBL622175,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9521,1,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",50597,A,,CHEMBL622176,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9522,1,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",50597,A,,CHEMBL622177,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9523,1,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",50597,A,,CHEMBL622178,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9524,1,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",50597,A,,CHEMBL622179,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9525,1,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",50597,A,,CHEMBL622180,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,,,9526,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL622181,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9527,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL622182,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9528,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL622183,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9529,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL622184,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9530,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL622185,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9531,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL622186,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9532,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL622187,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9533,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL625002,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9534,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL622090,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9535,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL622091,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9536,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL622092,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9537,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL622093,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9538,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL622094,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9539,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL622095,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9540,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL622264,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Spleen,,9541,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL622265,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9542,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL622266,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9543,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL622267,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9544,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL622268,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9545,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL622269,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9546,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL625071,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9547,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL621621,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9548,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL621622,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9549,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL621623,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9550,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL621624,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9551,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL621625,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9552,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL621626,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9553,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL621627,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9554,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL621628,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9555,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL875328,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9556,1,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL621629,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9557,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL621630,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9558,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL621631,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9559,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL621632,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9560,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL621633,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9561,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL621634,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9562,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL621635,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9563,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL621636,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9564,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL621637,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9565,1,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL621638,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,,,9566,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL618883,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9567,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,A,,CHEMBL618884,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9568,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL628627,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9569,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL628628,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9570,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,A,,CHEMBL628629,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9571,1,,,Half life after administering orally a dose of 3 mg/kg,50597,A,,CHEMBL628630,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9572,1,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,50597,A,,CHEMBL628631,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9573,1,,,Half life after administering intravenously a dose of 1 mg/kg,50597,A,,CHEMBL628632,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9574,1,,,Half life after oral dosing in rats,50597,A,,CHEMBL628633,,526,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9575,1,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,50597,A,,CHEMBL628634,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9576,1,,,Half life by intravenous administration of 3.4 mg/kg in rat,50597,A,,CHEMBL627789,,4368,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9577,1,,,Half life in rat,50597,A,,CHEMBL627790,,3371,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9578,1,,,Half life in rat,50597,A,,CHEMBL627791,,6448,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9579,1,,,Half life in rat,50597,A,,CHEMBL627792,,6453,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9580,1,,,Half life in rat after intravenous administration of the compound,50597,A,,CHEMBL627793,,4353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9581,1,,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,50597,A,,CHEMBL627794,,4353,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9582,1,,,Half life in rat after po administration of the compound,50597,A,,CHEMBL627795,,4353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9583,1,,,Half life in rat after po administration of the compound; ND means Not determined,50597,A,,CHEMBL627796,,4353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9584,1,,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,50597,A,,CHEMBL875335,,4353,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,9585,1,,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,50597,A,,CHEMBL627797,,4353,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9586,1,,,Half life in rat i.v.,50597,A,,CHEMBL627798,,5789,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9587,1,,,Half life in rat i.v. at 2 mg/kg concentration,50597,A,,CHEMBL627799,,17686,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9588,1,,,Half life in rats,50597,A,,CHEMBL627800,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9589,1,,,Half life in rats after intravenous administration,50597,A,,CHEMBL627801,,484,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9590,1,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,50597,A,,CHEMBL627802,,6467,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9591,1,,,Half life in rat,50597,A,,CHEMBL627803,,6642,10116.0,Expert,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9592,1,,,Half life was evaluated after intravenous administration to rats,50597,A,,CHEMBL873820,,16367,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9593,1,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),50597,A,,CHEMBL627804,,1369,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9594,1,,,Half life was evaluated in rat,50597,A,,CHEMBL627805,,5472,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9595,1,,,Half life was evaluated in rat,50597,A,,CHEMBL627806,,6049,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9596,1,,,Half life was evaluated in rat; Not tested,50597,A,,CHEMBL627107,,5472,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9597,1,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,50597,A,,CHEMBL627108,,16366,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9598,1,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,50597,A,,CHEMBL627109,,11149,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Blood,,9599,1,,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,50597,A,,CHEMBL627110,,11149,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,,,9600,1,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,A,,CHEMBL627111,,2891,9443.0,Intermediate,,,0,U,Primates,
In vivo,BAO_0000218,,,9601,1,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,A,,CHEMBL627112,,2891,9443.0,Intermediate,,,0,U,Primates,
In vivo,BAO_0000218,,,9602,1,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,22224,A,,CHEMBL627113,,2891,10116.0,Intermediate,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,9603,1,,,Half life was measured in rat at dose of 30 mg/kg by po administration,22224,A,,CHEMBL627114,,2891,10116.0,Intermediate,,,0,U,Rattus norvegicus,
,BAO_0000218,,,9604,1,,,Half life (t1/2) was determined,50597,A,,CHEMBL627115,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9605,1,,,Half life period at a dose of 10 uM/kg in rat was determined,50597,A,,CHEMBL627116,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9606,1,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,50597,A,,CHEMBL627117,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9607,1,,,Half life period was determined,50597,A,,CHEMBL627118,,5503,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9608,1,,,Half life period after intravenous administration at 20 mpk in rats,50597,A,,CHEMBL627119,,4426,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9609,1,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,50597,A,,CHEMBL627120,,4426,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9610,1,,,Half life period after intravenous administration in rat,50597,A,,CHEMBL626922,,6109,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9611,1,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,A,,CHEMBL626923,,5654,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9612,1,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,A,,CHEMBL626924,,5654,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9613,1,,,Half life period in 80% rat plasma at 37 degree Centigrade,50597,A,,CHEMBL626925,,4755,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9614,1,,,Half life period in SD rats,50597,A,,CHEMBL626926,,5862,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9615,1,,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),50597,A,,CHEMBL626927,,1515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9616,1,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),50597,A,,CHEMBL626928,,1515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9617,1,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,A,,CHEMBL626929,,1515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9618,1,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,A,,CHEMBL626930,,1515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9619,1,,,Half life period in rat,50597,A,,CHEMBL626931,,5960,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9620,1,,,Half life period in rat,50597,A,,CHEMBL626932,,6103,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9621,1,,,Half life period in rat,50597,A,,CHEMBL626933,,6317,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9622,1,,,Half life period in rat after oral administration at 10.5 mg/kg dose,50597,A,,CHEMBL873826,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9623,1,,,Half life period in rat after oral administration at 11.2 mg/kg dose,50597,A,,CHEMBL626934,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9624,1,,,Half life period in rat after oral administration at 13 mg/kg dose,50597,A,,CHEMBL626935,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9625,1,,,Half life period in rat after oral administration at 9.7 mg/kg dose,50597,A,,CHEMBL626936,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9626,1,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL626937,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9627,1,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,A,,CHEMBL625906,,6295,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9628,1,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,A,,CHEMBL625907,,6296,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9629,1,,,PK study was carried to determine AUC (area under curve) value in rat,50597,A,,CHEMBL625908,,16427,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9630,1,,,Pharmacokinetic parameter AUC after intravenous administration to rats,50597,A,,CHEMBL625909,,16367,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9631,1,,,Pharmacokinetic parameter AUC after oral administration to rats,50597,A,,CHEMBL625910,,16367,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9632,1,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,50597,A,,CHEMBL625911,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9633,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,50597,A,,CHEMBL625912,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9634,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,50597,A,,CHEMBL626538,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9635,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,50597,A,,CHEMBL876794,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9636,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,50597,A,,CHEMBL626539,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9637,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,50597,A,,CHEMBL626540,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9638,1,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,50597,A,,CHEMBL626541,,5394,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9639,1,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,50597,A,,CHEMBL626542,,5394,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9640,1,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,50597,A,,CHEMBL626543,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9641,1,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,50597,A,,CHEMBL626544,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9642,1,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,50597,A,,CHEMBL626545,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9643,1,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,50597,A,,CHEMBL626546,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9644,1,,,Pharmacokinetic parameter area under curve was reported,50597,A,,CHEMBL626547,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9645,1,,,Pharmacokinetic property (AUC) in rat,50597,A,,CHEMBL626548,,4408,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9646,1,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,A,,CHEMBL626549,,5983,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9647,1,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,50597,A,,CHEMBL626550,,4397,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9648,1,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,50597,A,,CHEMBL626551,,4397,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9649,1,,,Pharmacokinetic property was determined,50597,A,,CHEMBL623777,,5491,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9650,1,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,50597,A,,CHEMBL623778,,5491,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9651,1,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,50597,A,,CHEMBL623779,,5491,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9652,1,,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,A,,CHEMBL623780,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9653,1,,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,50597,A,,CHEMBL622015,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9654,1,,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,50597,A,,CHEMBL622016,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9655,1,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",50597,A,,CHEMBL622017,,5173,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9656,1,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",50597,A,,CHEMBL622018,,5173,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9657,1,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",50597,A,,CHEMBL622019,,5173,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9658,1,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",50597,A,,CHEMBL622020,,5173,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9659,1,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,50597,A,,CHEMBL622021,,16366,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9660,1,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,50597,A,,CHEMBL622022,,16366,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9661,1,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,50597,A,,CHEMBL622023,,5327,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9662,1,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,50597,A,,CHEMBL622024,,6681,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9663,1,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),50597,A,,CHEMBL622693,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9664,1,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),50597,A,,CHEMBL622694,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9665,1,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,A,,CHEMBL622695,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9666,1,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,A,,CHEMBL622696,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9667,1,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",50597,A,,CHEMBL622697,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9668,1,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",50597,A,,CHEMBL622874,,6619,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9669,1,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",50597,A,,CHEMBL622875,,6619,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9670,1,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,50597,A,,CHEMBL622876,,10363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9671,1,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,A,,CHEMBL622877,,4796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9672,1,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,A,,CHEMBL622878,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9673,1,,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,50597,A,,CHEMBL622879,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9674,1,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,50597,A,,CHEMBL877602,,4839,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9675,1,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL622880,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9676,1,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL622881,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9677,1,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL622882,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9678,1,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL622883,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Thyroid gland,,9679,1,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",50597,A,,CHEMBL622884,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,9680,1,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",50597,A,,CHEMBL622885,,11450,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,,,9681,1,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,A,,CHEMBL622886,,8151,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9682,1,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,50597,A,,CHEMBL622887,,8151,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Urine,,9683,1,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,A,,CHEMBL622888,,8151,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
In vivo,BAO_0000218,Blood,,9684,1,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622889,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,9685,1,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622890,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,9686,1,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622891,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,9687,1,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL877603,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Brain,,9688,1,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622892,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,9689,1,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622893,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,9690,1,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622894,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,9691,1,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622895,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,9692,1,,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,50597,A,,CHEMBL622896,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Heart,,9693,1,,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622897,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,9694,1,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622898,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,9695,1,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622899,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Kidney,,9696,1,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622900,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,9697,1,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624114,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,9698,1,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL624115,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,9699,1,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624116,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Liver,,9700,1,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL624117,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,9701,1,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624118,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,9702,1,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL624119,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,9703,1,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624120,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Lung,,9704,1,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL624121,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,9705,1,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624122,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,9706,1,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL624123,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,9707,1,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624124,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Muscle tissue,,9708,1,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL624125,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,9709,1,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624126,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,9710,1,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL624127,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,9711,1,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624128,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Zone of skin,,9712,1,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL624129,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,9713,1,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL624130,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,9714,1,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622340,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,9715,1,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622341,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Intestine,,9716,1,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622342,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,9717,1,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622343,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,9718,1,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622344,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Intestine,,9719,1,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622345,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,160.0
In vivo,BAO_0000218,Spleen,,9720,1,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622346,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,9721,1,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622347,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,9722,1,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622348,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,9723,1,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622349,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,,,9724,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,A,,CHEMBL622350,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9725,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,A,,CHEMBL622351,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9726,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,A,,CHEMBL622352,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9727,1,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,A,,CHEMBL622353,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9728,1,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,A,,CHEMBL622354,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9729,1,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,A,,CHEMBL622355,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9730,1,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,A,,CHEMBL622356,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9731,1,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,A,,CHEMBL622357,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9732,1,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,A,,CHEMBL622358,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9733,1,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,A,,CHEMBL622359,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9734,1,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,A,,CHEMBL874393,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9735,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL622872,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9736,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL622873,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9737,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL623047,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9738,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,A,,CHEMBL623048,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9739,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL623049,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9740,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL623050,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9741,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,A,,CHEMBL623051,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9742,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL623052,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9743,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL626343,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9744,1,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,A,,CHEMBL626344,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9745,1,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,A,,CHEMBL626345,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9746,1,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,A,,CHEMBL626346,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9747,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,A,,CHEMBL626347,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9748,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,A,,CHEMBL626348,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9749,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,A,,CHEMBL626349,,16434,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9750,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,F,,CHEMBL626350,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9751,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,A,,CHEMBL626351,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9752,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,A,,CHEMBL627650,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9753,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,F,,CHEMBL627651,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9754,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,A,,CHEMBL627652,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9755,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,A,,CHEMBL627653,,16435,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9756,1,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,50597,A,,CHEMBL627654,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9757,1,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,50597,A,,CHEMBL627835,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9758,1,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,50597,A,,CHEMBL627836,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9759,1,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,50597,A,,CHEMBL627837,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9760,1,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,50597,A,,CHEMBL627838,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9761,1,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,50597,A,,CHEMBL875338,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9762,1,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,50597,A,,CHEMBL627839,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9763,1,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,50597,A,,CHEMBL627840,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9764,1,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,50597,A,,CHEMBL627841,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9765,1,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,50597,A,,CHEMBL627842,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9766,1,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,50597,A,,CHEMBL627843,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9767,1,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,50597,A,,CHEMBL627844,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9768,1,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,50597,A,,CHEMBL627845,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9769,1,,,Half life period in rat by iv administration at a dose of 3 mg/kg,50597,A,,CHEMBL627846,,5874,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9770,1,,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),50597,A,,CHEMBL627847,,1515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9771,1,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),50597,A,,CHEMBL873821,,1515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9772,1,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,A,,CHEMBL626079,,1515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9773,1,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,A,,CHEMBL626080,,1515,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9774,1,,,Half life period was evaluated in rat plasma,50597,A,,CHEMBL626081,,5491,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9775,1,,,Half life period was evaluated in rat plasma; Not tested,50597,A,,CHEMBL875344,,5491,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9776,1,,,Half life period was evaluated in rats,50597,A,,CHEMBL626082,,1918,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9777,1,,,"Half life period was evaluated in rats, iv",50597,A,,CHEMBL626250,,1918,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9778,1,,,Half life period after intravenous administration at 5 mg/kg in rat,50597,A,,CHEMBL626251,,6113,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9779,1,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,A,,CHEMBL626252,,5546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9780,1,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,50597,A,,CHEMBL626253,,5553,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9781,1,,,Half life stability of compound was evaluated in rat plasma,50597,A,,CHEMBL626254,,4188,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9782,1,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,50597,A,,CHEMBL626255,,6215,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9783,1,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,A,,CHEMBL626256,,6141,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9784,1,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,A,,CHEMBL626257,,5182,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9785,1,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,50597,A,,CHEMBL626258,,5182,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9786,1,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,50597,A,,CHEMBL626259,,5710,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9787,1,,,Half in rat i.v.,50597,A,,CHEMBL626260,,5789,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9788,1,,,Half period in rat after intravenous administration,50597,A,,CHEMBL875345,,6011,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9789,1,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,50597,A,,CHEMBL626261,,17594,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,Liver,,9790,1,,,Half-life measured in in vitro Cathepsin B assay in rat liver,50597,A,,CHEMBL626262,,12357,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,9791,1,,,Half-life of compound was determined in rats,50597,A,,CHEMBL626263,,5210,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9792,1,,,Half-life at 10 mg/kg in rat upon intravenous administration,50597,A,,CHEMBL625270,,17596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9793,1,,,Half-life determined in rat,50597,A,,CHEMBL625271,,6672,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9794,1,,,Half-life determined in rat,50597,A,,CHEMBL625272,,6673,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Brain,,9795,1,,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,50597,A,,CHEMBL625273,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Plasma,,9796,1,,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",50597,A,,CHEMBL625274,,3741,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9797,1,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,A,,CHEMBL625275,,17671,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,9798,1,,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,50597,A,,CHEMBL625276,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9799,1,,,Half-life in rat plasma,50597,A,,CHEMBL625277,,17537,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9800,1,,,Half-life in rat plasma was determined,50597,A,,CHEMBL625278,,4965,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9801,1,,,Half-life in rat plasma; Not tested,50597,A,,CHEMBL625279,,17537,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Serum,,9802,1,,,Half-life in rat serum,50597,A,,CHEMBL625280,,6124,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,Serum,,9803,1,,,Half-life in rat serum; na is not available,50597,A,,CHEMBL876797,,6124,10116.0,Intermediate,,,1,N,Rattus norvegicus,1977.0
,BAO_0000218,,,9804,1,,,Half-life was calculated in rat,50597,A,,CHEMBL625281,,6078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9805,1,,,Half-life was calculated in rat plasma,50597,A,,CHEMBL873827,,17668,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9806,1,,,Half-life was determined,50597,A,,CHEMBL625282,,3185,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9807,1,,,Half-life was determined,50597,A,,CHEMBL625283,,4883,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9808,1,,,Half-life after administration of 20 mg/Kg oral dose in rat,50597,A,,CHEMBL625284,,2959,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9809,1,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,50597,A,,CHEMBL625285,,4029,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9810,1,,,Half-life after intravenous administration in female rat,50597,A,,CHEMBL625286,,4029,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9811,1,,,Half-life after intravenous administration in male rat,50597,A,,CHEMBL625287,,4029,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9812,1,,,Half-life after intravenous dose in rat,50597,A,,CHEMBL625288,,6180,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Liver,,9813,1,,,Half-life in a rat liver homogenate preparation,50597,A,,CHEMBL625289,,1557,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Plasma,,9814,1,,,Half-life in plasma of rat,50597,A,,CHEMBL625290,,12500,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9815,1,,,Half-life in plasma of rat at dose of 3-10 mgkg,50597,A,,CHEMBL876798,,12500,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9816,1,,,Half-life in rat,50597,A,,CHEMBL625291,,5064,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9817,1,,,Half-life in rat,50597,A,,CHEMBL625292,,5145,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9818,1,,,Half-life in rat,50597,A,,CHEMBL625293,,5147,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9819,1,,,Half-life in rat,50597,A,,CHEMBL622832,,5833,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9820,1,,,Half-life in rat,50597,A,,CHEMBL622833,,6596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9821,1,,,Half-life in rat,50597,A,,CHEMBL622834,,17655,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9822,1,,,Half-life in rat after oral administration at 10 mg/kg,50597,A,,CHEMBL622835,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9823,1,,,Half-life in rat after po administration at a dose of 10 mg/kg,50597,A,,CHEMBL622836,,17538,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9824,1,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,A,,CHEMBL622837,,17538,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9825,1,,,Half-life in rat at 3 mg/kg dose administered intravenously,50597,A,,CHEMBL622838,,10,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Brain,,9826,1,,,Half-life in rat brain homogenate,50597,A,,CHEMBL622839,,17669,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Plasma,,9827,1,,,Half-life in rat plasma,50597,A,,CHEMBL622840,,17065,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9828,1,,,Half-life in rats,50597,A,,CHEMBL622841,,4333,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9829,1,,,Half-life in Dawley rats,50597,A,,CHEMBL622842,,6827,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,Plasma,,9830,1,,,Half-life in vitro in rat plasma,50597,A,,CHEMBL622843,,889,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vitro,BAO_0000218,Plasma,,9831,1,,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,50597,A,,CHEMBL622844,,889,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9832,1,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",50597,A,,CHEMBL622845,,3747,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9833,1,,,The area under the curve of compound was measured at the dose of 100 umol/kg,50597,A,,CHEMBL622846,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9834,1,,,The area under the curve of compound was measured at the dose of 300 umol/kg,50597,A,,CHEMBL622847,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9835,1,,,The area under the curve of compound was measured at the dose of 30 umol/kg,50597,A,,CHEMBL622848,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9836,1,,,Bioavailability as oral AUC in rats,50597,A,,CHEMBL622849,,3360,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9837,1,,,The plasma concentration versus time curve (AUC) was determined,50597,A,,CHEMBL622850,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9838,1,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL876807,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9839,1,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL622851,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9840,1,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL622852,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9841,1,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,50597,A,,CHEMBL622853,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9842,1,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,50597,A,,CHEMBL622854,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9843,1,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,A,,CHEMBL622855,,17411,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9844,1,,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",50597,A,,CHEMBL622856,,14941,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9845,1,,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",50597,A,,CHEMBL622857,,14941,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9846,1,,,AUC in rat after po administration at a dose of 10 mg/kg,50597,A,,CHEMBL622858,,17538,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9847,1,,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,50597,A,,CHEMBL622859,,17752,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9848,1,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,50597,A,,CHEMBL622860,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9849,1,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,50597,A,,CHEMBL622861,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9850,1,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,50597,A,,CHEMBL622862,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9851,1,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,50597,A,,CHEMBL622863,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9852,1,,,Area under curve value 6 hr after po administration in rat,50597,A,,CHEMBL623817,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9853,1,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,A,,CHEMBL623818,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9854,1,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",50597,A,,CHEMBL623819,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9855,1,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,A,,CHEMBL623820,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9856,1,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,50597,A,,CHEMBL623821,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9857,1,,,AUC normalized for dose (AUCN) in rat,50597,A,,CHEMBL623822,,6642,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9858,1,,,Area under curve in rat after p.o. administration,50597,A,,CHEMBL623823,,6640,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9859,1,,,Area under curve in rat after p.o. administration,50597,A,,CHEMBL623824,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9860,1,,,Area under curve in rat after p.o. administration; Not determined,50597,A,,CHEMBL623825,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9861,1,,,Area under curve in rat after peroral administration,50597,A,,CHEMBL622070,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9862,1,,,Area under curve (carotid artery) value of the compound,50597,A,,CHEMBL622071,,3603,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9863,1,,,Bioavailability expressed as the area under curve of rat carotid artery,50597,A,,CHEMBL622072,,3550,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9864,1,,,Area under curve in male SD rats was observed after intravenous administration in rat,50597,A,,CHEMBL622073,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9865,1,,,Area under curve of the compound was determined,50597,A,,CHEMBL622074,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9866,1,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,50597,A,,CHEMBL622075,,5407,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9867,1,,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,50597,A,,CHEMBL622076,,17752,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9868,1,,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,50597,A,,CHEMBL622077,,17752,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9869,1,,,Area under curve (portal vein) value of the compound,50597,A,,CHEMBL622078,,3603,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9870,1,,,Bioavailability expressed as the area under curve of rat portal vein,50597,A,,CHEMBL622079,,3550,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9871,1,,,Area Under plasma concentration time curve in rat upon peroral administration,50597,A,,CHEMBL622080,,17655,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,9872,1,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,50597,A,,CHEMBL877612,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9873,1,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,50597,A,,CHEMBL622081,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9874,1,,,Compound was evaluated for oral bioavailability in rats,50597,A,,CHEMBL622082,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9875,1,,,Compound was evaluated for oral bioavailability in rats after iv administration,50597,A,,CHEMBL622083,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9876,1,,,Compound was evaluated for oral bioavailability in rats; 30-80,50597,A,,CHEMBL622084,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9877,1,,,Compound was evaluated for oral bioavailability in rats; 50-60,50597,A,,CHEMBL622085,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9878,1,,,Compound was evaluated for oral bioavailability in rats; no data,50597,A,,CHEMBL622086,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9879,1,,,Compound was evaluated for oral bioavailability in rats; peptide,50597,A,,CHEMBL622087,,17791,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Blood,,9880,1,,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",50597,A,,CHEMBL622088,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,9881,1,,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",50597,A,,CHEMBL622089,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,9882,1,,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",50597,A,,CHEMBL623685,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,9883,1,,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",50597,A,,CHEMBL623686,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Stomach,,9884,1,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL623687,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,9885,1,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL623688,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,9886,1,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL623689,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Stomach,,9887,1,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622485,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,945.0
In vivo,BAO_0000218,Thyroid gland,,9888,1,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622486,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,9889,1,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL877613,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,9890,1,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622487,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Thyroid gland,,9891,1,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622488,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,Heart,,9892,1,,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,A,,CHEMBL622489,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Urine,,9893,1,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,A,,CHEMBL622490,,6899,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Urine,,9894,1,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,A,,CHEMBL622491,,6899,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Liver,,9895,1,,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,50597,A,,CHEMBL622492,,6899,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Urine,,9896,1,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,A,,CHEMBL622493,,6899,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Urine,,9897,1,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,A,,CHEMBL622494,,6899,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Muscle tissue,,9898,1,,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,A,,CHEMBL622495,,8677,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,,,9899,1,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,50597,A,,CHEMBL622496,,6899,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Urine,,9900,1,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,A,,CHEMBL622497,,6899,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,,,9901,1,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,50597,A,,CHEMBL622498,,2189,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Urine,,9902,1,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,50597,A,,CHEMBL624918,,2189,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Urine,,9903,1,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,50597,A,,CHEMBL624919,,2189,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
In vivo,BAO_0000218,Blood,,9904,1,,,Biodistribution of compound in rat blood after 5 min of administration,50597,A,,CHEMBL624920,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,9905,1,,,Biodistribution of compound in rat blood after 5 min of administration.,50597,A,,CHEMBL624921,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Brain,,9906,1,,,Biodistribution of compound in rat brain after 5 min of administration,50597,A,,CHEMBL624922,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Heart,,9907,1,,,Biodistribution of compound in rat heart after 5 min of administration,50597,A,,CHEMBL624923,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,9908,1,,,Biodistribution of compound in rat heart after 5 min of administration.,50597,A,,CHEMBL624924,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Kidney,,9909,1,,,Biodistribution of compound in rat kidney after 5 min of administration,50597,A,,CHEMBL624925,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,9910,1,,,Biodistribution of compound in rat kidney after 5 min of administration.,50597,A,,CHEMBL624926,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Liver,,9911,1,,,Biodistribution of compound in rat liver after 5 min of administration,50597,A,,CHEMBL624927,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,9912,1,,,Biodistribution of compound in rat liver after 5 min of administration.,50597,A,,CHEMBL874402,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Lung,,9913,1,,,Biodistribution of compound in rat lung after 5 min of administration,50597,A,,CHEMBL624928,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,9914,1,,,Biodistribution of compound in rat lung after 5 min of administration.,50597,A,,CHEMBL624929,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Muscle tissue,,9915,1,,,Biodistribution of compound in rat muscle after 5 min of administration,50597,A,,CHEMBL624930,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,9916,1,,,Biodistribution of compound in rat muscle after 5 min of administration.,50597,A,,CHEMBL624931,,10839,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Heart,,9917,1,,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624932,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,9918,1,,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624933,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Liver,,9919,1,,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624934,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9920,1,,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624935,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,9921,1,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624936,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9922,1,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624937,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Spleen,,9923,1,,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624938,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,Spleen,,9924,1,,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624939,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
,BAO_0000218,,,9925,1,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL624940,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9926,1,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,A,,CHEMBL874403,,4043,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9927,1,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,50597,A,,CHEMBL624941,,1446,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Urine,,9928,1,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,50597,A,,CHEMBL624942,,9971,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,Urine,,9929,1,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,50597,A,,CHEMBL624943,,9971,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
In vivo,BAO_0000218,,,9930,1,,,% Bioavailability after 1 day of the drug administration in rats,50597,A,,CHEMBL624944,,5765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9931,1,,,% Bioavailability after 4 day of the drug administration in rats,50597,A,,CHEMBL624945,,5765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9932,1,,,Absolute bioavailability was evaluated in rat,50597,A,,CHEMBL624946,,4257,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9933,1,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,50597,A,,CHEMBL624947,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9934,1,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,50597,A,,CHEMBL624948,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9935,1,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,50597,A,,CHEMBL624949,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Kidney,,9936,1,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,50597,A,,CHEMBL622025,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9937,1,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,50597,A,,CHEMBL622026,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9938,1,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,50597,A,,CHEMBL622027,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,9939,1,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,50597,A,,CHEMBL622028,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Liver,,9940,1,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,50597,A,,CHEMBL622029,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9941,1,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,50597,A,,CHEMBL622208,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9942,1,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,50597,A,,CHEMBL622209,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,9943,1,,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,50597,A,,CHEMBL622210,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,9944,1,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,50597,A,,CHEMBL622211,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9945,1,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,50597,A,,CHEMBL622212,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9946,1,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,50597,A,,CHEMBL622213,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9947,1,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,50597,A,,CHEMBL874404,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Muscle tissue,,9948,1,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,50597,A,,CHEMBL620452,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9949,1,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,50597,A,,CHEMBL620453,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9950,1,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,50597,A,,CHEMBL620454,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9951,1,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,50597,A,,CHEMBL624067,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,,,9952,1,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,50597,A,,CHEMBL624068,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Female gonad,,9953,1,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,50597,A,,CHEMBL624069,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,992.0
,BAO_0000218,Female gonad,,9954,1,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,50597,A,,CHEMBL624070,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,992.0
,BAO_0000218,Female gonad,,9955,1,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,50597,A,,CHEMBL624071,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,992.0
,BAO_0000218,Uterus,,9956,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,50597,A,,CHEMBL624072,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,Uterus,,9957,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,50597,A,,CHEMBL624073,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,Uterus,,9958,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,50597,A,,CHEMBL624788,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,Uterus,,9959,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,50597,A,,CHEMBL624789,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,,,9960,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,50597,A,,CHEMBL624790,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9961,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,50597,A,,CHEMBL624791,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9962,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,50597,A,,CHEMBL624792,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9963,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,50597,A,,CHEMBL624793,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Muscle tissue,,9964,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,50597,A,,CHEMBL877491,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9965,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,50597,A,,CHEMBL624957,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9966,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,50597,A,,CHEMBL624958,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,Muscle tissue,,9967,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,50597,A,,CHEMBL624959,,13091,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
,BAO_0000218,,,9968,1,,,Dissociation constant was determined,50597,A,,CHEMBL624960,,11977,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9969,1,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",50597,A,,CHEMBL624961,,14941,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9970,1,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL624962,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9971,1,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL624963,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9972,1,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,50597,A,,CHEMBL624964,,4755,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9973,1,,,LogP value was evaluated in the in situ rat gut perfusion assay,50597,A,,CHEMBL624965,,589,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9974,1,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,A,,CHEMBL624966,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9975,1,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,50597,A,,CHEMBL624967,,5031,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9976,1,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,50597,A,,CHEMBL624968,,17764,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9977,1,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,A,,CHEMBL624969,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9978,1,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,50597,F,,CHEMBL624970,,2862,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9979,1,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,50597,A,,CHEMBL624971,,16423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9980,1,,,Half-life was evaluated after 20 uM/kg of peroral administration,50597,A,,CHEMBL624972,,16423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9981,1,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,A,,CHEMBL624973,,6005,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9982,1,,,Half-life was evaluated in plasma of rat,50597,A,,CHEMBL624974,,2938,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9983,1,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,50597,A,,CHEMBL624975,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9984,1,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,50597,A,,CHEMBL877492,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9985,1,,,Half-life was measured in rat after an iv dose of 1 mg/kg,50597,A,,CHEMBL624976,,6062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9986,1,,,Half-life period of compound in rats after peroral administration,50597,A,,CHEMBL624977,,6571,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,9987,1,,,Half-life period of compound was measured in rat plasma.,50597,A,,CHEMBL626848,,3136,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9988,1,,,Half-life period of compound was measured in rat plasma; ND is not determined,50597,A,,CHEMBL626849,,3136,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,9989,1,,,Half-life period of compound was measured in rat plasma; not determined,50597,A,,CHEMBL626850,,3136,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,9990,1,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,A,,CHEMBL626851,,4521,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9991,1,,,Half-life period in rat by iv administration,50597,A,,CHEMBL626852,,5871,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9992,1,,,Half-life period in rats following intravenous administration at 2 mg/kg,50597,A,,CHEMBL626853,,6077,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9993,1,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,A,,CHEMBL626854,,6679,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,9994,1,,,Half-life period was determined for the compound in rat,50597,A,,CHEMBL627486,,5144,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9995,1,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",50597,A,,CHEMBL627487,,4498,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9996,1,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",50597,A,,CHEMBL627488,,4498,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9997,1,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,50597,A,,CHEMBL627489,,1908,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9998,1,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,A,,CHEMBL627490,,6211,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,9999,1,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),50597,A,,CHEMBL873829,,5529,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10000,1,,,Half-life was determined in rat at a dose of 1 mpk i.v.,50597,A,,CHEMBL627655,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10001,1,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,A,,CHEMBL625994,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10002,1,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,A,,CHEMBL625995,,6444,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10003,1,,,Half-life in rat,50597,A,,CHEMBL625996,,5207,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,Plasma,,10004,1,,,In vitro half life in rat plasma,50597,A,,CHEMBL625850,,530,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vitro,BAO_0000218,Plasma,,10005,1,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",50597,A,,CHEMBL625851,,1116,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vitro,BAO_0000218,,,10006,1,,,In vitro half life in rat,50597,A,,CHEMBL625852,,3219,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10007,1,,,In vivo half life period after intravenous administration in rat,50597,A,,CHEMBL625853,,6109,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10008,1,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,A,,CHEMBL625854,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10009,1,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,A,,CHEMBL874450,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10010,1,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL625855,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10011,1,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL625856,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10012,1,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL625857,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10013,1,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL873831,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10014,1,,,Longer half-life in rat (i.v.) at 0.5 mpk,50597,A,,CHEMBL625858,,17853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10015,1,,,Longer half-life in rat (p.o.) at 2.0 mpk,50597,A,,CHEMBL625859,,17853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10016,1,,,Pharmacokinetic property (half life) in rat,50597,A,,CHEMBL625860,,3457,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10017,1,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,50597,A,,CHEMBL625861,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10018,1,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,50597,A,,CHEMBL625862,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10019,1,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,50597,A,,CHEMBL625863,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10020,1,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,50597,A,,CHEMBL625864,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10021,1,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,50597,A,,CHEMBL625865,,5739,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10022,1,,,Pharmacokinetic half time was determined intravenously in rats.,50597,A,,CHEMBL625866,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10023,1,,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,50597,A,,CHEMBL625867,,6567,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10024,1,,,Plasma half life of hydrolysis of the compound,50597,A,,CHEMBL625868,,2448,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10025,1,,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,50597,A,,CHEMBL625869,,5423,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10026,1,,,Plasma half life period was calculated in rat,50597,A,,CHEMBL874451,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10027,1,,,Plasma half-life in Sprague-Dawley rats,50597,A,,CHEMBL625870,,4514,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10028,1,,,Plasma half-life in Sprague-Dawley rats; Not determined,50597,A,,CHEMBL625871,,4514,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10029,1,,,Plasma half-life in rats,50597,A,,CHEMBL625872,,1500,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10030,1,,,Plasma half-life in rats; <MQL,50597,A,,CHEMBL625873,,1500,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10031,1,,,Plasma half-life period (0-8 h) was determined,50597,A,,CHEMBL625874,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10032,1,,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,50597,A,,CHEMBL625875,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10033,1,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,A,,CHEMBL625876,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10034,1,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,A,,CHEMBL631258,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10035,1,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,50597,A,,CHEMBL631259,,4956,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10036,1,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,50597,A,,CHEMBL631260,,4956,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Blood,,10037,1,,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",50597,A,,CHEMBL631261,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,10038,1,,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",50597,A,,CHEMBL631262,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,10039,1,,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",50597,A,,CHEMBL631263,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,,,10040,1,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",50597,A,,CHEMBL631264,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10041,1,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",50597,A,,CHEMBL631265,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10042,1,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",50597,A,,CHEMBL631266,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10043,1,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",50597,A,,CHEMBL631267,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10044,1,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",50597,A,,CHEMBL631268,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10045,1,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",50597,A,,CHEMBL631269,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10046,1,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",50597,A,,CHEMBL631270,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Heart,,10047,1,,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,A,,CHEMBL631271,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10048,1,,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",50597,A,,CHEMBL631272,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10049,1,,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",50597,A,,CHEMBL631273,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10050,1,,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",50597,A,,CHEMBL631274,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10051,1,,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",50597,A,,CHEMBL631275,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10052,1,,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",50597,A,,CHEMBL626984,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10053,1,,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",50597,A,,CHEMBL626985,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Liver,,10054,1,,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,A,,CHEMBL626986,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10055,1,,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",50597,A,,CHEMBL626987,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10056,1,,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",50597,A,,CHEMBL626988,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10057,1,,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",50597,A,,CHEMBL626989,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10058,1,,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",50597,A,,CHEMBL626990,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10059,1,,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",50597,A,,CHEMBL626991,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10060,1,,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",50597,A,,CHEMBL626992,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Lung,,10061,1,,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",50597,A,,CHEMBL626993,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,10062,1,,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",50597,A,,CHEMBL874593,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,10063,1,,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",50597,A,,CHEMBL626994,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,10064,1,,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",50597,A,,CHEMBL626995,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,10065,1,,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",50597,A,,CHEMBL626190,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,10066,1,,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",50597,A,,CHEMBL626191,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,10067,1,,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",50597,A,,CHEMBL626364,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Thyroid gland,,10068,1,,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",50597,A,,CHEMBL626365,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,10069,1,,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",50597,A,,CHEMBL626366,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,10070,1,,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",50597,A,,CHEMBL626367,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,10071,1,,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",50597,A,,CHEMBL626368,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,10072,1,,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",50597,A,,CHEMBL626369,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,Thyroid gland,,10073,1,,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",50597,A,,CHEMBL626370,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
In vivo,BAO_0000218,,,10074,1,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",50597,A,,CHEMBL626371,,4498,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10075,1,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",50597,A,,CHEMBL626372,,4498,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10076,1,,,Bioavailability after a dose of 10 mg/kg p.o.,50597,A,,CHEMBL626373,,3603,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10077,1,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,50597,A,,CHEMBL626374,,6215,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10078,1,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,50597,A,,CHEMBL626375,,5710,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10079,1,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),50597,A,,CHEMBL626376,,5710,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10080,1,,,Bioavailability in rat po was determined,50597,A,,CHEMBL626377,,5676,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10081,1,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,50597,A,,CHEMBL626378,,17667,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10082,1,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,50597,A,,CHEMBL626379,,17667,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10083,1,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,A,,CHEMBL626380,,6848,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10084,1,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,A,,CHEMBL626381,,6848,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10085,1,,,Bioavailability in rat,50597,A,,CHEMBL626382,,17267,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10086,1,,,Bioavailability in rat (Sprague-Dawley) (female),50597,A,,CHEMBL626383,,6362,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10087,1,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,A,,CHEMBL874652,,17671,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10088,1,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),50597,A,,CHEMBL626384,,17671,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10089,1,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,50597,A,,CHEMBL626385,,4333,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10090,1,,,Bioavailability in rat at an oral dose of 2 mg/kg,50597,A,,CHEMBL626386,,6077,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10091,1,,,Bioavailability in rat,50597,A,,CHEMBL626387,,3278,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10092,1,,,Bioavailability in rat,50597,A,,CHEMBL626388,,5964,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10093,1,,,Bioavailability in rat,50597,A,,CHEMBL626389,,4884,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10094,1,,,Bioavailability in rat,50597,A,,CHEMBL626390,,4905,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10095,1,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,50597,A,,CHEMBL626391,,4884,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10096,1,,,Bioavailability in rat,50597,A,,CHEMBL626392,,6850,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10097,1,,,Oral bioavailability in rat,50597,A,,CHEMBL626393,,2864,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10098,1,,,Bioavailability was determined in rat,50597,A,,CHEMBL623026,,5780,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10099,1,,,Bioavailability,50597,A,,CHEMBL623027,,1465,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10100,1,,,Bioavailability,50597,A,,CHEMBL623028,,5199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10101,1,,,Bioavailability in rat after 1 day dosing,50597,A,,CHEMBL623029,,5765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10102,1,,,Bioavailability in rat after 4 day dosing,50597,A,,CHEMBL623030,,5765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10103,1,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,50597,A,,CHEMBL623031,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10104,1,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,50597,A,,CHEMBL623032,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10105,1,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,50597,A,,CHEMBL623033,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10106,1,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,50597,A,,CHEMBL623034,,6518,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10107,1,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,A,,CHEMBL623035,,2083,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10108,1,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,A,,CHEMBL623036,,17260,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10109,1,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,A,,CHEMBL623037,,4956,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10110,1,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,50597,A,,CHEMBL623038,,4368,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10111,1,,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,50597,A,,CHEMBL874385,,17752,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,10112,1,,,Bioavailability in rat (Fisher) (fasted),50597,A,,CHEMBL623039,,1446,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10113,1,,,Bioavailability in monkey after po administration of 10 mg/kg dose,22224,A,,CHEMBL623040,,2891,9443.0,Intermediate,,,0,U,Primates,
In vivo,BAO_0000218,,,10114,1,,,Oral bioavailability in monkey (dose 10 mg/kg),22224,A,,CHEMBL623041,,2891,9443.0,Intermediate,,,0,U,Primates,
In vivo,BAO_0000218,,,10115,1,,,Bioavailability in rat,50597,A,,CHEMBL623741,,6672,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10116,1,,,Bioavailability in rat,50597,A,,CHEMBL623742,,6673,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10117,1,,,Bioavailability in rat,50597,A,,CHEMBL623743,,17655,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10118,1,,,Bioavailability in rat,50597,A,,CHEMBL623744,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10119,1,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),50597,A,,CHEMBL623745,,17853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10120,1,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),50597,A,,CHEMBL623746,,4521,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10121,1,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),50597,A,,CHEMBL623747,,4940,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10122,1,,,Bioavailability in rat after po administration of 30 mg/kg dose,22224,A,,CHEMBL623748,,2891,10116.0,Intermediate,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,10123,1,,,Bioavailability in rat after po administration of 30 mg/kg dose,22224,A,,CHEMBL623916,,2891,10116.0,Intermediate,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,10124,1,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,A,,CHEMBL623917,,4521,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10125,1,,,Bioavailability in rat (dose 2 mg/kg i.v.),50597,A,,CHEMBL623918,,17686,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10126,1,,,Bioavailability in rat,50597,A,,CHEMBL874386,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10127,1,,,Bioavailability in rat; Only traces detected in rat plasma,50597,A,,CHEMBL623919,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,10128,1,,,Bioavailability in rat,50597,A,,CHEMBL623920,,5064,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10129,1,,,Bioavailability upon oral administration of compound,50597,A,,CHEMBL623148,,5147,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10130,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),50597,A,,CHEMBL623149,,1916,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10131,1,,,Bioavailability in rat,50597,A,,CHEMBL623150,,6049,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10132,1,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",50597,A,,CHEMBL623151,,1445,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10133,1,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",50597,A,,CHEMBL623152,,1445,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10134,1,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,50597,F,,CHEMBL623153,,2862,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10135,1,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,50597,F,,CHEMBL623154,,2862,10116.0,Expert,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10136,1,,,In vitro and metabolic stability was determined,50597,A,,CHEMBL623155,,4194,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10137,1,,,In vitro metabolic stability in rat hepatocytes,50597,A,,CHEMBL623156,,4194,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10138,1,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,50597,A,,CHEMBL623157,,5486,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,Liver,,10139,1,,,Metabolic rate for compound was observed in rat hepatocytes,50597,A,401.0,CHEMBL623158,Hepatocyte,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,10140,1,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,50597,A,,CHEMBL623159,,5600,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10141,1,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),50597,A,,CHEMBL874390,,14294,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10142,1,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),50597,A,,CHEMBL623160,,14294,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10143,1,,,Metabolism of compound in rat S9 microsomes; Trace,50597,A,,CHEMBL623161,,14294,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10144,1,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,50597,A,,CHEMBL623162,,17847,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10145,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,50597,A,,CHEMBL623163,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10146,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,50597,A,,CHEMBL623164,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10147,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,50597,A,,CHEMBL623165,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10148,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,50597,A,,CHEMBL623166,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10149,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,50597,A,,CHEMBL624983,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10150,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,50597,A,,CHEMBL624984,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10151,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,50597,A,,CHEMBL624985,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10152,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,50597,A,,CHEMBL622970,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10153,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,50597,A,,CHEMBL622971,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10154,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,50597,A,,CHEMBL622972,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10155,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,50597,A,,CHEMBL622973,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10156,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,50597,A,,CHEMBL622974,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10157,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,50597,A,,CHEMBL622975,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10158,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,50597,A,,CHEMBL622976,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10159,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,50597,A,,CHEMBL622977,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10160,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,A,,CHEMBL624351,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10161,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,A,,CHEMBL624352,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10162,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,A,,CHEMBL624353,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10163,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,A,,CHEMBL622397,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10164,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,50597,A,,CHEMBL622398,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10165,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,50597,A,,CHEMBL622399,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10166,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,A,,CHEMBL622400,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10167,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,A,,CHEMBL628428,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10168,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,50597,A,,CHEMBL628590,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10169,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,A,,CHEMBL628591,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10170,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,50597,A,,CHEMBL628592,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10171,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,A,,CHEMBL628593,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10172,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,50597,A,,CHEMBL875333,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10173,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,A,,CHEMBL628594,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,10174,1,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,50597,A,,CHEMBL628595,,4969,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10175,1,,,Stability in rat plasma was determined,50597,A,,CHEMBL628596,,6737,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10176,1,,,Stability in rat plasma was determined; ND= no data,50597,A,,CHEMBL628597,,6737,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10177,1,,,Tested for plasma half life period in rat (0-8 hr),50597,A,,CHEMBL628598,,5089,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10178,1,,,Tested for plasma half life period in rat (0-8 hr); Not determined,50597,A,,CHEMBL628599,,5089,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,10179,1,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,50597,A,,CHEMBL628600,,1466,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10180,1,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,50597,A,,CHEMBL628601,,1466,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10181,1,,,Tested for the half life in rat,50597,A,,CHEMBL628602,,4950,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,,,10182,1,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,50597,A,,CHEMBL628603,,2412,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,,,10183,1,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,50597,A,,CHEMBL628604,,2412,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,,,10184,1,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,50597,A,,CHEMBL628605,,2412,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,,,10185,1,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,50597,A,,CHEMBL628606,,2412,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vitro,BAO_0000218,,,10186,1,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,50597,A,,CHEMBL628607,,2412,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10187,1,,,The biological half life the compound was measured at the dose of 100 umol/kg,50597,A,,CHEMBL628608,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10188,1,,,The biological half life the compound was measured at the dose of 30 umol/kg,50597,A,,CHEMBL628609,,15022,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,10189,1,,,The compound was evaluated for plasma half life period in rat,50597,A,,CHEMBL628610,,406,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,10190,1,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL873819,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10191,1,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",50597,A,,CHEMBL628611,,15078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10192,1,,,The pharmacokinetic parameter half-life period in vivo in rats,50597,A,,CHEMBL628612,,5247,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10193,1,,,"The pharmacokinetic property, Half-life was determined",50597,A,,CHEMBL628613,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10194,1,,,"The pharmacokinetic property, Half-life in rat in vivo",50597,A,,CHEMBL628614,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10195,1,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",50597,A,,CHEMBL628615,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10196,1,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",50597,A,,CHEMBL628616,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Plasma,,10197,1,,,The plasma half life period in rats,50597,A,,CHEMBL627924,,3918,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Liver,,10198,1,,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,50597,A,,CHEMBL627925,,2906,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,,,10199,1,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,A,,CHEMBL627926,,6467,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10200,1,,,t1/2 (apparent elimination)of the compound was determined,50597,A,,CHEMBL627927,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10201,1,,,t1/2 value in rat,50597,A,,CHEMBL627928,,3788,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10202,1,,,Half life in rat,50597,A,,CHEMBL627539,,17796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10203,1,,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,A,,CHEMBL876790,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,10204,1,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,50597,A,,CHEMBL858186,,5983,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10205,1,,,Half-life period in fasted rats,50597,A,,CHEMBL627540,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10206,1,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,50597,A,,CHEMBL627541,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10207,1,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,50597,A,,CHEMBL627715,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10208,1,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,A,,CHEMBL627716,,429,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10209,1,,,Maximum time required to achieve Cmax was determined in rat,50597,A,,CHEMBL627717,,17655,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10210,1,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,A,,CHEMBL627718,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10211,1,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,A,,CHEMBL627719,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10212,1,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,50597,A,,CHEMBL627720,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10213,1,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,50597,A,,CHEMBL627721,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10214,1,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,50597,A,,CHEMBL627722,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10215,1,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL627723,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10216,1,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL626058,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10217,1,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL626059,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10218,1,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL626060,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10219,1,,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,A,,CHEMBL626061,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,10220,1,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL876791,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10221,1,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,A,,CHEMBL626062,,4723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10222,1,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,50597,A,,CHEMBL626063,,4756,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10223,1,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,50597,A,,CHEMBL626064,,4756,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10224,1,,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,A,,CHEMBL626065,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10225,1,,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,A,,CHEMBL626066,,17720,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,10226,1,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,50597,A,,CHEMBL626067,,1466,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10227,1,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,50597,F,,CHEMBL626068,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10228,1,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,50597,F,,CHEMBL626069,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10229,1,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,50597,F,,CHEMBL626070,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10230,1,,,Percent total excretion of N-methoxyacetaminophen glucuronide,50597,F,,CHEMBL626071,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10231,1,,,Percent total excretion of N-methoxyacetaminophen sulfate,50597,F,,CHEMBL626072,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10232,1,,,Percent total excretion of acetaminophen,50597,F,,CHEMBL626073,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Thyroid gland,,10233,1,,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",50597,A,,CHEMBL626741,,7768,10116.0,Intermediate,,,1,N,Rattus norvegicus,2046.0
,BAO_0000218,,,10234,1,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",50597,A,,CHEMBL626742,,17655,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10235,1,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,50597,A,,CHEMBL626743,,17735,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10236,1,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,A,,CHEMBL876792,,5960,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10237,1,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,A,,CHEMBL626744,,17735,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10238,1,,,Compound was tested for antidiuretic activity in rats,50597,A,,CHEMBL626745,,7116,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10239,1,,,AUC in rat after 3mg/kg oral dose,50597,A,,CHEMBL626746,,4878,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,10240,1,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,50597,A,,CHEMBL626747,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10241,1,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,50597,A,,CHEMBL626748,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10242,1,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,50597,A,,CHEMBL626749,,16367,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10243,1,,,Oral Bioavailability was determined,50597,A,,CHEMBL626750,,16366,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10244,1,,,Oral bioavailability in rat,50597,A,,CHEMBL626751,,4426,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10245,1,,,Oral bioavailability in rat; Not performed.,50597,A,,CHEMBL626913,,4426,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10246,1,,,Bioavailability,50597,A,,CHEMBL626914,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10247,1,,,Bioavailability was determined; ND denotes no data,50597,A,,CHEMBL626915,,5041,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10248,1,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,50597,A,,CHEMBL626916,,1500,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10249,1,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,50597,A,,CHEMBL626917,,1500,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10250,1,,,Binding towards rat plasma protein at 10 uM,50597,A,,CHEMBL626918,,17409,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10251,1,,,Binding towards rat plasma protein at 100 uM,50597,A,,CHEMBL626919,,17409,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10252,1,,,Bioavailability in rat (dose 20 mg/kg p.o.),50597,A,,CHEMBL626920,,2959,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10253,1,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,A,,CHEMBL621976,,13501,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10254,1,,,Bioavailability in rat after 5 mg/kg oral gavage,50597,A,,CHEMBL877599,,6567,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10255,1,,,Bioavailability in rat,50597,A,,CHEMBL621977,,6571,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10256,1,,,Bioavailability in rat (dose 1 mg/kg i.v.),50597,A,,CHEMBL621978,,6715,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10257,1,,,Bioavailability in rat (dose 3 mg/kg p.o.),50597,A,,CHEMBL621979,,6715,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10258,1,,,Oral bioavailability in rat,50597,A,,CHEMBL621980,,2932,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10259,1,,,Bioavailability of the compound in rats after administration of 30 mg/kg,50597,A,,CHEMBL621981,,4171,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10260,1,,,Bioavailability after administration of 10 mg/kg in rats,50597,A,,CHEMBL621982,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10261,1,,,Bioavailability after administration of 2 mg/kg in rats,50597,A,,CHEMBL882953,,17509,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10262,1,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,50597,A,,CHEMBL621983,,4527,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10263,1,,,Bioavailability in dogs was determined; high,50597,A,,CHEMBL621984,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10264,1,,,Bioavailability in monkey after intravenous administration at 1 mpk,50597,A,,CHEMBL621985,,6659,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10265,1,,,Bioavailability in monkey after peroral administration at 10 mpk,50597,A,,CHEMBL621986,,6659,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10266,1,,,Bioavailability in rat after intravenous administration at 1 mpk,50597,A,,CHEMBL621987,,6659,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10267,1,,,Bioavailability in rat after intravenous administration at 2 mpk,50597,F,,CHEMBL877600,,6659,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10268,1,,,Bioavailability in rat after peroral administration at 30 mpk,50597,A,,CHEMBL621988,,6659,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10269,1,,,Bioavailability in rat after peroral administration at at 100 mpk,50597,F,,CHEMBL621989,,6659,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10270,1,,,Bioavailability in rats was evaluated,50597,A,,CHEMBL621990,,6597,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10271,1,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,50597,A,,CHEMBL621991,,1202,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10272,1,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,50597,A,,CHEMBL621992,,1202,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10273,1,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,50597,A,,CHEMBL621993,,1202,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10274,1,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,50597,A,,CHEMBL621994,,1202,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10275,1,,,Bioavailability in rat,50597,A,,CHEMBL621995,,5207,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10276,1,,,Bioavailability in rat,50597,A,,CHEMBL621996,,5970,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10277,1,,,Oral bioavailability in rat (dose 10 mg/kg),50597,A,,CHEMBL621997,,17538,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10278,1,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,A,,CHEMBL621998,,17538,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10279,1,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,50597,A,,CHEMBL621999,,1466,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10280,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622000,,2879,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10281,1,,,Bioavailability was measured in rat after oral administration; 2-4,50597,A,,CHEMBL622001,,2879,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10282,1,,,Bioavailability was measured in rat after oral administration; 3-7,50597,A,,CHEMBL622002,,2879,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10283,1,,,Bioavailability in rat (intraduodenal administration),50597,A,,CHEMBL622003,,3777,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10284,1,,,Bioavailability in rat (intraduodenal administration),50597,A,,CHEMBL877601,,3777,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10285,1,,,Oral bioavailability in rat,50597,A,,CHEMBL624871,,3777,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10286,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622004,,3777,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10287,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),50597,A,,CHEMBL882954,,5423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10288,1,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,50597,A,,CHEMBL622005,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10289,1,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,50597,A,,CHEMBL622006,,16365,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10290,1,,,Bioavailability was measured in rat,50597,A,,CHEMBL622007,,4239,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10291,1,,,Bioavailability was reported,50597,A,,CHEMBL622008,,5438,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10292,1,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,A,,CHEMBL622009,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10293,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,A,,CHEMBL622010,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10294,1,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,A,,CHEMBL622011,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10295,1,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),50597,A,,CHEMBL622012,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10296,1,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),50597,A,,CHEMBL622013,,4199,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10297,1,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,A,,CHEMBL622014,,4890,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10298,1,,,Bioavailability was determined at 3 mg/kg po dose in rats,50597,A,,CHEMBL624749,,2792,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10299,1,,,Oral bioavailability in rat (dose 2 mg/kg),50597,A,,CHEMBL624750,,5529,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10300,1,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",50597,A,,CHEMBL624751,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10301,1,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,A,,CHEMBL624752,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10302,1,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,A,,CHEMBL624753,,6685,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10303,1,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,50597,A,,CHEMBL624754,,6005,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10304,1,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,A,,CHEMBL624755,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10305,1,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,A,,CHEMBL624756,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10306,1,,,Bioavailability in rat,50597,A,,CHEMBL624757,,6103,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10307,1,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,A,,CHEMBL624758,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10308,1,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,A,,CHEMBL622270,,6410,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10309,1,,,Bioavailability in rat (Sprague-Dawley),50597,A,,CHEMBL622271,,5353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10310,1,,,Bioavailability in rat at the dose of 2 mg/kg,50597,A,,CHEMBL622272,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10311,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622273,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10312,1,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,A,,CHEMBL622274,,5809,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10313,1,,,Bioavailability value of compound in rats was determined after peroral administration,50597,A,,CHEMBL622275,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10314,1,,,Oral bioavailability in rat (dose 20 mg/kg),50597,A,,CHEMBL622276,,3634,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10315,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622277,,3341,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10316,1,,,Oral bioavailability in rat (dose 5 mg/kg),50597,A,,CHEMBL622278,,2690,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10317,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622279,,3184,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10318,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622280,,740,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10319,1,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,50597,A,,CHEMBL624083,,1806,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10320,1,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,50597,A,,CHEMBL624084,,4891,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10321,1,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),50597,A,,CHEMBL624085,,3634,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10322,1,,,Compound was tested for bioavailability in rats,50597,A,,CHEMBL624086,,64,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10323,1,,,Bioavailability in rat,50597,A,,CHEMBL624087,,4839,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10324,1,,,Oral bioavailability in rat,50597,A,,CHEMBL624088,,1094,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10325,1,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,22224,A,,CHEMBL624089,,5005,9544.0,Intermediate,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,10326,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),22224,A,,CHEMBL624090,,5005,10116.0,Intermediate,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,10327,1,,,Evaluated for the bioavailability in rat (in vivo),50597,A,,CHEMBL624091,,4687,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10328,1,,,F value of compound in rats was determined after peroral administration,50597,A,,CHEMBL624092,,17804,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10329,1,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL624093,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10330,1,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL624094,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10331,1,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL624095,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10332,1,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,A,,CHEMBL624096,,5974,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10333,1,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",50597,A,,CHEMBL624097,,1088,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10334,1,,,Maximum fall in carotid flow in rat,50597,A,,CHEMBL624098,,1742,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10335,1,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,50597,A,,CHEMBL874392,,4689,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10336,1,,,Oral bioavailability in rat (dose 5 mg/kg),50597,A,,CHEMBL624099,,2463,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10337,1,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,A,,CHEMBL624100,,5654,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10338,1,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,A,,CHEMBL624101,,5654,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10339,1,,,Oral bioavailability in rat (male Wistar),50597,A,,CHEMBL624102,,6874,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10340,1,,,Oral bioavailability after administration (30 mg/kg) in rat; good,50597,A,,CHEMBL624103,,5633,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10341,1,,,Oral bioavailability at the dose of 2 mg/kg in rat,50597,A,,CHEMBL624104,,5496,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10342,1,,,Oral bioavailability determined in rats,50597,A,,CHEMBL624105,,2358,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10343,1,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),50597,A,,CHEMBL624106,,16456,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10344,1,,,Oral bioavailability in rat (dose single 10 mg/kg),50597,A,,CHEMBL624107,,5302,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10345,1,,,Oral bioavailability in rat (dose single 10 mg/kg),50597,A,,CHEMBL623943,,5302,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10346,1,,,Oral bioavailability in rat (dose 5 mg/kg,50597,A,,CHEMBL623944,,5302,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10347,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,50597,A,,CHEMBL623945,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10348,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,50597,A,,CHEMBL623946,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10349,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,50597,A,,CHEMBL623947,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10350,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,50597,A,,CHEMBL623948,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10351,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,50597,A,,CHEMBL623949,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10352,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,50597,A,,CHEMBL623950,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10353,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,50597,A,,CHEMBL874398,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10354,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,50597,A,,CHEMBL623951,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10355,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,50597,A,,CHEMBL623952,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10356,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,50597,A,,CHEMBL623953,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10357,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,50597,A,,CHEMBL623954,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10358,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,50597,A,,CHEMBL623955,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10359,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,50597,A,,CHEMBL623956,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10360,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,50597,A,,CHEMBL627807,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10361,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,50597,A,,CHEMBL627808,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10362,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,50597,A,,CHEMBL627809,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10363,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,50597,A,,CHEMBL627810,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10364,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",50597,A,,CHEMBL627811,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10365,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",50597,A,,CHEMBL627812,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10366,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",50597,A,,CHEMBL627813,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10367,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",50597,A,,CHEMBL627814,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10368,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",50597,A,,CHEMBL875336,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10369,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",50597,A,,CHEMBL627815,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10370,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",50597,A,,CHEMBL627816,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10371,1,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",50597,A,,CHEMBL627817,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10372,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",50597,A,,CHEMBL627818,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10373,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",50597,A,,CHEMBL627819,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10374,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",50597,A,,CHEMBL627820,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10375,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",50597,A,,CHEMBL627821,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10376,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,A,,CHEMBL628464,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10377,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,A,,CHEMBL626239,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10378,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,50597,A,,CHEMBL626240,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10379,1,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,A,,CHEMBL626241,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10380,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,50597,A,,CHEMBL626242,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10381,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,50597,A,,CHEMBL626243,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10382,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,A,,CHEMBL626244,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10383,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,50597,A,,CHEMBL626907,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10384,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,A,,CHEMBL626908,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10385,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,A,,CHEMBL626909,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10386,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,A,,CHEMBL626910,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10387,1,,,Percent total excretion of acetaminophen cysteine conjugate,50597,F,,CHEMBL875342,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10388,1,,,Percent total excretion of acetaminophen glucuronide,50597,F,,CHEMBL626911,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10389,1,,,Percent total excretion of acetaminophen sulfate,50597,F,,CHEMBL626912,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10390,1,,,Percent total excretion of acetaminophen-mercapturic acid,50597,F,,CHEMBL627065,,7449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Urine,,10391,1,,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,50597,A,,CHEMBL627066,,3172,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
In vivo,BAO_0000218,,,10392,1,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,A,,CHEMBL627067,,16456,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Muscle tissue,,10393,1,,,Biodistribution of compound in rat muscle after 5 min of administration,22224,A,,CHEMBL627068,,10839,8656.0,Autocuration,,,0,U,ratrat,2385.0
In vivo,BAO_0000218,Muscle tissue,,10394,1,,,Biodistribution of compound in rat muscle after 5 min of administration.,22224,A,,CHEMBL627069,,10839,8656.0,Autocuration,,,0,U,ratrat,2385.0
In vivo,BAO_0000218,,,10395,1,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,A,,CHEMBL627070,,5334,9940.0,Autocuration,,,0,U,Ovis aries,
In vivo,BAO_0000218,,,10396,1,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,A,,CHEMBL627071,,5334,9940.0,Autocuration,,,0,U,Ovis aries,
In vivo,BAO_0000218,,,10397,1,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,A,,CHEMBL627072,,5334,9940.0,Autocuration,,,0,U,Ovis aries,
In vivo,BAO_0000218,,,10398,1,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,A,,CHEMBL627073,,5334,9940.0,Autocuration,,,0,U,Ovis aries,
In vivo,BAO_0000218,,,10399,1,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,A,,CHEMBL625387,,5334,9940.0,Autocuration,,,0,U,Ovis aries,
In vivo,BAO_0000218,,,10400,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,A,,CHEMBL625388,,5334,9940.0,Autocuration,,,0,U,Ovis aries,
In vivo,BAO_0000218,Plasma,,10401,1,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,A,,CHEMBL625389,,5334,9940.0,Autocuration,,,0,U,Ovis aries,1969.0
In vivo,BAO_0000218,Plasma,,10402,1,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,A,,CHEMBL875343,,5334,9940.0,Autocuration,,,0,U,Ovis aries,1969.0
,BAO_0000218,,,10403,1,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),50497,A,,CHEMBL876795,,1735,8570.0,Intermediate,,,1,N,Serpentes,
,BAO_0000218,,,10404,1,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,50497,A,,CHEMBL626552,,1469,8570.0,Intermediate,,,1,N,Serpentes,
,BAO_0000218,,,10405,1,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,50497,A,,CHEMBL626553,,1336,8570.0,Intermediate,,,1,N,Serpentes,
,BAO_0000366,Plasma,,10406,1,,,The human biological plasma half life of the compound,22224,A,,CHEMBL626554,,12403,9606.0,Autocuration,,,0,U,Homo sapiens,1969.0
,BAO_0000218,Urine,,10407,1,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,A,,CHEMBL626555,,8151,10116.0,Intermediate,,,1,N,Rattus norvegicus,1088.0
,BAO_0000218,,,10408,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,50597,A,,CHEMBL626556,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10409,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,50597,A,,CHEMBL626557,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10410,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,50597,A,,CHEMBL626558,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10411,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,A,,CHEMBL626559,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10412,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,A,,CHEMBL626560,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10413,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,A,,CHEMBL876803,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10414,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,50597,A,,CHEMBL627964,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10415,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,50597,A,,CHEMBL627965,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10416,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,50597,A,,CHEMBL627966,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10417,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,A,,CHEMBL627967,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10418,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,A,,CHEMBL627968,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10419,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,A,,CHEMBL627969,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10420,1,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,A,,CHEMBL627970,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Blood,,10421,1,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,50597,A,,CHEMBL627971,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,10422,1,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,50597,A,,CHEMBL627972,,8004,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000357,,,10423,1,,,Dissociation constant against binding to human cyclophilin A,180,B,,CHEMBL856029,,15917,9606.0,Expert,,,9,D,Homo sapiens,
,BAO_0000019,,,10424,1,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,11591,B,,CHEMBL627973,,12396,9913.0,Expert,,,8,H,Bos taurus,
,BAO_0000019,,,10425,1,,,-Log C was determined by performing the electroshock minimum test,22224,A,,CHEMBL627974,,7065,,Autocuration,,,0,U,,
,BAO_0000019,,,10426,1,,,-Log C was determined by performing the foot shock test,22224,A,,CHEMBL627975,,7065,,Autocuration,,,0,U,,
,BAO_0000019,,,10427,1,,,-Log C was determined by performing the incl screen test,22224,A,,CHEMBL627976,,7065,,Autocuration,,,0,U,,
,BAO_0000019,,,10428,1,,,-Log C was determined by performing the maximum electroshock test,22224,A,,CHEMBL627977,,7065,,Autocuration,,,0,U,,
,BAO_0000019,,,10429,1,,,-Log C was determined by performing the pentylenetetrazole test,22224,A,,CHEMBL627978,,7065,,Autocuration,,,0,U,,
,BAO_0000019,,,10430,1,,,Tested for experimental arotinoid inhibitory dose,22224,A,,CHEMBL627979,,12415,,Autocuration,,,0,U,,
,BAO_0000019,,,10431,1,,,Negative log transformed activity,22224,A,,CHEMBL876804,,10256,,Autocuration,,,0,U,,
,BAO_0000019,,,10432,1,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",22224,A,,CHEMBL627980,,7991,,Autocuration,,,0,U,,
,BAO_0000218,,,10433,1,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,50512,A,,CHEMBL627981,,14342,10141.0,Intermediate,,,1,N,Cavia porcellus,
,BAO_0000218,,,10434,1,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,50512,A,,CHEMBL627982,,14342,10141.0,Intermediate,,,1,N,Cavia porcellus,
,BAO_0000218,,,10435,1,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,50512,A,,CHEMBL627983,,14342,10141.0,Intermediate,,,1,N,Cavia porcellus,
,BAO_0000218,Ileum,,10436,1,,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,50512,A,,CHEMBL627984,,14342,10141.0,Intermediate,,,1,N,Cavia porcellus,2116.0
,BAO_0000100,,,10437,1,,,Solubility in water was determined; values expressed as -log,22229,P,,CHEMBL627985,,6047,,Autocuration,,,0,U,,
,BAO_0000019,,,10438,1,,,Ratio of Kcat to that of Km was determined,22224,A,,CHEMBL627986,,17269,,Autocuration,,,0,U,,
,BAO_0000019,,,10439,1,,,Observed first order rate constant,22224,A,,CHEMBL627987,,10026,,Autocuration,,,0,U,,
,BAO_0000019,,,10440,1,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,22224,A,,CHEMBL627988,,14583,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10441,1,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,50597,A,,CHEMBL627989,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10442,1,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,50597,A,,CHEMBL627990,,2661,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10443,1,,,Oral Bioavailability after administration of 10 mg/kg in male rat,50597,A,,CHEMBL876805,,4029,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10444,1,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),50597,A,,CHEMBL627991,,17735,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10445,1,,,Oral bioavailability in rat,50597,A,,CHEMBL627992,,4576,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10446,1,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,A,,CHEMBL627993,,17582,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10447,1,,,Oral bioavailability at 1 mg/kg was determined in rat,50597,A,,CHEMBL622817,,17651,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10448,1,,,Oral bioavailability at 10 mg/kg was determined in rat,50597,A,,CHEMBL622818,,17651,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10449,1,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",50597,A,,CHEMBL622819,,17670,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10450,1,,,Oral bioavailability in rat,50597,A,,CHEMBL872267,,5045,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10451,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622820,,1696,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10452,1,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,50597,A,,CHEMBL622821,,17764,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10453,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622822,,6448,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10454,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622823,,6596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10455,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622824,,17547,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10456,1,,,Oral bioavailability in rat at a dose of 3 mg/kg,50597,A,,CHEMBL622825,,17771,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10457,1,,,Oral bioavailability in rat after oral administration at 10 mg/kg,50597,A,,CHEMBL622901,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10458,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622902,,4558,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10459,1,,,Oral bioavailability in rat,50597,A,,CHEMBL621844,,17596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10460,1,,,Oral bioavailability in Dawley rats,50597,A,,CHEMBL621845,,6827,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10461,1,,,Oral bioavailability,50597,A,,CHEMBL621846,,4026,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10462,1,,,Oral bioavailability in rat (dose 30 mg/kg),50597,A,,CHEMBL621847,,10,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10463,1,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,A,,CHEMBL877609,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10464,1,,,Bioavailability in rat (dose 3 mg/kg i.v.),50597,A,,CHEMBL621848,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10465,1,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,A,,CHEMBL621849,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10466,1,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,A,,CHEMBL622030,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10467,1,,,Percent oral bioavailability determined in rats,50597,A,,CHEMBL622031,,4796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10468,1,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,A,,CHEMBL622032,,4883,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10469,1,,,The compound was evaluated for bioavailability in rats; 32-51,50597,A,,CHEMBL622033,,2137,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10470,1,,,Bioavailability in rat (dose 20 mg/kg p.o.),50597,A,,CHEMBL622034,,2959,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10471,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622035,,1361,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10472,1,,,Bioavailability percent in rat at the dose of 2 mg/kg,50597,A,,CHEMBL882966,,4727,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10473,1,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,50597,A,,CHEMBL622036,,16423,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10474,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622037,,5206,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10475,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622038,,6448,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10476,1,,,Bioavailability in rats,50597,A,,CHEMBL622039,,17723,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Blood,,10477,1,,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,50597,A,,CHEMBL622040,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,10478,1,,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622041,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,10479,1,,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622042,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,10480,1,,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL622043,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,10481,1,,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL622044,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Bone,,10482,1,,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622045,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,10483,1,,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622046,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,10484,1,,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL622047,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Bone,,10485,1,,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL877610,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,10000001.0
In vivo,BAO_0000218,Brain,,10486,1,,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622048,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,10487,1,,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622049,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,10488,1,,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL622050,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,10489,1,,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL622051,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,,,10490,1,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622052,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10491,1,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622053,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10492,1,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL622054,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10493,1,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL622055,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10494,1,,,Oral bioavailability in rats was determined; High,50597,A,,CHEMBL622056,,5237,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10495,1,,,Oral bioavailability in the rat was determined,50597,A,,CHEMBL622057,,5503,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10496,1,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,50597,A,,CHEMBL628008,,15765,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10497,1,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),50597,A,,CHEMBL622058,,15660,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10498,1,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL622059,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10499,1,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL622060,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10500,1,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL622061,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10501,1,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,A,,CHEMBL622062,,5978,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10502,1,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,50597,A,,CHEMBL622063,,5656,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10503,1,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,A,,CHEMBL877611,,3598,10116.0,Expert,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10504,1,,,Oral bioavailability of compound in Sprague Dawley rats,50597,A,,CHEMBL622064,,4216,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10505,1,,,Oral bioavailability of compound in rat,50597,A,,CHEMBL622065,,17839,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10506,1,,,Oral bioavailability in rat (dose 2 mg/kg),50597,A,,CHEMBL622066,,6570,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10507,1,,,Oral bioavailability of compound in rat was determined,50597,A,,CHEMBL622067,,5334,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10508,1,,,Oral bioavailability of compound in rats,50597,A,,CHEMBL622068,,6886,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10509,1,,,Oral bioavailability of compound was determined in rats,50597,A,,CHEMBL622069,,5210,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10510,1,,,Oral bioavailability at a dose of 30 mg/kg in rats,50597,A,,CHEMBL624796,,4170,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10511,1,,,Oral bioavailability in rat (dose 10 mg/kg),50597,A,,CHEMBL624797,,6028,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10512,1,,,Oral bioavailability in rat (dose 10 mg/kg),50597,A,,CHEMBL623053,,6028,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10513,1,,,Oral bioavailability evaluated in rat,50597,A,,CHEMBL623054,,6078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10514,1,,,Oral bioavailability in fasted rat,50597,A,,CHEMBL623055,,6168,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10515,1,,,Oral bioavailability in fed rat,50597,A,,CHEMBL623056,,6168,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10516,1,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),50597,A,,CHEMBL623057,,5160,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10517,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623058,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10518,1,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,A,,CHEMBL623059,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10519,1,,,Oral bioavailability in rat after administration of 10 mg/kg po,50597,A,,CHEMBL623060,,6535,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10520,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623061,,4194,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10521,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623062,,6230,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10522,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623063,,6619,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10523,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623064,,17607,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10524,1,,,Oral bioavailability in ratrs,50597,A,,CHEMBL623065,,4942,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10525,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623066,,4942,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10526,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623067,,6646,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10527,1,,,Oral bioavailability in rats was determined; High,50597,A,,CHEMBL623068,,5237,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10528,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623069,,6646,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10529,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623070,,4449,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10530,1,,,Oral bioavailability was calculated in rat,50597,A,,CHEMBL623071,,6057,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10531,1,,,Oral bioavailability,50597,A,,CHEMBL623072,,2552,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10532,1,,,Oral bioavailability,50597,A,,CHEMBL623073,,5496,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10533,1,,,Oral bioavailability,50597,A,,CHEMBL623074,,6484,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10534,1,,,Oral bioavailability,50597,A,,CHEMBL623075,,6485,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10535,1,,,Oral bioavailability after i.v. administration,50597,A,,CHEMBL623076,,6616,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10536,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,A,,CHEMBL623077,,4969,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10537,1,,,Oral bioavailability in rat (Sprague-Dawley),50597,A,,CHEMBL623078,,5862,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10538,1,,,Oral bioavailability in Sprague-Dawley rats,50597,A,,CHEMBL623079,,4514,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10539,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,A,,CHEMBL623080,,4514,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10540,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,A,,CHEMBL623081,,4514,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10541,1,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,50597,A,,CHEMBL623082,,5546,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10542,1,,,Oral bioavailability in fasted rat,50597,A,,CHEMBL874400,,6168,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10543,1,,,Oral bioavailability in fed rat,50597,A,,CHEMBL623083,,6168,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10544,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623084,,3624,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10545,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623085,,5213,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10546,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623086,,5496,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10547,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623087,,5553,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10548,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623088,,5833,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10549,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623089,,5836,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10550,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623090,,5865,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10551,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623091,,5960,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10552,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623092,,6249,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10553,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623093,,6448,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10554,1,,,Oral bioavailability in rat,50597,A,,CHEMBL874401,,6453,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10555,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623094,,6640,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10556,1,,,Oral bioavailability in rat,50597,A,,CHEMBL623095,,17607,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10557,1,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,50597,A,,CHEMBL623096,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10558,1,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,50597,A,,CHEMBL624913,,5939,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10559,1,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),50597,A,,CHEMBL624914,,6281,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10560,1,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,50597,A,,CHEMBL624915,,5874,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10561,1,,,Oral bioavailability in rat; Not measured,50597,A,,CHEMBL624916,,5213,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10562,1,,,Oral bioavailability in rat,50597,A,,CHEMBL624917,,4964,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10563,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,50597,A,,CHEMBL625157,,11020,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Liver,,10564,1,,,In vitro metabolic potential in rat liver microsomes,50597,A,,CHEMBL625158,,6251,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,,,10565,1,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",50597,A,,CHEMBL625159,,1568,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10566,1,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",50597,A,,CHEMBL625160,,3032,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10567,1,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,50597,A,,CHEMBL625161,,3748,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10568,1,,,Oral bioavailability in rat,50597,A,,CHEMBL625162,,401,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10569,1,,,Oral bioavailability in rat,50597,A,,CHEMBL625163,,6512,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10570,1,,,Oral bioavailability in rats at 10 mg/kg,50597,A,,CHEMBL625164,,17617,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10571,1,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,A,,CHEMBL625165,,6679,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10572,1,,,Oral bioavailability in rat,50597,A,,CHEMBL625166,,6742,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10573,1,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,50597,A,,CHEMBL625167,,589,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10574,1,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,50597,A,,CHEMBL625168,,589,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10575,1,,,Plasma clearance of the compound,50597,A,,CHEMBL625169,,3185,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10576,1,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,50597,A,,CHEMBL626264,,17596,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10577,1,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,50597,A,,CHEMBL626265,,2713,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10578,1,,,The compound was tested for plasma clearance in rat,50597,A,,CHEMBL626266,,12500,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10579,1,,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,50597,A,,CHEMBL626267,,12500,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,,,10580,1,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,50597,A,,CHEMBL626268,,2713,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10581,1,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,50597,A,,CHEMBL626269,,1446,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10582,1,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,50597,A,,CHEMBL626270,,6227,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10583,1,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,50597,A,,CHEMBL626271,,4709,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10584,1,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",50597,A,,CHEMBL626272,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10585,1,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,A,,CHEMBL626273,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10586,1,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,A,,CHEMBL875346,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10587,1,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",50597,A,,CHEMBL626274,,5510,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10588,1,,,Compound was tested for protein binding in rat plasma,50597,A,,CHEMBL626275,,4514,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10589,1,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,50597,A,,CHEMBL624646,,2713,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10590,1,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,50597,A,,CHEMBL624647,,2713,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Liver,,10591,1,,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,50597,A,,CHEMBL624648,,5340,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,10592,1,,,Area under curve ratio was determined (po/iv) in rat,50597,A,,CHEMBL624649,,12058,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10593,1,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,50597,A,,CHEMBL624650,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10594,1,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,50597,A,,CHEMBL624651,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10595,1,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,50597,A,,CHEMBL624652,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10596,1,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,50597,A,,CHEMBL624653,,6495,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10597,1,,,Ratio of AUCbrain to AUCplasma,50597,A,,CHEMBL624654,,6078,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10598,1,,,Ratio of brain to plasma,50597,A,,CHEMBL624655,,5656,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10599,1,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,50597,A,,CHEMBL624656,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10600,1,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,A,,CHEMBL624657,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10601,1,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,A,,CHEMBL624658,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10602,1,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,50597,A,,CHEMBL624659,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10603,1,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,50597,A,,CHEMBL624660,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10604,1,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,50597,A,,CHEMBL624661,,10130,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10605,1,,,Steady state brain :blood ratio was determined,50597,A,,CHEMBL624662,,5213,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10606,1,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,A,,CHEMBL625199,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10607,1,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,A,,CHEMBL625200,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10608,1,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,A,,CHEMBL625201,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10609,1,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,A,,CHEMBL625202,,4910,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10610,1,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,50597,A,,CHEMBL625203,,2083,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10611,1,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,50597,A,,CHEMBL625204,,2082,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10612,1,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,50597,A,,CHEMBL625205,,2082,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10613,1,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,50597,A,,CHEMBL625206,,6351,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000019,,,10614,1,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",22224,A,,CHEMBL625207,,14583,,Autocuration,,,0,U,,
,BAO_0000019,,,10615,1,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,22224,A,,CHEMBL625208,,14583,,Autocuration,,,0,U,,
,BAO_0000218,,,10616,1,,,In vivo absorption in Caco-2 cell line monolayers was determined,50587,A,495.0,CHEMBL625209,Caco-2,4608,9606.0,Intermediate,,,1,N,Homo sapiens,
,BAO_0000100,,,10617,1,,,Calculated partition coefficient (clogP),22229,P,,CHEMBL625210,,13668,,Autocuration,,,0,U,,
,BAO_0000218,,,10618,1,,,Area under curve was determine after peroral administration at 10 mpk in Rat,50597,A,,CHEMBL625211,,5669,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10619,1,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,50797,A,,CHEMBL625212,,5669,9544.0,Intermediate,,,1,N,Macaca mulatta,
,BAO_0000218,,,10620,1,,,Area under curve was determine after peroral administration at 160 mpk in Rat,50597,A,,CHEMBL625213,,5669,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10621,1,,,Area under curve was determine after peroral administration at 20 mpk in Rat,50597,A,,CHEMBL625214,,5669,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10622,1,,,Area under curve was determine after peroral administration at 50 mpk in Rat,50597,A,,CHEMBL874542,,5669,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000100,,,10623,1,,,Calculated partition coefficient (clogP) (AlogP),22229,P,,CHEMBL625215,,6472,,Autocuration,,,0,U,,
,BAO_0000019,,,10624,1,,,Activated partial thromboplastin time measured,22224,A,,CHEMBL625216,,15106,,Autocuration,,,0,U,,
,BAO_0000100,,,10625,1,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),22224,P,,CHEMBL625217,,15207,,Autocuration,,,0,U,,
,BAO_0000100,,,10626,1,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),22224,P,,CHEMBL625218,,15207,,Autocuration,,,0,U,,
,BAO_0000218,Plasma,,10627,1,,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,50588,A,,CHEMBL622864,,13941,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,10628,1,,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,50597,A,,CHEMBL622865,,13941,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10629,1,,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,50597,A,,CHEMBL622866,,13941,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10630,1,,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,50588,A,,CHEMBL622867,,13941,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
,BAO_0000218,Plasma,,10631,1,,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,50512,A,,CHEMBL876808,,15240,10141.0,Intermediate,,,1,N,Cavia porcellus,1969.0
,BAO_0000019,Brain,,10632,1,,,AUC in brain,22224,A,,CHEMBL627725,,10655,,Autocuration,,,0,U,,955.0
,BAO_0000019,Serum,,10633,1,,,AUC in serum,22224,A,,CHEMBL627726,,10655,,Autocuration,,,0,U,,1977.0
,BAO_0000019,Plasma,,10634,1,,,AUC was determined,22224,A,,CHEMBL627727,,6504,,Autocuration,,,0,U,,1969.0
,BAO_0000019,Plasma,,10635,1,,,AUC of the compound.,22224,A,,CHEMBL627728,,10615,,Autocuration,,,0,U,,1969.0
,BAO_0000019,Plasma,,10636,1,,,AUC value (0-4 hr),22224,A,,CHEMBL627729,,10353,,Autocuration,,,0,U,,1969.0
,BAO_0000019,Plasma,,10637,1,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",22224,A,,CHEMBL627730,,14907,,Autocuration,,,0,U,,1969.0
,BAO_0000019,Plasma,,10638,1,,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,22224,A,,CHEMBL627731,,14907,,Autocuration,,,0,U,,1969.0
,BAO_0000019,Plasma,,10639,1,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",22224,A,,CHEMBL627732,,14907,,Autocuration,,,0,U,,1969.0
,BAO_0000019,Plasma,,10640,1,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",22224,A,,CHEMBL627733,,14907,,Autocuration,,,0,U,,1969.0
,BAO_0000218,Plasma,,10641,1,,,AUC(area under curve) was determined after intravenous administration in rats,50597,A,,CHEMBL627734,,16359,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10642,1,,,AUC(area under curve) was determined after oral administration in rats,50597,A,,CHEMBL627735,,16359,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,10643,1,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,50512,A,,CHEMBL627736,,15240,10141.0,Intermediate,,,1,N,Cavia porcellus,1969.0
,BAO_0000218,Plasma,,10644,1,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,50597,A,,CHEMBL876809,,15240,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000019,,,10645,1,,,Area Under Curve after oral dosing of 100 uM/Kg,22224,A,,CHEMBL627737,,15469,,Autocuration,,,0,U,,
,BAO_0000019,,,10646,1,,,Area Under Curve after oral dosing of 30 uM/Kg,22224,A,,CHEMBL627738,,15469,,Autocuration,,,0,U,,
,BAO_0000019,,,10647,1,,,Area Under Curve was measured by ploting the graph between concentration verses time,22224,A,,CHEMBL627739,,13520,,Autocuration,,,0,U,,
,BAO_0000218,,,10648,1,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,50588,A,,CHEMBL626143,,17025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10649,1,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,22224,A,,CHEMBL626144,,17025,314293.0,Autocuration,,,0,U,Simiiformes,
,BAO_0000218,,,10650,1,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,50592,A,,CHEMBL626145,,17025,9986.0,Intermediate,,,1,N,Oryctolagus cuniculus,
,BAO_0000218,,,10651,1,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,50597,A,,CHEMBL626146,,17025,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Blood,,10652,1,,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,50597,A,,CHEMBL626147,,12032,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000019,,,10653,1,,,Area under curve (AUC) was determined,22224,A,,CHEMBL626148,,10291,,Autocuration,,,0,U,,
,BAO_0000218,,,10654,1,,,Area under curve (AUC) following ip administration at 1 mg/kg,22224,A,,CHEMBL626149,,5767,,Autocuration,,,0,U,,
,BAO_0000019,,,10655,1,,,Area under curve (AUC) was determined; ND is Not determined,22224,A,,CHEMBL626150,,1434,,Autocuration,,,0,U,,
,BAO_0000218,,,10656,1,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,50588,A,,CHEMBL626151,,14925,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10657,1,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,50588,A,,CHEMBL626152,,14925,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10658,1,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,50588,A,,CHEMBL626153,,14925,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000019,,,10659,1,,,Area under curve (AUR) was determined,22224,A,,CHEMBL626154,,1434,,Autocuration,,,0,U,,
,BAO_0000019,,,10660,1,,,Area under curve at 1 uM/dg administered intravenously,22224,A,,CHEMBL626155,,11883,,Autocuration,,,0,U,,
,BAO_0000019,,,10661,1,,,Area under curve at 10 uM/dg administered perorally,22224,A,,CHEMBL626156,,11883,,Autocuration,,,0,U,,
,BAO_0000019,,,10662,1,,,Area under curve at 2 uM/dg administered intravenously,22224,A,,CHEMBL626157,,11883,,Autocuration,,,0,U,,
,BAO_0000019,,,10663,1,,,Area under curve at 20 uM/dg administered perorally,22224,A,,CHEMBL626158,,11883,,Autocuration,,,0,U,,
,BAO_0000218,,,10664,1,,,Area under curve at a peroral dose of 3 mg/kg in dog,50588,A,,CHEMBL626159,,15233,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10665,1,,,Area under curve at a peroral dose of 3 mg/kg in rat,50597,A,,CHEMBL626160,,15233,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10666,1,,,Area under curve at an iv dose of 1 mg/kg in dog,50588,A,,CHEMBL626161,,15233,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10667,1,,,Area under curve at an iv dose of 1 mg/kg in rat,50597,A,,CHEMBL626162,,15233,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000019,,,10668,1,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,22224,A,,CHEMBL626163,,12978,,Autocuration,,,0,U,,
,BAO_0000019,,,10669,1,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,22224,A,,CHEMBL626164,,12978,,Autocuration,,,0,U,,
,BAO_0000218,,,10670,1,,,Area under curve measured as conc vs time after intravenous administration to mice.,50594,A,,CHEMBL626165,,11355,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,10671,1,,,Area under curve measured as conc vs time after peroral administration to mice.,50594,A,,CHEMBL626166,,11355,10090.0,Intermediate,,,1,N,Mus musculus,
,BAO_0000218,,,10672,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,A,,CHEMBL626167,,12923,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10673,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,50588,A,,CHEMBL626168,,12923,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10674,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,50588,A,,CHEMBL877463,,12923,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10675,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,50588,A,,CHEMBL626169,,12923,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Heart,,10676,1,,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL626170,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,10677,1,,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL626171,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,10678,1,,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL626172,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,10679,1,,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL626173,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Kidney,,10680,1,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,50597,A,,CHEMBL626174,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,10681,1,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL626175,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,10682,1,,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL626176,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,10683,1,,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL626177,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,10684,1,,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL622499,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Liver,,10685,1,,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,50597,A,,CHEMBL622500,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,10686,1,,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622501,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,10687,1,,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL622502,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,10688,1,,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL622503,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,10689,1,,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL877614,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Lung,,10690,1,,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL624839,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,10691,1,,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL624840,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,10692,1,,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL624841,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,10693,1,,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL624842,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Muscle tissue,,10694,1,,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,50597,A,,CHEMBL624843,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,10695,1,,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,50597,A,,CHEMBL624844,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,10696,1,,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,50597,A,,CHEMBL624845,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,10697,1,,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,50597,A,,CHEMBL621904,,17738,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Blood,,10698,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,50597,A,,CHEMBL621905,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,10699,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,50597,A,,CHEMBL874382,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,10700,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,50597,A,,CHEMBL621906,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Brain,,10701,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,50597,A,,CHEMBL621907,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,10702,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,50597,A,,CHEMBL622096,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,10703,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,50597,A,,CHEMBL622097,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Heart,,10704,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,50597,A,,CHEMBL622098,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,10705,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,50597,A,,CHEMBL622099,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Heart,,10706,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,50597,A,,CHEMBL622100,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
In vivo,BAO_0000218,Kidney,,10707,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,50597,A,,CHEMBL622101,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,10708,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,50597,A,,CHEMBL622102,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Kidney,,10709,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,50597,A,,CHEMBL622103,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
In vivo,BAO_0000218,Liver,,10710,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,50597,A,,CHEMBL622104,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,10711,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,50597,A,,CHEMBL622105,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Liver,,10712,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,50597,A,,CHEMBL622106,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
In vivo,BAO_0000218,Lung,,10713,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,50597,A,,CHEMBL622107,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,10714,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,50597,A,,CHEMBL622108,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Lung,,10715,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,50597,A,,CHEMBL622109,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
In vivo,BAO_0000218,Muscle tissue,,10716,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,50597,A,,CHEMBL622110,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,10717,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,50597,A,,CHEMBL622111,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Muscle tissue,,10718,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,50597,A,,CHEMBL874383,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2385.0
In vivo,BAO_0000218,Zone of skin,,10719,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,50597,A,,CHEMBL622112,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,10720,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,50597,A,,CHEMBL622113,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Zone of skin,,10721,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,50597,A,,CHEMBL622114,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,14.0
In vivo,BAO_0000218,Spleen,,10722,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,50597,A,,CHEMBL622115,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,Spleen,,10723,1,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,50597,A,,CHEMBL622116,,11195,10116.0,Intermediate,,,1,N,Rattus norvegicus,2106.0
In vivo,BAO_0000218,,,10724,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622117,,6193,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10725,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622118,,6803,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10726,1,,,Oral bioavailability in rats at 6 mg/kg,50597,A,,CHEMBL622119,,6647,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10727,1,,,Oral bioavailability in rat (dose 6 mg/kg),50597,A,,CHEMBL622120,,6647,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10728,1,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,50597,A,,CHEMBL622121,,6647,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10729,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622122,,6640,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10730,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622123,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10731,1,,,Oral bioavailability in rat,50597,A,,CHEMBL622124,,6641,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10732,1,,,Bioavailability in rat,50597,A,,CHEMBL622125,,6642,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10733,1,,,Oral bioavailability,50597,A,,CHEMBL622126,,5472,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10734,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,A,,CHEMBL620455,,6141,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10735,1,,,Oral bioavailability in rat,50597,A,,CHEMBL620456,,4390,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10736,1,,,Oral bioavailability in rat,50597,A,,CHEMBL620457,,5472,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10737,1,,,Oral bioavailability was evaluated; Not tested,50597,A,,CHEMBL620458,,5472,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10738,1,,,Oral bioavailability,50597,A,,CHEMBL620459,,5438,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10739,1,,,Oral bioavailability in rat by oral dosing,50597,A,,CHEMBL620460,,4883,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10740,1,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,A,,CHEMBL620461,,1908,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10741,1,,,Oral bioavailability in rat (Sprague-Dawley),50597,A,,CHEMBL620462,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10742,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,A,,CHEMBL620463,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10743,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,A,,CHEMBL620464,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10744,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,A,,CHEMBL620465,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10745,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),50597,A,,CHEMBL620466,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10746,1,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,50597,A,,CHEMBL620467,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10747,1,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,50597,A,,CHEMBL620468,,4853,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10748,1,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,50597,A,,CHEMBL620469,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10749,1,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,50597,A,,CHEMBL620470,,12873,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10750,1,,,Oral bioavailability in rat,50597,A,,CHEMBL620471,,3169,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10751,1,,,Oral bioavailability in rat,50597,A,,CHEMBL620472,,6305,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10752,1,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,50597,A,,CHEMBL620473,,4762,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10753,1,,,Oral bioavailability in rat,50597,A,,CHEMBL620474,,17847,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10754,1,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),50597,A,,CHEMBL620475,,6211,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10755,1,,,Oral bioavailability in rat,50597,A,,CHEMBL620476,,6011,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10756,1,,,Oral bioavailability in rat,50597,A,,CHEMBL620477,,6317,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10757,1,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,50597,A,,CHEMBL620478,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10758,1,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,50597,A,,CHEMBL618768,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10759,1,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,50597,A,,CHEMBL618769,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10760,1,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,50597,A,,CHEMBL618770,,6644,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10761,1,,,Oral bioavailability (dose 20 mg/kg p.o.),50597,A,,CHEMBL618771,,6113,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10762,1,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,50597,A,,CHEMBL618772,,5937,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10763,1,,,Oral bioavailability in rat at 10 mg/kg of the compound,50597,A,,CHEMBL618773,,5711,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10764,1,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,A,,CHEMBL875842,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10765,1,,,Bioavailability in rat (dose 3 mg/kg i.v.),50597,A,,CHEMBL618774,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10766,1,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,A,,CHEMBL618775,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10767,1,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,A,,CHEMBL618776,,17717,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10768,1,,,Percent bioavailability (F) in rats after iv administration,50597,A,,CHEMBL618777,,4722,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10769,1,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,50597,A,,CHEMBL618778,,4722,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10770,1,,,Bioavailability in rat (dose 5 uM/kg p.o.),50597,A,,CHEMBL618779,,4353,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10771,1,,,Oral bioavailability,50597,A,,CHEMBL618780,,15662,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10772,1,,,Bioavailability in rat (dose 2 mg/kg p.o.),50597,A,,CHEMBL618781,,4756,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10773,1,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,50597,A,,CHEMBL618782,,4756,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10774,1,,,Oral bioavailability in rat (dose 20 mg/kg),50597,A,,CHEMBL618783,,3436,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10775,1,,,Oral bioavailability in rat,50597,A,,CHEMBL618784,,17800,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10776,1,,,Percent oral bioavailability evaluated in rat,50597,A,,CHEMBL618785,,15762,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10777,1,,,Oral bioavailability in rat,50597,A,,CHEMBL618786,,5089,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10778,1,,,Percent oral bioavailability in rat; Not determined,50597,A,,CHEMBL618787,,5089,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10779,1,,,Oral bioavailability in rat,50597,A,,CHEMBL618788,,3185,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10780,1,,,Bioavailability in rat,50597,A,,CHEMBL618789,,5145,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10781,1,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),50597,A,,CHEMBL618790,,3457,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10782,1,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),50597,A,,CHEMBL618791,,3457,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10783,1,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,50597,A,,CHEMBL875843,,5983,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10784,1,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),50597,A,,CHEMBL618792,,5739,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10785,1,,,Cmax at a dose of 30 mg/kg in rat,50597,A,,CHEMBL623395,,3579,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10786,1,,,Cmax in monkeys at a dose of 1 mg/kg,22224,A,,CHEMBL623396,,17788,314293.0,Autocuration,,,0,U,Simiiformes,
In vivo,BAO_0000218,,,10787,1,,,Cmax in rat,50597,A,,CHEMBL623397,,14956,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10788,1,,,Cmax in rats at a dose of 1 mg/kg,50597,A,,CHEMBL623398,,17788,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10789,1,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,50594,A,,CHEMBL623399,,9750,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,10790,1,,,"Cmax value at a dose of 12.7 uM/kg, po",22224,A,,CHEMBL623400,,12767,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10791,1,,,"Cmax value at a dose of 6.3 uM/kg, iv",22224,A,,CHEMBL623401,,12767,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10792,1,,,"Cmax value at a dose of 7.1 uM/kg, iv",22224,A,,CHEMBL623402,,12767,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10793,1,,,Cmax value of compound was determined after 1 hr,22224,A,,CHEMBL623403,,12703,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10794,1,,,Cmax value of the compound,22224,A,,CHEMBL623404,,15778,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10795,1,,,Cmax value administered intraintestinal in rats.,50597,A,,CHEMBL625997,,12818,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10796,1,,,Cmax value administered perorally was determined in rat; Not determined,50597,A,,CHEMBL625998,,14964,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10797,1,,,Cmax value at the dose of 2.3 mg/kg,22224,A,,CHEMBL625999,,15808,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10798,1,,,Cmax value at the dose of 5 mg/kg,22224,A,,CHEMBL626000,,15808,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10799,1,,,Cmax value in the period of 8 hr after dosing. ,22224,A,,CHEMBL626001,,15778,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10800,1,,,Cmax value at a oral dose of 20 mg/kg; Not tested,22224,A,,CHEMBL626002,,3715,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10801,1,,,Cmax value at a oral dose of 20 mg/kg,22224,A,,CHEMBL626003,,3715,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10802,1,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,A,,CHEMBL626004,,1446,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10803,1,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,50512,A,,CHEMBL626005,,15240,10141.0,Intermediate,,,1,N,Cavia porcellus,
In vivo,BAO_0000218,,,10804,1,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,50597,A,,CHEMBL626006,,15240,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,10805,1,,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,50597,A,,CHEMBL626007,,14810,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10806,1,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,A,,CHEMBL626008,,14239,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Liver,,10807,1,,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,50588,A,,CHEMBL626009,,12555,9615.0,Intermediate,,,1,N,Canis lupus familiaris,2107.0
In vivo,BAO_0000218,,,10808,1,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,50588,A,,CHEMBL626010,,10754,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Blood,,10809,1,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,50594,A,,CHEMBL626011,,10754,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,10810,1,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,50594,A,,CHEMBL626012,,10754,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,10811,1,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,50594,A,,CHEMBL626013,,10754,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,10812,1,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,50594,A,,CHEMBL626014,,10754,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Blood,,10813,1,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,50594,A,,CHEMBL877496,,10754,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,,,10814,1,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,50588,F,,CHEMBL626015,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,10815,1,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,50588,F,,CHEMBL626016,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,10816,1,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,50588,F,,CHEMBL626017,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,10817,1,,,Bioavailability as maximal plasma concentration in dogs,50588,A,,CHEMBL626018,,13543,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,10818,1,,,Bioavailability as maximal plasma concentration in dogs,50588,A,,CHEMBL626692,,13543,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,10819,1,,,Bioavailability as maximal plasma concentration in rats,50597,A,,CHEMBL626693,,13543,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10820,1,,,Bioavailability as maximal plasma concentration in rats,22224,A,,CHEMBL626694,,13543,10116.0,Autocuration,,,0,U,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Blood,,10821,1,,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,A,,CHEMBL626695,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,10822,1,,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,A,,CHEMBL626696,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,10823,1,,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,A,,CHEMBL626697,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,10824,1,,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,50588,A,,CHEMBL626859,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,10825,1,,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,A,,CHEMBL626860,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,Blood,,10826,1,,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,A,,CHEMBL626861,,14600,9615.0,Intermediate,,,1,N,Canis lupus familiaris,178.0
In vivo,BAO_0000218,,,10827,1,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,A,,CHEMBL626296,,14681,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10828,1,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,22224,A,,CHEMBL626297,,15905,,Autocuration,,,0,U,,
In vivo,BAO_0000218,Plasma,,10829,1,,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,22224,A,,CHEMBL626298,,15905,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,10830,1,,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",50597,A,,CHEMBL626299,,13304,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10831,1,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,50597,A,,CHEMBL626300,,15137,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10832,1,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,50597,A,,CHEMBL626301,,15137,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10833,1,,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,50597,A,,CHEMBL626962,,15137,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10834,1,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,50597,A,,CHEMBL626963,,15137,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10835,1,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,50597,A,,CHEMBL626964,,15137,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10836,1,,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,100710,A,,CHEMBL626965,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,1969.0
In vivo,BAO_0000218,Plasma,,10837,1,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,A,,CHEMBL626966,,14839,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,10838,1,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,A,,CHEMBL626967,,14839,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,10839,1,,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,100710,A,,CHEMBL626968,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,1969.0
,BAO_0000218,Heart,,10840,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,50597,A,,CHEMBL626969,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10841,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,50597,A,,CHEMBL627126,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10842,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,50597,A,,CHEMBL631276,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10843,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,50597,A,,CHEMBL631277,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10844,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,50597,A,,CHEMBL631278,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10845,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,50597,A,,CHEMBL874457,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10846,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,50597,A,,CHEMBL631279,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10847,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,50597,A,,CHEMBL631280,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10848,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,50597,A,,CHEMBL631281,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10849,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,50597,A,,CHEMBL631968,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10850,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,50597,A,,CHEMBL631969,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10851,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,50597,A,,CHEMBL631970,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10852,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,50597,A,,CHEMBL631971,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10853,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,50597,A,,CHEMBL631972,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10854,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,50597,A,,CHEMBL630435,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10855,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,50597,A,,CHEMBL630436,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10856,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,50597,A,,CHEMBL630437,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10857,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,50597,A,,CHEMBL630438,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Heart,,10858,1,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,50597,A,,CHEMBL630439,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,948.0
,BAO_0000218,Kidney,,10859,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,50597,A,,CHEMBL630440,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10860,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,50597,A,,CHEMBL630441,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10861,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,50597,A,,CHEMBL630442,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10862,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,50597,A,,CHEMBL625234,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10863,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,50597,A,,CHEMBL625235,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10864,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,50597,A,,CHEMBL625236,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10865,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,50597,A,,CHEMBL625237,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10866,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,50597,A,,CHEMBL626125,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10867,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,50597,A,,CHEMBL626126,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10868,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,50597,A,,CHEMBL626127,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10869,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,50597,A,,CHEMBL626128,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10870,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,50597,A,,CHEMBL626129,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10871,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,50597,A,,CHEMBL626130,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10872,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,50597,A,,CHEMBL626131,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10873,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,50597,A,,CHEMBL626132,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10874,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,50597,A,,CHEMBL626752,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10875,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,50597,A,,CHEMBL626753,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10876,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,50597,A,,CHEMBL626754,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Kidney,,10877,1,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,50597,A,,CHEMBL626755,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2113.0
,BAO_0000218,Liver,,10878,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,50597,A,,CHEMBL626756,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10879,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,50597,A,,CHEMBL626757,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10880,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,50597,A,,CHEMBL626758,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10881,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,50597,A,,CHEMBL626759,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,10882,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,50597,A,,CHEMBL626760,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,10883,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL626394,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10884,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,50588,A,,CHEMBL626395,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10885,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL626396,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10886,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,A,,CHEMBL626397,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10887,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,A,,CHEMBL626398,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10888,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL626399,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10889,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,50597,A,,CHEMBL874653,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10890,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL626400,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10891,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,A,,CHEMBL626401,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10892,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,A,,CHEMBL626402,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10893,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,A,,CHEMBL626403,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10894,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL626404,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10895,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,50597,A,,CHEMBL626405,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10896,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL625529,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10897,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,A,,CHEMBL625530,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10898,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,A,,CHEMBL625531,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10899,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,A,,CHEMBL625532,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10900,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL625533,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10901,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,50597,A,,CHEMBL875474,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10902,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL625534,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10903,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,A,,CHEMBL625535,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10904,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),50597,A,,CHEMBL625536,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10905,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,A,,CHEMBL625537,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10906,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL625538,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10907,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,50597,A,,CHEMBL625539,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10908,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL625540,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10909,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,A,,CHEMBL625541,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10910,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,A,,CHEMBL625542,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10911,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,A,,CHEMBL625543,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10912,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL625544,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,10913,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,50588,A,,CHEMBL625545,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10914,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL625546,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10915,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,50588,A,,CHEMBL625547,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10916,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL625548,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10917,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL625549,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10918,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL625550,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10919,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL625551,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10920,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL875475,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10921,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL625552,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10922,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL625553,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10923,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,A,,CHEMBL625554,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10924,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,A,,CHEMBL625555,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10925,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL625556,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10926,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,50588,A,,CHEMBL624986,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10927,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL624987,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,10928,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,A,,CHEMBL624988,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Artery,,10929,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,50588,A,,CHEMBL624989,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10930,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,50588,A,,CHEMBL624990,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10931,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,50588,A,,CHEMBL874391,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10932,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,50588,A,,CHEMBL624991,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10933,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,50588,A,,CHEMBL624992,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10934,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,50588,A,,CHEMBL624993,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10935,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,50588,A,,CHEMBL624994,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10936,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,50588,A,,CHEMBL624995,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10937,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,50588,A,,CHEMBL624996,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10938,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,50588,A,,CHEMBL624997,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10939,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,50588,A,,CHEMBL624998,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10940,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,50588,A,,CHEMBL624999,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10941,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,50588,A,,CHEMBL882955,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10942,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,50588,A,,CHEMBL625000,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10943,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,50588,A,,CHEMBL625001,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10944,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,50588,A,,CHEMBL625089,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10945,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,50588,A,,CHEMBL625090,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10946,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,50588,A,,CHEMBL625091,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10947,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,50588,A,,CHEMBL625092,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10948,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,50588,A,,CHEMBL625093,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10949,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,50588,A,,CHEMBL625094,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,Artery,,10950,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,50588,A,,CHEMBL625095,,9025,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1637.0
In vivo,BAO_0000218,,,10951,1,,,Compound was evaluated for its bioavailability in the dogs,50588,A,,CHEMBL625096,,2249,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,10952,1,,,Compound was evaluated for its bioavailability in the rats,50597,A,,CHEMBL625097,,2249,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10953,1,,,Compound was evaluated for oral bioavailability,22224,A,,CHEMBL882956,,17515,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10954,1,,,Compound was evaluated for percentage of Oral bioavailability in rats,50597,A,,CHEMBL625098,,14541,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10955,1,,,Bioavailability in guinea pig,22224,A,,CHEMBL625099,,12797,10141.0,Autocuration,,,0,U,Cavia porcellus,
In vivo,BAO_0000218,,,10956,1,,,Compound was evaluated for the oral bioavailability in rat,50597,A,,CHEMBL625100,,12797,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10957,1,,,Compound was evaluated for the oral bioavailability in dog,50588,A,,CHEMBL625101,,12797,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,10958,1,,,Compound was evaluated for the oral bioavailability in rat,50597,A,,CHEMBL874396,,12797,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10959,1,,,Bioavailability in dog (dosed i.v.),22224,F,,CHEMBL625102,,11727,9615.0,Autocuration,,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,10960,1,,,Compound was tested for in vivo bioavailability in dog,50588,A,,CHEMBL625103,,13249,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,10961,1,,,Compound was tested for in vivo bioavailability in hamsters,100712,A,,CHEMBL625104,,13249,10026.0,Intermediate,,,1,N,Cricetinae,
In vivo,BAO_0000218,,,10962,1,,,Compound was tested for in vivo bioavailability in monkey,22224,A,,CHEMBL625105,,13249,314293.0,Autocuration,,,0,U,Simiiformes,
In vivo,BAO_0000218,,,10963,1,,,Compound was tested for in vivo bioavailability in rat,50597,A,,CHEMBL625106,,13249,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10964,1,,,Oral bioavailability in mouse,22224,A,,CHEMBL625107,,9552,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,10965,1,,,Compound was tested for percent of oral bioavailability in mice; 56-74,50594,A,,CHEMBL625108,,9552,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,10966,1,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),22224,A,,CHEMBL625109,,14839,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,10967,1,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),22224,A,,CHEMBL625110,,14839,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,10968,1,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),22224,A,,CHEMBL625111,,14839,9541.0,Autocuration,,,0,U,Macaca fascicularis,
In vivo,BAO_0000218,,,10969,1,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),50594,A,,CHEMBL625112,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,10970,1,,,Oral bioavailability in nude mice,50594,A,,CHEMBL875334,,14839,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,10971,1,,,Bioavailability in monkey (i.d. dosing),22224,A,,CHEMBL628617,,11219,9443.0,Autocuration,,,0,U,Primates,
In vivo,BAO_0000218,,,10972,1,,,Bioavailability in rat,22224,A,,CHEMBL628618,,9552,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,10973,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,22224,A,,CHEMBL628619,,11732,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10974,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,22224,A,,CHEMBL628620,,11732,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,10975,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,A,,CHEMBL628621,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
In vivo,BAO_0000218,,,10976,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,A,,CHEMBL628622,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
In vivo,BAO_0000218,,,10977,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,A,,CHEMBL628623,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,
In vivo,BAO_0000218,Plasma,,10978,1,,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,100710,A,,CHEMBL628624,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,1969.0
In vivo,BAO_0000218,Plasma,,10979,1,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,A,,CHEMBL628625,,14839,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,10980,1,,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,100710,A,,CHEMBL628626,,14839,9541.0,Intermediate,,,1,N,Macaca fascicularis,1969.0
In vivo,BAO_0000218,Plasma,,10981,1,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,A,,CHEMBL627041,,14839,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,10982,1,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,A,,CHEMBL627042,,14839,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,10983,1,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,A,,CHEMBL627043,,14839,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,10984,1,,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,22224,A,,CHEMBL627044,,13932,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,10985,1,,,Cmax in mouse plasma,50594,A,,CHEMBL627045,,11637,10090.0,Intermediate,,,1,N,Mus musculus,1969.0
In vivo,BAO_0000218,Plasma,,10986,1,,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,22224,A,,CHEMBL627046,,11637,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,10987,1,,,Maximal plasma concentration in rat,50597,A,,CHEMBL627047,,13960,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,10988,1,,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,50597,A,,CHEMBL627048,,15905,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,10989,1,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,50597,A,,CHEMBL627049,,14062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10990,1,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,50597,A,,CHEMBL627050,,14062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10991,1,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,50597,A,,CHEMBL627051,,14062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10992,1,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,50597,A,,CHEMBL627052,,14062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10993,1,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,50597,A,,CHEMBL627053,,14062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10994,1,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,50597,A,,CHEMBL627054,,14062,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,10995,1,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,A,,CHEMBL627055,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,10996,1,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,A,,CHEMBL627056,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,10997,1,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,A,,CHEMBL627057,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,10998,1,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,A,,CHEMBL627058,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,10999,1,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,A,,CHEMBL626211,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,11000,1,,,Maximum Concentration of the compound.,22224,A,,CHEMBL626212,,10291,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11001,1,,,Maximum Concentration was measured after iv administration into Beagle dog,50588,A,,CHEMBL626213,,14599,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11002,1,,,Maximum Concentration was measured after iv administration into Beagle dog.,50588,A,,CHEMBL626214,,14599,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11003,1,,,Maximum Concentration was measured after po administration into Beagle dog,50588,A,,CHEMBL626215,,14599,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11004,1,,,Maximum Concentration was measured after po administration into Beagle dog.,50588,A,,CHEMBL626216,,14599,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Blood,,11005,1,,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,22224,A,,CHEMBL626217,,12767,,Autocuration,,,0,U,,178.0
In vivo,BAO_0000218,Blood,,11006,1,,,Maximum blood level reached after an iv dose of 12.2 uM/kg,22224,A,,CHEMBL626218,,12767,,Autocuration,,,0,U,,178.0
In vivo,BAO_0000218,Blood,,11007,1,,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,22224,A,,CHEMBL626219,,12767,,Autocuration,,,0,U,,178.0
In vivo,BAO_0000218,Blood,,11008,1,,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,22224,A,,CHEMBL626220,,12767,,Autocuration,,,0,U,,178.0
In vivo,BAO_0000218,Blood,,11009,1,,,Maximum blood level reached after an oral dose of 5.0 mg/kg,22224,A,,CHEMBL626221,,12767,,Autocuration,,,0,U,,178.0
In vivo,BAO_0000218,Blood,,11010,1,,,Maximum blood level reached at dose of 10.6 uM/kg orally,22224,A,,CHEMBL626222,,12767,,Autocuration,,,0,U,,178.0
In vivo,BAO_0000218,,,11011,1,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,50512,A,,CHEMBL626223,,14706,10141.0,Intermediate,,,1,N,Cavia porcellus,
In vivo,BAO_0000218,,,11012,1,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,50512,A,,CHEMBL626224,,14706,10141.0,Intermediate,,,1,N,Cavia porcellus,
In vivo,BAO_0000218,Brain,,11013,1,,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,50597,A,,CHEMBL626225,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,11014,1,,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,50597,A,,CHEMBL626226,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,11015,1,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,50597,A,,CHEMBL626227,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,Brain,,11016,1,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,50597,A,,CHEMBL626228,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
In vivo,BAO_0000218,,,11017,1,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,A,,CHEMBL626229,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11018,1,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,50597,A,,CHEMBL626921,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11019,1,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,50597,A,,CHEMBL876793,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11020,1,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,50597,A,,CHEMBL625309,,14793,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11021,1,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50278,A,,CHEMBL625310,,10524,1423.0,Intermediate,,,1,N,Bacillus subtilis,
In vivo,BAO_0000218,,,11022,1,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,22224,A,,CHEMBL625311,,11871,314293.0,Autocuration,,,0,U,Simiiformes,
In vivo,BAO_0000218,,,11023,1,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,50597,A,,CHEMBL625312,,11871,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11024,1,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,22224,A,,CHEMBL625313,,3437,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11025,1,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,50594,A,,CHEMBL625314,,12038,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,11026,1,,,Maximum concentration in male rats after iv administration of 20 mg/kg,50597,A,,CHEMBL625315,,12038,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Liver,,11027,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,50597,A,,CHEMBL625316,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11028,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,50597,A,,CHEMBL625317,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11029,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,50597,A,,CHEMBL625318,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11030,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,50597,A,,CHEMBL625319,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11031,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,50597,A,,CHEMBL625320,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11032,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,50597,A,,CHEMBL625321,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11033,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,50597,A,,CHEMBL625322,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11034,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,50597,A,,CHEMBL876801,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11035,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,50597,A,,CHEMBL625323,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11036,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,50597,A,,CHEMBL625324,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11037,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,50597,A,,CHEMBL625325,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11038,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,50597,A,,CHEMBL625326,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11039,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,50597,A,,CHEMBL625327,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11040,1,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,50597,A,,CHEMBL625328,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Lung,,11041,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,50597,A,,CHEMBL625329,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11042,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,50597,A,,CHEMBL625330,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11043,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,50597,A,,CHEMBL627774,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11044,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,50597,A,,CHEMBL627775,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11045,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,50597,A,,CHEMBL627949,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11046,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,50597,A,,CHEMBL627950,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11047,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,50597,A,,CHEMBL627951,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11048,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,50597,A,,CHEMBL627952,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11049,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,50597,A,,CHEMBL627953,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11050,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,50597,A,,CHEMBL627954,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11051,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,50597,A,,CHEMBL627955,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11052,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,50597,A,,CHEMBL627956,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11053,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,50597,A,,CHEMBL876802,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11054,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,50597,A,,CHEMBL627957,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11055,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,50597,A,,CHEMBL627958,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11056,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,50597,A,,CHEMBL627959,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11057,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,50597,A,,CHEMBL627960,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11058,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,50597,A,,CHEMBL627961,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,Lung,,11059,1,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,50597,A,,CHEMBL627962,,8418,10116.0,Intermediate,,,1,N,Rattus norvegicus,2048.0
,BAO_0000218,,,11060,1,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,A,,CHEMBL627963,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11061,1,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL624759,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11062,1,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL624760,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11063,1,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL624761,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11064,1,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL877607,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Liver,,11065,1,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,A,,CHEMBL624762,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11066,1,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL624763,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11067,1,,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL624764,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11068,1,,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL624765,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,Liver,,11069,1,,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL624766,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,2107.0
,BAO_0000218,,,11070,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL624767,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11071,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,50588,A,,CHEMBL624768,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11072,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL624769,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11073,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,A,,CHEMBL624770,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11074,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,A,,CHEMBL624771,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11075,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL624772,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11076,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,50597,A,,CHEMBL624773,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11077,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL624774,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11078,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,A,,CHEMBL624775,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11079,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,A,,CHEMBL624776,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11080,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,A,,CHEMBL624777,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11081,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL624778,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11082,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,50597,A,,CHEMBL624779,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11083,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,A,,CHEMBL624780,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11084,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,A,,CHEMBL624781,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11085,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL877608,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11086,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,A,,CHEMBL624782,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11087,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL624783,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11088,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,50597,A,,CHEMBL624784,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11089,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL624785,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11090,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,A,,CHEMBL624786,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11091,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,A,,CHEMBL624787,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11092,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL628676,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11093,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,50597,A,,CHEMBL621842,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11094,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL621843,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11095,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,A,,CHEMBL623873,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11096,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,A,,CHEMBL623874,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11097,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,A,,CHEMBL623875,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11098,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,A,,CHEMBL623876,,6996,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11099,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,50588,A,,CHEMBL623877,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11100,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL623878,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11101,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,50588,A,,CHEMBL623879,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11102,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL623880,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11103,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL623881,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11104,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL623957,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11105,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL623958,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11106,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL623959,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11107,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL623960,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11108,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL623961,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11109,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,A,,CHEMBL623962,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11110,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,A,,CHEMBL624676,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11111,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL624677,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11112,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,50588,A,,CHEMBL624678,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11113,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,A,,CHEMBL624679,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
,BAO_0000218,,,11114,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,A,,CHEMBL624680,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11115,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,22224,A,,CHEMBL624849,,11732,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11116,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,22224,A,,CHEMBL624850,,11732,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11117,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,22224,A,,CHEMBL874399,,11732,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11118,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,22224,A,,CHEMBL624851,,11732,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11119,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,22224,A,,CHEMBL624852,,11732,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11120,1,,,Oral bioavailability in rat (dose 10 mg/kg),22224,A,,CHEMBL624853,,13359,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11121,1,,,Oral bioavailability in rat (Sprague-Dawley),22224,A,,CHEMBL624854,,16618,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11122,1,,,Oral bioavailability in rat,22224,A,,CHEMBL624855,,13960,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11123,1,,,Oral bioavailability in rats was determined in vivo,22224,A,,CHEMBL624856,,13917,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11124,1,,,Oral bioavailability in dog,22224,A,,CHEMBL882957,,14266,9615.0,Autocuration,,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,11125,1,,,Oral bioavailability of compound in monkey,22224,A,,CHEMBL624857,,12359,314293.0,Autocuration,,,0,U,Simiiformes,
In vivo,BAO_0000218,,,11126,1,,,Oral bioavailability of compound in rat,50597,A,,CHEMBL622202,,12359,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11127,1,,,Bioavailability in rat of PMEA prodrug,22224,A,,CHEMBL622203,,12359,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11128,1,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,50597,A,,CHEMBL625522,,12359,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11129,1,,,Serum conc at 3 hours following 25 mg/kg dose,22224,A,,CHEMBL622868,,10791,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,Urine,,11130,1,,,Urine conc 0-5 hours following 25 mg/kg dose,22224,A,,CHEMBL622869,,10791,9544.0,Autocuration,,,0,U,Macaca mulatta,1088.0
In vivo,BAO_0000218,Urine,,11131,1,,,Urine conc 0-24 hours following 25 mg/kg dose,22224,A,,CHEMBL622870,,10791,9544.0,Autocuration,,,0,U,Macaca mulatta,1088.0
In vivo,BAO_0000218,,,11132,1,,,Oral bioavailability in African green monkeys; 20-25,22224,A,,CHEMBL622871,,138,9534.0,Autocuration,,,0,U,Chlorocebus aethiops,
In vivo,BAO_0000218,,,11133,1,,,Oral bioavailability in cynomolgus monkey.,100710,A,,CHEMBL620560,,14521,9541.0,Intermediate,,,1,N,Macaca fascicularis,
In vivo,BAO_0000218,,,11134,1,,,Oral bioavailability in dog,22224,A,,CHEMBL620561,,13953,9615.0,Autocuration,,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,11135,1,,,Oral bioavailability in dog at 10 mg/kg oral dose,50588,A,,CHEMBL620562,,12836,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11136,1,,,Oral bioavailability in hamster at 10 mg/kg oral dose,100712,A,,CHEMBL620563,,12836,10026.0,Intermediate,,,1,N,Cricetinae,
In vivo,BAO_0000218,,,11137,1,,,Oral bioavailability in rat at 10 mg/kg oral dose,50597,A,,CHEMBL620564,,12836,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11138,1,,,Oral bioavailability in rat,22224,A,,CHEMBL872265,,14521,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11139,1,,,Oral bioavailability in rat,22224,A,,CHEMBL620565,,13953,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11140,1,,,Oral bioavailability,22224,A,,CHEMBL620566,,6799,9347.0,Autocuration,,,0,U,Eutheria,
In vivo,BAO_0000218,,,11141,1,,,Oral bioavailability was determined; range 49-102%,22224,A,,CHEMBL620567,,11311,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11142,1,,,Oral bioavailability was determined in dogs,50588,A,,CHEMBL620568,,4013,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11143,1,,,Oral bioavailability in rat,22224,A,,CHEMBL620569,,4013,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11144,1,,,Oral bioavailability,22224,A,,CHEMBL620570,,17591,9347.0,Autocuration,,,0,U,Eutheria,
In vivo,BAO_0000218,,,11145,1,,,Oral bioavailability was determined; Not orally available,22224,A,,CHEMBL620571,,17591,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11146,1,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),50594,A,,CHEMBL620572,,15011,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,,,11147,1,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),22224,A,,CHEMBL620573,,15011,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,11148,1,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,22224,A,,CHEMBL620574,,15011,10090.0,Autocuration,,,0,U,Mus musculus,
In vivo,BAO_0000218,,,11149,1,,,Oral bioavailability in Rhesus monkey,22224,A,,CHEMBL620575,,9552,9544.0,Autocuration,,,0,U,Macaca mulatta,
In vivo,BAO_0000218,,,11150,1,,,Oral bioavailability in dog (female mongrel),22224,A,,CHEMBL620576,,9552,9615.0,Autocuration,,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,11151,1,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,22224,A,,CHEMBL875846,,3639,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11152,1,,,Oral bioavailability in dog,22224,A,,CHEMBL620577,,13397,9615.0,Autocuration,,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,11153,1,,,Percentage Bioavailability was evaluated.,22224,A,,CHEMBL620578,,3031,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11154,1,,,Bioavailability in rat administered i.d.,22224,A,,CHEMBL620579,,12818,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11155,1,,,Bioavailability,22224,A,,CHEMBL621248,,4847,9347.0,Autocuration,,,0,U,Eutheria,
In vivo,BAO_0000218,,,11156,1,,,Bioavailability in dog (male Beagle) i.v. administration,22224,A,,CHEMBL625390,,12421,9615.0,Autocuration,,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,11157,1,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",22224,A,,CHEMBL625391,,11966,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11158,1,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),22224,A,,CHEMBL872266,,11218,9443.0,Autocuration,,,0,U,Primates,
In vivo,BAO_0000218,,,11159,1,,,Oral bioavailability in rat (Sprague-Dawley) (male),22224,A,,CHEMBL625392,,13129,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11160,1,,,The oral bioavailability was measured on rats after oral administration,50597,A,,CHEMBL625393,,12350,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11161,1,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,A,,CHEMBL625394,,2231,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11162,1,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,A,,CHEMBL625395,,2231,9544.0,Intermediate,,,1,N,Macaca mulatta,
In vivo,BAO_0000218,,,11163,1,,,Bioavailability in rat (dose 10 mg/kg i.d.),22224,A,,CHEMBL625396,,12187,10116.0,Autocuration,,,0,U,Rattus norvegicus,
In vivo,BAO_0000218,,,11164,1,,,Bioavailability in dog (male Beagle) i.v. administration,22224,A,,CHEMBL625397,,12421,9615.0,Autocuration,,,0,U,Canis lupus familiaris,
In vivo,BAO_0000218,,,11165,1,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,A,,CHEMBL625398,,13256,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Blood,,11166,1,,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,A,,CHEMBL625399,,13256,10090.0,Intermediate,,,1,N,Mus musculus,178.0
In vivo,BAO_0000218,Cerebellum,,11167,1,,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,A,,CHEMBL626074,,13256,10090.0,Intermediate,,,1,N,Mus musculus,2037.0
In vivo,BAO_0000218,,,11168,1,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,A,,CHEMBL626075,,13256,10090.0,Intermediate,,,1,N,Mus musculus,
In vivo,BAO_0000218,Plasma,,11169,1,,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,A,,CHEMBL626076,,2231,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11170,1,,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,A,,CHEMBL626077,,2231,9544.0,Intermediate,,,1,N,Macaca mulatta,1969.0
In vivo,BAO_0000218,Blood,,11171,1,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),50597,A,,CHEMBL626078,,12178,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
In vivo,BAO_0000218,Blood,,11172,1,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),22224,A,,CHEMBL625846,,12178,,Autocuration,,,0,U,,178.0
In vivo,BAO_0000218,Blood,,11173,1,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),22224,A,,CHEMBL625847,,12178,,Autocuration,,,0,U,,178.0
In vivo,BAO_0000218,,,11174,1,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,50597,A,,CHEMBL625848,,15633,10116.0,Expert,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,Plasma,,11175,1,,,Maximum concentration of compound in plasma administered orally to rats,50597,A,,CHEMBL625849,,14258,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11176,1,,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",50588,A,,CHEMBL626023,,14224,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,11177,1,,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",50588,A,,CHEMBL626024,,14224,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,11178,1,,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",50588,A,,CHEMBL626025,,14224,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,,,11179,1,,,Maximum concentration after 10 mg/kg by oral administration,22224,A,,CHEMBL626026,,5566,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11180,1,,,Maximum concentration at a dose of 1.5 mg/kg,22224,A,,CHEMBL626027,,16935,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11181,1,,,Maximum concentration at a dose of 2.0 mg/kg,22224,A,,CHEMBL626028,,16935,,Autocuration,,,0,U,,
In vivo,BAO_0000218,Plasma,,11182,1,,,Maximum concentration in dog plasma,50588,A,,CHEMBL626029,,14224,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,11183,1,,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,22224,A,,CHEMBL626030,,12536,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,11184,1,,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,22224,A,,CHEMBL626031,,12536,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,11185,1,,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,22224,A,,CHEMBL626032,,12536,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,11186,1,,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,22224,A,,CHEMBL626033,,12536,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,11187,1,,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,22224,A,,CHEMBL626034,,12536,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,11188,1,,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),50588,A,,CHEMBL626035,,9994,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,11189,1,,,Maximum concentration in plasma at Tmax,22224,A,,CHEMBL626036,,1434,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,11190,1,,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,50588,A,,CHEMBL626037,,12836,9615.0,Expert,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,11191,1,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,100712,A,,CHEMBL626038,,12836,10026.0,Intermediate,,,1,N,Cricetinae,1969.0
In vivo,BAO_0000218,Plasma,,11192,1,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,50597,A,,CHEMBL626039,,12836,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11193,1,,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,50597,A,,CHEMBL626040,,12545,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11194,1,,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,50592,A,,CHEMBL626041,,13856,9986.0,Intermediate,,,1,N,Oryctolagus cuniculus,1969.0
In vivo,BAO_0000218,,,11195,1,,,Maximum concentration was calculated,22224,A,,CHEMBL626042,,3550,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11196,1,,,Maximum concentration was calculated.,22224,A,,CHEMBL626043,,2632,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11197,1,,,Maximum concentration at a peroral dose of 10 mg/kg,22224,A,,CHEMBL626044,,5566,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11198,1,,,Maximum concentration of the drug at 10 uM/dg administered perorally,22224,A,,CHEMBL626045,,11883,,Autocuration,,,0,U,,
In vivo,BAO_0000218,,,11199,1,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,22224,A,,CHEMBL626046,,11883,,Autocuration,,,0,U,,
In vivo,BAO_0000218,Plasma,,11200,1,,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",50588,A,,CHEMBL626047,,14122,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,11201,1,,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",100712,A,,CHEMBL626048,,14122,10026.0,Intermediate,,,1,N,Cricetinae,1969.0
In vivo,BAO_0000218,Plasma,,11202,1,,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",50597,A,,CHEMBL626049,,14122,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11203,1,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,50597,A,,CHEMBL626050,,12542,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11204,1,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,50588,A,,CHEMBL874541,,12542,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,11205,1,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,100712,A,,CHEMBL622826,,12542,10026.0,Intermediate,,,1,N,Cricetinae,1969.0
In vivo,BAO_0000218,Plasma,,11206,1,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,100712,A,,CHEMBL622827,,12542,10026.0,Intermediate,,,1,N,Cricetinae,1969.0
In vivo,BAO_0000218,Plasma,,11207,1,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,50597,A,,CHEMBL622828,,12542,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11208,1,,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,50597,A,,CHEMBL622829,,14080,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,,,11209,1,,,Maximum concentration reached following intravenous administration in male rat,50597,A,,CHEMBL876806,,11911,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11210,1,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,50588,A,,CHEMBL622830,,13204,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11211,1,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,50597,A,,CHEMBL622831,,13204,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11212,1,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,50588,A,,CHEMBL626794,,14346,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11213,1,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,50597,A,,CHEMBL626795,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11214,1,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,50597,A,,CHEMBL626796,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11215,1,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,50597,A,,CHEMBL626797,,14346,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11216,1,,,Maximum drug concentration is determined after oral dosing in rats.,50597,A,,CHEMBL626798,,14127,10116.0,Intermediate,,,1,N,Rattus norvegicus,
In vivo,BAO_0000218,,,11217,1,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,50588,A,,CHEMBL626799,,14339,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,,,11218,1,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,50588,A,,CHEMBL626800,,14339,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
In vivo,BAO_0000218,Plasma,,11219,1,,,Maximum plasma concentration,22224,A,,CHEMBL626801,,13494,,Autocuration,,,0,U,,1969.0
In vivo,BAO_0000218,Plasma,,11220,1,,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,50597,A,,CHEMBL876816,,14925,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11221,1,,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,50597,A,,CHEMBL626802,,14474,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
In vivo,BAO_0000218,Plasma,,11222,1,,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,50588,A,,CHEMBL626803,,14474,9615.0,Intermediate,,,1,N,Canis lupus familiaris,1969.0
In vivo,BAO_0000218,Plasma,,11223,1,,,Maximum plasma concentration following oral administration of 30 umol/kg,22224,A,,CHEMBL626804,,13917,,Autocuration,,,0,U,,1969.0
,BAO_0000218,Plasma,,11224,1,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,50597,A,,CHEMBL626805,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,11225,1,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,A,,CHEMBL626309,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,11226,1,,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL626310,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,11227,1,,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL626311,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Plasma,,11228,1,,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL626312,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,1969.0
,BAO_0000218,Uterus,,11229,1,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL626313,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,Uterus,,11230,1,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,A,,CHEMBL626314,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,Uterus,,11231,1,,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL626315,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,Uterus,,11232,1,,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL626316,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,Uterus,,11233,1,,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,A,,CHEMBL626317,,9796,10116.0,Intermediate,,,1,N,Rattus norvegicus,995.0
,BAO_0000218,,,11234,1,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),50597,A,,CHEMBL626318,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11235,1,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),50597,A,,CHEMBL626319,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11236,1,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),50597,A,,CHEMBL626320,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11237,1,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),50597,A,,CHEMBL875053,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11238,1,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),50597,A,,CHEMBL626321,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11239,1,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),50597,A,,CHEMBL626322,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11240,1,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),50597,A,,CHEMBL626323,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11241,1,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),50597,A,,CHEMBL626324,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11242,1,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),50597,A,,CHEMBL626325,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11243,1,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),50597,A,,CHEMBL626326,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11244,1,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),50597,A,,CHEMBL626327,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11245,1,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),50597,A,,CHEMBL626328,,8363,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,Blood,,11246,1,,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",50597,A,,CHEMBL626329,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,11247,1,,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",50597,A,,CHEMBL626330,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,11248,1,,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL626331,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,11249,1,,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL626332,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,11250,1,,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",50597,A,,CHEMBL626333,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,11251,1,,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL626334,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,11252,1,,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL626335,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Blood,,11253,1,,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL624798,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,178.0
,BAO_0000218,Brain,,11254,1,,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",50597,A,,CHEMBL624799,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,11255,1,,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",50597,A,,CHEMBL624800,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,11256,1,,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",50597,A,,CHEMBL624801,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,11257,1,,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",50597,A,,CHEMBL624802,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,11258,1,,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",50597,A,,CHEMBL624803,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,11259,1,,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",50597,A,,CHEMBL624804,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,11260,1,,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",50597,A,,CHEMBL624805,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,Brain,,11261,1,,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",50597,A,,CHEMBL624806,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,955.0
,BAO_0000218,,,11262,1,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",50597,A,,CHEMBL624807,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11263,1,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL624808,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11264,1,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL624809,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11265,1,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",50597,A,,CHEMBL624810,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11266,1,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL877618,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11267,1,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",50597,A,,CHEMBL624811,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11268,1,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL624812,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11269,1,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL624813,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11270,1,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",50597,A,,CHEMBL624814,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11271,1,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL624815,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11272,1,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",50597,A,,CHEMBL624816,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11273,1,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",50597,A,,CHEMBL624817,,8684,10116.0,Intermediate,,,1,N,Rattus norvegicus,
,BAO_0000218,,,11274,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,A,,CHEMBL624818,,6996,9615.0,Intermediate,,,1,N,Canis lupus familiaris,
